{
  "symbol": "IVA",
  "company_name": "Inventiva S.A. ADR",
  "ir_website": "https://inventivapharma.com/investors/",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "H1 2024 Financial Results",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/10/Inventiva-PR-H1-2024-EN-10-14-2024-.pdf",
          "content": "PRESS RELEASE\nInventiva announces Filing of 2024 Half-Year Report – Conditions\nCOMMUNIQUE DE PRESSE\nfor Accessing or Consulting the Report\nDaix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and\nNasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the\ndevelopment of oral small molecule therapies for the treatment of metabolic dysfunction-associated\nsteatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with\nsignificant unmet medical needs, today announced the filing, for the six-month period ended June 30, 2024 of its\nHalf-Year Report (the “2024 Half-Year Report”) with the French financial markets authority, “Autorité des\nMarchés Financiers” (“AMF”).\nThe Company's condensed consolidated interim financial statements for the six-month period ended June 30,\n2024 were prepared under the responsibility of the Board of Directors and approved by it on a going concern basis\non October 14, 2024.\nThe financial information presented in the 2024 Half Year Report has not been qualified by the statutory auditors\nin their reports for the periods concerned. The statutory auditors' report on the Company's consolidated financial\nstatements for the year ended December 31, 2023 states that there is a material uncertainty related to events or\ncircumstances that could affect the Company's ability to continue as a going concern. The limited review report\non the condensed consolidated financial statements for the first half of 2024 contains an emphasis of matter\nparagraph relating to the going concern assumption.\nThe 2024 Half-Year Report can be consulted on the Company's website at www.inventivapharma.com, in the\n“Investors” section, and on the AMF website at www.amf-france.org. Copies of the universal registration\ndocument, as amended, are also available free of charge, on request, from the Company's registered office at 50\nRue de Dijon, 21121 Daix, France.\nAbout Inventiva\nInventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small\nmolecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet\nmedical need. The Company benefits from a strong expertise and experience in the domain of compounds\ntargeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one\nclinical candidate, has a pipeline of two preclinical programs and continues to explore other development\nopportunities to add to its pipeline.\nInventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the\ntreatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.\nInventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part\nof Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts\nrelating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva\nis also in the process of selecting a candidate for its Hippo signaling pathway program.\nThe Company has a scientific team of approximately 90 people with deep expertise in the fields of biology,\nmedicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns\nan extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which\nare proprietary, as well as a wholly-owned research and development facility.\n1\nPRESS RELEASE\nInventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:\nFR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com\nContacts\nInventiva Brunswick Group Westwicke, an ICR Company\nPascaline Clerc, PhD Tristan Roquet Montegon / Patricia L. Bank\nEVP, Strategy and Corporate Affairs Aude Lepreux / Investor relations\nmedia@inventivapharma.com Julia Cailleteau patti.bank@westwicke.com\n+1 202 499 8937 Media relations +1 415 513-1284\ninventiva@brunswickgroup.com\n+33 1 53 96 83 83\n2"
        },
        {
          "title": "H1 2024 Revenues and Cash Position",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/07/Inventiva-PR-Preliminary-Financial-information-H1-2024-EN-07-31-2024-1.pdf",
          "content": "PRESS RELEASE\nInventiva Reports Preliminary 2024 First-Half Financial\nInformation1\n► Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to\ncash and cash equivalents at €26.9 million, €0.012 million of short-term\ndeposits and €9.03 million of long-term deposits as of December 31, 2023.\n► On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara\nBioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng)\nfor an amount of approximately €20.1 million.\n► No Revenues recorded in H1 2024, compared to €1.9 million for the same\nperiod in 2023.\nDaix (France), Long Island City (New York, United States), July 31, 2024 – Inventiva (Euronext Paris and Nasdaq:\nIVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known\nas non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today\nreported certain preliminary financial results for the first half of 2024, including its cash, cash equivalents, and\nrevenues.\nPreliminary Financial Results\nAs of June 30, 2024, the Company’s cash and cash equivalents amounted to €10.1 million, compared to €26.9\nmillion, €0.01 million of short-term deposit2 and €9.0 million of long-term deposit3 as of December 31, 2023.\nNet cash used in operating activities amounted to (€48.3) million in the first half of 2024, compared to (€45.2)\nmillion for the same period in 2023 while the R&D expenses for the first half of 2024 were (€48.7) million, down\n10% compared to the first half of 2023. The decrease in R&D expenses over the period is primarily due to the\ntemporary pause in the recruitment of the patients in the NATiV3 Phase III clinical trial of lanifibranor in\nMASH/NASH (“NATiV3\") following the Suspected Unexpected Serious Adverse Reaction (SUSAR) previously\nreported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase IIa\ncombination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes (“T2D”).\nR&D expenses are expected to increase in the second half of 2024 following the effective restart of patient\nrecruitment in NATiV3, as well as the planned clinical development activities and related costs associated with\nthe NATiV3 for the second half of 2024.\nNet cash generated in investing activities for the first half of 2024 amounted to €8.9 million, compared to (€7.7)\nmillion used in the first half of 2023. The change is mostly due to the variation in deposits between both periods.\nNet cash generated in financing activities for the first half of 2024 amounted to €22.6 million, compared to (€2.2)\nmillion used in the first half of 2023. The change is due to the second tranche of €25 million drawn in January\n1 Preliminary, non-audited financial information\n2 Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by\nthe Company as liquid and easily available.\n3 The long-term deposit had a two year-term, were accessible prior to the expiration of the term with a notice period of 31 days and were considered as\nliquid by the Company.\n1\nPRESS RELEASE\n2024 under the unsecured loan agreement granted by the European Investment Bank (“EIB”). As a condition to\nthe drawdown, the Company issued 3,144,654 warrants to the EIB.\nOver the first half of 2024, the Company recorded a positive exchange rate effect on cash and cash equivalents\nof €0.1 million, compared to a negative effect of (€0.4) million for the first half of 2023, due to the evolution of\nEUR/USD exchange rate.\nIssuance of Royalty Certificates after June 30, 2024\nOn July 18, 2024, Inventiva announced the issuance of Royalty Certificates subscribed by Samsara BioCapital, and\nexisting shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of approximately €20.1 million.\nThe royalty certificates give the holders the right to an annual payment of royalties equal to 3% of the potential\nfuture net sales of lanifibranor4.\nConsidering its current cost structure and forecasted expenditures and including the proceeds of approximately\n€20.1 million from the issuance of the royalty certificates and the cash preservation measures in the short term\nset up by the Company with its creditors, the Company estimates that its cash, cash equivalents and deposits\nshould allow the Company to fund its operations through September 20245. These factors raise substantial doubt\nregarding the Company’s ability to continue as a going concern beyond the end of September 2024.\nIn order to finance its activities, the Company needs to raise additional funds, and it is continuing to actively review\npotential financing (including debt, equity and equity-linked or other instruments) and strategic options.\nRevenues\nThe Company did not record any revenues in the first half of 2024, as compared to €1.9 million amounted for the\nsame period in 2023. The revenues recorded by the Company in the first half of 2023, were attributed to a\nmilestone payment after CTTQ, Sino Biopharm’s subsidiary, received the Investigational New Drug (IND) approval\nfrom the Chinese National Medical Products Administration (NMPA) in May 2023, allowing the initiation of the\nclinical development of lanifibranor in MASH/NASH in mainland China.\nAnticipated potential key milestones\n Last Patient First Visit of the NATiV3 Phase III clinical trial evaluating lanifibranor in MASH/NASH – targeted\nfor the second half of 2024.\nUpcoming investor conference participation\n Canaccord Genuity's 44th Annual Growth Conference - August 13-15 - Boston\n H.C. Wainwright 26th Annual Global Investment Conference - September 9-11 - New York\n 7th edition of Forum Lyon Pôle Bourse – September 24 – Lyon\n KBC Securities life sciences conference - September 26 – Brussels\n H.C. Wainwright 9th Annual MASH Investor Conference – October 7 - Virtual\n Portzamparc BNP Paribas Séminaire Biotech & Santé – October 8-9 – Virtual\n Guggenheim Global Healthcare Conference - November 11-13 – Boston\n Stifel Healthcare Conference – November 18-19 – New York\n4 Inventiva-PR-Royalty-Deal-EN-07-18-2024.pdf (inventivapharma.com)\n5 This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional\nexpenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on\nassumptions that are incorrect, and the Company may end up using its resources sooner than anticipated.\n2\nPRESS RELEASE\nUpcoming scientific conference participation\n ALEH 2024 Congress – September 9-11 – Santiago, Chile\n AASLD The Liver Meeting – November 15-19 – San Diego, United States\nNext financial results publication\n Financial results for the half of 2024: Wednesday September 25, 2024 (after U.S. market close)\nAbout Inventiva\nInventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small\nmolecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet\nmedical need. The Company benefits from a strong expertise and experience in the domain of compounds\ntargeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one\nclinical candidate and has a pipeline of two preclinical programs\nInventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the\ntreatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.\nInventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part\nof Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts\nrelating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva\nis also in the process of selecting a candidate for its Hippo signaling pathway program.\nThe Company has a scientific team of approximately 90 people with deep expertise in the fields of biology,\nmedicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns\nan extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which\nare proprietary, as well as a wholly-owned research and development facility.\nInventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:\nFR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com\nContacts\nInventiva Brunswick Group Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montegon / Patricia L. Bank\nEVP, Strategy and Corporate Affairs Aude Lepreux / Investor relations\nmedia@inventivapharma.com Julia Cailleteau patti.bank@westwicke.com\n+1 202 499 8937 Media relations +1 415 513-1284\ninventiva@brunswickgroup.com\n+33 1 53 96 83 83\nImportant Notice\nThis press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the\nPrivate Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included\nin this press release are forward-looking statements. These statements include, but are not limited to, preliminary\n3\nPRESS RELEASE\nunaudited financial information, forecasts and estimates with respect to Inventiva’s pre-clinical programs and\nclinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials,\nincluding the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, potential development of\nand regulatory pathway for odiparcil, clinical trial data releases and publications, the information, insights and\nimpacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product\ncandidates, including lanifibranor, potential regulatory submissions and approvals, and Inventiva’s pipeline and\npreclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva,\nbusiness and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales\nrelated thereto, potential payment of royalties and anticipated future performance, the sufficiency of Inventiva’s\ncash resources and estimated cash runway, including the effects thereon by cash preservation measures, and\nInventiva’s ability to execute any potential financing or strategic options or further arrangements with creditors,\nincluding the impacts of any such transaction or arrangement. Certain of these statements, forecasts and\nestimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”,\n“intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”,\n“hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such\nstatements are not historical facts but rather are statements of future expectations and other forward-looking\nstatements that are based on management's beliefs. These statements reflect such views and assumptions\nprevailing as of the date of the statements and involve known and unknown risks and uncertainties that could\ncause future results, performance or future events to differ materially from those expressed or implied in such\nstatements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control.\nThere can be no guarantees with respect to pipeline product candidates that the clinical trial results will be\navailable on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva\nor its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially\ndifferent from the anticipated future results, performance or achievements expressed or implied by such\nstatements, forecasts and estimates due to a number of factors, including the completion of financial closing\nprocedures, final adjustments and other developments that may arise that could cause the preliminary financial\nresults for first half of 2024 to differ from the financial results that will be reflected in Inventiva’s final financial\nstatements, that Inventiva cannot provide assurance on the impacts of the SUSAR on enrollment or the ultimate\nimpact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a\nclinical-stage company with no approved products and no historical product revenues, Inventiva has incurred\nsignificant losses since inception, Inventiva has a limited operating history and has never generated any revenue\nfrom product sales, Inventiva will require additional capital to finance its operations, in the absence of which,\nInventiva may be required to significantly curtail, delay or discontinue one or more of its research or development\nprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be\nunable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential\ntransactions or further arrangements with its creditors and the impacts therefrom, Inventiva's future success is\ndependent on the successful clinical development, regulatory approval and subsequent commercialization of\ncurrent and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive\nof future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its\npartners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong\nand regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s\nexpectations with respect to the changes to the clinical development plan for lanifibranor for the treatment of\nNASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners\nmay encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and\nefficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit\nand retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and\ntime-consuming process and could be made more difficult or rendered impossible by multiple factors outside\nInventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have\nother properties that could delay or prevent their regulatory approval, or limit their commercial potential,\nInventiva faces substantial competition and Inventiva’s and its partners’ business, and preclinical studies and\nclinical development programs and timelines, its financial condition and results of operations could be materially\n4\nPRESS RELEASE\nand adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related\nsanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its\npartners’ clinical trials on anticipated timelines, and the state of war between Israel and Hamas and the related\nrisk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest\nrates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no\nrepresentations are made as to the accuracy or fairness of such forward-looking statements, forecasts and\nestimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this\npress release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023 filed with the\nAutorité des Marchés Financiers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024 for other risks\nand uncertainties affecting Inventiva, including those described under the caption “Risk Factors,” and in our\nfuture filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect\nits forward-looking statements and may cause actual results and the timing of events to differ materially from\nthose anticipated.\nAll information in this press release is as of the date of the release. Except as required by law, Inventiva has no\nintention and is under no obligation to update or review the forward-looking statements referred to above.\nConsequently, Inventiva accepts no liability for any consequences arising from the use of any of the above\nstatements.\n5"
        },
        {
          "title": "Q1 2024 Revenues and Cash Position",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/05/Inventiva-PR-Q1-2024-CA-Cash-EN-05-21-2024-1.pdf",
          "content": "PRESS RELEASE\nInventiva reports 2024 First Quarter Financial Information1\nand provides a corporate update\n► Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million,\nand long-term deposit at €19.1 million3 as of March 31, 2024, compared to\n€26.9 million, €0.01 million and €9.0 million as of December 31, 2023,\nrespectively.\n► The fourth scheduled DMC meeting recommended to continue the NATiV3\nPhase III clinical trial without modification of the current protocol, based on the\npre-planned review of interim safety data of more than 900 patients\nrandomized in the main and exploratory cohorts.\n► 280 sites in 15 countries have restarted screening patients in NATiV3 Phase III\nclinical trial.\n► First visit of the last patient of NATiV3 Phase III clinical trial with lanifibranor is\ntargeted for first half of 2024.\nDaix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq:\nIVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known\nas non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today\nreported financial information for the first quarter of 2024, including its cash, cash equivalents and revenues, and\nprovided a corporate update.\nKey Financial Results\nCash, cash equivalents and deposits\nAs of March 31, 2024, the Company’s cash and cash equivalents amounted to €11.0 million, short-term deposits\nto 0.1 million, and long-term deposit to €19.0 million2, compared to €26.9 million, €0.01 million and €9.0 million\nas of December 31, 2023, respectively.\nNet cash used in operating activities amounted to (€29.4) million in the first quarter of 2024, compared to (€20.4)\nmillion for the same period in 2023. R&D expenses for the first quarter of 2024 were up 82% compared to the first\nquarter of 2023. This increase is in line with the clinical development activities planned for 2024 and driven by\ncosts associated with the NATiV3 Phase III clinical trial of lanifibranor in MASH/NASH, and, to a lesser extent, with\nthe completion of the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with\nMASH/NASH and type 2 diabetes (“T2D”).\n1 Non-audited financial information.\n2 Short-term deposits are included in the category “other current assets” in the IFRS consolidated statement of financial position and are considered by the\nCompany as liquid and easily available.\n3 The long-term deposit has a two year-term, is accessible prior to the expiration of the term with a notice period of 31 days and is considered as liquid by\nthe Company.\n1\nPRESS RELEASE\nNet cash used in investing activities for the first quarter of 2024 amounted to (€10.3) million, compared to (€8.4)\nmillion in the first quarter of 2023. The change is mostly due to the change in deposits between both periods.\nNet cash generated in financing activities for the first quarter of 2024 amounted to €23.7 million, compared to\n(€1.2) million in the first quarter of 2023. The change is due to the second tranche of €25 million drawn in January\n2024 under the unsecured loan agreement granted by the European Investment Bank (“EIB”). As a\ncondition to the drawdown, the Company issued 3,144,654 warrants to EIB.\nOver the first quarter of 2024, the Company recorded a positive exchange rate effect on cash and cash equivalents\nof €0.1 million, compared to a negative effect of (€0.5) million for the first quarter of 2023, due to the evolution\nof EUR/USD exchange rate.\nConsidering its current cost structure and forecasted expenditures, the Company estimates that its cash, cash\nequivalents and deposits2,3 should allow the Company to fund its operations as currently planned until the\nbeginning of the third quarter of 20244. Therefore, it indicates that a material uncertainty exists on the Company’s\nability to continue as a going concern. The Company is actively reviewing potential financing (including debt,\nequity and equity-linked or other instruments) and strategic options with potential counterparties and its financial\nadvisors.\nRevenues\nThe Company did not recognize revenues for the first quarter of 2024, in line with the first quarter of 2023.\nMain areas of progress in the R&D portfolio and corporate update\n▪ On March 28, 2024, the Company announced the nomination to its Board of Directors of Andre Turenne,\nPresident and CEO of the Boston-based biotech Matchpoint Therapeutics, and Advisor to Atlas Venture since\n2021. Mr. Turenne’s appointment will be submitted to the Company’s shareholders for ratification at the\nnext general shareholder meeting.\n▪ On May 13, 2024, the Company announced the publication of additional results from its NATIVE Phase II\nclinical trial, which demonstrated improvement of markers of cardiometabolic health in patients with\nMASH/NASH treated with lanifibranor, regardless of the patients’ diabetes and obesity status or weight\nchange during treatment.\n▪ On May 16, 2024, the Company announced that following the fourth scheduled meeting, the DMC\nrecommended the NATiV3 Phase III clinical trial continue without modification of the current protocol. This\nrecommendation was based on the pre-planned review of interim safety data of more than 900 patients\nrandomized in the main and exploratory cohorts.\n▪ To date 280 sites in 15 countries have resumed screening and randomization of new patients in the NATiV3\nPhase III clinical trial, following the implementation of the additional screening criteria, previously disclosed,\nrecommended by the DMC in response to the SUSAR.\nAnticipated potential key milestones\n▪ Last Patient First Visit of the NATiV3 Phase III clinical trial evaluating lanifibranor in MASH/NASH - targeted\nfor the first half of 2024.\n4 This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional\nexpenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on\nassumptions that are incorrect and the Company may end up using its resources sooner than anticipated.\n2\nPRESS RELEASE\nUpcoming investor conference participation\n▪ Portzamparc mid and small caps conference – June 11-12 - Paris\n▪ Stifel European Healthcare Summit - June 25-27 - Lyon\n▪ Canaccord Genuity's 44th Annual Growth Conference - August 13-15 - Boston\n▪ H.C. Wainwright 26th Annual Global Investment Conference - September 9-11 - New York\n▪ 7th edition of Forum Lyon Pôle Bourse – September 24 – Lyon\n▪ KBC Securities life sciences conference - September 26 - Brussels\n▪ Guggenheim Global Healthcare Conference - November 11-13 - Boston\nUpcoming scientific conferences\n▪ The EASL International Liver CongressTM – June 5-8 – Milan, Italy\nNext financial results publication\n▪ Financial results, cash, cash equivalents, deposits and revenues, for the first half of 2024: Wednesday, July\n31, 2024 (after U.S. market close)\nAbout Inventiva\nInventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small\nmolecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet\nmedical need. The Company benefits from a strong expertise and experience in the domain of compounds\ntargeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one\nclinical candidate, has a pipeline of two preclinical programs and continues to explore other development\nopportunities to add to its pipeline.\nInventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the\ntreatment of adult patients with MASH/NASH, a common and progressive chronic liver disease for which there\nare currently no approved therapies.\nInventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part\nof Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts\nrelating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva\nis also in the process of selecting a candidate for its Hippo signaling pathway program.\nThe Company has a scientific team of approximately 90 people with deep expertise in the fields of biology,\nmedicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns\nan extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which\nare proprietary, as well as a wholly-owned research and development facility.\nInventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:\nFR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com\nContacts\nInventiva Brunswick Group Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montegon / Patricia L. Bank\nEVP, Strategy and Corporate Affairs Aude Lepreux / Investor relations\n3\nPRESS RELEASE\nmedia@inventivapharma.com Julia Cailleteau patti.bank@westwicke.com\n+1 202 499 8937 Media relations +1 415 513-1284\ninventiva@brunswickgroup.com\n+33 1 53 96 83 83\nImportant Notice\nThis press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the\nPrivate Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included\nin this press release are forward-looking statements. These statements include, but are not limited to, unaudited\nfinancial results for Inventiva’s three months ended March 31, 2024, forecasts and estimates with respect to\nInventiva’s cash resources, including expectations and assumptions in connection with Inventiva’s estimated cash\nrunway, Inventiva’s review of potential financing and strategic options, their outcome and likelihood of success,\npre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and\nenrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH,\nthe LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and type 2\ndiabetes and the study with lanifibranor in patients with MAFLD/NAFLD and T2D, and the results and timing\nthereof, potential development of and regulatory pathway for odiparcil, clinical trial data releases and\npublications, the information, insights and impacts that may be gathered from clinical trials, the potential\ntherapeutic benefits, including reduction in HbA1c, reduction in several markers of liver injury, markers of glucose,\nlipid metabolism, hepatic steatosis and markers of cardiometabolic health and cardiovascular risk, of Inventiva’s\nproduct candidates, including lanifibranor alone and in combination with empagliflozin, potential regulatory\nsubmissions and approvals, and Inventiva’s pipeline and preclinical and clinical development plans, future\nactivities, expectations, plans, growth and prospects of Inventiva, the results of the review of potential financing\nor strategic transactions, if any, including any potential transaction, or receipt of additional funds, and future\naccess to the two-year short-term deposit, forecasts and estimates with respect to the annual general meeting of\nshareholders, including with respect to the appointment of Mr. Turenne. Certain of these statements, forecasts\nand estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”,\n“expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”,\n“hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such\nstatements are not historical facts but rather are statements of future expectations and other forward-looking\nstatements that are based on management’s beliefs. These statements reflect such views and assumptions\nprevailing as of the date of the statements and involve known and unknown risks and uncertainties that could\ncause future results, performance or future events to differ materially from those expressed or implied in such\nstatements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control.\nThere can be no guarantees with respect to pipeline product candidates that the clinical trial results will be\navailable on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva\nor its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially\ndifferent from the anticipated future results, performance or achievements expressed or implied by such\nstatements, forecasts and estimates, due to a number of factors, including that interim data or data from any\ninterim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the\nDMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts\nof the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results\nor timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company\nwith no approved products and no historical product revenues, Inventiva has incurred significant losses since\ninception, Inventiva has a limited operating history and has never generated any revenue from product sales,\nInventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be\nrequired to significantly curtail, delay or discontinue one or more of its research or development programs or be\nunable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue\nas a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva’s\n4\nPRESS RELEASE\nfuture success is dependent on the successful clinical development, regulatory approval and subsequent\ncommercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not\nnecessarily predictive of future results and the results of Inventiva’s and its partners’ clinical trials may not support\nInventiva’s and its partners’ product candidate claims, Inventiva’s expectations with respect to its clinical trials\nmay prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical\ntrials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of\nMASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its\npartners may encounter substantial delays beyond expectations in their clinical trials or Inventiva may fail to\ndemonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and\nits partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is\nan expensive and time-consuming process and could be made more difficult or rendered impossible by multiple\nfactors outside Inventiva’s and its partners’ control, Inventiva’s product candidates may cause adverse drug\nreactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial\npotential, Inventiva faces substantial competition and Inventiva’s and its partners’ business, and preclinical studies\nand clinical development programs and timelines, its financial condition and results of operations could be\nmaterially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and\nrelated sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and\nits partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related\nrisk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest\nrates, uncertain financial markets and disruptions in banking systems. The review of potential financial and\nstrategic options may not result in any particular action or transaction being pursued, entered into or\nconsummated, and there is no assurance as to the timing, sequence or outcome of any action or transaction or\nseries of actions or transactions. If Inventiva is unable to continue as a going concern, it may have to liquidate its\nassets and may receive less than the value at which those assets are carried on its financial statements, and it is\nlikely that investors will lose all or part of their investment. Given these risks and uncertainties, no representations\nare made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore,\nforward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are\ncautioned not to place undue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023 filed with the\nAutorité des Marchés Financiers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024 for other risks and\nuncertainties affecting Inventiva, including those described from time to time under the caption “Risk Factors”.\nOther risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking\nstatements and may cause actual results and the timing of events to differ materially from those anticipated.\nAll information in this press release is as of the date of the release. Except as required by law, Inventiva has no\nintention and is under no obligation to update or review the forward-looking statements referred to above.\nConsequently, Inventiva accepts no liability for any consequences arising from the use of any of the above\nstatements.\n5"
        },
        {
          "title": "Total voting rights and shares – October 31st, 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/11/Inventiva_-English-Version_-2024-10-31.pdf",
          "content": "Statement of total voting rights and shares forming the\ncompany’s share capital on October 31st, 2024\nArticle 223-16 of the General Regulations of the AMF (French Financial Markets Authority)\nMarket: Euronext Paris\nISIN code / Mnemo: FR0013233012/ IVA\nWeb site: www.inventivapharma.com\nDate Number of Shares Total voting rights, Total voting rights,\nOutstanding gross (1) net (2)\n31 October 2024 87 077 695 100 059 052 99 939 331\n(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of\nthe AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting\nrights have been suspended.\n(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting\nrights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the\npublic is properly informed, in accordance with the AMF recommendation of July 17, 2007.\n1"
        },
        {
          "title": "Interim financial report for the six months ended june 30, 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/10/RFS-Inventiva-ENG-H1-FY24-1.pdf",
          "content": "INVENTIVA S.A.\nA joint-stock company (société anonyme) with a share capital of 524,771.88 euros\nRegistered office: 50, rue de Dijon, 21121 Daix, France\nDijon Trade and Companies Register 537 530 255\nINTERIM FINANCIAL REPORT\nFOR THE SIX MONTHS ENDED JUNE 30, 2024\nWS0101.38343396.1\nTable of contents\n1. Interim Financial Report ............................................................................. 4\n1.1. General overview of activities ..................................................................................... 4\n1.2. Significant events in the first half of 2024 .................................................................. 6\n1.3. Recent events and prospects ........................................................................................ 9\n1.4. Risk factors ................................................................................................................ 11\n1.5. Earnings analysis ....................................................................................................... 14\n1.6. Analysis of the financial situation ............................................................................. 19\n2. Cash flow and equity .................................................................................. 22\n2.1. Cash and cash equivalents ......................................................................................... 22\n2.2. Cash flow analysis ..................................................................................................... 24\n2.3. Anticipated sources of funds ..................................................................................... 27\n3. Unaudited interim condensed consolidated financial statements .......... 28\n3.1. Statutory Auditors’ Review Report on the Half-yearly Financial Information ......... 28\n3.2. Interim Condensed Consolidated financial statement ............................................... 30\n4. Other information ....................................................................................... 70\n4.1. Table of delegations ................................................................................................... 70\nWS0101.38343396.1\nDefinitions\nIn this half-yearly report (the “Interim Financial Report”), and unless otherwise specified, the terms\nInventiva or the Company are taken to mean the company Inventiva S.A. with its registered office at\n50, rue de Dijon, 21121 Daix, France, and which is listed with the Dijon Trade and Companies Register\nunder number 537 530 255 and its subsidiary, 100% owned, Inventiva Inc. with its registered office at\n10-34 44th Dr, Long Island City, 11101 New York, USA, created in January 2021.\nCertain terms used in this Interim Financial Report are defined in the Company’s annual report on Form\n20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on\nApril 3, 2024 (“the Annual Report”).\nSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\nThis document contains forward-looking statements within the meaning of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are\nbased on our management’s beliefs and assumptions and on information currently available to our\nmanagement. All statements other than present and historical facts and conditions contained in this\ndocument, including statements regarding our future results of operations and financial positions,\nbusiness strategy, plans and our objectives for future operations, are forward-looking statements. When\nused in this document, the words “anticipate,” “believe,” “can,” “continue”, “could,” “estimate,”\n“expect,” “goal”, “intend,” “is designed to,” “may,” “might,” “plan,” “will,” “would,” “potential,”\n“predict,” “objective,” “should,” “target”, or the negative of these and similar expressions identify\nforward-looking statements. Forward-looking statements include, but are not limited to, statements\nabout:\n• our plans to develop and commercialize our product candidates;\n• the timing of, design, duration, recruitment costs, screening and enrollment of our planned and\nongoing clinical trials;\n• clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from our planned and ongoing clinical trials;\n• the timing of any planned investigational new drug (“IND”) application or new drug\napplication (“NDA”);\n• our plans to research, develop and commercialize our current and future product candidates;\n• expectations with respect to the benefits of our existing and future partnerships, including our\npartnerships with Chia Tai Tianqing Pharmaceutical Group, Co., LTD. (“CTTQ”), and with\nHepalys Pharma, Inc. (“Hepalys”), on the clinical development, commercialization and\nregulatory approvals of our product candidates, including potential acceleration of the\ncommercialization of lanifibranor in Mainland China, Hong Kong Special Administrative\nRegion, Macau Special Administrative Region, Taiwan, Japan and South Korea, if approved;\n• our ability to successfully cooperate with existing partners or enter into new partnerships, and\nto fulfill our obligations under any such partnership agreements;\n• the potential for further development of odiparcil;\n• our ability to potentially enter into a partnership with a third party for the development and\ncommercialization of odiparcil;\n• the clinical utility, potential benefits and market acceptance of our product candidates;\n• our commercialization, marketing and manufacturing capabilities and strategy;\n• our ability to identify additional products or product candidates with significant commercial\npotential;\nWS0101.38343396.11\n• our expectations related to the sufficiency of our capital resources and our ability to continue\nas a going concern, including our expectations with respect to raising of additional funds,\nexecuting any potential transactions and achievement of milestones and operating targets;\n• the expected use of proceeds from any financing transactions, including capital increases,\nroyalty certificates and debt financing, and our ability to fulfill our obligations under any such\nagreements, including our ability to repay debt in a timely manner, or at all;\n• expectations with respect to the Tranche 2 and Tranche 3 Events (as defined below), and the\nexercise of the warrants and other rights to subscribe to ordinary shares by investors,\n• developments and projections relating to our competitors and our industry;\n• the impact of government laws and regulations;\n• the effects of the epidemics or pandemics on our business and, operations and clinical\ndevelopment timelines and plans;\n• our intellectual property position;\n• our estimate regarding future revenue, expenses, capital requirements and need for additional\nfinancing;\n• unfavorable conditions in our industry, the global economy or global supply chain, including\nfinancial and credit market fluctuations, international trade relations, political turmoil, natural\ncatastrophes, warfare (such as the conflict involving Russia and Ukraine, the state of war\nbetween Israel and Hamas and the related risk of a larger conflict), and terrorist attacks; and\n• other risks and uncertainties, including those listed in our Annual Report and Section 1.4\nhereof under the caption “Risk Factors.”\nWe encourage you to read and carefully consider all of the risk factors disclosed in “Item 3.D—Risk\nFactors” of our Annual Report and Section 1.4 hereof, for a discussionof the risks and uncertainties\nmaterial to our business, including important factors that may cause our actual results to differ materially\nfrom those expressed or implied by our forward-looking statements. As a result of these factors, we\ncannot assure you that the forward-looking statements in this document will prove to be accurate.\nFurthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these\nstatements as a representation or warranty by us or any other person that we will achieve our objectives\nand plans in any specified time frame or at all. These forward-looking statements represent our plans,\nobjectives, estimates, expectations and intentions only as of the date of this filing. We undertake no\nobligation to publicly update any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law.\nYou should read this document and the documents that we reference herein completely and with the\nunderstanding that our actual future results may be materially different from what we expect. We qualify\nall of our forward-looking statements by these cautionary statements.\nMarket and competitive position\nThis Interim Financial Report also contains information about the Company’s activities and the markets\non which it operates. This information comes from studies or surveys carried out internally or externally.\nOther information contained in this Interim Financial Report is available to the general public. The\nCompany considers that all of this information is reliable, but it has not been verified by an independent\nexpert. The Company cannot guarantee that a third party using different methods to gather, analyze or\ncalculate market data would obtain the same results.\nRounding of figures\nWS0101.38343396.12\nCertain figures (including data expressed in thousands or millions of euros or dollars) and the\npercentages presented in this Interim Financial Report have been rounded up or down. Accordingly,\ntotals given may vary slightly from those obtained by adding the exact (unrounded) values of those same\nfigures.\nAbbreviations\nCertain figures are given in thousands or millions of euros and are indicated as € thousand or € million\nrespectively in this Interim Financial Report.\nWS0101.38343396.13\n1. Interim Financial Report\n1.1. General overview of activities\nInventiva S.A. is a public limited company registered and domiciled in France. Its head office is located\nat 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include\nInventiva S.A. and its subsidiary Inventiva Inc., created in January 2021.\nInventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since\nFebruary 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary\nshare, have been listed on the Nasdaq Global Market since July 2020.\nInventiva is a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),\nalso known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet\nmedical need.\nLeveraging its expertise and experience in the domain of compounds targeting nuclear receptors,\ntranscription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the\ntreatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.\nLanifibranor, its lead product candidate, is being developed for the treatment of patients with\nMASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive\ntopline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with\nMASH/NASH and announced that the U.S. Food and Drug Administration (\"FDA\") had granted the\nCompany the status of Breakthrough Therapy and Fast Track designation. The Company initiated the\npivotal Phase III trial of lanifibranor in MASH/NASH (“NATiV3”) in the second half of 2021. In March\n2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor\nand empagliflozin in patients with MASH/NASH and Type 2 Diabetes (“DT2”) (“LEGEND”).\nIn the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a\nhigher than originally projected screen failure rate resulting in slower than anticipated enrollment rate.\nIn addition, the Company experienced slower than predicted site activation, screening and enrollment\ndue to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the\nCompany was unable to conduct clinical trial activities at sites originally located in Ukraine due to the\nwar between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in\nUkraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the\nmarkets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could\naffect the Company.\nIn January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially\naccelerate enrollment and identified additional sites to help compensate for the inability to use sites in\nUkraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks\ninstead of up to seven years, reduces the number of biopsies from three to two and included a 48-week\nactive treatment extension study. The Company expects that the changes to the clinical development\nplan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and\ncompensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of\nbiopsies and the trial duration, eventually offering all patients in the trial access to treatment and\npotentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to\npatients with NASH and compensated cirrhosis.\n4\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nIn September 2022, the Company entered into a license and collaboration agreement with Chia Tai\nTianqing Pharmaceutical (Guangzhou), Co., LTD (“CTTQ”), a Sino Biopharm group company, to\ndevelop and commercialize, subject to regulatory approval, lanifibranor for the treatment of\nMASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative\nRegion, Macau Special Administrative Region and Taiwan (“CTTQ Territory”). In May 2023, the\nCompany announced that CTTQ had received the Investigational New Drug (“IND”) approval from the\nChinese National Medicine Products Administration (“NMPA”) allowing CTTQ to initiate the clinical\ndevelopment of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing\nNATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of\nits participation in the Company’s NATiV3 Phase III global clinical trials, pursuant to the terms of the\nagreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory.\nOn September 20,2023, the Company and Hepalys Pharma, Inc. (“Hepalys”) announced an exclusive\nlicensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the “Hepalys\nLicense Agreement”). Hepalys is a new company created by Catalys Pacific Fund II, LP (“Catalys”).\nUnder the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to\n€9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical,\nregulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to\nlow twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval.\nIn parallel with the Hepalys License Agreement, the Company entered into an option agreement with\nCatalys to acquire 30% of the shares of Hepalys (the “Catalys Option Agreement”). The Company\nexercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate\nexercise price of ¥300 (equal to €1.90). Also on September 20, 2023, the Company entered into a\nshareholders agreement with Catalys and Hepalys (the “Catalys Shareholders Agreement”). Pursuant to\nthe Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of\nHepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal\nif Hepalys receives an offer for the license or rights related to lanifibranor.\nIn the first quarter of 2024, following a routine visit during Company’s NATiV3 clinical trial of\nlanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (“SUSAR”) was\nreported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the Data Monitoring Committee1(“DMC”).\nOn March 7, 2024, the Company announced that screening activities had resumed in American sites\nunder central Institutional Review Board (“IRB”). The impact of the pause on the overall timeline of the\ntrial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate,\nand the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial\nparticipants.\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH /NASH and DT2.\nThe Company expects the first visit of the last patient to be in the fourth quarter of 2024 (versus the first\nquarter of 2024 as previously announced) and to complete randomization in the first half of 2025. Due\nto a delay of around 3 to 5 months in recruitment, the Company is currently targeting the topline results\nfor the second half of 2026 (versus the beginning of the second half of 2026 as previously announced).\n1 A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.\n5\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nIf the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the\nCompany plans to file an application for accelerated approval in the United States and conditional\nauthorization in the European Union for the marketing of lanifibranor.\nThe Company’s pipeline also includes odiparcil, which it was previously developing for the treatment\nof patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. As\nannounced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor.\nBased on feedback from the FDA, the Company believes there is potential for an efficient development\npathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further\ndevelop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership,\nlicense or other transaction.\n1.2. Significant events in the first half of 2024\n1.2.1. Operations and product portfolio\nTreatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024\nOn February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in\nliver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient\nhad been without clinical symptoms throughout the period of observation. This event has been assessed\nas a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial\nparticipants have also been reported in the trial. The Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients already enrolled\nin the Phase III NATiV3 trial continued to receive treatment under the new liver monitoring schedule\nrecommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.\nOn March 7, 2024, the Company received approval from the central IRB overseeing clinical research in\nthe United States to resume screening activities in its sites. This was an important milestone as 152 sites\nof the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60%\nof the patients in the main cohort.\nDue to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit\nof the last patient for the fourth quarter of 2024, completion of randomization in the first half of 2025\nand the main results are expected for the second half of 2026 (versus the beginning of the second half\nof 2026 as previously disclosed).\nThe Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and\nempagliflozin in patients with MASH/NASH and T2D\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and type 2 diabetes.\nThe LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled\nPhase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the\nSGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D.\nThe trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for\nthe combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm. The diagnosis of\n6\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nnon-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-\ninvasive methods including diagnostic methods including imaging. As planned per protocol, the interim\nanalysis was done once half of the 63 planned randomized patients with MASH completed the 24-week\ntreatment period or prematurely discontinued from treatment.\nThe study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c\n(HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily)\nor in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26%\nobserved in the placebo arm.\nThe study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-\nPDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -\n38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone\nor in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their\nhepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically\nsignificant effect on several secondary and exploratory endpoints, including liver enzymes (alanine\naminotransferase (“ALT”) and aspartate aminotransferase (“AST”)), insulin resistance (HOMA-IR),\nHDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1)\nassessed by LiverMultiScan®) were assessed for the first time with lanifibranor and showed a significant\neffect with lanifibranor alone and in combination with empagliflozin.\nThe study also demonstrated that patients treated with lanifibranor in combination with empagliflozin\nmaintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically\nhealthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore,\nthese results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and\nsubcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with\nempagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.\nThis result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose\ntissue.\nThe treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily\nfor 24 weeks appears to be well tolerated, with no safety concerns reported.\nGiven that the primary endpoint of LEGEND was met, and statistically significant results were achieved\non several key additional markers, the Company has decided to stop the recruitment as defined per\nprotocol. More details on these results are expected to be presented in upcoming scientific conferences\nand submitted for publication.\nAdditional results from NATIVE Phase IIb clinical trial\nOn May 13, 2024, the Company announced the publication in Nature Communications of additional\nresults from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic\nhealth in patients with MASH/NASH treated with lanifibranor.\nImprovements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism\n(triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG)\nlevels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.\nRecommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in\npatients with MASH/NASH\n7\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nOn May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the\nNATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.\nThe DMC recommended to continue the clinical trial without further modification of the protocol, as\namended immediately after learning about the SUSAR based on the pre-planned review of safety data.\nThe recommendation was based on the unblinded review by the DMC of safety data from more than\n900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients\nthat have been treated for more than 48 and 72 weeks, respectively.\nThe patient who experienced the adverse event of increased liver test results, which was reported as a\nSUSAR, had been without clinical symptoms throughout the period of observation and has fully\nrecovered.\n1.2.2. Other events\nThe Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B\nOn January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment\nBank (“EIB”) and such warrants (the “EIB Tranche B Warrants”), in accordance with the terms of the\n6th resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-\n138 of the French Commercial Code, as a condition to the drawdown of the second tranche of €25.0\nmillion (“Tranche B”) under the finance contract between the Company and EIB (“Finance Contract”).\nThe 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the\nCompany's then-outstanding share capital. If all the warrants issued to the EIB in connection with\ndrawdown of the first tranche of €25.0 million (“Tranche A”) under the Finance Contract (the “EIB\nTranche A Warrants” and, together with the EIB Tranche B Warrants, the “EIB Warrants”) and the EIB\nTranche B Warrants were exercised, the EIB would hold approximately 11.3% of the Company's share\ncapital as of June 30, 2024.\nThe exercise price of the EIB Tranche B Warrants is equal to €3.95 and corresponds to 95% of the\nvolume-weighted average price of the Company's shares on the regulated market of Euronext Paris\nduring the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).\nThe EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the\nearliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control\nevent, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the\nFinance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within\nthe twelve-year period.\nEIB has a put option which may require the Company to repurchase all or part of the unexercised EIB\nTranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn\nunder the Finance Contract) under certain circumstances (for example, in the event of a change of control\nor on the maturity date of Tranche A or in the event of default). The Company (or a substitute third\nparty) has a call option to require EIB to sell all shares and other securities of the Company, including\nthe EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company\nhas a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party,\nsubject to certain terms and conditions.\n8\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nOn the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB\nTranche B Warrants at a price of €3.95 per new share, the Company could potentially receive gross\nproceeds of up to €12,421,383. There is no assurance that EIB will exercise any or all of the EIB\nWarrants or that the Company will receive any proceeds from the exercise of the warrants.\nThe exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of EIB Tranche B\nWarrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche\nA Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.\nThe Company drew down Tranche B of €25 million under Finance Contract with EIB\nOn January 18, 2024, the Company drew down Tranche B under the Finance Contract for an amount of\n€25 million.\nAfter the drawdown of Tranche A in December 2022, the Company had an option to access further €25\nmillion tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the\nachievement of those conditions, the Company decided to draw on Tranche B. The Company intends to\nuse the proceeds to fund part of NATiV3.\nTranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in\nJanuary 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among\nother conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of\nthe Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million that\nwas a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company,\nor through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with\nan upfront payment of at least €10 million, (iv) operational criteria based on patient enrollment and\nnumber of sites activated in the Company’s NATiV3 Phase III clinical trial of lanifibranor in patients\nwith MASH/NASH and (v) the Company issuing EIB Tranche B Warrants (see above - The Company\nissued 3,144,654 warrants to European Investment Bank in connection with the drawdown of Tranche\nB) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (warrants) at inception and the borrowing costs.\nOn June 12, 2024, the Company and EIB amended the warrant to modify the rules for adjusting the\nexercise ratios of the EIB Warrants.\n1.3. Recent events and prospects\n1.3.1. Operations and product portfolio\nUpdate on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.\nOn July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating\nlanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both\ncohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the\nexploratory cohort of NATiV3.\nThe first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024,\nand topline results are expected in the second half of 2026. The Company strengthened its patent\nportfolio with a new patent in Japan that provides intellectual property rights on the potential use of\n9\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nlanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term\nadjustments or extensions that may provide additional protection until 2043.\n1.3.2. Other events\nIssuance of royalty certificates\nOn July 18, 2024, the Company announced the issuance of 201 royalty certificates (“2024 Royalty\nCertificates”) for aggregate gross proceeds of approximately €20.1 million. Royalties amount to 3% on\nfuture net sales of lanifibranor in the United States of America, the European Union and the United\nKingdom over a 14-year term.\nApproving of patent application\nOn July 25, 2024 the Company announces that the Japan Patent Office (“JPO”) approved Inventiva’s\npatent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients\nwith cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent\nterm adjustments or extensions that may provide additional protection.\nFinancing in three tranches for a maximum amount of €348 million\nThe Company announced the following financing on 14 October 2024 structured in three tranches:\n(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific\ncategory of beneficiaries (“à catégorie de personnes”), of new ordinary shares at a gross value, including\nissuance premium, of €94.1 million through the issuance of 34,600,507 new ordinary shares, par value\n€0.01 per share (each, a “T1 New Shares”), and 35,399,481 prefunded warrants to subscribe for shares\nin the Company at a price outstanding of €0.01 per new ordinary share, each giving the right, in the\nevent of exercise, to one new ordinary share (the “T1 BSAs”);\n(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”), of new ordinary shares, par\nvalue €0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each,\na “T1bis New Shares”), for a total amount of €21.4 million (excluding exercise of pre-funded warrants);\n(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”) subject to operational conditions\nto be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before\nDecember 16, 2024, (or prefunded warrants) to which share warrants (the “ABSAs”) are attached for a\ntotal amount of €116,000,000. Each ABSA will consist of a number of new ordinary shares with a par\nvalue of €0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a\n“T2 New Share”) to which will be attached a number warrants exercisable at an exercise price of €1.50\n(each, a “T3 BSA”) allowing the subscription of a number of new ordinary shares of the Company for\na maximum total amount of €116,000,000.\nThe subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024,\nand the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October\n17, 2024, subject to the absence of any material adverse event between the signing of the agreements\nand the settlement-delivery of the T1 New Shares and the T1 BSA.\nAmendment to the exclusive license and collaboration agreement with CTTQ\nOn October 11, 2024, the Company has entered into an amendment (the “Amendment”) to the exclusive\nlicense and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (“CTTQ”),\ndated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription\ncommitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three\n10\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\ntranches, for a total gross amount of at least €180,000,000 (the “Fund Raising”), CTTQ shall pay to the\nCompany (i) $10,000, 000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants\nin the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000\nin the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon\npublication by the Company of the pivotal data announcing that the primary endpoint or one of the two\nkey secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met.\nUnder the terms of the Amendment, the total amount of potential clinical, regulatory and commercial\nmilestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been\nreduced to a low figure.\n1.4. Risk factors\nThe Company’s business faces significant risks. You should carefully consider all of the information set\nforth in this document and in the Company’s other filings with the United States Securities and Exchange\nCommission, or the SEC, including the risk factors which the Company faces and which are faced by\nthe Company’s industry described in Chapter 2 of the Company’s 2023 Universal Registration\nDocument Part I, Item 1A. “ Risk Factors” of the Company’s Annual Report on Form 20-F for the fiscal\nyear ended December 31, 2023, in addition to the following risk factors. Our business, financial\ncondition or results of operations could be materially adversely affected by any of these risks.\nPlease refer to chapter 2.1 of the 2023 Universal Registration Document and as amended in Section 5\nof the amendment to the universal document as filed with the AMF under number D.24-0227-A01 on\nOctober 14, 2024 (the \"Amendment to the 2023 Universal Registration Document \"), which are\nincorporated herein by reference.\nThe risk factor in the 2023 Universal Registration Document amended in the context of the Amendment\nto the 2023 Universal Registration Document is as follows:\nLiquidity risk: the Company believes that it will be able to finance its activities until the end of the\nsecond half of 2025, and there is doubt regarding our ability to continue as a going concern.\nAs of 30 June 2024, the Company had cash and cash equivalents of EUR 10.1 million, compared to\n€26.9 million, and €9.0 million of long-term deposit2 as of December 31, 2023.\nAs of the date of this document, the Company believes, taking into account its current cost structure and\nforecast expenditure commitments, and the events after the reporting period presented in Note 6.4 –\nEvents after the reporting period of the section 3.2 – Interim Condensed Consolidated financial\nstatements as of June 30, 2024, mainly the issue of royalty certificates and the T1 capital increase, that\nit will have sufficient net working capital to meet its current obligations until the end of the second half\nof 2025.\nAccordingly, our current cash position will not be sufficient to cover operating needs for at least the\nnext 12 months.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\n2 The long-term deposit had a two year-term, were accessible prior to the expiration of the term with a notice\nperiod of 31 days and were considered as liquid by the Company.\n11\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nthe reporting period of the section 3.2 – Interim Condensed Consolidated financial statements as of\nJune 30, 2024.\nIn order to finance its activities, the Company needs to raise additional funds, and is currently actively\nreviewing potential financing (including debt, equity and equity-linked or other instruments) and\nstrategic options (for more on complementary financing, see section 2.3 of this document).\nThe Company may have based itself on incorrect assumptions and may have to use its resources sooner\nthan expected. Although the Company is actively discussing financial and strategic options for financing\nits activities beyond its cash horizon, notably with its financial partners and financial advisors, the\nCompany cannot guarantee that it will be able to obtain the necessary financing, through any of the\nforegoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions,\non a timely basis, or at all. If we are unable to obtain funding on a timely basis, we may be required to\nsignificantly curtail, delay or discontinue one or more of our research or development programs or the\ncommercialization of any approved product or be unable to expand our operations or otherwise\ncapitalize on our business opportunities, as desired, which could impair our growth prospects. The\nperception that we may be unable to continue as a going concern may impede our ability to pursue any\npotential strategic opportunities or operate our business.\nUltimately, if we are unable to continue as a going concern, we may have to liquidate our assets and\nmay receive less than the value at which those assets are carried on our financial statements.\nRisks associated with seeking and arranging financing and risks associated with uncertain\nadditional financing\nThe development of the Company's programs has required, and will continue to require, significant\nfinancial investment, particularly for Phase III of lanifibranor, its YAP/TEAD program and the\ncontinued development of a portfolio of products at the preclinical stage. The Company will require\nadditional funding as its clinical programs reach advanced stages of development, in particular to\ncomplete its clinical trials and, if successful, to manufacture and market the Company's drug candidates.\nTo meet this financing requirement, the Company needs to raise additional funds, and continues to\nactively explore financing options (including debt, equity-linked or other instruments) and strategic\noptions.\nHowever, taking on additional debt could lead to an increase in financial expenses and could also result\nin the Company having to comply with certain additional covenants, such as limitations on the\nCompany's ability to take on additional debt or to carry out certain transactions.\nSimilarly, the conclusion of a financing agreement could be accompanied by undertakings limiting the\nCompany's ability to acquire or grant intellectual property rights, particularly if it has to provide security\nand accept other operating restrictions that could have a negative impact on the Company's ability to\ncontinue its business.\nIt should be noted that additional financing, particularly in the form of equity instruments, could result\nin significant dilution. In addition, financing in the form of financial debt would worsen the Company's\nfinancial structure. The need for and pursuit of additional financing could also divert the Company's\nmanagement from its day-to-day activities, which could affect the future development and marketing of\nits drug candidates.\nThe Company will also need additional funds to consider the pre-commercialisation and subsequent\ncommercialisation of its drug candidate, or to make new investments that are unknown at this time or\ndifficult to assess because they relate to projects in development. It is difficult to anticipate precisely all\nthe costs associated with the preclinical and clinical development of the Company's products while some\nof its products are still at an early stage of development. The amount and timing of future additional\n12\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nfunding requirements will depend in particular on the Company's ability to achieve milestones under its\nexisting collaboration agreements, but also on the operating conditions associated with the Transaction\nand its ability to enter into new agreements, on market acceptance of any approved drug candidates, on\nthe Company's need for and ability to recruit additional management and scientific personnel, and on\nthe Company's ability to implement additional internal systems and infrastructure, including in its\nfinancial and IT management.\nIf the Company is unable to find such additional financing on acceptable terms or in a timely manner,\nparticularly given the generally unfavorable environment for financing companies in the biotechnology\nsector, its business, organisation, results and development could be adversely affected, and it could be\nforced to delay or halt one or more of its research programs, the development or marketing of any\napproved products, not be able to expand its activities or take advantage of its commercial opportunities\nas desired. The Company may also have to implement a plan to reduce and manage its fixed costs or\nenter into new collaboration agreements that may be less favorable to it than those it could have obtained\nin a different context, which could harm its growth prospects or commercial activities, as set out in the\nliquidity risk factor above.\n13\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5. Earnings analysis\n1.5.1. Revenue and other income\nOperating income Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nRevenue 41 1,901\nTotal revenue 41 1,901\nTax credits 2,630 3,631\nSubsidies 5 3\nOther 58 1,087\nOther income 2,693 4,721\nTotal revenue and other income 2,734 6,622\nRevenue\nThe Company recorded minimal revenues in the first half of 2024, as compared to €1.9 million for the\nsame period in 2023. The €1.9 million revenue as of June 30, 2023, was mainly related to the milestone\npayment the Company invoiced to CTTQ for $2.1 million on May 22, 2023, following the IND approval\nfrom the NMPA.\nOther income\nOther income decreased by €2.0 million, or 43%, compared to the first half of 2023. Other income are\nmainly composed of research tax credits. The Research Tax Credit (\"CIR\") generated over the first six\nmonths of the fiscal year amounts to €2.7 million in 2024 as in 2023.\nAs of June 30, 2023, other operating income are composed of:\n• The R&D Tax Research Credit from Inventiva Inc amounting to €1.0 million, compared to €0.8\nmillion in tax income as of June 30, 2024;\n• The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to €0.3 million as\nof June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3,\nand the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to\n€0.7 million, compared to €2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as\na reduction in research and development expenses.\n1.5.2. Operating expenses\nOperating expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nResearch and development expenses (46,822) (54,062)\nMarketing – Business development expenses (598) (705)\nGeneral and administrative expenses (7,701) (6,812)\nTotal operating expenses (55,122) (61,580)\n14\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of June 30, 2024, the decrease in operating expenses of €6.5 million, or 10%, compared to the first\nhalf of 2023 is mainly driven by the decrease in research and development expenses of €7.2 million.\n1.5.2.1.Research and development expenses\nResearch and development expenses for the six months ended June 30, 2024 break down as follows:\nResearch and development expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nStudies (34,073) (42,847)\nPersonnel costs (7,637) (7,065)\nDepreciation, amortization, and provisions (1,732) (1,061)\nDisposables (887) (943)\nPatents (643) (257)\nMaintenance (526) (459)\nEnergy and liquids (447) (479)\nIT systems (405) (440)\nFees (118) (61)\nOther research and development costs (352) (450)\nTotal research and development expenses (46,822) (54,062)\nThe decrease in R&D expenses is primarily due to the temporary pause in the recruitment of the patients\nin the NATiV3 Phase III clinical trial of lanifibranor in MASH/NASH following the SUSAR reported\nin the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND trial with\nlanifibranor and empagliflozin in patients with MASH/NASH and DT2. R&D expenses are expected to\nincrease in the second half of 2024 following the effective restart of patient recruitment in NATiV3, as\nwell as the planned clinical development activities and related costs associated with NATiV3 for the\nsecond half of 2024 including costs related to the SUSAR protocol change and the reactivation of sites\nand patient recruitment. The €7.2 million (13%) decrease in research and development expenses as\ncompared to the six months ended June 30, 2023, was primarily driven by:\n- a €8.8 million decrease in spending on studies in research and development for lanifibranor,\nmainly for the NATiV3 Phase III trial of lanifibranor in patients with MASH/NASH and Phase\nIIa LEGEND trial of lanifibranor in combination with empagliflozin; and\n- a €0.7 million increase in depreciation and amortization costs mainly related to the right of use\nof Fibroscans equipment; and\n- a €0.6 million increase in personnel costs mainly due to salary increases and bonuses.\nThe main expenses incurred in connection with the Company’s research and development activities in\nthe six months ended June 30, 2024, are described below:\n Lanifibranor\nClinical trial-related expenses for lanifibranor development decreased by €7.1 million compared to the\nfirst half of 2023, totaling €34.8 million in the first half of 2024.\nCosts relating to lanifibranor’s development in the first half of 2024 can be broken down into two main\ncategories:\n(i) activities related to clinical studies amounted to €28.5 million, mainly including the NATiV3\nPhase III trial in MASH/NASH, the LEGEND Phase IIa trial in patients with MASH/NASH\nand T2D, and Phase I studies as detailed below; and\n15\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n(ii) development activities amounted to €6.2 million, mainly including pharmaceutical development\nand non-clinical, preclinical pharmacology and toxicology trials in animals and the activities\nrelated to regulatory consulting.\nCosts linked to clinical trial activities included the following developments over the six months ended\nJune 30, 2024:\nTreatments for MASH/NASH\n- Costs related to the NATiV3 Phase III trial related to the qualification and opening of\ninvestigator sites, regulatory submissions and patient recruitments, leasing of Fibroscans\nequipment, the expenses related to packaging campaigns for the treatment units, costs related to\nbiopsy slides reading and consulting including committees.\nLEGEND Phase IIa trial of lanifibranor in combination with empagliflozin in patients with\nMASH/NASH and T2D\n- The completion of the LEGEND Phase IIa trial with regulatory submissions, the monitoring of\npatients recruited into the study, and generation of the results of the Interim Analysis carried out\nin the first quarter of 2024. Other expenses for the period include packaging and distribution\ncosts for treatment units, and pharmacokinetics analysis.\nPhase I studies\n- The completion of the Renal Impairment study, with CRO expenses related to statistical\nanalyses and drafting of the Clinical Study Report (“CSR”); and\n- Data Management activities and the preparation of the CSR for the Hepatic Impairment study,\nas well as the bioanalysis and pharmacokinetics analysis expenses.\n YAP-TEAD\nTrial-related expenses for the YAP-TEAD project increased by €0.2 million compared to the first half\nof 2023, totaling €0.6 million in the first half of 2024.\nCosts incurred are mainly related to chemistry studies, biophysic and bio pharmaco study.\n1.5.2.2.Marketing and business development expenses\nMarketing and business development expenses break down as follows:\nFor the first six months ended June 30, 2024, and June 30, 2023\nMarketing – Business development Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nPersonnel costs (153) (126)\nIT systems (6) (9)\nFees (2) -\nOther operating expenses (437) (570)\nTotal marketing and business development\n(598) (705)\nexpenses\nMarketing and business development expenses for the first half of 2024 decreased by €0.1 million\ncompared to the first half of 2023 mainly due to the decrease by €0.1 million of fees related to the\nbusiness development.\n16\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5.2.3.General and administrative expenses\nGeneral and administrative expenses are mainly composed of administrative staff costs, support costs\n(mainly consisting of security costs, taxes and various rentals), non-scientific IT costs and consulting\nfees.\nGeneral and administrative expenses break down as follows:\nFor the first six months ended June 30, 2024, and June 30, 2023\nGeneral and administrative expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nConsulting fees (2,675) (1,884)\nPersonnel costs (2,600) (2,347)\nInsurances (921) (1,121)\nSupport costs (including taxes) (375) (343)\nDepreciation, amortization and provisions (122) (104)\nIT systems (33) (50)\nOther general and administrative expenses (975) (964)\nTotal general and administrative expenses (7,701) (6,812)\nGeneral and administrative expenses for the first half of 2024 increased by €0.9 million compared to the\nfirst half of 2023 mainly due to the increase in consulting fees by €0.8 million related to the double\nlisting, personnel costs by €0.3 million and the decrease of insurances expenses by €0.2 million.\n1.5.3. Other operating income and expenses\nOther operating income and expenses break down as follows:\nSix months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nOther operating income 160 -\nOther operating expenses (22) (44)\nOther operating income and expenses 138 (44)\nFor the first half of 2024, other operating income and expenses are mainly due to disposal of assets and\ntransaction costs.\nFor the first half of 2023, other operating income and expenses are exclusively due to transaction costs.\n17\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5.4. Financial income and expenses\nFinancial income and expenses break down as follows:\nFinancial income and expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nIncome from cash equivalents 430 564\nForeign exchange gains 157 187\nFair value gains 8,506 1,623\nTotal financial income 9,093 2,373\nInterest cost (5,218) (1,941)\nForeign exchange losses (323) (683)\nOther financial expenses (46) (23)\nTotal financial expenses (5,586) (2,646)\nNet financial income 3,507 (273)\nNet financial income for the first six months of 2024 increased by €3.8 million compared to the first half\nof 2023. This increase is mainly due to:\n- fair value gains by €8.5 million related to change in fair value of:\nthe EIB Tranche A Warrants; as of June 30, 2024, the fair value amounted to €6.7\no\nmillion, a decrease by €3.5 million since December 31, 2023 (see note 4.9 –\nShareholders’ equity of the Unaudited interim condensed consolidated financial\nstatements as of June 30, 2024);\nthe EIB Tranche B Warrants since the initiation, as of June 30, 2024, the fair value\no\namounted to €6.8 million, a decrease by €5.0 million since the grant date (see note 4.9\n– Shareholders’ equity of the Unaudited interim condensed consolidated financial\nstatements as of June 30, 2024)\n- increase in interest cost for the first six months of 2024 by €3.3 million compared to June 30,\n2023 mainly due to:\nThe increase in interest expenses on the EIB loan by €2.3 million, , with (i) 2.1 million\no\neuros in interest expense for Tranche A over the first six months of 2024 compared with\n1.7 million euros over the first six months of 2023, an increase of 0.4 million euros, and\n(ii) 1.9 million euros for Tranche B over the first six months of 2024 (and an increase\nof the same amount, Tranche B having been subscribed in 2024) ;\nand interest on 2023 royalty certificates of 0.9 million euros in the first six months of\no\n2024 (compared with 0 in the first six months of 2023, as the royalty certificates were\nissued in the last six months of 2023).\n- foreign exchange result of the first six months of 2024 as a result of the unfavorable position of\nthe foreign currency term deposit contracts at the maturity date for €0.3 million.\n1.5.5. Income tax\nIn accordance with IAS 34, the income tax recognized in the financial statements for each interim period\nis adjusted based on a best estimate calculated by applying the expected weighted average tax rate for\nthe entire year.\nCurrent taxes\nAs the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered\nunlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December\n18\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A. However, a €119\nthousand tax expense was recorded related to Inventiva Inc (mainly due to the bonuses).\nDeferred taxes\nInventiva S.A. recorded tax losses in the first half of 2024. As recovery of these losses in future periods\nis considered unlikely due to the uncertainty inherent to the Company’s activity, no deferred tax assets\nwere recognized on this basis on June 30, 2024.\n1.5.6. Net loss for the period\nThe Company recorded a net loss of €49.0 million in the first half of 2024 versus a net loss of €55.3\nmillion in the first half of 2023, which was a decrease in net loss of €6.2 million year over year.\n1.6. Analysis of the financial situation\n1.6.1. Non-current assets\nNon-current assets mainly consist of:\n- other non-current assets mainly comprising term accounts with progressive interest rates.\n- property, plant, and equipment, mainly comprising assets acquired on the incorporation of the\nCompany and the right of use from Fibroscans leasing.\n- investments accounted for using equity method related to investment in Hepalys; and\n- intangible assets, mainly comprising the compound and software library.\nNon-current assets\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nIntangible assets 451 541\nProperty, plant and equipment 7,979 9,126\nDeferred tax assets 210 225\nInvestments accounted for using the equity method 1,131 1,425\nOther non-current assets 1,047 10,055\nTotal non-current assets 10,818 21,372\nNon-current assets decreased by €10.6 million (49%) compared to December 31, 2023. This was mainly\nattributable to:\n- the decrease by €9.0 million of long-term deposit accounts with more than a year of maturity,\nrelated to the early closure of a €9 million two-year deposit forward contract (see note 4.5 –\nOther non-current assets of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024); and\n- the decrease in property, plant and equipment mainly due to the depreciation of €1.2 million of\nthe right of use related to Fibroscan.\n1.6.2. Current assets\n19\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nCurrent assets\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nInventories 393 417\nTrade receivables 809 3,807\nTax receivables 2,704 5,352\nOther current assets 14,554 11,696\nCash and cash equivalents 10,147 26,918\nTotal current assets 28,608 48,189\nCurrent assets decreased by €19.6 million (41%) compared to December 31, 2023. This was mainly\nattributable to the €16.8 million (62%) decrease in cash and cash equivalents and the €3.0 million\ndecrease in trade receivables, both related to the Company’s activity (see section 2 Cash flow and\nequity).\nAs of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the\namount of €2.7 million corresponding to the 2024 CIR as of June 30, 2024.\nThe €2.9 million increase in other current assets is mainly due to:\n- an increase in other receivable by €1.8 million including an increase in prepaid expenses by\n€2.4 million mainly related to trial costs incurred under NATiV3 Phase III global trial; and\n- an increase in current accrued income by €0.6 million which included the rebilling to CTTQ of\nspecific costs (see note 4.7 – Trade receivables, tax receivables and other current assets of the\nUnaudited interim condensed consolidated financial statements as of June 30, 2024); and\n- a decrease in sales tax receivable by €1.8 million.\n1.6.3. Shareholders’ equity\nShareholders’ equity\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nShare capital 525 521\nPremiums related to share capital 201,859 201,862\nReserves (232,789) (124,584)\nForeign currency translation reserve 375 596\nNet loss for the period (49,029) (110,426)\nTotal shareholders’ equity (79,060) (32,032)\nOn June 30, 2024, shareholders’ equity decreased by €47.0 million, or 147%, compared to December\n31, 2023. This change is mainly due to the net loss of the first six months of 2024.\nChanges in shareholders’ equity during the first six months of 2024 are described in further detail in\nnote 4.9 – Shareholders’ equity of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024, and in section 2 Cash flow and equity of this document.\n20\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.6.4. Non-current liabilities\nNon-current liabilities\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nLong-term debt 46,846 32,181\nRoyalty certificates liabilities 7,263 6,327\nDerivatives instruments 13,569 10,265\nProvisions for retirement benefit obligations 1,555 1,559\nLong-term contract liabilities 76 70\nOther non-current liabilities 1,032 1,032\nTotal non-current liabilities 70,340 51,434\nThe €18.9 million (37%) increase of non-current liabilities compared to December 31, 2023, is mainly\ndue to the €14.7 million increase of long-term debt (the drawdown of Tranche B subscription), the €3.3\nmillion increase of derivatives instruments (change in fair value) and the €0.9 million increase of 2023\nRoyalty Certificates liabilities related to the interests (see note 4.10 – Financial debt of the Unaudited\ninterim condensed consolidated financial statements as of June 30, 2024).\n1.6.5. Current liabilities\nCurrent liabilities\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nShort-term debt 5,726 5,308\nTrade payables 36,583 37,679\nShort-term contract liabilities 3 6\nOther current liabilities 5,834 7,165\nTotal current liabilities 48,146 50,158\nCurrent liabilities decreased by €2.0 million (4%) for the six months ended June 30, 2024, compared to\nDecember 31, 2023. This change is mainly due to:\n- the €1.1 million decrease in trade payables (see note 4.14 – Trade payables and short-term\ncontract liabilities of the Unaudited interim condensed consolidated financial statements as of\nJune 30, 2024); and\n- the €1.4 million decrease in sales tax payables (including in other current liabilities) (see note\n4.13 – Other current and non-current liabilities of the Unaudited interim condensed\nconsolidated financial statements as of June 30, 2024); and\n- the €0.4 million increase of short-term debt (see note 4.10 – Financial debt of the Unaudited\ninterim condensed consolidated financial statements as of June 30, 2024).\n21\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2. Cash flow and equity\nThis section discusses the Company’s shareholders’ equity, cash position and sources of funding for the\nsix months ended June 30, 2024, and the fiscal year ended December 31, 2023.\n2.1. Cash and cash equivalents\nNet cash and cash equivalents\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nOther cash equivalents(1) 10,273 17,933\nCash at bank and at hand 1,212 8,985\nBank overdrafts (1,338) -\nCash and cash equivalents 10,147 26,918\nSince its inception, the Company has financed its growth through successive capital increases (see\nsection 4.5. Cash flow and equity of the 2023 Universal Registration Document), debt, collaboration and\nlicense agreements and reimbursements of CIR receivables. The Company continues to pursue its\nresearch and development activities for its product candidates.\nAs of June 30, 2024, cash and cash equivalents amounted to €10.1 million compared to €26.9 million\nas of December 31, 2023, with a decrease of €16.8 million (62%), mainly related to the Company’s\nongoing research activities, in particular the NATiV3 Phase III trial with lanifibranor for the treatment\nof MASH/NASH and, to a lesser extent, to the Phase IIa LEGEND trial.\nCash at hand and marketable securities held by the Company are generally invested in short-term deposit\naccounts that are readily convertible into known amounts of cash.\nCash at hand and marketable securities are used to finance the Company’s activities, in particular its\nR&D costs.\nAfter deducting debt, the Company has a net cash deficit as of June 30, 2024, of €1.3 million due to\nbank overdrafts. Borrowings are set out in section 2.1.2 Financing from bank loans below.\nAnalysis of debt\nJune 30, 2024 June 30, 2023\nIn thousands of euros\nShort-term debt 5,726 5,308\nLong-term debt 67,677 48,773\nTotal debt 73,404 54,082\nCash and cash equivalents (10,147) (26,918)\nNet debt 63,256 27,164\nNet debt is a non-standard measure that includes cash and cash equivalents, long-term financial debt,\nlong-term financial debt - derivative instruments, liabilities under royalty certificates, and short-term\nfinancial debt.\nHere are no restrictions on the use of the Company’s cash and cash equivalents resources.\n22\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.1.1. Equity financing\nAs of June 30, 2024, the Company’s share capital increased by €3.6 thousand compared to December\n31, 2023, and set at €524.8 thousand (see note 4.9 – Shareholders’ equity of the Unaudited interim\ncondensed consolidated financial statements as of June 30, 2024).\n2.1.2. Financing from bank loans\nDebt carried\nAnalysis of debt Debt carried on the Proceeds Repayments Fair Value Exchange rate on the\nbalance sheet at Interest capitalize gain/losses\n(+) (-) Variation balance\nIn thousands of euros Dec. 31, 2023 (+/-)\nsheet on\nLease liabilities 6,566 345 (1,173) - - 24 5,762\nPGE SG 2020 (state-guaranteed) 2,096 - (417) - - - 1,679\nPGE BPI France 2020 (state-guaranteed) 2,269 - (413) - - - 1,856\nPGE CA 2020 (state-guaranteed) 2,096 - (347) - - - 1,748\nPPR CA 2022 1,780 - - - - - 1,780\nPPR SG 2022 1,780 - - - - - 1,780\nPGE BPI France 2022 (state-guaranteed) 1,780 - - - - - 1,780\nEIB borowing Tranche A 2022 15,400 - - 3,374 - - 18,774\nEIB borowing Tranche B 2024 - 13,102 - - - - 13,102\nEIB Warrants 2022 and 2024 10,265 11,809 - - (8,506) - 13,569\nRoyalty certificates 6,327 - - 936 - - 7,263\nOther(1) 3,724 - (36) 623 - - 4,311\nTotal Debt 54,082 25,256 (2,386) 4,933 (8,506) 24 73,404\n(1) Corresponding to accrued interests payable on loans.\nOn May 16, 2022, the Company entered into the Finance Contract with EIB for up to €50 million,\ndivided into two tranches of €25 million each. On January 18, 2024, the Company received the\ndisbursement of Tranche B (see Note 1.2. – Significant events in the first half of 2024 of this document\nand note 4.10 – Financial debt of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024).\nThe Company’s loans and debt maturity profile as of June 30, 2024, is as follows:\nJune 30, 2024 Less than one Between 1 and 3 Between 3 and 5 More than five\nIn thousands of euros year years years years\nBank borrowings 3,229 36,164 2,225 890\nDerivatives - 13,569 - -\nOther loans and similar borrowings(1) 42 4,260 - -\nLease liabilities 2,455 3,306 - -\nRoyalty certificates liabilities - - - 7,263\nTotal Debt 5,726 57,299 2,225 8,153\n(1) Including accrued interests payable on loans.\n2.1.3. Financing from Research Tax Credits\nDue to its status as a European small and medium-sized enterprise (“SME”), the Company receives\npayment for research tax credits granted in the previous period. Consequently, cash proceeds from\nresearch tax credits in a given period correspond to the amount of credits calculated on eligible\nexpenditure for the previous period.\nAs of June 30, 2024, Tax credits related to the 2024 CIR are set at €2.7 million. CIR tax credit amounted\nto €5.3 million for the year ended December 31, 2023.\n23\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nResearch tax credits during the six months ended June 30, 2024, and June 30, 2023 were as follows:\nFinancing from research tax credits\nIn thousands of euros June 30, 2024 June 30, 2023\nIncome statement impact of research tax credits 2,630 3,631\nCash flow impact of research tax credits 5,333 5,220\nThe decrease of €1.0 million compared to the first half of 2023 is primarily attributable to the decrease\nin research and development expenses incurred by the Company.\n2.2. Cash flow analysis\nThe following table sets forth the Company’s cash flow for the first half of 2024 and the first half of\n2023:\nCash flow\nJune 30, 2024 June 30, 2023\nIn thousands of euros\nNet cash used in operating activities (48,342) (45,233)\nNet cash from (used in) investing activities 8,912 (7,702)\nNet cash from (used in) financing activities 22,568 (2,153)\nNet increase (decrease) in cash and cash equivalents (16,863) (55,088)\nIn the first six months of 2024 and 2023, the main financing needs of the Company related to its\noperating activities, including its working capital requirements.\n24\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2.1. Cash flow linked to operating activities\nIn thousands of euros June 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nElimination of non-cash or non-operating\nincome and expenses\nDepreciation, amortization and provisions 1,878 1,138\nDeferred and current taxes 22 (35)\nTax credits (2,657) (3,643)\nCost of net debt 5,180 1,900\nIFRS 2 expenses 2,238 2,046\nUnrealized foreign exchange losses/(gains) (73) 503\nFair value variation (8,506) (1,623)\nOther - 18\nCash flows used in operations before tax, interest and\n(50,939) (54,965)\nchanges in working capital\nIncrease (decrease) in operating and other receivables 4,075 (2,322)\n(Increase) decrease in operating and other payables (2,409) 8,147\nIncrease (decrease) in inventories 24 (28)\nTax credit received 5,333 5,220\nOther (4,426) (1,285)\nTax, interest and changes in operating working capital 2,597 9,732\nNet cash used in operating activities (48,342) (45,233)\nNet cash used in operating activities amounted to €48.3 million in the first half of 2024, compared to\n€45.2 million for the first half of 2023, a decrease of 3.1 million euros due to changes in working capital\nrequirements, and in particular linked to:\n• A decrease in trade receivables of 0 million euros as of June 30, 2024, compared with 2.2\nmillion euros at June 30, 2023, corresponding to a milestone payment from CTTQ received on\nJuly 20, 2023.\n• 0.9 million euros increase in future fund-raising costs (other liabilities)\nHowever, the operating expenses, excluding depreciation, amortization, provision, and IFRS 2 expenses\nfor the first half of 2024 decreased by €7.3 million compared to the first half of 2023. The decrease\nmainly related to R&D expenses over the period is primarily due to the temporary pause in the\nrecruitment of the patients in the NATiV3 Phase III clinical trial related to the SUSAR (see Note 1.2. –\nSignificant events in the first half of 2024 of this document) and, to a lesser extent, due to the completion\nof the LEGEND Phase IIa trial.\n25\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2.2. Cash flow linked to investing activities\nCash flow used in investing activities over the periods presented was as follows:\nIn thousands of euros June 30, 2024 June 30, 2023\nPurchases of property, plant and equipment and intangible\n(255) (230)\nassets\nDisposals of property, plant and equipment and intangible\n90 130\nassets\n(Increase)/decrease in current term accounts 70 998\nNet change in other non-current financial assets 9,008 (8,600)\nNet cash used in investing activities 8,912 (7,702)\nIn the first half of 2024, net cash from investing activities amounted to €8.9 million, compared to €7.7\nmillion used in the first half of 2023 the change is mainly related to the early closure of a €9 million\ntwo-year deposit forward contract (see note 4.5 – Other non-current assets of the Unaudited interim\ncondensed consolidated financial statements as of June 30, 2024).\n2.2.3. Cash flow linked to financing activities\nIn thousands of euros June 30, 2024 June 30, 2023\nCapital increase 6 2\nSubscription of borrowings 24,911 -\nRepayment of debt (1,177) (1,448)\nRepayment of lease liabilities (1,173) (707)\nNet cash (from) used in financing activities 22,568 (2,153)\nNet cash from financing activities amounted to €22.6 million in the first half of 2024, compared to €2.2\nmillion used for the first half of 2023. The change is mainly related to the company’s drawdown of\nTranche B, amounting to €25 million, under the Finance Contract (see Note 1.2. – Significant events in\nthe first half of 2024 of this document).\n26\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.3. Anticipated sources of funds\nFrom inception, the Company has financed its growth through successive capital increases, debt,\ncollaboration and license agreements and reimbursements of CIR receivables. The Company continues\nto pursue its research and development activities for its product candidates.\nThe Company has incurred operating losses and negative cash flows from operations since inception\ndue to the innovative nature of the product candidates it is developing, which necessitates a research and\ndevelopment phase spanning several years. The Company does not expect to generate revenue from\nproduct sales in the near future. With the biopharmaceutical industry's product development phases\nrequiring increasing investments, the Company's financing needs will continue to grow as clinical trials\nof the Company's drug candidates progress and the Company invests to develop existing and new\nproduct candidates.\nAs of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting\nof cash and short-term deposit accounts that are liquid and easily convertible within 3 months without\npenalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents of the section 3.2 –\nInterim Condensed Consolidated financial statements as of June 30, 2024). In accordance with IAS 7.8,\nbank overdrafts which are repayable on demand are included as a component of cash and cash\nequivalents in the amount of €1.3 million as of June 30, 2024.\nAs of the date of authorization of the issuance of these financial statements, given its current cost\nstructure, its projected expenditure commitments, and the events after the reporting period presented in\nNote 6.4 – Events after the reporting period of the section 3.2 – Interim Condensed Consolidated\nfinancial statements as of June 30, 2024, mainly the issue of royalty certificates and the T1 capital\nincrease, the Company estimates that it should have sufficient funds to finance its activities through the\nend of the second half of 2025.\nAccordingly, as of the date of authorization of the issuance of these financial statements, the Company's\ncurrent cash and cash equivalents are not expected to be sufficient to cover its operating needs for at\nleast the next 12 months. These events and conditions indicate that an uncertainty exists that may cast\nsignificant doubt on the Company’s ability to continue as a going concern and, therefore, the Company\nmay be unable to realize its assets and discharge its liabilities in the normal course of business.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\nthe reporting period of the section 3.2 – Interim Condensed Consolidated financial statements as of\nJune 30, 2024. The Company may have based this estimate on assumptions that may prove to be\nincorrect, and the Company may end up using its resources sooner than anticipated.\nBased on the above, the unaudited interim condensed consolidated financial statements for the six-month\nperiod ended June 30, 2024, have been prepared on a going concern basis assuming the Company will\ncontinue to operate for the foreseeable future. As such, they do not include any adjustments related to\nthe amount or classification of assets and liabilities that may be required if the Company were not able\nto continue as a going concern.\n27\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n3. Unaudited interim condensed consolidated\nfinancial statements\n3.1. Statutory Auditors’ Review Report on the Half-yearly\nFinancial Information\nStatutory Auditors’ Review Report on the Half-yearly Financial Information\nFor the period from January 1 to June 30, 2024\nTo the Shareholders,\nIn compliance with the assignment entrusted to us by General Annual Meeting and in accordance\nwith the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (\"Code\nmonétaire et financier\"), we hereby report to you on:\n• the review of the accompanying condensed half-yearly consolidated financial statements of\nInventiva S.A., for the period from January 1 to June 30, 2024,\n• the verification of the information presented in the half-yearly management report.\nThese condensed half-yearly consolidated financial statements are the responsibility of the Board of\nDirectors. Our role is to express a conclusion on these financial statements based on our review.\nI- Conclusion on the financial statements\nWe conducted our review in accordance with professional standards applicable in France.\nA review of interim financial information consists of making inquiries, primarily of persons\nresponsible for financial and accounting matters, and applying analytical and other review\nprocedures. A review is substantially less in scope than an audit conducted in accordance with\nprofessional standards applicable in France and consequently does not enable us to obtain assurance\nthat we would become aware of all significant matters that might be identified in an audit.\nAccordingly, we do not express an audit opinion.\nBased on our review, nothing has come to our attention that causes us to believe that the\naccompanying condensed half-yearly consolidated financial statements are not prepared, in all\nmaterial respects, in accordance with IAS 34 - standard of the IFRSs as adopted by the European\nUnion applicable to interim financial information.\nWithout qualifying our conclusion, we draw your attention to the matter set out in note 3.4 to the\ncondensed half-yearly consolidated financial statements regarding events and conditions indicating\nthat an uncertainty exists that may cast doubt on the Company’s ability to continue as a going\nconcern.\nII Specific verification\nWe have also verified the information presented in the half-yearly management report on the\ncondensed half-yearly consolidated financial statements subject to our review. We have no matters\nto report as to its fair presentation and consistency with the condensed half-yearly consolidated\nfinancial statements.\n28\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nParis La Défense, October 14,2024 Paris, October 14, 2024\nKPMG SA LCA Audit\nKPMG.signature] [sc_sign.coCAC.signature]\n[/sc_sign.KPMG.signature] [/sc_sign.coCAC.signature]\nPhilippe Grandclerc Lison Dahan Chouraki\n29\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n3.2. Interim Condensed Consolidated financial statement\nTable of contents\n3.2. Interim Condensed Consolidated financial statement ............................................................. 30\nNote 1. Company information .................................................................................................. 37\n1.1 Company information .......................................................................................................... 37\n1.2 Significant events in the first half of 2024 ........................................................................... 39\nNote 2. Basis of preparation and statement of compliance .......................................................... 42\n2.1. Basis of preparation for the consolidated financial statements ........................................ 42\n2.2. Statement of compliance.................................................................................................. 43\n2.3. Scope and method of consolidation ........................................................................................ 43\n2.4 Foreign currency translation .................................................................................................... 44\nNote 3. Accounting principles .................................................................................................. 45\n3.1. Use of estimates and judgment ........................................................................................ 45\n3.2. Fair value measurement ................................................................................................... 45\n3.3. Specific disclosure requirements for unaudited interim financial statements.................. 46\n3.4. Going concern .................................................................................................................. 46\nNote 4. Notes to the interim condensed consolidated statement of financial position .................... 47\n4.1 Intangible assets ...................................................................................................................... 47\n4.2 Property, plant and equipment ................................................................................................. 47\n4.3 Deferred tax asset .................................................................................................................... 47\n4.4 Investments accounted for using the equity method ............................................................... 47\n4.5 Other non-current assets .......................................................................................................... 50\n4.6 Inventories ............................................................................................................................... 50\n4.7 Trade receivables, tax receivables and other current assets .................................................... 50\n4.8 Cash and cash equivalents ....................................................................................................... 51\n4.9 Shareholders’ equity ................................................................................................................ 51\n4.10 Financial debt ........................................................................................................................ 54\n4.11 Provisions .............................................................................................................................. 59\n4.12 Provisions for retirement benefit obligations ........................................................................ 59\n4.13 Other current and non-current liabilities ............................................................................... 60\n4.14 Trade payables and short-term contract liabilities ................................................................. 61\n4.15 Financial assets and liabilities ............................................................................................... 61\nNote 5. Notes to the interim condensed consolidated statement of (income) loss .......................... 63\n5.1 Revenues and other income ..................................................................................................... 63\n5.2 Operating expenses .................................................................................................................. 63\n5.3 Other operating income and expenses ..................................................................................... 65\n5.4 Financial income and expenses ............................................................................................... 65\n5.5 Share of net profit – Equity method ........................................................................................ 65\n5.6 Income tax ............................................................................................................................... 66\n5.7 Basic and diluted loss per share ............................................................................................... 66\nNote 6. Other financial information .......................................................................................... 67\n6.1 Commitments related to operational activities ........................................................................ 67\n30\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n6.2. Related-party transactions ...................................................................................................... 68\n6.3 Financial risk management ...................................................................................................... 68\n6.4 Events after the reporting date ................................................................................................. 68\n31\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of financial position\n(in thousands of euros)\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros Notes\nIntangible assets 4.1 451 541\nProperty, plant and equipment 4.2 7,979 9,125\nDeferred tax assets 4.3 210 225\nInvestments accounted for using the equity method 4.4 1,131 1,425\nOther non-current assets 4.5 1,047 10,055\nTotal non-current assets 10,818 21,371\nInventories 4.6 393 417\nTrade receivables and others 4.7 809 3,807\nTax receivables 4.7 2,704 5,352\nOther current assets 4.7 14,554 11,696\nCash and cash equivalents 4.8 10,147 26,918\nTotal current assets 28,608 48,189\nTotal assets 39,426 69,561\nShare capital 525 521\nPremiums related to share capital 201,859 201,862\nReserves (232,789) (124,584)\nTranslation reserve 375 596\nNet loss for the period (49,029) (110,426)\nShareholders’ equity 4.9 (79,060) (32,032)\nLong-term debt 4.10 46,846 32,181\nLong‑term debt – derivatives 4.10 13,569 10,265\nRoyalty certificates liabilities 4.10 7,263 6,327\nProvisions for retirement benefit obligations 4.12 1,555 1,559\nLong-term contract liabilities 76 70\nOther non-current liabilities 4.13 1,032 1,032\nTotal non-current liabilities 70,340 51,434\nShort-term debt 4.10 5,726 5,308\nTrade payables 4.14 36,583 37,679\nShort-term contract liabilities 4.14 3 6\nOther current liabilities 4.13 5,834 7,165\nTotal current liabilities 48,146 50,158\nTotal liabilities 118,486 101,592\nTotal equity and liabilities 39,426 69,561\nThe accompanying notes form an integral part of these financial statements\n32\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of income (loss)\n(in thousands of euros)\nSix months ended\nNotes June 30, 2024 June 30, 2023\nRevenue 5.1 41 1,901\nOther income 5.1 2,693 4,721\nTotal revenues and other income 2,734 6,622\nResearch and development costs 5.2 (46,822) (54,062)\nMarketing – Business development expenses 5.2 (598) (705)\nGeneral and administrative expenses 5.2 (7,701) (6,812)\nOther operating income (expenses) 5.3 138 (44)\nNet operating loss (52,249) (55,003)\nFinancial income 5.4 9,093 2,373\nFinancial expenses 5.4 (5,586) (2,646)\nNet financial income 3,507 (273)\nShare of net loss - Equity method 5.5 (168) -\nIncome tax 5.6 (119) 7\nNet loss for the period (49,029) (55,269)\nBasic/diluted loss per share (euros/share) (0.94) (1.31)\nWeighted average number of shares outstanding\n5.7 51,982,093 42,044,796\nused to calculate basic/diluted loss per share\nThe accompanying notes form an integral part of these financial statements\n33\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of comprehensive\n(income) loss\n(in thousands of euros)\nSix months ended\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nItems that will be reclassified subsequently to profit or loss (220) 104\nCurrency translation differences - equity method (286) -\nCurrency translation differences 66 104\nItems that will not be reclassified subsequently to profit or\n74 (14)\nloss\nRemeasurement of defined benefit plans 74 (14)\nTotal comprehensive loss (49,175) (55,179)\nThe accompanying notes form an integral part of these financial statements\n34\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of changes in\nshareholders’ equity\n(in thousands of euros)\nPremiums Net income\nTranslation Shareholders’\nNotes Share capital related to share (loss) for the Reserves\nReserves equity\ncapital period\nAt January 1, 2024 521 201,862 (110,426) 596 (124,584) (32,032)\nNet income (loss) for the period - - (49,029) - - (49,029)\nRemeasurement of defined benefit plans - - - - 74 74\nCurrency translation differences - - - (220) - (220)\nTotal comprehensive income (loss) - - (49,029) (220) 74 (49,175)\nAppropriation of 2023 net income (loss) - - 110,426 - (110,426) -\nShare-based payment compensation expenses 4.9 - - - - 2,238 2,238\nBSA share warrants subscription premium 4 (4) - - 6 6\nTreasury shares - - - - (138) (138)\nOther - - - - 41 41\nJune 30, 2024 525 201,859 (49,029) 375 (232,789) (79,060)\nPremiums Net income\nTranslation Shareholders’\nNotes Share capital related to share (loss) for the Reserves\nReserves equity\ncapital period\nAt January 1, 2023 421 173,886 (54,274) (271) (74,286) 45,476\nNet income (loss) for the period - - (55,269) - - (55,269)\nRemeasurement of defined benefit plans - - - - (14) (14)\nCurrency translation differences - - - 104 - 104\nTotal comprehensive income (loss) - - (55,269) 104 (14) (55,179)\nAppropriation of 2022 net income (loss) - - 54,274 - (54,274) -\nShare-based payment compensation expenses 4.9 - - - - 2,046 2,046\nBSA share warrants subscription premium - - - - 2 2\nTreasury shares - - - - 10 10\nOther - - - - (22) (22)\nAt June 30, 2023 421 173,886 (55,269) (168) (126,537) (7,667)\nThe accompanying notes form an integral part of these financial statements\n35\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of cash flows\n(in thousands of euros)\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nElimination of non-cash or non-operating\nincome and expenses\nDepreciation, amortization and provisions 1,878 1,138\nDeferred and current taxes 22 (35)\nTax credits (2,657) (3,643)\nCost of debt 5,180 1,900\nShare-based compensation expense 2,238 2,046\nShareofnetprofitofassociatesandjointventuresaccountedfor usingthe\n8 -\nequity method\nExchange (gains) / losses (73) 503\nFair value variation through profit and loss (8,506) (1,623)\nOther - 18\nCashflowsusedinoperationsbeforetax,interestandchangesinworking\n(50,939) (54,965)\ncapital\nDecrease / (increase) in operating and other receivables 4,075 (2,322)\nIncrease / (decrease) in operating and other payables (2,409) 8,147\nDecrease / (increase) in inventories 24 (28)\nTax credit received 5,333 5,220\nOther(1) (4,426) (1,285)\nTax, interest and changes in operating working capital 2,597 9,732\nNet cash used in operating activities (48,342) (45,233)\nPurchases of property, plant and equipment and intangible assets (255) (230)\nDisposals of property, plant and equipment and intangible assets 90 130\nDecrease / (Increase) in short-term deposit accounts 70 998\nIncrease / (Decrease) in other non-current financial assets 9,008 (8,600)\nNet cash from (used in) investing activities 8,912 (7,702)\nCapital increase net of transaction cost 6 2\nSubscription of borrowings and warrants net of transaction cost 24,911 -\nRepayment of debt (1,177) (1,448)\nRepayment of lease liabilities (1,173) (707)\nNet cash from (used in) financing activities 22,568 (2,153)\n-\nNet increase (decrease) in cash and cash equivalents (16,863) (55,087)\nCash and cash equivalents at beginning of period 26,918 86,736\nExchange gains / (losses) 92 (409)\nNet cash and cash equivalents at the end of period 10,147 31,240\n(1) Mainly include an increase in prepaid expense\nThe accompanying notes form an integral part of these financial statements\n36\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nNotes to the unaudited interim condensed consolidated financial statements\nNote 1. Company information\n1.1 Company information\nInventiva S.A. is a public limited company registered and domiciled in France. Its head office is located\nat 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include\nInventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as\n“Inventiva” or the “Company”).\nInventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since\nFebruary 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary\nshare, have been listed on the Nasdaq Global Market since July 2020.\nInventiva is a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),\nalso known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet\nmedical need.\nLeveraging its expertise and experience in the domain of compounds targeting nuclear receptors,\ntranscription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the\ntreatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.\nLanifibranor, its lead product candidate, is being developed for the treatment of patients with\nMASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive\ntopline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with\nMASH/NASH and announced that the U.S. Food and Drug Administration (\"FDA\") had granted the\nCompany the status of Breakthrough Therapy and Fast Track designation. The Company initiated the\npivotal Phase III trial of lanifibranor in MASH/NASH (“NATiV3”) in the second half of 2021. In March\n2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor\nand empagliflozin in patients with MASH/NASH and Type 2 Diabetes (“DT2”) (“LEGEND”).\nIn the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a\nhigher than originally projected screen failure rate resulting in slower than anticipated enrollment rate.\nIn addition, the Company experienced slower than predicted site activation, screening and enrollment\ndue to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the\nCompany was unable to conduct clinical trial activities at sites originally located in Ukraine due to the\nwar between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in\nUkraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the\nmarkets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could\naffect the Company.\nIn January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially\naccelerate enrollment and identified additional sites to help compensate for the inability to use sites in\nUkraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks\ninstead of up to seven years, reduces the number of biopsies from three to two and included a 48-week\nactive treatment extension study. The Company expects that the changes to the clinical development\nplan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and\ncompensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of\nbiopsies and the trial duration, eventually offering all patients in the trial access to treatment and\n37\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\npotentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to\npatients with MASH/NASH and compensated cirrhosis.\nIn September 2022, the Company entered into a license and collaboration agreement with Chia Tai\nTianqing Pharmaceutical Group, Co., LTD (“CTTQ”), a Sino Biopharm group company, to develop and\ncommercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other\nmetabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special\nAdministrative Region and Taiwan (“CTTQ Territory”). In May 2023, the Company announced that\nCTTQ had received the Investigational New Drug (“IND”) approval from the Chinese National\nMedicine Products Administration (“NMPA”) allowing CTTQ to initiate the clinical development of\nlanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase\nIII trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation\nin the Company’s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ\nbears all costs associated with these trials conducted in the CTTQ Territory.\nIn September 2023, the Company and Hepalys Pharma, Inc. (“Hepalys”) announced an exclusive\nlicensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the “Hepalys\nLicense Agreement”). Hepalys is a new company created by Catalys Pacific Fund II, LP (“Catalys”).\nUnder the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to\n€9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical,\nregulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to\nlow twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval.\nIn parallel with the Hepalys License Agreement, the Company entered into an option agreement with\nCatalys to acquire 30% of the shares of Hepalys (the “Catalys Option Agreement”). The Company\nexercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate\nexercise price of ¥300 (equal to €1.90). Also on September 20, 2023, the Company entered into a\nshareholders agreement with Catalys and Hepalys (the “Catalys Shareholders Agreement”). Pursuant to\nthe Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of\nHepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal\nif Hepalys receives an offer for the license or rights related to lanifibranor.\nIn the first quarter of 2024, following a routine visit during the Company’s NATiV3 clinical trial of\nlanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (“SUSAR”) was\nreported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the Data Monitoring Committee (“DMC”)3.\nOn March 7, 2024, the Company announced that screening activities had resumed in American sites\nunder central Institutional Review Board (“IRB”). The impact of the pause on the overall timeline of the\ntrial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate,\nand the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial\nparticipants.\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and DT2.\n3 A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.\n38\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nThe Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete\nrandomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the\nCompany is currently targeting the first visit of the last patient for the second half of 2024 and the\npublication of the main results for the beginning of the second half of 2026. The publication of the\ntopline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the\nbeginning of the second half of 2026 as previously announced). If the results of the trial confirm\nsufficient clinical benefit and a continued good safety profile, the Company plans to file an application\nfor accelerated approval in the United States and conditional authorization in the European Union for\nthe marketing of lanifibranor.\nThe Company’s pipeline also includes odiparcil, which it was previously developing for the treatment\nof patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. As\nannounced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor.\nBased on feedback from the FDA, the Company believes there is potential for an efficient development\npathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further\ndevelop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership,\nlicense or other transaction.\n1.2 Significant events in the first half of 2024\nThe Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B (see\nNote 4.10 Financial debt)\nOn January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment\nBank (“EIB”) and such warrants, the “EIB Tranche B Warrants”, in accordance with the terms of the\n6th resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-\n138 of the French Commercial Code, as a condition to the drawdown of the second tranche of €25.0\nmillion (“Tranche B”) under the finance contract between the Company and EIB (“Finance Contract”).\nThe 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the\nCompany's then-outstanding share capital. If all the warrants issued to the EIB in connection with\ndrawdown of the first tranche of €25.0 million (“Tranche A”) under the Finance Contract (the “EIB\nTranche A Warrants” and, together with the EIB Tranche B Warrants, the “EIB Warrants”) and the EIB\nTranche B Warrants were exercised, the EIB would hold approximately 9.9% of the Company's share\ncapital as of June 30, 2024.\nThe exercise price of the EIB Tranche B Warrants is equal to €3.95 and corresponds to 95% of the\nvolume-weighted average price of the Company's shares on the regulated market of Euronext Paris\nduring the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).\nThe EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the\nearliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control\nevent, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the\nFinance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within\nthe twelve-year period.\nEIB has a put option which may require the Company to repurchase all or part of the unexercised EIB\nTranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn\nunder the Finance Contract) under certain circumstances (for example, in the event of a change of control\nor on the maturity date of Tranche A or in the event of default). The Company (or a substitute third\nparty) has a call option to require EIB to sell all shares and other securities of the Company, including\n39\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nthe EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company\nhas a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party,\nsubject to certain terms and conditions.\nOn the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB\nTranche B Warrants at a price of €3.95 per new share, the Company could potentially receive gross\nproceeds of up to €12,421,383. There is no assurance that EIB will exercise any or all of the EIB\nWarrants or that the Company will receive any proceeds from the exercise of the warrants.\nThe exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B\nTranche B Warrants. As of the date of authorization of the issuance of these financial statements, one\nEIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.\nThe Company draws down Tranche B of €25 million under Finance Contract with EIB (see Note\n4.10 Financial debt)\nOn January 18, 2024, the Company drew down Tranche B of €25 million under the Finance Contract\nwith EIB.\nAfter the drawdown of Tranche A in December 2022, the Company had an option to access further €25\nmillion tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the\nachievement of those conditions, the Company decided to draw on Tranche B. The Company intends to\nuse the proceeds to fund part of NATiV3.\nTranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in\nJanuary 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among\nother conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of\nthe Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million that\nwas a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company,\nor through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with\nan upfront payment of at least €10 million, (iv) operational criteria based on patient enrollment and\nnumber of sites activated in the Company’s NATiV3 Phase III clinical trial of lanifibranor in patients\nwith NASH and (v) the Company issuing EIB Tranche B Warrants (see above - The Company issued\n3,144,654 warrants to EIB in connection with the drawdown of Tranche B) in accordance with the terms\nand conditions of the warrant agreement entered into on July 1, 2022.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (warrants) at inception and the borrowing costs.\nOn June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for\nadjusting the exercise ratios of the EIB Warrants.\nTreatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024\nOn February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in\nliver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient\nhad been without clinical symptoms throughout the period of observation. This event has been assessed\nas a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial\nparticipants have also been reported in the trial. The Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\n40\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nenrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the\ntrial continued to receive treatment under the new liver monitoring schedule recommended by the DMC.\nThis SUSAR is the first reported in all clinical trials with lanifibranor.\nOn March 7, 2024, the Company received approval from the central IRB overseeing clinical research in\nthe United States to resume screening activities in its sites. This was an important milestone as 152 sites\nof the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60%\nof the patients in the main cohort.\nDue to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit\nof the last patient for the second half of 2024, to complete randomization in the first half of 2025 and\nthe main results for the second half of 2026 (versus the beginning of the second half of 2026 as\npreviously disclosed).\nThe Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and\nempagliflozin in patients with MASH/NASH and T2D\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and T2D.\nThe LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled\nPhase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the\nSGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D.\nThe trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for\nthe combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm. The diagnosis of\nnon-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-\ninvasive methods including diagnostic methods including imaging. As planned per protocol, the interim\nanalysis was done once half of the 63 planned randomized patients with MASH completed the 24-week\ntreatment period or prematurely discontinued from treatment.\nThe study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c\n(HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily)\nor in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26%\nobserved in the placebo arm.\nThe study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-\nPDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -\n38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone\nor in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their\nhepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically\nsignificant effect on several secondary and exploratory endpoints, including liver enzymes (alanine\naminotransferase (“ALT”) and aspartate aminotransferase (“AST”)), insulin resistance (HOMA-IR),\nHDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1)\nassessed by LiverMultiScan®) were assessed for the first time with lanifibranor and showed a significant\neffect with lanifibranor alone and in combination with empagliflozin.\nThe study also demonstrated that patients treated with lanifibranor in combination with empagliflozin\nmaintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically\nhealthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore,\nthese results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and\n41\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nsubcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with\nempagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.\nThis result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose\ntissue.\nThe treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily\nfor 24 weeks appears to be well tolerated, with no safety concerns reported.\nGiven that the primary endpoint of LEGEND was met, and statistically significant results were achieved\non several key additional markers, the Company has decided to stop the recruitment as defined per\nprotocol. More details on these results are expected to be presented in upcoming scientific conferences\nand submitted for publication.\nAdditional results from NATIVE Phase IIb clinical trial\nOn May 13, 2024, the Company announced the publication in Nature Communications of additional\nresults from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic\nhealth in patients with MASH/NASH treated with lanifibranor.\nImprovements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism\n(triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG)\nlevels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.\nRecommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in\npatients with MASH/NASH\nOn May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the\nNATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.\nThe DMC recommended to continue the clinical trial without further modification of the protocol, as\namended immediately after learning about SUSAR, based on the pre-planned review of safety data.\nThe recommendation was based on the unblinded review by the DMC of safety data from more than\n900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients\nthat have been treated for more than 48 and 72 weeks, respectively.\nThe patient who experienced the adverse event of increased liver test results, which was reported as a\nSUSAR, had been without clinical symptoms throughout the period of observation and has fully\nrecovered.\nNote 2. Basis of preparation and statement of compliance\n2.1. Basis of preparation for the consolidated financial statements\nThe Company has prepared these unaudited interim condensed consolidated financial statements in\naccordance with International Financial Reporting Standards (“IFRS”) as adopted by the European\nUnion and IFRS Accounting Standards as issued by the International Accounting Standard Board\n(“IASB”).\nThese unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved\nby the Board of Directors of the Company on 14 October, 2024.\n42\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2. Statement of compliance\nThese unaudited interim condensed consolidated financial statements were prepared in compliance with\nInternational Accounting Standards (IAS) 34 — Interim Financial Reporting, which provides for the\npresentation of selected explanatory notes. The accompanying notes do not contain all the disclosures\nrequired for annual financial statements and should therefore be read in conjunction with the Company’s\nfinancial statements prepared in accordance with IFRS ®Accounting Standards, referred to as IFRS as\nof and for the year ended December 31, 2023 except for the accounting principles described in Note 3\n– Accounting principles.\nIFRS Accounting Standards basis adopted\nThe accounting policies applied by the Company in the preparation of the unaudited interim condensed\nconsolidated financial statements for the six-month period ended June 30, 2024, are identical to those\nused in the annual financial statements prepared in accordance with IFRS Accounting Standards as of\nand for the year ended December 31, 2023, with the exception of specific provisions for the preparation\nof unaudited interim condensed consolidated financial statements.\nStandards, amendments to existing standards and interpretations published by the IASB whose\napplication has been mandatory since January 1, 2024\nThe application of standards, amendments to existing standards and interpretations whose application\nhas been mandatory since January 1, 2024 in the European Union primarily concern:\n- Amendment to IFRS 16 – Lease liability in a sale and leaseback\n- Amendment to IAS 1 – Non-current liabilities with covenants\n- Amendment to IAS 7 and IFRS 7 - Supplier finance arrangements\nThose amendments had no material impact on the Company’s unaudited interim condensed consolidated\nfinancial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had\nnot published any amendments that would be expected to have a material impact on the Company’s\nconsolidated financial statements.\nStandards, amendments to existing standards and interpretations published by the IASB whose\napplication is not yet mandatory\nThe new standards, interpretations and amendments to existing standards that have been published but\nare not yet applicable concern:\n- Amendments to IAS 21 – Lack of Exchangeability\n- Amendment to IFRS 9 and IFRS 7 – Classification and Measurement of Financial Instruments\n- New Standard – IFRS 18 – Presentation and Disclosure in Financial Statements\n- New standard – IFRS 19 Subsidiaries without Public Accountability: Disclosures\nThese new standards, interpretations and amendments are under analysis to see if there are applicable\nto Inventiva.\n2.3. Scope and method of consolidation\n• Accounting policy\nIn accordance with IFRS 10 Consolidated Financial Statements, an entity (subsidiary) is consolidated\nwhen it is controlled by the company (the parent).\n43\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nSubsidiaries are all entities over which the Company has control. The Company controls an entity when\nit is exposed to, or has rights to, variable returns from its involvement with the entity and could affect\nthose returns through its power to direct the activities of the entity. Subsidiaries are consolidated from\nthe date on which control is transferred to the Company. They are deconsolidated from the date such\ncontrol ceases.\nAll intercompany transactions, balances, and unrealized gains on transactions between group companies\nare eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an\nimpairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies\nadopted by the Company.\n• Consolidated entities\nAs of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and\nits 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.\nPercent of\nDate of Ownership\nincorporation Interest Accounting Method\nINVENTIVA Inc. 01/05/2021 100% Fully Consolidated\n• Interests in associates and joint ventures\nHepalys is incorporated and has its principal place of business in Japan. The Company’s proportion of\nownership interest is 14.6% and is the same as the proportion of voting rights held. In accordance with\nIAS 28 Investments in Associates and Joint Ventures, Hepalys is an associate of the Company and is\naccounted for using the equity method (see Note 4.4. – Investments accounted for using the equity\nmethod).\n2.4 Foreign currency translation\n• Functional and presentation currency\nThe Company’s consolidated financial statements are presented in euros, which is also the functional\ncurrency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S.\ndollar. All amounts presented in these notes to the consolidated financial statements are denominated in\neuros unless otherwise stated.\n• Translation of financial statements into presentation currency\nThe results and financial position of foreign operations that have a functional currency different from\nthe presentation currency are translated into euros, the presentation currency, as follows:\n• Assets and liabilities for each balance sheet presented are translated at the closing rate on the date\nof that balance sheet,\n• Income and expenses for each statement of (income) loss and statement of comprehensive (income)\nloss are translated at average exchange rates (which is an approximate value of the exchange rate\non the transaction date in the absence of significant fluctuations. Income and expenses are translated\nat the transaction dates if the exchange rates fluctuate significantly), and\n• All resulting exchange differences are recognized in other comprehensive income.\n44\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of December As of June 30,\nExchange rate (USD per EUR) As of June 30, 2024\n31, 2023 2023\nAverage exchange rate for the period 1.0813 1.0803 1.0807\nExchange rate at period end 1.0705 1.1050 1.0866\nNote 3. Accounting principles\n3.1. Use of estimates and judgment\nThe preparation of financial statements requires management to make judgments and estimates and\napply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as\nwell as the information presented in the accompanying notes. Actual reported values may differ from\nthe accounting estimates made.\nThere have been no significant changes in the material judgments and main estimates used by\nmanagement when applying the Company’s accounting policies in the preparation of these unaudited\ninterim condensed consolidated financial statements from those described in the annual financial\nstatements prepared in accordance with IFRS Accounting Standards for the year ended December 31,\n2023.\nThe conflict in Ukraine and the state of war between Israel and Hamas have not led to any material\nchanges in the estimates or judgements made by management in the preparation of the Company’s\nunaudited interim condensed consolidated financial statements.\n3.2. Fair value measurement\nIn the table below, financial instruments are measured at fair value according to a hierarchy comprising\nthree levels of valuation inputs:\n• Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that\nthe entity can access at the measurement date.\n• Level 2: Inputs other than quoted market prices included within Level 1 that are observable\nfor the asset or liability, either directly or indirectly.\n• Level 3: Unobservable inputs for the asset or liability.\nThe table below presents the financial assets and liabilities of the Company measured at fair value as of\nJune 30, 2024:\nAt June 30, 2024 (in thousands of euros) Level 1 Level 2 Level 3\nFinancial liabilities at fair value through profit or loss\nLong‑term financial debt – derivatives – – 13,569\nTotal liabilities – – 13,569\nThe table below presents the financial assets and liabilities of the Company measured at fair value as of\nDecember 31, 2023:\n45\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAt December 31, 2023 (in thousands of euros) Level 1 Level 2 Level 3\nFinancial liabilities at fair value through profit or loss\nLong‑term financial debt – derivatives – – 10,265\nTotal liabilities – – 10,265\n3.3. Specific disclosure requirements for unaudited interim financial statements\nSeasonality of operations\nThe Company’s operations are not subject to material seasonal fluctuations.\nIncome tax\nIncome tax is recognized in the financial statements for each interim period. The amount corresponds\nto a best estimate calculated by applying the expected weighted average tax rate for the entire year.\nThe income tax amount recorded as due for an interim period may have to be adjusted in the subsequent\ninterim period of the same year if the estimated annual average tax rate changes.\n3.4. Going concern\nFrom inception, the Company has financed its growth through successive capital increases, debt,\ncollaboration and license agreements and reimbursements of CIR receivables. The Company continues\nto pursue its research and development activities for its product candidates.\nThe Company has incurred operating losses and negative cash flows from operations since inception\ndue to the innovative nature of the product candidates it is developing, which necessitates a research and\ndevelopment phase spanning several years. The Company does not expect to generate revenue from\nproduct sales in the near future. With the biopharmaceutical industry's product development phases\nrequiring increasing investments, the Company's financing needs will continue to grow as clinical trials\nof the Company's drug candidates progress and the Company invests to develop existing and new\nproduct candidates.\nAs of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting\nof cash and short-term deposit accounts that are liquid and easily convertible within 3 months without\npenalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents). In accordance with\nIAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash\nequivalents in the amount of €1.3 million as of June 30, 2024.\nAs of the date of authorization of the issuance of these financial statements, given its current cost\nstructure, its projected expenditure commitments, and the events after the reporting period presented in\nNote 6.4 – Events after the reporting period, mainly the issue of royalty certificates and the T1 capital\nincrease, the Company estimates that it should have sufficient funds to finance its activities through the\nend of the second half of 2025.\nAccordingly, as of the date of authorization of the issuance of these financial statements, the Company's\ncurrent cash and cash equivalents are not expected to be sufficient to cover its operating needs for at\nleast the next 12 months. These events and conditions indicate that an uncertainty exists that may cast\nsignificant doubt on the Company’s ability to continue as a going concern and, therefore, the Company\nmay be unable to realize its assets and discharge its liabilities in the normal course of business.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\n46\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\nthe reporting period. The Company may have based this estimate on assumptions that may prove to be\nincorrect, and the Company may end up using its resources sooner than anticipated.\nBased on the above, the unaudited interim condensed consolidated financial statements for the six-month\nperiod ended June 30, 2024, have been prepared on a going concern basis assuming the Company will\ncontinue to operate for the foreseeable future. As such, they do not include any adjustments related to\nthe amount or classification of assets and liabilities that may be required if the Company were not able\nto continue as a going concern.\nNote 4. Notes to the interim condensed consolidated statement of financial position\n4.1 Intangible assets\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nIntangible assets, gross 3,947 3,926\nAmortization and impairment (3,496) (3,384)\nIntangible assets, net 451 541\n4.2 Property, plant and equipment\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nProperty, plant and equipment, gross 20,376 19,840\nDepreciation and impairment (12,396) (10,714)\nProperty, plant and equipment, net 7,979 9,126\nAs of June 30, 2024, the gross value of property, plant and equipment increased by €0.5 million mainly\ndue to the recognition of the right of use related to the Fibroscans lease agreement for €0.4 million.\nDepreciation and impairment increased by €1.7 million mainly due to the depreciation of €1.2 million\nof the right of use and €0.3 million due to an impairment of the right of use related to Fibroscan.\n4.3 Deferred tax asset\nInventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax\nconsolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the\nconsolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient\nevidence that it will have a sufficient taxable benefit available to use the unused tax losses in the\nforeseeable future.\nAs recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the\nInventiva S.A.’s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for\nInventiva Inc.\n4.4 Investments accounted for using the equity method\nInventiva became an equity shareholder in Hepalys with the acquisition of 1,500,000 ordinary shares on\nOctober 11, 2023.\nOn January 15, 2024, Hepalys’s shareholders approved a capital increase of €1.6 million by issuing new\nshares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently,\nthe Company’s ownership in Hepalys was diluted to 14.6%. As of June 30, 2024, the Company holds\n14.6% of Hepalys's shares, down from 15% ownership as of December 31, 2023.\n47\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nThe Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a\nsignificant influence but not control or joint control of Hepalys. The significant influence is reflected\nthrough the ownership of percentage of interests held, the percentage of potential voting rights owned\nby the Company including the option, under the Catalys Shareholders Agreement, to acquire all\noutstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as\nat June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the\nHepalys License Agreement.\nThe investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024.\nThe tables below provide the summarized statement of financial position of Hepalys. The disclosed\ninformation reflects the amounts presented in the financial statements of Hepalys and not the Company's\nshare of those amounts. They have been amended to reflect adjustments made by the Company when\nusing the equity method, in this case fair value adjustments. The tables below provide also the\nreconciliation between the Hepalys statement of financial position and the carrying amount in the\nCompany statement of financial position.\n48\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDecember 31,\nJune 30, 2024\n2023\n(in thousands of euros)\nIntangible assets 17,217 20,278\nTotal non-current assets 17,217 20,278\nOther current assets 17 44\nCash and cash equivalents 1,997 1,082\nTotal current assets 2,015 1,126\nDeferred assets 2 41\nTotal assets 19,233 21,444\nCapital stock 523 640\nCapital reserve 20,379 22,655\nCapital surplus-others 774 -\nEarnings brought forward (1,018) (178)\nNet loss for the period (1,444) (1,111)\nTreasury Shares - (812)\nShareholders’ equity 19,214 21,194\nTotal non-current liabilities - -\nTrade payables 7 237\nOther current liabilities 12 13\nTotal current liabilities 19 250\nTotal equity and liabilities 19,233 21,444\nOpening net assets 21,122 22,645\nLoss for the period (1,509) (879)\nOther comprehensive income (1,964) 247\nCapital variations 1,566 (819)\nClosing net assets 19,214 21,194\nGroup's share in % 15% 15%\n(in thousands of euros)\nGroup's share 2,813 3,267\nElimination of unrealised profit on downstream sales (1,718) (1,881)\nGoodwill 37 39\nCarrying amount 1,131 1,425\n49\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n4.5 Other non-current assets\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nLong-term deposit accounts 0 9,000\nAdvance payments – non-current 1,047 1,047\nAccrued income 0 0\nSecurity deposits 0 8\nOther non-current assets 1,047 10,055\nAs of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by\n€9.0 million, related to the early closure of a €9.0 million two-year deposit forward contract.\nAs of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to\n€1.0 million, corresponding to the advance paid under the contract research organization (“CRO”)\ncontract with Pharmaceutical Research Associates Groupe B.V (“PRA”) (see Note 6.1 – Commitments\nrelated to operational activities).\n4.6 Inventories\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nLaboratory inventories 402 426\nInventories write-down (9) (9)\nInventories 393 417\n4.7 Trade receivables, tax receivables and other current assets\nTrade receivables\nTrade receivables break down as follows:\nIn thousands of euros Dec. 31,\nJune 30, 2024\n2023\n3 months or less 809 3,807\nBetween 3 and 6 months - -\nBetween 6 and 12 months - -\nMore than 12 months - -\nTrade receivables 809 3,807\nThe average payment period is 30 days.\nAs of June 30, 2024, trade receivables decreased by €3.0 million mainly due to the receipt of a payment\nfrom CTTQ for the reinvoicing of specific costs related to the NATiV3 trial.\nTax receivables and Other current assets\n50\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDec. 31,\nIn thousands of euros June 30, 2024\n2023\nCIR and other research tax credits 2,657 5,333\nOther 47 19\nTax receivables 2,704 5,352\nPrepaid expenses 7,039 4,656\nShort-term deposit accounts - 70\nCurrent accrued income 1,687 1,047\nLiquidity agreement - Cash 289 422\nSales tax receivable 3,311 5,066\nOther receivables 2,229 435\nOther current assets 14,554 11,696\nOther current assets and receivables 17,258 17,048\nAs of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the\namount of €2.7 million corresponding to the 2024 CIR as of June 30, 2024.\nPrepaid expenses, which increased by about €2.4 million, are mainly composed of costs related to the\nNATiV3 Phase III clinical trial.\n4.8 Cash and cash equivalents\nNet cash and cash equivalents\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nOther cash equivalents(1) 10,273 17,933\nCash at bank and at hand 1,212 8,985\nBank overdrafts (1,338) -\nCash and cash equivalents 10,147 26,918\n(1) Other cash equivalents correspond to short-term bank deposits.\nIn accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a\ncomponent of cash and cash equivalents in the amount of €1.3 million as of June 30, 2024.\n4.9 Shareholders’ equity\nShare capital\nThe share capital is set at €524,772 at June 30, 2024 divided into 52,477,188 fully authorized, subscribed\nand paid-up shares with a nominal value of €0.01.\nShare capital variation during the first six months of 2024 is set forth in the table below:\nIn euros, except number of shares\nPremiums related to\nDate Nature of the transactions Share capital Number of shares Nominal value\nshare capital\nBalance at December 31, 2023 521,158 201,862,263 52,115,807 0.01\n3/25/2024 AGA 2021 & AGA 2021 bis 3,614 (3,614) 361,381 0.01\nBalance at June 30, 2024 524,772 201,858,649 52,477,188 0.01\nLiquidity agreement\nOn January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing\nthe previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended\n51\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nin 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms\nof the agreement, the investment services provider (“ISP”) is authorized to buy and sell the Company’s\ntreasury shares without interference from the Company in order to ensure the liquidity of the shares on\nthe Euronext market.\nThe liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from\nJanuary 1, 2023, and has been renewed again for a new period of 12 months from January 1, 2024.\nAt June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses\nresulting from share purchase, sale, issue and cancellation transactions during the first six months of\n2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact\non the Company’s results.\nOptions and share warrants (BSA and BSPCE)\nShare-based payments correspond to:\n- BSA share warrants granted to Company directors in 2017, with a subscription price set at\n€0.534;\n- BSA share warrants granted to Company service providers in 2018, with a subscription price\nset at €0.48;\n- BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.18;\n- BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group\nLLC, and Jérémy Goldberg, a member of PG Healthcare LLC, both service providers of\nInventiva, with a subscription price set at €0.29;\n- BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company’s\nDirectors;\n- BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at €2.45\n;\n- BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.20 and an exercise price\nof €2.51; and\n- BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.31 and an exercise price\nof €3.91.\nBSA and BSPCE plan characteristics\nAs of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021.\nThe BSPCE and BSA share warrant plans are described in the note 12.3 “Share warrants plans” of the\n2023 annual financial statements.\nNo new share warrants plan has been attributed in the first six months of 2024.\nMovements in BSPCE share warrants and BSA share warrants (in number of shares issuable\nupon exercise)\n52\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nNumber of\nExercice price Outstanding at Forfeited / Outstanding at exercisable\nType Grant Date (in euros) Jan 1, 2024 Issued Exercised Lapsed June 30, 2024 shares\nBSPCE - Plan 2021 04/16/2021 11.74 430,000 - - - 430,000 430,000\nTOTAL BSPCE share warrrants 430,000 430,000 430,000\nBSA - Plan 2017 05/29/2017 6.68 130,000 - - - 130,000 130,000\nBSA - Plan 2018 12/14/2018 6.07 116,000 - - - 116,000 116,000\nBSA 2019 06/28/2019 2.20 10,000 - - - 10,000 10,000\nBSA 2019 bis 03/09/2020 3.68 10,000 - - - 10,000 10,000\nBSA 2019 ter 03/09/2020 3.68 36,000 - - - 36,000 36,000\nBSA 2021 04/16/2021 11.74 14,333 - - - 14,333 14,333\nBSA 2023 05/25/2023 2.51 10,000 - - - 10,000 -\nBSA 2023 - 2 12/15/2023 3.91 20,000 - - - 20,000 -\nTOTAL BSA share warrants 346,333 346,333 316,333\nTotal share warrants 776,333 - - - 776,333 746,333\nAt June 30, 2024, a total of 430,000 BSPCEs (or 430,000 shares) and 346,333 BSAs were outstanding,\ncorresponding to a total of 776,333 shares, the maximum number of shares to be issued when all related\nconditions are met.\nFree share awards\nAGA free share award plans\nAs of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis,\nAGA 2023-1, and AGA 2023-2.\nNo bonus share award plan has been attributed in the first six months of 2024.\nMovements in AGA free shares (in number of shares issuable upon exercise)\nStock price\nat grant date Outstanding at Forfeited / Outstanding at\nType Grant Date (in euros) Jan 1, 2024 Granted Vested Lapsed June 30, 2024\nAGA - Plan 2021 - 1 04/16/2021 11.30 297,599 - (296,166) (1,433) -\nAGA - Plan 2021 - bis 12/08/2021 12.20 65,215 - (65,215) - -\nAGA 2023-1 05/25/2023 2.60 300,000 300,000 - - 600,000\nAGA 2023-2 12/15/2023 3.90 748,000 - - (23,350) 724,650\nTOTAL free shares 1,410,814 300,000 (361,381) (24,783) 1,324,650\nAt June 30, 2024, a total of 1,324,650 AGA bonus shares were outstanding.\nFollowing the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-\n1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant 300,000 free\nshares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the\nregulations of the AGA 2023-1 plan.\nFollowing the AGA 2021 and AGA 2021 bis acquisition period, a total of 361,381 shares were\ndefinitively acquired, resulting in a capital increase of €3,613.81.\nUpon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of\n361,381 shares were acquired, resulting in a capital increase of €3,613.81.\nThe free share award plan is described in the Note 12.4 “Bonus share award plans” of the annual\nconsolidated financial statements for the year ended on December 31, 2023.\nShare-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled\n€2.2 million for the six months ended June 30, 2024, compared to €2.0 million for the six months ended\nJune 30, 2023. They are recognized in personnel costs (see Note 5.2 – Operating expenses).\n53\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nPerformance units (“PAGUP”)\nAs of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.\nNo performance units award plan has been attributed in the first six months of 2024.\nReference Number of\nprice (in Outstanding at Outstanding at exercisable\nType Grant Date euros) Jan 1, 2024 Issued Exercised Convert AGA June 30, 2024 shares\nPAGUP 2023 05/25/2023 2.60 300,000 - - (300,000) - -\nTOTAL PAGUP 300,000 - - (300,000) - -\nAt June 30, 2024, no PAGUP shares were outstanding.\nFollowing the changes introduced by the French law n°2023-1107, the PAGUP 2023 granted on May\n25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted 300,000\nfree shares (governed by the AGA 2023-1 regulations) to Frédéric Cren, thereby lapsing the 300,000\nPAGUP 2023.\nThe performance units plan is described in the Note 12.5 “Performance units” of the annual\nconsolidated financial statements for the year ended on December 31, 2023.\n4.10 Financial debt\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nBank borrowings 42,509 27,206\nDerivatives instruments 13,569 10,265\nOther loans and similar borrowings(1) 4,302 3,719\nLease liabilities 5,761 6,565\nRoyalty certificates liabilities 7,263 6,327\nTotal debt 73,404 54,082\n(1) include accrued interests.\nMovements in the period break down as follows:\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nJanuary 1, 2024 54,083 44,390\nSubscription of derivatives instruments(2) 11,809 -\nSubscription of bank borrowings(1)(2) 13,102 -\nSubscription of lease liabilities 345 3,706\nIssue of royalty certificates - 5,100\nRepayment of bank borrowings (1,177) (2,485)\nRepayment of lease liabilities (1,173) (1,612)\nInterests on royalty certificates 936 1,227\nCapitalized interest 3,961 3,405\nChange in fair value of derivatives instruments(2) (8,506) 389\nExchange rate change 24 (38)\nJune 30, 2024 73,404 54,083\n(1) Net proceed\n(2) EIB’s loan and warrants.\n54\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nFrench state-guaranteed loan (“PGE”) and equity recovery loans (“PPR”)\nIn May 2020, the Company entered into three credit agreements pursuant to which it received\n€10.0 million in the form of state-guaranteed loans (Prêts Garantis par l’Etat, or “PGE”) which are\nprovided by a syndicate of French banks and guaranteed by the French government in the context of the\nCOVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the\nthird quarter of 2022. The amendments provide for reimbursements to be made over four years,\nbeginning in July 2022 for the loan from Crédit Agricole and in September 2022 for the loans from\nBpifrance and Société Générale.\nIn June 2022, the Company entered into three loan agreements with a syndicate of French banks for a\ntotal amount of €5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with\nBpifrance and the other two loan agreements were part of a stimulus economic plan (Prêts Participatifs\nRelance, or “PPR”) granted by Crédit Agricole Champagne-Bourgogne and Société Générale.\nThe PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government with an\ninitial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to\nalign with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the\nFrench government and feature an eight-year financing period and a four-year repayment period.\nThe PGE repayments in the first six months of 2024 amounted to €1.2 million.\nCredit facility agreement with the European Investment Bank\nOn May 16, 2022, the Company entered into the Finance Contract with the EIB for up to €50 million,\ndivided into two tranches of €25 million each.\n• On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized\ninterest for Tranche A is 8% and repayment is due in December 2026, four years after its\ndisbursement.\n• On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. –\nSignificant events in the first six months of 2024). Capitalized interest for Tranche B is 7% and\nrepayment is due in January 2027, three years after its disbursement.\nThe Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment\nfee, either at the election of the Company or as a result of EIB’s demand following certain prepayment\nevents, including a change of control or change in senior management of the Company.\nSubject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including\npayment default, misrepresentation, cross default), EIB may demand immediate repayment by the\nCompany of all or part of the outstanding loan. As of June 30, 2024 there was no demand of\nreimbursement of the outstanding loan. Tranche A of €25 million was recognized as financial debt at\namortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at\ninception and the borrowing costs of €0.1 million. The amortized cost of the loan is €15.4 million on\nDecember 31, 2023, and is € 21.1 million on June 30, 2024, with an effective interest rate of 21.9%. The\nfair value of the loan as of June 30, 2024, amount to €20.6 million, with a market rate of 22.9%.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of €0.1\nmillion. The amortized cost of the loan is €15.0 million on June 30, 2024, with an effective interest rate\nof 32.7%. The fair value of the loan as of June 30, 2024, amount to €14.7 million, with a market rate of\n33.2%.\nThe capitalized interest for both Tranche A and Tranche B in the period amounted to €4.0 million.\n55\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDerivatives\nOn July 1, 2022, in connection with the Finance Contract (see section above “Credit facility agreement\nwith the European Investment Bank”), the Company entered into a warrant agreement as a condition to\nthe funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of €0.01\nand gives the right to subscribe to one share.\nThe number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by\nthe Company through one or more equity offerings, or through upfront or milestone payments, from the\ndate of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the\naverage price per share paid for the Company’s shares in its most recent qualifying equity offering or\n(ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price\nper share of the Company over the last 180 calendar days.\nThe EIB Warrants have a maturity of twelve years and are exercisable following the earliest to occur of\n(i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the\nFinance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants\nshall automatically be deemed null and void if they are not exercised within the twelve-year period.\nEach EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise\nprice (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has\nbeen adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB\nTranche A Warrant entitles its holder to subscribe for 1.20 ordinary shares in the Company. EIB is\nentitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB\nWarrants not yet exercised in certain of these occurrences.\nOn November 28, 2022, the Company issued 2,266,023 EIB Tranche A Warrants to EIB, in accordance\nwith the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022\nand Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A,\nrepresenting approximately 4.7% of the Company’s share capital as of June 30, 2024. The exercise price\nof the EIB Tranche A Warrants is €4.0152, if and when they may be exercised. The potential gross\nproceeds if all EIB Tranche A Warrants were exercised would amount to €9.1 million. The transactions\ncosts for the issuance of the EIB Tranche A Warrants amounted to €56 thousands.\nOn January 4, 2024, the Company issued 3,144,654 EIB Tranche B Warrants to EIB, representing\napproximately 5.2% of the Company’s share capital as of June 30, 2024, in accordance with the terms\nof the 6th resolution of the Combined General Shareholders' Meeting of January 25, 2023, and Article\nL. 225-138 of the French Commercial Code. The exercise price of the EIB Tranche B Warrants is €3.95,\nif and when they may be exercised. The potential gross proceeds if all EIB Tranche B Warrants were\nexercised would amount to €12.4 million. The transactions costs for the issuance of the EIB Tranche B\nWarrants amounted to €90 thousands.\nThe EIB Warrants do not meet the “fixed for fixed” criteria (non-cash settlement option which may\nresult in exchanging a variable number of shares for a variable price) and are accounted for as standalone\nderivative instruments. The Company’s put options meet the definition of a derivative that are valued\nwith the EIB Warrants.\nThe warrant agreement includes a put option: EIB may request the Company to buy back the EIB\nWarrants in cash. In this context the purchase price will be defined as the difference between the volume\nweighted average of the trading price of the ordinary shares over the last 90 trading days and the strike\nprice. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise\nthe put option.\nAt inception, the financial debts are split between i) a debt component accounted for at amortized cost,\nand ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at\n56\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nfair value through profit and loss) including a component corresponding to the put options.\nValuation approach\nThe fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach,\nincluding the put option and the attached cap.\nThis approach enables the estimation of the value of American options (that may be exercised during a\nspecific period of time) with complex way of exercise (the warrant holder may exercise the warrants on\nthe market based on the Company’s share price or exercise the put option based on the 90 days average\nshare price of the Company).\nThe Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the\nvaluation date, the volatility observed on the historical share price of the Company, and the contractual\nlifespan associated equity instruments.\nThe hypothesis and results are detailed in the following tables:\nBSA 2022 BSA 2024\nGrant date 11/28/2022 01/04/2024\nExpiration date 11/28/2034 01/04/2036\nNumber of BSA issued 2,266,023 3,144,654\nNumber of shares per BSA 1 1\nSubscription premium price per share (€) 0.01 0.01\nExercise price per share (€) 4.02 3.95\nValuation method Longstaff Schwartz Longstaff Schwartz\n57\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of November 28, 2022 As of December As of June 30,\nEIB Tranche A Warrants (Grant Date) 31, 2023 2024\nNumber of BSA outstanding 2,266,023 2,266,023 2,266,023\nNumber of shares per BSA 1.00 1.20 1.27\nStock price (€) 4.13 4.10 2.79\nMaturity (years) 12 10.9 10.4\nVolatility 68% 62% 59.6%\nCap of the put option (m€) 25.0 25.0 25.0\nRisk free rate Euribor 6M Euribor 6M Euribor 6M\nExpected dividends — — —\nFair Value (k€) 9,469 10,266 6,738\nUnit fair value (€) 4.18 4.53 2.97\nAs of January 4, 2024 As of June 30,\nEIB Tranche B Warrants (Grant Date) 2024\nNumber of BSA outstanding 3,144,654 3,144,654\nNumber of shares per BSA 1.00 1.00\nStock price (€) 4.12 2.79\nMaturity (years) 12 11.5\nVolatility 62% 59.6%\nCap of the put option (m€) 25.0 25.0\nRisk free rate Euribor 6M Euribor 6M\nExpected dividends — —\nFair Value (k€) 11,809 6,830\nUnit fair value (€) 3.76 2.17\nLease liabilities\nLease liabilities amount to €5.8 million as of June 30, 2024, and decreased by €0.8 million compared to\nDecember 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period\nof three or four years regarding the location of use. Lease liabilities are calculated using specific discount\nrates, in connection with the geographic area, the maturity of the debt, and the commencement date,\naccording to the method described in Note 3.2 of the consolidated financial statements as of December\n31, 2023. The rates for contracts in progress as of June 30, 2024 range from 1.89% to 5.18%.\nThe breakdown between long-term and short-term debt is as follows:\n58\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nJune 30, 2024 Between 1 and Between 3 and More than\nTotal Less than 1 year\nIn thousands of euros 3 years 5 years 5 years\nBank borrowings 42,509 3,229 36,164 2,225 890\nDerivatives 13,569 - 13,569 - -\nOther loans 4,302 42 4,260 - -\nLease liabilities 5,761 2,455 3,306 - -\nRoyalty certificates liabilities 7,263 - - - 7,263\nTotal debt 73,404 5,726 57,299 2,225 8,153\nDec. 31, 2023 Between 1 and Between 3 and More than\nTotal Less than 1 year\nIn thousands of euros 3 years 5 years 5 years\nBank borrowings 27,206 2,928 4,872 17,848 1,558\nDerivatives 10,265 − − 10,265 −\nOther loans and similar borrowings 3,719 82 - 3,636 -\nLease liabilities 6,565 2,298 4,267 - -\nRoyalty certificates liabilities 6,327 - - - 6,327\nTotal debt 54,082 5,308 9,140 31,749 7,885\nThe maturity of long-term debt and of short-term borrowings and debt is determined according to\ncontractual repayment terms as of June 30, 2024 and December 31, 2023.\nRoyalty Certificates liabilities\nOn August 31, 2023, the Company announced the issuance of the royalty certificates (“2023 Royalty\nCertificates”) for an aggregate amount of €5.1 million.\nThe 2023 Royalty Certificates are accounted at the inception at the fair value (€5.1 million on August\n31, 2023), and then at the amortized cost (€7.3 million on June 30, 2024 vs. €6.3 million on December\n31, 2023) with an effective interest rate of 31.9%.\nFair value as of June 30, 2024\nOn June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow\napproach, amounts to €9.1 million.\nThe fair value corresponds to the net present value of royalties, which depend on assumptions made by\nthe Company with regards to the probability of success of its studies, the markets sales of lanifibranor\nand the discount rate (27.9%). The discount rate has been estimated based on a reconciliation between\nthe Company’s business plan and the Company’s market capitalization as of June 30, 2024.\n4.11 Provisions\nThe Company has no provisions as of June 30, 2024, and December 31, 2023.\n4.12 Provisions for retirement benefit obligations\nRetirement benefit obligations are determined based on the rights set forth in the national collective\nbargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in\n59\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\naccordance with IAS 19 – Employee Benefits. These rights depend on the employee’s final salary and\nseniority within the Company at his/her retirement date.\nNet provision\nThe provision recorded in respect of defined benefit schemes at the end of each reporting period is\nshown in the table below:\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nRetirement benefit obligations 1,555 1,559\nTotal obligation 1,555 1,559\nGiven the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the\nprovision corresponds to the estimated obligation at those dates.\nChanges in the net provision\nChanges in the provision recorded in respect of defined benefit schemes break down as follows:\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nProvision at beginning of period (1,559) (1,234)\nExpense for the period (70) (228)\nActuarial gains or losses recognized in other comprehensive\n74 (97)\nincome\nProvision at end of period (1,555) (1,559)\nBreakdown of expense recognized for the period\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nService cost for the period (104) (183)\nInterest cost for the period (25) (46)\nBenefits for the period 59 -\nTotal (70) (228)\n4.13 Other current and non-current liabilities\nOther non-current liabilities\nAs of June 30, 2024 and December 31, 2023 non-current liabilities amount to €1.0 million related to an\nagreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance\nfor certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ.\nOther current liabilities\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nEmployee-related payables 1,739 1,869\nAccrued payroll and other employee-related taxes 1,801 1,540\nSales tax payables 2,140 3,569\nOther accrued taxes and employee-related expense 142 164\nOther miscellaneous payables 12 23\nOther current liabilities 5,834 7,165\nNo discounting has been performed on other current liabilities as their maturity is less than one year at\nthe end of the period.\n60\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAccrued payroll and other employee-related taxes mainly relate to payables to social security and\nemployee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024.\nOther accrued taxes and employee-related expenses concern provisions for payroll taxes, such as\nprofessional training charges, apprenticeship tax, the employer’s contribution to construction investment\nin France and the payroll tax.\n4.14 Trade payables and short-term contract liabilities\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nTrade payables 36,583 37,679\nShort-term contract liabilities 3 6\nOther current liabilities - -\nTrade payables and other current liabilities 36,586 37,685\nNo calculations have been made to discount trade payables to present value as payment is due within\none year at the end of the reporting period.\nTrade payables\nTrade payables break down as follows:\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nDue in 30 days 26,217 24,995\nDue in 30-60 days 10,362 12,684\nDue in more than 60 days 4 0\nTrade payable 36,583 37,679\nAs of June 30, 2024, trade payables mainly included accrued liabilities for €24.0 million of which €20.2\nmillion relate to scientific projects.\nAs of June 30, 2024, trade payables decreased by €1.1 million compared to December 31, 2023. Trade\npayables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than\n3%).\n4.15 Financial assets and liabilities\nThe table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting\ncategory:\n61\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nJune 30, 2024\nFinancial\nBook value Financial\nassets/liabilitie Liabilities\non the assets\ns carried at carried at\nstatement of carrieds at Fair value\nfair value amortized\nfinancial amortized\nthrough profit cost\nposition cost\nFinancial assets or loss\nLong-term accrued income 0 - 0 - 0\nLong-term deposit accounts - - - - -\nAdvance payment 1,047 - 1,047 - 1,047\nCurrent accrued income 1,687 - 1,687 - 1,687\nShort-term deposit accounts - - - - -\nTrade receivables 809 - 809 - 809\nOther receivables 2,518 - 2,518 - 2,518\nCash and cash equivalents 10,147 - 10,147 - 10,147\nTotal 16,208 - 16,208 - 16,208\nFinancial liabilities\nLong-term debt (1) 46,846 - - 46,846 45,994\nDerivative instruments 13,569 13,569 - - 13,569\nRoyalty certificates liabilities 7,263 - - 7,263 9,050\nShort-term debt 5,726 - - 5,726 5,726\nTrade payables 36,583 - - 36,583 36,583\nOther miscellaneous payables 12 - - 12 12\nTotal 109,998 13,569 - 96,429 110,933\n(1) See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB\n62\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDec. 31, 2023\nFinancial\nBook value Financial\nassets/liabilitie Liabilities\non the assets\ns carried at carried at\nstatement of carrieds at Fair value\nfair value amortized\nfinancial amortized\nthrough profit cost\nposition cost\nFinancial assets or loss\nLong-term deposit accounts 9,000 - 9,000 - 9,000\nLong-term security deposits 8 - 8 - 8\nAdvance payment 1,047 - 1,047 - 1,047\nShort-term deposit accounts 70 - 70 - 70\nTrade receivables 3,807 - 3,807 - 3,807\nOther receivables 857 - 857 - 857\nCash and cash equivalents 26,918 - 26,918 - 26,918\nTotal 41,706 - 41,706 - 41,706\nFinancial liabilities\nLong-term debt (1) 32,181 - - 32,181 29,701\nDerivative instruments 10,265 10,265 - — 10,265\nRoyalty certificates liabilities 6,327 - - 6,327 9,617\nShort-term debt 5,308 - - 5,308 5,308\nTrade payables 37,679 - - 37,679 37,679\nOther miscellaneous payables 23 - - 23 23\nTotal 91,784 10,265 - 81,518 92,594\nNote 5. Notes to the interim condensed consolidated statement of (income) loss\n5.1 Revenues and other income\nFor the six months ended June 30, 2024, and June 30, 2023\nOperating income Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nRevenue 41 1,901\nTotal revenue 41 1,901\nTax credits 2,630 3,631\nSubsidies 5 3\nOther 58 1,087\nOther income 2,693 4,721\nTotal revenue and other income 2,734 6,622\nOther operating income\nThe Research Tax Credit (\"CIR\") generated over the first six months of the fiscal year amounts to €2.7\nmillion in 2024 as in 2023.\nAs of June 30, 2023, other operating income are composed of:\n• The R&D Tax Research Credit from Inventiva Inc amounting to €1.0 million, compared to €0.8\nmillion in tax income as of June 30, 2024;\n• The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to €0.3 million as\nof June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3,\nand the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to\n€0.7 million, compared to €2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as\na reduction in research and development expenses.\n5.2 Operating expenses\n63\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended June 30, 2024 Research and Marketing – General and\ndevelopment Business administrative Total\nIn thousands of euros\ncosts development expenses\nDisposables (887) - - (887)\nEnergy and liquids (447) - - (447)\nPatents (643) - - (643)\nStudies (34,073) - - (34,073)\nMaintenance (526) - - (526)\nFees (118) (2) (2,675) (2,795)\nIT systems (405) (6) (33) (444)\nSupport costs (including taxes) - - (375) (375)\nPersonnel costs (7,637) (153) (2,600) (10,391)\nDepreciation, amortization and provisions (1,732) - (122) (1,854)\nInsurances - - (921) (921)\nOther operating expenses (352) (437) (975) (1,764)\nTotal operating expenses (46,822) (598) (7,701) (55,122)\nSix months ended June 30, 2023 Research and Marketing – General and\nBusiness administrative Total\nen milliers d’euros development costs development expenses\nDisposables (943) - - (943)\nEnergy and liquids (479) - - (479)\nPatents (257) - - (257)\nStudies (42,847) - - (42,847)\nMaintenance (459) - - (459)\nFees (61) - (1,884) (1,945)\nIT systems (440) (9) (50) (498)\nSupport costs (including taxes) - - (343) (343)\nPersonnel costs (7,065) (126) (2,347) (9,538)\nDepreciation, amortization and provisions (1,061) - (104) (1,166)\nInsurances - - (1,121) (1,121)\nOther operating expenses (450) (570) (964) (1,985)\nTotal operating expenses (54,062) (705) (6,812) (61,580)\nPersonnel costs and headcount\nMarketing –\nResearch and General and\nSix months ended June 30, 2024 Business\ndevelopment administrative Total\ndevelopment\ncosts expenses\nexpenses\nIn thousands of euros\nWages, salaries and similar costs (4,824) (120) (1,237) (6,181)\nPayroll taxes (1,312) (10) (563) (1,886)\nProvisions for retirement benefit obligations (51) - (35) (86)\nShare-based payments (1,450) (24) (765) (2,238)\nTotal personnel costs (7,637) (153) (2,600) (10,391)\nThe Company has 123 employees as of June 30, 2024, of which 112 are employed by Inventiva S.A.\nand 11 are employed by Inventiva Inc.\n64\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nSix months ended June 30, 2023 Marketing –\nResearch and General and\nBusiness\ndevelopment administrative Total\ndevelopment\nIn thousands of euros costs expenses\nexpenses\nWages, salaries and similar costs (4,399) (104) (1,191) (5,694)\nPayroll taxes (1,222) (10) (476) (1,708)\nProvisions for retirement benefit obligations (61) - (29) (90)\nShare-based payments (1,383) (13) (650) (2,046)\nTotal personnel costs (7,065) (126) (2,347) (9,538)\nThe Company had 117 employees as of June 30, 2023, including 105 people employed by Inventiva\nS.A. and 12 people employed by Inventiva Inc.\n5.3 Other operating income and expenses\nOther operating income and expenses break down as follows:\nSix months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nOther operating income 160 -\nOther operating expenses (22) (44)\nOther operating income and expenses 138 (44)\n5.4 Financial income and expenses\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended\nIn thousands of euros\nJune 30, 2024 June 30, 2023\nIncome from cash equivalents 430 564\nForeign exchange gains 157 187\nGain on fair value variation 8,506 1,623\nTotal financial income 9,093 2,373\nInterest cost (5,218) (1,941)\nForeign exchange losses (323) (683)\nOther financial expenses (46) (23)\nTotal financial expenses (5,586) (2,646)\nNet financial income 3,507 (273)\nIn the first six months of 2024, financial income is mainly composed of a €8.5 million change in fair\nvalue of the EIB Warrants issued in connection with Tranches A and B.\nFinancial expenses mainly include exchange losses, financial interests related to PGE and PPR credit\nagreements and the financing agreement with the EIB, and financial interests related to lease liabilities.\n5.5 Share of net profit – Equity method\nThe tables below provide the summarized statement of income (loss) for the associate Hepalys. The\ninformation disclosed reflects the amounts presented in the financial statements of Hepalys and not the\nCompany's share of those amounts. They have been amended to reflect adjustments made by the\n65\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nCompany when using the equity method, in this case fair value adjustments. The tables below provide\nalso the reconciliation between Hepalys' loss and the share of net loss recognized in the Company\nstatement of financial position.\n(in thousands of euros) For the period started January 1, 2024, to June 30, 2024\nResearch and development costs (51)\nGeneral and administrative expenses (1,475)\nNet operating loss (1,526)\nFinancial income 20\nFinancial expenses (3)\nNet financial income 17\nIncome (expense) tax -\nNet loss for the period (1,509)\nExchange difference on translation of foreign operations (1,964)\nItems that will be reclassified subsequently to profit or loss (3,473)\nTotal comprehensive loss (3,473)\nGroup's share in % 14.64%\nShare of net profit 235\nElimination of downstream sales (66)\nShare of net profit - Equity method 168\nIn 2024, Hepalys did not generate any sales.\n5.6 Income tax\nThe income tax calculation for interim periods is set out in Note 3.3 – Specific disclosure requirements\nfor unaudited interim financial statements.\nAs the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered\nunlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December\n31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A.\nThe €119 thousand income tax recorded was related Inventiva Inc.\n5.7 Basic and diluted loss per share\nBasic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the\nCompany by the weighted average number of ordinary shares outstanding during the six-month period\nended June 30, 2024.\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nWeighted average number of shares outstanding used to calculate\n51,982,093 42,044,796\nbasic/diluted loss per share(1)\nBasic/diluted loss per share (0.94) (1.31)\n(1) In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group\nas of June 30, 2024 and 2023.\n66\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the\nsame as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and\nPAGUP) are not included as their effects would be anti-dilutive.\nNote 6. Other financial information\n6.1 Commitments related to operational activities\nObligations under the terms of subcontracting agreements\nIn the ordinary course of its business, the Company enters into agreements with CROs for clinical trials,\nas well as with contract manufacturing organizations (“CMOs”) for clinical and commercial supply\nmanufacturing, commercial and pre-commercial activities, research and development activities and\nother services and products for operating purposes. The Company’s agreements generally provide for\ntermination with specified periods of advance notice.\nSuch agreements are generally cancellable contracts and are not included in the description of the\nCompany’s contractual obligations and commitments.\nCommitments given and received\nJune 30, 2024 December 31, 2023\nIn thousands of euros\nCRO1 175,461 183,366\nCMO 6,846 5,733\nLease 7,592 8,595\nOthers 20,361 23,442\nTotal commitments given 210,261 221,136\nAgreements concerning the provision of facilities 296 260\nTotal commitments received 296 260\n1Including CRO with Pharmaceutical Research Associates B.V.\nCRO Contract with Pharmaceutical Research Associates Group B.V.\nIn April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered\ninto an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract\naims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United\nStates.\nThe Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa\nclinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical\ntrial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2\ninhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this\nagreement amounts to an aggregate of €13.3 million.\nOn June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered\ninto a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA.\nThe amendment updates the provisions relating to study information following changes to the trial\nprotocol. In June 2024, the Company entered into a new amendment, the new commitment amount to\nPRA is €254.3, with a bonus or malus will decrease from €3.4 million to €0.7 million in 2026. The\ncommitment also includes €20.2 million to be paid by CTTQ.\n67\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of June 30, 2024, the amount remaining to be paid under the contract is €158.6 million.\n6.2. Related-party transactions\nNo other new material transactions were entered into with related parties of the Company during the\nfirst six months of 2024.\n6.3 Financial risk management\nThrough its business activities, the Company is exposed to various types of financial risk: foreign\nexchange risk, credit risk and liquidity risk.\nThe financial risks are those described in the financial statements prepared in accordance with IFRS for\nthe year ended December 31, 2023, as updated for risks regarding liquidity which are described in the\nNote 3.4 — Going Concern.\n6.4 Events after the reporting date\nUpdate on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.\nOn July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating\nlanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both\ncohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the\nexploratory cohort of NATiV3.\nThe first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024,\nand topline results are expected at the beginning of the second half of 2026. The Company’s patent\nportfolio strengthened with new a patent secured in Japan that that provides intellectual property rights\non protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039,\nexcluding any potential patent term adjustments or extensions that may provide additional protection\nuntil 2043.\nIssuance of royalty certificates\nOn July 18, 2024, the Company announced the issuance of 201 royalty certificates (the “2024 Royalty\nCertificates”) for aggregate gross proceeds of approximately €20.1 million. The 2024 Royalty\nCertificates will provide the holders thereof with the right to an annual payment of royalties equal to 3%\nof the future net sales, if any, of lanifibranor beginning on the fiscal year following the start of the sales\nof lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States\nof America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs the\nfirst, if at all. The 2024 Royalty Certificates have a term of 14 years following the date of issue.\nApproving of patent application\nOn July 25, 2024 the Company announced that the Japan Patent Office (“JPO”) approved Inventiva’s\npatent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients\nwith cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent\nterm adjustments or extensions that may provide additional protection.\nFinancing in three tranches for a maximum amount of €348 million\nThe Company announced the following financing on 14 October 2024 structured in three tranches:\n(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific\ncategory of beneficiaries (“à catégorie de personnes”), of new ordinary shares at a gross value, including\nissuance premium, of €94.1 million through the issuance of 34,600,507 new ordinary shares, par value\n€0.01 per share (each, a “T1 New Shares”), and 35,399,481 prefunded warrants to subscribe for shares\n68\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nin the Company at a price outstanding of €0.01 per new ordinary share, each giving the right, in the\nevent of exercise, to one new ordinary share (the “T1 BSAs”);\n(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”), of new ordinary shares, par\nvalue €0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each,\na “T1bis New Shares”), for a total amount of €21.4 million (excluding exercise of pre-funded warrants);\n(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”) subject to operational conditions\nto be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before\nDecember 16, 2024, (or prefunded warrants) to which share warrants (the “ABSAs”) are attached for a\ntotal amount of €116,000,000. Each ABSA will consist of a number of new ordinary shares with a par\nvalue of €0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a\n“T2 New Share”) to which will be attached a number warrants exercisable at an exercise price of €1.50\n(each, a “T3 BSA”) allowing the subscription of a number of new ordinary shares of the Company for\na maximum total amount of €116,000,000.\nThe subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024,\nand the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October\n17, 2024, subject to the absence of any material adverse event between the signing of the agreements\nand the settlement-delivery of the T1 New Shares and the T1 BSA.\nAmendment to the exclusive license and collaboration agreement with CTTQ\nOn October 11, 2024, the Company has entered into an amendment (the “Amendment”) to the exclusive\nlicense and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (“CTTQ”),\ndated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription\ncommitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three\ntranches, for a total gross amount of at least €180,000,000 (the “Fund Raising”), CTTQ shall pay to the\nCompany (i) $10,000, 000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants\nin the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000\nin the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon\npublication by the Company of the pivotal data announcing that the primary endpoint or one of the two\nkey secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met.\nUnder the terms of the Amendment, the total amount of potential clinical, regulatory and commercial\nmilestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been\nreduced to a low figure.\n69\n4. Other information\n4.1. Table of delegations\nOn June 20, 2024, shareholders met in a Combined General Meeting to determine the financial authorizations to be granted to the Board of Directors.\nThe current delegations and their use are presented in the table below:\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nDelegation of authority to the Board of Directors to\nincrease the share capital by issuance of ordinary shares\nor securities giving access to ordinary shares, to be Capital increase:\nissued immediately or in the future by the Company, EUR 700,000\nwith shareholders’ preemptive subscription rights, in Twenty-first Securities giving\n26 months None\naccordance with the provisions of articles L.225-129 resolution access to capital to\nand L.22-10-49 and seq. of the French Commercial be issued: EUR Capital increase:\nCode, and in particular articles L.225-129-2, L.225-132 150,000,000 EUR 700,000\nto L.225-134, and the provisions of articles L.228-91\nSecurities giving\nand seq. of the French Commercial Code\naccess to capital to\nbe issued: EUR\n150,000,000\nDelegation of authority to the Board of Directors to\nincrease the share capital of the Company by issuance Capital increase:\nof EUR 700,000\nordinary shares or securities giving access to the share Twenty-second Securities giving\n26 months Refer to (1) below None\ncapital of the Company, immediately or in the future, resolution access to capital to\nwithout shareholders’ preemptive subscription rights, be issued: EUR\nby way of public offerings, excluding offers referred to 150,000,000\nin Article L.411-2- 1° of the French Code monétaire et\n70\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nfinancier, in accordance with the provisions of Articles\nL.225-129 and L.22-10-49 and seq. of the French\nCommercial Code, and in particular Articles L.225-\n129-2, L.22-10-51 and L.22-10-52, and with the\nprovisions of Articles L.228-91 and seq. of the French\nCommercial Code\nDelegation of authority to the Board of Directors to\nincrease the share capital by issuance of ordinary shares\nor securities giving access to ordinary shares, to be Capital increase:\nissued immediately or in the future by the Company, EUR 625,000 and up\nwithout shareholders’ preemptive subscription rights, to the limit of 30%\nby way of public offerings referred to in Article L.411- of the share capital\nTwenty-third\n2 1° of the French Code monétaire et financier, in 26 months per year. Refer to (1) below None\nresolution\naccordance with the provisions of articles L.225-129 Securities giving\nand seq. and article L.22-10-49 of the French access to the capital\nCommercial Code, and in particular articles L.225-129- to be issued: EUR\n2, L.22-10-51 and L.22-10-52, and the provisions of 150,000,000\narticles L.228-91 and seq. of the French Commercial\nCode\nAuthorization and/or delegation to the Board of\nDirectors to set the issuance price on the capital\nincreases by way of public offerings, without 10% of the share\nshareholders’ preemptive rights, pursuant to the terms Twenty-fourth capital per 12-month\n26 months Refer to (2) below None\nset by the General Shareholders' Meeting, and up to the resolution period from June 20,\nlimit of 10% of the share capital, in accordance with the 2024\nprovisions of Article L.22-10-52 of the French\nCommercial Code\n71\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nDelegation of authority to the Board of Directors to\nincrease the share capital of the company by issuance\nof ordinary shares or securities giving access to Decision of the\nCapital increase:\nordinary shares of the Company, immediately or in the Board of Directors on\nEUR 700,000\nfuture, reserved for certain specific categories of 11/10/2024: issue of\nTwenty-fifth Securities giving\nbeneficiaries, without shareholders’ preemptive 18 months Refer to (3) below 34.600.507 T1 New\nresolution access to the capital\nsubscription rights4, in accordance with Articles L.225- Shares and\nto be issued: EUR\n129 and seq. and L.22-10-49 of the French Commercial 35.399.481 T1\n150,000,000\nCode, and in particular Articles L.225-129-2, L.225- Warrants.\n129-4, L.22-10-51, L.225-138, L.228-91 and seq. of the\nFrench Commercial Code\nDelegation of authority to the Board of Directors to\ndecide to issue ordinary shares to be issued\nimmediately or in the future by the Company, without Twenty-sixth Capital increase:\n18 months Refer to (4) below None\nshareholders' preemptive subscription right in favor of resolution EUR 250,000,000\na category of persons meeting certain specified\ncharacteristics in the context of an equity financing\n4 The categories of beneficiaries must have one of the following characteristics: (i) natural or legal persons (including companies), trusts or investment funds, or other investment vehicles, in any form, established under\nFrench or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or (ii) companies, institutions or entities, in any form, French or foreign, exercising a significant\npart of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or (iii) French or foreign investment services companies, or any\nforeign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities\nthat are being issued.\n72\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nagreement on the American market known as \"At-the-\nmarket\" or \"ATM\"\nAuthorization to the Board of Directors to increase the\n26 months or 18\nnumber of securities to be issued as part of share capital\nTwenty-seventh months (if used in the 15% of the initial Same price as the\nincreases with or without shareholders’ preemptive None\nresolution context of resolution issuance initial issuance\nsubscription rights, in accordance with Articles L.225-\n25 or resolution 26)\n135-1 and R.225-118 of the French Commercial Code\nDelegation of authority to the Board of Directors to\nincrease the share capital of the company by issuance\nof ordinary shares or securities giving access to Capital increase:\nordinary shares of the Company, immediately or in the EUR 420,000\nfuture, as part of a public exchange offer initiated by Twenty-eight Securities giving\n26 months None\nthe Company, in accordance with Articles L.225-129 resolution access to the capital\nand seq. and L.22-10-49 of the French Commercial to be issued: EUR\nCode, in particular Articles L.225-129-2 and L.22-10- 150,000,000\n54, and Articles L.228-91 and seq. of the French\nCommercial Code\n73\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nCapital increase:\nDelegation of authority to the Board of Directors to within the limit\nincrease the share capital of the company by issuance provided for by the\nof ordinary shares or securities giving access to laws and regulations\nordinary shares of the Company, immediately or in the in force at the time\nfuture, in consideration for contributions in kind up this delegation is\nwithin the limits set by laws and regulations, excluding Twenty-ninth used (currently ten\n26 months None\nthe case of a public exchange offer initiated by the resolution (10) % of the share\nCompany, in accordance with the provisions of Articles capital over a twelve\nL.225-129 et seq. and L.22-10-49 of the French (12) month period)\nCommercial Code, in particular Articles L.225-129-2 Securities giving\nand L.22-10-53, and the provisions of Articles L.228- access to the capital\n91 and seq. of the French Commercial Code to be issued: EUR\n150,000,000\nDelegation of authority granted to the Board of\nDirectors to increase the share capital by issuing\nordinary shares or securities giving access to ordinary\nshares to be issued immediately or in the future by the\nCapital increase:\nCompany reserved for members of a company savings Thirtieth resolution 26 months Refer to (5) below None\nEUR 3,000\nplan to be set up by the Company in accordance with\nthe conditions set out in Articles L.3332-18 and seq. of\nthe French Labour Code, without shareholders' pre-\nemptive subscription rights.\n74\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nAuthorization to the Board of Directors to increase the\nshare capital of the Company by incorporating reserves,\nThirty-first Capital increase:\nprofits or premiums, in accordance with the provisions 26 months None\nresolution EUR 20,000\nof Articles L.225-129-2 and L.22-10-5 of the French\nCommercial Code\nCapital increase: 5%\nAuthorization for the Board of Directors to grant free of the share capital\nshares to employees and/or certain corporate officers, Thirty-second on the date of the\n38 months N/A None\nin accordance with Articles L.225-110-59 and L.225-resolution Board of Directors'\n197-2 of the French Commercial Code decision to grant\nthem\nAuthorization to the Board of Directors to grant\ncompany's' share subscription and/or purchase options\nCapital increase: 5%\nto corporate officers and employees of the Company or\nof the share capital\nof companies in the group, entailing the waiver by the\nThirty-third on the date of the\nshareholders of their preemptive subscription rights to 38 months Refer to (6) below None\nresolution Board of Directors'\nthe shares issued as a result of the exercise of\ndecision to grant\nsubscription options, in accordance with Articles\nthem\nL.225-177 and seq. and L. 22-10-56 of the French Capital increase:\nCommercial Code EUR 700,000\nDelegation of authority to the Board of Directors to 600,000 ordinary\ndecide on the issue of ordinary share subscription Thirty-fourth share subscription\n18 months Refer to (7) below None\nwarrants, without shareholders' preemptive resolution warrants Capital\nsubscription rights, to the benefit of categories of increase: EUR 6,000\n75\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\npersons5, in accordance with Articles L.225-138,\nL.225-129-2 and L.228-91 and seq. of the French\nCommercial Code\n(1) The issue price will be determined as follows: (i) the issue price of the shares to be issued under this resolution will be at least equal to the minimum authorized by the legislation in force\n(as of the date hereof, the weighted average of the prices for the last three trading sessions on the regulated market of Euronext in Paris preceding the start of the public offering, possibly\nreduced by a maximum discount of 10%), and (ii) the issue price of the securities to be issued under this resolution other than shares shall be such that the amount received immediately\nby the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities, at least equal\nto the amount referred to in (i) above.\n(2) The combined General Meeting of June 20, 2024 delegated to the Board of Directors the power to set the issue price of the shares within the limit provided for by the laws and regulations\nin force at the time this delegation is used (currently ten (10) % of the share capital over a twelve (12) month period), in accordance with the following conditions: (a) the issue price must\nbe at least equal to: (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting\nof the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris over a period chosen by the Board of Directors\ncomprising between three and seven consecutive trading sessions out of the last 30 trading sessions prior to the setting of the issue price; possibly reduced by a maximum discount of\n15%, the Board of Directors being free to use either of the two options set out above; and (b) the issue price of securities other than shares shall be such that the amount received\nimmediately by the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities,\nat least equal to the amount referred to in (a) above. In the absence of a minimum amount provided for by the laws and regulations in force as referred to in the 22nd and 23rd resolutions,\nthe Board of Directors is empowered to set the issue price of the securities to be issued under these resolutions in accordance with the following conditions: (i) the issue price must be at\nleast equal to: (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting of the\nissue price, or (b) the volume-weighted average of the Company's share prices on the regulated market of Euronext in Paris selected from a period comprising between three and seven\nconsecutive trading sessions among the last 30 trading sessions prior to the setting of the issue price, possibly reduced by a maximum discount of 15%, the Board of Directors being free\n5 Targeted categories: (i) executive employees or executive officers or members of the Company's management team who are not corporate officers, or (ii) members of the\nBoard of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of\nthe Company or one of its subsidiaries, or consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service\nagreement with the Company in force at the time of use of this delegation by the Board of Directors, or (iii) employees of the Company.\n76\nto use either of the two formulas set out above, and (ii) the issue price of the securities to be issued under this resolution, other than shares, will be such that the amount immediately\nreceived by the Company plus, where applicable, any amount that may subsequently be received by the Company is, for each share issued as a result of the issue of these securities, at\nleast equal to the amount referred to in paragraph (i) above.\n(3) The issue price must be at least equal to : (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading\nsession preceding the setting of the issue price; or (b) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive\ntrading sessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being\nfree to use either of the two options set out above; and (ii) (a) the issue price of shares that may result from the exercise, conversion, exchange or redemption of securities giving access\nto the Company's capital issued under this authorization may be set, at the discretion of the Board of Directors, by reference to a calculation formula defined by the Board and applicable\nafter the issue of said securities (for example, on exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be applied, if the Board of\nDirectors deems it appropriate, on the date of application of the said formula (and not on the date of issue of the securities), and (b) the issue price of the securities to be issued under this\nresolution, other than shares, shall be such that the amount immediately received by the Company plus, if applicable, the amount that may subsequently be received by the Company is,\nfor each share issued as a result of the issue of these securities, at least equal to the amount referred to in paragraph (i) above.\n(4) The issue price must be at least equal to : (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session\npreceding the setting of the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive trading\nsessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being free to\nuse either of the two options set out above\n(5) The issue price(s) of the new shares or securities to be issued pursuant to this resolution will be determined in accordance with Article L.3332-19 of the French Labour Code, and resolves\nto set the maximum discount at 20%. However, the General Meeting expressly authorizes the Board of Directors to reduce or waive the discount, in particular to take account of the\nregulations applicable in the countries where the offer will be implemented.\n(6) The exercise price of the options granted under this resolution will be set by the Board of Directors as follows: (i) the exercise price of options to subscribe for ordinary shares may not\nbe less than 80% of the average of the prices quoted for the Company's shares on the regulated market Euronext Paris over the twenty (20) trading sessions preceding the day on which\nthe options are granted, and (ii) the exercise price of options to purchase shares may not be less than 80% of the average purchase price of the shares held by the Company under Article\nL. 22-10-61 of the French Commercial Code or, as the case may be, of the share buyback program authorized by the 19th resolution submitted to this General Meeting (i.e. January 25,\n2023) under Article L.22-10-62 of the French Commercial Code or of any share buyback program applicable previously or subsequently.\n(7) The issue price of a BSA 2024 will be determined by the Board of Directors on the date of issue of the BSA 2024, depending on their characteristics, and will in any event be at least\nequal to 8% of the market value of an ordinary share in the Company on the date of allocation of the BSA 2024, this market value corresponding to the weighted average of the prices\nfor the last twenty (20) trading sessions preceding the date of allocation of the said BSA 2024 by the Board of Directors for as long as the Company's shares are admitted to trading on\nthe regulated market of Euronext in Paris.\n77"
        },
        {
          "title": "Corporate presentation July 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/07/07-Inventiva-Presentation-ENG-07-31-2024.pdf",
          "content": "Developing innovative therapies in\nNASH\nCorporate Presentation\nJuly 2024\nDISCLAIMER\nThis presentation contains “forward-looking statements” within the meaning of the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical\nfacts, included in this press release are forward-looking statements.\nThese statements include, but are not limited to, forecasts and estimates with respect to Inventiva’scash resources and potential financing or strategic options and potential counterparties, forecasts and estimates\nwith respect to Inventiva’spre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollmentfor those trials, including the ongoing NATiV3 Phase III clinical trial\nwith lanifibranor in MASH/NASH, and the results and timing thereof and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from clinical trials, the potential therapeutic benefits of Inventiva’sproduct candidates, including lanifibranor alone and in combination with empagliflozin in patients with MASH/NASH and T2D, the\npotential of lanifibranor to address patient needs, the estimated market size and patient population, potential regulatory submissions, approvals and commercialization, Inventiva’spipeline and preclinical and\nclinical development plans, the expected benefit of having received Breakthrough Therapy Designation from the FDA and NMPA, including its impact on the development and review timeline of Inventiva’sproduct\ncandidates, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, the expected benefit of Inventiva’s\npartnerships and Inventiva’sability to achieve milestones and receive potential milestones under its partnership agreements. Certain of these statements,forecasts and estimates can be recognized by the use of\nwords such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”,\n“opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but ratherare statements of future expectations and other forward-looking statements that are based\non management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results,\nperformance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva'scontrol. There\ncan be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be\nmaterially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that Inventiva cannot\nprovide assurance on the impacts of the SUSAR on enrollmentor the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company\nwith no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product\nsales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development\nprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’sability to obtain financing and to enter into\npotential transactions, Inventiva'sfuture success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,\npreclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva'sand its partners’ clinical trials may not support Inventiva'sand its partners’ product candidate\nclaims, Inventiva'sexpectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’sclinical trials, Inventiva’sexpectations with\nrespect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not supportthe approval of a New Drug Application, Inventiva and its partners may encounter\nsubstantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and\nretain patients in clinical studies, enrollmentand retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors\noutside Inventiva'sand its partners’ control, Inventiva'sproduct candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial\npotential, Inventiva faces substantial competition and Inventiva’sand its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations\ncould be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollmentand completion\nof Inventiva’sand its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related riskof a larger conflict, health epidemics, and macroeconomic conditions,\nincluding global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates onlyspeak as of the date of this press release. Readers are cautioned not to place\nundue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes MarchésFinanciers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024. Other risks and uncertainties of whichInventiva is not currently aware may also affect its forward-looking statements and\nmay cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention\nand is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva acceptsno liability for any consequences arising from the use of any of the above\nstatements.\nCorporate Presentation | July2024 Property of Inventiva│ 2\nKey take-aways\nA Phase III ready program in R&D Capabilities and Cash\nA Phase III asset in NASH\nMPS(1) Position\nLanifibranor: only pan-PPAR agonist in Odiparcil: a GAG reduction therapy to R&D capabilities including wholly-\nclinical development for NASH potentially treat several forms of MPS owned ‘pharma scale’ discovery\nfacilities with a discovery engine\nPositive Phase IIb results with statistically Reduces GAG accumulation in multiple focused on nuclear receptors,\nsignificant efficacy on histological NASH organs in MPS VI models. Well-tolerated transcription factors and epigenetic\nresolution and one stage fibrosis reduction in MPS VI patients and in 1000s of targets\npatients previously tested(2)\nPositive Phase II, Proof-of-Concept, results of Clinical Ops team in place in Europe\nLEGEND with lanifibranor/empagliflozin Functional improvements to mobility and and the United States\nannounced in Q1 2024 respiratory function and clinical efficacy\nsignals in both ERT treated patients and Strong U.S. and European\nMechanism of action addressing all key ERT-naïve MPS VI patients shareholder base and experienced\nfeatures of NASH senior management team\nMPS VI Orphan Drug Designation\nBreakthrough Therapy Designation granted by granted in the U.S. and in the EU. Rare Cash position allowing a runway until\nFDA and Chinese NMPA Pediatric Disease Designation in MPS VI the beginning of Q3 2024\ngranted in the U.S.\nPivotal Phase III initiated in Q3 2021 with\ntopline results expected H1 2026 Guidance on path to regulatory\nsubmission from FDA with a single\nLicensing and commercialization agreements Phase II/III trial\nin Greater China, Japan and South Korea\nInventiva continues to review potential\noptions to further develop odiparcil which\nmay include pursuing a partnership\n(1)MPS:mucopolysaccharidosis;(2)TrialsconductedbyGSKpriortoInventiva’sfounding\nCorporate Presentation | July2024 Property of Inventiva│ 3\nManagement team with extensive global experience across all stages of\ndrug development and commercialization\nFrédéric Cren, MA/MBA, CEO and Co-Founder Pierre Broqua, Ph.D., CSO and Co-Founder\n Wide expertise within the areas of R&D, marketing,  Successfully managed numerous research programs\nstrategy and commercial operations leading to the discovery, development and\ncommercialization of innovative compounds, including\n Held senior positions at Abbott, Fournier, Solvay\nlanifibranor and Degarelix/ Firmagon®\nPharma and The Boston Consulting Group\n Held several senior research positions at Fournier,\n Former member of both Fournier and Solvay Pharma\nSolvay Pharma and Abbott\nExecutive Committees\nMichael Cooreman, MD, CMO\nJean Volatier, MA, CFO\n Gastroenterologist-hepatologist\n Former Head of controlling at URGO & Financial\nDirector International Operations of Fournier  Held global roles in several companies including\nTakeda Pharmaceuticals, Merck, Mitsubishi Tanabe,\n Held various positions as CFO\nImmusanT and Novartis\n Started his career with PwC in Paris and Philadelphia\nAlice Roudot-Ketelers, PharmD, COO\nPascaline Clerc, Ph.D., EVP Strategy and\nCorporate Affairs  Previously in charge of all drug development programs\nand cross-functional teams in Chemistry, CMC, non-\n Held global roles in academia, non-profit organization,\nclinical and clinical development up to Phase III at one\ngovernment and biotech companies\nof the major biotech companies in the NASH field\nKristina Meyer, Ph.D., Business Development\nDavid Nikodem, Ph.D., VP U.S. Operations\n& Alliance Management\n Former buyside portfolio manager and analyst for +15\n 20+ years experience in business development in the\nyears in public equities and VC\nbiotech industry\nCorporate Presentation | July 2024 Property of Inventiva│ 4\nDeep pipeline\nProgram Indication Discovery IND Enabling Phase I Phase II Phase III\nLanifibranor NASH pan-PPAR\nOdiparcil MPS VI GAG clearance\nYap-Tead\nOncology\nTGF-β\nFibrosis\nCorporate Presentation | July 2024\nProperty of Inventiva│ 5\nKey financials and shareholder base\nKey financials Shareholder base\nFree Float Founders\n25.2% 18.4%\nEmployees & Others BVF\nISIN code FR0013233012 / US46124U1079 2.3% 16.2%\nYiheng\n7.4%\nMarket Euronext Paris / Nasdaq GM\nSofinnova NEA\n9.8% 10.8%\nQatar Holding LLC\nShares outstanding 52,477,188\n9.9%\nEuronext Paris: €117m\nMarket cap\nAnalyst coverage\n(July 31, 2024) Nasdaq Global Market: $121m\nJefferies L. Codrington / M. J. Yee\n€10.1m(1) (vs €35.9m as of December\nGuggenheim S. Fernandez\nCash position 31, 2023(2))\n(as of June 30, 2024) Current cash runway through September, incl. the Stifel A. Samimy\n€20.1m royalty certificates deal of July 18, 2024(3)\nHC Wainwright E. Arce\nCanaccord Genuity E. Nash\nRevenues(1) No revenue end of H1 2024 (vs\n(as of June 30, 2024) €1.9m in H1 2023) LifeSci Capital R. Katkhuda\nKBC J. Mekhael\nR&D expenditures €48.7m in H1 2024 (compared to € Portzamparc M. Kaabouni\n(as of June 30, 2024) 54.1m in H1 2023(1))\nGilbert Dupont P.A. Desir\n(1)Unaudited\n(2)Cashpositionalsoincluded:i.short-termdepositsrecordedinthecategory“othercurrentassets”intheIFRSconsolidatedstatementoffinancialpositionandwereconsideredbytheCompanyasliquidandeasilyavailable,ii.thelong-termdeposithadatwo-yeartermaccessiblepriortothe\nexpirationofthetermwithanoticeperiodof31daysandwasconsideredasliquidbytheCompany.\n(3)https://inventivapharma.com/wp-content/uploads/2024/07/Inventiva-PR-Royalty-Deal-EN-07-18-2024.pdf\nCorporate Presentation | July 2024 Property of Inventiva│ 6\nLanifibranor: licensing and commercialization agreement in Greater China,\nJapan and South Korea\nLicensing agreement in Greater China Licensing agreement in Japan / South Korea\nAgreement with CTTQ an affiliate of Sino Biopharm one of Licensing agreement with Hepalys Pharma, Inc. backed by\nthe largest Chinese pharmaceutical groups listed in Hong Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and\nKong Exchange (HSI composite) with a market cap of MEDIPAL Innovation Fund\nc.US$10bn(1) and c.US$4bn of revenue(2) and ranked top\n$10M upfront payment\n40th pharma globally(3)\nUp to $231M of clinical, regulatory and commercial\n$17 million of non-dilutive payments received\nmilestone payments\nUp to $290 million of clinical, regulatory and commercial\nTiered royalties from mid double digits to low twenties on\nmilestone payments\nnet sales\nTiered royalties from high single-digit to mid-teen double\nInventiva owns a stake of Hepalys Pharma, Inc. and has an\ndigits on net sales made during the first three years of\noption to acquire all outstanding shares at a pre-agreed\ncommercialization and from low to mid-teen double digits\nmultiple of post-money valuation\nstarting from year four.\nRight of first refusal in the event Hepalys receives an offer\nCTTQ will bear all costs associated with the trials conducted\nto sell the license or rights related to lanifibranor.\nin Greater China\nHepalys will bear all costs associated with the trials\nCTTQ to randomize patients into the NATiV3 Phase III\nconducted in Japan and South Korea\nclinical trial in mainland China\nDevelopment includes PK/PD Phase I studies and following\nphase I and NATiV3 results an independent pivotal Phase III\nstudy in Japan and South Korea\nInventiva eligible to more than 500M$ of milestones plus sales royalties\n(1) Information about Sino Biopharm, its business, operations and finances are based on third-party information and disclosures. Inventiva makes no representations regarding the accuracy of such information presented herein; (2) Market\ndata as of Sept 2022 ; (3) Converted from RMB to USD\nCorporate Presentation | July 2024 Property of Inventiva│ 7\nLanifibranor in Nonalcoholic\nSteatohepatitis (NASH)\nLanifibranor: a pan-PPAR agonist in Phase III development in NASH\nModerate and balanced pan-PPAR agonist activity\n Small molecule that activates all three PPAR isoforms in humans\nPPARα\n Differentiated chemical structure: not a fibrate or a TZD\n Once daily oral administration\n Positive Phase IIb trial topline results in NASH\n FAST Track (including in NASH patients with compensated cirrhosis) and\nBreakthrough Therapy designations granted by FDA and Chinese NMPA\n FDA confirmation that the non-clinical toxicology package is complete and\nPPARβ/δ PPARγ\nacceptable for NDA filing\nLANIFIBRANOR  IP: 19 families covering the compound, method of treatment, combination therapy,\nprocess, formulation and diagnostic methods. Last expiry expected in 2045\nPan-PPAR activity expected to improve efficacy in NASH\nINFLAMMATION AND\nMETABOLISM STEATOSIS FIBROSIS VASCULAR\nBALLOONING\nPPARα PPARδ PPARγ PPARγ PPARα PPARδ PPARγ PPARδ PPARγ PPARα PPARγ\nStellate cell\nInsulin sensitivity FA uptake NFkB-dependent Portal pressure\nproliferation and\ngene activation\nactivation\nHDLc FA catabolism LSEC capillarization\nInflammasome\nCollagen and\nTriglycerides Lipogenesis Intrahepatic vascular\nfibronectin\nBallooning resistance\nproduction\nCorporate Presentation | July 2024 Property of Inventiva│ 9\nPatent Extension Timeline\n2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045\nGranted Patent\nProduct:Composition\nof matter\nGranted Patent\nProduct: Crystallines forms of lanifibranor\nGranted patent - Pending Application in the US\nProduct: Deuterated forms of lanifibranor\nPending Application\nProduct: Crystallines forms of lanifibranor\nPending Application\nPCT\nProduct: Crystallines forms of lanifibranor\nGranted Patent Projected Potential Extensions\nApplication : Disease treatment (method claim; fibrosis condition; NASH)\nGranted Patent\nApplication : Disease treatment (method claim; cirrhosis)\nWe expect that NASH patent will be selected for Patent Term Extension (PTE).\nEligibility of the method of use patents for PTE assessed and confirmed by globally recognized IP law firm.\nComposition of matter patent and NASH patent have been granted in > 50 countries incl. EP, US, CN, JP, KR, AU, CA, RU.\nCorporate Presentation | July 2024 Confidential –Property of Inventiva│ 10\nLanifibranor is a differentiated pan-PPAR agonist with moderate and well\nbalanced activity on the three PPAR isoforms\nDifferentiated oral small molecule …\n Small molecule that\nactivates all three PPAR\nisoforms\n Differentiated chemical\nstructure with once daily\noral administration\n Offered in two dosage\nforms (800 mg, 1200 mg)\nModerate and balanced pan-PPAR agonist activity\n150\nPPARα PPARδ PPARγ\nCompound\nEC50 (nM) EC50 (nM) EC50 (nM)\n125\nLanifibranor* 1630 850 230\n100\n75 Fenofibrate 2400 - -\n50 Pioglitazone - - 263\nRosiglitazone - - 13\n25\nElafibranor** 10 100 -\n0\n-10 -8 -6 -4 Seladelpar^ - 2 -\nlanifibranor (M)\nSource: * Company data ** HanfR et al, Diabetes & Vascular Dis Res 2014 ^ Cymabaycompany presentation ^^ J Med Chem. 2018 Feb 15. doi: 10.1021/acs.jmedchem.7b01285\nProperty of Inventiva│ 11\nnoitavitcA%\nLANIFIBRANOR\n… that binds differently than glitazone to PPARγ\nROSI\nLANI\n Induces different coactivator recruitment^^\nhPPARα\nhPPARδ\nhPPARγ\nCorporate Presentation | July 2024\nAdverse events and toxicity previously seen in other single and dual PPAR\nagonists have not been observed with lanifibranor\nSAFETY\nOrgan Isoforms activated Reported PPAR side effects lanifibranor effects\n Fluid retention\nHEART PPARγ\n Cardiac hypertrophy\nSKELETAL\nPPARα  Myofiber degeneration\nMUSCLE\nNOT\nOBSERVED\n > 50% increases in creatinine, degenerative\nKIDNEY PPARα\nchanges in renal tubules\nURINARY\nPPARγ  Proliferative changes in bladder epithelium\nBLADDER\nAdverse events and toxicity of single / dual PPAR agonists not observed in primate and rodent studies\n No adverse clinical signs observed at any dose-level tested\nFAVOURABLE\n No effects on body and heart weight, no haemodilution or creatinine increase\nTOLERABILITY PROFILE in\na 12-month monkey study …  Electrocardiography and clinical pathology investigations did not reveal any\nundesirable effects\n Rat: no observed neoplastic change or increase in tumor types commonly associated\n… and in two-year with single PPARγ and dual PPARα/γ agonists (liver, adipose, bladder, renal and\nCARCINOGENITY STUDIES skin)\nperformed in rat and mice\n Mice: no observed neoplastic changes of human relevance\nConfirmation by FDA that the non-clinical toxicology package is complete and acceptable\nto support NDA filing in NASH\nSource: Company data\nCorporate Presentation | July 2024 Property of Inventiva│ 12\nLanifibranor: comprehensive impact on the histology and biology of NASH\nHISTOLOGY AND MARKERS\n1\nFibrosis Regression\nFibrosis NASH\n&\nRegression Resolution\nNASH Resolution\nHealthy liver Steatosis Steatohepatitis Liver fibrosis Cirrhosis\nSteatosis measured by Biomarkers of inflammation Circulating biomarkers of\nhistological grading, MRI-PDFF (ferritin, CRP), tissue injury fibrosis: Pro-C3, TIMP-\nCAP/Fibroscan; Intra-hepatic (ALT,AST) and apoptosis 1/MMP-2, MACK-3\nTG content by 1H-MRS(1); (CK18) Improvement seen with CT1\nNAFLD resolution scan\nGLUCOSE METABOLISM MARKERS CARDIOVASCULAR RISK MARKERS\nImproves insulin sensitivity and glycemic control in patients with or Improves markers of cardiovascular risk and lipid metabolism\nwithout diabetes\nAPO-B DBP\nHDL-C\nTreatment with lanifibranor decreases the ratio of visceral abdominal\nAPO-B/APO-A1 Adiponectin\nfat to subcutaneous fat, reflecting a shift from pro-inflammatory Triglycerides levels\nAPO-C3\nvisceral fat towards metabolically healthy adipose tissue LDL-cholesterol level\nHs-CRP\nFasting glucose HOMA-IR index Insulin resistance\nFasting insulin Hepatic glucose Hepatic and muscle Improves markers of cardiometabolic health independently of weight\nHbA1c production insulin resistance gain which has been shown to be metabolically healthy\nIncreases adiponectin known to regulate glucose levels, lipid\nmetabolism and insulin sensitivity through its anti-inflammatory, anti-\nfibrotic and antioxidant effects\n(1) Proton magnetic resonance spectroscopy\nCorporate Presentation | July 2024 Property of Inventiva│ 13\nThe Phase IIb NATIVE trial evaluated 800 mg and 1200 mg once-daily\nlanifibranor versus placebo in 247 patients\nPHASE IIb DESIGN OVERVIEW\n24-week treatment + 4-week follow-up\nScreening End of treatment\nDouble blind, randomized, placebo-controlled\n Liver biopsy  Liver biopsy\nPlacebo\nlanifibranor, 800 mg once daily\n• Randomisation 1/1/1\n• Stratification on\nlanifibranor, 1200 mg once daily\ntype 2 diabetes\nmellitus (T2D)\nPatient population # patients Definition\nPatients randomized having received at least one dose of\nSafety / Intention-to-Treat (ITT) 247\nlanifibranor/placebo\nPatients with paired biopsies and without deviation impacting efficacy\nPer Protocol (PP) 194\nresults\n Main inclusion criteria: patients with biopsy-proven NASH confirmed by central reader having Steatosis-Activity-Fibrosis\n(SAF) scores of 1-3 for steatosis, 3-4 for activity, and <4 for fibrosis\n Results published in the New England Journal of Medicine(1):\n(1) https://www.nejm.org/doi/full/10.1056/NEJMoa2036205\nCorporate Presentation | July 2024 Property of Inventiva│ 14\nThe majority of patients successfully completed the 24-week treatment\nPHASE IIb DESIGN TREATMENT ARMS\n247 patients randomised and treated\nPlacebo lanifibranor 800 mg/day lanifibranor 1200 mg/day\nN = 81 N = 83 N = 83\n74 (91%) patients completed 77 (93%) patients completed 77 ( 93%) patients completed\nthe 24-week treatment the 24-week treatment the 24-week treatment\n7 (9%) patients prematurely 6 (7%) patients prematurely 6 (7%) patients prematurely\nwithdrawn: withdrawn: withdrawn:\n- Adverse events (n=3) - Adverse events (n=3) - Adverse events (n=3)\n- Withdrawal by patient (n=2) - Lost to follow-up (n=1) - Lost to follow-up (n=1)\n- Forbidden concomitant - Withdrawal by patient* (n=1) - Withdrawal by patient (n=2)\nmedication (n=2)\n- Non-compliance (n=1)\nNote: * And adverse event as secondary reason\nCorporate Presentation | July 2024 Property of Inventiva│ 15\nPatient population included 58% of female and 42% of patients with T2D\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor Overall\nParameters (unit)\n- 800 mg/day 1200 mg/day -\nn (%) or mean ± SD\nN = 81 N = 83 N = 83 N = 247\nDemographics\nFemale 41 (51%) 54 (65%) 49 (59%) 144 (58%)\nAge (years) 53.4 ± 13.1 55.0 ± 10.4 52.2 ± 13.8 53.6 ± 12.5\nWhite 74 (91%) 80 (96%) 78 (94%) 232 (94%)\nWeight (kg) 95.1 ± 17.3 91.6 ± 19.3 93.0 ± 19.9 93.2 ± 18.9\nBody Mass Index (kg/m²) 32.8 ± 5.1 32.5 ± 5.5 33.3 ± 5.5 32.9 ± 5.4\nType 2 diabetes 35 (43%) 33 (40%) 35 (42%) 103 (42%)\nLiver biopsy characteristics\nSAF Activity score\n3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.5 3.3 ± 0.5\n(inflammation + ballooning)\nNAFLD Activity Score (NAS) ≥6 56 (69.1%) 63 (75.9%) 61 (73.5%) 180 (72.9%)\nFibrosis stage F2/F3 57 (70.4%) 68 (81.9%) 63 (75.9%) 188 (76.1%)\nCorporate Presentation | July 2024 Property of Inventiva│ 16\nSeveral liver tests and markers of lipid and glucose metabolism were\nrecorded\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor\nParameters (unit)\n- 800 mg/day 1200 mg/day\nmean ± SD\nN = 81 N = 83 N = 83\nLiver enzymes\nAlanine aminotransferase, ALT (UI/L) 56.9 ± 31.6 64.1 ± 41.4 63.6 ± 43.4\nAspartate aminotransferase, AST (UI/L) 43.3 ± 24.1 53.9 ± 43.4 43.9 ± 24.8\nGamma glutamyl transferase, GGT (UI/L) 67.9 ± 80.4 101.6 ± 146.1 67.1 ± 93.1\nPlasma lipid levels\nHDL-Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3\nTriglycerides (mmol/L) 2.0 ± 0.8 1.9 ± 0.9 2.0 ± 0.9\nGlucose metabolism for patients with T2D\n(n= 103)\nFasting Glucose (mmol/L) 6.9 ± 2.0 7.3 ± 2.2 6.6 ±1.2\nHbA1c (%) 6.5 ± 0.7 6.7 ± 0.8 6.6 ± 0.7\nInsulin (pmol/L) 222.7 ± 186.5 246.3 ± 213.4 278.5 ± 233.5\nCorporate Presentation | July 2024 Property of Inventiva│ 17\nLanifibranor achieves statistically significant results on the key Phase III\nFDA and EMA primary endpoints\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint: ITT population\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83)\nResolution of NASH and no\n45%\nworsening of fibrosis*\n33%\n19%\n0.043 <0.001\nImprovement of fibrosis by at\nleast one stage and no\n42%\nworsening of NASH** 28%\n24%\n0.53 0.011\nResolution of NASH and\n31%\nimprovement of fibrosis***\n21%\n7%\n0.017 <0.001\n Statistical significance was also demonstrated for the main key histological endpoints in patients with F2-F3 fibrosis stage\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of\nliver fibrosis ≥ 1 stage and no worsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1\nstage\nCorporate Presentation | July 2024 Property of Inventiva│ 18\nResolution of NASH and improvement of fibrosis: effect size is increased in\nF2/F3 patients as well as patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and\nimprovement of fibrosis(1) 3,0more 4,4more\nresponders on 31% responders on\n(N=247) 21%\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in 8,0more 9,6more\nresponders on 29% responders on\npatients with TD2M (N=103) 24%\n3% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3\n3,4more 4,7more\n33%\npatients (N=188) 24% responders on responders on\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3 7,5more 7more responders\n30% responders on 28% on 1200mg vs\npatients with TD2M (N=83)\n4% 800mg vs placebo placebo\n(1) ) Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | July 2024 Property of Inventiva│ 19\nImprovement of fibrosis and no worsening of NASH is achieved in all\nsubgroups analyzed with similar level of effect size\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nImprovement of fibrosis by at least\none stage and no worsening of 1,2more 1,7more\nNASH(1) (N=247) 24% 28% responders on 42% responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\n1,3more 2,0more\nNASH(1) in patients with TD2M\nresponders on 46% responders on\n30%\n(N=103) 23% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nImprovement of fibrosis by at least\none stage and no worsening of\n1,1more 1,6more\nNASH(1) in F2 / F3 patients (N=188) 48%\n30% 32% responders on responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\nNASH(1) in F2 / F3 patients with\n1,2more 1,6more\n48%\nTD2M (N=83) 37% responders on responders on\n30%\n800mg vs placebo 1200mg vs placebo\n(1) improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24\nCorporate Presentation | July 2024 Property of Inventiva│ 20\nResolution of NASH and no worsening of fibrosis: effect size is increased in\nF2/F3 patients as well as in patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and no\n1,7more 2,4more\nworsening of fibrosis(1) (N=247) 45%\n33% responders on responders on\n19%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in patients 2,3more 3,0more\n43%\nwith TD2M (N=103) 33% responders on responders on\n14%\n800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n3,8more 4,8more\n44%\npatients (N=188) 34% responders on responders on\n9%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n8,2more 10,2more\n41%\npatients with TD2M (N=83) 33% responders on responders on\n4%\n800mg vs placebo 1200mg vs placebo\n(1) Resolution of NASH with no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline\nCorporate Presentation | July 2024 Property of Inventiva│ 21\nLanifibranor efficacy on resolution of NASH and improvement of fibrosis of\nat least 1 stage is superior to resmetirom and at par with FGF-21\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=320 N=223 (F2/F3) N=190\nN=247 N=955 N=128 N=126 N=222\nITT ITT ITT PP\nEffect size Effect size Effect size Effect size Effect size\n24% 11% 28% 28% 20%\n35%\n33%\n31%\n26% 28%\n21%\n20%\n16%\n14% 15% 14%\nEndpoint not\n7% 7% reported on\n5% 5%\n0%\nPlacebo 800mg 1200mg Pbo 80mg 100mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg 30mg 44mg\n0.017* <0.001* <0.0001* <0.0001* 0.009* 0.002* <0.01* <0.01* QW(1) QW Q2W\n*** ***\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results; Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023 ; SemaglutideA\nPlacebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome et al. NEJM 2021; 384:1113-1124.; Resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10 and EASL 2023 presentation pg. 8; Efruxifermin EASL 2023 presentation pg.\n8, corporate presentation of March 2024 pg 22 ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Firbosis, The NEJM DOI:\n10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 22\nLanifibranor efficacy on ≥1 stage fibrosis improvement and no worsening\nof NASH is superior to resmetirom and at par with injectables\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n18% 12% 5% 14% 30% 20% 10% 21% 21%\n55%\n51% 51%\n49% 49%\n42% 43% 43%\n38%\n36%\n28% 29% 33% 30% 33% 32% 34% 30%\n24% 24%\n26%\n24%\n26%27%\n22% 22%\n19% 19%\n14%\n7%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo15mg30mg 44mg Pbo 0.1mg 0.2mg 0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\n0.53 0.011* 0.0002* <0.0001* 0.65 QW QW Q2W QW QW QW\n0.033*0.123 <0.01* 0.1*0.008*0.008* 0.48\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 23\nLanifibranor efficacy on NASH resolution and no worsening of fibrosis is\nsuperior to resmetirom and at par with pegozafermin\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n26% 20% 18% 46% 18% 24% 42% 35% 52%\n60% 59% 62%\n56%\n45% 43% 45% 46% 45% 44%\n40% 40%\n33% 37% 37% 36%\n30%\n26% 25% 26%\n23%\n19% 19%\n17%\n14%\n10% 10% 10%\n7%\n2%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg30mg44mg Pbo 0.1mg 0.2mg0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\nQW QW Q2W QW QW QW\n<0.043* <0.001* <0.0001*<0.0001* 0.024* 0.005*<0.001* 0.005* <0.0001* 0.0005* <0.001*\n0.0009*\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 24\nA statistically significant decrease in liver enzymes was observed\n10\n0\n-10\n-20\n0 4 8 12 16 20 24\nProperty of Inventiva│ 25\n)L/IU(\negnahc\netulosba\nnaeM\n10\n0\n-10\n-20\n-30\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/IU(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in ALT Absolute change from baseline in AST\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nAbsolute change from baseline in GGT\n10\n0\n-10\n-20\n-30\n-40\n-50\n0 4 8 12 16 20 24\n)L/IU(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247)\n**\n*\n** ** * **\n** *\n** ** * **\n0 W4 W14 W24\n* p<0.01 **p<0.001\nA statistically significant decrease of ALT,\nAST and GGT in both lanifibranor dose\n** ** groups observed after 4 weeks\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nSTNIOPDNE\nYRADNOCES\nCorporate Presentation | July 2024\nA statistically significant change in HDL-cholesterol and triglycerides was\nseen, without a change in LDL-cholesterol\n0.25\n0.15\n0.05\n-0.05\n0 4 8 12 16 20 24\nProperty of Inventiva│ 26\n)L/lomm(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in HDL-C Absolute change from baseline in triglycerides\n0.2\n0\n**\n-0.2\n-0.4\n-0.6\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/lomm(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247) * p<0.01 **p<0.001\n**\n**\n**\n*\n**\n** **\n**\n**\n0 W4 W14 W24\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200m**g\n No change in LDL-cholesterol\nSTNIOPDNE\nYRADNOCES\nStatistically significant change Statistically significant change\nin HDL-cholesterol in triglycerides\nCorporate Presentation | July 2024\n0.5\n0\n-0.5\n-1\n-1.5\n-2\n0 4 8 12 16 20 24\nProperty of Inventiva│ 27\n)L/lomm(\negnahc\netulosba\nnaeM\nIn patients with NASH and T2D, statistically significant reductions of\nfasting glucose and insulin, HbA1c were observed\nAbsolute change from baseline in HbA1c Absolute change from baseline in fasting glucose\n0.5\n0\n-0.5 **\n**\n**\n**\n-1 **\n**\n0 4 8 12 16 20 24\n0 W4 W14 W24\nPlacebo (N= 35) Lanifibranor 800mg (N= 33)\nLanifibranor 1200mg (N= 35)\n**p<0.001\n)%(\negnahc\netulosba\nnaeM\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo (N = 35) Lanifibranor 800mg (N = 33)\nLanifibranor 1200mg (N = 35)\nAbsolute change from baseline in insulin at W24\n0\n-10\n-20\n-30\nweek 24\n)Lm/UIµ(\negnahc\netulosba\nnaeM\nSecondary endpoints in patients with NASH and T2D (N = 103)\n**\n**\nPlacebo (N= 32) Lanifibranor 800mg (N= 31)\nLanifibranor 1200mg (N= 33)\nSTNIOPDNE\nYRADNOCES\nPHASE IIb EFFICACY OTHER\nLanifibranor associated with improvements\nin insulin sensitivity and glycemic control in\nNASH patients\nCorporate Presentation | July 2024\nLanifibranor leads to significant improvements in hepatic and muscular\ninsulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 28\nnim/gk/gm\nLS mean absolute change from baseline LS mean absolute change from baseline to LS mean absolute change from\nto week 24 in week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\n Data from the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating\nlanifibranor (800mg/day) in patients with NAFLD and type 2 diabetes mellitus (T2D) for 24 weeks\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nDr. Cusi - IIS\nCorporate Presentation | July 2024\nLanifibranor induces a significant decrease in circulating biomarkers\nlanifibranor\nMedian relative change (%) Placebo Pvalue\n(Two doses pooled)\nPro-C3 (4.1%) (13.9%) p= 0.005*\nPro-C3 >14 at\nFibrosis (12.8%) (20.5%) p= 0.017*\nbaseline(1)\nRatio TIMP-1/MMP-2 (4.6%) (22.5%) p < 0.001*\nApoptosis CK18-M30 0.5% (41.1%) p < 0.001*\nFerritin (9.1%) (29.4%) p < 0.001*\nInflammation\nhs-CRP 13.0% (35.5%) p < 0.001*\n(1) Level where it is estimated that fibrogenesis is active and corresponding to F2/F3 patients\nFAS (Full Analysis Set) population with available data at baseline and at week 24\n* Statistically significant\nProperty of Inventiva│ 29\nSERUSAEM\nEMOCTUO\nREHTO\n Data from NATIVE clinical study evaluating lanifibranor (800mg/day and 1200mg/day ) in patients with NASH for 24 weeks\nCorporate Presentation | July 2024\nLanifibranor significantly reduces hepatic steatosis measured by MRI-\nPDFF and MR-spectroscopy\n Data from the Legend clinical study evaluating lanifibranor  Data from the clinical study conducted by Dr. Kenneth\n(800mg/day) in combination with empagliflozin in patients Cusi from the University of Florida, evaluating lanifibranor\nwith NASH and poorly controlled Type 2 Diabetes (T2D) (800mg/day) in patients with NAFLD and type 2 diabetes\nfor 24 weeks mellitus (T2D) for 24 weeks\nDr. Cusi - IIS\nLiver fat measured by MRI-PDFF Liver fat (IHTG) measured by MR-spectroscopy\nN=26 from baseline at week 24 N=38 from baseline at week 24\nLS means relative percent change, FAS LS means relative percent change, FAS\n0% 0%\n0%\n-10% -10%\n-12%\n-20% -20%\n-30% -30%\n*\n-40% -37% -40%\n*\n-44% pa=0.002\n-50%\n-47%*\n-50%\nPlacebo Lani Lani Placebo Lani\nn= 5 n= 12 + Empa n=18 n=20\nn= 9\nBaseline 17.1-19.7%  65% of patients achieved liver fat reduction ≥30% vs 22% under\nplacebo\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)  25% of patients achieved NAFLD resolutions vs 0% under placebo\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before a P-value from an Analysis of Covariance (ANCOVA) using the relative change from baseline to week 24\nWeek 24 as the response, the treatment as covariate as well as the baseline of IHTG. In the FAS, missing data at\nWeek 24 were imputed by baseline data.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 30\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Tirzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo 30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 31\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\n Data from the clinical study evaluating lanifibranor (800mg/day) in combination with empagliflozin in patients with NASH and\npoorly controlled Type 2 Diabetes (T2D) for 24 weeks\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 32\nLanifibranor has a favourable safety profile\nPHASE IIb SAFETY OVERALL\nPlacebo 800 mg 1200 mg\nN (%) patients reporting Adverse Event (AE)\n(N = 81) (N = 83) (N = 83)\n Any Treatment-Emergent AE (TEAE)\n50 (61.7%) 59 (71.1%) 62 (74.7%)\nDrug-related TEAE 19 (23.5%) 25 (30.1%) 23 (27.7%)\n Any TEAE leading to drug withdrawal\n3 (3.7%) 4 (4.8%) 3 (3.6%)\nDrug-related TEAE leading to drug withdrawal 2 (2.5%) 1 (1.2%)(1) 2 (2.4%)(2)\n Any Serious TEAE\n3 (3.7%) 3 (3.6%) 7 (8.4%)\nDrug-related Serious TEAE 2 (2.5%)(3) - -\nFocus of next slide\n(1) One patient with moderate diarrhea ; (2) One patient with mild cardiac failure; one patient with mild diarrhea, abdominal pain, dizziness ;\n(3) 2 SUSARs (placebo arm): one patient with mild cardiac failure; one patient with moderate urticaria\n Consistent with known insulin sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at the\n800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed.\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 81)\n Peripheral edema 2 (2.5%) 5 (6.0%) 7* (8.4%)\nDrug-related peripheral edema - 2 (2.4%) 2 (2.4%)\n Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few\npatients received diuretics. 4 cases were considered study drug related by the investigator (2 at 800\nand 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor\n1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female\n* One AE of severe intensity\npatients\nCorporate Presentation | July 2024 Property of Inventiva│ 33\nA limited number of serious TEAEs occurred\nPHASE IIb SAFETY SERIOUS TEAE\nPatients reporting treatment-emergent Placebo 800 mg 1200 mg\nSerious AE (SAE); N (%) (N = 81) (N = 83) (N = 83)\nTotal 3 (3.7%) 3 (3.6%) 7 (8.4%)\nTreatment-Emergent Serious AE linked to biopsy procedure\nPost-procedural haematoma/haemorrhage - 1 (1.2%) 1 (1.2%)\nPost-procedural pain - - 1 (1.2%)\nPneumobilia (post-procedural) - - 1 (1.2%)\nOther Treatment-Emergent Serious AE\nWrist fracture 1 (1.2%) - -\nAngina unstable - - 1 (1.2%)\nCardiac failure 1 (1.2%) - -\nGastroenteritis - - 1 (1.2%)\nPyelonephritis - - 1 (1.2%)\nPancreatitis - 1 (1.2%) -\nUndifferentiated connective tissue disease - 1 (1.2%) -\nUrticaria 1 (1.2%) - -\nFoot operation - - 1 (1.2%)\nCorporate Presentation | July 2024 Property of Inventiva│ 34\nPhase II results have demonstrated modest weight increase with no impact\non efficacy\n Consistent with known insulin-sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at\nthe 800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed\n According to a six-month study with pioglitazone in patients * with NASH body weight gain is likely attributed to an\nincrease in adipose tissue and not water retention\n Based on a 52-week lanifibranor trial in systemic sclerosis (SSc) patient weight gain is expected to reach a maximum\nby week 24\nSSc lanifibranor study: weight (kg) relative change from baseline over 52 weeks\n(Observed cases under treatment – FAS population)\nExcept for two patients (one placebo, one 600mg BID),\nTEAE time of onset related to weight increase happened in\nKg\n6 the first 24 weeks of treatment\n4\n2\n0 Weeks\n0 2 4 8 12 16 20 24 28 32 36 40 44 48 52\nLanifibranor 600 mg BID Placebo\nNote: * Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholivsteatohepatitis ; Balas, Belfort, Harrison et al. ; Journal of Hepatology 47 (2007) 565-570\nCorporate Presentation | July 2024 Property of Inventiva│ 35\nWeight changes in NATIVE trial: approximately 33% of patients\non lanifibranor show a weight increase of more than 5%\nWeight changes at end of treatment (Week 24) in patients treated with\nlanifibranor versus placebo\nLanifibranor Placebo\n100%\nN=144 N=73\n84%,\nN=61\n80%\n51%,\n60%\nN=73\n33%,\n40%\nN=48\n16%,\n20% N=23 11%,\nN=8 6%,\nN=4\n0%\nStable Moderate Weight Stable Moderate Weight\nweight weight gain weight weight gain\n(≤2.5%) gain (>5%) (≤2.5%) gain (>5%)\n(2.5%-5%) (2.5%-5%)\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 36\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (I/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nFasting HOMA-IR ALT\nMean absolute change at Week 24 from baseline Mean absolute change at Week 24 from baseline (U/L)\nLanifibranor Placebo Lanifibranor Placebo\n4.0\n10 8\n1.7\n2.0 5\n0.0 0\n-0.6\n-2.0 -5\n-5\n-10\n-4.0\n-15\n-6.0 -5.1\n-5.8\n-20\n-8.0 -20\n-8.2 -25 -22\n-10.0\n-26\n-30\nTriglycerides CAP\nMean absolute change at Week 24 from baseline (mmol/L) Mean absolute change at Week 24 from baseline (dB.m-1)\n1\n0.8 Lanifibranor Placebo Lanifibranor Placebo\n35\n30.6\n0.6\n25\n0.4\n0.2 0.12\n0.03 15\n0\n-0.2 5\n-0.4\n-0.42 -0.44 -0.45 -5\n-0.6 -4.6\n-0.8  LDL level do not change but HDL level improves in -15 -10.2\npatients treated with lanifibranorindependently of weight -14.7\n-1 -17\nchanges\n-25\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 37\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (II/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nAPO-C3 APO-B\nMean absolute change at week 24 from baseline (μg/ml) Mean absolute change at week 24 from baseline (mg/dl)\n25 Lanifibranor Placebo Lanifibranor Placebo\n19.1 0\n20\n-0.08\n-2\n15\n-2.58\n-4\n8.9\n10\n-6\n5\n-8\n0\n-10\n-9.66\n-5\n-12\n-10 -7.3 -14 -13.04\n-9.3\n-10.7\n-14.56\n-15 -16\n-20 -18\n-20\nhs-CRP hs-CRP\nMean absolutechange at Week 24 from baseline (%) Mean relativechange at Week 24 from baseline (%)\nLanifibranor Placebo Lanifibranor Placebo\n1.0 0.6\n10\n3\n0.0 0\n-0.1 -1\n-1.0 -0.6 -10\n-20\n-2.0 -21\n-30\n-3.0 -2.7\n-40\n-41\n-4.0 -50\n-4.1\n-60\n-5.0\n-61\n-70\n-6.0\n-80\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 38\nEffect on weight when combining lanifibranor with empagliflozine\nWeight change, N=32 Ratio VAT/SAT, N=19\nRelative change from Baseline (%) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 93-102 kg\n5 11\n3.6 10\n4\n3 5\n2\n2 1.4 0\n1\n00 -5\n-0.4 -0.4 -5*\n0\n-0.9\n0 -10\n-1\n-0.8 -0.8\n-1.1 -15\n-2\nWeek 4 Week 12 Week 24\nBaseline -17**\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8 -20\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nPlacebo Lani Lani + Empa n= 4 n= 8 n= 7\nAt Week 24, 7 patients without weight values available : SAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n- 5 patients under placebo who prematurely stopped before Week 24 * p=0.08, **p<0.01, versus placebo (ANCOVA)\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly Thirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\nmodified his/her diet (intercurrentevent) before Week 24.\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nThe combination of empagliflozin and lanifibranor addresses the Lanifibranor alone and in combination with empagliflozin leads to\nweight gain observed in some patients treated with lanifibranor alone a shift towards metabolically healthy adipose tissue\nCorporate Presentation | July 2024 Property of Inventiva│ 39\nPhase III NATiV3 should, if positive, allow to file for accelerated approval\nMain Cohort Accelerated\nApproval\n72 weeks treatment\nN~ 950\nLanifibranor: 1200 mg once daily\nNon-cirrhotic NASH &\nLanifibranor: 800 mg once daily\nF2-F3 fibrosis\nActive Treatment Extension\nPlacebo: Once daily\n►Stratification\n48 weeks\n- By diabetic status\nExploratory Cohort\n- By fibrosis stage F2/F3 EoT\n72 weeks treatment Lanifibranor: 1200 mg once daily\nN~ 200\nLanifibranor: 800 mg once daily\nLanifibranor: 1200 mg once daily\nScreen failed patients from the\n►All patients who complete the main or the exploratory cohort\nmain cohort are eligible for the active treatment extension study\nLanifibranor: 800 mg once daily\nNon-cirrhotic NASH & ►Patients to switch to the active treatment extension after the\nF1-F4 fibrosis week 72 visit of the last patient randomized in the main cohort\nPlacebo: Once daily\nor after 120 weeks of treatment, whichever happens first\n►Stratification\n- By diabetic status\n- By fibrosis stage F1-F3/F4\nPrincipal investigators: Dr. S. Francque / Dr. A. Sanyal for the main cohort\nPrimary endpoint: Composite endpoint of patients having both NASH resolution and one stage fibrosis improvement\nKey secondary endpoints: NASH resolution and no worsening of fibrosis / Fibrosis improvement and no worsening of NASH\nGLP1: Patients under a stable dose of GLP1-RA for at least 3 months prior to screening can be included\nStatistical powering: 90% considered for sample size calculations\nCentral biopsy reading: Tie breaker approach by three expert pathologists\nCorporate Presentation | July 2024 Property of Inventiva│ 40\nOver 400 sites and 24 countries involved in NATIV3\nPHASE III DESIGN SITE SELECTION\n► 478 sites activated in 24 countries (as\nof April 1, 2024)\n► 914 randomized patients: 731 in the\nmain cohort and 183 in the exploratory\ncohort (prior to the voluntary pause)\n► Target to achieve LPFV H1 2024\n► Topline data expected H1 2026\nNATiV3 countries\nCorporate Presentation | July 2024 Property of Inventiva│ 41\nOpportunity for lanifibranor\nLanifibranor well positioned alone or in combination in the NASH market\npan-PPAR THR-β FGF-21 GLP-1\nROUTE OF\nOral Oral Injectable Injectable\nADMINISTRATION\nIndirect\nDirect activity Indirect Direct activity Not seen with sema.\nEfficacy on fibrosis\nseen at 6 months seen after 12 months seen at 6 months Reported by BI & Lilly\nafter 12 months\nNASH resolution\nInsulin resistance\nLimited drop-out High drop out due to High drop out due to\nTolerability Limited drop-out GI side effects on GI side-effects & GI side-effects &\ninitiation injections injections\nPatients with advanced F1 patients\nPatients with F2/F3: induction\nTarget patients fibrosis (F2/F3) F2/F3: in\nadvanced fibrosis therapy\npopulation T2D patients combination with\n(F2/F3) F4 patients\nLean patients anti-fibrotic drugs\nCorporate Presentation | July 2024 Property of Inventiva│ 43\nLanifibranor expected to meet key decision drivers for surveyed payers\nand prescribers\nSurveyed Payers Surveyed Prescribers\n Improvement in fibrosis is expected to be the key driver of  Prescribers see improvement in fibrosis and joint\nP&TC decisions* in NASH\nachievement of fibrosis improvement and resolution of\nsteatohepatitisas the key benefits of a new NASH drug\n Payers see lanifibranor as stronger than resmetirom\n(Madrigal) and semaglutide(Novo Nordisk) on fibrosis  Both histological endpoints: over 85% of prescribers\nimprovement\nrate as major benefit\nTop 6 Key attributes (n = 95)\nBoth improves fibrosis and resolves steatohepatitis 99%\nImproves fibrosis 98%\nResolves steatohepatitis 99%\nImproves portal hypertension 93%\nImproves key markers of glucose metabolism 92%\nOral 88%\n% of prescribers 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%\nNot a factor Benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for lanifibranor,\nwhich is currently in Phase III clinical trial and has not been approved.\n*P&TC: Pharmacy & Therapeutics Committee\nCorporate Presentation | July 2024 Property of Inventiva│ 44\nLanifibranor well rated versus resmetirom(1) and the combination of\nlanifibranor + GLP-1 versus GLP-1 alone\nSurveyed prescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.7\n* 5.49\n*\n5.5 5.42\n5.3\n5.1\n4.94\n4.88\n4.9\n4.7\n4.5\nPre-diabetic patients with F2 / F3 Diabetic patients with F2 / F3 NASH\nNASH\nResmetirom Lanifibranor\n* indicates results are statistically significantly higher than the comparator (p<0.05)\nSource: (1) US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on available trial results for lanifibranor, which is currently in Phase III clinical trial\nand has not been approved. *Survey conducted before Resmetiromapproval by the FDA.\nCorporate Presentation | July 2024 Property of Inventiva│ 45\ntifeneb\ndeviecreP\nLanifibranor versus resmetirom Lanifibranor in combination versus GLP-1\n5.7\n* 5.52\n5.5\n5.26\n5.3\n5.1\n4.9\n4.7\n4.5\nNASH patients\nGLP-1 GLP-1 + Lanifibranor\nLanifibranor well positioned in patients with T2D and Lanifibranor could address the need in patients treated\nNASH, a population more present in patients with F2/F3 with GLP-1 to reduce fibrosis with an oral treatment and\nfibrosis and with a faster progressing form of fibrosis without the GI side effects present in the GLP-1 and\nFGF-21 class\nModerate metabolically healthy weight gain induced by lanifibranor is not a\nconcern for payers, and is deemed manageable by surveyed prescribers\nSurveyed Payers Surveyed Prescribers\n Surveyed payers see lanifibranoras safe for chronic use  A majority of surveyed HEPs and ~ half of surveyed GEs stated that\nand any associated moderate weight gain is seen as they would not hesitate to prescribe a new NASH drug that causes 2-3\nmanageable with lifestyle choices or weight loss agents. kg weight gain\n 72% of surveyed prescribers expect they could manage a moderate\n Surveyed payers: “If the message is that you'll weight gain with diet, exercise and counselling.\ngain 3 or 4 lbs but you'll feel better, and you  78% of surveyed prescribers agree that “Combining lanifibranorwith an\nexplain the difference between healthy and SGLT2 or GLP-1 is an opportunity to maintain effectiveness in NASH\nunhealthy weight, you can get through that. If while mitigating weight gain.”\nsomeone is 200 pounds and goes up to 205  73% of surveyed prescribers agree that the benefits of lanifibranor\npounds, I don't think they're going to notice it....” outweigh the moderate weight gain.\n Surveyed prescribers see other SEs as bigger drawbacks\nIs associated with neoplasm growth 63%\nIs associated with sarcopenia 40%\nIs associated with 2-3 kg weight gain 12%\n% of prescribers 0% 20% 40% 60% 80%\nMajor drawback\nThe importance of adherence to treatment and convenience of administration favors\nlanifibranor\n 80% of surveyed prescribers see low discontinuation rate as critical, very critical\nor absolute necessity\n 80% of surveyed prescribers rate oral administration as a key benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists (HEPs), 25 gastroenterologists (GEs), 25 endocrinologists in the United States in Q1 2024. Onlyassets in Phase III clinical trial in NASH at the\ntime of the survey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for\nlanifibranor, which is currently in Phase III clinical trial and has not been approved.\nCorporate Presentation | July 2024 Property of Inventiva│ 46\nPrescribers expect GLP-1 + lanifibranor to be significantly more beneficial than\nGLP-1 alone; suggests a perception of synergy, with lanifibranor enhancing GLP-1\nPrescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.60\n5.52\n5.50\n5.40\n5.30 5.26\n5.20\n5.10\n5.00\nMASH patients\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH/MASH at the time of the survey were\nincluded.\nProperty of Inventiva│ 47\ntifeneb\ndeviecreP\n*\nGLP-1 GLP-1 + Lanifibranor\n* indicates results are significantly higher than the comparator (p<0.05)\nLanifibranor could address the need in patients treated with GLP-1 to reduce fibrosis with an oral treatment\nand without the GI side effects present in the GLP-1 and FGF-21 class\nCorporate Presentation | July 2024\nOpportunity for lanifibranor for the treatment of NASH based on current\nclinical program (F2/F3)\nSteatosis Steatohepatitis Advanced fibrosis\nF1 F2 F3 F4 CC\nPatients with NASH estimated in 2030 (US) 9.0M 6.1M 4.5M 3.5M\nIMPROVEMENT OF FIBROSIS\nLanifibranor RESOLUTION OF NASH\nCARDIOVASCULAR IMPROVEMENT\nINSULIN RESISTANCE IMPROVEMENT\nLean NASH Lanifibranor Even if GLP-1 dominate the\n(10-15%) market, lanifibranor would\nT2D Lanifibranor still target 50-60%of\nEstimated\n(15-20%) patients with NASH:\nNASH patient\npopulation T2D & obesity • Lean NASH: 10-15%\nGLP1+Lani\n(20-25%) • “Needle phobia”: 10-15%\n(%)(1)\n• GLP-1 drop-outs: 32% (40%\nObesity & prediabetes\nDO * 80% of NASH patients\n(50-55%) GLP1+Lani\nunder GLP-1)\nSurveyed prescribers expect to write lanifibranor for ~ 30% of NASH patients if approved –across all of the following:\n30%\n• F2 and F3\n• Pre-diabetic and diabetic patients\n• BMI groups –suggests 2-3 kg weight gain is not a key barrier in surveyed prescribers 70%\nSource: Estes C,RazaviH,Loomba R,YounossiZ,Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology2018;67:123-133; US prescriber survey, February 2024 conducted in 45 hepatologists,\n25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in Phase III clinical trial in NASH/MASH at the time of the survey were included; US Payer Advisory Board, March 2023\nCorporate Presentation | July 2024 Property of Inventiva│ 48\nUpcoming catalysts\nCatalysts\n2024 2025 2026\nLanifibranor\nH1 2024 H2 2024 H1 2026 H2 2026\nLast Patient Last Patient • Last Patient New Drug\nFirst Visit randomized Last Visit Approval\n• Topline filing with\nresults FDA\nOdiparcil\nReview potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing\na partnership\nCorporate Presentation | July 2024 Property of Inventiva│ 50\nContacts\nInventiva Brunswick Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montégon Patricia L. Bank\nExecutive VP Aude Lepreux Investor relations\nStrategy and Corporate Affairs Julia Cailleteau\nMedia relations\npascaline.clerc@inventivapharma.com inventiva@brunswickgroup.com patti.bank@westwicke.com\n+1 202 499 8937 + 33 1 53 96 83 83 +1 415 513 1284\nLanifibranor : back-ups slides\nPhase I and Phase IIa clinical trials* in type 2 diabetes (T2D) patients:\nbeneficial changes in key metabolic markers\n300 p=0.05\np=0.05\n200\np=0.08\n100\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nProperty of Inventiva│ 53\nenilesab\nfo\negnahc\ntnecreP\nAdiponectin (PPARγ)**\nenilesab\nmorf\negnahc\ntnecreP\n40\np<0.05\n30\np<0.05\n20\np=0.13\n10\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nHDL Cholesterol (PPARα/δ)^\nenilesab\nmorf\negnahc\ntnecreP\n0\n-10\n-20\n-30 p=0.08\np<0.05\n-40\np<0.05\n-50\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nTriglycerides (PPARα/δ) ^^\nenilesab\nmorf\negnahc\ntnecreP\nPHASE I AND IIa\nLanifibranor metabolic markers in patients with T2D\nlanifibranor lanifibranor lanifibranor\nPhase I and IIa* clinical findings support the favorable tolerability of lanifibranor\n Phase I trials: > 200 healthy volunteers  Good overall tolerability and no major safety findings\n Phase IIa trial with 47 T2D patients  No increases of creatinine, LFTs, or CPK\n Phase IIb: > 250 patients treated for 24 or 48  No changes in blood pressure, no signal of fluid overload or haemodilution\nweeks  No clinically relevant weight gain\nThorough QT/QTc study demonstrates no impact of the drug on QT intervals\n Study carried out in 2020 and 2021 to prepare the NDA package\n A randomized, double-blind, double-dummy, placebo, positive-controlled (400mg of moxifloxacin) and multiple-dose\n(1200mg and 2400mg as the supratherapeutic dose) cardiac safety study to evaluate the effect of lanifibranor on the QT\ninterval in healthy adult subjects\n At doses of 1200 mg and 2400 mg, lanifibranor has no impact on QT intervals\nNote: * Conducted by Abbott; ** Adiponectin is associated with PPARγactivation; ^ HDL-C is associated with PPARαand d activation; ^^ Triglycerides are associated with PPARαand δ activation\nSource: Company data\nCorporate Presentation | July 2024\n247 patients were randomised across 71 sites worldwide, with the majority\nof patients based in Europe\nPHASE IIb DESIGN SITE SELECTION\n4 sites in 49 sites in\nCanada Europe\nPatients\nCountry\nrandomized\nEurope 183 (74%)\nU.S. 36 (15%)\nAustralia 13 (5%)\n12 sites in the Canada 8 (3%)\nUnited States\nMauritius 7 (3%)\nTotal 247 (100%)\n1 site in 5 sites in\nMauritius Australia\n16 countries worldwide (number of sites having randomized at least 1 patient)\n► Europe: Austria (1), Belgium (5), Bulgaria (5), Czech Republic (3), France (13), Germany (5), Italy (4), Poland (3),\nSlovenia (1), Spain (4), Switzerland (2), United Kingdom (3)\n► North America: United States (12), Canada (4)\n► Australia (5)\n► Mauritius (1)\nCorporate Presentation | July 2024 Property of Inventiva│ 54\nProperty of Inventiva│ 55\nYRAMIRP\nSTNIOPDNE\nYRADNOCES\nTNIOPDNE\nLanifibranor demonstrated statistical significance on all histological\nendpoints in both ITT and PP populations\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint\nN = 247 ITT population N = 197 PP population\nPlacebo 800 mg 1200 mg Placebo 800 mg 1200 mg\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83) (N = 62) (N = 63) (N = 69)\nDecrease of ≥2 points of SAF 27% 41% 49% 34% 51% 55%\nactivity score* and no worsening\n0.061 0.004 0.058 0.015\nof fibrosis\nResolution of NASH and no 19% 33% 45% 23% 40% 49%\nworsening of fibrosis**\n0.043 <0.001 0.039 0.002\nImprovement of fibrosis by at\n42% 46%\nleast one stage and no 24% 28% 29% 32%\nworsening of NASH*** 0.53 0.011 0.75 0.04\nResolution of NASH and 7% 21% 31% 10% 24% 33%\nimprovement of fibrosis^\n0.017 <0.001 0.036 0.001\nDecrease of ≥2 points of NAS\nscore^^ (NAFLD activity score) 32% 52% 64% 40% 62% 71%\nand no worsening of fibrosis\n0.01 <0.001 0.02 <0.001\n* Response is defined as a decrease from baseline to week 24 of at least 2 points of the SAF Activity score (SAF-A) with no worsening of the NAS Fibrosis score (NAS-F). No worsening means that score remains stable or\ndecreases ; ** Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; *** Improvement of liver fibrosis ≥ 1\nstage and no worsening of NASH at week 24; ^ Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage; ^^ NAS score is a commonly accepted,\nsemi-quantitative evaluation of biopsy results that assesses the severity of steatosis, inflammation and ballooning in the liver.\nCorporate Presentation | July 2024\nStatistical significance was also demonstrated for the main key histological\nendpoints in patients with F2-F3 fibrosis stage\nPHASE IIb EFFICACY F2-F3 POPULATION\nxx Statistically significant xx Non-statistically significant\nKey secondary endpoints in FAS F2-F3 patients (N=188)\nlanifibranor\nPPllaacceebboo 880000 mmgg 11220000 mmgg\n(N = 57) (N = 68) (N = 63)\nResolution of NASH and no\n44%\n34%\nworsening of fibrosis* 9%\n0.001 <0.001\nImprovement of fibrosis by at least\n48%\none stage and no worsening of\n30% 32%\nNASH**\n0.736 0.048\nResolution of NASH and improvement\n33%\nof fibrosis*** 7% 24%\n0.012 <0.001\n Similar results in the PP population\n Consistent response in diabetic and non-diabetic patients\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of liver fibrosis ≥ 1 stage and no\nworsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | July 2024 Property of Inventiva│ 56\nPhase III NATiV3 clinical trial confirmatory trial: anticipated\nexpected design to support broader “full approval”\nPHASE III OVERVIEW\nAnticipated event driven trial in patients with NASH compensated cirrhosis\nPhase 3: event driven\nN~ 800\nEoT\nPatients with\nLanifibranor: Once daily Potential full approval in U.S.\nNASH and\ncompensated and EU\nPlacebo: Once daily\ncirrhosis\nKEY ENDPOINTS (non-exhaustive) TRIAL END DATE\n Based on time to first clinical event on c.800 patients  Trial expected to last up to 3 years\n• all cause mortality\n• hepatic decompensation events\n− hepatic encephalopathy\n− variceal bleeding or progression to varices that require prophylactic\ntreatment\n− new onset ascites requiring treatment\n• MELD score ≥15\n• liver transplantation\nCorporate Presentation | July 2024 Property of Inventiva│ 57\nLanifibranor clinical trial in patients\nwith NAFLD and T2D\nLanifibranor clinical trial in patients with NAFLD and T2D\nObjective of investigator-initiated trial: Establish safety, efficacy and mechanism of action of lanifibranor in patients with T2D\nand NAFLD. Specifically determine if lanifibranor decreases IHTG(1), improves hepatic insulin sensitivity, endogenous (hepatic)\nglucose production, gluconeogenesis and DNL(2).\nPatients with NAFLD and T2D\n Fasting plasma glucose: 100mg - 250mg/dL\n HbA1c: 6.0% to 9.5%\n Hepatic steatosis: >10%\n24 weeks treatment\nPlacebo\nLanifibranor 800mg/daily\n24 weeks\n6 weeks 4 weeks\nEOT\nRun-in period Run-in period Follow-up\nPrimary endpoint: change in Intrahepatic triglycerides (IHTG)\nSecondary endpoints:\n Proportion of responders reaching a decrease in IHTG from baseline ≥ 30% quantified by proton magnetic resonance\nspectroscopy (¹H-MRS)3\n Proportion of patients with NAFLD resolution (patients with IHTG ≤ 5%) quantified by ¹H-MRS\n Change in hepatic and muscle insulin sensitivity and lipid metabolism\n Safety\n(1) Intrahepatic triglycerides; (2) De-novo lipogenesis; (3) proton magnetic resonance spectroscopy\nCorporate Presentation | July 2024 Property of Inventiva│ 59\nLanifibranor significanty reduces liver fat and resolves NAFLD\nLS means relative percent change Percentage of patients achieving Percentage of patients achieving\nfrom baseline in liver fat (IHTG) at liver fat reduction ≥30% at week 24 NAFLD resolution at week 24\nweek 24 (FAS N=38) (FAS N=38) (FAS N=38)\n0% 100% 100%\n90% 90%\n-10%\n80% pa=0.008 80%\n-12%\n70% 65% 70%\n-20%\n60% 60%\n50% 50%\n-30%\n40% 40%\npb=0.048\n-40% 30% 30% 25%\n22%\n20% 20%\n-44%\n-50% Placebo Lanifibranor 10% 10%\nn=18 800mg\n0%\nn=20 0% 0%\nPlacebo Lanifibranor Placebo Lanifibranor\npa=0.002 n=18 800mg n=18 800mg\nn=20 n=20\na P-value from an Analysis of Covariance (ANCOVA) using the aChi² test bFisher test\nrelative change from baseline to week 24 as the response, the In the FAS, missing data at Week 24 were imputed as NAFLD resolution is defined as IHTG ≤ 5.5% at week 24.\ntreatment as covariate as well as the baseline of IHTG. In the FAS, non-achieving reduction. In the FAS, missing data at Week 24 were imputed as non-\nmissing data at Week 24 were imputed by baseline data. responders\nCorporate Presentation | July 2024 Property of Inventiva│ 60\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Terzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo 30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 61\nLanifibranor leads to significant improvements in hepatic and\nmuscular insulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 62\nnim/gk/gm\nLS mean absolute change from LS mean absolute change from LS mean absolute change from\nbaseline to week 24 in baseline to week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nCorporate Presentation | July 2024\nLanifibranor treatment increases HDL and adiponectin levels\n9\n7\n6.3\n5\n3\n1\n-0.3 -1\nProperty of Inventiva│ 63\nld/gm\nLS Mean absolute change from baseline to week\n24 in HDL cholesterol (completers N=28)\n9.0\npa=0.016\n7.5\n7.0\n5.0\n3.0\n1.0\n-0.2\n-1.0\naMixed Model Repeated Measures (MMRM).\n No change in LDL-cholesterol\nLm/gμ\nLS Mean absolute change from baseline to week\n24 in adiponectin (completers N=28)\npa<0.001\nPlacebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg\nn=14 n=14\nCorporate Presentation | July 2024\nKey take-aways\n Lanifibranor met the primary efficacy endpoint by inducing a liver fat reduction of 44% in patients with T2D\nand NAFLD treated for 24 weeks.\n– 65% of patients with T2D and NAFLD treated with lanifibranor achieved a greater than 30% liver\ntriglyceride reduction and 25% achieved NAFLD resolution after 24 weeks.\n Lanifibranor has a potent therapeutic effect on insulin sensitivity, and corresponding metabolic markers in\npatients with T2D and NAFLD\n– Potent effect as insulin sensitizer on hepatic and muscular insulin sensitivity\n Lanifibranor significantly improved adiponectin, which is known to regulate glucose levels, lipid metabolism,\nand insulin sensitivity through its anti-inflammatory, anti-fibrotic, and antioxidant effects\n Study confirms the favorable safety and tolerability profile of lanifibranor\nCorporate Presentation | July 2024 Property of Inventiva│ 64\nLegend\nLanifibranor in Combination with the SGLT2 Inhibitor in\npatients with NASH and T2D\nLanifibranor and SGLT2 Inhibitor mechanism of action and\nrationale for LEGEND\nLanifibranor: balanced pan-PPAR Empagliflozin: inhibitor of Sodium-\nagonist (PPARα, PPARγ and PPARδ)1 glucose co-transporter-22\n• Lanifibranorimproves insulin sensitivity, lipid and glucose metabolism, inflammation, liver tissue injury (MASH activity) and fibrosis.\n• Empagliflozinimproves glycaemia, insulin sensitivity, has weight reducing and diuretic effects.\n• The combination of lanifibranor + empagliflozinmay\n• Add additional metabolic benefits\n• Address metabolically healthy weight gain observed in some patients on lanifibranor\nHaas, Francque & Staels. Ann Rev Physiol 2016; Wanner & Marx. Diabetolgia 2018; Goossens G Obes Facts 2017; Pavlides et al. Journal of Hepatology 2016; Alexopoulos et al. Hepatology 2021\nCorporate Presentation | July 2024 Property of Inventiva│ 66\nLEGEND Study Design\nLanifibranor in Combination with the SGLT2 Inhibitor empagliflozin in patients with NASH and Type 2 Diabetes\nLEGEND Study\n24 weeks treatment\nRandomized, double-blind for lanifibranor and placebo, open label\nKey inclusion criteria:\nfor the combination, placebo-controlled\n4 weeks\n1) Adult patients with MASH/NASH:\nFollow-up\n• historical biopsy with NAS ≥ 4 Lanifibranor 800 mg + empagliflozin 10 mg\n• or cT1 ≥ 875 ms\n• or cT1 ≥ 825 ms and MRI-PDFF Lanifibranor 800mg\n≥ 10%\nPlacebo\n2) T2D diagnosed\n3) Screening HbA1c in 7-10%\nSecondary outcome\nPre-specified interim Other outcome\nPrimary outcome measures:\nanalysis planned to be measures:\nmeasure:  Insulin resistance\nconducted when 50% of\n Body weight Safety and\npatients have completed  Hepatic fat (MRI-PDFF)\nHbA1c reduction  Body fat composition tolerability\nthe 24-week treatment  Liver injury markers (AST,\nat Week 24\nperiod, or prematurely ALT)  Hepatic inflammation\ndiscontinued and fibrosis markers\n Lipid markers\nCorporate Presentation | July 2024 Property of Inventiva│ 67\nPatient disposition\nFull Analysis Set (FAS): 32 patients randomized and treated\nLanifibranor 800 mg/day +\nPlacebo Lanifibranor 800 mg/day\nEmpaglifozin 10mg/day\nN = 10 N = 12\nN = 10\n5 (50%) patients completed the 12 (100%) patients completed 10 (100%) patients completed\n24-week treatment the 24-week treatment the 24-week treatment\n5 (50%) patients prematurely\ndiscontinued from study\ntreatment*:\n- Withdrawal by patient (n=2)\n- Lost to follow-up (n=2)\n- Non-compliance with study drug\n(n=1)\n* All but one patient discontinued after week 12.\nOne patient (Withdrawal by patient) discontinued before week 4.\nCorporate Presentation | July 2024 Property of Inventiva│ 68\nBaseline demographics\nPlacebo Lanifibranor + Total\nParameter (unit) [Normal ranges] Lanifibranor (n=12)\n(n=10) Empagliflozin (n=10) (n=32)\nAge (years) 55.5 55.5 56.5 55.5\nSex (% female) 60 50 60 56\nWeight (kg) 92.6 93.9 102.0 96.8\nBMI (kg/m²) 33 33 37 35\nHbA1c (%), [4.0 - 6.0] 7.7 7.7 8.2 7.8\nInsulin (pmol/L) [18.1 - 172.9] 278 152 238 223\nHOMA-IR 19.5 9.4 12.0 10.9\nHDL-C (mmol/L) [F ≥ 0.91, M ≥ 0.78] / (mg/dL) 1.08 / 41.8 1.07 / 41.4 1.02 / 39.4 1.07 / 41.4\nLDL-C (mmol/L) [F ≤ 4.14, M ≤ 3.89] / (mg/dL) 2.26 / 87.4 2.52 / 97.5 2.45 / 94.7 2.52 / 97.5\ncT1 (ms) 942 949 921 931\nHepatic fat content (MRI-PDFF) (%) 17.1 18.5 19.7 18.8\nALT (U/L), [F ≤ 33, M ≤ 41] 33 53 54 39\nAST (U/L), [F ≤ 32, M ≤ 40] 24 30 35 30\nAdiponectin (ug/mL), [0.9 - 21.4] 2.6 3.1 4.0 3.0\nMedian values are presented for continuous parameters.\nALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, BMI: Body Mass Index, cT1: Corrected T1, F: Female, HDL-C: High density lipoprotein cholesterol, HOMA: Homeostasicmodel\nassessment, M: Male, MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction\nCorporate Presentation | July 2024 Property of Inventiva│ 69\nPrimary endpoint was met: statistically significant reductions in HbA1c at week 24\nunder lanifibranor alone and in combination with empaglifozin versus placebo\nFAS, N=30 Completers, N=24\nLS Mean Absolute Change from Baseline to Week 24 Percentage of responders at Week 24\nHbA1c (%) HbA1c < 6.5% HbA1c absolute decrease ≥1%\nWeek 12 Week 24\n100 100\n0.4 0.26 88%\n0.2\n0\n75 75\n-0.2 -0.08 63% 64%\n-0.4 55%\n-0.6 50 50\n-0.8\n-1\n-1.2 * 25 25\n-1.19* -1.14\n-1.4\n*\n-1.6 -1.44\n** 0% 0%\n-1.59\n-1.8 0 0\nPlacebo Lani Lani Placebo Lani Lani Placebo Lani Lani Placebo Lani Lani\n-2\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa n= 5 n=11 + Empa n= 5 n=11 + Empa\nn= 10 n= 10 n= 8 n= 8\n*p<0.01, **p<0.001, versus placebo (Mixed Model Repeated Measure [MMRM]) Eight patients were not considered in the Completers set:\nTwo patients were not considered in the FAS because not having post-treatment HbA1c values - 5 patients under placebo who prematurely stopped before Week 24\navailable: - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent event) before Week\n- 1 patient under placebo who prematurely stopped before Week 4 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nevent) before Week 4 (Results were similar including this patient in a sensitivity analysis). modified his/her diet (intercurrent event) before Week 24.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 70\nLanifibranor improves insulin sensitivity which is further\nimproved in combination with empagliflozin\nInsulin - FAS, N=30 HOMA-IR - FAS, N=30\nLS Mean Absolute Change from Baseline to Week 24 (pmol/L) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 152-278 pmol/L Baseline 9.4-19.5\n0\n-5\n-25 -7\n-15\n-50\n-25\n-58.3\n-75\n-35\n-100 -93.9† -45\n-125 -55 -51*\n-150 -65\n*\n-155.1\n-175 -75 -69**\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM), † p<0.05, versus baseline (MMRM) *p<0.05, **p<0.01, versus placebo (MMRM)\nTwo patients were not considered in the FAS because not having post-treatment insulin values Two patients were not considered in the FAS because not having post-treatment HOMA-IR values\navailable: available:\n- 1 patient under placebo who prematurely stopped before Week 4 - 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent\nevent) before Week 4 event) before Week 4\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 71\nLanifibranor alone and in combination with empagliflozin\nsignificantly improves markers of liver injury\nALT - FAS, N=31 AST - FAS, N=31\nLS Mean Relative change (%) from Baseline to Week 24 LS Mean Relative change (%) from Baseline to Week 24\nBaseline 33-54 IU/L Baseline 24-35 IU/L\n10 20\n0\n10\n-10\n0\n-20\n* -10\n-30 *\n**\n* -20 **\n-40\n*\n-30\n-50 **\n**\n-60 *** -40 ***\nBaseline Week 4 Week 12 Week 24 Baseline Week 4 Week 12 Week 24\nPlacebo n= 9 Lani n= 12 Lani + Empa n= 10 Placebo n= 9 Lani n= 12 Lani + Empa n= 10\n*p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM) *p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because no post-treatment ALT values One patient under placebo was not considered in the FAS because no post-treatment AST values\navailable (Premature discontinuation before Week 4) available (Premature discontinuation before Week 4)\nCorporate Presentation | July 2024 Property of Inventiva│ 72\nLanifibranor alone and in combination with empagliflozin\nsignificantly reduce hepatic steatosis measured by MRI-PDFF\nLiver fat measured by MRI-PDFF, N=26 from Baseline at Week 24\nLS Mean Relative change (%) Individual Relative changes (%)\nBaseline 17.1-19.7%\n20\n0\n0\n-5\n0\n-10\n-15\n-20\n-20\n-25\n-40\n-30\n-35\n-40 -60\n-38*\n-45\n-50 -47* -80 Placebo\nLani Lani\nPlacebo Lani\n+ Empa\nn= 5 n= 12 -100 Lani + Empa\nn= 9\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)\nlanifibranor +\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24: Percentage of responders Lanifibranor\nPlacebo (n=5) empagliflozin\n- 5 patients under placebo who prematurely stopped before Week 24 at Week 24 (n=12)\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before (n=9)\nWeek 24\nMRI-PDFF ≥ 30% 0% 82% 67%\nAbsolute reduction of ≥ 5% 0% 67% 67%\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 73\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 74\nLanifibranor alone and in combination with empagliflozin\nimproves HDL-C and adiponectin\nHDL-C, N=31 Adiponectin, N=30\nLS Mean Absolute change (mmol/L) from Baseline to Week 24 LS Mean Fold change from Baseline to Week 24\nBaseline 1.02-1.07 mmol/L Baseline 2.6-4.0 ug/mL\n0.5 4\n3.5\n0.4 3.0 *\n3 2.8*\n0.3\n2.5\n0.22*\n0.2\n0.17†\n2\n1.5\n0.1 1.1\n1\n0.0\n0.5\n-0.01\n-0.1 0\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 12 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM) † p<0.01, versus baseline (MMRM) *p<0.05, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because of no post-treatment HDL-C Two patients were not considered in the FAS because not having post-treatment adiponectin\nvalues available (premature discontinuation before Week 4) values available:\n- 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as rescue medication (intercurrent event)\nbefore Week 4\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 75\nThe combination of empagliflozin and lanifibranor addresses the weight\ngain observed in some patients treated with lanifibranor alone\nWeight change, N=32\nRelative change from Baseline (%)\nBaseline 93-102 kg\n5\n3.6\n4\n3\n2\n2 1.4\n1\n00\n-0.4 -0.4\n0\n-0.9\n0\n-1\n-0.8 -0.8\n-1.1\n-2\nBaseline Week 4 Week 12 Week 24\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nAt Week 24, 7 patients without weight values available :\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nmodified his/her diet (intercurrentevent) before Week 24.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 76\nLanifibranor alone and in combination with empagliflozin leads\nto a shift towards metabolically healthy adipose tissue\nRatio VAT/SAT, N=19\nLS Mean Relative change (%) from Baseline to Week 24\n11\n10\n5\n0\n-5\n-5*\n-10\n-15\n**\n-17\n-20\nPlacebo Lani Lani + Empa\nn= 4 n= 8 n= 7\nSAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n* p=0.08, **p<0.01, versus placebo (ANCOVA)\nThirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 77\nSafety and tolerability: Treatment-Emergent Adverse Events\n(TEAE)\nPlacebo Lanifibranor Lanifibranor +\nTEAE Overview\n(n=10) (n=12) Empagliflozin (n=10)\nTEAE 6 (60%) 10 (83%) 8 (80%)\nDrug-related TEAE 2 (20%) 3 (30%) 5 (50%)\nTEAE leading to drug withdrawal 0 0 0\nSerious TEAE 0 0 0\nSevere TEAE 0 0 0\nAny AE of Specific Interest\nAminotransferase elevation 0 0 0\nAnemia a 1 2 0\nPeripheral edema 0 0 1b\nHypoglycaemia c 1 0 1d\nMost Frequent (≥10%) TEAEs by SOC\nInfections and infestations 3 ( 30%) 2 ( 17%) 5 ( 50%)\nMusculoskeletal and connective tissue\n3 ( 30%) 1 ( 8%) 1 ( 10%)\ndisorders\nGastrointestinal disorders 2 ( 20%) 3 ( 25%) 2 ( 20%)\nSkin and subcutaneous tissue disorders 2 ( 20%) 4 ( 33%) 0 ( 0%)\nNervous system disorders 1 ( 10%) 2 ( 17%) 1 ( 10%)\na Defined as haemoglobin levels <Lower Limit Normal. The 3 events reported were assessed as not related to study drug.\nb The event was assessed as related to lanifibranor/not related to empaglifozin, of mild severity with no associated symptoms, that further recovered without corrective treatment.\nc Defined as glucose levels <Lower Limit Normal. Glucose values were > 3 mmol/L for the 2 events reported. Both events were assessed as not related to study drug, of mild intesityand required no treatment.\nd Related to empaglifozinonly.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 78\nConclusions\n The primary efficacy endpoint based on reduction of HbA1c was met for both lanifibranor alone and\nfor the combination with empagliflozin.\n The combination of lanifibranor with empagliflozin addresses / neutralizes weight gain seen in some\npatients on lanifibranor alone.\n Both lanifibranor alone and the combination with empagliflozin induce a redistribution of fat from\nvisceral to subcutaneous fat. This is consistent with the improved insulin sensitivity seen with both\nlanifibranor alone and the combination.\n Lanifibranor improves markers of cardiometabolic health, the effect size appear to be further\nimproved when lanifibranor is combined with empagliflozin.\n Lanifibranor alone and in combination with empagliflozin appear to be safe and well tolerated.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 79"
        },
        {
          "title": "Corporate presentation June 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/06/06-Inventiva-Presentation-ENG-06-17-2024-1.pdf",
          "content": "Developing innovative therapies in\nNASH\nCorporate Presentation\nJune 2024\nDISCLAIMER\nThis presentation contains “forward-looking statements” within the meaning of the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical\nfacts, included in this press release are forward-looking statements.\nThese statements include, but are not limited to, forecasts and estimates with respect to Inventiva’scash resources and potential financing or strategic options and potential counterparties, forecasts and estimates\nwith respect to Inventiva’spre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollmentfor those trials, including the ongoing NATiV3 Phase III clinical trial\nwith lanifibranor in MASH/NASH, and the results and timing thereof and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from clinical trials, the potential therapeutic benefits of Inventiva’sproduct candidates, including lanifibranor alone and in combination with empagliflozin in patients with MASH/NASH and T2D, the\npotential of lanifibranor to address patient needs, the estimated market size and patient population, potential regulatory submissions, approvals and commercialization, Inventiva’spipeline and preclinical and\nclinical development plans, the expected benefit of having received Breakthrough Therapy Designation from the FDA and NMPA, including its impact on the development and review timeline of Inventiva’sproduct\ncandidates, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, the expected benefit of Inventiva’s\npartnerships and Inventiva’sability to achieve milestones and receive potential milestones under its partnership agreements. Certain of these statements,forecasts and estimates can be recognized by the use of\nwords such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”,\n“opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but ratherare statements of future expectations and other forward-looking statements that are based\non management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results,\nperformance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva'scontrol. There\ncan be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be\nmaterially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that Inventiva cannot\nprovide assurance on the impacts of the SUSAR on enrollmentor the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company\nwith no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product\nsales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development\nprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’sability to obtain financing and to enter into\npotential transactions, Inventiva'sfuture success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,\npreclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva'sand its partners’ clinical trials may not support Inventiva'sand its partners’ product candidate\nclaims, Inventiva'sexpectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’sclinical trials, Inventiva’sexpectations with\nrespect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not supportthe approval of a New Drug Application, Inventiva and its partners may encounter\nsubstantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and\nretain patients in clinical studies, enrollmentand retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors\noutside Inventiva'sand its partners’ control, Inventiva'sproduct candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial\npotential, Inventiva faces substantial competition and Inventiva’sand its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations\ncould be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollmentand completion\nof Inventiva’sand its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related riskof a larger conflict, health epidemics, and macroeconomic conditions,\nincluding global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates onlyspeak as of the date of this press release. Readers are cautioned not to place\nundue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes MarchésFinanciers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024. Other risks and uncertainties of whichInventiva is not currently aware may also affect its forward-looking statements and\nmay cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention\nand is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva acceptsno liability for any consequences arising from the use of any of the above\nstatements.\nCorporate Presentation | June 2024 Property of Inventiva│ 2\nKey take-aways\nA Phase III ready program in R&D Capabilities and Cash\nA Phase III asset in NASH\nMPS(1) Position\nLanifibranor: only pan-PPAR agonist in Odiparcil: a GAG reduction therapy to R&D capabilities including wholly-\nclinical development for NASH potentially treat several forms of MPS owned ‘pharma scale’ discovery\nfacilities with a discovery engine\nPositive Phase IIb results with statistically Reduces GAG accumulation in multiple focused on nuclear receptors,\nsignificant efficacy on histological NASH organs in MPS VI models. Well-tolerated transcription factors and epigenetic\nresolution and one stage fibrosis reduction in MPS VI patients and in 1000s of targets\npatients previously tested(2)\nPositive Phase II, Proof-of-Concept, results of Clinical Ops team in place in Europe\nLEGEND with lanifibranor/empagliflozin Functional improvements to mobility and and the United States\nannounced in Q1 2024 respiratory function and clinical efficacy\nsignals in both ERT treated patients and Strong U.S. and European\nMechanism of action addressing all key ERT-naïve MPS VI patients shareholder base and experienced\nfeatures of NASH senior management team\nMPS VI Orphan Drug Designation\nBreakthrough Therapy Designation granted by granted in the U.S. and in the EU. Rare Cash position allowing a runway until\nFDA and Chinese NMPA Pediatric Disease Designation in MPS VI the beginning of Q3 2024\ngranted in the U.S.\nPivotal Phase III initiated in Q3 2021 with\ntopline results expected H1 2026 Guidance on path to regulatory\nsubmission from FDA with a single\nLicensing and commercialization agreements Phase II/III trial\nin Greater China, Japan and South Korea\nInventiva continues to review potential\noptions to further develop odiparcil which\nmay include pursuing a partnership\n(1)MPS:mucopolysaccharidosis;(2)TrialsconductedbyGSKpriortoInventiva’sfounding\nCorporate Presentation | June 2024 Property of Inventiva│ 3\nManagement team with extensive global experience across all stages of\ndrug development and commercialization\nFrédéric Cren, MA/MBA, CEO and Co-Founder Pierre Broqua, Ph.D., CSO and Co-Founder\n Wide expertise within the areas of R&D, marketing,  Successfully managed numerous research programs\nstrategy and commercial operations leading to the discovery, development and\ncommercialization of innovative compounds, including\n Held senior positions at Abbott, Fournier, Solvay\nlanifibranor and Degarelix/ Firmagon®\nPharma and The Boston Consulting Group\n Held several senior research positions at Fournier,\n Former member of both Fournier and Solvay Pharma\nSolvay Pharma and Abbott\nExecutive Committees\nMichael Cooreman, MD, CMO\nJean Volatier, MA, CFO\n Gastroenterologist-hepatologist\n Former Head of controlling at URGO & Financial\nDirector International Operations of Fournier  Held global roles in several companies including\nTakeda Pharmaceuticals, Merck, Mitsubishi Tanabe,\n Held various positions as CFO\nImmusanT and Novartis\n Started his career with PwC in Paris and Philadelphia\nAlice Roudot-Ketelers, PharmD, COO\nPascaline Clerc, Ph.D., EVP Strategy and\nCorporate Affairs  Previously in charge of all drug development programs\nand cross-functional teams in Chemistry, CMC, non-\n Held global roles in academia, non-profit organization,\nclinical and clinical development up to Phase III at one\ngovernment and biotech companies\nof the major biotech companies in the NASH field\nKristina Meyer, Ph.D., Business Development\nDavid Nikodem, Ph.D., VP U.S. Operations\n& Alliance Management\n Former buyside portfolio manager and analyst for +15\n 20+ years experience in business development in the\nyears in public equities and VC\nbiotech industry\nCorporate Presentation | June 2024 Property of Inventiva│ 4\nDeep pipeline\nProgram Indication Discovery IND Enabling Phase I Phase II Phase III\nLanifibranor NASH pan-PPAR\nOdiparcil MPS VI GAG clearance\nYap-Tead\nOncology\nTGF-β\nFibrosis\nCorporate Presentation | June 2024\nProperty of Inventiva│ 5\nKey financials and shareholder base\nKey financials Shareholder base\nFree Float Founders\n25.2% 18.4%\nEmployees & Others BVF\nISIN code FR0013233012 / US46124U1079 2.3% 16.2%\nYiheng\n7.4%\nMarket Euronext Paris / Nasdaq GM\nSofinnova NEA\n9.8% 10.8%\nQatar Holding LLC\nShares outstanding 52,477,188\n9.9%\nEuronext Paris: €145 m\nMarket cap\nAnalyst coverage\n(June14, 2024) Nasdaq Global Market: $155m\nJefferies L. Codrington / M. J. Yee\n€30.2m(1) (vs €35.9m as of December\nGuggenheim S. Fernandez\nCash position 31, 2023)(2)\n(as of March 31, 2024) Current cash runway until early Q3 2024; nb: EIB Stifel A. Samimy\nsecond €25m tranche drawn Jan. 18, 2024\nHC Wainwright E. Arce\nCanaccord Genuity E. Nash\nRevenues(1)\nNo revenue end of Q1 2024 and 2023\n(as of March 31, 2024) LifeSci Capital R. Katkhuda\nKBC J. Mekhael\nR&D expenditures Portzamparc M. Kaabouni\n€110m compared to €60.5m in 2022\n(as of December 31, 2023)\nGilbert Dupont P.A. Desir\n(1)Unaudited\n(2)Cashpositionalsoincludes:i.short-termdepositsrecordedinthecategory“othercurrentassets”intheIFRSconsolidatedstatementoffinancialpositionandareconsideredbytheCompanyasliquidandeasilyavailable,ii.thelong-termdeposithasatwo-yeartermaccessiblepriortothe\nexpirationofthetermwithanoticeperiodof31daysandisconsideredasliquidbytheCompany.\nCorporate Presentation | June 2024 Property of Inventiva│ 6\nLanifibranor: licensing and commercialization agreement in Greater China,\nJapan and South Korea\nLicensing agreement in Greater China Licensing agreement in Japan / South Korea\nAgreement with CTTQ an affiliate of Sino Biopharm one of Licensing agreement with Hepalys Pharma, Inc. backed by\nthe largest Chinese pharmaceutical groups listed in Hong Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and\nKong Exchange (HSI composite) with a market cap of MEDIPAL Innovation Fund\nc.US$10bn(1) and c.US$4bn of revenue(2) and ranked top\n$10M upfront payment\n40th pharma globally(3)\nUp to $231M of clinical, regulatory and commercial\n$17 million of non-dilutive payments received\nmilestone payments\nUp to $290 million of clinical, regulatory and commercial\nTiered royalties from mid double digits to low twenties on\nmilestone payments\nnet sales\nTiered royalties from high single-digit to mid-teen double\nInventiva owns a stake of Hepalys Pharma, Inc. and has an\ndigits on net sales made during the first three years of\noption to acquire all outstanding shares at a pre-agreed\ncommercialization and from low to mid-teen double digits\nmultiple of post-money valuation\nstarting from year four.\nRight of first refusal in the event Hepalys receives an offer\nCTTQ will bear all costs associated with the trials conducted\nto sell the license or rights related to lanifibranor.\nin Greater China\nHepalys will bear all costs associated with the trials\nCTTQ to randomize patients into the NATiV3 Phase III\nconducted in Japan and South Korea\nclinical trial in mainland China\nDevelopment includes PK/PD Phase I studies and following\nphase I and NATiV3 results an independent pivotal Phase III\nstudy in Japan and South Korea\nInventiva eligible to more than 500M$ of milestones plus sales royalties\n(1) Information about Sino Biopharm, its business, operations and finances are based on third-party information and disclosures. Inventiva makes no representations regarding the accuracy of such information presented herein; (2) Market\ndata as of Sept 2022 ; (3) Converted from RMB to USD\nCorporate Presentation | June 2024 Property of Inventiva│ 7\nLanifibranor in Nonalcoholic\nSteatohepatitis (NASH)\nLanifibranor: a pan-PPAR agonist in Phase III development in NASH\nModerate and balanced pan-PPAR agonist activity\n Small molecule that activates all three PPAR isoforms in humans\nPPARα\n Differentiated chemical structure: not a fibrate or a TZD\n Once daily oral administration\n Positive Phase IIb trial topline results in NASH\n FAST Track (including in NASH patients with compensated cirrhosis) and\nBreakthrough Therapy designations granted by FDA and Chinese NMPA\n FDA confirmation that the non-clinical toxicology package is complete and\nPPARβ/δ PPARγ\nacceptable for NDA filing\nLANIFIBRANOR  IP: 19 families covering the compound, method of treatment, combination therapy,\nprocess, formulation and diagnostic methods. Last expiry expected in 2045\nPan-PPAR activity expected to improve efficacy in NASH\nINFLAMMATION AND\nMETABOLISM STEATOSIS FIBROSIS VASCULAR\nBALLOONING\nPPARα PPARδ PPARγ PPARγ PPARα PPARδ PPARγ PPARδ PPARγ PPARα PPARγ\nStellate cell\nInsulin sensitivity FA uptake NFkB-dependent Portal pressure\nproliferation and\ngene activation\nactivation\nHDLc FA catabolism LSEC capillarization\nInflammasome\nCollagen and\nTriglycerides Lipogenesis Intrahepatic vascular\nfibronectin\nBallooning resistance\nproduction\nCorporate Presentation | June 2024 Property of Inventiva│ 9\nPatent Extension Timeline\n2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045\nGranted Patent\nProduct:Composition\nof matter\nGranted Patent\nProduct: Crystallines forms of lanifibranor\nPending Application\nProduct: Deuterated forms of lanifibranor\nPending Application\nProduct: Crystallines forms of lanifibranor\nPending Application\nPCT\nProduct: Crystallines forms of lanifibranor\nGranted Patent Projected Potential Extensions\nApplication : Disease treatment (method claim; fibrosis condition; NASH)\nGranted Patent\nApplication : Disease treatment (method claim; cirrhosis)\nWe expect that NASH patent will be selected for Patent Term Extension (PTE).\nEligibility of the method of use patents for PTE assessed and confirmed by globally recognized IP law firm.\nComposition of matter patent and NASH patent have been granted in > 50 countries incl. EP, US, CN, JP, KR, AU, CA, RU.\nLanifibranor IP review | 2024 Confidential –Property of Inventiva│ 10\nLanifibranor is a differentiated pan-PPAR agonist with moderate and well\nbalanced activity on the three PPAR isoforms\nDifferentiated oral small molecule …\n Small molecule that\nactivates all three PPAR\nisoforms\n Differentiated chemical\nstructure with once daily\noral administration\n Offered in two dosage\nforms (800 mg, 1200 mg)\nModerate and balanced pan-PPAR agonist activity\n150\nPPARα PPARδ PPARγ\nCompound\nEC50 (nM) EC50 (nM) EC50 (nM)\n125\nLanifibranor* 1630 850 230\n100\n75 Fenofibrate 2400 - -\n50 Pioglitazone - - 263\nRosiglitazone - - 13\n25\nElafibranor** 10 100 -\n0\n-10 -8 -6 -4 Seladelpar^ - 2 -\nlanifibranor (M)\nSource: * Company data ** HanfR et al, Diabetes & Vascular Dis Res 2014 ^ Cymabaycompany presentation ^^ J Med Chem. 2018 Feb 15. doi: 10.1021/acs.jmedchem.7b01285\nProperty of Inventiva│ 11\nnoitavitcA%\nLANIFIBRANOR\n… that binds differently than glitazone to PPARγ\nROSI\nLANI\n Induces different coactivator recruitment^^\nhPPARα\nhPPARδ\nhPPARγ\nCorporate Presentation | June 2024\nAdverse events and toxicity previously seen in other single and dual PPAR\nagonists have not been observed with lanifibranor\nSAFETY\nOrgan Isoforms activated Reported PPAR side effects lanifibranor effects\n Fluid retention\nHEART PPARγ\n Cardiac hypertrophy\nSKELETAL\nPPARα  Myofiber degeneration\nMUSCLE\nNOT\nOBSERVED\n > 50% increases in creatinine, degenerative\nKIDNEY PPARα\nchanges in renal tubules\nURINARY\nPPARγ  Proliferative changes in bladder epithelium\nBLADDER\nAdverse events and toxicity of single / dual PPAR agonists not observed in primate and rodent studies\n No adverse clinical signs observed at any dose-level tested\nFAVOURABLE\n No effects on body and heart weight, no haemodilution or creatinine increase\nTOLERABILITY PROFILE in\na 12-month monkey study …  Electrocardiography and clinical pathology investigations did not reveal any\nundesirable effects\n Rat: no observed neoplastic change or increase in tumor types commonly associated\n… and in two-year with single PPARγ and dual PPARα/γ agonists (liver, adipose, bladder, renal and\nCARCINOGENITY STUDIES skin)\nperformed in rat and mice\n Mice: no observed neoplastic changes of human relevance\nConfirmation by FDA that the non-clinical toxicology package is complete and acceptable\nto support NDA filing in NASH\nSource: Company data\nCorporate Presentation | June 2024 Property of Inventiva│ 12\nLanifibranor: comprehensive impact on the histology and biology of NASH\nHISTOLOGY AND MARKERS\n1\nFibrosis Regression\nFibrosis NASH\n&\nRegression Resolution\nNASH Resolution\nHealthy liver Steatosis Steatohepatitis Liver fibrosis Cirrhosis\nSteatosis measured by Biomarkers of inflammation Circulating biomarkers of\nhistological grading, MRI-PDFF (ferritin, CRP), tissue injury fibrosis: Pro-C3, TIMP-\nCAP/Fibroscan; Intra-hepatic (ALT,AST) and apoptosis 1/MMP-2, MACK-3\nTG content by 1H-MRS(1); (CK18) Improvement seen with CT1\nNAFLD resolution scan\nGLUCOSE METABOLISM MARKERS CARDIOVASCULAR RISK MARKERS\nImproves insulin sensitivity and glycemic control in patients with or Improves markers of cardiovascular risk and lipid metabolism\nwithout diabetes\nAPO-B DBP\nHDL-C\nTreatment with lanifibranor decreases the ratio of visceral abdominal\nAPO-B/APO-A1 Adiponectin\nfat to subcutaneous fat, reflecting a shift from pro-inflammatory Triglycerides levels\nAPO-C3\nvisceral fat towards metabolically healthy adipose tissue LDL-cholesterol level\nHs-CRP\nFasting glucose HOMA-IR index Insulin resistance\nFasting insulin Hepatic glucose Hepatic and muscle Improves markers of cardiometabolic health independently of weight\nHbA1c production insulin resistance gain which has been shown to be metabolically healthy\nIncreases adiponectin known to regulate glucose levels, lipid\nmetabolism and insulin sensitivity through its anti-inflammatory, anti-\nfibrotic and antioxidant effects\n(1) Proton magnetic resonance spectroscopy\nCorporate Presentation | June 2024 Property of Inventiva│ 13\nThe Phase IIb NATIVE trial evaluated 800 mg and 1200 mg once-daily\nlanifibranor versus placebo in 247 patients\nPHASE IIb DESIGN OVERVIEW\n24-week treatment + 4-week follow-up\nScreening End of treatment\nDouble blind, randomized, placebo-controlled\n Liver biopsy  Liver biopsy\nPlacebo\nlanifibranor, 800 mg once daily\n• Randomisation 1/1/1\n• Stratification on\nlanifibranor, 1200 mg once daily\ntype 2 diabetes\nmellitus (T2D)\nPatient population # patients Definition\nPatients randomized having received at least one dose of\nSafety / Intention-to-Treat (ITT) 247\nlanifibranor/placebo\nPatients with paired biopsies and without deviation impacting efficacy\nPer Protocol (PP) 194\nresults\n Main inclusion criteria: patients with biopsy-proven NASH confirmed by central reader having Steatosis-Activity-Fibrosis\n(SAF) scores of 1-3 for steatosis, 3-4 for activity, and <4 for fibrosis\n Results published in the New England Journal of Medicine(1):\n(1) https://www.nejm.org/doi/full/10.1056/NEJMoa2036205\nCorporate Presentation | June 2024 Property of Inventiva│ 14\nThe majority of patients successfully completed the 24-week treatment\nPHASE IIb DESIGN TREATMENT ARMS\n247 patients randomised and treated\nPlacebo lanifibranor 800 mg/day lanifibranor 1200 mg/day\nN = 81 N = 83 N = 83\n74 (91%) patients completed 77 (93%) patients completed 77 ( 93%) patients completed\nthe 24-week treatment the 24-week treatment the 24-week treatment\n7 (9%) patients prematurely 6 (7%) patients prematurely 6 (7%) patients prematurely\nwithdrawn: withdrawn: withdrawn:\n- Adverse events (n=3) - Adverse events (n=3) - Adverse events (n=3)\n- Withdrawal by patient (n=2) - Lost to follow-up (n=1) - Lost to follow-up (n=1)\n- Forbidden concomitant - Withdrawal by patient* (n=1) - Withdrawal by patient (n=2)\nmedication (n=2)\n- Non-compliance (n=1)\nNote: * And adverse event as secondary reason\nCorporate Presentation | June 2024 Property of Inventiva│ 15\nPatient population included 58% of female and 42% of patients with T2D\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor Overall\nParameters (unit)\n- 800 mg/day 1200 mg/day -\nn (%) or mean ± SD\nN = 81 N = 83 N = 83 N = 247\nDemographics\nFemale 41 (51%) 54 (65%) 49 (59%) 144 (58%)\nAge (years) 53.4 ± 13.1 55.0 ± 10.4 52.2 ± 13.8 53.6 ± 12.5\nWhite 74 (91%) 80 (96%) 78 (94%) 232 (94%)\nWeight (kg) 95.1 ± 17.3 91.6 ± 19.3 93.0 ± 19.9 93.2 ± 18.9\nBody Mass Index (kg/m²) 32.8 ± 5.1 32.5 ± 5.5 33.3 ± 5.5 32.9 ± 5.4\nType 2 diabetes 35 (43%) 33 (40%) 35 (42%) 103 (42%)\nLiver biopsy characteristics\nSAF Activity score\n3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.5 3.3 ± 0.5\n(inflammation + ballooning)\nNAFLD Activity Score (NAS) ≥6 56 (69.1%) 63 (75.9%) 61 (73.5%) 180 (72.9%)\nFibrosis stage F2/F3 57 (70.4%) 68 (81.9%) 63 (75.9%) 188 (76.1%)\nCorporate Presentation | June 2024 Property of Inventiva│ 16\nSeveral liver tests and markers of lipid and glucose metabolism were\nrecorded\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor\nParameters (unit)\n- 800 mg/day 1200 mg/day\nmean ± SD\nN = 81 N = 83 N = 83\nLiver enzymes\nAlanine aminotransferase, ALT (UI/L) 56.9 ± 31.6 64.1 ± 41.4 63.6 ± 43.4\nAspartate aminotransferase, AST (UI/L) 43.3 ± 24.1 53.9 ± 43.4 43.9 ± 24.8\nGamma glutamyl transferase, GGT (UI/L) 67.9 ± 80.4 101.6 ± 146.1 67.1 ± 93.1\nPlasma lipid levels\nHDL-Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3\nTriglycerides (mmol/L) 2.0 ± 0.8 1.9 ± 0.9 2.0 ± 0.9\nGlucose metabolism for patients with T2D\n(n= 103)\nFasting Glucose (mmol/L) 6.9 ± 2.0 7.3 ± 2.2 6.6 ±1.2\nHbA1c (%) 6.5 ± 0.7 6.7 ± 0.8 6.6 ± 0.7\nInsulin (pmol/L) 222.7 ± 186.5 246.3 ± 213.4 278.5 ± 233.5\nCorporate Presentation | June 2024 Property of Inventiva│ 17\nLanifibranor achieves statistically significant results on the key Phase III\nFDA and EMA primary endpoints\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint: ITT population\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83)\nResolution of NASH and no\n45%\nworsening of fibrosis*\n33%\n19%\n0.043 <0.001\nImprovement of fibrosis by at\nleast one stage and no\n42%\nworsening of NASH** 28%\n24%\n0.53 0.011\nResolution of NASH and\n31%\nimprovement of fibrosis***\n21%\n7%\n0.017 <0.001\n Statistical significance was also demonstrated for the main key histological endpoints in patients with F2-F3 fibrosis stage\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of\nliver fibrosis ≥ 1 stage and no worsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1\nstage\nCorporate Presentation | June 2024 Property of Inventiva│ 18\nResolution of NASH and improvement of fibrosis: effect size is increased in\nF2/F3 patients as well as patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and\nimprovement of fibrosis(1) 3,0more 4,4more\nresponders on 31% responders on\n(N=247) 21%\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in 8,0more 9,6more\nresponders on 29% responders on\npatients with TD2M (N=103) 24%\n3% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3\n3,4more 4,7more\n33%\npatients (N=188) 24% responders on responders on\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3 7,5more 7more responders\n30% responders on 28% on 1200mg vs\npatients with TD2M (N=83)\n4% 800mg vs placebo placebo\n(1) ) Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | June 2024 Property of Inventiva│ 19\nImprovement of fibrosis and no worsening of NASH is achieved in all\nsubgroups analyzed with similar level of effect size\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nImprovement of fibrosis by at least\none stage and no worsening of 1,2more 1,7more\nNASH(1) (N=247) 24% 28% responders on 42% responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\n1,3more 2,0more\nNASH(1) in patients with TD2M\nresponders on 46% responders on\n30%\n(N=103) 23% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nImprovement of fibrosis by at least\none stage and no worsening of\n1,1more 1,6more\nNASH(1) in F2 / F3 patients (N=188) 48%\n30% 32% responders on responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\nNASH(1) in F2 / F3 patients with\n1,2more 1,6more\n48%\nTD2M (N=83) 37% responders on responders on\n30%\n800mg vs placebo 1200mg vs placebo\n(1) improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24\nCorporate Presentation | June 2024 Property of Inventiva│ 20\nResolution of NASH and no worsening of fibrosis: effect size is increased in\nF2/F3 patients as well as in patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and no\n1,7more 2,4more\nworsening of fibrosis(1) (N=247) 45%\n33% responders on responders on\n19%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in patients 2,3more 3,0more\n43%\nwith TD2M (N=103) 33% responders on responders on\n14%\n800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n3,8more 4,8more\n44%\npatients (N=188) 34% responders on responders on\n9%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n8,2more 10,2more\n41%\npatients with TD2M (N=83) 33% responders on responders on\n4%\n800mg vs placebo 1200mg vs placebo\n(1) Resolution of NASH with no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline\nCorporate Presentation | June 2024 Property of Inventiva│ 21\nLanifibranor efficacy on resolution of NASH and improvement of fibrosis of\nat least 1 stage is superior to resmetirom and at par with FGF-21\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=320 N=223 (F2/F3) N=190\nN=247 N=955 N=128 N=126 N=222\nITT ITT ITT PP\nEffect size Effect size Effect size Effect size Effect size\n24% 11% 28% 28% 20%\n35%\n33%\n31%\n26% 28%\n21%\n20%\n16%\n14% 15% 14%\nEndpoint not\n7% 7% reported on\n5% 5%\n0%\nPlacebo 800mg 1200mg Pbo 80mg 100mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg 30mg 44mg\n0.017* <0.001* <0.0001* <0.0001* 0.009* 0.002* <0.01* <0.01* QW(1) QW Q2W\n*** ***\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results; Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023 ; SemaglutideA\nPlacebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome et al. NEJM 2021; 384:1113-1124.; Resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10 and EASL 2023 presentation pg. 8; Efruxifermin EASL 2023 presentation pg.\n8, corporate presentation of March 2024 pg 22 ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Firbosis, The NEJM DOI:\n10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 22\nLanifibranor efficacy on ≥1 stage fibrosis improvement and no worsening\nof NASH is superior to resmetirom and at par with injectables\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n18% 12% 5% 14% 30% 20% 10% 21% 21%\n55%\n51% 51%\n49% 49%\n42% 43% 43%\n38%\n36%\n28% 29% 33% 30% 33% 32% 34% 30%\n24% 24%\n26%\n24%\n26%27%\n22% 22%\n19% 19%\n14%\n7%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo15mg30mg 44mg Pbo 0.1mg 0.2mg 0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\n0.53 0.011* 0.0002* <0.0001* 0.65 QW QW Q2W QW QW QW\n0.033*0.123 <0.01* 0.1*0.008*0.008* 0.48\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 23\nLanifibranor efficacy on NASH resolution and no worsening of fibrosis is\nsuperior to resmetirom and at par with pegozafermin\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n26% 20% 18% 46% 18% 24% 42% 35% 52%\n60% 59% 62%\n56%\n45% 43% 45% 46% 45% 44%\n40% 40%\n33% 37% 37% 36%\n30%\n26% 25% 26%\n23%\n19% 19%\n17%\n14%\n10% 10% 10%\n7%\n2%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg30mg44mg Pbo 0.1mg 0.2mg0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\nQW QW Q2W QW QW QW\n<0.043* <0.001* <0.0001*<0.0001* 0.024* 0.005*<0.001* 0.005* <0.0001* 0.0005* <0.001*\n0.0009*\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 24\nA statistically significant decrease in liver enzymes was observed\n10\n0\n-10\n-20\n0 4 8 12 16 20 24\nProperty of Inventiva│ 25\n)L/IU(\negnahc\netulosba\nnaeM\n10\n0\n-10\n-20\n-30\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/IU(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in ALT Absolute change from baseline in AST\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nAbsolute change from baseline in GGT\n10\n0\n-10\n-20\n-30\n-40\n-50\n0 4 8 12 16 20 24\n)L/IU(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247)\n**\n*\n** ** * **\n** *\n** ** * **\n0 W4 W14 W24\n* p<0.01 **p<0.001\nA statistically significant decrease of ALT,\nAST and GGT in both lanifibranor dose\n** ** groups observed after 4 weeks\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nSTNIOPDNE\nYRADNOCES\nCorporate Presentation | June 2024\nA statistically significant change in HDL-cholesterol and triglycerides was\nseen, without a change in LDL-cholesterol\n0.25\n0.15\n0.05\n-0.05\n0 4 8 12 16 20 24\nProperty of Inventiva│ 26\n)L/lomm(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in HDL-C Absolute change from baseline in triglycerides\n0.2\n0\n**\n-0.2\n-0.4\n-0.6\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/lomm(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247) * p<0.01 **p<0.001\n**\n**\n**\n*\n**\n** **\n**\n**\n0 W4 W14 W24\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200m**g\n No change in LDL-cholesterol\nSTNIOPDNE\nYRADNOCES\nStatistically significant change Statistically significant change\nin HDL-cholesterol in triglycerides\nCorporate Presentation | June 2024\n0.5\n0\n-0.5\n-1\n-1.5\n-2\n0 4 8 12 16 20 24\nProperty of Inventiva│ 27\n)L/lomm(\negnahc\netulosba\nnaeM\nIn patients with NASH and T2D, statistically significant reductions of\nfasting glucose and insulin, HbA1c were observed\nAbsolute change from baseline in HbA1c Absolute change from baseline in fasting glucose\n0.5\n0\n-0.5 **\n**\n**\n**\n-1 **\n**\n0 4 8 12 16 20 24\n0 W4 W14 W24\nPlacebo (N= 35) Lanifibranor 800mg (N= 33)\nLanifibranor 1200mg (N= 35)\n**p<0.001\n)%(\negnahc\netulosba\nnaeM\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo (N = 35) Lanifibranor 800mg (N = 33)\nLanifibranor 1200mg (N = 35)\nAbsolute change from baseline in insulin at W24\n0\n-10\n-20\n-30\nweek 24\n)Lm/UIµ(\negnahc\netulosba\nnaeM\nSecondary endpoints in patients with NASH and T2D (N = 103)\n**\n**\nPlacebo (N= 32) Lanifibranor 800mg (N= 31)\nLanifibranor 1200mg (N= 33)\nSTNIOPDNE\nYRADNOCES\nPHASE IIb EFFICACY OTHER\nLanifibranor associated with improvements\nin insulin sensitivity and glycemic control in\nNASH patients\nCorporate Presentation | June 2024\nLanifibranor leads to significant improvements in hepatic and muscular\ninsulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 28\nnim/gk/gm\nLS mean absolute change from baseline LS mean absolute change from baseline to LS mean absolute change from\nto week 24 in week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\n Data from the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating\nlanifibranor (800mg/day) in patients with NAFLD and type 2 diabetes mellitus (T2D) for 24 weeks\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nDr. Cusi - IIS\nCorporate Presentation | June 2024\nLanifibranor induces a significant decrease in circulating biomarkers\nlanifibranor\nMedian relative change (%) Placebo Pvalue\n(Two doses pooled)\nPro-C3 (4.1%) (13.9%) p= 0.005*\nPro-C3 >14 at\nFibrosis (12.8%) (20.5%) p= 0.017*\nbaseline(1)\nRatio TIMP-1/MMP-2 (4.6%) (22.5%) p < 0.001*\nApoptosis CK18-M30 0.5% (41.1%) p < 0.001*\nFerritin (9.1%) (29.4%) p < 0.001*\nInflammation\nhs-CRP 13.0% (35.5%) p < 0.001*\n(1) Level where it is estimated that fibrogenesis is active and corresponding to F2/F3 patients\nFAS (Full Analysis Set) population with available data at baseline and at week 24\n* Statistically significant\nProperty of Inventiva│ 29\nSERUSAEM\nEMOCTUO\nREHTO\n Data from NATIVE clinical study evaluating lanifibranor (800mg/day and 1200mg/day ) in patients with NASH for 24 weeks\nCorporate Presentation | June 2024\nLanifibranor significantly reduces hepatic steatosis measured by MRI-\nPDFF and MR-spectroscopy\n Data from the Legend clinical study evaluating lanifibranor  Data from the clinical study conducted by Dr. Kenneth\n(800mg/day) in combination with empagliflozin in patients Cusi from the University of Florida, evaluating lanifibranor\nwith NASH and poorly controlled Type 2 Diabetes (T2D) (800mg/day) in patients with NAFLD and type 2 diabetes\nfor 24 weeks mellitus (T2D) for 24 weeks\nDr. Cusi - IIS\nLiver fat measured by MRI-PDFF Liver fat (IHTG) measured by MR-spectroscopy\nN=26 from baseline at week 24 N=38 from baseline at week 24\nLS means relative percent change, FAS LS means relative percent change, FAS\n0% 0%\n0%\n-10% -10%\n-12%\n-20% -20%\n-30% -30%\n*\n-40% -37% -40%\n*\n-44% pa=0.002\n-50%\n-47%*\n-50%\nPlacebo Lani Lani Placebo Lani\nn= 5 n= 12 + Empa n=18 n=20\nn= 9\nBaseline 17.1-19.7%  65% of patients achieved liver fat reduction ≥30% vs 22% under\nplacebo\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)  25% of patients achieved NAFLD resolutions vs 0% under placebo\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before a P-value from an Analysis of Covariance (ANCOVA) using the relative change from baseline to week 24\nWeek 24 as the response, the treatment as covariate as well as the baseline of IHTG. In the FAS, missing data at\nWeek 24 were imputed by baseline data.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 30\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Tirzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 31\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\n Data from the clinical study evaluating lanifibranor (800mg/day) in combination with empagliflozin in patients with NASH and\npoorly controlled Type 2 Diabetes (T2D) for 24 weeks\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 32\nLanifibranor has a favourable safety profile\nPHASE IIb SAFETY OVERALL\nPlacebo 800 mg 1200 mg\nN (%) patients reporting Adverse Event (AE)\n(N = 81) (N = 83) (N = 83)\n Any Treatment-Emergent AE (TEAE)\n50 (61.7%) 59 (71.1%) 62 (74.7%)\nDrug-related TEAE 19 (23.5%) 25 (30.1%) 23 (27.7%)\n Any TEAE leading to drug withdrawal\n3 (3.7%) 4 (4.8%) 3 (3.6%)\nDrug-related TEAE leading to drug withdrawal 2 (2.5%) 1 (1.2%)(1) 2 (2.4%)(2)\n Any Serious TEAE\n3 (3.7%) 3 (3.6%) 7 (8.4%)\nDrug-related Serious TEAE 2 (2.5%)(3) - -\nFocus of next slide\n(1) One patient with moderate diarrhea ; (2) One patient with mild cardiac failure; one patient with mild diarrhea, abdominal pain, dizziness ;\n(3) 2 SUSARs (placebo arm): one patient with mild cardiac failure; one patient with moderate urticaria\n Consistent with known insulin sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at the\n800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed.\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 81)\n Peripheral edema 2 (2.5%) 5 (6.0%) 7* (8.4%)\nDrug-related peripheral edema - 2 (2.4%) 2 (2.4%)\n Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few\npatients received diuretics. 4 cases were considered study drug related by the investigator (2 at 800\nand 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor\n1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female\n* One AE of severe intensity\npatients\nCorporate Presentation | June 2024 Property of Inventiva│ 33\nA limited number of serious TEAEs occurred\nPHASE IIb SAFETY SERIOUS TEAE\nPatients reporting treatment-emergent Placebo 800 mg 1200 mg\nSerious AE (SAE); N (%) (N = 81) (N = 83) (N = 83)\nTotal 3 (3.7%) 3 (3.6%) 7 (8.4%)\nTreatment-Emergent Serious AE linked to biopsy procedure\nPost-procedural haematoma/haemorrhage - 1 (1.2%) 1 (1.2%)\nPost-procedural pain - - 1 (1.2%)\nPneumobilia (post-procedural) - - 1 (1.2%)\nOther Treatment-Emergent Serious AE\nWrist fracture 1 (1.2%) - -\nAngina unstable - - 1 (1.2%)\nCardiac failure 1 (1.2%) - -\nGastroenteritis - - 1 (1.2%)\nPyelonephritis - - 1 (1.2%)\nPancreatitis - 1 (1.2%) -\nUndifferentiated connective tissue disease - 1 (1.2%) -\nUrticaria 1 (1.2%) - -\nFoot operation - - 1 (1.2%)\nCorporate Presentation | June 2024 Property of Inventiva│ 34\nPhase II results have demonstrated modest weight increase with no impact\non efficacy\n Consistent with known insulin-sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at\nthe 800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed\n According to a six-month study with pioglitazone in patients * with NASH body weight gain is likely attributed to an\nincrease in adipose tissue and not water retention\n Based on a 52-week lanifibranor trial in systemic sclerosis (SSc) patient weight gain is expected to reach a maximum\nby week 24\nSSc lanifibranor study: weight (kg) relative change from baseline over 52 weeks\n(Observed cases under treatment – FAS population)\nExcept for two patients (one placebo, one 600mg BID),\nTEAE time of onset related to weight increase happened in\nKg\n6 the first 24 weeks of treatment\n4\n2\n0 Weeks\n0 2 4 8 12 16 20 24 28 32 36 40 44 48 52\nLanifibranor 600 mg BID Placebo\nNote: * Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholivsteatohepatitis ; Balas, Belfort, Harrison et al. ; Journal of Hepatology 47 (2007) 565-570\nCorporate Presentation | June 2024 Property of Inventiva│ 35\nWeight changes in NATIVE trial: approximately 33% of patients\non lanifibranor show a weight increase of more than 5%\nWeight changes at end of treatment (Week 24) in patients treated with\nlanifibranor versus placebo\nLanifibranor Placebo\n100%\nN=144 N=73\n84%,\nN=61\n80%\n51%,\n60%\nN=73\n33%,\n40%\nN=48\n16%,\n20% N=23 11%,\nN=8 6%,\nN=4\n0%\nStable Moderate Weight Stable Moderate Weight\nweight weight gain weight weight gain\n(≤2.5%) gain (>5%) (≤2.5%) gain (>5%)\n(2.5%-5%) (2.5%-5%)\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 36\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (I/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nFasting HOMA-IR ALT\nMean absolute change at Week 24 from baseline Mean absolute change at Week 24 from baseline (U/L)\nLanifibranor Placebo Lanifibranor Placebo\n4.0\n10 8\n1.7\n2.0 5\n0.0 0\n-0.6\n-2.0 -5\n-5\n-10\n-4.0\n-15\n-6.0 -5.1\n-5.8\n-20\n-8.0 -20\n-8.2 -25 -22\n-10.0\n-26\n-30\nTriglycerides CAP\nMean absolute change at Week 24 from baseline (mmol/L) Mean absolute change at Week 24 from baseline (dB.m-1)\n1\n0.8 Lanifibranor Placebo Lanifibranor Placebo\n35\n30.6\n0.6\n25\n0.4\n0.2 0.12\n0.03 15\n0\n-0.2 5\n-0.4\n-0.42 -0.44 -0.45 -5\n-0.6 -4.6\n-0.8  LDL level do not change but HDL level improves in -15 -10.2\npatients treated with lanifibranorindependently of weight -14.7\n-1 -17\nchanges\n-25\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 37\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (II/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nAPO-C3 APO-B\nMean absolute change at week 24 from baseline (μg/ml) Mean absolute change at week 24 from baseline (mg/dl)\n25 Lanifibranor Placebo Lanifibranor Placebo\n19.1 0\n20\n-0.08\n-2\n15\n-2.58\n-4\n8.9\n10\n-6\n5\n-8\n0\n-10\n-9.66\n-5\n-12\n-10 -7.3 -14 -13.04\n-9.3\n-10.7\n-14.56\n-15 -16\n-20 -18\n-20\nhs-CRP hs-CRP\nMean absolutechange at Week 24 from baseline (%) Mean relativechange at Week 24 from baseline (%)\nLanifibranor Placebo Lanifibranor Placebo\n1.0 0.6\n10\n3\n0.0 0\n-0.1 -1\n-1.0 -0.6 -10\n-20\n-2.0 -21\n-30\n-3.0 -2.7\n-40\n-41\n-4.0 -50\n-4.1\n-60\n-5.0\n-61\n-70\n-6.0\n-80\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 38\nEffect on weight when combining lanifibranor with empagliflozine\nWeight change, N=32 Ratio VAT/SAT, N=19\nRelative change from Baseline (%) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 93-102 kg\n5 11\n3.6 10\n4\n3 5\n2\n2 1.4 0\n1\n00 -5\n-0.4 -0.4 -5*\n0\n-0.9\n0 -10\n-1\n-0.8 -0.8\n-1.1 -15\n-2\nWeek 4 Week 12 Week 24\nBaseline -17**\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8 -20\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nPlacebo Lani Lani + Empa n= 4 n= 8 n= 7\nAt Week 24, 7 patients without weight values available : SAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n- 5 patients under placebo who prematurely stopped before Week 24 * p=0.08, **p<0.01, versus placebo (ANCOVA)\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly Thirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\nmodified his/her diet (intercurrentevent) before Week 24.\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nThe combination of empagliflozin and lanifibranor addresses the Lanifibranor alone and in combination with empagliflozin leads to\nweight gain observed in some patients treated with lanifibranor alone a shift towards metabolically healthy adipose tissue\nCorporate Presentation | June 2024 Property of Inventiva│ 39\nPhase III NATiV3 should, if positive, allow to file for accelerated approval\nMain Cohort Accelerated\nApproval\n72 weeks treatment\nN~ 950\nLanifibranor: 1200 mg once daily\nNon-cirrhotic NASH &\nLanifibranor: 800 mg once daily\nF2-F3 fibrosis\nActive Treatment Extension\nPlacebo: Once daily\n►Stratification\n48 weeks\n- By diabetic status\nExploratory Cohort\n- By fibrosis stage F2/F3 EoT\n72 weeks treatment Lanifibranor: 1200 mg once daily\nN~ 200\nLanifibranor: 800 mg once daily\nLanifibranor: 1200 mg once daily\nScreen failed patients from the\n►All patients who complete the main or the exploratory cohort\nmain cohort are eligible for the active treatment extension study\nLanifibranor: 800 mg once daily\nNon-cirrhotic NASH & ►Patients to switch to the active treatment extension after the\nF1-F4 fibrosis week 72 visit of the last patient randomized in the main cohort\nPlacebo: Once daily\nor after 120 weeks of treatment, whichever happens first\n►Stratification\n- By diabetic status\n- By fibrosis stage F1-F3/F4\nPrincipal investigators: Dr. S. Francque / Dr. A. Sanyal for the main cohort\nPrimary endpoint: Composite endpoint of patients having both NASH resolution and one stage fibrosis improvement\nKey secondary endpoints: NASH resolution and no worsening of fibrosis / Fibrosis improvement and no worsening of NASH\nGLP1: Patients under a stable dose of GLP1-RA for at least 3 months prior to screening can be included\nStatistical powering: 90% considered for sample size calculations\nCentral biopsy reading: Tie breaker approach by three expert pathologists\nCorporate Presentation | June 2024 Property of Inventiva│ 40\nOver 400 sites and 24 countries involved in NATIV3\nPHASE III DESIGN SITE SELECTION\n► 478 sites activated in 24 countries (as\nof April 1, 2024)\n► 914 randomized patients: 731 in the\nmain cohort and 183 in the exploratory\ncohort (prior to the voluntary pause)\n► Target to achieve LPFV H1 2024\n► Topline data expected H1 2026\nNATiV3 countries\nCorporate Presentation | June 2024 Property of Inventiva│ 41\nOpportunity for lanifibranor\nLanifibranor well positioned alone or in combination in the NASH market\npan-PPAR THR-β FGF-21 GLP-1\nROUTE OF\nOral Oral Injectable Injectable\nADMINISTRATION\nIndirect\nDirect activity Indirect Direct activity Not seen with sema.\nEfficacy on fibrosis\nseen at 6 months seen after 12 months seen at 6 months Reported by BI & Lilly\nafter 12 months\nNASH resolution\nInsulin resistance\nLimited drop-out High drop out due to High drop out due to\nTolerability Limited drop-out GI side effects on GI side-effects & GI side-effects &\ninitiation injections injections\nPatients with advanced F1 patients\nPatients with F2/F3: induction\nTarget patients fibrosis (F2/F3) F2/F3: in\nadvanced fibrosis therapy\npopulation T2D patients combination with\n(F2/F3) F4 patients\nLean patients anti-fibrotic drugs\nCorporate Presentation | June 2024 Property of Inventiva│ 43\nLanifibranor expected to meet key decision drivers for surveyed payers\nand prescribers\nSurveyed Payers Surveyed Prescribers\n Improvement in fibrosis is expected to be the key driver of  Prescribers see improvement in fibrosis and joint\nP&TC decisions* in NASH\nachievement of fibrosis improvement and resolution of\nsteatohepatitisas the key benefits of a new NASH drug\n Payers see lanifibranor as stronger than resmetirom\n(Madrigal) and semaglutide(Novo Nordisk) on fibrosis  Both histological endpoints: over 85% of prescribers\nimprovement\nrate as major benefit\nTop 6 Key attributes (n = 95)\nBoth improves fibrosis and resolves steatohepatitis 99%\nImproves fibrosis 98%\nResolves steatohepatitis 99%\nImproves portal hypertension 93%\nImproves key markers of glucose metabolism 92%\nOral 88%\n% of prescribers 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%\nNot a factor Benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for lanifibranor,\nwhich is currently in Phase III clinical trial and has not been approved.\n*P&TC: Pharmacy & Therapeutics Committee\nCorporate Presentation | June 2024 Property of Inventiva│ 44\nLanifibranor well rated versus resmetirom(1) and the combination of\nlanifibranor + GLP-1 versus GLP-1 alone\nSurveyed prescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.7\n* 5.49\n*\n5.5 5.42\n5.3\n5.1\n4.94\n4.88\n4.9\n4.7\n4.5\nPre-diabetic patients with F2 / F3 Diabetic patients with F2 / F3 NASH\nNASH\nResmetirom Lanifibranor\n* indicates results are statistically significantly higher than the comparator (p<0.05)\nSource: (1) US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on available trial results for lanifibranor, which is currently in Phase III clinical trial\nand has not been approved. *Survey conducted before Resmetiromapproval by the FDA.\nCorporate Presentation | June 2024 Property of Inventiva│ 45\ntifeneb\ndeviecreP\nLanifibranor versus resmetirom Lanifibranor in combination versus GLP-1\n5.7\n* 5.52\n5.5\n5.26\n5.3\n5.1\n4.9\n4.7\n4.5\nNASH patients\nGLP-1 GLP-1 + Lanifibranor\nLanifibranor well positioned in patients with T2D and Lanifibranor could address the need in patients treated\nNASH, a population more present in patients with F2/F3 with GLP-1 to reduce fibrosis with an oral treatment and\nfibrosis and with a faster progressing form of fibrosis without the GI side effects present in the GLP-1 and\nFGF-21 class\nModerate metabolically healthy weight gain induced by lanifibranor is not a\nconcern for payers, and is deemed manageable by surveyed prescribers\nSurveyed Payers Surveyed Prescribers\n Surveyed payers see lanifibranoras safe for chronic use  A majority of surveyed HEPs and ~ half of surveyed GEs stated that\nand any associated moderate weight gain is seen as they would not hesitate to prescribe a new NASH drug that causes 2-3\nmanageable with lifestyle choices or weight loss agents. kg weight gain\n 72% of surveyed prescribers expect they could manage a moderate\n Surveyed payers: “If the message is that you'll weight gain with diet, exercise and counselling.\ngain 3 or 4 lbs but you'll feel better, and you  78% of surveyed prescribers agree that “Combining lanifibranorwith an\nexplain the difference between healthy and SGLT2 or GLP-1 is an opportunity to maintain effectiveness in NASH\nunhealthy weight, you can get through that. If while mitigating weight gain.”\nsomeone is 200 pounds and goes up to 205  73% of surveyed prescribers agree that the benefits of lanifibranor\npounds, I don't think they're going to notice it....” outweigh the moderate weight gain.\n Surveyed prescribers see other SEs as bigger drawbacks\nIs associated with neoplasm growth 63%\nIs associated with sarcopenia 40%\nIs associated with 2-3 kg weight gain 12%\n% of prescribers 0% 20% 40% 60% 80%\nMajor drawback\nThe importance of adherence to treatment and convenience of administration favors\nlanifibranor\n 80% of surveyed prescribers see low discontinuation rate as critical, very critical\nor absolute necessity\n 80% of surveyed prescribers rate oral administration as a key benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists (HEPs), 25 gastroenterologists (GEs), 25 endocrinologists in the United States in Q1 2024. Onlyassets in Phase III clinical trial in NASH at the\ntime of the survey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for\nlanifibranor, which is currently in Phase III clinical trial and has not been approved.\nCorporate Presentation | June 2024 Property of Inventiva│ 46\nPrescribers expect GLP-1 + lanifibranor to be significantly more beneficial than\nGLP-1 alone; suggests a perception of synergy, with lanifibranor enhancing GLP-1\nPrescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.60\n5.52\n5.50\n5.40\n5.30 5.26\n5.20\n5.10\n5.00\nMASH patients\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH/MASH at the time of the survey were\nincluded.\nProperty of Inventiva│ 47\ntifeneb\ndeviecreP\n*\nGLP-1 GLP-1 + Lanifibranor\n* indicates results are significantly higher than the comparator (p<0.05)\nLanifibranor could address the need in patients treated with GLP-1 to reduce fibrosis with an oral treatment\nand without the GI side effects present in the GLP-1 and FGF-21 class\nCorporate Presentation | June 2024\nOpportunity for lanifibranor for the treatment of NASH based on current\nclinical program (F2/F3)\nSteatosis Steatohepatitis Advanced fibrosis\nF1 F2 F3 F4 CC\nPatients with NASH estimated in 2030 (US) 9.0M 6.1M 4.5M 3.5M\nIMPROVEMENT OF FIBROSIS\nLanifibranor RESOLUTION OF NASH\nCARDIOVASCULAR IMPROVEMENT\nINSULIN RESISTANCE IMPROVEMENT\nLean NASH Lanifibranor Even if GLP-1 dominate the\n(10-15%) market, lanifibranor would\nT2D Lanifibranor still target 50-60%of\nEstimated\n(15-20%) patients with NASH:\nNASH patient\npopulation T2D & obesity • Lean NASH: 10-15%\nGLP1+Lani\n(20-25%) • “Needle phobia”: 10-15%\n(%)(1)\n• GLP-1 drop-outs: 32% (40%\nObesity & prediabetes\nDO * 80% of NASH patients\n(50-55%) GLP1+Lani\nunder GLP-1)\nSurveyed prescribers expect to write lanifibranor for ~ 30% of NASH patients if approved –across all of the following:\n30%\n• F2 and F3\n• Pre-diabetic and diabetic patients\n• BMI groups –suggests 2-3 kg weight gain is not a key barrier in surveyed prescribers 70%\nSource: Estes C,RazaviH,Loomba R,YounossiZ,Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology2018;67:123-133; US prescriber survey, February 2024 conducted in 45 hepatologists,\n25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in Phase III clinical trial in NASH/MASH at the time of the survey were included; US Payer Advisory Board, March 2023\nCorporate Presentation | June 2024 Property of Inventiva│ 48\nUpcoming catalysts\nCatalysts\n2024 2025 2026\nLanifibranor\nH1 2024 H2 2024 H1 2026 H2 2026\nLast Patient Last Patient • Last Patient New Drug\nFirst Visit randomized Last Visit Approval\n• Topline filing with\nresults FDA\nOdiparcil\nReview potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing\na partnership\nCorporate Presentation | June 2024 Property of Inventiva│ 50\nContacts\nInventiva Brunswick Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montégon Patricia L. Bank\nExecutive VP Aude Lepreux Investor relations\nStrategy and Corporate Affairs Julia Cailleteau\nMedia relations\npascaline.clerc@inventivapharma.com inventiva@brunswickgroup.com patti.bank@westwicke.com\n+1 202 499 8937 + 33 1 53 96 83 83 +1 415 513 1284\nLanifibranor : back-ups slides\nPhase I and Phase IIa clinical trials* in type 2 diabetes (T2D) patients:\nbeneficial changes in key metabolic markers\n300 p=0.05\np=0.05\n200\np=0.08\n100\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nProperty of Inventiva│ 53\nenilesab\nfo\negnahc\ntnecreP\nAdiponectin (PPARγ)**\nenilesab\nmorf\negnahc\ntnecreP\n40\np<0.05\n30\np<0.05\n20\np=0.13\n10\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nHDL Cholesterol (PPARα/δ)^\nenilesab\nmorf\negnahc\ntnecreP\n0\n-10\n-20\n-30 p=0.08\np<0.05\n-40\np<0.05\n-50\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nTriglycerides (PPARα/δ) ^^\nenilesab\nmorf\negnahc\ntnecreP\nPHASE I AND IIa\nLanifibranor metabolic markers in patients with T2D\nlanifibranor lanifibranor lanifibranor\nPhase I and IIa* clinical findings support the favorable tolerability of lanifibranor\n Phase I trials: > 200 healthy volunteers  Good overall tolerability and no major safety findings\n Phase IIa trial with 47 T2D patients  No increases of creatinine, LFTs, or CPK\n Phase IIb: > 250 patients treated for 24 or 48  No changes in blood pressure, no signal of fluid overload or haemodilution\nweeks  No clinically relevant weight gain\nThorough QT/QTc study demonstrates no impact of the drug on QT intervals\n Study carried out in 2020 and 2021 to prepare the NDA package\n A randomized, double-blind, double-dummy, placebo, positive-controlled (400mg of moxifloxacin) and multiple-dose\n(1200mg and 2400mg as the supratherapeutic dose) cardiac safety study to evaluate the effect of lanifibranor on the QT\ninterval in healthy adult subjects\n At doses of 1200 mg and 2400 mg, lanifibranor has no impact on QT intervals\nNote: * Conducted by Abbott; ** Adiponectin is associated with PPARγactivation; ^ HDL-C is associated with PPARαand d activation; ^^ Triglycerides are associated with PPARαand δ activation\nSource: Company data\nCorporate Presentation | June 2024\n247 patients were randomised across 71 sites worldwide, with the majority\nof patients based in Europe\nPHASE IIb DESIGN SITE SELECTION\n4 sites in 49 sites in\nCanada Europe\nPatients\nCountry\nrandomized\nEurope 183 (74%)\nU.S. 36 (15%)\nAustralia 13 (5%)\n12 sites in the Canada 8 (3%)\nUnited States\nMauritius 7 (3%)\nTotal 247 (100%)\n1 site in 5 sites in\nMauritius Australia\n16 countries worldwide (number of sites having randomized at least 1 patient)\n► Europe: Austria (1), Belgium (5), Bulgaria (5), Czech Republic (3), France (13), Germany (5), Italy (4), Poland (3),\nSlovenia (1), Spain (4), Switzerland (2), United Kingdom (3)\n► North America: United States (12), Canada (4)\n► Australia (5)\n► Mauritius (1)\nCorporate Presentation | June 2024 Property of Inventiva│ 54\nProperty of Inventiva│ 55\nYRAMIRP\nSTNIOPDNE\nYRADNOCES\nTNIOPDNE\nLanifibranor demonstrated statistical significance on all histological\nendpoints in both ITT and PP populations\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint\nN = 247 ITT population N = 197 PP population\nPlacebo 800 mg 1200 mg Placebo 800 mg 1200 mg\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83) (N = 62) (N = 63) (N = 69)\nDecrease of ≥2 points of SAF 27% 41% 49% 34% 51% 55%\nactivity score* and no worsening\n0.061 0.004 0.058 0.015\nof fibrosis\nResolution of NASH and no 19% 33% 45% 23% 40% 49%\nworsening of fibrosis**\n0.043 <0.001 0.039 0.002\nImprovement of fibrosis by at\n42% 46%\nleast one stage and no 24% 28% 29% 32%\nworsening of NASH*** 0.53 0.011 0.75 0.04\nResolution of NASH and 7% 21% 31% 10% 24% 33%\nimprovement of fibrosis^\n0.017 <0.001 0.036 0.001\nDecrease of ≥2 points of NAS\nscore^^ (NAFLD activity score) 32% 52% 64% 40% 62% 71%\nand no worsening of fibrosis\n0.01 <0.001 0.02 <0.001\n* Response is defined as a decrease from baseline to week 24 of at least 2 points of the SAF Activity score (SAF-A) with no worsening of the NAS Fibrosis score (NAS-F). No worsening means that score remains stable or\ndecreases ; ** Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; *** Improvement of liver fibrosis ≥ 1\nstage and no worsening of NASH at week 24; ^ Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage; ^^ NAS score is a commonly accepted,\nsemi-quantitative evaluation of biopsy results that assesses the severity of steatosis, inflammation and ballooning in the liver.\nCorporate Presentation | June 2024\nStatistical significance was also demonstrated for the main key histological\nendpoints in patients with F2-F3 fibrosis stage\nPHASE IIb EFFICACY F2-F3 POPULATION\nxx Statistically significant xx Non-statistically significant\nKey secondary endpoints in FAS F2-F3 patients (N=188)\nlanifibranor\nPPllaacceebboo 880000 mmgg 11220000 mmgg\n(N = 57) (N = 68) (N = 63)\nResolution of NASH and no\n44%\n34%\nworsening of fibrosis* 9%\n0.001 <0.001\nImprovement of fibrosis by at least\n48%\none stage and no worsening of\n30% 32%\nNASH**\n0.736 0.048\nResolution of NASH and improvement\n33%\nof fibrosis*** 7% 24%\n0.012 <0.001\n Similar results in the PP population\n Consistent response in diabetic and non-diabetic patients\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of liver fibrosis ≥ 1 stage and no\nworsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | June 2024 Property of Inventiva│ 56\nPhase III NATiV3 clinical trial confirmatory trial: anticipated\nexpected design to support broader “full approval”\nPHASE III OVERVIEW\nAnticipated event driven trial in patients with NASH compensated cirrhosis\nPhase 3: event driven\nN~ 800 EoT\nPatients with\nLanifibranor: Once daily Potential full approval in U.S.\nNASH and\ncompensated and EU\nPlacebo: Once daily\ncirrhosis\nKEY ENDPOINTS (non-exhaustive) TRIAL END DATE\n Based on time to first clinical event on c.800 patients  Trial expected to last up to 3 years\n• all cause mortality\n• hepatic decompensation events\n− hepatic encephalopathy\n− variceal bleeding or progression to varices that require prophylactic\ntreatment\n− new onset ascites requiring treatment\n• MELD score ≥15\n• liver transplantation\nCorporate Presentation | June 2024 Property of Inventiva│ 57\nLanifibranor clinical trial in patients\nwith NAFLD and T2D\nLanifibranor clinical trial in patients with NAFLD and T2D\nObjective of investigator-initiated trial: Establish safety, efficacy and mechanism of action of lanifibranor in patients with T2D\nand NAFLD. Specifically determine if lanifibranor decreases IHTG(1), improves hepatic insulin sensitivity, endogenous (hepatic)\nglucose production, gluconeogenesis and DNL(2).\nPatients with NAFLD and T2D\n Fasting plasma glucose: 100mg - 250mg/dL\n HbA1c: 6.0% to 9.5%\n Hepatic steatosis: >10%\n24 weeks treatment\nPlacebo\nLanifibranor 800mg/daily\n24 weeks\n6 weeks 4 weeks\nEOT\nRun-in period Run-in period Follow-up\nPrimary endpoint: change in Intrahepatic triglycerides (IHTG)\nSecondary endpoints:\n Proportion of responders reaching a decrease in IHTG from baseline ≥ 30% quantified by proton magnetic resonance\nspectroscopy (¹H-MRS)3\n Proportion of patients with NAFLD resolution (patients with IHTG ≤ 5%) quantified by ¹H-MRS\n Change in hepatic and muscle insulin sensitivity and lipid metabolism\n Safety\n(1) Intrahepatic triglycerides; (2) De-novo lipogenesis; (3) proton magnetic resonance spectroscopy\nCorporate Presentation | June 2024 Property of Inventiva│ 59\nLanifibranor significanty reduces liver fat and resolves NAFLD\nLS means relative percent change Percentage of patients achieving Percentage of patients achieving\nfrom baseline in liver fat (IHTG) at liver fat reduction ≥30% at week 24 NAFLD resolution at week 24\nweek 24 (FAS N=38) (FAS N=38) (FAS N=38)\n0% 100% 100%\n90% 90%\n-10%\n80% pa=0.008 80%\n-12%\n70% 65% 70%\n-20%\n60% 60%\n50% 50%\n-30%\n40% 40%\npb=0.048\n-40% 30% 30% 25%\n22%\n20% 20%\n-44%\n-50% Placebo Lanifibranor 10% 10%\nn=18 800mg\n0%\nn=20 0% 0%\nPlacebo Lanifibranor Placebo Lanifibranor\npa=0.002 n=18 800mg n=18 800mg\nn=20 n=20\na P-value from an Analysis of Covariance (ANCOVA) using the aChi² test bFisher test\nrelative change from baseline to week 24 as the response, the In the FAS, missing data at Week 24 were imputed as NAFLD resolution is defined as IHTG ≤ 5.5% at week 24.\ntreatment as covariate as well as the baseline of IHTG. In the FAS, non-achieving reduction. In the FAS, missing data at Week 24 were imputed as non-\nmissing data at Week 24 were imputed by baseline data. responders\nCorporate Presentation | June 2024 Property of Inventiva│ 60\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Terzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 61\nLanifibranor leads to significant improvements in hepatic and\nmuscular insulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 62\nnim/gk/gm\nLS mean absolute change from LS mean absolute change from LS mean absolute change from\nbaseline to week 24 in baseline to week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nCorporate Presentation | June 2024\nLanifibranor treatment increases HDL and adiponectin levels\n9\n7\n6.3\n5\n3\n1\n-0.3 -1\nProperty of Inventiva│ 63\nld/gm\nLS Mean absolute change from baseline to week\n24 in HDL cholesterol (completers N=28)\n9.0\npa=0.016\n7.5\n7.0\n5.0\n3.0\n1.0\n-0.2\n-1.0\naMixed Model Repeated Measures (MMRM).\n No change in LDL-cholesterol\nLm/gμ\nLS Mean absolute change from baseline to week\n24 in adiponectin (completers N=28)\npa<0.001\nPlacebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg\nn=14 n=14\nCorporate Presentation | June 2024\nKey take-aways\n Lanifibranor met the primary efficacy endpoint by inducing a liver fat reduction of 44% in patients with T2D\nand NAFLD treated for 24 weeks.\n– 65% of patients with T2D and NAFLD treated with lanifibranor achieved a greater than 30% liver\ntriglyceride reduction and 25% achieved NAFLD resolution after 24 weeks.\n Lanifibranor has a potent therapeutic effect on insulin sensitivity, and corresponding metabolic markers in\npatients with T2D and NAFLD\n– Potent effect as insulin sensitizer on hepatic and muscular insulin sensitivity\n Lanifibranor significantly improved adiponectin, which is known to regulate glucose levels, lipid metabolism,\nand insulin sensitivity through its anti-inflammatory, anti-fibrotic, and antioxidant effects\n Study confirms the favorable safety and tolerability profile of lanifibranor\nCorporate Presentation | June 2024 Property of Inventiva│ 64\nLegend\nLanifibranor in Combination with the SGLT2 Inhibitor in\npatients with NASH and T2D\nLanifibranor and SGLT2 Inhibitor mechanism of action and\nrationale for LEGEND\nLanifibranor: balanced pan-PPAR Empagliflozin: inhibitor of Sodium-\nagonist (PPARα, PPARγ and PPARδ)1 glucose co-transporter-22\n• Lanifibranorimproves insulin sensitivity, lipid and glucose metabolism, inflammation, liver tissue injury (MASH activity) and fibrosis.\n• Empagliflozinimproves glycaemia, insulin sensitivity, has weight reducing and diuretic effects.\n• The combination of lanifibranor + empagliflozinmay\n• Add additional metabolic benefits\n• Address metabolically healthy weight gain observed in some patients on lanifibranor\nHaas, Francque & Staels. Ann Rev Physiol 2016; Wanner & Marx. Diabetolgia 2018; Goossens G Obes Facts 2017; Pavlides et al. Journal of Hepatology 2016; Alexopoulos et al. Hepatology 2021\nCorporate Presentation | June 2024 Property of Inventiva│ 66\nLEGEND Study Design\nLanifibranor in Combination with the SGLT2 Inhibitor empagliflozin in patients with NASH and Type 2 Diabetes\nLEGEND Study\n24 weeks treatment\nRandomized, double-blind for lanifibranor and placebo, open label\nKey inclusion criteria:\nfor the combination, placebo-controlled\n4 weeks\n1) Adult patients with MASH/NASH:\nFollow-up\n• historical biopsy with NAS ≥ 4 Lanifibranor 800 mg + empagliflozin 10 mg\n• or cT1 ≥ 875 ms\n• or cT1 ≥ 825 ms and MRI-PDFF Lanifibranor 800mg\n≥ 10%\nPlacebo\n2) T2D diagnosed\n3) Screening HbA1c in 7-10%\nSecondary outcome\nPre-specified interim Other outcome\nPrimary outcome measures:\nanalysis planned to be measures:\nmeasure:  Insulin resistance\nconducted when 50% of\n Body weight Safety and\npatients have completed  Hepatic fat (MRI-PDFF)\nHbA1c reduction  Body fat composition tolerability\nthe 24-week treatment  Liver injury markers (AST,\nat Week 24\nperiod, or prematurely ALT)  Hepatic inflammation\ndiscontinued and fibrosis markers\n Lipid markers\nCorporate Presentation | June 2024 Property of Inventiva│ 67\nPatient disposition\nFull Analysis Set (FAS): 32 patients randomized and treated\nLanifibranor 800 mg/day +\nPlacebo Lanifibranor 800 mg/day\nEmpaglifozin 10mg/day\nN = 10 N = 12\nN = 10\n5 (50%) patients completed the 12 (100%) patients completed 10 (100%) patients completed\n24-week treatment the 24-week treatment the 24-week treatment\n5 (50%) patients prematurely\ndiscontinued from study\ntreatment*:\n- Withdrawal by patient (n=2)\n- Lost to follow-up (n=2)\n- Non-compliance with study drug\n(n=1)\n* All but one patient discontinued after week 12.\nOne patient (Withdrawal by patient) discontinued before week 4.\nCorporate Presentation | June 2024 Property of Inventiva│ 68\nBaseline demographics\nPlacebo Lanifibranor + Total\nParameter (unit) [Normal ranges] Lanifibranor (n=12)\n(n=10) Empagliflozin (n=10) (n=32)\nAge (years) 55.5 55.5 56.5 55.5\nSex (% female) 60 50 60 56\nWeight (kg) 92.6 93.9 102.0 96.8\nBMI (kg/m²) 33 33 37 35\nHbA1c (%), [4.0 - 6.0] 7.7 7.7 8.2 7.8\nInsulin (pmol/L) [18.1 - 172.9] 278 152 238 223\nHOMA-IR 19.5 9.4 12.0 10.9\nHDL-C (mmol/L) [F ≥ 0.91, M ≥ 0.78] / (mg/dL) 1.08 / 41.8 1.07 / 41.4 1.02 / 39.4 1.07 / 41.4\nLDL-C (mmol/L) [F ≤ 4.14, M ≤ 3.89] / (mg/dL) 2.26 / 87.4 2.52 / 97.5 2.45 / 94.7 2.52 / 97.5\ncT1 (ms) 942 949 921 931\nHepatic fat content (MRI-PDFF) (%) 17.1 18.5 19.7 18.8\nALT (U/L), [F ≤ 33, M ≤ 41] 33 53 54 39\nAST (U/L), [F ≤ 32, M ≤ 40] 24 30 35 30\nAdiponectin (ug/mL), [0.9 - 21.4] 2.6 3.1 4.0 3.0\nMedian values are presented for continuous parameters.\nALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, BMI: Body Mass Index, cT1: Corrected T1, F: Female, HDL-C: High density lipoprotein cholesterol, HOMA: Homeostasicmodel\nassessment, M: Male, MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction\nCorporate Presentation | June 2024 Property of Inventiva│ 69\nPrimary endpoint was met: statistically significant reductions in HbA1c at week 24\nunder lanifibranor alone and in combination with empaglifozin versus placebo\nFAS, N=30 Completers, N=24\nLS Mean Absolute Change from Baseline to Week 24 Percentage of responders at Week 24\nHbA1c (%) HbA1c < 6.5% HbA1c absolute decrease ≥1%\nWeek 12 Week 24\n100 100\n0.4 0.26 88%\n0.2\n0\n75 75\n-0.2 -0.08 63% 64%\n-0.4 55%\n-0.6 50 50\n-0.8\n-1\n-1.2 * 25 25\n-1.19* -1.14\n-1.4\n*\n-1.6 -1.44\n** 0% 0%\n-1.59\n-1.8 0 0\nPlacebo Lani Lani Placebo Lani Lani Placebo Lani Lani Placebo Lani Lani\n-2\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa n= 5 n=11 + Empa n= 5 n=11 + Empa\nn= 10 n= 10 n= 8 n= 8\n*p<0.01, **p<0.001, versus placebo (Mixed Model Repeated Measure [MMRM]) Eight patients were not considered in the Completers set:\nTwo patients were not considered in the FAS because not having post-treatment HbA1c values - 5 patients under placebo who prematurely stopped before Week 24\navailable: - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent event) before Week\n- 1 patient under placebo who prematurely stopped before Week 4 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nevent) before Week 4 (Results were similar including this patient in a sensitivity analysis). modified his/her diet (intercurrent event) before Week 24.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 70\nLanifibranor improves insulin sensitivity which is further\nimproved in combination with empagliflozin\nInsulin - FAS, N=30 HOMA-IR - FAS, N=30\nLS Mean Absolute Change from Baseline to Week 24 (pmol/L) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 152-278 pmol/L Baseline 9.4-19.5\n0\n-5\n-25 -7\n-15\n-50\n-25\n-58.3\n-75\n-35\n-100 -93.9† -45\n-125 -55 -51*\n-150 -65\n*\n-155.1\n-175 -75 -69**\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM), † p<0.05, versus baseline (MMRM) *p<0.05, **p<0.01, versus placebo (MMRM)\nTwo patients were not considered in the FAS because not having post-treatment insulin values Two patients were not considered in the FAS because not having post-treatment HOMA-IR values\navailable: available:\n- 1 patient under placebo who prematurely stopped before Week 4 - 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent\nevent) before Week 4 event) before Week 4\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 71\nLanifibranor alone and in combination with empagliflozin\nsignificantly improves markers of liver injury\nALT - FAS, N=31 AST - FAS, N=31\nLS Mean Relative change (%) from Baseline to Week 24 LS Mean Relative change (%) from Baseline to Week 24\nBaseline 33-54 IU/L Baseline 24-35 IU/L\n10 20\n0\n10\n-10\n0\n-20\n* -10\n-30 *\n**\n* -20 **\n-40\n*\n-30\n-50 **\n**\n-60 *** -40 ***\nBaseline Week 4 Week 12 Week 24 Baseline Week 4 Week 12 Week 24\nPlacebo n= 9 Lani n= 12 Lani + Empa n= 10 Placebo n= 9 Lani n= 12 Lani + Empa n= 10\n*p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM) *p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because no post-treatment ALT values One patient under placebo was not considered in the FAS because no post-treatment AST values\navailable (Premature discontinuation before Week 4) available (Premature discontinuation before Week 4)\nCorporate Presentation | June 2024 Property of Inventiva│ 72\nLanifibranor alone and in combination with empagliflozin\nsignificantly reduce hepatic steatosis measured by MRI-PDFF\nLiver fat measured by MRI-PDFF, N=26 from Baseline at Week 24\nLS Mean Relative change (%) Individual Relative changes (%)\nBaseline 17.1-19.7%\n20\n0\n0\n-5\n0\n-10\n-15\n-20\n-20\n-25\n-40\n-30\n-35\n-40 -60\n-38*\n-45\n-50 -47* -80 Placebo\nLani Lani\nPlacebo Lani\n+ Empa\nn= 5 n= 12 -100 Lani + Empa\nn= 9\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)\nlanifibranor +\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24: Percentage of responders Lanifibranor\nPlacebo (n=5) empagliflozin\n- 5 patients under placebo who prematurely stopped before Week 24 at Week 24 (n=12)\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before (n=9)\nWeek 24\nMRI-PDFF ≥ 30% 0% 82% 67%\nAbsolute reduction of ≥ 5% 0% 67% 67%\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 73\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 74\nLanifibranor alone and in combination with empagliflozin\nimproves HDL-C and adiponectin\nHDL-C, N=31 Adiponectin, N=30\nLS Mean Absolute change (mmol/L) from Baseline to Week 24 LS Mean Fold change from Baseline to Week 24\nBaseline 1.02-1.07 mmol/L Baseline 2.6-4.0 ug/mL\n0.5 4\n3.5\n0.4 3.0 *\n3 2.8*\n0.3\n2.5\n0.22*\n0.2\n0.17†\n2\n1.5\n0.1 1.1\n1\n0.0\n0.5\n-0.01\n-0.1 0\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 12 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM) † p<0.01, versus baseline (MMRM) *p<0.05, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because of no post-treatment HDL-C Two patients were not considered in the FAS because not having post-treatment adiponectin\nvalues available (premature discontinuation before Week 4) values available:\n- 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as rescue medication (intercurrent event)\nbefore Week 4\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 75\nThe combination of empagliflozin and lanifibranor addresses the weight\ngain observed in some patients treated with lanifibranor alone\nWeight change, N=32\nRelative change from Baseline (%)\nBaseline 93-102 kg\n5\n3.6\n4\n3\n2\n2 1.4\n1\n00\n-0.4 -0.4\n0\n-0.9\n0\n-1\n-0.8 -0.8\n-1.1\n-2\nBaseline Week 4 Week 12 Week 24\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nAt Week 24, 7 patients without weight values available :\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nmodified his/her diet (intercurrentevent) before Week 24.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 76\nLanifibranor alone and in combination with empagliflozin leads\nto a shift towards metabolically healthy adipose tissue\nRatio VAT/SAT, N=19\nLS Mean Relative change (%) from Baseline to Week 24\n11\n10\n5\n0\n-5\n-5*\n-10\n-15\n**\n-17\n-20\nPlacebo Lani Lani + Empa\nn= 4 n= 8 n= 7\nSAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n* p=0.08, **p<0.01, versus placebo (ANCOVA)\nThirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 77\nSafety and tolerability: Treatment-Emergent Adverse Events\n(TEAE)\nPlacebo Lanifibranor Lanifibranor +\nTEAE Overview\n(n=10) (n=12) Empagliflozin (n=10)\nTEAE 6 (60%) 10 (83%) 8 (80%)\nDrug-related TEAE 2 (20%) 3 (30%) 5 (50%)\nTEAE leading to drug withdrawal 0 0 0\nSerious TEAE 0 0 0\nSevere TEAE 0 0 0\nAny AE of Specific Interest\nAminotransferase elevation 0 0 0\nAnemia a 1 2 0\nPeripheral edema 0 0 1b\nHypoglycaemia c 1 0 1d\nMost Frequent (≥10%) TEAEs by SOC\nInfections and infestations 3 ( 30%) 2 ( 17%) 5 ( 50%)\nMusculoskeletal and connective tissue\n3 ( 30%) 1 ( 8%) 1 ( 10%)\ndisorders\nGastrointestinal disorders 2 ( 20%) 3 ( 25%) 2 ( 20%)\nSkin and subcutaneous tissue disorders 2 ( 20%) 4 ( 33%) 0 ( 0%)\nNervous system disorders 1 ( 10%) 2 ( 17%) 1 ( 10%)\na Defined as haemoglobin levels <Lower Limit Normal. The 3 events reported were assessed as not related to study drug.\nb The event was assessed as related to lanifibranor/not related to empaglifozin, of mild severity with no associated symptoms, that further recovered without corrective treatment.\nc Defined as glucose levels <Lower Limit Normal. Glucose values were > 3 mmol/L for the 2 events reported. Both events were assessed as not related to study drug, of mild intesityand required no treatment.\nd Related to empaglifozinonly.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 78\nConclusions\n The primary efficacy endpoint based on reduction of HbA1c was met for both lanifibranor alone and\nfor the combination with empagliflozin.\n The combination of lanifibranor with empagliflozin addresses / neutralizes weight gain seen in some\npatients on lanifibranor alone.\n Both lanifibranor alone and the combination with empagliflozin induce a redistribution of fat from\nvisceral to subcutaneous fat. This is consistent with the improved insulin sensitivity seen with both\nlanifibranor alone and the combination.\n Lanifibranor improves markers of cardiometabolic health, the effect size appear to be further\nimproved when lanifibranor is combined with empagliflozin.\n Lanifibranor alone and in combination with empagliflozin appear to be safe and well tolerated.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 79"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": []
    },
    {
      "section_name": "Regulated Information",
      "links": [
        {
          "title": "Total voting rights and shares – October 31st, 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/11/Inventiva_-English-Version_-2024-10-31.pdf",
          "content": "Statement of total voting rights and shares forming the\ncompany’s share capital on October 31st, 2024\nArticle 223-16 of the General Regulations of the AMF (French Financial Markets Authority)\nMarket: Euronext Paris\nISIN code / Mnemo: FR0013233012/ IVA\nWeb site: www.inventivapharma.com\nDate Number of Shares Total voting rights, Total voting rights,\nOutstanding gross (1) net (2)\n31 October 2024 87 077 695 100 059 052 99 939 331\n(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of\nthe AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting\nrights have been suspended.\n(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting\nrights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the\npublic is properly informed, in accordance with the AMF recommendation of July 17, 2007.\n1"
        },
        {
          "title": "Interim financial report for the six months ended june 30, 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/10/RFS-Inventiva-ENG-H1-FY24-1.pdf",
          "content": "INVENTIVA S.A.\nA joint-stock company (société anonyme) with a share capital of 524,771.88 euros\nRegistered office: 50, rue de Dijon, 21121 Daix, France\nDijon Trade and Companies Register 537 530 255\nINTERIM FINANCIAL REPORT\nFOR THE SIX MONTHS ENDED JUNE 30, 2024\nWS0101.38343396.1\nTable of contents\n1. Interim Financial Report ............................................................................. 4\n1.1. General overview of activities ..................................................................................... 4\n1.2. Significant events in the first half of 2024 .................................................................. 6\n1.3. Recent events and prospects ........................................................................................ 9\n1.4. Risk factors ................................................................................................................ 11\n1.5. Earnings analysis ....................................................................................................... 14\n1.6. Analysis of the financial situation ............................................................................. 19\n2. Cash flow and equity .................................................................................. 22\n2.1. Cash and cash equivalents ......................................................................................... 22\n2.2. Cash flow analysis ..................................................................................................... 24\n2.3. Anticipated sources of funds ..................................................................................... 27\n3. Unaudited interim condensed consolidated financial statements .......... 28\n3.1. Statutory Auditors’ Review Report on the Half-yearly Financial Information ......... 28\n3.2. Interim Condensed Consolidated financial statement ............................................... 30\n4. Other information ....................................................................................... 70\n4.1. Table of delegations ................................................................................................... 70\nWS0101.38343396.1\nDefinitions\nIn this half-yearly report (the “Interim Financial Report”), and unless otherwise specified, the terms\nInventiva or the Company are taken to mean the company Inventiva S.A. with its registered office at\n50, rue de Dijon, 21121 Daix, France, and which is listed with the Dijon Trade and Companies Register\nunder number 537 530 255 and its subsidiary, 100% owned, Inventiva Inc. with its registered office at\n10-34 44th Dr, Long Island City, 11101 New York, USA, created in January 2021.\nCertain terms used in this Interim Financial Report are defined in the Company’s annual report on Form\n20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on\nApril 3, 2024 (“the Annual Report”).\nSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\nThis document contains forward-looking statements within the meaning of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are\nbased on our management’s beliefs and assumptions and on information currently available to our\nmanagement. All statements other than present and historical facts and conditions contained in this\ndocument, including statements regarding our future results of operations and financial positions,\nbusiness strategy, plans and our objectives for future operations, are forward-looking statements. When\nused in this document, the words “anticipate,” “believe,” “can,” “continue”, “could,” “estimate,”\n“expect,” “goal”, “intend,” “is designed to,” “may,” “might,” “plan,” “will,” “would,” “potential,”\n“predict,” “objective,” “should,” “target”, or the negative of these and similar expressions identify\nforward-looking statements. Forward-looking statements include, but are not limited to, statements\nabout:\n• our plans to develop and commercialize our product candidates;\n• the timing of, design, duration, recruitment costs, screening and enrollment of our planned and\nongoing clinical trials;\n• clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from our planned and ongoing clinical trials;\n• the timing of any planned investigational new drug (“IND”) application or new drug\napplication (“NDA”);\n• our plans to research, develop and commercialize our current and future product candidates;\n• expectations with respect to the benefits of our existing and future partnerships, including our\npartnerships with Chia Tai Tianqing Pharmaceutical Group, Co., LTD. (“CTTQ”), and with\nHepalys Pharma, Inc. (“Hepalys”), on the clinical development, commercialization and\nregulatory approvals of our product candidates, including potential acceleration of the\ncommercialization of lanifibranor in Mainland China, Hong Kong Special Administrative\nRegion, Macau Special Administrative Region, Taiwan, Japan and South Korea, if approved;\n• our ability to successfully cooperate with existing partners or enter into new partnerships, and\nto fulfill our obligations under any such partnership agreements;\n• the potential for further development of odiparcil;\n• our ability to potentially enter into a partnership with a third party for the development and\ncommercialization of odiparcil;\n• the clinical utility, potential benefits and market acceptance of our product candidates;\n• our commercialization, marketing and manufacturing capabilities and strategy;\n• our ability to identify additional products or product candidates with significant commercial\npotential;\nWS0101.38343396.11\n• our expectations related to the sufficiency of our capital resources and our ability to continue\nas a going concern, including our expectations with respect to raising of additional funds,\nexecuting any potential transactions and achievement of milestones and operating targets;\n• the expected use of proceeds from any financing transactions, including capital increases,\nroyalty certificates and debt financing, and our ability to fulfill our obligations under any such\nagreements, including our ability to repay debt in a timely manner, or at all;\n• expectations with respect to the Tranche 2 and Tranche 3 Events (as defined below), and the\nexercise of the warrants and other rights to subscribe to ordinary shares by investors,\n• developments and projections relating to our competitors and our industry;\n• the impact of government laws and regulations;\n• the effects of the epidemics or pandemics on our business and, operations and clinical\ndevelopment timelines and plans;\n• our intellectual property position;\n• our estimate regarding future revenue, expenses, capital requirements and need for additional\nfinancing;\n• unfavorable conditions in our industry, the global economy or global supply chain, including\nfinancial and credit market fluctuations, international trade relations, political turmoil, natural\ncatastrophes, warfare (such as the conflict involving Russia and Ukraine, the state of war\nbetween Israel and Hamas and the related risk of a larger conflict), and terrorist attacks; and\n• other risks and uncertainties, including those listed in our Annual Report and Section 1.4\nhereof under the caption “Risk Factors.”\nWe encourage you to read and carefully consider all of the risk factors disclosed in “Item 3.D—Risk\nFactors” of our Annual Report and Section 1.4 hereof, for a discussionof the risks and uncertainties\nmaterial to our business, including important factors that may cause our actual results to differ materially\nfrom those expressed or implied by our forward-looking statements. As a result of these factors, we\ncannot assure you that the forward-looking statements in this document will prove to be accurate.\nFurthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these\nstatements as a representation or warranty by us or any other person that we will achieve our objectives\nand plans in any specified time frame or at all. These forward-looking statements represent our plans,\nobjectives, estimates, expectations and intentions only as of the date of this filing. We undertake no\nobligation to publicly update any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law.\nYou should read this document and the documents that we reference herein completely and with the\nunderstanding that our actual future results may be materially different from what we expect. We qualify\nall of our forward-looking statements by these cautionary statements.\nMarket and competitive position\nThis Interim Financial Report also contains information about the Company’s activities and the markets\non which it operates. This information comes from studies or surveys carried out internally or externally.\nOther information contained in this Interim Financial Report is available to the general public. The\nCompany considers that all of this information is reliable, but it has not been verified by an independent\nexpert. The Company cannot guarantee that a third party using different methods to gather, analyze or\ncalculate market data would obtain the same results.\nRounding of figures\nWS0101.38343396.12\nCertain figures (including data expressed in thousands or millions of euros or dollars) and the\npercentages presented in this Interim Financial Report have been rounded up or down. Accordingly,\ntotals given may vary slightly from those obtained by adding the exact (unrounded) values of those same\nfigures.\nAbbreviations\nCertain figures are given in thousands or millions of euros and are indicated as € thousand or € million\nrespectively in this Interim Financial Report.\nWS0101.38343396.13\n1. Interim Financial Report\n1.1. General overview of activities\nInventiva S.A. is a public limited company registered and domiciled in France. Its head office is located\nat 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include\nInventiva S.A. and its subsidiary Inventiva Inc., created in January 2021.\nInventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since\nFebruary 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary\nshare, have been listed on the Nasdaq Global Market since July 2020.\nInventiva is a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),\nalso known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet\nmedical need.\nLeveraging its expertise and experience in the domain of compounds targeting nuclear receptors,\ntranscription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the\ntreatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.\nLanifibranor, its lead product candidate, is being developed for the treatment of patients with\nMASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive\ntopline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with\nMASH/NASH and announced that the U.S. Food and Drug Administration (\"FDA\") had granted the\nCompany the status of Breakthrough Therapy and Fast Track designation. The Company initiated the\npivotal Phase III trial of lanifibranor in MASH/NASH (“NATiV3”) in the second half of 2021. In March\n2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor\nand empagliflozin in patients with MASH/NASH and Type 2 Diabetes (“DT2”) (“LEGEND”).\nIn the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a\nhigher than originally projected screen failure rate resulting in slower than anticipated enrollment rate.\nIn addition, the Company experienced slower than predicted site activation, screening and enrollment\ndue to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the\nCompany was unable to conduct clinical trial activities at sites originally located in Ukraine due to the\nwar between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in\nUkraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the\nmarkets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could\naffect the Company.\nIn January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially\naccelerate enrollment and identified additional sites to help compensate for the inability to use sites in\nUkraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks\ninstead of up to seven years, reduces the number of biopsies from three to two and included a 48-week\nactive treatment extension study. The Company expects that the changes to the clinical development\nplan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and\ncompensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of\nbiopsies and the trial duration, eventually offering all patients in the trial access to treatment and\npotentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to\npatients with NASH and compensated cirrhosis.\n4\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nIn September 2022, the Company entered into a license and collaboration agreement with Chia Tai\nTianqing Pharmaceutical (Guangzhou), Co., LTD (“CTTQ”), a Sino Biopharm group company, to\ndevelop and commercialize, subject to regulatory approval, lanifibranor for the treatment of\nMASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative\nRegion, Macau Special Administrative Region and Taiwan (“CTTQ Territory”). In May 2023, the\nCompany announced that CTTQ had received the Investigational New Drug (“IND”) approval from the\nChinese National Medicine Products Administration (“NMPA”) allowing CTTQ to initiate the clinical\ndevelopment of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing\nNATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of\nits participation in the Company’s NATiV3 Phase III global clinical trials, pursuant to the terms of the\nagreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory.\nOn September 20,2023, the Company and Hepalys Pharma, Inc. (“Hepalys”) announced an exclusive\nlicensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the “Hepalys\nLicense Agreement”). Hepalys is a new company created by Catalys Pacific Fund II, LP (“Catalys”).\nUnder the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to\n€9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical,\nregulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to\nlow twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval.\nIn parallel with the Hepalys License Agreement, the Company entered into an option agreement with\nCatalys to acquire 30% of the shares of Hepalys (the “Catalys Option Agreement”). The Company\nexercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate\nexercise price of ¥300 (equal to €1.90). Also on September 20, 2023, the Company entered into a\nshareholders agreement with Catalys and Hepalys (the “Catalys Shareholders Agreement”). Pursuant to\nthe Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of\nHepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal\nif Hepalys receives an offer for the license or rights related to lanifibranor.\nIn the first quarter of 2024, following a routine visit during Company’s NATiV3 clinical trial of\nlanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (“SUSAR”) was\nreported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the Data Monitoring Committee1(“DMC”).\nOn March 7, 2024, the Company announced that screening activities had resumed in American sites\nunder central Institutional Review Board (“IRB”). The impact of the pause on the overall timeline of the\ntrial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate,\nand the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial\nparticipants.\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH /NASH and DT2.\nThe Company expects the first visit of the last patient to be in the fourth quarter of 2024 (versus the first\nquarter of 2024 as previously announced) and to complete randomization in the first half of 2025. Due\nto a delay of around 3 to 5 months in recruitment, the Company is currently targeting the topline results\nfor the second half of 2026 (versus the beginning of the second half of 2026 as previously announced).\n1 A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.\n5\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nIf the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the\nCompany plans to file an application for accelerated approval in the United States and conditional\nauthorization in the European Union for the marketing of lanifibranor.\nThe Company’s pipeline also includes odiparcil, which it was previously developing for the treatment\nof patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. As\nannounced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor.\nBased on feedback from the FDA, the Company believes there is potential for an efficient development\npathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further\ndevelop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership,\nlicense or other transaction.\n1.2. Significant events in the first half of 2024\n1.2.1. Operations and product portfolio\nTreatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024\nOn February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in\nliver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient\nhad been without clinical symptoms throughout the period of observation. This event has been assessed\nas a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial\nparticipants have also been reported in the trial. The Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients already enrolled\nin the Phase III NATiV3 trial continued to receive treatment under the new liver monitoring schedule\nrecommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.\nOn March 7, 2024, the Company received approval from the central IRB overseeing clinical research in\nthe United States to resume screening activities in its sites. This was an important milestone as 152 sites\nof the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60%\nof the patients in the main cohort.\nDue to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit\nof the last patient for the fourth quarter of 2024, completion of randomization in the first half of 2025\nand the main results are expected for the second half of 2026 (versus the beginning of the second half\nof 2026 as previously disclosed).\nThe Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and\nempagliflozin in patients with MASH/NASH and T2D\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and type 2 diabetes.\nThe LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled\nPhase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the\nSGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D.\nThe trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for\nthe combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm. The diagnosis of\n6\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nnon-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-\ninvasive methods including diagnostic methods including imaging. As planned per protocol, the interim\nanalysis was done once half of the 63 planned randomized patients with MASH completed the 24-week\ntreatment period or prematurely discontinued from treatment.\nThe study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c\n(HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily)\nor in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26%\nobserved in the placebo arm.\nThe study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-\nPDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -\n38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone\nor in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their\nhepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically\nsignificant effect on several secondary and exploratory endpoints, including liver enzymes (alanine\naminotransferase (“ALT”) and aspartate aminotransferase (“AST”)), insulin resistance (HOMA-IR),\nHDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1)\nassessed by LiverMultiScan®) were assessed for the first time with lanifibranor and showed a significant\neffect with lanifibranor alone and in combination with empagliflozin.\nThe study also demonstrated that patients treated with lanifibranor in combination with empagliflozin\nmaintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically\nhealthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore,\nthese results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and\nsubcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with\nempagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.\nThis result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose\ntissue.\nThe treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily\nfor 24 weeks appears to be well tolerated, with no safety concerns reported.\nGiven that the primary endpoint of LEGEND was met, and statistically significant results were achieved\non several key additional markers, the Company has decided to stop the recruitment as defined per\nprotocol. More details on these results are expected to be presented in upcoming scientific conferences\nand submitted for publication.\nAdditional results from NATIVE Phase IIb clinical trial\nOn May 13, 2024, the Company announced the publication in Nature Communications of additional\nresults from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic\nhealth in patients with MASH/NASH treated with lanifibranor.\nImprovements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism\n(triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG)\nlevels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.\nRecommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in\npatients with MASH/NASH\n7\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nOn May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the\nNATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.\nThe DMC recommended to continue the clinical trial without further modification of the protocol, as\namended immediately after learning about the SUSAR based on the pre-planned review of safety data.\nThe recommendation was based on the unblinded review by the DMC of safety data from more than\n900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients\nthat have been treated for more than 48 and 72 weeks, respectively.\nThe patient who experienced the adverse event of increased liver test results, which was reported as a\nSUSAR, had been without clinical symptoms throughout the period of observation and has fully\nrecovered.\n1.2.2. Other events\nThe Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B\nOn January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment\nBank (“EIB”) and such warrants (the “EIB Tranche B Warrants”), in accordance with the terms of the\n6th resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-\n138 of the French Commercial Code, as a condition to the drawdown of the second tranche of €25.0\nmillion (“Tranche B”) under the finance contract between the Company and EIB (“Finance Contract”).\nThe 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the\nCompany's then-outstanding share capital. If all the warrants issued to the EIB in connection with\ndrawdown of the first tranche of €25.0 million (“Tranche A”) under the Finance Contract (the “EIB\nTranche A Warrants” and, together with the EIB Tranche B Warrants, the “EIB Warrants”) and the EIB\nTranche B Warrants were exercised, the EIB would hold approximately 11.3% of the Company's share\ncapital as of June 30, 2024.\nThe exercise price of the EIB Tranche B Warrants is equal to €3.95 and corresponds to 95% of the\nvolume-weighted average price of the Company's shares on the regulated market of Euronext Paris\nduring the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).\nThe EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the\nearliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control\nevent, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the\nFinance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within\nthe twelve-year period.\nEIB has a put option which may require the Company to repurchase all or part of the unexercised EIB\nTranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn\nunder the Finance Contract) under certain circumstances (for example, in the event of a change of control\nor on the maturity date of Tranche A or in the event of default). The Company (or a substitute third\nparty) has a call option to require EIB to sell all shares and other securities of the Company, including\nthe EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company\nhas a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party,\nsubject to certain terms and conditions.\n8\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nOn the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB\nTranche B Warrants at a price of €3.95 per new share, the Company could potentially receive gross\nproceeds of up to €12,421,383. There is no assurance that EIB will exercise any or all of the EIB\nWarrants or that the Company will receive any proceeds from the exercise of the warrants.\nThe exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of EIB Tranche B\nWarrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche\nA Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.\nThe Company drew down Tranche B of €25 million under Finance Contract with EIB\nOn January 18, 2024, the Company drew down Tranche B under the Finance Contract for an amount of\n€25 million.\nAfter the drawdown of Tranche A in December 2022, the Company had an option to access further €25\nmillion tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the\nachievement of those conditions, the Company decided to draw on Tranche B. The Company intends to\nuse the proceeds to fund part of NATiV3.\nTranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in\nJanuary 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among\nother conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of\nthe Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million that\nwas a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company,\nor through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with\nan upfront payment of at least €10 million, (iv) operational criteria based on patient enrollment and\nnumber of sites activated in the Company’s NATiV3 Phase III clinical trial of lanifibranor in patients\nwith MASH/NASH and (v) the Company issuing EIB Tranche B Warrants (see above - The Company\nissued 3,144,654 warrants to European Investment Bank in connection with the drawdown of Tranche\nB) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (warrants) at inception and the borrowing costs.\nOn June 12, 2024, the Company and EIB amended the warrant to modify the rules for adjusting the\nexercise ratios of the EIB Warrants.\n1.3. Recent events and prospects\n1.3.1. Operations and product portfolio\nUpdate on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.\nOn July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating\nlanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both\ncohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the\nexploratory cohort of NATiV3.\nThe first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024,\nand topline results are expected in the second half of 2026. The Company strengthened its patent\nportfolio with a new patent in Japan that provides intellectual property rights on the potential use of\n9\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nlanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term\nadjustments or extensions that may provide additional protection until 2043.\n1.3.2. Other events\nIssuance of royalty certificates\nOn July 18, 2024, the Company announced the issuance of 201 royalty certificates (“2024 Royalty\nCertificates”) for aggregate gross proceeds of approximately €20.1 million. Royalties amount to 3% on\nfuture net sales of lanifibranor in the United States of America, the European Union and the United\nKingdom over a 14-year term.\nApproving of patent application\nOn July 25, 2024 the Company announces that the Japan Patent Office (“JPO”) approved Inventiva’s\npatent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients\nwith cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent\nterm adjustments or extensions that may provide additional protection.\nFinancing in three tranches for a maximum amount of €348 million\nThe Company announced the following financing on 14 October 2024 structured in three tranches:\n(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific\ncategory of beneficiaries (“à catégorie de personnes”), of new ordinary shares at a gross value, including\nissuance premium, of €94.1 million through the issuance of 34,600,507 new ordinary shares, par value\n€0.01 per share (each, a “T1 New Shares”), and 35,399,481 prefunded warrants to subscribe for shares\nin the Company at a price outstanding of €0.01 per new ordinary share, each giving the right, in the\nevent of exercise, to one new ordinary share (the “T1 BSAs”);\n(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”), of new ordinary shares, par\nvalue €0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each,\na “T1bis New Shares”), for a total amount of €21.4 million (excluding exercise of pre-funded warrants);\n(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”) subject to operational conditions\nto be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before\nDecember 16, 2024, (or prefunded warrants) to which share warrants (the “ABSAs”) are attached for a\ntotal amount of €116,000,000. Each ABSA will consist of a number of new ordinary shares with a par\nvalue of €0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a\n“T2 New Share”) to which will be attached a number warrants exercisable at an exercise price of €1.50\n(each, a “T3 BSA”) allowing the subscription of a number of new ordinary shares of the Company for\na maximum total amount of €116,000,000.\nThe subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024,\nand the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October\n17, 2024, subject to the absence of any material adverse event between the signing of the agreements\nand the settlement-delivery of the T1 New Shares and the T1 BSA.\nAmendment to the exclusive license and collaboration agreement with CTTQ\nOn October 11, 2024, the Company has entered into an amendment (the “Amendment”) to the exclusive\nlicense and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (“CTTQ”),\ndated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription\ncommitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three\n10\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\ntranches, for a total gross amount of at least €180,000,000 (the “Fund Raising”), CTTQ shall pay to the\nCompany (i) $10,000, 000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants\nin the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000\nin the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon\npublication by the Company of the pivotal data announcing that the primary endpoint or one of the two\nkey secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met.\nUnder the terms of the Amendment, the total amount of potential clinical, regulatory and commercial\nmilestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been\nreduced to a low figure.\n1.4. Risk factors\nThe Company’s business faces significant risks. You should carefully consider all of the information set\nforth in this document and in the Company’s other filings with the United States Securities and Exchange\nCommission, or the SEC, including the risk factors which the Company faces and which are faced by\nthe Company’s industry described in Chapter 2 of the Company’s 2023 Universal Registration\nDocument Part I, Item 1A. “ Risk Factors” of the Company’s Annual Report on Form 20-F for the fiscal\nyear ended December 31, 2023, in addition to the following risk factors. Our business, financial\ncondition or results of operations could be materially adversely affected by any of these risks.\nPlease refer to chapter 2.1 of the 2023 Universal Registration Document and as amended in Section 5\nof the amendment to the universal document as filed with the AMF under number D.24-0227-A01 on\nOctober 14, 2024 (the \"Amendment to the 2023 Universal Registration Document \"), which are\nincorporated herein by reference.\nThe risk factor in the 2023 Universal Registration Document amended in the context of the Amendment\nto the 2023 Universal Registration Document is as follows:\nLiquidity risk: the Company believes that it will be able to finance its activities until the end of the\nsecond half of 2025, and there is doubt regarding our ability to continue as a going concern.\nAs of 30 June 2024, the Company had cash and cash equivalents of EUR 10.1 million, compared to\n€26.9 million, and €9.0 million of long-term deposit2 as of December 31, 2023.\nAs of the date of this document, the Company believes, taking into account its current cost structure and\nforecast expenditure commitments, and the events after the reporting period presented in Note 6.4 –\nEvents after the reporting period of the section 3.2 – Interim Condensed Consolidated financial\nstatements as of June 30, 2024, mainly the issue of royalty certificates and the T1 capital increase, that\nit will have sufficient net working capital to meet its current obligations until the end of the second half\nof 2025.\nAccordingly, our current cash position will not be sufficient to cover operating needs for at least the\nnext 12 months.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\n2 The long-term deposit had a two year-term, were accessible prior to the expiration of the term with a notice\nperiod of 31 days and were considered as liquid by the Company.\n11\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nthe reporting period of the section 3.2 – Interim Condensed Consolidated financial statements as of\nJune 30, 2024.\nIn order to finance its activities, the Company needs to raise additional funds, and is currently actively\nreviewing potential financing (including debt, equity and equity-linked or other instruments) and\nstrategic options (for more on complementary financing, see section 2.3 of this document).\nThe Company may have based itself on incorrect assumptions and may have to use its resources sooner\nthan expected. Although the Company is actively discussing financial and strategic options for financing\nits activities beyond its cash horizon, notably with its financial partners and financial advisors, the\nCompany cannot guarantee that it will be able to obtain the necessary financing, through any of the\nforegoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions,\non a timely basis, or at all. If we are unable to obtain funding on a timely basis, we may be required to\nsignificantly curtail, delay or discontinue one or more of our research or development programs or the\ncommercialization of any approved product or be unable to expand our operations or otherwise\ncapitalize on our business opportunities, as desired, which could impair our growth prospects. The\nperception that we may be unable to continue as a going concern may impede our ability to pursue any\npotential strategic opportunities or operate our business.\nUltimately, if we are unable to continue as a going concern, we may have to liquidate our assets and\nmay receive less than the value at which those assets are carried on our financial statements.\nRisks associated with seeking and arranging financing and risks associated with uncertain\nadditional financing\nThe development of the Company's programs has required, and will continue to require, significant\nfinancial investment, particularly for Phase III of lanifibranor, its YAP/TEAD program and the\ncontinued development of a portfolio of products at the preclinical stage. The Company will require\nadditional funding as its clinical programs reach advanced stages of development, in particular to\ncomplete its clinical trials and, if successful, to manufacture and market the Company's drug candidates.\nTo meet this financing requirement, the Company needs to raise additional funds, and continues to\nactively explore financing options (including debt, equity-linked or other instruments) and strategic\noptions.\nHowever, taking on additional debt could lead to an increase in financial expenses and could also result\nin the Company having to comply with certain additional covenants, such as limitations on the\nCompany's ability to take on additional debt or to carry out certain transactions.\nSimilarly, the conclusion of a financing agreement could be accompanied by undertakings limiting the\nCompany's ability to acquire or grant intellectual property rights, particularly if it has to provide security\nand accept other operating restrictions that could have a negative impact on the Company's ability to\ncontinue its business.\nIt should be noted that additional financing, particularly in the form of equity instruments, could result\nin significant dilution. In addition, financing in the form of financial debt would worsen the Company's\nfinancial structure. The need for and pursuit of additional financing could also divert the Company's\nmanagement from its day-to-day activities, which could affect the future development and marketing of\nits drug candidates.\nThe Company will also need additional funds to consider the pre-commercialisation and subsequent\ncommercialisation of its drug candidate, or to make new investments that are unknown at this time or\ndifficult to assess because they relate to projects in development. It is difficult to anticipate precisely all\nthe costs associated with the preclinical and clinical development of the Company's products while some\nof its products are still at an early stage of development. The amount and timing of future additional\n12\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nfunding requirements will depend in particular on the Company's ability to achieve milestones under its\nexisting collaboration agreements, but also on the operating conditions associated with the Transaction\nand its ability to enter into new agreements, on market acceptance of any approved drug candidates, on\nthe Company's need for and ability to recruit additional management and scientific personnel, and on\nthe Company's ability to implement additional internal systems and infrastructure, including in its\nfinancial and IT management.\nIf the Company is unable to find such additional financing on acceptable terms or in a timely manner,\nparticularly given the generally unfavorable environment for financing companies in the biotechnology\nsector, its business, organisation, results and development could be adversely affected, and it could be\nforced to delay or halt one or more of its research programs, the development or marketing of any\napproved products, not be able to expand its activities or take advantage of its commercial opportunities\nas desired. The Company may also have to implement a plan to reduce and manage its fixed costs or\nenter into new collaboration agreements that may be less favorable to it than those it could have obtained\nin a different context, which could harm its growth prospects or commercial activities, as set out in the\nliquidity risk factor above.\n13\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5. Earnings analysis\n1.5.1. Revenue and other income\nOperating income Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nRevenue 41 1,901\nTotal revenue 41 1,901\nTax credits 2,630 3,631\nSubsidies 5 3\nOther 58 1,087\nOther income 2,693 4,721\nTotal revenue and other income 2,734 6,622\nRevenue\nThe Company recorded minimal revenues in the first half of 2024, as compared to €1.9 million for the\nsame period in 2023. The €1.9 million revenue as of June 30, 2023, was mainly related to the milestone\npayment the Company invoiced to CTTQ for $2.1 million on May 22, 2023, following the IND approval\nfrom the NMPA.\nOther income\nOther income decreased by €2.0 million, or 43%, compared to the first half of 2023. Other income are\nmainly composed of research tax credits. The Research Tax Credit (\"CIR\") generated over the first six\nmonths of the fiscal year amounts to €2.7 million in 2024 as in 2023.\nAs of June 30, 2023, other operating income are composed of:\n• The R&D Tax Research Credit from Inventiva Inc amounting to €1.0 million, compared to €0.8\nmillion in tax income as of June 30, 2024;\n• The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to €0.3 million as\nof June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3,\nand the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to\n€0.7 million, compared to €2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as\na reduction in research and development expenses.\n1.5.2. Operating expenses\nOperating expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nResearch and development expenses (46,822) (54,062)\nMarketing – Business development expenses (598) (705)\nGeneral and administrative expenses (7,701) (6,812)\nTotal operating expenses (55,122) (61,580)\n14\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of June 30, 2024, the decrease in operating expenses of €6.5 million, or 10%, compared to the first\nhalf of 2023 is mainly driven by the decrease in research and development expenses of €7.2 million.\n1.5.2.1.Research and development expenses\nResearch and development expenses for the six months ended June 30, 2024 break down as follows:\nResearch and development expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nStudies (34,073) (42,847)\nPersonnel costs (7,637) (7,065)\nDepreciation, amortization, and provisions (1,732) (1,061)\nDisposables (887) (943)\nPatents (643) (257)\nMaintenance (526) (459)\nEnergy and liquids (447) (479)\nIT systems (405) (440)\nFees (118) (61)\nOther research and development costs (352) (450)\nTotal research and development expenses (46,822) (54,062)\nThe decrease in R&D expenses is primarily due to the temporary pause in the recruitment of the patients\nin the NATiV3 Phase III clinical trial of lanifibranor in MASH/NASH following the SUSAR reported\nin the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND trial with\nlanifibranor and empagliflozin in patients with MASH/NASH and DT2. R&D expenses are expected to\nincrease in the second half of 2024 following the effective restart of patient recruitment in NATiV3, as\nwell as the planned clinical development activities and related costs associated with NATiV3 for the\nsecond half of 2024 including costs related to the SUSAR protocol change and the reactivation of sites\nand patient recruitment. The €7.2 million (13%) decrease in research and development expenses as\ncompared to the six months ended June 30, 2023, was primarily driven by:\n- a €8.8 million decrease in spending on studies in research and development for lanifibranor,\nmainly for the NATiV3 Phase III trial of lanifibranor in patients with MASH/NASH and Phase\nIIa LEGEND trial of lanifibranor in combination with empagliflozin; and\n- a €0.7 million increase in depreciation and amortization costs mainly related to the right of use\nof Fibroscans equipment; and\n- a €0.6 million increase in personnel costs mainly due to salary increases and bonuses.\nThe main expenses incurred in connection with the Company’s research and development activities in\nthe six months ended June 30, 2024, are described below:\n Lanifibranor\nClinical trial-related expenses for lanifibranor development decreased by €7.1 million compared to the\nfirst half of 2023, totaling €34.8 million in the first half of 2024.\nCosts relating to lanifibranor’s development in the first half of 2024 can be broken down into two main\ncategories:\n(i) activities related to clinical studies amounted to €28.5 million, mainly including the NATiV3\nPhase III trial in MASH/NASH, the LEGEND Phase IIa trial in patients with MASH/NASH\nand T2D, and Phase I studies as detailed below; and\n15\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n(ii) development activities amounted to €6.2 million, mainly including pharmaceutical development\nand non-clinical, preclinical pharmacology and toxicology trials in animals and the activities\nrelated to regulatory consulting.\nCosts linked to clinical trial activities included the following developments over the six months ended\nJune 30, 2024:\nTreatments for MASH/NASH\n- Costs related to the NATiV3 Phase III trial related to the qualification and opening of\ninvestigator sites, regulatory submissions and patient recruitments, leasing of Fibroscans\nequipment, the expenses related to packaging campaigns for the treatment units, costs related to\nbiopsy slides reading and consulting including committees.\nLEGEND Phase IIa trial of lanifibranor in combination with empagliflozin in patients with\nMASH/NASH and T2D\n- The completion of the LEGEND Phase IIa trial with regulatory submissions, the monitoring of\npatients recruited into the study, and generation of the results of the Interim Analysis carried out\nin the first quarter of 2024. Other expenses for the period include packaging and distribution\ncosts for treatment units, and pharmacokinetics analysis.\nPhase I studies\n- The completion of the Renal Impairment study, with CRO expenses related to statistical\nanalyses and drafting of the Clinical Study Report (“CSR”); and\n- Data Management activities and the preparation of the CSR for the Hepatic Impairment study,\nas well as the bioanalysis and pharmacokinetics analysis expenses.\n YAP-TEAD\nTrial-related expenses for the YAP-TEAD project increased by €0.2 million compared to the first half\nof 2023, totaling €0.6 million in the first half of 2024.\nCosts incurred are mainly related to chemistry studies, biophysic and bio pharmaco study.\n1.5.2.2.Marketing and business development expenses\nMarketing and business development expenses break down as follows:\nFor the first six months ended June 30, 2024, and June 30, 2023\nMarketing – Business development Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nPersonnel costs (153) (126)\nIT systems (6) (9)\nFees (2) -\nOther operating expenses (437) (570)\nTotal marketing and business development\n(598) (705)\nexpenses\nMarketing and business development expenses for the first half of 2024 decreased by €0.1 million\ncompared to the first half of 2023 mainly due to the decrease by €0.1 million of fees related to the\nbusiness development.\n16\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5.2.3.General and administrative expenses\nGeneral and administrative expenses are mainly composed of administrative staff costs, support costs\n(mainly consisting of security costs, taxes and various rentals), non-scientific IT costs and consulting\nfees.\nGeneral and administrative expenses break down as follows:\nFor the first six months ended June 30, 2024, and June 30, 2023\nGeneral and administrative expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nConsulting fees (2,675) (1,884)\nPersonnel costs (2,600) (2,347)\nInsurances (921) (1,121)\nSupport costs (including taxes) (375) (343)\nDepreciation, amortization and provisions (122) (104)\nIT systems (33) (50)\nOther general and administrative expenses (975) (964)\nTotal general and administrative expenses (7,701) (6,812)\nGeneral and administrative expenses for the first half of 2024 increased by €0.9 million compared to the\nfirst half of 2023 mainly due to the increase in consulting fees by €0.8 million related to the double\nlisting, personnel costs by €0.3 million and the decrease of insurances expenses by €0.2 million.\n1.5.3. Other operating income and expenses\nOther operating income and expenses break down as follows:\nSix months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nOther operating income 160 -\nOther operating expenses (22) (44)\nOther operating income and expenses 138 (44)\nFor the first half of 2024, other operating income and expenses are mainly due to disposal of assets and\ntransaction costs.\nFor the first half of 2023, other operating income and expenses are exclusively due to transaction costs.\n17\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.5.4. Financial income and expenses\nFinancial income and expenses break down as follows:\nFinancial income and expenses Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nIncome from cash equivalents 430 564\nForeign exchange gains 157 187\nFair value gains 8,506 1,623\nTotal financial income 9,093 2,373\nInterest cost (5,218) (1,941)\nForeign exchange losses (323) (683)\nOther financial expenses (46) (23)\nTotal financial expenses (5,586) (2,646)\nNet financial income 3,507 (273)\nNet financial income for the first six months of 2024 increased by €3.8 million compared to the first half\nof 2023. This increase is mainly due to:\n- fair value gains by €8.5 million related to change in fair value of:\nthe EIB Tranche A Warrants; as of June 30, 2024, the fair value amounted to €6.7\no\nmillion, a decrease by €3.5 million since December 31, 2023 (see note 4.9 –\nShareholders’ equity of the Unaudited interim condensed consolidated financial\nstatements as of June 30, 2024);\nthe EIB Tranche B Warrants since the initiation, as of June 30, 2024, the fair value\no\namounted to €6.8 million, a decrease by €5.0 million since the grant date (see note 4.9\n– Shareholders’ equity of the Unaudited interim condensed consolidated financial\nstatements as of June 30, 2024)\n- increase in interest cost for the first six months of 2024 by €3.3 million compared to June 30,\n2023 mainly due to:\nThe increase in interest expenses on the EIB loan by €2.3 million, , with (i) 2.1 million\no\neuros in interest expense for Tranche A over the first six months of 2024 compared with\n1.7 million euros over the first six months of 2023, an increase of 0.4 million euros, and\n(ii) 1.9 million euros for Tranche B over the first six months of 2024 (and an increase\nof the same amount, Tranche B having been subscribed in 2024) ;\nand interest on 2023 royalty certificates of 0.9 million euros in the first six months of\no\n2024 (compared with 0 in the first six months of 2023, as the royalty certificates were\nissued in the last six months of 2023).\n- foreign exchange result of the first six months of 2024 as a result of the unfavorable position of\nthe foreign currency term deposit contracts at the maturity date for €0.3 million.\n1.5.5. Income tax\nIn accordance with IAS 34, the income tax recognized in the financial statements for each interim period\nis adjusted based on a best estimate calculated by applying the expected weighted average tax rate for\nthe entire year.\nCurrent taxes\nAs the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered\nunlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December\n18\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A. However, a €119\nthousand tax expense was recorded related to Inventiva Inc (mainly due to the bonuses).\nDeferred taxes\nInventiva S.A. recorded tax losses in the first half of 2024. As recovery of these losses in future periods\nis considered unlikely due to the uncertainty inherent to the Company’s activity, no deferred tax assets\nwere recognized on this basis on June 30, 2024.\n1.5.6. Net loss for the period\nThe Company recorded a net loss of €49.0 million in the first half of 2024 versus a net loss of €55.3\nmillion in the first half of 2023, which was a decrease in net loss of €6.2 million year over year.\n1.6. Analysis of the financial situation\n1.6.1. Non-current assets\nNon-current assets mainly consist of:\n- other non-current assets mainly comprising term accounts with progressive interest rates.\n- property, plant, and equipment, mainly comprising assets acquired on the incorporation of the\nCompany and the right of use from Fibroscans leasing.\n- investments accounted for using equity method related to investment in Hepalys; and\n- intangible assets, mainly comprising the compound and software library.\nNon-current assets\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nIntangible assets 451 541\nProperty, plant and equipment 7,979 9,126\nDeferred tax assets 210 225\nInvestments accounted for using the equity method 1,131 1,425\nOther non-current assets 1,047 10,055\nTotal non-current assets 10,818 21,372\nNon-current assets decreased by €10.6 million (49%) compared to December 31, 2023. This was mainly\nattributable to:\n- the decrease by €9.0 million of long-term deposit accounts with more than a year of maturity,\nrelated to the early closure of a €9 million two-year deposit forward contract (see note 4.5 –\nOther non-current assets of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024); and\n- the decrease in property, plant and equipment mainly due to the depreciation of €1.2 million of\nthe right of use related to Fibroscan.\n1.6.2. Current assets\n19\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nCurrent assets\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nInventories 393 417\nTrade receivables 809 3,807\nTax receivables 2,704 5,352\nOther current assets 14,554 11,696\nCash and cash equivalents 10,147 26,918\nTotal current assets 28,608 48,189\nCurrent assets decreased by €19.6 million (41%) compared to December 31, 2023. This was mainly\nattributable to the €16.8 million (62%) decrease in cash and cash equivalents and the €3.0 million\ndecrease in trade receivables, both related to the Company’s activity (see section 2 Cash flow and\nequity).\nAs of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the\namount of €2.7 million corresponding to the 2024 CIR as of June 30, 2024.\nThe €2.9 million increase in other current assets is mainly due to:\n- an increase in other receivable by €1.8 million including an increase in prepaid expenses by\n€2.4 million mainly related to trial costs incurred under NATiV3 Phase III global trial; and\n- an increase in current accrued income by €0.6 million which included the rebilling to CTTQ of\nspecific costs (see note 4.7 – Trade receivables, tax receivables and other current assets of the\nUnaudited interim condensed consolidated financial statements as of June 30, 2024); and\n- a decrease in sales tax receivable by €1.8 million.\n1.6.3. Shareholders’ equity\nShareholders’ equity\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nShare capital 525 521\nPremiums related to share capital 201,859 201,862\nReserves (232,789) (124,584)\nForeign currency translation reserve 375 596\nNet loss for the period (49,029) (110,426)\nTotal shareholders’ equity (79,060) (32,032)\nOn June 30, 2024, shareholders’ equity decreased by €47.0 million, or 147%, compared to December\n31, 2023. This change is mainly due to the net loss of the first six months of 2024.\nChanges in shareholders’ equity during the first six months of 2024 are described in further detail in\nnote 4.9 – Shareholders’ equity of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024, and in section 2 Cash flow and equity of this document.\n20\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n1.6.4. Non-current liabilities\nNon-current liabilities\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nLong-term debt 46,846 32,181\nRoyalty certificates liabilities 7,263 6,327\nDerivatives instruments 13,569 10,265\nProvisions for retirement benefit obligations 1,555 1,559\nLong-term contract liabilities 76 70\nOther non-current liabilities 1,032 1,032\nTotal non-current liabilities 70,340 51,434\nThe €18.9 million (37%) increase of non-current liabilities compared to December 31, 2023, is mainly\ndue to the €14.7 million increase of long-term debt (the drawdown of Tranche B subscription), the €3.3\nmillion increase of derivatives instruments (change in fair value) and the €0.9 million increase of 2023\nRoyalty Certificates liabilities related to the interests (see note 4.10 – Financial debt of the Unaudited\ninterim condensed consolidated financial statements as of June 30, 2024).\n1.6.5. Current liabilities\nCurrent liabilities\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nShort-term debt 5,726 5,308\nTrade payables 36,583 37,679\nShort-term contract liabilities 3 6\nOther current liabilities 5,834 7,165\nTotal current liabilities 48,146 50,158\nCurrent liabilities decreased by €2.0 million (4%) for the six months ended June 30, 2024, compared to\nDecember 31, 2023. This change is mainly due to:\n- the €1.1 million decrease in trade payables (see note 4.14 – Trade payables and short-term\ncontract liabilities of the Unaudited interim condensed consolidated financial statements as of\nJune 30, 2024); and\n- the €1.4 million decrease in sales tax payables (including in other current liabilities) (see note\n4.13 – Other current and non-current liabilities of the Unaudited interim condensed\nconsolidated financial statements as of June 30, 2024); and\n- the €0.4 million increase of short-term debt (see note 4.10 – Financial debt of the Unaudited\ninterim condensed consolidated financial statements as of June 30, 2024).\n21\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2. Cash flow and equity\nThis section discusses the Company’s shareholders’ equity, cash position and sources of funding for the\nsix months ended June 30, 2024, and the fiscal year ended December 31, 2023.\n2.1. Cash and cash equivalents\nNet cash and cash equivalents\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nOther cash equivalents(1) 10,273 17,933\nCash at bank and at hand 1,212 8,985\nBank overdrafts (1,338) -\nCash and cash equivalents 10,147 26,918\nSince its inception, the Company has financed its growth through successive capital increases (see\nsection 4.5. Cash flow and equity of the 2023 Universal Registration Document), debt, collaboration and\nlicense agreements and reimbursements of CIR receivables. The Company continues to pursue its\nresearch and development activities for its product candidates.\nAs of June 30, 2024, cash and cash equivalents amounted to €10.1 million compared to €26.9 million\nas of December 31, 2023, with a decrease of €16.8 million (62%), mainly related to the Company’s\nongoing research activities, in particular the NATiV3 Phase III trial with lanifibranor for the treatment\nof MASH/NASH and, to a lesser extent, to the Phase IIa LEGEND trial.\nCash at hand and marketable securities held by the Company are generally invested in short-term deposit\naccounts that are readily convertible into known amounts of cash.\nCash at hand and marketable securities are used to finance the Company’s activities, in particular its\nR&D costs.\nAfter deducting debt, the Company has a net cash deficit as of June 30, 2024, of €1.3 million due to\nbank overdrafts. Borrowings are set out in section 2.1.2 Financing from bank loans below.\nAnalysis of debt\nJune 30, 2024 June 30, 2023\nIn thousands of euros\nShort-term debt 5,726 5,308\nLong-term debt 67,677 48,773\nTotal debt 73,404 54,082\nCash and cash equivalents (10,147) (26,918)\nNet debt 63,256 27,164\nNet debt is a non-standard measure that includes cash and cash equivalents, long-term financial debt,\nlong-term financial debt - derivative instruments, liabilities under royalty certificates, and short-term\nfinancial debt.\nHere are no restrictions on the use of the Company’s cash and cash equivalents resources.\n22\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.1.1. Equity financing\nAs of June 30, 2024, the Company’s share capital increased by €3.6 thousand compared to December\n31, 2023, and set at €524.8 thousand (see note 4.9 – Shareholders’ equity of the Unaudited interim\ncondensed consolidated financial statements as of June 30, 2024).\n2.1.2. Financing from bank loans\nDebt carried\nAnalysis of debt Debt carried on the Proceeds Repayments Fair Value Exchange rate on the\nbalance sheet at Interest capitalize gain/losses\n(+) (-) Variation balance\nIn thousands of euros Dec. 31, 2023 (+/-)\nsheet on\nLease liabilities 6,566 345 (1,173) - - 24 5,762\nPGE SG 2020 (state-guaranteed) 2,096 - (417) - - - 1,679\nPGE BPI France 2020 (state-guaranteed) 2,269 - (413) - - - 1,856\nPGE CA 2020 (state-guaranteed) 2,096 - (347) - - - 1,748\nPPR CA 2022 1,780 - - - - - 1,780\nPPR SG 2022 1,780 - - - - - 1,780\nPGE BPI France 2022 (state-guaranteed) 1,780 - - - - - 1,780\nEIB borowing Tranche A 2022 15,400 - - 3,374 - - 18,774\nEIB borowing Tranche B 2024 - 13,102 - - - - 13,102\nEIB Warrants 2022 and 2024 10,265 11,809 - - (8,506) - 13,569\nRoyalty certificates 6,327 - - 936 - - 7,263\nOther(1) 3,724 - (36) 623 - - 4,311\nTotal Debt 54,082 25,256 (2,386) 4,933 (8,506) 24 73,404\n(1) Corresponding to accrued interests payable on loans.\nOn May 16, 2022, the Company entered into the Finance Contract with EIB for up to €50 million,\ndivided into two tranches of €25 million each. On January 18, 2024, the Company received the\ndisbursement of Tranche B (see Note 1.2. – Significant events in the first half of 2024 of this document\nand note 4.10 – Financial debt of the Unaudited interim condensed consolidated financial statements\nas of June 30, 2024).\nThe Company’s loans and debt maturity profile as of June 30, 2024, is as follows:\nJune 30, 2024 Less than one Between 1 and 3 Between 3 and 5 More than five\nIn thousands of euros year years years years\nBank borrowings 3,229 36,164 2,225 890\nDerivatives - 13,569 - -\nOther loans and similar borrowings(1) 42 4,260 - -\nLease liabilities 2,455 3,306 - -\nRoyalty certificates liabilities - - - 7,263\nTotal Debt 5,726 57,299 2,225 8,153\n(1) Including accrued interests payable on loans.\n2.1.3. Financing from Research Tax Credits\nDue to its status as a European small and medium-sized enterprise (“SME”), the Company receives\npayment for research tax credits granted in the previous period. Consequently, cash proceeds from\nresearch tax credits in a given period correspond to the amount of credits calculated on eligible\nexpenditure for the previous period.\nAs of June 30, 2024, Tax credits related to the 2024 CIR are set at €2.7 million. CIR tax credit amounted\nto €5.3 million for the year ended December 31, 2023.\n23\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nResearch tax credits during the six months ended June 30, 2024, and June 30, 2023 were as follows:\nFinancing from research tax credits\nIn thousands of euros June 30, 2024 June 30, 2023\nIncome statement impact of research tax credits 2,630 3,631\nCash flow impact of research tax credits 5,333 5,220\nThe decrease of €1.0 million compared to the first half of 2023 is primarily attributable to the decrease\nin research and development expenses incurred by the Company.\n2.2. Cash flow analysis\nThe following table sets forth the Company’s cash flow for the first half of 2024 and the first half of\n2023:\nCash flow\nJune 30, 2024 June 30, 2023\nIn thousands of euros\nNet cash used in operating activities (48,342) (45,233)\nNet cash from (used in) investing activities 8,912 (7,702)\nNet cash from (used in) financing activities 22,568 (2,153)\nNet increase (decrease) in cash and cash equivalents (16,863) (55,088)\nIn the first six months of 2024 and 2023, the main financing needs of the Company related to its\noperating activities, including its working capital requirements.\n24\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2.1. Cash flow linked to operating activities\nIn thousands of euros June 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nElimination of non-cash or non-operating\nincome and expenses\nDepreciation, amortization and provisions 1,878 1,138\nDeferred and current taxes 22 (35)\nTax credits (2,657) (3,643)\nCost of net debt 5,180 1,900\nIFRS 2 expenses 2,238 2,046\nUnrealized foreign exchange losses/(gains) (73) 503\nFair value variation (8,506) (1,623)\nOther - 18\nCash flows used in operations before tax, interest and\n(50,939) (54,965)\nchanges in working capital\nIncrease (decrease) in operating and other receivables 4,075 (2,322)\n(Increase) decrease in operating and other payables (2,409) 8,147\nIncrease (decrease) in inventories 24 (28)\nTax credit received 5,333 5,220\nOther (4,426) (1,285)\nTax, interest and changes in operating working capital 2,597 9,732\nNet cash used in operating activities (48,342) (45,233)\nNet cash used in operating activities amounted to €48.3 million in the first half of 2024, compared to\n€45.2 million for the first half of 2023, a decrease of 3.1 million euros due to changes in working capital\nrequirements, and in particular linked to:\n• A decrease in trade receivables of 0 million euros as of June 30, 2024, compared with 2.2\nmillion euros at June 30, 2023, corresponding to a milestone payment from CTTQ received on\nJuly 20, 2023.\n• 0.9 million euros increase in future fund-raising costs (other liabilities)\nHowever, the operating expenses, excluding depreciation, amortization, provision, and IFRS 2 expenses\nfor the first half of 2024 decreased by €7.3 million compared to the first half of 2023. The decrease\nmainly related to R&D expenses over the period is primarily due to the temporary pause in the\nrecruitment of the patients in the NATiV3 Phase III clinical trial related to the SUSAR (see Note 1.2. –\nSignificant events in the first half of 2024 of this document) and, to a lesser extent, due to the completion\nof the LEGEND Phase IIa trial.\n25\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2.2. Cash flow linked to investing activities\nCash flow used in investing activities over the periods presented was as follows:\nIn thousands of euros June 30, 2024 June 30, 2023\nPurchases of property, plant and equipment and intangible\n(255) (230)\nassets\nDisposals of property, plant and equipment and intangible\n90 130\nassets\n(Increase)/decrease in current term accounts 70 998\nNet change in other non-current financial assets 9,008 (8,600)\nNet cash used in investing activities 8,912 (7,702)\nIn the first half of 2024, net cash from investing activities amounted to €8.9 million, compared to €7.7\nmillion used in the first half of 2023 the change is mainly related to the early closure of a €9 million\ntwo-year deposit forward contract (see note 4.5 – Other non-current assets of the Unaudited interim\ncondensed consolidated financial statements as of June 30, 2024).\n2.2.3. Cash flow linked to financing activities\nIn thousands of euros June 30, 2024 June 30, 2023\nCapital increase 6 2\nSubscription of borrowings 24,911 -\nRepayment of debt (1,177) (1,448)\nRepayment of lease liabilities (1,173) (707)\nNet cash (from) used in financing activities 22,568 (2,153)\nNet cash from financing activities amounted to €22.6 million in the first half of 2024, compared to €2.2\nmillion used for the first half of 2023. The change is mainly related to the company’s drawdown of\nTranche B, amounting to €25 million, under the Finance Contract (see Note 1.2. – Significant events in\nthe first half of 2024 of this document).\n26\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.3. Anticipated sources of funds\nFrom inception, the Company has financed its growth through successive capital increases, debt,\ncollaboration and license agreements and reimbursements of CIR receivables. The Company continues\nto pursue its research and development activities for its product candidates.\nThe Company has incurred operating losses and negative cash flows from operations since inception\ndue to the innovative nature of the product candidates it is developing, which necessitates a research and\ndevelopment phase spanning several years. The Company does not expect to generate revenue from\nproduct sales in the near future. With the biopharmaceutical industry's product development phases\nrequiring increasing investments, the Company's financing needs will continue to grow as clinical trials\nof the Company's drug candidates progress and the Company invests to develop existing and new\nproduct candidates.\nAs of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting\nof cash and short-term deposit accounts that are liquid and easily convertible within 3 months without\npenalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents of the section 3.2 –\nInterim Condensed Consolidated financial statements as of June 30, 2024). In accordance with IAS 7.8,\nbank overdrafts which are repayable on demand are included as a component of cash and cash\nequivalents in the amount of €1.3 million as of June 30, 2024.\nAs of the date of authorization of the issuance of these financial statements, given its current cost\nstructure, its projected expenditure commitments, and the events after the reporting period presented in\nNote 6.4 – Events after the reporting period of the section 3.2 – Interim Condensed Consolidated\nfinancial statements as of June 30, 2024, mainly the issue of royalty certificates and the T1 capital\nincrease, the Company estimates that it should have sufficient funds to finance its activities through the\nend of the second half of 2025.\nAccordingly, as of the date of authorization of the issuance of these financial statements, the Company's\ncurrent cash and cash equivalents are not expected to be sufficient to cover its operating needs for at\nleast the next 12 months. These events and conditions indicate that an uncertainty exists that may cast\nsignificant doubt on the Company’s ability to continue as a going concern and, therefore, the Company\nmay be unable to realize its assets and discharge its liabilities in the normal course of business.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\nthe reporting period of the section 3.2 – Interim Condensed Consolidated financial statements as of\nJune 30, 2024. The Company may have based this estimate on assumptions that may prove to be\nincorrect, and the Company may end up using its resources sooner than anticipated.\nBased on the above, the unaudited interim condensed consolidated financial statements for the six-month\nperiod ended June 30, 2024, have been prepared on a going concern basis assuming the Company will\ncontinue to operate for the foreseeable future. As such, they do not include any adjustments related to\nthe amount or classification of assets and liabilities that may be required if the Company were not able\nto continue as a going concern.\n27\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n3. Unaudited interim condensed consolidated\nfinancial statements\n3.1. Statutory Auditors’ Review Report on the Half-yearly\nFinancial Information\nStatutory Auditors’ Review Report on the Half-yearly Financial Information\nFor the period from January 1 to June 30, 2024\nTo the Shareholders,\nIn compliance with the assignment entrusted to us by General Annual Meeting and in accordance\nwith the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (\"Code\nmonétaire et financier\"), we hereby report to you on:\n• the review of the accompanying condensed half-yearly consolidated financial statements of\nInventiva S.A., for the period from January 1 to June 30, 2024,\n• the verification of the information presented in the half-yearly management report.\nThese condensed half-yearly consolidated financial statements are the responsibility of the Board of\nDirectors. Our role is to express a conclusion on these financial statements based on our review.\nI- Conclusion on the financial statements\nWe conducted our review in accordance with professional standards applicable in France.\nA review of interim financial information consists of making inquiries, primarily of persons\nresponsible for financial and accounting matters, and applying analytical and other review\nprocedures. A review is substantially less in scope than an audit conducted in accordance with\nprofessional standards applicable in France and consequently does not enable us to obtain assurance\nthat we would become aware of all significant matters that might be identified in an audit.\nAccordingly, we do not express an audit opinion.\nBased on our review, nothing has come to our attention that causes us to believe that the\naccompanying condensed half-yearly consolidated financial statements are not prepared, in all\nmaterial respects, in accordance with IAS 34 - standard of the IFRSs as adopted by the European\nUnion applicable to interim financial information.\nWithout qualifying our conclusion, we draw your attention to the matter set out in note 3.4 to the\ncondensed half-yearly consolidated financial statements regarding events and conditions indicating\nthat an uncertainty exists that may cast doubt on the Company’s ability to continue as a going\nconcern.\nII Specific verification\nWe have also verified the information presented in the half-yearly management report on the\ncondensed half-yearly consolidated financial statements subject to our review. We have no matters\nto report as to its fair presentation and consistency with the condensed half-yearly consolidated\nfinancial statements.\n28\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nParis La Défense, October 14,2024 Paris, October 14, 2024\nKPMG SA LCA Audit\nKPMG.signature] [sc_sign.coCAC.signature]\n[/sc_sign.KPMG.signature] [/sc_sign.coCAC.signature]\nPhilippe Grandclerc Lison Dahan Chouraki\n29\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n3.2. Interim Condensed Consolidated financial statement\nTable of contents\n3.2. Interim Condensed Consolidated financial statement ............................................................. 30\nNote 1. Company information .................................................................................................. 37\n1.1 Company information .......................................................................................................... 37\n1.2 Significant events in the first half of 2024 ........................................................................... 39\nNote 2. Basis of preparation and statement of compliance .......................................................... 42\n2.1. Basis of preparation for the consolidated financial statements ........................................ 42\n2.2. Statement of compliance.................................................................................................. 43\n2.3. Scope and method of consolidation ........................................................................................ 43\n2.4 Foreign currency translation .................................................................................................... 44\nNote 3. Accounting principles .................................................................................................. 45\n3.1. Use of estimates and judgment ........................................................................................ 45\n3.2. Fair value measurement ................................................................................................... 45\n3.3. Specific disclosure requirements for unaudited interim financial statements.................. 46\n3.4. Going concern .................................................................................................................. 46\nNote 4. Notes to the interim condensed consolidated statement of financial position .................... 47\n4.1 Intangible assets ...................................................................................................................... 47\n4.2 Property, plant and equipment ................................................................................................. 47\n4.3 Deferred tax asset .................................................................................................................... 47\n4.4 Investments accounted for using the equity method ............................................................... 47\n4.5 Other non-current assets .......................................................................................................... 50\n4.6 Inventories ............................................................................................................................... 50\n4.7 Trade receivables, tax receivables and other current assets .................................................... 50\n4.8 Cash and cash equivalents ....................................................................................................... 51\n4.9 Shareholders’ equity ................................................................................................................ 51\n4.10 Financial debt ........................................................................................................................ 54\n4.11 Provisions .............................................................................................................................. 59\n4.12 Provisions for retirement benefit obligations ........................................................................ 59\n4.13 Other current and non-current liabilities ............................................................................... 60\n4.14 Trade payables and short-term contract liabilities ................................................................. 61\n4.15 Financial assets and liabilities ............................................................................................... 61\nNote 5. Notes to the interim condensed consolidated statement of (income) loss .......................... 63\n5.1 Revenues and other income ..................................................................................................... 63\n5.2 Operating expenses .................................................................................................................. 63\n5.3 Other operating income and expenses ..................................................................................... 65\n5.4 Financial income and expenses ............................................................................................... 65\n5.5 Share of net profit – Equity method ........................................................................................ 65\n5.6 Income tax ............................................................................................................................... 66\n5.7 Basic and diluted loss per share ............................................................................................... 66\nNote 6. Other financial information .......................................................................................... 67\n6.1 Commitments related to operational activities ........................................................................ 67\n30\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n6.2. Related-party transactions ...................................................................................................... 68\n6.3 Financial risk management ...................................................................................................... 68\n6.4 Events after the reporting date ................................................................................................. 68\n31\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of financial position\n(in thousands of euros)\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros Notes\nIntangible assets 4.1 451 541\nProperty, plant and equipment 4.2 7,979 9,125\nDeferred tax assets 4.3 210 225\nInvestments accounted for using the equity method 4.4 1,131 1,425\nOther non-current assets 4.5 1,047 10,055\nTotal non-current assets 10,818 21,371\nInventories 4.6 393 417\nTrade receivables and others 4.7 809 3,807\nTax receivables 4.7 2,704 5,352\nOther current assets 4.7 14,554 11,696\nCash and cash equivalents 4.8 10,147 26,918\nTotal current assets 28,608 48,189\nTotal assets 39,426 69,561\nShare capital 525 521\nPremiums related to share capital 201,859 201,862\nReserves (232,789) (124,584)\nTranslation reserve 375 596\nNet loss for the period (49,029) (110,426)\nShareholders’ equity 4.9 (79,060) (32,032)\nLong-term debt 4.10 46,846 32,181\nLong‑term debt – derivatives 4.10 13,569 10,265\nRoyalty certificates liabilities 4.10 7,263 6,327\nProvisions for retirement benefit obligations 4.12 1,555 1,559\nLong-term contract liabilities 76 70\nOther non-current liabilities 4.13 1,032 1,032\nTotal non-current liabilities 70,340 51,434\nShort-term debt 4.10 5,726 5,308\nTrade payables 4.14 36,583 37,679\nShort-term contract liabilities 4.14 3 6\nOther current liabilities 4.13 5,834 7,165\nTotal current liabilities 48,146 50,158\nTotal liabilities 118,486 101,592\nTotal equity and liabilities 39,426 69,561\nThe accompanying notes form an integral part of these financial statements\n32\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of income (loss)\n(in thousands of euros)\nSix months ended\nNotes June 30, 2024 June 30, 2023\nRevenue 5.1 41 1,901\nOther income 5.1 2,693 4,721\nTotal revenues and other income 2,734 6,622\nResearch and development costs 5.2 (46,822) (54,062)\nMarketing – Business development expenses 5.2 (598) (705)\nGeneral and administrative expenses 5.2 (7,701) (6,812)\nOther operating income (expenses) 5.3 138 (44)\nNet operating loss (52,249) (55,003)\nFinancial income 5.4 9,093 2,373\nFinancial expenses 5.4 (5,586) (2,646)\nNet financial income 3,507 (273)\nShare of net loss - Equity method 5.5 (168) -\nIncome tax 5.6 (119) 7\nNet loss for the period (49,029) (55,269)\nBasic/diluted loss per share (euros/share) (0.94) (1.31)\nWeighted average number of shares outstanding\n5.7 51,982,093 42,044,796\nused to calculate basic/diluted loss per share\nThe accompanying notes form an integral part of these financial statements\n33\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of comprehensive\n(income) loss\n(in thousands of euros)\nSix months ended\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nItems that will be reclassified subsequently to profit or loss (220) 104\nCurrency translation differences - equity method (286) -\nCurrency translation differences 66 104\nItems that will not be reclassified subsequently to profit or\n74 (14)\nloss\nRemeasurement of defined benefit plans 74 (14)\nTotal comprehensive loss (49,175) (55,179)\nThe accompanying notes form an integral part of these financial statements\n34\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of changes in\nshareholders’ equity\n(in thousands of euros)\nPremiums Net income\nTranslation Shareholders’\nNotes Share capital related to share (loss) for the Reserves\nReserves equity\ncapital period\nAt January 1, 2024 521 201,862 (110,426) 596 (124,584) (32,032)\nNet income (loss) for the period - - (49,029) - - (49,029)\nRemeasurement of defined benefit plans - - - - 74 74\nCurrency translation differences - - - (220) - (220)\nTotal comprehensive income (loss) - - (49,029) (220) 74 (49,175)\nAppropriation of 2023 net income (loss) - - 110,426 - (110,426) -\nShare-based payment compensation expenses 4.9 - - - - 2,238 2,238\nBSA share warrants subscription premium 4 (4) - - 6 6\nTreasury shares - - - - (138) (138)\nOther - - - - 41 41\nJune 30, 2024 525 201,859 (49,029) 375 (232,789) (79,060)\nPremiums Net income\nTranslation Shareholders’\nNotes Share capital related to share (loss) for the Reserves\nReserves equity\ncapital period\nAt January 1, 2023 421 173,886 (54,274) (271) (74,286) 45,476\nNet income (loss) for the period - - (55,269) - - (55,269)\nRemeasurement of defined benefit plans - - - - (14) (14)\nCurrency translation differences - - - 104 - 104\nTotal comprehensive income (loss) - - (55,269) 104 (14) (55,179)\nAppropriation of 2022 net income (loss) - - 54,274 - (54,274) -\nShare-based payment compensation expenses 4.9 - - - - 2,046 2,046\nBSA share warrants subscription premium - - - - 2 2\nTreasury shares - - - - 10 10\nOther - - - - (22) (22)\nAt June 30, 2023 421 173,886 (55,269) (168) (126,537) (7,667)\nThe accompanying notes form an integral part of these financial statements\n35\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nUnaudited interim condensed consolidated statement of cash flows\n(in thousands of euros)\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nElimination of non-cash or non-operating\nincome and expenses\nDepreciation, amortization and provisions 1,878 1,138\nDeferred and current taxes 22 (35)\nTax credits (2,657) (3,643)\nCost of debt 5,180 1,900\nShare-based compensation expense 2,238 2,046\nShareofnetprofitofassociatesandjointventuresaccountedfor usingthe\n8 -\nequity method\nExchange (gains) / losses (73) 503\nFair value variation through profit and loss (8,506) (1,623)\nOther - 18\nCashflowsusedinoperationsbeforetax,interestandchangesinworking\n(50,939) (54,965)\ncapital\nDecrease / (increase) in operating and other receivables 4,075 (2,322)\nIncrease / (decrease) in operating and other payables (2,409) 8,147\nDecrease / (increase) in inventories 24 (28)\nTax credit received 5,333 5,220\nOther(1) (4,426) (1,285)\nTax, interest and changes in operating working capital 2,597 9,732\nNet cash used in operating activities (48,342) (45,233)\nPurchases of property, plant and equipment and intangible assets (255) (230)\nDisposals of property, plant and equipment and intangible assets 90 130\nDecrease / (Increase) in short-term deposit accounts 70 998\nIncrease / (Decrease) in other non-current financial assets 9,008 (8,600)\nNet cash from (used in) investing activities 8,912 (7,702)\nCapital increase net of transaction cost 6 2\nSubscription of borrowings and warrants net of transaction cost 24,911 -\nRepayment of debt (1,177) (1,448)\nRepayment of lease liabilities (1,173) (707)\nNet cash from (used in) financing activities 22,568 (2,153)\n-\nNet increase (decrease) in cash and cash equivalents (16,863) (55,087)\nCash and cash equivalents at beginning of period 26,918 86,736\nExchange gains / (losses) 92 (409)\nNet cash and cash equivalents at the end of period 10,147 31,240\n(1) Mainly include an increase in prepaid expense\nThe accompanying notes form an integral part of these financial statements\n36\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nNotes to the unaudited interim condensed consolidated financial statements\nNote 1. Company information\n1.1 Company information\nInventiva S.A. is a public limited company registered and domiciled in France. Its head office is located\nat 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include\nInventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as\n“Inventiva” or the “Company”).\nInventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since\nFebruary 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary\nshare, have been listed on the Nasdaq Global Market since July 2020.\nInventiva is a clinical-stage biopharmaceutical company focused on the development of oral small\nmolecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),\nalso known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet\nmedical need.\nLeveraging its expertise and experience in the domain of compounds targeting nuclear receptors,\ntranscription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the\ntreatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.\nLanifibranor, its lead product candidate, is being developed for the treatment of patients with\nMASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive\ntopline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with\nMASH/NASH and announced that the U.S. Food and Drug Administration (\"FDA\") had granted the\nCompany the status of Breakthrough Therapy and Fast Track designation. The Company initiated the\npivotal Phase III trial of lanifibranor in MASH/NASH (“NATiV3”) in the second half of 2021. In March\n2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor\nand empagliflozin in patients with MASH/NASH and Type 2 Diabetes (“DT2”) (“LEGEND”).\nIn the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a\nhigher than originally projected screen failure rate resulting in slower than anticipated enrollment rate.\nIn addition, the Company experienced slower than predicted site activation, screening and enrollment\ndue to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the\nCompany was unable to conduct clinical trial activities at sites originally located in Ukraine due to the\nwar between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in\nUkraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the\nmarkets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could\naffect the Company.\nIn January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially\naccelerate enrollment and identified additional sites to help compensate for the inability to use sites in\nUkraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks\ninstead of up to seven years, reduces the number of biopsies from three to two and included a 48-week\nactive treatment extension study. The Company expects that the changes to the clinical development\nplan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and\ncompensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of\nbiopsies and the trial duration, eventually offering all patients in the trial access to treatment and\n37\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\npotentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to\npatients with MASH/NASH and compensated cirrhosis.\nIn September 2022, the Company entered into a license and collaboration agreement with Chia Tai\nTianqing Pharmaceutical Group, Co., LTD (“CTTQ”), a Sino Biopharm group company, to develop and\ncommercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other\nmetabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special\nAdministrative Region and Taiwan (“CTTQ Territory”). In May 2023, the Company announced that\nCTTQ had received the Investigational New Drug (“IND”) approval from the Chinese National\nMedicine Products Administration (“NMPA”) allowing CTTQ to initiate the clinical development of\nlanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase\nIII trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation\nin the Company’s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ\nbears all costs associated with these trials conducted in the CTTQ Territory.\nIn September 2023, the Company and Hepalys Pharma, Inc. (“Hepalys”) announced an exclusive\nlicensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the “Hepalys\nLicense Agreement”). Hepalys is a new company created by Catalys Pacific Fund II, LP (“Catalys”).\nUnder the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to\n€9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical,\nregulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to\nlow twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval.\nIn parallel with the Hepalys License Agreement, the Company entered into an option agreement with\nCatalys to acquire 30% of the shares of Hepalys (the “Catalys Option Agreement”). The Company\nexercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate\nexercise price of ¥300 (equal to €1.90). Also on September 20, 2023, the Company entered into a\nshareholders agreement with Catalys and Hepalys (the “Catalys Shareholders Agreement”). Pursuant to\nthe Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of\nHepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal\nif Hepalys receives an offer for the license or rights related to lanifibranor.\nIn the first quarter of 2024, following a routine visit during the Company’s NATiV3 clinical trial of\nlanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (“SUSAR”) was\nreported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\nenrolled in the trial as recommended by the Data Monitoring Committee (“DMC”)3.\nOn March 7, 2024, the Company announced that screening activities had resumed in American sites\nunder central Institutional Review Board (“IRB”). The impact of the pause on the overall timeline of the\ntrial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate,\nand the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial\nparticipants.\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and DT2.\n3 A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.\n38\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nThe Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete\nrandomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the\nCompany is currently targeting the first visit of the last patient for the second half of 2024 and the\npublication of the main results for the beginning of the second half of 2026. The publication of the\ntopline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the\nbeginning of the second half of 2026 as previously announced). If the results of the trial confirm\nsufficient clinical benefit and a continued good safety profile, the Company plans to file an application\nfor accelerated approval in the United States and conditional authorization in the European Union for\nthe marketing of lanifibranor.\nThe Company’s pipeline also includes odiparcil, which it was previously developing for the treatment\nof patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. As\nannounced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor.\nBased on feedback from the FDA, the Company believes there is potential for an efficient development\npathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further\ndevelop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership,\nlicense or other transaction.\n1.2 Significant events in the first half of 2024\nThe Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B (see\nNote 4.10 Financial debt)\nOn January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment\nBank (“EIB”) and such warrants, the “EIB Tranche B Warrants”, in accordance with the terms of the\n6th resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-\n138 of the French Commercial Code, as a condition to the drawdown of the second tranche of €25.0\nmillion (“Tranche B”) under the finance contract between the Company and EIB (“Finance Contract”).\nThe 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the\nCompany's then-outstanding share capital. If all the warrants issued to the EIB in connection with\ndrawdown of the first tranche of €25.0 million (“Tranche A”) under the Finance Contract (the “EIB\nTranche A Warrants” and, together with the EIB Tranche B Warrants, the “EIB Warrants”) and the EIB\nTranche B Warrants were exercised, the EIB would hold approximately 9.9% of the Company's share\ncapital as of June 30, 2024.\nThe exercise price of the EIB Tranche B Warrants is equal to €3.95 and corresponds to 95% of the\nvolume-weighted average price of the Company's shares on the regulated market of Euronext Paris\nduring the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).\nThe EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the\nearliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control\nevent, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the\nFinance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within\nthe twelve-year period.\nEIB has a put option which may require the Company to repurchase all or part of the unexercised EIB\nTranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn\nunder the Finance Contract) under certain circumstances (for example, in the event of a change of control\nor on the maturity date of Tranche A or in the event of default). The Company (or a substitute third\nparty) has a call option to require EIB to sell all shares and other securities of the Company, including\n39\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nthe EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company\nhas a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party,\nsubject to certain terms and conditions.\nOn the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB\nTranche B Warrants at a price of €3.95 per new share, the Company could potentially receive gross\nproceeds of up to €12,421,383. There is no assurance that EIB will exercise any or all of the EIB\nWarrants or that the Company will receive any proceeds from the exercise of the warrants.\nThe exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B\nTranche B Warrants. As of the date of authorization of the issuance of these financial statements, one\nEIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.\nThe Company draws down Tranche B of €25 million under Finance Contract with EIB (see Note\n4.10 Financial debt)\nOn January 18, 2024, the Company drew down Tranche B of €25 million under the Finance Contract\nwith EIB.\nAfter the drawdown of Tranche A in December 2022, the Company had an option to access further €25\nmillion tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the\nachievement of those conditions, the Company decided to draw on Tranche B. The Company intends to\nuse the proceeds to fund part of NATiV3.\nTranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in\nJanuary 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among\nother conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of\nthe Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million that\nwas a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company,\nor through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with\nan upfront payment of at least €10 million, (iv) operational criteria based on patient enrollment and\nnumber of sites activated in the Company’s NATiV3 Phase III clinical trial of lanifibranor in patients\nwith NASH and (v) the Company issuing EIB Tranche B Warrants (see above - The Company issued\n3,144,654 warrants to EIB in connection with the drawdown of Tranche B) in accordance with the terms\nand conditions of the warrant agreement entered into on July 1, 2022.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (warrants) at inception and the borrowing costs.\nOn June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for\nadjusting the exercise ratios of the EIB Warrants.\nTreatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024\nOn February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in\nliver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient\nhad been without clinical symptoms throughout the period of observation. This event has been assessed\nas a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial\nparticipants have also been reported in the trial. The Company decided to voluntarily pause screening\nand randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with\na predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients\n40\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nenrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the\ntrial continued to receive treatment under the new liver monitoring schedule recommended by the DMC.\nThis SUSAR is the first reported in all clinical trials with lanifibranor.\nOn March 7, 2024, the Company received approval from the central IRB overseeing clinical research in\nthe United States to resume screening activities in its sites. This was an important milestone as 152 sites\nof the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60%\nof the patients in the main cohort.\nDue to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit\nof the last patient for the second half of 2024, to complete randomization in the first half of 2025 and\nthe main results for the second half of 2026 (versus the beginning of the second half of 2026 as\npreviously disclosed).\nThe Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and\nempagliflozin in patients with MASH/NASH and T2D\nOn March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study\ncombining lanifibranor with empagliflozin in patients with MASH/NASH and T2D.\nThe LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled\nPhase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the\nSGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D.\nThe trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for\nthe combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm. The diagnosis of\nnon-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-\ninvasive methods including diagnostic methods including imaging. As planned per protocol, the interim\nanalysis was done once half of the 63 planned randomized patients with MASH completed the 24-week\ntreatment period or prematurely discontinued from treatment.\nThe study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c\n(HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily)\nor in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26%\nobserved in the placebo arm.\nThe study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-\nPDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -\n38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone\nor in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their\nhepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically\nsignificant effect on several secondary and exploratory endpoints, including liver enzymes (alanine\naminotransferase (“ALT”) and aspartate aminotransferase (“AST”)), insulin resistance (HOMA-IR),\nHDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1)\nassessed by LiverMultiScan®) were assessed for the first time with lanifibranor and showed a significant\neffect with lanifibranor alone and in combination with empagliflozin.\nThe study also demonstrated that patients treated with lanifibranor in combination with empagliflozin\nmaintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically\nhealthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore,\nthese results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and\n41\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nsubcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with\nempagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.\nThis result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose\ntissue.\nThe treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily\nfor 24 weeks appears to be well tolerated, with no safety concerns reported.\nGiven that the primary endpoint of LEGEND was met, and statistically significant results were achieved\non several key additional markers, the Company has decided to stop the recruitment as defined per\nprotocol. More details on these results are expected to be presented in upcoming scientific conferences\nand submitted for publication.\nAdditional results from NATIVE Phase IIb clinical trial\nOn May 13, 2024, the Company announced the publication in Nature Communications of additional\nresults from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic\nhealth in patients with MASH/NASH treated with lanifibranor.\nImprovements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism\n(triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG)\nlevels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.\nRecommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in\npatients with MASH/NASH\nOn May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the\nNATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.\nThe DMC recommended to continue the clinical trial without further modification of the protocol, as\namended immediately after learning about SUSAR, based on the pre-planned review of safety data.\nThe recommendation was based on the unblinded review by the DMC of safety data from more than\n900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients\nthat have been treated for more than 48 and 72 weeks, respectively.\nThe patient who experienced the adverse event of increased liver test results, which was reported as a\nSUSAR, had been without clinical symptoms throughout the period of observation and has fully\nrecovered.\nNote 2. Basis of preparation and statement of compliance\n2.1. Basis of preparation for the consolidated financial statements\nThe Company has prepared these unaudited interim condensed consolidated financial statements in\naccordance with International Financial Reporting Standards (“IFRS”) as adopted by the European\nUnion and IFRS Accounting Standards as issued by the International Accounting Standard Board\n(“IASB”).\nThese unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved\nby the Board of Directors of the Company on 14 October, 2024.\n42\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n2.2. Statement of compliance\nThese unaudited interim condensed consolidated financial statements were prepared in compliance with\nInternational Accounting Standards (IAS) 34 — Interim Financial Reporting, which provides for the\npresentation of selected explanatory notes. The accompanying notes do not contain all the disclosures\nrequired for annual financial statements and should therefore be read in conjunction with the Company’s\nfinancial statements prepared in accordance with IFRS ®Accounting Standards, referred to as IFRS as\nof and for the year ended December 31, 2023 except for the accounting principles described in Note 3\n– Accounting principles.\nIFRS Accounting Standards basis adopted\nThe accounting policies applied by the Company in the preparation of the unaudited interim condensed\nconsolidated financial statements for the six-month period ended June 30, 2024, are identical to those\nused in the annual financial statements prepared in accordance with IFRS Accounting Standards as of\nand for the year ended December 31, 2023, with the exception of specific provisions for the preparation\nof unaudited interim condensed consolidated financial statements.\nStandards, amendments to existing standards and interpretations published by the IASB whose\napplication has been mandatory since January 1, 2024\nThe application of standards, amendments to existing standards and interpretations whose application\nhas been mandatory since January 1, 2024 in the European Union primarily concern:\n- Amendment to IFRS 16 – Lease liability in a sale and leaseback\n- Amendment to IAS 1 – Non-current liabilities with covenants\n- Amendment to IAS 7 and IFRS 7 - Supplier finance arrangements\nThose amendments had no material impact on the Company’s unaudited interim condensed consolidated\nfinancial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had\nnot published any amendments that would be expected to have a material impact on the Company’s\nconsolidated financial statements.\nStandards, amendments to existing standards and interpretations published by the IASB whose\napplication is not yet mandatory\nThe new standards, interpretations and amendments to existing standards that have been published but\nare not yet applicable concern:\n- Amendments to IAS 21 – Lack of Exchangeability\n- Amendment to IFRS 9 and IFRS 7 – Classification and Measurement of Financial Instruments\n- New Standard – IFRS 18 – Presentation and Disclosure in Financial Statements\n- New standard – IFRS 19 Subsidiaries without Public Accountability: Disclosures\nThese new standards, interpretations and amendments are under analysis to see if there are applicable\nto Inventiva.\n2.3. Scope and method of consolidation\n• Accounting policy\nIn accordance with IFRS 10 Consolidated Financial Statements, an entity (subsidiary) is consolidated\nwhen it is controlled by the company (the parent).\n43\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nSubsidiaries are all entities over which the Company has control. The Company controls an entity when\nit is exposed to, or has rights to, variable returns from its involvement with the entity and could affect\nthose returns through its power to direct the activities of the entity. Subsidiaries are consolidated from\nthe date on which control is transferred to the Company. They are deconsolidated from the date such\ncontrol ceases.\nAll intercompany transactions, balances, and unrealized gains on transactions between group companies\nare eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an\nimpairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies\nadopted by the Company.\n• Consolidated entities\nAs of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and\nits 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.\nPercent of\nDate of Ownership\nincorporation Interest Accounting Method\nINVENTIVA Inc. 01/05/2021 100% Fully Consolidated\n• Interests in associates and joint ventures\nHepalys is incorporated and has its principal place of business in Japan. The Company’s proportion of\nownership interest is 14.6% and is the same as the proportion of voting rights held. In accordance with\nIAS 28 Investments in Associates and Joint Ventures, Hepalys is an associate of the Company and is\naccounted for using the equity method (see Note 4.4. – Investments accounted for using the equity\nmethod).\n2.4 Foreign currency translation\n• Functional and presentation currency\nThe Company’s consolidated financial statements are presented in euros, which is also the functional\ncurrency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S.\ndollar. All amounts presented in these notes to the consolidated financial statements are denominated in\neuros unless otherwise stated.\n• Translation of financial statements into presentation currency\nThe results and financial position of foreign operations that have a functional currency different from\nthe presentation currency are translated into euros, the presentation currency, as follows:\n• Assets and liabilities for each balance sheet presented are translated at the closing rate on the date\nof that balance sheet,\n• Income and expenses for each statement of (income) loss and statement of comprehensive (income)\nloss are translated at average exchange rates (which is an approximate value of the exchange rate\non the transaction date in the absence of significant fluctuations. Income and expenses are translated\nat the transaction dates if the exchange rates fluctuate significantly), and\n• All resulting exchange differences are recognized in other comprehensive income.\n44\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of December As of June 30,\nExchange rate (USD per EUR) As of June 30, 2024\n31, 2023 2023\nAverage exchange rate for the period 1.0813 1.0803 1.0807\nExchange rate at period end 1.0705 1.1050 1.0866\nNote 3. Accounting principles\n3.1. Use of estimates and judgment\nThe preparation of financial statements requires management to make judgments and estimates and\napply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as\nwell as the information presented in the accompanying notes. Actual reported values may differ from\nthe accounting estimates made.\nThere have been no significant changes in the material judgments and main estimates used by\nmanagement when applying the Company’s accounting policies in the preparation of these unaudited\ninterim condensed consolidated financial statements from those described in the annual financial\nstatements prepared in accordance with IFRS Accounting Standards for the year ended December 31,\n2023.\nThe conflict in Ukraine and the state of war between Israel and Hamas have not led to any material\nchanges in the estimates or judgements made by management in the preparation of the Company’s\nunaudited interim condensed consolidated financial statements.\n3.2. Fair value measurement\nIn the table below, financial instruments are measured at fair value according to a hierarchy comprising\nthree levels of valuation inputs:\n• Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that\nthe entity can access at the measurement date.\n• Level 2: Inputs other than quoted market prices included within Level 1 that are observable\nfor the asset or liability, either directly or indirectly.\n• Level 3: Unobservable inputs for the asset or liability.\nThe table below presents the financial assets and liabilities of the Company measured at fair value as of\nJune 30, 2024:\nAt June 30, 2024 (in thousands of euros) Level 1 Level 2 Level 3\nFinancial liabilities at fair value through profit or loss\nLong‑term financial debt – derivatives – – 13,569\nTotal liabilities – – 13,569\nThe table below presents the financial assets and liabilities of the Company measured at fair value as of\nDecember 31, 2023:\n45\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAt December 31, 2023 (in thousands of euros) Level 1 Level 2 Level 3\nFinancial liabilities at fair value through profit or loss\nLong‑term financial debt – derivatives – – 10,265\nTotal liabilities – – 10,265\n3.3. Specific disclosure requirements for unaudited interim financial statements\nSeasonality of operations\nThe Company’s operations are not subject to material seasonal fluctuations.\nIncome tax\nIncome tax is recognized in the financial statements for each interim period. The amount corresponds\nto a best estimate calculated by applying the expected weighted average tax rate for the entire year.\nThe income tax amount recorded as due for an interim period may have to be adjusted in the subsequent\ninterim period of the same year if the estimated annual average tax rate changes.\n3.4. Going concern\nFrom inception, the Company has financed its growth through successive capital increases, debt,\ncollaboration and license agreements and reimbursements of CIR receivables. The Company continues\nto pursue its research and development activities for its product candidates.\nThe Company has incurred operating losses and negative cash flows from operations since inception\ndue to the innovative nature of the product candidates it is developing, which necessitates a research and\ndevelopment phase spanning several years. The Company does not expect to generate revenue from\nproduct sales in the near future. With the biopharmaceutical industry's product development phases\nrequiring increasing investments, the Company's financing needs will continue to grow as clinical trials\nof the Company's drug candidates progress and the Company invests to develop existing and new\nproduct candidates.\nAs of June 30, 2024, the Company had €10.1 million of available cash and cash equivalents, consisting\nof cash and short-term deposit accounts that are liquid and easily convertible within 3 months without\npenalty or risk of change in value (refer to Note 4.8 – Cash and Cash equivalents). In accordance with\nIAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash\nequivalents in the amount of €1.3 million as of June 30, 2024.\nAs of the date of authorization of the issuance of these financial statements, given its current cost\nstructure, its projected expenditure commitments, and the events after the reporting period presented in\nNote 6.4 – Events after the reporting period, mainly the issue of royalty certificates and the T1 capital\nincrease, the Company estimates that it should have sufficient funds to finance its activities through the\nend of the second half of 2025.\nAccordingly, as of the date of authorization of the issuance of these financial statements, the Company's\ncurrent cash and cash equivalents are not expected to be sufficient to cover its operating needs for at\nleast the next 12 months. These events and conditions indicate that an uncertainty exists that may cast\nsignificant doubt on the Company’s ability to continue as a going concern and, therefore, the Company\nmay be unable to realize its assets and discharge its liabilities in the normal course of business.\nThis estimate is based on the Company’s current business plan and excludes (i) other expenses related\nto the potential development of odiparcil or resulting from any potential in-licensing or acquisition of\n46\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nadditional product candidates or technologies, or any associated development the Company may pursue,\n(ii) any potential milestone payments that may be received or paid by the Company or potential\nadditional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 – Events after\nthe reporting period. The Company may have based this estimate on assumptions that may prove to be\nincorrect, and the Company may end up using its resources sooner than anticipated.\nBased on the above, the unaudited interim condensed consolidated financial statements for the six-month\nperiod ended June 30, 2024, have been prepared on a going concern basis assuming the Company will\ncontinue to operate for the foreseeable future. As such, they do not include any adjustments related to\nthe amount or classification of assets and liabilities that may be required if the Company were not able\nto continue as a going concern.\nNote 4. Notes to the interim condensed consolidated statement of financial position\n4.1 Intangible assets\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nIntangible assets, gross 3,947 3,926\nAmortization and impairment (3,496) (3,384)\nIntangible assets, net 451 541\n4.2 Property, plant and equipment\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nProperty, plant and equipment, gross 20,376 19,840\nDepreciation and impairment (12,396) (10,714)\nProperty, plant and equipment, net 7,979 9,126\nAs of June 30, 2024, the gross value of property, plant and equipment increased by €0.5 million mainly\ndue to the recognition of the right of use related to the Fibroscans lease agreement for €0.4 million.\nDepreciation and impairment increased by €1.7 million mainly due to the depreciation of €1.2 million\nof the right of use and €0.3 million due to an impairment of the right of use related to Fibroscan.\n4.3 Deferred tax asset\nInventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax\nconsolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the\nconsolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient\nevidence that it will have a sufficient taxable benefit available to use the unused tax losses in the\nforeseeable future.\nAs recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the\nInventiva S.A.’s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for\nInventiva Inc.\n4.4 Investments accounted for using the equity method\nInventiva became an equity shareholder in Hepalys with the acquisition of 1,500,000 ordinary shares on\nOctober 11, 2023.\nOn January 15, 2024, Hepalys’s shareholders approved a capital increase of €1.6 million by issuing new\nshares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently,\nthe Company’s ownership in Hepalys was diluted to 14.6%. As of June 30, 2024, the Company holds\n14.6% of Hepalys's shares, down from 15% ownership as of December 31, 2023.\n47\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nThe Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a\nsignificant influence but not control or joint control of Hepalys. The significant influence is reflected\nthrough the ownership of percentage of interests held, the percentage of potential voting rights owned\nby the Company including the option, under the Catalys Shareholders Agreement, to acquire all\noutstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as\nat June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the\nHepalys License Agreement.\nThe investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024.\nThe tables below provide the summarized statement of financial position of Hepalys. The disclosed\ninformation reflects the amounts presented in the financial statements of Hepalys and not the Company's\nshare of those amounts. They have been amended to reflect adjustments made by the Company when\nusing the equity method, in this case fair value adjustments. The tables below provide also the\nreconciliation between the Hepalys statement of financial position and the carrying amount in the\nCompany statement of financial position.\n48\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDecember 31,\nJune 30, 2024\n2023\n(in thousands of euros)\nIntangible assets 17,217 20,278\nTotal non-current assets 17,217 20,278\nOther current assets 17 44\nCash and cash equivalents 1,997 1,082\nTotal current assets 2,015 1,126\nDeferred assets 2 41\nTotal assets 19,233 21,444\nCapital stock 523 640\nCapital reserve 20,379 22,655\nCapital surplus-others 774 -\nEarnings brought forward (1,018) (178)\nNet loss for the period (1,444) (1,111)\nTreasury Shares - (812)\nShareholders’ equity 19,214 21,194\nTotal non-current liabilities - -\nTrade payables 7 237\nOther current liabilities 12 13\nTotal current liabilities 19 250\nTotal equity and liabilities 19,233 21,444\nOpening net assets 21,122 22,645\nLoss for the period (1,509) (879)\nOther comprehensive income (1,964) 247\nCapital variations 1,566 (819)\nClosing net assets 19,214 21,194\nGroup's share in % 15% 15%\n(in thousands of euros)\nGroup's share 2,813 3,267\nElimination of unrealised profit on downstream sales (1,718) (1,881)\nGoodwill 37 39\nCarrying amount 1,131 1,425\n49\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\n4.5 Other non-current assets\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nLong-term deposit accounts 0 9,000\nAdvance payments – non-current 1,047 1,047\nAccrued income 0 0\nSecurity deposits 0 8\nOther non-current assets 1,047 10,055\nAs of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by\n€9.0 million, related to the early closure of a €9.0 million two-year deposit forward contract.\nAs of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to\n€1.0 million, corresponding to the advance paid under the contract research organization (“CRO”)\ncontract with Pharmaceutical Research Associates Groupe B.V (“PRA”) (see Note 6.1 – Commitments\nrelated to operational activities).\n4.6 Inventories\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nLaboratory inventories 402 426\nInventories write-down (9) (9)\nInventories 393 417\n4.7 Trade receivables, tax receivables and other current assets\nTrade receivables\nTrade receivables break down as follows:\nIn thousands of euros Dec. 31,\nJune 30, 2024\n2023\n3 months or less 809 3,807\nBetween 3 and 6 months - -\nBetween 6 and 12 months - -\nMore than 12 months - -\nTrade receivables 809 3,807\nThe average payment period is 30 days.\nAs of June 30, 2024, trade receivables decreased by €3.0 million mainly due to the receipt of a payment\nfrom CTTQ for the reinvoicing of specific costs related to the NATiV3 trial.\nTax receivables and Other current assets\n50\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDec. 31,\nIn thousands of euros June 30, 2024\n2023\nCIR and other research tax credits 2,657 5,333\nOther 47 19\nTax receivables 2,704 5,352\nPrepaid expenses 7,039 4,656\nShort-term deposit accounts - 70\nCurrent accrued income 1,687 1,047\nLiquidity agreement - Cash 289 422\nSales tax receivable 3,311 5,066\nOther receivables 2,229 435\nOther current assets 14,554 11,696\nOther current assets and receivables 17,258 17,048\nAs of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the\namount of €2.7 million corresponding to the 2024 CIR as of June 30, 2024.\nPrepaid expenses, which increased by about €2.4 million, are mainly composed of costs related to the\nNATiV3 Phase III clinical trial.\n4.8 Cash and cash equivalents\nNet cash and cash equivalents\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nOther cash equivalents(1) 10,273 17,933\nCash at bank and at hand 1,212 8,985\nBank overdrafts (1,338) -\nCash and cash equivalents 10,147 26,918\n(1) Other cash equivalents correspond to short-term bank deposits.\nIn accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a\ncomponent of cash and cash equivalents in the amount of €1.3 million as of June 30, 2024.\n4.9 Shareholders’ equity\nShare capital\nThe share capital is set at €524,772 at June 30, 2024 divided into 52,477,188 fully authorized, subscribed\nand paid-up shares with a nominal value of €0.01.\nShare capital variation during the first six months of 2024 is set forth in the table below:\nIn euros, except number of shares\nPremiums related to\nDate Nature of the transactions Share capital Number of shares Nominal value\nshare capital\nBalance at December 31, 2023 521,158 201,862,263 52,115,807 0.01\n3/25/2024 AGA 2021 & AGA 2021 bis 3,614 (3,614) 361,381 0.01\nBalance at June 30, 2024 524,772 201,858,649 52,477,188 0.01\nLiquidity agreement\nOn January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing\nthe previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended\n51\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nin 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms\nof the agreement, the investment services provider (“ISP”) is authorized to buy and sell the Company’s\ntreasury shares without interference from the Company in order to ensure the liquidity of the shares on\nthe Euronext market.\nThe liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from\nJanuary 1, 2023, and has been renewed again for a new period of 12 months from January 1, 2024.\nAt June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses\nresulting from share purchase, sale, issue and cancellation transactions during the first six months of\n2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact\non the Company’s results.\nOptions and share warrants (BSA and BSPCE)\nShare-based payments correspond to:\n- BSA share warrants granted to Company directors in 2017, with a subscription price set at\n€0.534;\n- BSA share warrants granted to Company service providers in 2018, with a subscription price\nset at €0.48;\n- BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.18;\n- BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group\nLLC, and Jérémy Goldberg, a member of PG Healthcare LLC, both service providers of\nInventiva, with a subscription price set at €0.29;\n- BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company’s\nDirectors;\n- BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at €2.45\n;\n- BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.20 and an exercise price\nof €2.51; and\n- BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group\nLLC, a service provider of Inventiva, with a subscription price set at €0.31 and an exercise price\nof €3.91.\nBSA and BSPCE plan characteristics\nAs of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021.\nThe BSPCE and BSA share warrant plans are described in the note 12.3 “Share warrants plans” of the\n2023 annual financial statements.\nNo new share warrants plan has been attributed in the first six months of 2024.\nMovements in BSPCE share warrants and BSA share warrants (in number of shares issuable\nupon exercise)\n52\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nNumber of\nExercice price Outstanding at Forfeited / Outstanding at exercisable\nType Grant Date (in euros) Jan 1, 2024 Issued Exercised Lapsed June 30, 2024 shares\nBSPCE - Plan 2021 04/16/2021 11.74 430,000 - - - 430,000 430,000\nTOTAL BSPCE share warrrants 430,000 430,000 430,000\nBSA - Plan 2017 05/29/2017 6.68 130,000 - - - 130,000 130,000\nBSA - Plan 2018 12/14/2018 6.07 116,000 - - - 116,000 116,000\nBSA 2019 06/28/2019 2.20 10,000 - - - 10,000 10,000\nBSA 2019 bis 03/09/2020 3.68 10,000 - - - 10,000 10,000\nBSA 2019 ter 03/09/2020 3.68 36,000 - - - 36,000 36,000\nBSA 2021 04/16/2021 11.74 14,333 - - - 14,333 14,333\nBSA 2023 05/25/2023 2.51 10,000 - - - 10,000 -\nBSA 2023 - 2 12/15/2023 3.91 20,000 - - - 20,000 -\nTOTAL BSA share warrants 346,333 346,333 316,333\nTotal share warrants 776,333 - - - 776,333 746,333\nAt June 30, 2024, a total of 430,000 BSPCEs (or 430,000 shares) and 346,333 BSAs were outstanding,\ncorresponding to a total of 776,333 shares, the maximum number of shares to be issued when all related\nconditions are met.\nFree share awards\nAGA free share award plans\nAs of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis,\nAGA 2023-1, and AGA 2023-2.\nNo bonus share award plan has been attributed in the first six months of 2024.\nMovements in AGA free shares (in number of shares issuable upon exercise)\nStock price\nat grant date Outstanding at Forfeited / Outstanding at\nType Grant Date (in euros) Jan 1, 2024 Granted Vested Lapsed June 30, 2024\nAGA - Plan 2021 - 1 04/16/2021 11.30 297,599 - (296,166) (1,433) -\nAGA - Plan 2021 - bis 12/08/2021 12.20 65,215 - (65,215) - -\nAGA 2023-1 05/25/2023 2.60 300,000 300,000 - - 600,000\nAGA 2023-2 12/15/2023 3.90 748,000 - - (23,350) 724,650\nTOTAL free shares 1,410,814 300,000 (361,381) (24,783) 1,324,650\nAt June 30, 2024, a total of 1,324,650 AGA bonus shares were outstanding.\nFollowing the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-\n1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant 300,000 free\nshares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the\nregulations of the AGA 2023-1 plan.\nFollowing the AGA 2021 and AGA 2021 bis acquisition period, a total of 361,381 shares were\ndefinitively acquired, resulting in a capital increase of €3,613.81.\nUpon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of\n361,381 shares were acquired, resulting in a capital increase of €3,613.81.\nThe free share award plan is described in the Note 12.4 “Bonus share award plans” of the annual\nconsolidated financial statements for the year ended on December 31, 2023.\nShare-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled\n€2.2 million for the six months ended June 30, 2024, compared to €2.0 million for the six months ended\nJune 30, 2023. They are recognized in personnel costs (see Note 5.2 – Operating expenses).\n53\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nPerformance units (“PAGUP”)\nAs of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.\nNo performance units award plan has been attributed in the first six months of 2024.\nReference Number of\nprice (in Outstanding at Outstanding at exercisable\nType Grant Date euros) Jan 1, 2024 Issued Exercised Convert AGA June 30, 2024 shares\nPAGUP 2023 05/25/2023 2.60 300,000 - - (300,000) - -\nTOTAL PAGUP 300,000 - - (300,000) - -\nAt June 30, 2024, no PAGUP shares were outstanding.\nFollowing the changes introduced by the French law n°2023-1107, the PAGUP 2023 granted on May\n25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted 300,000\nfree shares (governed by the AGA 2023-1 regulations) to Frédéric Cren, thereby lapsing the 300,000\nPAGUP 2023.\nThe performance units plan is described in the Note 12.5 “Performance units” of the annual\nconsolidated financial statements for the year ended on December 31, 2023.\n4.10 Financial debt\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nBank borrowings 42,509 27,206\nDerivatives instruments 13,569 10,265\nOther loans and similar borrowings(1) 4,302 3,719\nLease liabilities 5,761 6,565\nRoyalty certificates liabilities 7,263 6,327\nTotal debt 73,404 54,082\n(1) include accrued interests.\nMovements in the period break down as follows:\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nJanuary 1, 2024 54,083 44,390\nSubscription of derivatives instruments(2) 11,809 -\nSubscription of bank borrowings(1)(2) 13,102 -\nSubscription of lease liabilities 345 3,706\nIssue of royalty certificates - 5,100\nRepayment of bank borrowings (1,177) (2,485)\nRepayment of lease liabilities (1,173) (1,612)\nInterests on royalty certificates 936 1,227\nCapitalized interest 3,961 3,405\nChange in fair value of derivatives instruments(2) (8,506) 389\nExchange rate change 24 (38)\nJune 30, 2024 73,404 54,083\n(1) Net proceed\n(2) EIB’s loan and warrants.\n54\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nFrench state-guaranteed loan (“PGE”) and equity recovery loans (“PPR”)\nIn May 2020, the Company entered into three credit agreements pursuant to which it received\n€10.0 million in the form of state-guaranteed loans (Prêts Garantis par l’Etat, or “PGE”) which are\nprovided by a syndicate of French banks and guaranteed by the French government in the context of the\nCOVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the\nthird quarter of 2022. The amendments provide for reimbursements to be made over four years,\nbeginning in July 2022 for the loan from Crédit Agricole and in September 2022 for the loans from\nBpifrance and Société Générale.\nIn June 2022, the Company entered into three loan agreements with a syndicate of French banks for a\ntotal amount of €5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with\nBpifrance and the other two loan agreements were part of a stimulus economic plan (Prêts Participatifs\nRelance, or “PPR”) granted by Crédit Agricole Champagne-Bourgogne and Société Générale.\nThe PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government with an\ninitial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to\nalign with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the\nFrench government and feature an eight-year financing period and a four-year repayment period.\nThe PGE repayments in the first six months of 2024 amounted to €1.2 million.\nCredit facility agreement with the European Investment Bank\nOn May 16, 2022, the Company entered into the Finance Contract with the EIB for up to €50 million,\ndivided into two tranches of €25 million each.\n• On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized\ninterest for Tranche A is 8% and repayment is due in December 2026, four years after its\ndisbursement.\n• On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. –\nSignificant events in the first six months of 2024). Capitalized interest for Tranche B is 7% and\nrepayment is due in January 2027, three years after its disbursement.\nThe Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment\nfee, either at the election of the Company or as a result of EIB’s demand following certain prepayment\nevents, including a change of control or change in senior management of the Company.\nSubject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including\npayment default, misrepresentation, cross default), EIB may demand immediate repayment by the\nCompany of all or part of the outstanding loan. As of June 30, 2024 there was no demand of\nreimbursement of the outstanding loan. Tranche A of €25 million was recognized as financial debt at\namortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at\ninception and the borrowing costs of €0.1 million. The amortized cost of the loan is €15.4 million on\nDecember 31, 2023, and is € 21.1 million on June 30, 2024, with an effective interest rate of 21.9%. The\nfair value of the loan as of June 30, 2024, amount to €20.6 million, with a market rate of 22.9%.\nTranche B of €25 million was recognized as financial debt at amortized cost, which takes into account\nthe fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of €0.1\nmillion. The amortized cost of the loan is €15.0 million on June 30, 2024, with an effective interest rate\nof 32.7%. The fair value of the loan as of June 30, 2024, amount to €14.7 million, with a market rate of\n33.2%.\nThe capitalized interest for both Tranche A and Tranche B in the period amounted to €4.0 million.\n55\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDerivatives\nOn July 1, 2022, in connection with the Finance Contract (see section above “Credit facility agreement\nwith the European Investment Bank”), the Company entered into a warrant agreement as a condition to\nthe funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of €0.01\nand gives the right to subscribe to one share.\nThe number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by\nthe Company through one or more equity offerings, or through upfront or milestone payments, from the\ndate of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the\naverage price per share paid for the Company’s shares in its most recent qualifying equity offering or\n(ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price\nper share of the Company over the last 180 calendar days.\nThe EIB Warrants have a maturity of twelve years and are exercisable following the earliest to occur of\n(i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the\nFinance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants\nshall automatically be deemed null and void if they are not exercised within the twelve-year period.\nEach EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise\nprice (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has\nbeen adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB\nTranche A Warrant entitles its holder to subscribe for 1.20 ordinary shares in the Company. EIB is\nentitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB\nWarrants not yet exercised in certain of these occurrences.\nOn November 28, 2022, the Company issued 2,266,023 EIB Tranche A Warrants to EIB, in accordance\nwith the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022\nand Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A,\nrepresenting approximately 4.7% of the Company’s share capital as of June 30, 2024. The exercise price\nof the EIB Tranche A Warrants is €4.0152, if and when they may be exercised. The potential gross\nproceeds if all EIB Tranche A Warrants were exercised would amount to €9.1 million. The transactions\ncosts for the issuance of the EIB Tranche A Warrants amounted to €56 thousands.\nOn January 4, 2024, the Company issued 3,144,654 EIB Tranche B Warrants to EIB, representing\napproximately 5.2% of the Company’s share capital as of June 30, 2024, in accordance with the terms\nof the 6th resolution of the Combined General Shareholders' Meeting of January 25, 2023, and Article\nL. 225-138 of the French Commercial Code. The exercise price of the EIB Tranche B Warrants is €3.95,\nif and when they may be exercised. The potential gross proceeds if all EIB Tranche B Warrants were\nexercised would amount to €12.4 million. The transactions costs for the issuance of the EIB Tranche B\nWarrants amounted to €90 thousands.\nThe EIB Warrants do not meet the “fixed for fixed” criteria (non-cash settlement option which may\nresult in exchanging a variable number of shares for a variable price) and are accounted for as standalone\nderivative instruments. The Company’s put options meet the definition of a derivative that are valued\nwith the EIB Warrants.\nThe warrant agreement includes a put option: EIB may request the Company to buy back the EIB\nWarrants in cash. In this context the purchase price will be defined as the difference between the volume\nweighted average of the trading price of the ordinary shares over the last 90 trading days and the strike\nprice. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise\nthe put option.\nAt inception, the financial debts are split between i) a debt component accounted for at amortized cost,\nand ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at\n56\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nfair value through profit and loss) including a component corresponding to the put options.\nValuation approach\nThe fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach,\nincluding the put option and the attached cap.\nThis approach enables the estimation of the value of American options (that may be exercised during a\nspecific period of time) with complex way of exercise (the warrant holder may exercise the warrants on\nthe market based on the Company’s share price or exercise the put option based on the 90 days average\nshare price of the Company).\nThe Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the\nvaluation date, the volatility observed on the historical share price of the Company, and the contractual\nlifespan associated equity instruments.\nThe hypothesis and results are detailed in the following tables:\nBSA 2022 BSA 2024\nGrant date 11/28/2022 01/04/2024\nExpiration date 11/28/2034 01/04/2036\nNumber of BSA issued 2,266,023 3,144,654\nNumber of shares per BSA 1 1\nSubscription premium price per share (€) 0.01 0.01\nExercise price per share (€) 4.02 3.95\nValuation method Longstaff Schwartz Longstaff Schwartz\n57\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of November 28, 2022 As of December As of June 30,\nEIB Tranche A Warrants (Grant Date) 31, 2023 2024\nNumber of BSA outstanding 2,266,023 2,266,023 2,266,023\nNumber of shares per BSA 1.00 1.20 1.27\nStock price (€) 4.13 4.10 2.79\nMaturity (years) 12 10.9 10.4\nVolatility 68% 62% 59.6%\nCap of the put option (m€) 25.0 25.0 25.0\nRisk free rate Euribor 6M Euribor 6M Euribor 6M\nExpected dividends — — —\nFair Value (k€) 9,469 10,266 6,738\nUnit fair value (€) 4.18 4.53 2.97\nAs of January 4, 2024 As of June 30,\nEIB Tranche B Warrants (Grant Date) 2024\nNumber of BSA outstanding 3,144,654 3,144,654\nNumber of shares per BSA 1.00 1.00\nStock price (€) 4.12 2.79\nMaturity (years) 12 11.5\nVolatility 62% 59.6%\nCap of the put option (m€) 25.0 25.0\nRisk free rate Euribor 6M Euribor 6M\nExpected dividends — —\nFair Value (k€) 11,809 6,830\nUnit fair value (€) 3.76 2.17\nLease liabilities\nLease liabilities amount to €5.8 million as of June 30, 2024, and decreased by €0.8 million compared to\nDecember 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period\nof three or four years regarding the location of use. Lease liabilities are calculated using specific discount\nrates, in connection with the geographic area, the maturity of the debt, and the commencement date,\naccording to the method described in Note 3.2 of the consolidated financial statements as of December\n31, 2023. The rates for contracts in progress as of June 30, 2024 range from 1.89% to 5.18%.\nThe breakdown between long-term and short-term debt is as follows:\n58\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nJune 30, 2024 Between 1 and Between 3 and More than\nTotal Less than 1 year\nIn thousands of euros 3 years 5 years 5 years\nBank borrowings 42,509 3,229 36,164 2,225 890\nDerivatives 13,569 - 13,569 - -\nOther loans 4,302 42 4,260 - -\nLease liabilities 5,761 2,455 3,306 - -\nRoyalty certificates liabilities 7,263 - - - 7,263\nTotal debt 73,404 5,726 57,299 2,225 8,153\nDec. 31, 2023 Between 1 and Between 3 and More than\nTotal Less than 1 year\nIn thousands of euros 3 years 5 years 5 years\nBank borrowings 27,206 2,928 4,872 17,848 1,558\nDerivatives 10,265 − − 10,265 −\nOther loans and similar borrowings 3,719 82 - 3,636 -\nLease liabilities 6,565 2,298 4,267 - -\nRoyalty certificates liabilities 6,327 - - - 6,327\nTotal debt 54,082 5,308 9,140 31,749 7,885\nThe maturity of long-term debt and of short-term borrowings and debt is determined according to\ncontractual repayment terms as of June 30, 2024 and December 31, 2023.\nRoyalty Certificates liabilities\nOn August 31, 2023, the Company announced the issuance of the royalty certificates (“2023 Royalty\nCertificates”) for an aggregate amount of €5.1 million.\nThe 2023 Royalty Certificates are accounted at the inception at the fair value (€5.1 million on August\n31, 2023), and then at the amortized cost (€7.3 million on June 30, 2024 vs. €6.3 million on December\n31, 2023) with an effective interest rate of 31.9%.\nFair value as of June 30, 2024\nOn June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow\napproach, amounts to €9.1 million.\nThe fair value corresponds to the net present value of royalties, which depend on assumptions made by\nthe Company with regards to the probability of success of its studies, the markets sales of lanifibranor\nand the discount rate (27.9%). The discount rate has been estimated based on a reconciliation between\nthe Company’s business plan and the Company’s market capitalization as of June 30, 2024.\n4.11 Provisions\nThe Company has no provisions as of June 30, 2024, and December 31, 2023.\n4.12 Provisions for retirement benefit obligations\nRetirement benefit obligations are determined based on the rights set forth in the national collective\nbargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in\n59\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\naccordance with IAS 19 – Employee Benefits. These rights depend on the employee’s final salary and\nseniority within the Company at his/her retirement date.\nNet provision\nThe provision recorded in respect of defined benefit schemes at the end of each reporting period is\nshown in the table below:\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nRetirement benefit obligations 1,555 1,559\nTotal obligation 1,555 1,559\nGiven the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the\nprovision corresponds to the estimated obligation at those dates.\nChanges in the net provision\nChanges in the provision recorded in respect of defined benefit schemes break down as follows:\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nProvision at beginning of period (1,559) (1,234)\nExpense for the period (70) (228)\nActuarial gains or losses recognized in other comprehensive\n74 (97)\nincome\nProvision at end of period (1,555) (1,559)\nBreakdown of expense recognized for the period\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nService cost for the period (104) (183)\nInterest cost for the period (25) (46)\nBenefits for the period 59 -\nTotal (70) (228)\n4.13 Other current and non-current liabilities\nOther non-current liabilities\nAs of June 30, 2024 and December 31, 2023 non-current liabilities amount to €1.0 million related to an\nagreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance\nfor certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ.\nOther current liabilities\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nEmployee-related payables 1,739 1,869\nAccrued payroll and other employee-related taxes 1,801 1,540\nSales tax payables 2,140 3,569\nOther accrued taxes and employee-related expense 142 164\nOther miscellaneous payables 12 23\nOther current liabilities 5,834 7,165\nNo discounting has been performed on other current liabilities as their maturity is less than one year at\nthe end of the period.\n60\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAccrued payroll and other employee-related taxes mainly relate to payables to social security and\nemployee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024.\nOther accrued taxes and employee-related expenses concern provisions for payroll taxes, such as\nprofessional training charges, apprenticeship tax, the employer’s contribution to construction investment\nin France and the payroll tax.\n4.14 Trade payables and short-term contract liabilities\nIn thousands of euros June 30, 2024 Dec. 31, 2023\nTrade payables 36,583 37,679\nShort-term contract liabilities 3 6\nOther current liabilities - -\nTrade payables and other current liabilities 36,586 37,685\nNo calculations have been made to discount trade payables to present value as payment is due within\none year at the end of the reporting period.\nTrade payables\nTrade payables break down as follows:\nJune 30, 2024 Dec. 31, 2023\nIn thousands of euros\nDue in 30 days 26,217 24,995\nDue in 30-60 days 10,362 12,684\nDue in more than 60 days 4 0\nTrade payable 36,583 37,679\nAs of June 30, 2024, trade payables mainly included accrued liabilities for €24.0 million of which €20.2\nmillion relate to scientific projects.\nAs of June 30, 2024, trade payables decreased by €1.1 million compared to December 31, 2023. Trade\npayables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than\n3%).\n4.15 Financial assets and liabilities\nThe table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting\ncategory:\n61\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nJune 30, 2024\nFinancial\nBook value Financial\nassets/liabilitie Liabilities\non the assets\ns carried at carried at\nstatement of carrieds at Fair value\nfair value amortized\nfinancial amortized\nthrough profit cost\nposition cost\nFinancial assets or loss\nLong-term accrued income 0 - 0 - 0\nLong-term deposit accounts - - - - -\nAdvance payment 1,047 - 1,047 - 1,047\nCurrent accrued income 1,687 - 1,687 - 1,687\nShort-term deposit accounts - - - - -\nTrade receivables 809 - 809 - 809\nOther receivables 2,518 - 2,518 - 2,518\nCash and cash equivalents 10,147 - 10,147 - 10,147\nTotal 16,208 - 16,208 - 16,208\nFinancial liabilities\nLong-term debt (1) 46,846 - - 46,846 45,994\nDerivative instruments 13,569 13,569 - - 13,569\nRoyalty certificates liabilities 7,263 - - 7,263 9,050\nShort-term debt 5,726 - - 5,726 5,726\nTrade payables 36,583 - - 36,583 36,583\nOther miscellaneous payables 12 - - 12 12\nTotal 109,998 13,569 - 96,429 110,933\n(1) See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB\n62\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nDec. 31, 2023\nFinancial\nBook value Financial\nassets/liabilitie Liabilities\non the assets\ns carried at carried at\nstatement of carrieds at Fair value\nfair value amortized\nfinancial amortized\nthrough profit cost\nposition cost\nFinancial assets or loss\nLong-term deposit accounts 9,000 - 9,000 - 9,000\nLong-term security deposits 8 - 8 - 8\nAdvance payment 1,047 - 1,047 - 1,047\nShort-term deposit accounts 70 - 70 - 70\nTrade receivables 3,807 - 3,807 - 3,807\nOther receivables 857 - 857 - 857\nCash and cash equivalents 26,918 - 26,918 - 26,918\nTotal 41,706 - 41,706 - 41,706\nFinancial liabilities\nLong-term debt (1) 32,181 - - 32,181 29,701\nDerivative instruments 10,265 10,265 - — 10,265\nRoyalty certificates liabilities 6,327 - - 6,327 9,617\nShort-term debt 5,308 - - 5,308 5,308\nTrade payables 37,679 - - 37,679 37,679\nOther miscellaneous payables 23 - - 23 23\nTotal 91,784 10,265 - 81,518 92,594\nNote 5. Notes to the interim condensed consolidated statement of (income) loss\n5.1 Revenues and other income\nFor the six months ended June 30, 2024, and June 30, 2023\nOperating income Six months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nRevenue 41 1,901\nTotal revenue 41 1,901\nTax credits 2,630 3,631\nSubsidies 5 3\nOther 58 1,087\nOther income 2,693 4,721\nTotal revenue and other income 2,734 6,622\nOther operating income\nThe Research Tax Credit (\"CIR\") generated over the first six months of the fiscal year amounts to €2.7\nmillion in 2024 as in 2023.\nAs of June 30, 2023, other operating income are composed of:\n• The R&D Tax Research Credit from Inventiva Inc amounting to €1.0 million, compared to €0.8\nmillion in tax income as of June 30, 2024;\n• The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to €0.3 million as\nof June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3,\nand the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to\n€0.7 million, compared to €2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as\na reduction in research and development expenses.\n5.2 Operating expenses\n63\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended June 30, 2024 Research and Marketing – General and\ndevelopment Business administrative Total\nIn thousands of euros\ncosts development expenses\nDisposables (887) - - (887)\nEnergy and liquids (447) - - (447)\nPatents (643) - - (643)\nStudies (34,073) - - (34,073)\nMaintenance (526) - - (526)\nFees (118) (2) (2,675) (2,795)\nIT systems (405) (6) (33) (444)\nSupport costs (including taxes) - - (375) (375)\nPersonnel costs (7,637) (153) (2,600) (10,391)\nDepreciation, amortization and provisions (1,732) - (122) (1,854)\nInsurances - - (921) (921)\nOther operating expenses (352) (437) (975) (1,764)\nTotal operating expenses (46,822) (598) (7,701) (55,122)\nSix months ended June 30, 2023 Research and Marketing – General and\nBusiness administrative Total\nen milliers d’euros development costs development expenses\nDisposables (943) - - (943)\nEnergy and liquids (479) - - (479)\nPatents (257) - - (257)\nStudies (42,847) - - (42,847)\nMaintenance (459) - - (459)\nFees (61) - (1,884) (1,945)\nIT systems (440) (9) (50) (498)\nSupport costs (including taxes) - - (343) (343)\nPersonnel costs (7,065) (126) (2,347) (9,538)\nDepreciation, amortization and provisions (1,061) - (104) (1,166)\nInsurances - - (1,121) (1,121)\nOther operating expenses (450) (570) (964) (1,985)\nTotal operating expenses (54,062) (705) (6,812) (61,580)\nPersonnel costs and headcount\nMarketing –\nResearch and General and\nSix months ended June 30, 2024 Business\ndevelopment administrative Total\ndevelopment\ncosts expenses\nexpenses\nIn thousands of euros\nWages, salaries and similar costs (4,824) (120) (1,237) (6,181)\nPayroll taxes (1,312) (10) (563) (1,886)\nProvisions for retirement benefit obligations (51) - (35) (86)\nShare-based payments (1,450) (24) (765) (2,238)\nTotal personnel costs (7,637) (153) (2,600) (10,391)\nThe Company has 123 employees as of June 30, 2024, of which 112 are employed by Inventiva S.A.\nand 11 are employed by Inventiva Inc.\n64\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nSix months ended June 30, 2023 Marketing –\nResearch and General and\nBusiness\ndevelopment administrative Total\ndevelopment\nIn thousands of euros costs expenses\nexpenses\nWages, salaries and similar costs (4,399) (104) (1,191) (5,694)\nPayroll taxes (1,222) (10) (476) (1,708)\nProvisions for retirement benefit obligations (61) - (29) (90)\nShare-based payments (1,383) (13) (650) (2,046)\nTotal personnel costs (7,065) (126) (2,347) (9,538)\nThe Company had 117 employees as of June 30, 2023, including 105 people employed by Inventiva\nS.A. and 12 people employed by Inventiva Inc.\n5.3 Other operating income and expenses\nOther operating income and expenses break down as follows:\nSix months ended\nIn thousands of euros June 30, 2024 June 30, 2023\nOther operating income 160 -\nOther operating expenses (22) (44)\nOther operating income and expenses 138 (44)\n5.4 Financial income and expenses\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended\nIn thousands of euros\nJune 30, 2024 June 30, 2023\nIncome from cash equivalents 430 564\nForeign exchange gains 157 187\nGain on fair value variation 8,506 1,623\nTotal financial income 9,093 2,373\nInterest cost (5,218) (1,941)\nForeign exchange losses (323) (683)\nOther financial expenses (46) (23)\nTotal financial expenses (5,586) (2,646)\nNet financial income 3,507 (273)\nIn the first six months of 2024, financial income is mainly composed of a €8.5 million change in fair\nvalue of the EIB Warrants issued in connection with Tranches A and B.\nFinancial expenses mainly include exchange losses, financial interests related to PGE and PPR credit\nagreements and the financing agreement with the EIB, and financial interests related to lease liabilities.\n5.5 Share of net profit – Equity method\nThe tables below provide the summarized statement of income (loss) for the associate Hepalys. The\ninformation disclosed reflects the amounts presented in the financial statements of Hepalys and not the\nCompany's share of those amounts. They have been amended to reflect adjustments made by the\n65\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nCompany when using the equity method, in this case fair value adjustments. The tables below provide\nalso the reconciliation between Hepalys' loss and the share of net loss recognized in the Company\nstatement of financial position.\n(in thousands of euros) For the period started January 1, 2024, to June 30, 2024\nResearch and development costs (51)\nGeneral and administrative expenses (1,475)\nNet operating loss (1,526)\nFinancial income 20\nFinancial expenses (3)\nNet financial income 17\nIncome (expense) tax -\nNet loss for the period (1,509)\nExchange difference on translation of foreign operations (1,964)\nItems that will be reclassified subsequently to profit or loss (3,473)\nTotal comprehensive loss (3,473)\nGroup's share in % 14.64%\nShare of net profit 235\nElimination of downstream sales (66)\nShare of net profit - Equity method 168\nIn 2024, Hepalys did not generate any sales.\n5.6 Income tax\nThe income tax calculation for interim periods is set out in Note 3.3 – Specific disclosure requirements\nfor unaudited interim financial statements.\nAs the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered\nunlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December\n31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A.\nThe €119 thousand income tax recorded was related Inventiva Inc.\n5.7 Basic and diluted loss per share\nBasic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the\nCompany by the weighted average number of ordinary shares outstanding during the six-month period\nended June 30, 2024.\nFor the six months ended June 30, 2024 and June 30, 2023\nSix months ended\nJune 30, 2024 June 30, 2023\nNet loss for the period (49,029) (55,269)\nWeighted average number of shares outstanding used to calculate\n51,982,093 42,044,796\nbasic/diluted loss per share(1)\nBasic/diluted loss per share (0.94) (1.31)\n(1) In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group\nas of June 30, 2024 and 2023.\n66\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the\nsame as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and\nPAGUP) are not included as their effects would be anti-dilutive.\nNote 6. Other financial information\n6.1 Commitments related to operational activities\nObligations under the terms of subcontracting agreements\nIn the ordinary course of its business, the Company enters into agreements with CROs for clinical trials,\nas well as with contract manufacturing organizations (“CMOs”) for clinical and commercial supply\nmanufacturing, commercial and pre-commercial activities, research and development activities and\nother services and products for operating purposes. The Company’s agreements generally provide for\ntermination with specified periods of advance notice.\nSuch agreements are generally cancellable contracts and are not included in the description of the\nCompany’s contractual obligations and commitments.\nCommitments given and received\nJune 30, 2024 December 31, 2023\nIn thousands of euros\nCRO1 175,461 183,366\nCMO 6,846 5,733\nLease 7,592 8,595\nOthers 20,361 23,442\nTotal commitments given 210,261 221,136\nAgreements concerning the provision of facilities 296 260\nTotal commitments received 296 260\n1Including CRO with Pharmaceutical Research Associates B.V.\nCRO Contract with Pharmaceutical Research Associates Group B.V.\nIn April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered\ninto an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract\naims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United\nStates.\nThe Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa\nclinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical\ntrial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2\ninhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this\nagreement amounts to an aggregate of €13.3 million.\nOn June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered\ninto a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA.\nThe amendment updates the provisions relating to study information following changes to the trial\nprotocol. In June 2024, the Company entered into a new amendment, the new commitment amount to\nPRA is €254.3, with a bonus or malus will decrease from €3.4 million to €0.7 million in 2026. The\ncommitment also includes €20.2 million to be paid by CTTQ.\n67\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nAs of June 30, 2024, the amount remaining to be paid under the contract is €158.6 million.\n6.2. Related-party transactions\nNo other new material transactions were entered into with related parties of the Company during the\nfirst six months of 2024.\n6.3 Financial risk management\nThrough its business activities, the Company is exposed to various types of financial risk: foreign\nexchange risk, credit risk and liquidity risk.\nThe financial risks are those described in the financial statements prepared in accordance with IFRS for\nthe year ended December 31, 2023, as updated for risks regarding liquidity which are described in the\nNote 3.4 — Going Concern.\n6.4 Events after the reporting date\nUpdate on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.\nOn July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating\nlanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both\ncohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the\nexploratory cohort of NATiV3.\nThe first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024,\nand topline results are expected at the beginning of the second half of 2026. The Company’s patent\nportfolio strengthened with new a patent secured in Japan that that provides intellectual property rights\non protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039,\nexcluding any potential patent term adjustments or extensions that may provide additional protection\nuntil 2043.\nIssuance of royalty certificates\nOn July 18, 2024, the Company announced the issuance of 201 royalty certificates (the “2024 Royalty\nCertificates”) for aggregate gross proceeds of approximately €20.1 million. The 2024 Royalty\nCertificates will provide the holders thereof with the right to an annual payment of royalties equal to 3%\nof the future net sales, if any, of lanifibranor beginning on the fiscal year following the start of the sales\nof lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States\nof America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs the\nfirst, if at all. The 2024 Royalty Certificates have a term of 14 years following the date of issue.\nApproving of patent application\nOn July 25, 2024 the Company announced that the Japan Patent Office (“JPO”) approved Inventiva’s\npatent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients\nwith cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent\nterm adjustments or extensions that may provide additional protection.\nFinancing in three tranches for a maximum amount of €348 million\nThe Company announced the following financing on 14 October 2024 structured in three tranches:\n(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific\ncategory of beneficiaries (“à catégorie de personnes”), of new ordinary shares at a gross value, including\nissuance premium, of €94.1 million through the issuance of 34,600,507 new ordinary shares, par value\n€0.01 per share (each, a “T1 New Shares”), and 35,399,481 prefunded warrants to subscribe for shares\n68\nINTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||\nin the Company at a price outstanding of €0.01 per new ordinary share, each giving the right, in the\nevent of exercise, to one new ordinary share (the “T1 BSAs”);\n(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”), of new ordinary shares, par\nvalue €0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each,\na “T1bis New Shares”), for a total amount of €21.4 million (excluding exercise of pre-funded warrants);\n(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription\nrights reserved to certain identified investors (“à personne dénommée”) subject to operational conditions\nto be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before\nDecember 16, 2024, (or prefunded warrants) to which share warrants (the “ABSAs”) are attached for a\ntotal amount of €116,000,000. Each ABSA will consist of a number of new ordinary shares with a par\nvalue of €0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a\n“T2 New Share”) to which will be attached a number warrants exercisable at an exercise price of €1.50\n(each, a “T3 BSA”) allowing the subscription of a number of new ordinary shares of the Company for\na maximum total amount of €116,000,000.\nThe subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024,\nand the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October\n17, 2024, subject to the absence of any material adverse event between the signing of the agreements\nand the settlement-delivery of the T1 New Shares and the T1 BSA.\nAmendment to the exclusive license and collaboration agreement with CTTQ\nOn October 11, 2024, the Company has entered into an amendment (the “Amendment”) to the exclusive\nlicense and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (“CTTQ”),\ndated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription\ncommitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three\ntranches, for a total gross amount of at least €180,000,000 (the “Fund Raising”), CTTQ shall pay to the\nCompany (i) $10,000, 000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants\nin the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000\nin the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon\npublication by the Company of the pivotal data announcing that the primary endpoint or one of the two\nkey secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met.\nUnder the terms of the Amendment, the total amount of potential clinical, regulatory and commercial\nmilestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been\nreduced to a low figure.\n69\n4. Other information\n4.1. Table of delegations\nOn June 20, 2024, shareholders met in a Combined General Meeting to determine the financial authorizations to be granted to the Board of Directors.\nThe current delegations and their use are presented in the table below:\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nDelegation of authority to the Board of Directors to\nincrease the share capital by issuance of ordinary shares\nor securities giving access to ordinary shares, to be Capital increase:\nissued immediately or in the future by the Company, EUR 700,000\nwith shareholders’ preemptive subscription rights, in Twenty-first Securities giving\n26 months None\naccordance with the provisions of articles L.225-129 resolution access to capital to\nand L.22-10-49 and seq. of the French Commercial be issued: EUR Capital increase:\nCode, and in particular articles L.225-129-2, L.225-132 150,000,000 EUR 700,000\nto L.225-134, and the provisions of articles L.228-91\nSecurities giving\nand seq. of the French Commercial Code\naccess to capital to\nbe issued: EUR\n150,000,000\nDelegation of authority to the Board of Directors to\nincrease the share capital of the Company by issuance Capital increase:\nof EUR 700,000\nordinary shares or securities giving access to the share Twenty-second Securities giving\n26 months Refer to (1) below None\ncapital of the Company, immediately or in the future, resolution access to capital to\nwithout shareholders’ preemptive subscription rights, be issued: EUR\nby way of public offerings, excluding offers referred to 150,000,000\nin Article L.411-2- 1° of the French Code monétaire et\n70\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nfinancier, in accordance with the provisions of Articles\nL.225-129 and L.22-10-49 and seq. of the French\nCommercial Code, and in particular Articles L.225-\n129-2, L.22-10-51 and L.22-10-52, and with the\nprovisions of Articles L.228-91 and seq. of the French\nCommercial Code\nDelegation of authority to the Board of Directors to\nincrease the share capital by issuance of ordinary shares\nor securities giving access to ordinary shares, to be Capital increase:\nissued immediately or in the future by the Company, EUR 625,000 and up\nwithout shareholders’ preemptive subscription rights, to the limit of 30%\nby way of public offerings referred to in Article L.411- of the share capital\nTwenty-third\n2 1° of the French Code monétaire et financier, in 26 months per year. Refer to (1) below None\nresolution\naccordance with the provisions of articles L.225-129 Securities giving\nand seq. and article L.22-10-49 of the French access to the capital\nCommercial Code, and in particular articles L.225-129- to be issued: EUR\n2, L.22-10-51 and L.22-10-52, and the provisions of 150,000,000\narticles L.228-91 and seq. of the French Commercial\nCode\nAuthorization and/or delegation to the Board of\nDirectors to set the issuance price on the capital\nincreases by way of public offerings, without 10% of the share\nshareholders’ preemptive rights, pursuant to the terms Twenty-fourth capital per 12-month\n26 months Refer to (2) below None\nset by the General Shareholders' Meeting, and up to the resolution period from June 20,\nlimit of 10% of the share capital, in accordance with the 2024\nprovisions of Article L.22-10-52 of the French\nCommercial Code\n71\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nDelegation of authority to the Board of Directors to\nincrease the share capital of the company by issuance\nof ordinary shares or securities giving access to Decision of the\nCapital increase:\nordinary shares of the Company, immediately or in the Board of Directors on\nEUR 700,000\nfuture, reserved for certain specific categories of 11/10/2024: issue of\nTwenty-fifth Securities giving\nbeneficiaries, without shareholders’ preemptive 18 months Refer to (3) below 34.600.507 T1 New\nresolution access to the capital\nsubscription rights4, in accordance with Articles L.225- Shares and\nto be issued: EUR\n129 and seq. and L.22-10-49 of the French Commercial 35.399.481 T1\n150,000,000\nCode, and in particular Articles L.225-129-2, L.225- Warrants.\n129-4, L.22-10-51, L.225-138, L.228-91 and seq. of the\nFrench Commercial Code\nDelegation of authority to the Board of Directors to\ndecide to issue ordinary shares to be issued\nimmediately or in the future by the Company, without Twenty-sixth Capital increase:\n18 months Refer to (4) below None\nshareholders' preemptive subscription right in favor of resolution EUR 250,000,000\na category of persons meeting certain specified\ncharacteristics in the context of an equity financing\n4 The categories of beneficiaries must have one of the following characteristics: (i) natural or legal persons (including companies), trusts or investment funds, or other investment vehicles, in any form, established under\nFrench or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or (ii) companies, institutions or entities, in any form, French or foreign, exercising a significant\npart of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or (iii) French or foreign investment services companies, or any\nforeign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities\nthat are being issued.\n72\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nagreement on the American market known as \"At-the-\nmarket\" or \"ATM\"\nAuthorization to the Board of Directors to increase the\n26 months or 18\nnumber of securities to be issued as part of share capital\nTwenty-seventh months (if used in the 15% of the initial Same price as the\nincreases with or without shareholders’ preemptive None\nresolution context of resolution issuance initial issuance\nsubscription rights, in accordance with Articles L.225-\n25 or resolution 26)\n135-1 and R.225-118 of the French Commercial Code\nDelegation of authority to the Board of Directors to\nincrease the share capital of the company by issuance\nof ordinary shares or securities giving access to Capital increase:\nordinary shares of the Company, immediately or in the EUR 420,000\nfuture, as part of a public exchange offer initiated by Twenty-eight Securities giving\n26 months None\nthe Company, in accordance with Articles L.225-129 resolution access to the capital\nand seq. and L.22-10-49 of the French Commercial to be issued: EUR\nCode, in particular Articles L.225-129-2 and L.22-10- 150,000,000\n54, and Articles L.228-91 and seq. of the French\nCommercial Code\n73\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nCapital increase:\nDelegation of authority to the Board of Directors to within the limit\nincrease the share capital of the company by issuance provided for by the\nof ordinary shares or securities giving access to laws and regulations\nordinary shares of the Company, immediately or in the in force at the time\nfuture, in consideration for contributions in kind up this delegation is\nwithin the limits set by laws and regulations, excluding Twenty-ninth used (currently ten\n26 months None\nthe case of a public exchange offer initiated by the resolution (10) % of the share\nCompany, in accordance with the provisions of Articles capital over a twelve\nL.225-129 et seq. and L.22-10-49 of the French (12) month period)\nCommercial Code, in particular Articles L.225-129-2 Securities giving\nand L.22-10-53, and the provisions of Articles L.228- access to the capital\n91 and seq. of the French Commercial Code to be issued: EUR\n150,000,000\nDelegation of authority granted to the Board of\nDirectors to increase the share capital by issuing\nordinary shares or securities giving access to ordinary\nshares to be issued immediately or in the future by the\nCapital increase:\nCompany reserved for members of a company savings Thirtieth resolution 26 months Refer to (5) below None\nEUR 3,000\nplan to be set up by the Company in accordance with\nthe conditions set out in Articles L.3332-18 and seq. of\nthe French Labour Code, without shareholders' pre-\nemptive subscription rights.\n74\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\nAuthorization to the Board of Directors to increase the\nshare capital of the Company by incorporating reserves,\nThirty-first Capital increase:\nprofits or premiums, in accordance with the provisions 26 months None\nresolution EUR 20,000\nof Articles L.225-129-2 and L.22-10-5 of the French\nCommercial Code\nCapital increase: 5%\nAuthorization for the Board of Directors to grant free of the share capital\nshares to employees and/or certain corporate officers, Thirty-second on the date of the\n38 months N/A None\nin accordance with Articles L.225-110-59 and L.225-resolution Board of Directors'\n197-2 of the French Commercial Code decision to grant\nthem\nAuthorization to the Board of Directors to grant\ncompany's' share subscription and/or purchase options\nCapital increase: 5%\nto corporate officers and employees of the Company or\nof the share capital\nof companies in the group, entailing the waiver by the\nThirty-third on the date of the\nshareholders of their preemptive subscription rights to 38 months Refer to (6) below None\nresolution Board of Directors'\nthe shares issued as a result of the exercise of\ndecision to grant\nsubscription options, in accordance with Articles\nthem\nL.225-177 and seq. and L. 22-10-56 of the French Capital increase:\nCommercial Code EUR 700,000\nDelegation of authority to the Board of Directors to 600,000 ordinary\ndecide on the issue of ordinary share subscription Thirty-fourth share subscription\n18 months Refer to (7) below None\nwarrants, without shareholders' preemptive resolution warrants Capital\nsubscription rights, to the benefit of categories of increase: EUR 6,000\n75\nFinancial authorizations approved by the Methods of\nPeriod of validity Maximum nominal Maximum common Use of the\nCombined General Shareholders’ Meeting of June Resolution determining the issue\nfrom June 20, 2024 amount nominal amount delegation\n20, 2024 price\npersons5, in accordance with Articles L.225-138,\nL.225-129-2 and L.228-91 and seq. of the French\nCommercial Code\n(1) The issue price will be determined as follows: (i) the issue price of the shares to be issued under this resolution will be at least equal to the minimum authorized by the legislation in force\n(as of the date hereof, the weighted average of the prices for the last three trading sessions on the regulated market of Euronext in Paris preceding the start of the public offering, possibly\nreduced by a maximum discount of 10%), and (ii) the issue price of the securities to be issued under this resolution other than shares shall be such that the amount received immediately\nby the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities, at least equal\nto the amount referred to in (i) above.\n(2) The combined General Meeting of June 20, 2024 delegated to the Board of Directors the power to set the issue price of the shares within the limit provided for by the laws and regulations\nin force at the time this delegation is used (currently ten (10) % of the share capital over a twelve (12) month period), in accordance with the following conditions: (a) the issue price must\nbe at least equal to: (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting\nof the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris over a period chosen by the Board of Directors\ncomprising between three and seven consecutive trading sessions out of the last 30 trading sessions prior to the setting of the issue price; possibly reduced by a maximum discount of\n15%, the Board of Directors being free to use either of the two options set out above; and (b) the issue price of securities other than shares shall be such that the amount received\nimmediately by the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities,\nat least equal to the amount referred to in (a) above. In the absence of a minimum amount provided for by the laws and regulations in force as referred to in the 22nd and 23rd resolutions,\nthe Board of Directors is empowered to set the issue price of the securities to be issued under these resolutions in accordance with the following conditions: (i) the issue price must be at\nleast equal to: (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting of the\nissue price, or (b) the volume-weighted average of the Company's share prices on the regulated market of Euronext in Paris selected from a period comprising between three and seven\nconsecutive trading sessions among the last 30 trading sessions prior to the setting of the issue price, possibly reduced by a maximum discount of 15%, the Board of Directors being free\n5 Targeted categories: (i) executive employees or executive officers or members of the Company's management team who are not corporate officers, or (ii) members of the\nBoard of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of\nthe Company or one of its subsidiaries, or consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service\nagreement with the Company in force at the time of use of this delegation by the Board of Directors, or (iii) employees of the Company.\n76\nto use either of the two formulas set out above, and (ii) the issue price of the securities to be issued under this resolution, other than shares, will be such that the amount immediately\nreceived by the Company plus, where applicable, any amount that may subsequently be received by the Company is, for each share issued as a result of the issue of these securities, at\nleast equal to the amount referred to in paragraph (i) above.\n(3) The issue price must be at least equal to : (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading\nsession preceding the setting of the issue price; or (b) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive\ntrading sessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being\nfree to use either of the two options set out above; and (ii) (a) the issue price of shares that may result from the exercise, conversion, exchange or redemption of securities giving access\nto the Company's capital issued under this authorization may be set, at the discretion of the Board of Directors, by reference to a calculation formula defined by the Board and applicable\nafter the issue of said securities (for example, on exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be applied, if the Board of\nDirectors deems it appropriate, on the date of application of the said formula (and not on the date of issue of the securities), and (b) the issue price of the securities to be issued under this\nresolution, other than shares, shall be such that the amount immediately received by the Company plus, if applicable, the amount that may subsequently be received by the Company is,\nfor each share issued as a result of the issue of these securities, at least equal to the amount referred to in paragraph (i) above.\n(4) The issue price must be at least equal to : (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session\npreceding the setting of the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive trading\nsessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being free to\nuse either of the two options set out above\n(5) The issue price(s) of the new shares or securities to be issued pursuant to this resolution will be determined in accordance with Article L.3332-19 of the French Labour Code, and resolves\nto set the maximum discount at 20%. However, the General Meeting expressly authorizes the Board of Directors to reduce or waive the discount, in particular to take account of the\nregulations applicable in the countries where the offer will be implemented.\n(6) The exercise price of the options granted under this resolution will be set by the Board of Directors as follows: (i) the exercise price of options to subscribe for ordinary shares may not\nbe less than 80% of the average of the prices quoted for the Company's shares on the regulated market Euronext Paris over the twenty (20) trading sessions preceding the day on which\nthe options are granted, and (ii) the exercise price of options to purchase shares may not be less than 80% of the average purchase price of the shares held by the Company under Article\nL. 22-10-61 of the French Commercial Code or, as the case may be, of the share buyback program authorized by the 19th resolution submitted to this General Meeting (i.e. January 25,\n2023) under Article L.22-10-62 of the French Commercial Code or of any share buyback program applicable previously or subsequently.\n(7) The issue price of a BSA 2024 will be determined by the Board of Directors on the date of issue of the BSA 2024, depending on their characteristics, and will in any event be at least\nequal to 8% of the market value of an ordinary share in the Company on the date of allocation of the BSA 2024, this market value corresponding to the weighted average of the prices\nfor the last twenty (20) trading sessions preceding the date of allocation of the said BSA 2024 by the Board of Directors for as long as the Company's shares are admitted to trading on\nthe regulated market of Euronext in Paris.\n77"
        },
        {
          "title": "Securities note – n° 24-432 (only in French)",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/10/IVA-Note-d_operation-VF-avec-numero-dapprobation.pdf",
          "content": "INVENTIVA\nSociété anonyme au capital social de 524.771,88 euros\nSiège social : 50 rue de Dijon, 21121 Daix, France\nRCS Dijon 537 530 255\nNOTE D’OPERATION\nMise à la disposition du public dans le cadre d’une augmentation de capital avec suppression du droit préférentiel de souscription\nau profit de catégories de personnes conformément à l'article L. 225-138 du Code de commerce, au prix de souscription unitaire\nde 1,35 euro par émission de 34.600.507 actions ordinaires nouvelles d’une valeur nominale de 0,01 euro (les « Actions\nNouvelles T1 ») et 35.399.481 bons de souscription d'actions préfinancés de la Société (les « BSA T1 ») chacun donnant droit,\nen cas d’exercice et au prix d’exercice de 1,35 euro, à une action ordinaire nouvelle et dont la caractéristique principale est que\nle prix d’exercice est libéré par anticipation à hauteur de 1,34 euro par BSA T1 au jour de l’émission des BSA T1 (ensemble,\nl’émission des Actions Nouvelles T1 et des BSA T1, l' « Opération »), à l’occasion de l’admission sur le marché réglementé\nd’Euronext à Paris (« Euronext Paris ») :\n- de 34.600.507 Actions Nouvelles T1, d’une valeur nominale de 0,01 euro ; et\n- d’un maximum de 35.399.481 actions ordinaires nouvelles, d’une valeur nominale unitaire de 0,01 euro, en cas\nd’exercice de la totalité des BSA T1, au prix unitaire de 1,35 euro (dont 1,34 euro aura été libéré par anticipation au\njour de l’émission des BSA T1) (les « Actions Issues des BSA T1 »).\nSous réserve de l’approbation des résolutions nécessaires par l’assemblée générale des actionnaires de la Société devant se tenir\nau plus tard le 16 décembre 2024 (l’ « Assemblée Générale ») et certaines autres conditions opérationnelles, il est également\nenvisagé (i) une deuxième augmentation de capital avec suppression du droit préférentiel de souscription au profit de personnes\ndénommées conformément à l'article L. 225-138 du Code de commerce par l'émission d’actions ordinaires nouvelles d’une\nvaleur nominale de 0,01 euro ou de bons de souscription d’actions préfinancés chacun donnant droit, en cas d’exercice, à une\naction ordinaire nouvelle (chacune, une « Action Nouvelle T1bis ») qui permettrait une levée de fonds potentielle d’un montant\ntotal de 21,4 millions d’euros (avant exercice des bons de souscription d’actions préfinancés) euros (ii) une troisième\naugmentation de capital avec suppression du droit préférentiel de souscription au profit de personnes dénommées conformément\nà l'article L. 225-138 du Code de commerce par l'émission d’actions à bons de souscription d’action (ou de bons de souscription\nd’actions préfinancés à bons de souscription d’actions) (les « ABSA ») pour un montant total prime d’émission incluse de 116\nmillions d’euros. Chaque ABSA consistera en un nombre d'actions ordinaires nouvelles d’une valeur nominale de 0,01 euro ou\nde bons de souscription d’actions préfinancés chacun donnant droit, en cas d’exercice, à une action ordinaire nouvelle (chacune,\nune « Action Nouvelle T2 ») auxquelles seront attachées un nombre de bons de souscription d’actions pouvant être exercés à\nun prix d’exercice de 1,50 € (chacun, un « BSA T3 ») permettant de souscrire un nombre d'actions ordinaires nouvelles de la\nSociété (les « Actions Issues des BSA T3 ») pour un montant total maximum de 116 millions d’euros. La Société demandera\nl’admission sur Euronext Paris des Actions T1bis, des Actions Nouvelles T2 et des Actions Issues des BSA T3.\nLe prospectus est composé de la présente note d’opération, d’un résumé du prospectus et du document d’enregistrement\nuniversel déposé le 3 avril 2024 ainsi que son amendement déposé le 14 octobre 2024.\nLe prospectus a été approuvé par l'Autorité des marchés financiers (l' « AMF »), en sa qualité d'autorité compétente au titre du\nrèglement (UE) 2017/1129 (le « Règlement Prospectus »). L'AMF approuve ce prospectus après avoir vérifié que les\ninformations qu'il contient sont complètes, cohérentes et compréhensibles.\n1 | 60\nLe prospectus a été approuvé le 14 octobre 2024 et est valide jusqu’au 14 octobre 2025 et devra, pendant cette période et dans\nles conditions de l'article 23 du Règlement Prospectus, être complété par un supplément au prospectus en cas de faits nouveaux\nsignificatifs ou d'erreurs ou inexactitudes substantielles. Le prospectus porte le numéro d'approbation suivant : 24-432.\nCette approbation ne doit pas être considérée comme un avis favorable sur l’émetteur et sur la qualité des titres financiers faisant\nl’objet du prospectus. Les investisseurs sont invités à procéder à leur propre évaluation quant à l’opportunité d’investir dans les\ntitres financiers concernés.\nIl est précisé que l’approbation du présent prospectus par l’AMF ne porte que sur les 34.600.507 Actions Nouvelles T1 et les\n35.399.481 Actions Issues des BSA T1. L’admission aux négociations sur Euronext Paris des Actions Nouvelles T1bis, des\nActions Nouvelles T2 et des Actions Issues des BSA T3 feront l’objet, le cas échéant et en fonction de la règlementation\napplicable, d’un prospectus soumis à l’approbation de l’AMF au moment de l'émission des ABSA.\nLe prospectus (le « Prospectus ») est composé :\n du document d’enregistrement universel d'Inventiva (« Inventiva » ou la « Société »), déposé auprès de l’AMF le 3\navril 2024 sous le numéro D. 24-0227 (le « Document d’Enregistrement Universel 2023 ») ainsi que l'amendement\nau document d'enregistrement universel 2023 déposé le 14 octobre 2024 sous le numéro D. 24-0227-A01 incorporant\npar référence le rapport financier semestriel au 30 juin 2024 publié le 14 octobre 2024 sur le site de la Société\n(l'« Amendement au Document d’Enregistrement Universel 2023 ») (ensemble, le « Document\nd’Enregistrement Universel ») ;\n de la présente note d’opération (la « Note d’Opération ») ; et\n du résumé du Prospectus (le « Résumé »).\nDes exemplaires du Prospectus sont disponibles sans frais au siège social de la Société, 50 rue de Dijon, 21121 Daix, France,\nsur le site Internet de la Société (www.inventivapharma.com), ainsi que sur le site Internet de l’AMF (www.amf-france.org).\nLa présente Note d’Opération est établie conformément à l’annexe 11 du règlement délégué (UE) n° 2019/980.\n2 | 60\nRemarques et avertissement\nDans le Prospectus, les termes « Inventiva » ou la « Société » désignent la société Inventiva, société anonyme dont le\nsiège social est situé 50 rue de Dijon, 21121 Daix, France, immatriculée au registre du commerce et des sociétés de Dijon\nsous le numéro 537 530 255.\nLe terme « Groupe » renvoie à la Société et sa filiale américaine, Inventiva Inc.\nInformations prospectives\nLe Prospectus comporte des indications sur les objectifs de la Société et des déclarations prospectives. Ces indications\nsont parfois identifiées par l’utilisation du futur, du conditionnel et de termes à caractère prospectif tels que « estimer »,\n« considérer », « avoir pour objectif », « s’attendre à », « entend », « devrait », « souhaite » et « pourrait » ou toute autre\nvariante ou terminologie similaire. L’attention du lecteur est attirée sur le fait que la réalisation de ces objectifs et de ces\ndéclarations prospectives peut être affectée par des risques connus et inconnus, des incertitudes et d’autres facteurs qui\npourraient faire en sorte que les résultats futurs, les performances et les réalisations de la Société soient significativement\ndifférents des objectifs formulés ou suggérés. Les informations prospectives mentionnées dans le Prospectus sont données\nuniquement à la date du Prospectus. Sauf obligation légale ou réglementaire qui s’appliquerait, la Société ne prend aucun\nengagement de publier des mises à jour des informations prospectives contenues dans le Prospectus afin de refléter tout\nchangement affectant ses objectifs ou les événements, conditions ou circonstances sur lesquels sont fondées les\ninformations prospectives contenues dans le Prospectus, étant rappelé qu’aucune de ces informations prospectives ne\nconstitue une garantie de résultats réels.\nInformations sur les marchés\nLe Prospectus contient des informations sur les marchés du Groupe et ses positions concurrentielles, y compris des\ninformations relatives à la taille de ses marchés. Sauf indication contraire, ces informations sont des estimations du Groupe\net ne sont fournies qu’à titre indicatif. Les estimations du Groupe sont fondées sur des informations obtenues auprès de\nclients, fournisseurs, organisations professionnelles et autres intervenants des marchés au sein desquels le Groupe opère.\nBien que le Groupe considère que ces estimations sont pertinentes à la date du Prospectus, il ne peut garantir l’exhaustivité\nou l’exactitude des données sur lesquelles ces estimations sont fondées, ou que ses concurrents retiennent les mêmes\ndéfinitions des marchés sur lesquels ils opèrent.\nFacteurs de risque\nLes investisseurs sont invités à prendre attentivement en considération les facteurs de risque décrits au chapitre 2 du\nDocument d’Enregistrement Universel 2023, ainsi que ceux décrits à la section 5 de l'Amendement au Document\nd'Enregistrement Universel 2023 et également à la section 2 de la Note d’Opération, avant de prendre leur décision\nd’investissement. La réalisation de tout ou partie de ces risques serait susceptible d’avoir un effet défavorable significatif\nsur les activités, la situation, les résultats financiers ou les objectifs de la Société. Par ailleurs, d’autres risques, non\nidentifiés ou considérés comme non significatifs par le Groupe pourraient avoir le même effet défavorable et les\ninvestisseurs pourraient perdre tout ou partie de leur investissement.\nArrondis\nCertaines données chiffrées (y compris les données exprimées en milliers ou millions) et pourcentages présentés dans le\nProspectus ont fait l’objet d’arrondis. Le cas échéant, les totaux présentés dans le Prospectus peuvent légèrement différer\nde ceux qui auraient été obtenus en additionnant les valeurs exactes (non arrondies) de ces données chiffrées.\n3 | 60\nSOMMAIRE\n1. PERSONNES RESPONSABLES, INFORMATIONS PROVENANT DE TIERS, RAPPORTS\nD’EXPERTS ET APPROBATION DE L’AUTORITE COMPETENTE ............................................ 13\n1.1 Personnes responsables des informations contenues dans la Note d’Opération .......................................... 13\n1.2 Attestation du responsable du prospectus .................................................................................................... 13\n1.3 Renseignements concernant l’expert ayant fourni des informations ........................................................... 13\n1.4 Renseignements concernant le tiers ayant fourni des informations ............................................................. 13\n1.5 Déclaration relative à la Note d’Opération .................................................................................................. 13\n2. FACTEURS DE RISQUE ......................................................................................................................... 14\n3. INFORMATIONS ESSENTIELLES ....................................................................................................... 17\n3.1 Déclaration sur le fonds de roulement net ................................................................................................... 17\n3.2 Capitaux propres et endettement.................................................................................................................. 18\n3.3 Intérêt des personnes physiques et morales participant à l’émission ........................................................... 20\n3.4 Raisons de l’émission et utilisation du produit ............................................................................................ 20\n4. INFORMATIONS SUR LES VALEURS MOBILIERES DESTINEES A ETRE ADMISES A LA\nNEGOCIATION SUR EURONEXT PARIS ........................................................................................... 21\n4.1 Nature, catégorie et code ISIN des valeurs mobilières destinées à être admises à la négociation ............... 21\n4.2 Droit applicable et tribunaux compétents .................................................................................................... 22\n4.3 Forme et mode d’inscription en compte des valeurs mobilières .................................................................. 22\n4.4 Devise d’émission ........................................................................................................................................ 23\n4.5 Droits attachés aux valeurs mobilières ........................................................................................................ 23\n4.6 Autorisations ................................................................................................................................................ 28\n4.7 Date prévue d’émission des valeurs mobilières ........................................................................................... 31\n4.8 Restrictions à la libre négociabilité des Actions Offertes et des BSA T3 .................................................... 32\n4.9 Réglementation française en matière d’offres publiques ............................................................................. 32\n4.10 Offres publiques d’acquisition lancées par des tiers sur le capital de l’émetteur durant le dernier exercice\net l’exercice en cours ................................................................................................................................... 34\n4.11 Traitement fiscal applicable aux revenus liés à la détention des actions de la Société et taxe sur les\ntransactions financières ................................................................................................................................ 34\n4.12 Incidence potentielle sur l’investissement d’une résolution au titre de la directive 2014/59/UE ................ 41\n4.13 Identité et coordonnées de l’offreur des valeurs mobilières ........................................................................ 41\n5. MODALITES ET CONDITIONS DE L’OFFRE DE VALEURS MOBILIERES .............................. 42\n5.1 Conditions, statistiques de l’Opération, calendrier prévisionnel et modalités d’une demande de\nsouscription .................................................................................................................................................. 42\n5.2 Plan de distribution et d’allocation des valeurs mobilières .......................................................................... 45\n5.3 Prix d’émission des actions dont l’admission est demandée ....................................................................... 45\n5.4 Placement et prise ferme .............................................................................................................................. 47\n6. ADMISSION A LA NEGOCIATION ET MODALITES DE NEGOCIATION ................................. 48\n6.1 Admission aux négociations ........................................................................................................................ 48\n6.2 Place de cotation .......................................................................................................................................... 48\n6.3 Offres simultanées d’actions de la Société .................................................................................................. 48\n4 | 60\n6.4 Contrat de liquidité ...................................................................................................................................... 48\n6.5 Stabilisation – Interventions sur le marché .................................................................................................. 48\n6.6 Surallocation et rallonge .............................................................................................................................. 48\n7. DETENTEURS DE VALEURS MOBILIERES SOUHAITANT LES VENDRE ............................... 49\n7.1 Personnes ou entités souhaitant vendre des titres de capital ou des valeurs mobilières donnant accès au\ncapital de la Société ..................................................................................................................................... 49\n7.2 Nombre et catégorie des valeurs mobilières offertes par chacun des détenteurs de valeurs mobilières\nsouhaitant vendre ......................................................................................................................................... 49\n7.3 Taille de la participation de l'actionnaire majoritaire cédant des valeurs mobilières. .................................. 49\n7.4 Engagements d'abstention et de conservation des titres............................................................................... 49\n8. DEPENSES LIEES A L’OPERATION ................................................................................................... 50\n9. DILUTION ................................................................................................................................................. 51\n9.1 Comparaisons .............................................................................................................................................. 51\n9.2 Incidence de l’émission sur la situation de l’actionnaire ............................................................................. 53\n10. INFORMATIONS SUPPLEMENTAIRES ............................................................................................. 60\n10.1 Conseillers ayant un lien avec l’Opération .................................................................................................. 60\n10.2 Autres informations vérifiées par les commissaires aux comptes................................................................ 60\n10.3 Responsables du contrôle des comptes ........................................................................................................ 60\n5 | 60\nRESUME DU PROSPECTUS\nSection 1 – Introduction\nNom et codes internationaux d’identification des valeurs mobilières (codes ISIN)\nLibellé des actions : Inventiva - Code ISIN : FR0013233012\nIdentité et coordonnées de l’émetteur, y compris son identifiant d’entité juridique (IEJ)\nDénomination sociale : Inventiva (la « Société », ou l'« Emetteur ») - Lieu et numéro d’immatriculation : R.C.S. Dijon 537 530 255\nAdresse du siège social : 50 rue de Dijon, 21121 Daix, France - Identifiant d’Identité Juridique (IEJ) : 969500I9Y690B3FZW590\nIdentité et coordonnées de l’offreur ou de la personne qui sollicite l’admission à la négociation sur un marché réglementé : Non applicable\nIdentité et coordonnées de l’autorité compétente ayant approuvé le Prospectus : Autorité des marchés financiers (l’« AMF ») – 17, place de la Bourse, 75002\nParis, France.\nDate d’approbation du Prospectus : 14 octobre 2024\nAvertissement au lecteur : Le présent résumé doit être lu comme une introduction au Prospectus. Toute décision d’investir dans les actions dont l’admission aux\nnégociations sur un marché réglementé est demandée doit être fondée sur un examen exhaustif de l'intégralité du Prospectus par l’investisseur. L’investisseur pourrait\nperdre la totalité ou une partie des sommes qu’il investirait dans les actions de la Société dans le cas d’une baisse du cours des actions de la Société. Lorsqu’une action\nconcernant l’information contenue dans le Prospectus est intentée devant un tribunal, l’investisseur plaignant peut, selon la législation nationale des États membres de\nl’Union européenne ou parties à l’accord sur l’Espace Economique Européen (« EEE »), avoir à supporter les frais de traduction du Prospectus avant le début de la\nprocédure judiciaire. Les personnes qui ont présenté le présent résumé, y compris sa traduction, n’engagent leur responsabilité civile que si le contenu du présent résumé\nest trompeur, inexact ou incohérent, lu en combinaison avec les autres parties du Prospectus, ou s’il ne fournit pas, lu en combinaison avec les autres parties du\nProspectus, les informations clés permettant d’aider les investisseurs lorsqu’ils envisagent d’investir dans ces valeurs mobilières. L’information faisant l’objet du présent\nProspectus permet de maintenir, et rétablir, le cas échéant, en tous points significatifs et en tant que de besoin, l’égalité d’accès entre les différents actionnaires et\ninvestisseurs à l’information relative à la Société.\nSection 2 – Informations clés sur l'Emetteur\n2.1 Qui est l’émetteur des valeurs mobilières ?\nIdentité et coordonnées de l'émetteur : Inventiva, société anonyme de droit français, dont le siège social est situé 50, rue de Dijon, 21121 Daix, France. - IEJ :\n969500PVBQFWQKVDMD80\nPrincipales activités : Inventiva est une société́ biopharmaceutique spécialisée dans le développement de médicaments agissant sur les récepteurs nucléaires, les facteurs\nde transcription et la modulation épigénétique. Inventiva développe des programmes thérapeutiques innovants dans le domaine des maladies fibrotiques, de l’oncologie\net des maladies orphelines pour lesquels le besoin médical est important.\nLa Société développe lanifibranor son candidat médicament le plus avancé, pour le traitement de la stéatohépatite non alcoolique (« MASH/NASH »), une maladie\nprogressive et chronique. Lanifibranor est une molécule chimique administrée par voie orale, dont l’action consiste à induire des effets anti-fibrotiques, anti-\ninflammatoires ainsi que des effets vasculaires et métaboliques positifs en activant les trois isoformes de proliférateurs de peroxysomes (PPARα, γ, δ). En septembre\n2021, la Société a annoncé le lancement de l'étude clinique pivot de Phase III évaluant lanifibranor dans la MASH/NASH (« NATiV3 »). En raison d'un retard d'environ\n3 à 5 mois dans le recrutement lié à la pause volontaire annoncée à la suite de la survenance d’une suspicion d’un évènement grave significatif (« SUSAR ») le 15 février\n2024, la Société cible actuellement la première visite du dernier patient pour le quatrième trimestre 2024 et la publication des principaux résultats au cours du second\nsemestre 2026. En cas de succès, la Société procèdera au dépôt de la demande d’autorisation de mise sur le marché accélérée aux Etats-Unis et conditionnelle dans\nl'Union européenne. Inventiva développe en parallèle un second programme clinique avec odiparcil pour le traitement des patients souffrant de MPS, un groupe de\nmaladies génétiques rares qui se caractérisent par une accumulation excessive dans les cellules, de macromolécules glucidiques, les glycosaminoglycanes. Comme\nannoncé en novembre 2020, la Société a décidé de concentrer ses activités cliniques sur le développement de lanifibranor pour le traitement de la MASH/NASH. Toutes\nles activités de recherche et développement liées à la MPS sont suspendues.\nLe 11 octobre 2024, la Société a conclu un amendement au contrat de licence exclusive et de collaboration avec Chia Tai Tianqing Pharmaceutical Group, Co., Ltd\n(« CTTQ »), en date du 21 septembre 2022, tel qu’amendé portant sur les montants de redevances à percevoir par la Société. Dans le cadre de cet amendement, si la\nSociété reçoit des engagements de souscription avant le 31 décembre 2024 de la part d’investisseurs de souscrire à une levée de fonds, en deux ou trois tranches, pour\nun montant brut total d’au moins €180,000,000 (la « Levée de Fonds »), CTTQ devra verser à la Société (i) $10,000,000 dans les 30 jours du règlement-livraison des\nActions Nouvelles T1 et des BSA T1 en cas d’émission de la tranche 1 de la Levée de Fonds devant être versé par CTTQ, (ii) $10,000,000 en cas d’émission de la\ntranche 2 de la Levée de Fonds et (iii) $10,000,000 à la publication par la Société des données de base annonçant que le critère principal ou l'un des deux critères\nsecondaires clés de NATiV3, avec l'un des schémas posologiques testés dans l'essai, ont été atteints. Selon les termes de l'Amendement, le montant total des paiements\nd'étape cliniques, réglementaires et commerciaux potentiels reste inchangé, tandis que les redevances que la Société est susceptible de recevoir ont été réduites à un\nchiffre faible.\nActionnariat à la date du Prospectus : A la date du Prospectus et avant le règlement-livraison des Actions Nouvelles T1 et des BSA T1 (tels que ces termes sont\ndéfinis en section 4.1 ci-dessous), le capital social s’élève à 524.771,88 euros, divisé en 52.477.188 actions ordinaires de même catégorie d’une valeur nominale unitaire\nde 0,01 euro. Les actions de la Société sont entièrement souscrites et libérées. La répartition du capital social et des droits de vote de la Société est à la date des présentes\net après le règlement-livraison des Actions Nouvelles T1 et des BSA T1, à la connaissance de la Société, est la suivante :\nSituation avant l’émission des Actions Nouvelles T1 et des BSA T1 (et hors émission des Actions Nouvelles T1bis, des Actions Nouvelles T2 et\nhors exercice des BSA T3)\nBase non diluée Base diluée\n% en droits de\nActionnaires Nombre d’actions % en capital Nombre d’actions % en capital % en droits de vote\nvote\nFrédéric Cren(1)(3) 5.612.224 10,8% 17,2% 6.127.224 10,1% 16,0%\nPierre Broqua(1) 3.882.500 7,4% 11,9% 4.397.500 7,3% 11,3%\nSous-total Pacte d'actionnaires 9.494.724 18,2% 29,1% 10.524.724 17,4% 27,3%\nBVF Partners L.P. 8.545.499 16,4% 13,1% 8.545.499 14,1% 11,6%\nNew Enterprise Associates (NEA) 5.572.953 10,7% 8,5% 5.572.953 9,2% 7,6%\n6 | 60\nSofinnova 5.070.266 9,7% 9,4% 5.070.266 8,4% 8,3%\nYiheng Capital 3.845.676 7,4% 5,9% 3.845.676 6,3% 5,2%\nQatar Holding LLC 5.157.233 9,9% 7,9% 5.157.233 8,5% 7,0%\nISLS Consulting(2) 111.000 0,2% 0,3% 241.333 0,4% 0,5%\nDavid Nikodem - - - 76.000 0,1% 0,1%\nM. J. Goldberg - - - 10.000 0,02% 0,01%\nBanque Européenne d'Investissement (BEI) - - - 6.022.504 9,9% 8,2%\nDirigeants et administrateurs(4) 10.000 0,02% 0,02% 140.000 0,2% 0,2%\nSalariés 1.338.127 2,6% 3,5% 2.057.777 3,4% 4,1%\nAutodétention 106.115 0,2% - 106.115 0,2% -\nFlottant 13.225.595 24,7% 22,2% 13.225.595 21,8% 19,9%\nTotal 52.477.188 100,0% 100,0% 60.595.6755 100,0% 100,0%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé. (2) Dont 75.000 BSA\n2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation de ISLS Consulting.\n(3) Dont (i) 475.993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5.136.231 actions détenues en propre par M. Fréderic Cren. (4) Montant inférieur à 0,1%. (5)\nDont 430.000 bons de souscription de parts de créateur d'entreprise, 6.368.837 bons de souscription d'actions, 1.019.650 actions gratuites et 300.000 unités de performance devenues des actions gratuites à la\nsuite de l’attribution substitutive décidée le 25 mars 2024 par le Conseil d’administration.\nAprès l’émission des Actions Nouvelles T1 et des BSA T1\nBase non diluée Base diluée\n% en droits de\nActionnaires Nombre d’actions % en capital Nombre d’actions % en capital % en droits de vote\nvote\nFrédéric Cren(1)(4) 5 612 224 6,4% 11,2% 6 127 224 4,6% 8,0%\nPierre Broqua(1) 3 882 500 4,5% 7,8% 4 397 500 3,3% 5,7%\nSous-total Pacte d'actionnaires 9 494 724 10,9% 19,0% 10 524 724 7,9% 13,7%\nBVF Partners L.P. 8 545 499 9,8% 8,6% 16 776 533 12,6% 11,4%\nNew Enterprise Associates (NEA) 7 835 884 9,0% 7,8% 20 659 160 15,5% 14,1%\nSofinnova 6 440 093 7,4% 7,5% 6 440 093 4,8% 5,1%\nYiheng Capital 5 474 986 6,3% 5,5% 5 474 986 4,1% 3,7%\nQatar Holding LLC 5 157 233 5,9% 5,2% 5 157 233 3,9% 3,5%\nInvus Public Equities L.P. 7 606 810 8,7% 7,6% 7 606 810 5,7% 5,2%\nPerceptive Life Sciences Master Fund, Ltd. 4 525 862 5,2% 4,5% 6,034,482 4.5% 4,1%\nAndera Partners 5 008 620 5,8% 5,0% 5 008 620 3,7% 3,4%\nISLS Consulting(2) 111 000 0,1% 0,2% 241 333 0,2% 0,2%\nDavid Nikodem - - - 76 000 0,1% 0,1%\nM. J. Goldberg - - - 10 000 0,0% 0,0%\nBanque Européenne d'Investissement (BEI) - - - 9 097 078 6,9% 6,2%\nDirigeants et administrateurs(3) 10 000 0,02% 0,02% 140 000 0,1% 0,1%\nSalariés 1 338 127 1,5% 2,3% 2 057 777 1,5% 2,0%\nAutodétention 106 115 0,1% - 105 115 0,1% 0,0%\nFlottant 25 422 742 29,2% 26,8% 38,259,293 28.6% 27,0%\nTotal 87 077 695 100,0% 100,0% 133 670 237 100,0% 100,0%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé. (2) Dont 75 000 BSA\n2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation de ISLS Consulting.\n(3) Montant inférieur à 0,1%. (4) Dont (i) 475 993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5 136 231 actions détenues en propre par M. Fréderic Cren.\nPacte d'actionnaires : Le 15 février 2017, Frédéric Cren et Pierre Broqua ont conclu un pacte d’actionnaires (modifié par deux avenants successifs en date du 4 octobre\n2019 et du 28 janvier 2020). Ce pacte prévoit notamment que (i) les deux fondateurs agissent de concert, (ii) ils continueront à siéger au Conseil d'Administration tant\nque chacun détiendra 7% du capital social et des droits de vote, (iii) ils se consulteront pour certaines décisions clefs. Enfin, toute cession de titres de la Société par un\ndes fondateurs est soumise à un droit d’information préalable sur le projet de cession et à un droit de sortie conjointe proportionnelle.\nPrincipaux dirigeants : Frédéric Cren, Président Directeur Général et Pierre Broqua, Directeur Général Délégué, étant précisé qu’après l’émission des Actions\nNouvelles T1 et des BSA T1 et sous réserve de l’approbation de l’assemblée générale des actionnaires de la Société devant se tenir au plus tard le 16 décembre 2024\n(l’ « Assemblée Générale »), les fonctions de Président du conseil d’administration et de Directeur Général seront dissociées et Monsieur Marc Pruzanski sera nommé\nPrésident du conseil d’administration.\nContrôleurs légaux des comptes : KPMG SA, 2, avenue Gambetta, CS 60055, 92066 Paris La Défense Cedex (membre de la compagnie régionale des Commissaires\naux comptes de Versailles) et LCA, 22, rue Foucroy 75017 Paris (membre de la compagnie régionale des Commissaires aux comptes de Paris).\n2.2 Quelles sont les informations financières clés concernant l’émetteur ?\nInformations financières sélectionnées aux 31 décembre 2021, 2022 et 2023 et au 30 juin 2024 et 30 juin 2023 (données semestrielles non auditées) :\nLes informations financières annuelles sélectionnées présentées ci-dessous sont issues des comptes consolidés de la Société établis selon le référentiel IFRS tel qu’adopté\npar l’Union Européenne. Les informations financières présentées ci-dessous n'ont pas fait l'objet de réserves émises par les commissaires aux comptes dans leurs rapports\npour les périodes concernées. Le rapport des commissaires aux comptes sur les comptes consolidés de l’exercice clos le 31 décembre 2023 de la Société précise qu’il\nexiste une incertitude significative liée à des événements ou à des circonstances susceptibles de mettre en cause la continuité d’exploitation.\nEtat de la situation financière :\nExercice clos le 30 juin\nExercice clos le 31 décembre (audités) (non audités)\n2024 2023\n2023 2022 2021\nEn milliers d’euros\nActif non courant 21 371 9 621 6 408 10 818 18 449\nActif courant 48 189 106 383 115 578 28 609 52 370\nDont :\nCréances d'impôt 5 352 6 007 4 373 2 704 4 405\nTrésorerie et équivalents de trésorerie (1) 26 918 86 736 86 553 10 147 31 240\nTotal actif 69 561 116 004 121 985 39 426 70 819\nCapitaux propres (32 032) 45 476 88 866 (79 060) (7 667)\nPassif non courant 51 434 39 827 10 266 70 340 40 688\nDont : Dette financière à long terme (2) 38 508 28 663 8 837 54 109 31 014\nPassif courant 50 158 30 701 22 853 48 146 37 798\nDont : Dette financière à court terme (3) 5 308 5 851 1 282 5 726 4 121\n7 | 60\nTotal passif et capitaux propres 69 561 116 004 121 985 39 426 70 819\nDette financière nette (2)+(3)- (1) 16 899 (52 222) (76 434) 49 688 3 895\nEtat des flux de trésorerie :\nExercice clos le 31 décembre (audités)\nExercice clos le 30 juin\n(non audités)\nEn milliers d’euros 2023 2022 2021 2024 2023\nFlux nets de trésorerie générés par l’activité (81 614) (44 928) (47 629) (48 342) (45 233)\nFlux nets de trésorerie liés aux opérations\n(7 731) 8 868 (1 793) 8 912 (7 702)\nd’investissement\nFlux nets de trésorerie liés aux opérations de\n29 081 37 268 25 447 22 568 (2 153)\nfinancement\nVariation de la trésorerie (60 263) 1 208 (23 975) (16 863) (55 087)\nTrésorerie et équivalents de trésorerie à\n86 736 86 553 105 687 26 918 86 736\nl’ouverture\nTrésorerie et équivalents de trésorerie à la\n26 918 86 736 86 553 10 147 31 240\nclôture\nCompte de résultat :\nExercice clos le 30 juin\nExercice clos le 31 décembre (audités)\n(non audités)\n2024 2023\nEn milliers d’euros 2023 2022 2021\nChiffre d’affaires 17 477 12 179 4 194 41 1 901\nRésultat opérationnel (102 709) (57 110) (52 114) (52 249) (55 003)\nRésultat financier (5 095) 2 816 2 842 3 507 ( 273)\nRésultat net (110 426) (54 274) (49 635) (49 029) (55 269)\nRésultats net (perte) de base/dilué par action (2,43) (1,31) (1,27) (0,94) (1,31)\n(euros/action)\nAu 31 décembre 2023, la Société a enregistré 26,9 millions d’euros de trésorerie et équivalents de trésorerie, 0,01 million d’euros de dépôt à court terme, et un dépôt long\nterme de 9 millions d’euros, contre 86,7 millions d’euros, 1,0 million d’euros et 0,7 million d’euros respectivement au 31 décembre 2022. La Société a généré un chiffre\nd'affaires de 17,5 millions d'euros au 31 décembre 2023. Au 30 juin 2024, la Société dispose de (chiffres non audités) 10,1 millions d’euros de trésorerie et équivalents\nde trésorerie. Le 16 juillet 2024, Inventiva a décidé l'émission de certificats de royalties pour un montant d'environ 20,1 millions d'euros.\nLes informations financières présentées ci-dessus n'ont pas fait l'objet de réserves émises par les commissaires aux comptes dans leurs rapports pour les périodes\nconcernées. Le rapport des commissaires aux comptes sur les comptes consolidés de l’exercice clos le 31 décembre 2023 de la Société précise qu’il existe une incertitude\nsignificative liée à des événements ou à des circonstances susceptibles de mettre en cause la continuité d’exploitation. Le rapport d’examen limité sur les comptes\nconsolidés résumés du premier semestre 2024 contient une observation en lien avec la continuité d’exploitation.\n2.3 Quels sont les risques spécifiques à l’émetteur ?\nLes principaux risques propres à la Société et à son secteur d’activité figurent ci-après. Ces risques sont à prendre en considération par les investisseurs avant toute\ndécision d’investissement :\n- Risques liés au développement de candidats médicaments : compte tenu du stade préliminaire de développement des programmes de recherche de la Société, les\nétudes précliniques ou les essais cliniques relatifs aux candidats médicaments de la Société pourraient subir des retards lors d’une des phases de développement ou\nse traduire par des échecs. (Criticité élevée)\n- La commercialisation, en particulier de lanifibranor, pourrait ne pas être un succès. La Société ne pourra procéder au dépôt de la demande d’autorisation de mise\nsur le marché accélérée aux Etats-Unis et conditionnelle dans l'Union européenne permettant la commercialisation de lanifibranor qu'à la suite des résultats\nprincipaux de l'étude de Phase III de lanifibranor dans la MASH/NASH attendus au cours du second semestre 2026 et uniquement si ceux-ci s'avéraient positifs.\n(Criticité élevée)\n- Risques liés aux essais cliniques : les essais cliniques de la Société pourraient être retardés ou ne pas obtenir les autorisations règlementaires nécessaires pour être\npoursuivis, notamment les essais cliniques de lanifibranor. De plus, des effets indésirables graves inattendus (SUSAR) peuvent survenir durant les essais cliniques.\n(Criticité élevée)\n- Risques liés à la recherche et à la conclusion d’accords de collaboration ou de licence pour le développement et la commercialisation de lanifibranor, son principal\ncandidat médicament. (Criticité élevée)\n- Risques liés (i) à l’obtention d’une autorisation de mise sur le marché (« AMM ») et (ii) au statut de « Fast Track » : la Société n’a pas encore reçu d’AMM de la\npart d’une quelconque autorité réglementaire et pourrait ne jamais en obtenir. (Criticité élevée)\n- Risques liés à la concurrence : des concurrents développent des médicaments alternatifs pouvant concurrencer lanifibranor et odiparcil. (Criticité élevée)\n- La Société est dépendante de ses sous-traitants pour la réalisation de ses essais précliniques et cliniques, pour l’approvisionnement en matières premières et pour la\nfabrication de ses candidats médicaments. (Criticité élevée)\n- Risque de liquidité : la Société estime pouvoir financer ses activités jusqu’à mi-octobre 2024 (avant la réalisation de l’Opération (tel que ce terme est défini en\nsection 3.1 ci-dessous)) et ne peut donc pas faire face à ses obligations actuelles au cours des douze prochains mois. Pour couvrir ses obligations jusqu’à début\noctobre 2025, au regard de son plan d’affaires actuel, la Société estime que son besoin de trésorerie supplémentaire s’élèvera à un montant compris entre 130 et 135\nmillions d’euros. La Société estime qu’à la suite de l’émission des Actions Nouvelles T1 et des BSA T1 et compte tenu du montant net de 8,6 millions d’euros\ndevant être versé par CTTQ dans les 30 jours du règlement-livraison des Actions Nouvelles T1 et des BSA T1, son besoin de trésorerie supplémentaire s’élèvera à\nenviron 40 millions d’euros afin de faire face à ses obligations actuelles au cours des douze prochains mois. (Criticité élevée)\n- Risques liés aux pertes historiques et futures : depuis sa création en 2011, la Société a focalisé ses efforts sur l’acquisition et le développement préclinique et clinique\nde ses candidats médicaments sans garantie de commercialisation ni de rentabilité et a subi d’importantes pertes. L'une des conséquences potentielles de ces pertes,\ndont la Société a pu faire le constat au 31 décembre 2023, est l'incapacité de maintenir le montant des capitaux propres de la Société à un niveau au moins égal à la\nmoitié de son capital social. La Société devra au plus tard le 31 décembre 2026, avoir reconstitué des capitaux propres positifs au moins égaux à la moitié du capital\nsocial, faute de quoi tout intéressé peut demander en justice la dissolution de la société. (Criticité élevée)\n- Risques liés aux financements supplémentaires incertains : au-delà de son horizon de financement (mi-octobre 2024 avant l’émission des Actions Nouvelles T1 et\ndes BSA T1 et jusqu'à la fin du deuxième trimestre 2025 en tenant compte du produit de l’émission des Actions Nouvelles T1 et des BSA T1 et du montant devant\nêtre versé par CTTQ dans les 30 jours du règlement-livraison des Actions Nouvelles T1 et des BSA T1 (hors émission des Actions Nouvelles T1bis, des Actions\nNouvelles T2 et exercice des BSA T3)), la Société pourrait avoir des difficultés à obtenir des financements supplémentaires. (Criticité moyenne)\nSection 3 – Informations clés sur les valeurs mobilières\n3.1 Quelles sont les principales caractéristiques des valeurs mobilières ?\nNature et catégorie des valeurs mobilières, code ISIN, mnémonique et compartiment :\n8 | 60\nLes actions nouvelles de la tranche 1 d’une valeur nominale unitaire de 0,01 euro (les « Actions Nouvelles T1 »), les actions nouvelles de la Société à provenir de\nl’exercice des BSA T1 (les « Actions Issues des BSA T1 » ensemble avec les Actions Nouvelles T1, les « Actions Offertes »).\nLibellé pour les actions : Inventiva - Mnémonique : IVA - ISIN : FR0013233012 – Compartiment : B\nDevise, dénomination, valeur nominale et nombre de valeurs mobilières émises :\nDevise : Euro - Dénomination : Inventiva - Valeur nominale des actions ordinaires : 0,01 euro ;\nNombre de valeurs mobilières émises : les actions dont l'admission aux négociations sur le marché réglementé d'Euronext à Paris (« Euronext Paris ») est demandée\nsont les suivantes :\n- 34.600.507 Actions Nouvelles T1 à émettre par la Société dans le cadre d’une augmentation de capital avec suppression du droit préférentiel de souscription des\nactionnaires par voie d’offre réservée à des catégories de personnes ; et\n- un nombre maximum de 35.399.481 Actions Issues des BSA T1 en cas d’exercice de la totalité des 35.399.481 BSA T1 émis (un BSA T1 donnant le droit de\nsouscrire à une action nouvelle de la Société (la « Parité d’Exercice »)).\nDès lors, le nombre effectif d’Actions Issues des BSA T1 qui seront effectivement admises aux négociations sur Euronext Paris dépendra du nombre de BSA T1 qui seront\nexercés.\nDroits attachés aux Actions Offertes : Les Actions Offertes seront, dès leur création, soumises à l’ensemble des stipulations des statuts de la Société. En l’état actuel de\nla législation française et des statuts de la Société, les principaux droits attachés aux Actions Offertes sont : (i) droit à dividendes, (ii) droit de vote (dont un droit de vote\ndouble pour les actions entièrement libérées en compte nominatif au profit du même actionnaire depuis deux ans au moins), (iii) droit préférentiel de souscription de titres\nde même catégorie, (iv) droit de participation à tout excédent en cas de liquidation et (v) droit d’information des actionnaires.\nDroits attachés aux BSA T1 : les BSA T1 sont des valeurs mobilières donnant accès au capital au sens de l’article L. 228-91 du Code de Commerce et ne sont pas\nattachés aux Actions Nouvelles T1. Les BSA T1 ne feront pas l'objet d'une demande d'admission aux négociations sur le marché réglementé d’Euronext à Paris ni sur le\nNasdaq ni sur aucun autre marché. Les BSA T1 seront émis sous la forme nominative pur jusqu’à la fin de l’engagement de conservation décrit en 4.1 ci-dessous. La\ncaractéristique principale des BSA T1 (issue d’une pratique usuelle sur les marché américains, dite des « pre-funded warrants ») que le prix d’exercice d’une Action Issue\ndes BSA T1, soit 1,35 euro, est libéré par anticipation à hauteur de 1,34 euro (soit le prix d'exercice moins la valeur nominale d'une Action Issue des BSA T1) au jour de\nl’émission des BSA T1 et non au jour de l’exercice des BSA T1 (le « Prix d’Exercice Préfinancé »). La libération du Prix d’Exercice Préfinancé est définitive et\nirrévocable. Les BSA T1 sont exerçables pendant une durée de 10 ans à compter de leur émission (la « Période d'Exercice »). L'exercice d’un BSA T1 donnera le droit\nde souscrire à une Action Issue des BSA T1 à un prix de 1,35 euro, étant précisé que (i) le prix d’exercice ayant été libéré par anticipation au jour de l’émission des BSA\nà concurrence du Prix d’Exercice Préfinancé, seul le solde, soit 0,01 euro (correspondant à la valeur nominale de l’action ordinaire nouvelle) devra être libéré au jour de\nl’exercice du BSA T1 et (ii) la Parité d'Exercice ou le prix d’exercice pourra être ajusté à l'issue d'opérations que la Société pourrait réaliser sur son capital ou sur ses\nréserves, à compter de la date d'émission des BSA T1, afin de maintenir les droits des porteurs des BSA T1 et ce conformément à la réglementation applicable. La valeur\ndes BSA T1 dépend principalement des caractéristiques propres aux BSA T1 (Prix d’Exercice Préfinancé, Parité d’Exercice) et des caractéristiques du sous-jacent et des\nconditions de marché (cours de l'action, volatilité de l'action et taux d'intérêt sans risque). Les BSA T1 non exercés à l'issue de la Période d’Exercice seront\nautomatiquement caducs et perdront toute valeur et le Prix d’Exercice Préfinancé versé par le souscripteur à la date de leur émission restera définitivement acquis à la\nSociété. En application des termes et conditions des BSA T1, le porteur d’un BSA ne pourra pas exercer le BSA T1 dans le cas où, du fait de l’exercice dudit BSA T1 et\npostérieurement audit exercice, sa participation au capital de la Société serait supérieure à 4,99% du capital ou des droits de vote de la Société (sous réserve que le Porteur\nd’un BSA T1 n’ait pas notifié à la Société une baisse ou une augmentation dudit pourcentage de 4,99%).\nTranches 1bis, 2 et 3 : L’émission par la Société des actions nouvelles ou des bons de souscriptions préfinancés donnant droit à des actions nouvelles de la tranche 1bis\nd’une valeur nominale unitaire de 0,01 euro (les « Actions Nouvelles T1bis ») (dont l’admission n’est pas demandée dans le cadre du présent prospectus) est soumise à\nl’adoption par l’Assemblée Générale des résolutions nécessaires permettant l’émission des Actions Nouvelles T1bis ainsi qu’à l’absence de changement défavorable\nsignificatif (défini comme tout événement, violation ou circonstance, individuellement ou dans l'ensemble, qui a eu ou pourrait raisonnablement avoir un effet négatif\nimportant sur les étapes du développement clinique du lanifibranor, ou sur la fabrication du nouveau médicament en vue de son lancement commercial, ou en ce qui\nconcerne la capacité de l'entreprise à mener à bien l'essai NATiV3 et à obtenir de la Food and Drug Administration (FDA) les autorisations nécessaires (un « Changement\nDéfavorable Significatif »)) entre l’émission des Actions Nouvelles T1 et des BSA T1 et le règlement-livraison des Actions Nouvelles T1bis. L’émission des Actions\nNouvelles T1bis permettrait une levée de fonds potentielle d’un montant total de 21.499.979,85 euros. L’adoption des résolutions nécessaires par l’Assemblée Générale\nfera l’objet d’un communiqué de presse, en ligne avec les obligations d’information de la Société. L’émission des Actions Nouvelles T1bis fera également l’objet d’un\ncommuniqué de presse au jour de la réunion du Conseil d’Administration ou du Directeur Général agissant sur délégation du Conseil d’Administration de la Société\ndécidant de cette émission. L’émission par la Société des actions nouvelles ou des bons de souscriptions préfinancés donnant droit à des actions nouvelles de la tranche 2\nd’une valeur nominale unitaire de 0,01 euro (les « Actions Nouvelles T2 ») auxquelles seront attachées un nombre de bons de souscription d'actions permettant de\nsouscrire un nombre d'actions ordinaires nouvelles de la Société de façon à procéder à une augmentation de capital d’un montant de 116 millions d’euros, qui pourront\nêtre exercés à un prix de 1,50 euro (les « BSA T3 » et avec les Actions Nouvelles T2, les « ABSA ») (dont l’admission n’est pas demandée dans le cadre du présent\nprospectus) est soumise aux conditions suivantes (les investisseurs peuvent décider de renoncer à une ou plusieurs des conditions (i) à (v) ci-dessous avec l'accord préalable\ndes investisseurs souhaitant souscrire aux ABSAs et représentant 60% de l'ensemble des investisseurs devant souscrire aux ABSAs) : (i) aucun Changement Défavorable\nSignificatif entre l’émission des Actions Nouvelles T1 et le règlement-livraison des ABSAs n’est survenu, (ii) la randomisation du dernier patient dans la cohorte principale\nde NATiV3 intervenant au plus tard le 30 avril 2025, (iii) le Data Monitoring Committee (le « DMC »), groupe indépendant d’experts chargé d’assurer le suivi de la\nsécurité des patients recrutés dans l’étude NATiV3, et dont la mise en place est usuelle dans le cadre de certains essais cliniques, ne recommande pas la suspension de\nl’étude NATiV3 et (iv) le taux d’abandon par les patients dans l’étude NATiV3 avant la semaine 72 est inférieur à 30% (les conditions (i) à (iv) ensemble, les « Évènements\nDéclencheurs T2 ») (v) la souscription et le paiement par les investisseurs de la totalité des Actions Nouvelles T2, (vi) l’adoption par l’Assemblée Générale des résolutions\nnécessaire permettant l’émission des Actions Nouvelles T2 et des BSA T3 attachés et (vii) les conditions de règlement-livraison usuelles. L’émission des ABSA fera\nl’objet d’un communiqué de presse au jour de la réunion du Conseil d’Administration ou du Directeur Général agissant sur délégation du Conseil d’Administration de la\nSociété constatant la réalisation des Evènements Déclencheurs T2 et décidant de cette émission. Sous réserve des conditions mentionnées ci-dessus, les ABSA seront\némises et souscrites sous réserve d’une décision du Conseil d’administration de la Société qui devra être prise dans une période comprise entre le 31 mars (exclu) et le 31\nmai 2025 et avec un préavis d’au moins quinze jours ouvrables. Les BSA T3 seront des valeurs mobilières donnant accès au capital au sens de l’article L. 228-91 du Code\nde Commerce. Les BSA T3 seront détachés des ABSA dès leur émission et ne feront pas l’objet d’une demande d’admission aux négociations sur le marché réglementé\nd’Euronext à Paris ni sur le Nasdaq ni sur aucun autre marché. Les BSA T3 seront émis au nominatif pur et feront, conformément à l’article L. 211-3 du Code de\ncommerce, l’objet d’une inscription en compte ouvert au nom de leur titulaire dans les livres du teneur de compte de la Société. L'exercice par tout investisseur des BSA\nT3 au plus tard le 30 juillet 2027 (la « Date de Maturité des BSA T3 ») est soumis à : (i) la publication par la Société des données de base annonçant que le critère\nprincipal ou l'un des deux critères secondaires clés de NATiV3 (la résolution de la NASH sans aggravation de la fibrose et l’amélioration de la fibrose hépatique sans\naggravation de la NASH), avec l'un des schémas posologiques testés dans l'essai ont été atteint au plus tard le 15 juin 2027 (l' « Évènement Déclencheur T3 ») et (ii) la\nsouscription par cet investisseur aux ABSAs. Les investisseurs peuvent renoncer à l’Evènement Déclencheur T3 et les BSA T3 pourront être exercés avant la réalisation\nde l’Evènement Déclencheur T3 avec l’accord préalable des investisseurs souhaitant exercer leurs BSA T3 et représentant 60 % de l'ensemble des porteurs des BSA T3\ndans l’un des cas suivant : (i) une personne, seule ou de concert, acquiert le contrôle de la Société (le contrôle ayant le sens prévu à l'Article L. 233-3 du Code de\ncommerce), (ii) l'annonce ou le dépôt d'une offre publique d'achat, offre publique d'échange, offre alternative, offre mixte, (iii) une fusion par laquelle les participations\ndes actionnaires de la Société sont diluées de 30% ou plus ou (iv) la cession de droits significatifs sur le lanifibranor à une entité dans laquelle la Société détient moins de\n51% du capital ou des droits de vote ou (v) un accord relatif au lanifibranor ayant ou pouvant raisonnablement avoir un effet significatif sur les activités, la situation\nfinancière ou les perspectives de la Société. Les BSA T3 pourront être exercés, en totalité ou en partie, à la discrétion du porteur, au plus tôt entre (x) le 45ème jour\ncalendaire suivant le jour la réalisation de l’Évènement Déclencheur T3 et (y) le troisième jour ouvrable (inclus) précédant la Date de Maturité des BSA T3 en cas de\nsurvenance de l’Évènement Déclencheur T3. L’exercice des BSA T3 fera l’objet d’un communiqué de presse au jour de la réunion du Conseil d’Administration ou du\nDirecteur Général agissant sur délégation du Conseil d’Administration de la Société constatant la réalisation de l’Évènement Déclencheur T3 ou la renonciation par les\ninvestisseurs à cette condition. Les BSA T3 non exercés à l’issue de leur période d’exercice seront automatiquement caducs et perdront toute valeur. Les BSA T3 sont\nlibrement cessibles. Tout cessionnaire s’engage à respecter les termes et conditions des BSA T3.\nRang relatif des valeurs mobilières dans la structure du capital de l’émetteur en cas d’insolvabilité : le capital social de la Société est intégralement composé\nd'actions ordinaires. Restriction imposée à la libre négociabilité des actions : aucune clause statutaire ne limite la libre négociabilité des actions composant le capital\n9 | 60\nde la Société. Politique en matière de dividendes : la Société n’a distribué aucun dividende au cours des trois derniers exercices. Il n’est pas prévu d’initier une politique\nde versement de dividende à court terme compte tenu du stade de développement de la Société.\n3.2 Où les valeurs mobilières seront-elles négociées ?\nLes Actions Offertes feront l’objet d’une demande d’admission aux négociations sur Euronext Paris. L’admission des Actions Nouvelles T1 sur Euronext Paris est\nprévue le 17 octobre 2024 sur la même ligne de cotation que les actions existantes de la Société. Les Actions Nouvelles T1 et les BSA T1 feront l’objet d’une demande\nd’admission aux opérations d’Euroclear France qui assurera la compensation entre teneurs de compte-conservateurs. Les Actions Issues des BSA T1 feront l’objet de\ndemandes périodiques d'admission aux négociations sur Euronext Paris jusqu’au troisième jour ouvré suivant la fin de la Période d’Exercice, soit au plus tard le 20\noctobre 2034.\n3.3 Les valeurs mobilières font-elles l’objet d’une garantie?\nL’émission des Actions Nouvelles T1 et des BSA T1 a fait l'objet de contrats de souscription conclus entre chaque investisseur et la Société. L'émission des Actions\nNouvelles T1 et l’émission des BSA T1 ne font pas l'objet d'une garantie.\n3.4 Quels sont les principaux risques spécifiques aux valeurs mobilières ?\nLes investisseurs sont invités à prendre en considération les principaux risques propres aux Actions Nouvelles T1 et aux BSA figurant ci-après :\n- Les actionnaires ne participant pas à l'Opération verront leur participation dans le capital social de la Société significativement diluée. La dilution potentielle\nreprésentera 40% du capital social et après émission des Actions Nouvelles T1, 57% du capital social après émission des Actions Issues des BSA T1 ;\n- En cas de nouvel appel au marché pour financer les futurs besoins de trésorerie de la Société, les actionnaires verront leur participation dans le capital social de\nla Société diluée ;\n- La volatilité et la liquidité des actions de la Société pourraient fluctuer significativement. A titre d'illustration, le cours le plus bas enregistré au cours de l'année\n2024 s'est situé à 1,43 euros le 8 octobre 2024 et le cours le plus haut à 4,44 euros le 4 janvier 2024 ;\n- Des cessions d’actions de la Société pourraient intervenir sur le marché et avoir un impact défavorable sur le cours de l’action de la Société. En particulier, des\nventes d'actions de la Société par des actionnaires importants de la Société pourraient avoir un impact défavorable sur le prix des actions de la Société ; et\n- Le prix de marché des actions de la Société pourrait fluctuer et baisser en-dessous du Prix de Souscription des Actions Nouvelles T1 et du Prix d’Exercice\nPréfinancé des BSA T1.\nSection 4 – Informations clés sur l’admission à la négociation sur un marché réglementé\n4.1 A quelles conditions et selon quel calendrier puis-je investir dans ces valeurs mobilières ?\nModalités et conditions de l'Opération : L'émission des Actions Nouvelles T1 et des BSA T1 a été réalisée dans le cadre d'une augmentation de capital avec\nsuppression du droit préférentiel de souscription réservée à des catégories de personnes au sens de l'article L. 225-138 du Code de commerce répondant aux\ncaractéristiques fixées par l’assemblée générale des actionnaires du 20 juin 2024 (l’ « Assemblée Générale Annuelle 2024 ») dans sa 25ème résolution et répondant\naux caractéristiques suivantes : (i) des personnes physiques ou morales, (en ce compris des sociétés), trusts ou fonds d’investissement, ou autres véhicules de\nplacement, quelle que soit leur forme, de droit français ou étranger, investissant à titre habituel dans le secteur pharmaceutique, biotechnologique, ou des technologies\nmédicales ; et/ou (ii) des sociétés, institutions ou entités quelle que soit leur forme, françaises ou étrangères, exerçant une part significative de leurs activités dans le\ndomaine pharmaceutique, cosmétique ou chimique ou des dispositifs et/ou technologies médicaux ou de la recherche dans ces domaines. Sur le territoire de l’Espace\nEconomique Européen (l'« EEE »), aucune action n’a été entreprise et ne sera entreprise à l’effet de permettre une offre au public des valeurs mobilières objet du\nProspectus rendant nécessaire la publication d’un prospectus dans l’un ou l’autre des États membres. Le 11 octobre 2024, le Conseil d'Administration a fait usage de\nla délégation consentie par l'Assemblée Générale Annuelle 2024 et a décidé de l’émission des Actions Nouvelles T1 et des BSA T1, notamment le Prix de\nSouscription des Actions Nouvelles T1 (tel que défini ci-après) et le Prix d’Exercice Préfinancé des BSA T1.\nPrix de Souscription des Actions Nouvelles T1 et Prix d’Exercice Préfinancé des BSA T1 : Le prix de souscription des Actions Nouvelles T1 a été fixé à 1,35 euro\npar action (0,01 euro de valeur nominale et 1,34 euro de prime d’émission) (le « Prix de Souscription des Actions Nouvelles T1 »). Compte tenu des caractéristiques\npropres des BSA T1, le prix de souscription des BSA T1 est égal au Prix de Souscription des Actions Nouvelles T1, soit 1,35 euro dont 1,34 euros est libéré au jour de\nl’émission du BSA T1 (le « Prix d’Exercice Préfinancé des BSA T1 ») (soit le Prix de Souscription des Actions Nouvelles T1 moins la valeur nominale d’une action\nordinaire). Le solde du Prix d’Exercice Préfinancé du BSA T1, égal à la valeur nominale d’une action ordinaire, soit 0,01 euro, sera libéré au jour de l'exercice du BSA\nT1. Conformément aux modalités de détermination du prix fixées par la 25ème résolution de l’Assemblée Générale Annuelle 2024, le Prix de Souscription des Actions\nNouvelles T1 fait ressortir une décote de 10% par rapport à la moyenne pondérée par les volumes (dans le carnet d’ordre central et hors blocs hors marché) des cours\nde l’action de la Société sur le marché réglementé Euronext Paris lors des 5 dernières séances de bourse précédant la fixation du Prix de Souscription des Actions\nNouvelles T1, soit 1,5048 euros (le « Prix de Référence »). Sous réserve des conditions mentionnées ci-dessus, le prix de souscription des Actions Nouvelles T1bis\ncorrespondra au Prix de Souscription des Actions Nouvelles T1, soit 1,35 euro (le « Prix de Souscription des Actions Nouvelles T1bis »). Sous réserve des conditions\nmentionnées ci-dessus, le prix des ABSA correspondra au prix le plus bas entre (i) le Prix de Souscription des Actions Nouvelles T1, soit 1,35 euro et (ii) la moyenne\npondérée par les volumes (dans le carnet d’ordre central et hors blocs hors marché) des cours de l’action de la Société sur le marché réglementé Euronext Paris lors des\n5 dernières séances de bourse précédant la fixation du prix des Actions Nouvelles T2 (étant précisé qu’aucune décote ne sera appliquée à cette moyenne), (le « Prix de\nSouscription des ABSA »). Sous réserve des conditions mentionnées ci-dessus, le prix d’exercice des BSA T3 correspondra au Prix de Référence (étant précisé\nqu’aucune décote ne sera appliquée sur ce prix), soit 1,50 € (le « Prix d’Exercice des BSA T3 »).\nAdmission et livraison des Actions Offertes : Les Actions Nouvelles T1 font l’objet d’une demande d’admission aux négociations sur Euronext Paris prévue le 17\noctobre 2024. Les souscriptions et versements au titre de l'émission des Actions Nouvelles T1 seront reçus et déposés auprès de Société Générale Securities Services,\nqui délivrera un certificat du dépositaire daté du jour du règlement-livraison des Actions Nouvelles T1 prévu le 17 octobre 2024. Les Actions Issues des BSA T1\npourront être admises à la négociation sur Euronext Paris jusqu'au troisième jour ouvré suivant la fin de la Période d'Exercice soit, au plus tard, le 20 octobre 2034 et\npourront faire l'objet d’une admission sur le marché Nasdaq Global Select Market aux Etats-Unis d’Amérique sous forme d’ADS (American Depositary Shares) lors\nde l’enregistrement auprès de la SEC d’un Registration Statement.\nEngagements d’abstention de la Société : sans objet. Engagements de conservation : Les investisseurs participant à l'Opération se sont engagés à conserver leurs\nActions Nouvelles T1 ou leurs BSA T1 et Actions Issues des BSA T1, selon le cas, jusqu’à la première des deux dates suivantes : (x) la date d’émission des Actions\nNouvelles T2 ou (y) le 20 mai 2025, sous réserve de certaines exceptions (transfert à un autre investisseur, à une société affiliée de l’investisseur ou sous réserve de\nl’accord de la Société à sa seule discrétion, à une tierce partie qui prendrait les mêmes engagements de conservation en ce qui concerne les Actions Nouvelles T1). En\ncas d’émission des Actions Nouvelles T1bis, les investisseurs s’engageront à les conserver dans les mêmes conditions que les Actions Nouvelles T1 et les BSA T1.\nActionnaires détenant plus de 5% à l'issue de l’émission des Actions Nouvelles T1 et des BSA et participant à l'Opération :\n- BVF Partners L.P., détenant une participation de 16,4% du capital social et 13,1% des droits de vote de la Société avant l'Opération, a souscrit pour un montant\nd'environ 11 millions d'euros correspondant à 8.231.034 BSA T1.\n- New Enterprise Associates, détenant une participation de 10,7% du capital social et 8,5% des droits de vote de la Société avant l'Opération, a souscrit pour un\nmontant d'environ 20 millions d'euros correspondant à 2.262.931 Actions Nouvelles T1 et 12.823.276 BSA T1.\n- Sofinnova Crossover I SLP, détenant une participation de 9,7% du capital social et 9,4% des droits de vote de la Société avant l'Opération, a souscrit pour un\nmontant d'environ 1,8 million d'euros correspondant à 1.369.827 Actions Nouvelles T1.\n- Yiheng Capital Management, L.P., détenant une participation de 7,4% du capital social et 5,9% des droits de vote de la Société avant l'Opération, a souscrit pour\nun montant d'environ 2,2 millions d'euros correspondant à 1.629.310 Actions Nouvelles T1.\n- Andera Partners a souscrit pour un montant d'environ 6,7 millions d'euros correspondant à 5.008.620 Actions Nouvelles T1 et détient une participation de 5,8%\naprès l’Opération.\n- Invus Public Equities a souscript pour un montant d'environ 8,1 millions d'euros correspondant à 6.034.482 Actions Nouvelles T1 et détient une participation de\n10 | 60\n8,7% après l’Opération.\n- Perceptive Life Sciences Master Fund, Ltd. a souscrit pour un montant d'environ 6,1 millions d'euros correspondant à 4.525.862 Actions Nouvelles T1 et pour un\nmontant d'environ 2,0 millions d'euros correspondant à 1.508.620 des BSA T1 et détient une participation de 5,2% après l’Opération.\nLe nombre d’Actions Nouvelles T1bis, d’ABSA et de BSA T3 sera souscrit par chaque investisseur au prorata de sa souscription d’Actions Nouvelles T1 ou BSA T1.\nEn cas de défaut de souscription des ABSA par un investisseur, la Société s'engage à offrir aux autres investisseurs le droit de souscrire à un nombre d’ABSA\nsupplémentaires, non souscrites par l'investisseur défaillant, qui sera alloué au prorata du nombre d'Actions Nouvelles T1, de BSA T1 et d’Actions Nouvelles T1bis\nsouscrits par chaque investisseur et souhaitant souscrire à ces ABSA. Il est rappelé que les investisseurs se sont engagés à souscrire à la totalité des Actions Nouvelles\nT1bis, des Actions Nouvelles T2 et des BSA T3 attachés et à voter en faveur des résolutions de l’Assemblée Générale relatives à l’émission des Actions Nouvelles\nT1bis et des ABSAs (à l'exception de la résolution relative à l'investissement propre de cet investisseur) et relatives à l’évolution de la gouvernance de la Société.\nCalendrier indicatif :\n14 octobre 2024 (avant ouverture Décision du Conseil d’Administration approuvant l’émission des Actions Nouvelles T1 et des BSA - Signature des contrats de souscription -\ndes marchés d’Euronext Paris) Diffusion d’un communiqué de presse annonçant les modalités de l’Opération et l’émission des Actions Nouvelles T1 et des BSA T1, et\nnommant Mark Pruzanski président du Conseil d’Administration sous réserve de l’approbation des résolutions soumises à l’Assemblée\nGénérale, notamment sa nomination en qualité de membre du Conseil d’Administration\n14 octobre 2024 Publication du rapport financier semestriel 2024\n14 octobre 2024 Dépôt de l’Amendement au Document d’Enregistrement Universel 2023 - Approbation du Prospectus par l’AMF\n15 octobre 2024 Publication de l'avis d'admission d'Euronext Paris des Actions Nouvelles T1\n17 octobre 2024 Règlement-Livraison des Actions Nouvelles T1 et des BSA T1 - Admission des Actions Nouvelles T1 aux négociations sur Euronext Paris et\nadmission des BSA T1 aux opérations d’Euroclear France\nau plus tard le 16 décembre 2024 Assemblée Générale (i) décidant l’émission des Actions Nouvelles T1bis et (ii) approuvant l’émission des Actions Nouvelles T2 et des BSA\nT3 et nommant Mark Pruzanski membre du conseil d’administration et Srinivas Akkaraju membre du conseil d’administration ainsi que\nd’autres administrateurs. Signature des contrats de souscription des Actions Nouvelles T1bis et des ABSAs\nAu plus tard le 30 avril 2025 Evènements Déclencheurs T2\nAu plus tard le 31 mai 2025 Règlement-Livraison des Actions Nouvelles T2 - Détachement des BSA T3\nAu plus tard le 15 juin 2027 Evènement Déclencheur T3\nAu plus tard le 30 juillet 2027 Date de Maturité des BSA T3\nAu plus tard le 30 juillet 2027 Création et admission au plus tard des Actions Issues des BSA T3 aux négociations sur Euronext Paris\n20 octobre 2034 Clôture de la Période d'Exercice et caducité des BSA\nMontant du pourcentage de dilution : Incidence de l'émission sur la quote-part des capitaux propres :\nQuote-part du capital en %\nBase non diluée Base diluée (1)\nAvant émission des Actions Nouvelles T1 1% 0,87%\nAprès émission des Actions Nouvelles T1 et de l’intégralité des Actions Issues des BSA T1 0,60% 0,45%\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1 et des Actions Nouvelles 0,55% 0,41%\nT1bis\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles 0,29% 0,26%\nT1bis et des Actions Nouvelles T2*\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles 0,20% 0,19%\nT1bis, des Actions Nouvelles T2* et de l’intégralité des Actions Issues des BSA T3\n(1) Les calculs sont effectués en prenant pour hypothèse l'émission de l’intégralité des actions ordinaires venant de l'exercice de l’ensemble des bons de souscription d’actions (BSA), bons de\nsouscription de parts de créateurs d’entreprise (BSPCE) et à l’acquisition définitive de toutes les actions gratuites attribuées.\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles T1bis et Actions Nouvelles T2 sont réunies, (ii) que les Actions\nNouvelles T2 ne seront émises qu’en actions ordinaires et (iii) un prix de souscription des ABSA équivalent au Prix de Souscription des Actions Nouvelles T1 (soit un nombre de\n85.925.919Actions Nouvelles T2).\nQuote-part des capitaux propres\npar action en euros\nBase non diluée Base diluée (1)\nAvant émission des Actions Nouvelles T1 -€1,88 -€1,04\nAprès émission des Actions Nouvelles T1 et de l’intégralité des Actions Issues des BSA T1 -€0,14 €0,18\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1 et des Actions Nouvelles T1bis €0,10 €0,30\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis et des €0,54 €0,56\nActions Nouvelles T2*\nAprès émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis, des €0,83 €0,80\nActions Nouvelles T2* et de l’intégralité des Actions Issues des BSA T3\n(1) Les calculs sont effectués en prenant pour hypothèse l'émission d'un maximum de l’intégralité des actions ordinaires venant de l'exercice de l’ensemble des bons de souscription d’actions\n(BSA), bons de souscription de parts de créateurs d’entreprise (BSPCE) et à l’acquisition définitive de toutes les actions gratuites attribuées.\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles T1bis et Actions Nouvelles T2 sont réunies, (ii) que les Actions\nNouvelles T2 ne seront émises qu’en actions ordinaires et (iii) un prix de souscription des ABSA équivalent au Prix de Souscription des Actions Nouvelles T1 (soit un nombre de\n85.925.919Actions Nouvelles T2).\nMontant brut de l'émission : l'émission des Actions Nouvelles T1 et des BSA T1 permettra une levée de fonds potentielle d'un montant brut de 94,1 millions d’euros\n(86,6 millions d’euros en montant net). Sous réserve des conditions mentionnées ci-dessus, l’émission des Actions Nouvelles T1bis permettrait une levée de fonds\npotentielle d’un montant brut de 21,4 millions d’euros et l’émission des Actions Nouvelles T2 auxquelles seraient attachés les BSA T3 permettrait une levée de fonds\npotentielle d'un montant brut de 116 millions d’euros. Sous réserve des conditions mentionnées ci-dessus et si la totalité des BSA T3 étaient exercés, les Actions Issues\ndes BSA T3 seraient émises et permettraient une levée de fonds potentielle d'un montant brut de 116 millions d’euros.\n11 | 60\nEstimations des dépenses totales liées à l'émission : à titre indicatif, les dépenses totales liées à l'émission des Actions Nouvelles T1 et des BSA T1 (frais juridiques\net administratifs) sont d’environ 5,7 millions d'euros.\n4.2 Pourquoi ce Prospectus est-il établi ?\nRaisons de l'émission et utilisation prévue du produit de celle-ci : La Société n’étant pas en mesure de financer ses opérations au-delà de la mi-octobre 2024, il en\nressort une incertitude significative quant à sa capacité à poursuivre ses activités au-delà de cette date et la Société doit donc lever des fonds supplémentaires afin de\nfinancer ses activités. Ainsi, le produit net de l’émission des Actions Nouvelles T1 et des BSA T1 est destiné à compléter les ressources financières actuelles de la\nSociété et devrait être alloué, avec la trésorerie disponible, comme suit (i) 85% pour le programme clinique évaluant lanifibranor pour le traitement de la\nMASH/NASH et, en cas de résultat positifs de NATiV3, pour la soumission d'une demande de nouveau médicament, et (ii) 15% du produit net pour ses besoins\ngénéraux. La Société s’est engagée à ne pas utiliser ce produit pour le remboursement anticipé de sa dette financière avant leur échéance prévue et pour le rachat des\nvaleurs mobilières émises lors de l’Opération, sous réserve de la mise en œuvre de son contrat de liquidité avec Kepler Cheuvreux. Le produit de l'émission des\nActions Nouvelles T1 et des BSA T1 (d’un montant brut de 94,1 millions d’euros et d’un montant net de 86,6 millions d’euros), de l’émission des Actions Nouvelles\nT1 bis (d’un montant brut de 21,4 millions d’euros) et de l’émission des Actions Nouvelles T2 (d’un montant brut de 116 millions), soit un montant brut maximum de\n232 millions d'euros si ces deux dernières tranches sont émises sous réserve de l’adoption des résolutions nécessaires par l’Assemblée Générale et de certaines\nconditions opérationnelles, sera destiné à financer la poursuite de l'essai de Phase III NATiV3 jusqu'à la publication attendue des résultats de NATiV3, ainsi que\nl’initiation de l’étude cirrhose compensée. Le produit brut de l'exercice des BSA T3 (s'ils étaient exercés en totalité), soit un montant brut maximum de 116 millions\nd'euros sera destiné à financer la poursuite des activités de pré-commercialisation de la Société, y compris les demandes d'autorisation réglementaire pour le\nlanifibranor si les résultats de NATiV3 justifient une telle demande.\nDéclaration sur le fonds de roulement : A la date du présent Prospectus, la Société atteste que, de son point de vue, avant l'Opération, son fonds de roulement net\nn’est pas suffisant au regard de ses obligations au cours des douze prochains mois. Au 30 juin 2024, la Société a enregistré 10,1 millions d’euros de trésorerie et\néquivalents de trésorerie contre 26,9 millions d’euros et un dépôt long terme de 9 millions d’euros1 au 31 décembre 2023. En juillet 2024, Inventiva a émis des\ncertificats de royalties pour un montant d'environ 20,1 millions d'euros. Compte tenu de la structure actuelle de ses coûts et des dépenses prévues, et en tenant compte\ndu produit de l'émission des certificats de royalties d'un montant d’environ 20,1 millions d'euros reçus en totalité et des mesures de préservation de la trésorerie à\ncourt terme mises en place par la Société, la Société estime que sa trésorerie, ses équivalents de trésorerie et ses dépôts lui permettaient de financer ses opérations\njusqu'à mi-octobre 2024. La Société ne peut donc pas faire face à ses obligations actuelles au cours des douze prochains mois avant l’Opération. Pour couvrir ses\nobligations jusqu’à début octobre 2025, au regard de son plan d’affaires actuel, la Société estime que son besoin de trésorerie supplémentaire s’élèvera à un montant\ncompris entre 130 et 135 millions d’euros. La Société estime également qu'elle aurait besoin, avant l'Opération, d'environ 250 millions d’euros pour financer ses\nactivités jusqu'à la publication des premiers résultats de son essai NATiV3, prévue au cours du second semestre 2026. Cette estimation inclut la fourchette comprise\nentre 130 et 135 millions d’euros nécessaires pour financer l’activité de la Société durant les douze prochains mois évoqués ci-dessus.\nAprès l’émission des Actions Nouvelles T1 et des BSA T1 (et hors émission des Actions Nouvelles T1bis, des Actions Nouvelles T2 et exercice des BSA T3) d'un\nmontant brut de 94,1 millions d’euros (soit un montant net de 86,6 millions d’euros), la Société ne disposera pas d’un fonds de roulement net suffisant pour faire face à\nses obligations actuelles au cours des 12 prochains mois et verra sa visibilité financière portée, compte tenu du montant net de 8,6 millions d’euros devant être versé par\nCTTQ dans les 30 jours du règlement-livraison des Actions Nouvelles T1 et des BSA T1, jusqu’à la fin du deuxième trimestre 2025. La Société estime qu’à la suite de\nl’émission des Actions Nouvelles T1 et des BSA T1 et compte tenu du montant devant être versé par CTTQ, hors émission des Actions Nouvelles T1bis, des ABSAs\net exercice des BSA T3, son besoin de trésorerie supplémentaire s’élèvera à environ 40 millions d’euros afin de faire face à ses obligations actuelles au cours des douze\nprochains mois. Si les Actions Nouvelles T1bis (représentant un montant brut de 21,4 millions d’euros) et les ABSAs (représentant un montant brut de 116 millions\nd’euros) sont émises, sous réserve de l’adoption des résolutions nécessaires par l’Assemblée Générale et sous réserve de conditions opérationnelles pour les ABSAs, la\nSociété pourrait étendre sa visibilité financière au-delà des douze mois. Si les Conditions Préalables T1 bis, les Conditions Préalables T2 ne sont pas réalisées et/ou si\nl’Evènement Déclencheur T3 n’est pas réalisé et par conséquent les Actions Nouvelles T1bis, les ABSAs ne sont pas émises et que la Société ne reçoit aucun des\nmontants bruts de l'émission des Actions Nouvelles T1bis, des ABSAs ou de l'exercice des BSA T3, alors la Société pourrait être amenée à lever des fonds\nsupplémentaires pour atteindre ses objectifs de développement pour ses programmes de recherche et de développement au travers (i) d'autres potentielles offres au\npublic ou des placements privés d’instruments de capital ou de dette ; et (ii) des options stratégiques potentielles telles que des partenariats de business développement\net/ou des accords de licences.\nPrincipaux conflits d’intérêts liés à l’Opération : Dans le cadre de l’Opération, la Société s’est engagée, sous réserve du règlement livraison des Actions Nouvelles\nT1 et des BSA T1 à proposer la nomination de Mark Pruzanski et de Srinivas Akkaraju en tant qu’administrateurs lors de l’assemblée générale devant être réunie au\nplus tard le 16 décembre 2024. Aussi, sous réserve (i) de l’adoption par l’assemblée générale devant être réunie au plus tard le 16 décembre 2024 des résolutions\nrelatives à l’émission des ABSA et (ii) du règlement-livraison des Actions Nouvelles T1 et des BSA T1, il pourra également être nommé ou coopté jusqu’à quatre\nadministrateurs additionnels en remplacement d’administrateurs actuellement en fonction (en dehors de Frédéric Cren, Mark Pruzanski et Srinivas Akkaraju) étant\nprécisé qu’un administrateur sera nommé ou coopté sur proposition de BVF Partners L.P et trois administrateurs sur proposition de chacun des trois investisseurs les\nplus importants. Le conseil d'administration a, le 11 octobre 2024, décidé irrévocablement, sous réserve de la nomination de Mark Pruzanski comme administrateur de\nla Société par l'assemblée générale qui se tiendra au plus tard le 16 décembre 2024, de dissocier les fonctions de président du conseil d'administration et de directeur\ngénéral, Frédéric Cren étant actuellement président directeur général de la Société, et de nommer Mark Pruzanski président du conseil d'administration et Frédéric Cren\ndirecteur général, à compter de la date de la prochaine réunion du conseil d'administration qui suivra cette assemblée générale.\nPlacement et prise ferme : aucun contrat de placement ou de prise ferme n’a été conclu.\n1 Le dépôt long terme d’une durée de deux ans était accessible avant expiration du terme avec un préavis de 31 jours et était considéré comme liquide par la Société.\n12 | 60\n1. PERSONNES RESPONSABLES, INFORMATIONS PROVENANT DE TIERS, RAPPORTS\nD’EXPERTS ET APPROBATION DE L’AUTORITE COMPETENTE\n1.1 Personnes responsables des informations contenues dans la Note d’Opération\nResponsable du prospectus :\nMonsieur Frédéric CREN,\nPrésident Directeur Général de la Société\n50, rue de Dijon, 21121 Daix, France\nwww.inventivapharma.com\n1.2 Attestation du responsable du prospectus\n« J’atteste, après avoir pris toute mesure raisonnable à cet effet, que les informations contenues dans le\nProspectus sont, à ma connaissance, conformes à la réalité et ne comportent pas d’omission de nature à en\naltérer la portée. »\nA Daix, le 14 octobre 2024\nMonsieur Frédéric CREN\nPrésident Directeur Général de la Société\n1.3 Renseignements concernant l’expert ayant fourni des informations\nSans objet.\n1.4 Renseignements concernant le tiers ayant fourni des informations\nSans objet.\n1.5 Déclaration relative à la Note d’Opération\nLe Prospectus a été approuvé par l’AMF, en tant qu’autorité compétente au titre du règlement (UE) 2017/1129.\nL’AMF n’approuve ce Prospectus qu’en tant que respectant les normes en matière d’exhaustivité, de\ncompréhensibilité et de cohérence imposées par le règlement (UE) 2017/1129.\nCette approbation ne doit pas être considérée comme un avis favorable sur la qualité des valeurs mobilières\nfaisant l’objet de ce Prospectus.\nLes investisseurs sont invités à procéder à leur propre évaluation de l’opportunité d’investir dans les Actions\nNouvelles T1 et les BSA T1 (tels que ces termes sont définis ci-dessous).\n13 | 60\n2. FACTEURS DE RISQUE\nLes facteurs de risque relatifs à la Société et à son activité sont décrits aux pages 80 à 118 du Document\nd’Enregistrement Universel 2023, aux pages 30 à 35 de l'Amendement au Document d'Enregistrement\nUniversel 2023.\nLa Société exerce son activité dans un environnement évolutif comportant de nombreux risques dont certains\néchappent à son contrôle. Les investisseurs, avant de procéder à la souscription ou à l’acquisition d’actions de\nla Société, sont invités à examiner l’ensemble des informations contenues dans le Document d’Enregistrement\nUniversel 2023 ainsi que dans la section 5 de l'Amendement au Document d'Enregistrement Universel 2023, y\ncompris les risques qui y sont décrits. Ces risques sont ceux que la Société estime comme étant susceptibles\nd’avoir un effet défavorable significatif sur la Société, son activité, ses perspectives, sa situation financière, ses\nrésultats et son développement et qu’elle estime comme importants pour une prise de décision\nd’investissement. L’attention des investisseurs est toutefois attirée sur le fait que la liste des risques présentée\ndans le chapitre 2 du Document d’Enregistrement Universel 2023 (ainsi que dans la section 5 de l'Amendement\nau Document d'Enregistrement Universel 2023) n’est pas exhaustive, étant donné que seuls les risques\nsignificatifs y sont cités conformément à l’article 16 du règlement (UE) 2017/1129 du Parlement européen et\ndu Conseil du 14 juin 2017.\nPour répondre aux exigences du règlement (UE) 2017/1129 applicables depuis le 21 juillet 2019 seuls les\nrisques importants et spécifiques aux Actions Nouvelles T1 et des BSA T1 (tels que ces termes sont définis en\nsection 4.1 de la Note d’Opération) destinées à être admises à la négociation sont présentés dans la présente\nsection. Les facteurs de risque ci-après sont présentés par ordre de criticité décroissant d’après l’évaluation de\nla Société compte tenu de leur incidence négative sur les valeurs mobilières et de leur probabilité de survenance.\nEn outre, l’attention des investisseurs est attirée sur le fait que les facteurs de risques suivants ne portent que\nsur les actions ordinaires nouvelles de la Société dont l’admission aux négociations sur Euronext Paris est\ndemandée.\nRisque lié à la dilution\nLes actionnaires verront leur participation dans le capital social de la Société diluée\nDans la mesure où les actionnaires n’auraient pas participé à la présente émission, leur quote-part de capital et\nde droits de vote de la Société serait significativement diminuée. La dilution potentielle représentera 40% du\ncapital social après émission des Actions Nouvelles T1 (tel que ce terme est défini en section 4.1 de la Note\nd’Opération) et 57% du capital social après émission des Actions Issues des BSA T1 (tel que ce terme est défini\nen section 4.1 de la Note d’Opération).\nLa dilution potentielle représentera 60% du capital social après émission des Actions Nouvelles T1, de\nl’intégralité des Actions Issues des BSA T1 et des Actions Nouvelles T1bis (tel que ce terme est défini en\nsection 4.1 de la Note d’Opération).\nLa dilution potentielle représentera 71% du capital social après émission des Actions Nouvelles T1, de\nl’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis et des Actions Nouvelles T2 (tel que\nce terme est défini en section 4.1 de la Note d’Opération).\nLa dilution potentielle représentera 80% du capital social après émission des Actions Nouvelles T1, de\nl’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis, des Actions Nouvelles T2 et de\nl’intégralité des Actions Issues des BSA T3 (tel que ce terme est défini en section 4.1 de la Note d’Opération).\n14 | 60\nEn cas de nouvel appel au marché, il en résulterait une dilution complémentaire pour les actionnaires\nA la date du présent Prospectus, la Société atteste que, de son point de vue, avant l'Opération (tel que ce terme\nest défini en section 4.1 de la Note d’Opération), son fonds de roulement net n’est pas suffisant au regard de\nses obligations au cours des douze prochains mois. Au 30 juin 2024, la Société a enregistré 10,1 millions\nd’euros de trésorerie et équivalents de trésorerie contre 26,9 millions d’euros et un dépôt long terme de 9\nmillions2 au 31 décembre 2023.\nEn juillet 2024, Inventiva a émis des certificats de royalties pour un montant d'environ 20,1 millions d'euros.\nCompte tenu de la structure actuelle de ses coûts et des dépenses prévues, et en tenant compte du produit de\nl'émission des certificats de royalties d'un montant d’environ 20,1 millions d'euros reçus en totalité et des\nmesures de préservation de la trésorerie à court terme mises en place par la Société, la Société estime que sa\ntrésorerie, ses équivalents de trésorerie et ses dépôts lui permettaient de financer ses opérations jusqu'à mi-\noctobre 2024. La Société ne peut donc pas faire face à ses obligations actuelles au cours des douze prochains\nmois avant l’Opération.\nPour couvrir ses obligations jusqu’à début octobre 2025, au regard de son plan d’affaires actuel, la Société\nestime que son besoin de trésorerie supplémentaire s’élèvera à un montant compris entre 130 et 135 millions\nd’euros.\nLa Société estime également qu'elle aurait besoin, avant l'Opération, d'environ 250 millions d'euros pour\nfinancer ses activités jusqu'à la publication des premiers résultats de son essai NATiV3, prévue au cours du\nsecond semestre 2026. Cette estimation inclut la fourchette comprise entre 130 et 135 millions d’euros\nnécessaires pour financer l’activité de la Société durant les douze prochains mois évoqués ci-dessus.\nAprès l’émission des Actions Nouvelles T1 et des BSA T1 (et hors émission des Actions Nouvelles T1bis, des\nActions Nouvelles T2 et exercice des BSA T3) d'un montant brut de 94,1 millions d’euros (soit un montant net\nde 86,6 millions d’euros), la Société ne disposera pas d’un fonds de roulement net suffisant pour faire face à\nses obligations actuelles au cours des 12 prochains mois et verra sa visibilité financière portée compte tenu du\nmontant net de 8,6 millions d’euros devant être versé par Chia Tai Tianqing Pharmaceutical Group, Co., Ltd\n(« CTTQ ») dans les 30 jours du règlement-livraison des Actions Nouvelles T1 et des BSA T1, jusqu’à la fin\ndu deuxième trimestre 2025. La Société estime qu’à la suite de l’émission des Actions Nouvelles T1 et des\nBSA T1 et compte tenu du montant devant être versé par CTTQ dans les 30 jours du règlement-livraison des\nActions Nouvelles T1 et des BSA T1, hors émission des Actions Nouvelles T1bis, des ABSAs et exercice des\nBSA T3, son besoin de trésorerie supplémentaire s’élèvera à environ 40 millions d’euros afin de faire face à\nses obligations actuelles au cours des douze prochains mois.\nCompte tenu de l’horizon de financement jusqu’à la fin du deuxième trimestre 2025 après l’émission des\nActions Nouvelles T1 et des BSA T1 et compte tenu du montant devant être versé par CTTQ dans les 30 jours\ndu règlement-livraison des Actions Nouvelles T1 et des BSA T1, hors émission des Actions Nouvelles T1bis,\ndes ABSAs et exercice des BSA T3, la Société devra rechercher des financements additionnels plus rapidement\nque ce qui était prévu si les Actions Nouvelles T1bis, et les ABSAs (tel que ce terme est défini en section 4.1\nde la Note d’Opération) ne sont pas émis ou si les Conditions Préalables T1 bis, les Conditions Préalables T2\n(tel que ce terme est défini en section 5.1.3 de la Note d’Opération) ne sont pas réalisées et/ou si l’Evènement\nDéclencheur T3 n’est pas réalisé ou si les investisseurs ne respectent pas leurs engagements, en ce compris,\nleur engagement de conservation de leurs Actions Nouvelles T1, des BSA T1 et des Actions Nouvelles T1bis\njusqu’à l’émission des ABSAs.\n2 Le dépôt long terme d’une durée de deux ans était accessible avant expiration du terme avec un préavis de 31 jours et était considéré comme liquide\npar la Société.\n15 | 60\nSi les Actions Nouvelles T1bis et les ABSAs ne sont pas émises, la Société devra rechercher des financements\nadditionnels plus rapidement que prévu. Quand bien même les Actions Nouvelles T1bis et les ABSAs seraient\némises, rien ne garantit que les BSA T3 seront exercés à la suite de l’Evènement Déclencheur T3 (tel que ce\nterme est défini dans la section 4.5.2.1 de la Note d’Opération). Dans ce cas, la Société devra trouver des\nsources de financements additionnels, notamment au travers d’émission de titres de capital ou de titres de\ncréances, de partenariats, alliances stratégiques et accords de licence ou bien une combinaison de ces différents\nmoyens de financement.\nRisque lié à la volatilité et à la liquidité\nLa volatilité et la liquidité des actions de la Société pourraient fluctuer significativement\nLes marchés boursiers ont connu ces dernières années d’importantes fluctuations qui ont souvent été sans\nrapport avec les résultats des sociétés dont les actions sont négociées. Les fluctuations de marché et la situation\nsanitaire, géopolitique et la conjoncture économique pourraient accroître la volatilité des actions de la Société.\nLe cours des actions de la Société pourrait fluctuer significativement, en réaction à différents facteurs et\névénements, parmi lesquels peuvent figurer les facteurs de risque décrits dans le Document d’Enregistrement\nUniversel 2023 ainsi que la liquidité du marché des actions de la Société. A titre d'illustration, le cours le plus\nbas enregistré au cours de l'année 2024 s'est situé à 1,43 euros le 8 octobre 2024 et le cours le plus haut à 4,44\neuros le 4 janvier 2024.\nPar ailleurs, dans l’hypothèse où la liquidité pour le marché des actions admises aux négociations sur Euronext\nParis n’est pas soutenue, le prix de l’action ordinaire pourrait être plus volatile et il deviendrait plus difficile\nd’acheter ou de céder des actions ordinaires sur le marché Euronext Paris que d’acheter ou de céder des ADS\nsur le marché Nasdaq Global Market aux Etats-Unis d'Amérique (« Nasdaq »). Une double cotation des actions\nde la Société dans deux devises différentes (euro et dollar américain) ouvre la possibilité d’une stratégie\nd’arbitrage entre les deux places de cotation qui pourrait avoir un impact sur les cours respectifs des ADS et\ndes actions.\nDes cessions d’actions de la Société pourraient intervenir sur le marché et avoir un impact défavorable sur le\ncours de l’action de la Société\nCompte tenu de la structure de l’actionnariat de la Société, la cession d’actions de la Société ou l’anticipation\nque de telles cessions puissent intervenir sont susceptibles d’avoir un impact défavorable sur le cours des\nactions de la Société. La Société ne peut prévoir les éventuels effets sur le prix de marché des actions des ventes\nd’actions par ses actionnaires.\nLes investisseurs participant à l’Opération se sont engagés à conserver leurs Actions Nouvelles T1 et BSA T1\njusqu'à la première des deux dates suivantes : (x) la date d’émission des Actions Nouvelles T2 ou (y) le 20 mai\n2025, sous réserve de certaines exceptions (telles que les transferts à un autre investisseur, à un affilié de\nl’investisseur ou, sous réserve de l’accord de la Société, à tout tiers qui prendrait les mêmes engagements de\nconservation des Actions Nouvelles T1 et des BSA T1). Dans l’hypothèse où ils décideraient de céder,\ndirectement ou indirectement, tout ou partie des Actions Nouvelles T1 et des BSA T1 sur le marché à\nl’expiration de ces engagements de conservation ou avant leur expiration en cas de levée de ces engagements,\nou si une telle cession était perçue comme imminente ou probable, le prix de marché des actions de la Société\npourrait être impacté à la baisse de façon significativement défavorable.\nEn cas d’émission des Actions Nouvelles T1bis, les investisseurs s’engageront à conserver les Actions\nNouvelles T1bis dans les mêmes conditions que les Actions Nouvelles T1 et les BSA T1.\nA titre indicatif, il est rappelé que BVF Partners L.P (« BVF »), New Entreprise Associates (« NEA »),\nSofinnova Crossover I SLP (« Sofinnova ») et Yiheng Capital Management, L.P. (« Yiheng ») détiennent à la\n16 | 60\ndate d'approbation du Prospectus et avant réalisation de l'Opération respectivement 16,4% du capital et 13,1%\ndes droits de vote, 10,7% du capital, 8,5% des droits de vote, 9,7% du capital et 9,4% des droits de vote.\nLe nombre d’Actions Nouvelles T1bis, d’Actions Nouvelles T2 et de BSA T3 sera souscrit par chaque\ninvestisseur au prorata de sa souscription d’Actions Nouvelles T1 ou BSA T1. En cas de défaut de souscription\ndes ABSA par un investisseur, la Société s'engage à offrir aux autres investisseurs le droit de souscrire à un\nnombre d’ABSA supplémentaires, non souscrites par l'investisseur défaillant, qui sera alloué au prorata du\nnombre d'Actions Nouvelles T1, de BSA T1 et d’Actions Nouvelles T1bis souscrits par chaque investisseur et\nsouhaitant souscrire à ces ABSA. Si aucun souscripteur d’ABSA ne fait défaut, à la suite de l’émission et de\nla souscription des ABSA par les investisseurs et de l’exercice des BSA T3, s’ils sont exercés en totalité, leur\nquote-part dans le capital de la Société devrait rester la même (sauf émissions réalisées entre l’émission des\nActions Nouvelles T1,des BSA T1 et des Actions Nouvelles T1bis et l’exercice des BSA T3, s’ils sont exercés\net/ou réallocation des ABSA entre investisseurs ayant souscrits aux Actions Nouvelles T1,aux BSA T1 et aux\nActions Nouvelles T1bis).\nLe prix de marché des actions de la Société pourrait fluctuer et baisser en-dessous du Prix de Souscription des\nActions Nouvelles T1 et du Prix d’Exercice Préfinancé des BSA T1\nÀ la date du Prospectus, les actions de la Société sont négociées au prix de 2,00 euros (cours d’ouverture) soit\nà un prix supérieur au Prix de Souscription des Actions Nouvelles T1. Aucune assurance ne peut être donnée\nquant au fait que le prix de marché des actions de la Société ne fluctuera pas à la baisse de telle sorte que le\nprix de marché des actions de la Société à la date d’émission des Actions Nouvelles T1 et des Actions Issues\ndes BSA T1 soit inférieur au Prix de Souscription des Actions Nouvelles T1 et au Prix d’Exercice Préfinancé\ndes BSA T1.\nSi cette baisse devait intervenir respectivement après la souscription des Actions Nouvelles T1 ou des Actions\nIssues des BSA T1 par les souscripteurs, ces derniers subiraient une perte en cas de vente immédiate desdites\nactions. Ainsi, aucune assurance ne peut être donnée sur le fait que, postérieurement à la souscription des\nActions Nouvelles T1 ou des Actions Issues des BSA T1, les investisseurs pourront vendre leurs actions de la\nSociété à un prix égal ou supérieur au Prix de Souscription des Actions Nouvelles T1 et du Prix d’Exercice\nPréfinancé des BSA T1.\n3. INFORMATIONS ESSENTIELLES\nL’information faisant l’objet de la Note d’Opération permet de maintenir, en tous points significatifs et en tant\nque de besoin, l’égalité d’accès entre les différents actionnaires et investisseurs à l’information relative à la\nSociété.\n3.1 Déclaration sur le fonds de roulement net\nA la date du présent Prospectus, la Société atteste que, de son point de vue, avant l'Opération, son fonds de\nroulement net n’est pas suffisant au regard de ses obligations au cours des douze prochains mois. Au 30 juin\n2024, la Société dispose de 10,1 millions d’euros de trésorerie et équivalents de trésorerie contre 26,9 millions\nd’euros et un dépôt long terme de 9 millions3 au 31 décembre 2023.\nEn juillet 2024, Inventiva a émis des certificats de royalties pour un montant d'environ 20,1 millions d'euros.\nCompte tenu de la structure actuelle de ses coûts et des dépenses prévues, et en tenant compte du produit de\nl'émission des certificats de royalties d'un montant d’environ 20,1 millions d'euros reçus en totalité et des\n3 Le dépôt long terme d’une durée de deux ans était accessible avant expiration du terme avec un préavis de 31 jours et était considéré comme liquide\npar la Société.\n17 | 60\nmesures de préservation de la trésorerie à court terme mises en place par la Société, la Société estime que sa\ntrésorerie, ses équivalents de trésorerie et ses dépôts lui permettaient de financer ses opérations jusqu'à mi-\noctobre 2024. Avant l’Opération, la Société ne peut donc pas faire face à ses obligations actuelles au cours des\ndouze prochains mois.\nPour couvrir ses obligations jusqu’à début octobre 2025, au regard de son plan d’affaires actuel, la Société\nestime que son besoin de trésorerie supplémentaire s’élèvera à un montant compris entre 130 et 135 millions\nd’euros.\nLa Société estime également qu'elle aurait besoin, avant l'Opération, d'environ 250 millions d’euros pour\nfinancer ses activités jusqu'à la publication des premiers résultats de son essai NATiV3, prévue au cours du\nsecond semestre 2026. Cette estimation inclut la fourchette comprise entre 130 et 135 millions d’euros\nnécessaires pour financer l’activité de la Société durant les douze prochains mois évoqués ci-dessus.\nAprès l’émission des Actions Nouvelles T1 et des BSA T1 (et hors émission des Actions Nouvelles T1bis, des\nActions Nouvelles T2 et exercice des BSA T3) d'un montant brut de 94,1 millions d’euros (soit un montant net\nde 86,6 millions d’euros), la Société ne disposera pas d’un fonds de roulement net suffisant pour faire face à\nses obligations actuelles au cours des 12 prochains mois et verra sa visibilité financière portée, compte tenu du\nmontant net de 8,6 millions d’euros devant être versé par Chia Tai Tianqing Pharmaceutical Group, Co., Ltd\n(« CTTQ ») dans les 30 jours du règlement-livraison des Actions Nouvelles T1 et des BSA T1, jusqu’à la fin\ndu deuxième trimestre 2025. La Société estime qu’à la suite de l’émission des Actions Nouvelles T1 et des\nBSA T1 et compte tenu du montant devant être versé par CTTQ dans les 30 jours du règlement-livraison des\nActions Nouvelles T1 et des BSA T1, hors émission des Actions Nouvelles T1bis, des ABSAs et exercice des\nBSA T3, son besoin de trésorerie supplémentaire s’élèvera à 40 millions d’euros afin de faire face à ses\nobligations actuelles au cours des douze prochains mois.\nSi les Actions Nouvelles T1bis (représentant un montant brut de 21,4 millions d’euros) et les ABSAs\n(représentant un montant brut de 116 millions d’euros) sont émises, sous réserve de l’adoption des résolutions\nnécessaires par l’assemblée générale des actionnaires de la Société devant se tenir au plus tard le 16 décembre\n2024 (l’ « Assemblée Générale ») et sous réserve de conditions opérationnelles pour les ABSAs, la Société\npourrait étendre sa visibilité financière au-delà des douze mois.\nSi les Conditions Préalables T1 bis, les Conditions Préalables T2 ne sont pas réalisées et/ou si l’Evènement\nDéclencheur T3 n’est pas réalisé et par conséquent les Actions Nouvelles T1bis et les ABSAs ne sont pas\némises et que la Société ne reçoit aucun des montants bruts de l'émission des Actions Nouvelles T1bis, des\nABSAs ou de l'exercice des BSA T3, alors la Société pourrait être amenée à lever des fonds supplémentaires\npour atteindre ses objectifs de développement pour ses programmes de recherche et de développement au\ntravers :\n• d'autres potentielles offres au public ou des placements privés d’instruments de capital ou de dette ; et\n• des options stratégiques potentielles telles que des partenariats de business développement et/ou des accords\nde licences.\n3.2 Capitaux propres et endettement\nConformément au paragraphe 3.2 de l’annexe 11 du Règlement délégué (UE) 2019/980 du 14 mars 2019 et\naux orientations de l'ESMA (European Securities Market Authority) de mars 2021 (ESMA32-382-1138,\nparagraphes 166-189, les tableaux ci-dessous présentent la situation (non auditée) de l’endettement et des\ncapitaux propres de la Société au 31 juillet 2024 établis selon le référentiel IFRS :\n18 | 60\nCapitaux propres et endettement - (en milliers d’euros / non audité) 31 juillet 2024\nTotal des dettes courantes (y compris la fraction courante des dettes non courantes) 5 978\nDettes financières courantes cautionnées (3) 2 834\nDettes financières courantes garanties 0\nDettes financières courantes non cautionnées et non garanties (1) 3 144\nTotal des dettes non courantes (à l’exclusion de la fraction courante des dettes non 88 017\ncourantes)\nDettes financières non courantes cautionnées (3) 6 601\nDettes financières non courantes garanties 0\nDettes financières non courantes non cautionnées et non garanties (1) (4) 81 416\nCapitaux propres (32 028)\nCapital social 525\nRéserve légale 39\nAutres réserves (2) (32 592)\nTotal 61 967\n(1) Inclut les dettes de loyers comptabilisées en application de la norme IFRS 16 – Contrats de location. Au 30 juin 2024,\nles dettes de loyer s’élèvent à 5,6 millions d’euros dont 2,5 millions d’euros à moins d’un an.\n(2) N’inclut pas le résultat net, ni les gains et pertes actuariels sur avantages au personnel, les écarts de conversion et\nles paiements fondés sur des actions de la période du 1er janvier 2024 au 31 juillet 2024\n(3) Les dettes financières cautionnées correspondent à la part garantie par l’état des Prêts Garantis par l’Etat et des\nPrêts Participatifs Relance.\n(4) Comprend les BSA BEI pour 13,6 millions d'euros qui correspondent à leur juste valeur au 30 juin 2024 et les\nRoyalties Certificates 2024 pour 20,1 millions d'euros qui correspondent à leur juste-valeur à l'initiation le 18 juillet\n2024\nEndettement net de la Société - (en milliers d'euros / non audité) 31 juillet 2024\nA. Trésorerie 3 802\nB. Equivalent de trésorerie 18 841\nC. Autres actifs financiers courants 0\nD. Liquidité (A+B+C) 22 643\nDettes financières courantes (y compris les instruments obligataires, mais à 24\nE.\nl’exclusion de la fraction courante des dettes financières non courantes)\nF. Fraction courante des dettes financières non courantes (1) 5 953\nG. Endettement financier courant (E+F) 5 978\nH. Endettement financier courant net (G-D) (16 666)\nEndettement financier non courant (à l’exclusion de la fraction courante et des 73 416\nI.\ninstruments obligataires) (2) (3)\nJ. Instruments de dette (2) 13 569\nK. Fournisseurs et autres créditeurs non courants(4) 1 032\nL. Endettement financier non courant (I+J+K) 88 017\nM. Endettement financier total (H+L) 71 351\n(1) Inclus les dettes de loyers comptabilisées en application de la norme IFRS 16 – Contrats de location. Au 31 juillet\n2024, les dettes de loyer s’élèvent à 5,6 millions d’euros dont 2,5 millions d’euros à moins d’un an.\n(2) Correspond à la juste-valeur des instruments au 30 juin 2024.\n(3) Comprend les Royalties Certificates 2024 dont la juste-valeur de 20,1 millions d'euros à la date de souscription le\n18 juillet 2024 a été conservée\n19 | 60\n(4) Correspond à une avance client dont l'échéance est estimée en 2027\nLa Société a enregistré une baisse de 50,8 millions d'euros de trésorerie et équivalents de trésorerie entre le 31\ndécembre 2023 et le 30 juin 2024 qui est principalement liée à la trésorerie consommée par les activités\nopérationnelles.\nEn juillet 2024, Inventiva a émis des certificats de royalties pour un montant d'environ 20,1 millions d'euros.\nDepuis le 30 juin 2024, la Société n’a pas connu d’autres événements notables susceptibles de modifier la\nsituation présentée ci-dessus.\nA la date du Prospectus, il n'existe pas de nouvelle dette indirecte ou éventuelles. Les engagements hors bilan\nsont décrits dans la note « 26. Engagements hors bilan liés aux activités opérationnelles » des comptes\nconsolidés annuels établis au 31 décembre 2023.\n3.3 Intérêt des personnes physiques et morales participant à l’émission\nDans le cadre de l’Opération, la Société s’est engagée, sous réserve du règlement livraison des Actions\nNouvelles T1 et des BSA T1 à proposer la nomination de Mark Pruzanski et de Srinivas Akkaraju en tant\nqu’administrateurs lors de l’assemblée générale devant être réunie au plus tard le 16 décembre 2024.\nAussi, sous réserve (i) de l’adoption par l’assemblée générale devant être réunie au plus tard le 16 décembre\n2024 des résolutions relatives à l’émission des ABSA et (ii) du règlement-livraison des Actions Nouvelles T1\net des BSA T1, il pourra également être nommé ou coopté jusqu’à quatre administrateurs additionnels en\nremplacement d’administrateurs actuellement en fonction (en dehors de Frédéric Cren, Mark Pruzanski et\nSrinivas Akkaraju) étant précisé qu’un administrateur sera nommé ou coopté sur proposition de BVF Partners\nL.P (« BVF ») et trois administrateurs sur proposition de chacun des trois investisseurs les plus importants.\nLe conseil d'administration a, le 11 octobre 2024, décidé irrévocablement, sous réserve de la nomination de\nMark Pruzanski comme administrateur de la Société par l'assemblée générale qui se tiendra au plus tard le 16\ndécembre 2024, de dissocier les fonctions de président du conseil d'administration et de directeur général,\nFrédéric Cren étant actuellement président directeur général de la Société, et de nommer Mark Pruzanski\nprésident du conseil d'administration et Frédéric Cren directeur général, à compter de la date de la prochaine\nréunion du conseil d'administration qui suivra cette assemblée générale.\nIl est rappelé que les investisseurs se sont engagés à souscrire aux Actions Nouvelles T1bis et à la totalité des\nActions Nouvelles T2 et des BSA T3 attachés et à voter en faveur des résolutions de l’Assemblée Générale\nrelatives à l’émission des Actions Nouvelles T1bis et des ABSAs (à l'exception de la résolution relative à\nl'investissement propre de cet investisseur) et relatives à l’évolution de la gouvernance de la Société.\n3.4 Raisons de l’émission et utilisation du produit\nLa Société n’étant pas en mesure de financer ses opérations au-delà de la mi-octobre 2024, il en ressort une\nincertitude significative quant à sa capacité à poursuivre ses activités au-delà de la mi-octobre 2024 et la Société\ndoit donc lever des fonds supplémentaires afin de financer ses activités. Ainsi, le produit net de l'émission des\nActions Nouvelles T1 et des BSA T1 est destiné à compléter les ressources financières actuelles de la Société\net devrait être alloué, avec la trésorerie disponible, comme suit : 85 % pour le programme clinique évaluant\nlanifibranor pour le traitement de la MASH/NASH et, en cas de résultat positifs de NATiV3, pour la soumission\nd'une demande de nouveau médicament, et 15 % pour ses besoins généraux. La Société s’est engagée à ne pas\nutiliser ce produit pour le remboursement anticipé de sa dette financière avant leur échéance prévue et pour le\nrachat des valeurs mobilières émises lors de l’Opération, sous réserve de la mise en œuvre de son contrat de\nliquidité avec Kepler Cheuvreux.\nLe produit de l'émission des Actions Nouvelles T1 et des BSA T1 (d’un montant brut de 94,1 millions d’euros\net d’un montant net de 86,6 millions d’euros), de l’émission des Actions Nouvelles T1 bis (d’un montant brut\nde 21,4 millions d’euros) et de l’émission des Actions Nouvelles T2 (d’un montant brut de 116 millions), soit\n20 | 60\nun montant brut maximum de 116 millions d'euros si ces deux dernières tranches sont émises sous réserve de\nl’adoption des résolutions nécessaires par l’Assemblée Générale et de certaines conditions opérationnelles, sera\ndestiné à financer la poursuite de l'essai de Phase III NATiV3 jusqu'à la publication attendue des résultats de\nNATiV3, ainsi que l’initiation de l’étude cirrhose compensée. Le produit brut de l'exercice des BSA T3 (s'ils\nétaient exercés en totalité), soit un montant brut maximum de 116 millions d'euros, sera destiné à financer les\nactivités de pré-commercialisation de la Société, y compris les demandes d'autorisation réglementaire pour le\nlanifibranor si les résultats de NATiV3 justifient une telle demande.\n4. INFORMATIONS SUR LES VALEURS MOBILIERES DESTINEES A ETRE ADMISES A LA\nNEGOCIATION SUR EURONEXT PARIS\n4.1 Nature, catégorie et code ISIN des valeurs mobilières destinées à être admises à la négociation\nLes actions dont l’admission aux négociations sur le marché réglementé d’Euronext à Paris (« Euronext\nParis ») est demandée sont les suivantes :\n- 34.600.507 actions ordinaires nouvelles d’une valeur nominale de 0,01 euro, souscrites en numéraire\ndans le cadre d’une augmentation de capital avec suppression du droit préférentiel de souscription au\nprofit de catégories de personnes conformément à l'article L. 225-138 du Code de commerce (les «\nActions Nouvelles T1 ») ; et\n- un nombre maximum de 35.399.481 actions nouvelles d'une valeur nominale unitaire de 0,01 euro en\ncas d'exercice de la totalité des 35.399.481 bons de souscription d’actions (les « BSA T1 ») (ensemble\navec les Actions Nouvelles T1, l’« Opération »), un BSA donnant droit à une action ordinaire nouvelle\nde la Société (la « Parité d’Exercice ») (les « Actions Issues des BSA T1 » et avec les Actions\nNouvelles T1, les « Actions Offertes »).\nDès lors, le nombre effectif d’Actions Offertes qui seront effectivement admises aux négociations sur Euronext\nParis dépendra du nombre de BSA T1 qui seront exercées.\nSous réserve de l’approbation des résolutions nécessaires par l’Assemblée Générale, la Société demandera (i)\nl’admission sur Euronext Paris des actions ordinaires nouvelles d’une valeur nominale unitaire de 0,01 euro ou\nde bons de souscription d’actions préfinancés donnant droit à des actions nouvelles d’une valeur nominale\nunitaire de 0,01 euro (les « Actions Nouvelles T1bis ») dans le cadre d’une augmentation de capital avec\nsuppression du droit préférentiel de souscription des actionnaires au profit de personnes dénommées pour un\nmontant total prime d’émission incluse de 21.499.979,85 euros conformément à l'article L. 225-138 du Code de\ncommerce, (ii) l’admission sur Euronext Paris des actions ordinaires nouvelles d’une valeur nominale unitaire\nde 0,01 euro ou de bons de souscription d’actions préfinancés donnant droit à des actions nouvelles d’une\nvaleur nominale unitaire de 0,01 euro (les « Actions Nouvelles T2 ») auxquelles seront attachées des bons de\nsouscription d’actions (les « BSA T3 » et avec les Actions Nouvelles T2, les « ABSA ») à émettre par la\nSociété pour un montant total de 116 millions d’euros dans le cadre d’une augmentation de capital avec\nsuppression du droit préférentiel de souscription des actionnaires au profit de personnes\ndénommées conformément à l'article L. 225-138 du Code de commerce sous réserve de la réalisation des\nEvènements Déclencheurs T2 ; et (ii) l’admission sur Euronext Paris d’actions nouvelles d’une valeur nominale\nunitaire de 0,01 euro en cas d’exercice de la totalité des BSA T3 (selon la parité d'exercice des BSA T3, tel\nqu’elle sera décidé par l’Assemblée Générale) (les « Actions Issues des BSA T3 ») en cas d’émission des\nABSA et selon leurs modalités d’exercice.\nLes Actions Nouvelles T1 feront l'objet d'une demande d'admission aux négociations sur Euronext Paris dès\nleur émission.\n21 | 60\nLes BSA T1, exerçables pendant une durée de 10 ans à compter de leur émission ne feront pas l'objet d'une\ndemande d'admission aux négociations sur le marché réglementé d'Euronext à Paris ni sur le Nasdaq ni sur\naucun autre marché.\nLes Actions Issues des BSA T1 feront l'objet de demandes périodiques d'admission aux négociations sur\nEuronext Paris jusqu'au troisième jour ouvré suivant la fin de la Période d'Exercice soit, au plus tard, le 20\noctobre 2034.\nLes Actions Offertes sont des actions ordinaires, toutes de même catégorie que les actions ordinaires existantes\nde la Société et de valeur nominale unitaire de 0,01 euro.\nLes Actions Offertes porteront jouissance courante et donneront droit, à compter de leur émission, à toutes les\ndistributions décidées par la Société à compter de cette date.\nElles seront admises aux négociations sur le marché d’Euronext Paris (compartiment B), sur la même ligne de\ncotation que les actions existantes sous le même code ISIN FR0013233012.\nÀ la date du Prospectus, le placement des Actions Nouvelles T1 et des BSA T1 auprès des investisseurs a été\nréalisé, mais la cotation des Actions Nouvelles T1 ne pourra intervenir qu’à la suite de leur émission, au terme\ndes opérations de règlement-livraison des Actions Nouvelles T1 et des BSA T1 prévues le 17 octobre 2024.\n4.2 Droit applicable et tribunaux compétents\nLes Actions Offertes et les BSA T1 seront émis dans le cadre de la législation française et toutes contestations\nqui pourraient s’élever pendant la vie de la Société ou sa liquidation, à l'encontre de la Société, seront jugées\nconformément à la loi et soumises à la juridiction des tribunaux compétents du siège social de la Société.\n4.3 Forme et mode d’inscription en compte des valeurs mobilières\n4.3.1 Forme et mode d’inscription en compte des Actions Offertes\nLes Actions Nouvelles T1, les BSA T1 et les Actions Issues des BSA T1, selon le cas, seront inscrits au\nnominatif pur jusqu'à la première des deux dates suivantes : (x) la date de règlement-livraison des Actions\nNouvelles T2 ou (y) le 20 mai 2025. Par la suite, les Actions Nouvelles T1, les BSA T1 et les Actions Issues\ndes BSA T1 pourront revêtir la forme nominative ou au porteur, au choix des investisseurs.\nConformément à l’article L. 211-3 du Code monétaire et financier, elles seront obligatoirement inscrites en\ncompte-titres tenu, selon le cas, par la Société ou un intermédiaire habilité.\nEn conséquence, les droits des titulaires seront représentés par une inscription sur un compte-titres ouvert à\nleur nom dans les livres :\n- de Société Générale Securities Services / Global Issuer Services (32, rue du Champ-de-tir, BP 81236, 44312\nNantes Cedex 03), mandatée par la Société, pour les actions conservées sous la forme nominative pure ;\n- d’un intermédiaire habilité de leur choix et de Société Générale Securities Services / Global Issuer Services\n(32, rue du Champ-de-tir, BP 81236, 44312 Nantes Cedex 03), mandatée par la Société, pour les actions\nconservées sous la forme nominative administrée ;\n- d’un intermédiaire habilité de leur choix pour les actions conservées sous la forme au porteur.\n22 | 60\nConformément aux articles L. 211-15 et L. 211-17 du Code monétaire et financier, les actions se transmettent\npar virement de compte à compte et le transfert de propriété des Actions Offertes résultera de leur inscription\nau compte-titres du souscripteur.\nLes Actions Nouvelles T1, les BSA T1 et les Actions Issues des BSA T1 feront l’objet d’une demande\nd’admission aux opérations d’Euroclear France qui assurera la compensation des actions entre teneurs de\ncompte-conservateurs. Elles feront également l’objet d’une demande d’admission aux opérations d’Euroclear\nBank S.A./N.V, et de Clearstream Banking, société anonyme (Luxembourg).\nSelon le calendrier indicatif de l'Opération, il est prévu que les Actions Nouvelles T1 soient inscrites en compte-\ntitres le 17 octobre 2024.\n4.3.2 Forme et mode d’inscription en compte des BSA T1\nLes BSA T1 seront émis au nominatif pur jusqu’à la fin de l’engagement de conservation décrit en 4.3.1 ci-\ndessus et feront, conformément à l’article L. 211-3 du Code de commerce, l’objet d’une inscription en compte\nouvert au nom de leur titulaire dans les livres d’un intermédiaire habilité de leur choix.\n4.4 Devise d’émission\nL’Opération était réalisée en euros et les Actions Nouvelles T1 et les Actions Issues des BSA T1 ainsi que les\nBSA T1 seront libellées en euros.\n4.5 Droits attachés aux valeurs mobilières\n4.5.1 Droits attachés aux valeurs Actions Offertes\nLes Actions Offertes seront, dès leur création, soumises à l'ensemble des dispositions des statuts de la Société.\nEn l’état actuel de la législation française et des statuts de la Société, les principaux droits attachés aux Actions\nOffertes sont décrits ci-après :\nBénéfice – Réserves légales - Droit à dividendes\nChaque action donne droit, dans la propriété de l’actif social, dans le partage des bénéfices, et dans le boni de\nliquidation à une quotité proportionnelle au nombre et à la valeur nominale des actions existantes.\nChaque fois qu’il est nécessaire de posséder plusieurs actions, qu’elles soient ou non de préférence, ou valeurs\nmobilières pour exercer un droit quelconque, les actionnaires ou titulaires de valeurs mobilières font leur affaire\npersonnelle du groupement du nombre d’actions ou de valeurs mobilières nécessaire.\nSur le bénéfice de l’exercice social, diminué le cas échéant des pertes antérieures, il est obligatoirement fait un\nprélèvement d’au moins cinq pour cent (5 %) affecté à la formation d’un fonds de réserve dit « réserve légale ».\nCe prélèvement cesse d’être obligatoire lorsque le montant de la réserve légale atteint le dixième du capital\nsocial.\nLe bénéfice distribuable est constitué par le bénéfice de l’exercice diminué des pertes antérieures et du\nprélèvement prévu à l’alinéa précédent, et augmenté du report bénéficiaire.\nS’il résulte des comptes de l’exercice, tels qu’approuvés par l’assemblée générale, l’existence d’un bénéfice\ndistribuable, l’assemblée générale décide de l’inscrire à un ou plusieurs postes de réserve dont elle règle\nl’affectation ou l’emploi, de le reporter à nouveau ou de le distribuer sous forme de dividendes.\n23 | 60\nAprès avoir constaté l’existence de réserves dont elle a la disposition, l’assemblée générale peut décider la\ndistribution de sommes prélevées sur ces réserves. Dans ce cas, la décision indique expressément les postes de\nréserves sur lesquels ces prélèvements sont effectués. Toutefois, les dividendes sont prélevés en priorité sur le\nbénéfice distribuable de l’exercice.\nLes modalités de mise en paiement des dividendes sont fixées par l’assemblée générale ou, à défaut, par le\nconseil d’administration.\nToutefois, la mise en paiement des dividendes doit avoir lieu dans le délai maximal de neuf mois après la\nclôture de l’exercice.\nL’assemblée générale statuant sur les comptes de l’exercice peut accorder à chaque actionnaire, pour tout ou\npartie du dividende mis en distribution, une option entre le paiement du dividende en numéraire ou en actions.\nDe la même façon, l’assemblée générale ordinaire, statuant dans les conditions prévues à l’article L. 232-12 du\nCode de commerce, peut accorder à chaque actionnaire un acompte sur dividendes et pour tout ou partie dudit\nacompte sur dividende, une option entre le paiement de l’acompte sur dividende en numéraire ou en actions.\nLes dividendes non réclamés dans les cinq années à partir de la date de leur mise en paiement sont prescrits et\ndoivent, passé ce délai, être reversés à l’Etat.\nLes dividendes versés à des non-résidents sont soumis à une retenue à la source en France (voir le paragraphe\n4.11 de la présente Note d’Opération).\nLa politique de distribution de dividendes de la Société est présentée à la section 6.1.5 du Document\nd'Enregistrement Universel 2023.\nDroit préférentiel de souscription\nLes actions comportent, sauf renonciation de la part des actionnaires, un droit préférentiel de souscription aux\naugmentations de capital. Les actionnaires ont, proportionnellement au montant de leurs actions, un droit de\npréférence à la souscription des actions de numéraire émises pour réaliser une augmentation de capital\nimmédiate ou à terme. Pendant la durée de la souscription, ce droit est négociable lorsqu’il est détaché d’actions\nelles-mêmes négociables. Dans le cas contraire, il est cessible dans les mêmes conditions que l’action elle-\nmême. Les actionnaires peuvent renoncer à titre individuel à leur droit préférentiel de souscription (articles L.\n225-132 et L. 228-91 du Code de commerce).\nDroit de vote\nSauf dans les cas où la loi ou les statuts en disposent autrement, chaque action confère à son propriétaire une\nvoix aux assemblées générales d'actionnaires.\nUn droit de vote double est toutefois attribué dans les conditions légales à toutes les actions entièrement libérées\npour lesquelles il est justifié d'une inscription nominative depuis au moins deux ans au nom du même\nactionnaire, ou au nom d'une personne aux droits de laquelle il se trouve, par suite de succession, de liquidation\nde communauté de biens entre époux ou de donation entre vifs consentie par un actionnaire à son conjoint ou\nà un parent au degré successible ou par suite d'un transfert résultant d'une fusion ou d'une scission d'une société\nactionnaire.\n24 | 60\nDroit de participation aux bénéfices de la Société\nLes actionnaires de la Société ont droit aux bénéfices dans les conditions définies par les articles L. 232-10 et\nsuivants du Code de commerce.\nDroit de participation à tout excédent en cas de liquidation\nChaque action donne droit dans la propriété de l’actif social, dans le partage des bénéfices et dans le boni de\nliquidation, à une quotité identique, sous réserve de la création d’actions de préférence.\nClauses de rachat ou de conversion\nLes statuts de la Société ne prévoient pas de clause de rachat ou de conversion des actions ordinaires.\nIdentification des détenteurs de titres\nLa Société se tient informée de la composition de son actionnariat dans les conditions prévues par la loi. A ce\ntitre, la Société peut faire usage de toutes les dispositions légales prévues en matière d’identification des\ndétenteurs de titres conférant immédiatement ou à terme le droit de vote dans ses assemblées d’actionnaires.\nFranchissement de seuils statutaires\nOutre l’obligation légale d’informer la Société de la détention de certaines fractions du capital ou des droits de\nvotes, toute personne agissant seule ou de concert, qui vient à détenir ou cesse de détenir, directement ou\nindirectement par l'intermédiaire de sociétés qu'elle contrôle au sens de l'article L. 233-3 du Code de commerce,\nun nombre d'actions représentant 2% du capital ou des droits de vote de la Société, est tenue, au plus tard avant\nla clôture des négociations du quatrième jour de bourse suivant le jour du franchissement du seuil de\nparticipation susvisé, d’en informer la Société par lettre recommandée avec accusé de réception en précisant le\nnombre total d'actions et de droits de vote qu'elle possède. La personne tenue à l’information prévue ci-dessus\nprécise le nombre de titres qu’elle possède donnant accès à terme au capital ainsi que les droits de vote qui y\nsont attachés ainsi que toutes autres informations requises par les textes.\nCette déclaration devra être renouvelée dans les conditions prévues ci-dessus chaque fois qu'une nouvelle\nfraction de 2% du capital ou des droits de vote sera franchie, à la hausse comme à la baisse.\nA défaut d’avoir été déclarées dans les conditions susvisées, les actions excédant la fraction qui aurait dû être\ndéclarée sont privées du droit de vote dans les assemblées d’actionnaires, si à l’occasion d’une assemblée, le\ndéfaut de déclaration a été constaté et si un ou plusieurs actionnaires détenant ensemble 5% au moins du capital\nen font la demande lors de cette assemblée. La privation du droit de vote s’appliquera pour toute assemblée\nd’actionnaires se tenant jusqu’à l’expiration d’un délai de deux ans suivant la date de régularisation de la\ndéclaration.\n4.5.2 Droits attachés aux BSA T1 et aux BSA T3\n4.5.2.1 Modalités d’exercice des BSA T1\nLes BSA T1 sont des valeurs mobilières donnant accès au capital au sens de l'article L. 228-91 du Code de\nCommerce et sont attachés aux actions nouvelles. Chacun des BSA T1 donnera le droit à la souscription par\nleur titulaire à une action ordinaire nouvelle de la Société.\nLa caractéristique principale des BSA T1 (issue d’une pratique usuelle sur les marché américains, dite « pre-\nfunded warrant ») est que le prix d’exercice d’une Action Issue des BSA T1, soit 1,35 euro, est libéré par\n25 | 60\nanticipation à hauteur de 1,34 euro (soit le prix d'exercice moins la valeur nominale d'une Action Issue des\nBSA T1) au jour de l’émission des BSA T1 et non au jour de l’exercice des BSA (le « Prix d’Exercice\nPréfinancé »). La libération du Prix d’Exercice Préfinancé est définitive et irrévocable.\nLes BSA T1 ont été souscrits par les investisseurs contre paiement du Prix d’Exercice Préfinancé et le solde\ndu prix d’exercice, soit 0,01€ correspondant à la valeur nominale de l’action ordinaire de la Société sera versé\npar les investisseurs au jour, et sous réserve, de l’exercice du BSA T1.\nLes BSA T1 sont exerçables pendant une durée de 10 ans à compter de leur émission (la « Période\nd'Exercice »). L'exercice d’un BSA T1 donnera le droit de souscrire à une Action Issue des BSA T1 à un prix\nde 1,35 euro, étant précisé que (i) le prix d’exercice ayant été libéré par anticipation au jour de l’émission des\nBSA T1 à concurrence du Prix d’Exercice Préfinancé, seul le solde, soit 0,01€ (correspondant à la valeur\nnominale de l’action ordinaire nouvelle) devra être libéré au jour de l’exercice du BSA T1 et (ii) la Parité\nd'Exercice ou le prix d’exercice pourra être ajusté à l'issue d'opérations que la Société pourrait réaliser sur son\ncapital ou sur ses réserves, à compter de la date d'émission des BSA T1, afin de maintenir les droits des porteurs\ndes BSA et ce conformément à la réglementation applicable.\nLa valeur des BSA T1 dépend principalement des caractéristiques propres aux BSA T1 (Prix d’Exercice\nPréfinancé, Parité d'Exercice) et des caractéristiques du sous-jacent et des conditions de marché (cours de\nl'action, volatilité de l'action et taux d'intérêt sans risque). Les BSA T1 non exercés à l'issue de la Période\nd'Exercice seront automatiquement caducs et perdront toute valeur, étant précisé que le Prix d’Exercice\nPréfinancé tel que libéré à la date de leur émission restera définitivement acquis à la Société.\nEn application des termes et conditions des BSA T1, le porteur d’un BSA T1 ne pourra pas exercer le BSA T1\ndans le cas où, du fait de l’exercice dudit BSA T1 et postérieurement audit exercice, sa participation au capital\nde la Société serait supérieure à 4,99% du capital ou des droits de vote de la Société (sous réserve que le porteur\nd’un BSA T1 n’ait pas notifié à la Société une baisse ou une augmentation dudit pourcentage de 4,99%).\nLe solde du prix de souscription des Actions Issues des BSA T1, soit 0,01€, devra être intégralement libéré en\nnuméraire au moment de l'exercice des BSA T1. Pour exercer leurs BSA T1, les porteurs devront faire parvenir\nà la Société ou à l'intermédiaire habilité mandaté par la Société leur bulletin de souscription dument rempli\n(avec copie à l'intermédiaire habilité), et verser le montant dû à la Société du fait de cet exercice.\nSGSS assurera la centralisation de ces opérations.\nLa date d'exercice des BSA T1 (la « Date d'Exercice ») sera la date de réception de la demande d'exercice par\nla Société. La livraison des Actions Issues des BSA T1 interviendra au plus tard le troisième jour de bourse\nsuivant la Date d'Exercice T1.\n4.5.2.2 Maintien du droit des porteurs des BSA T1\nA compter de l'émission des BSA T1, si la Société procède notamment à l'une des opérations mentionnées aux\narticles L.228-99 et L.228-101 du Code de commerce, le maintien des droits des titulaires de BSA T1 sera\nassuré conformément auxdits articles.\nPour la défense de leurs intérêts communs, en cas de pluralité de titulaires de BSA T1, ces derniers seront\nregroupés de plein droit en une masse jouissant de la personnalité morale, conformément aux articles L. 228-\n47 et L. 228-103 du Code de commerce.\n26 | 60\n4.5.2.3 Valeur de marché des BSA T1\nLes BSA T1 ont été émis sur la base du prix d’émission correspondant au prix retenu d’Action Nouvelle T1,\nle prix d’exercice étant libéré par anticipation à la date d’émission du BSA T1 moins la valeur nominale de\nladite action. Dès lors, il apparaît que le Prix d’Exercice Préfinancé libéré par anticipation par le souscripteur\nest décorrélé de sa valeur de marché théorique.\n4.5.2.4 Modalités d’exercice des BSA T3\nLes BSA T3 attachés aux Actions Nouvelles T2 dont l’admission n’est pas demandée dans le cadre du présent\nprospectus seront émis sous réserve de l’approbation des résolutions nécessaires par l’Assemblée Générale et\nde la réalisation des Evènements Déclencheurs T2. Les BSA T3 seront des valeurs mobilières donnant accès\nau capital au sens de l’article L. 228-91 du Code de Commerce. Les BSA T3 seront détachés des ABSA dès\nleur émission et ne feront pas l’objet d’une demande d’admission aux négociations sur le marché réglementé\nd’Euronext à Paris, ni sur le Nasdaq ni sur aucun autre marché. Les BSA T3 seront émis au nominatif pur et\nferont, conformément à l’article L. 211-3 du Code de commerce, l’objet d’une inscription en compte ouvert au\nnom de leur titulaire dans les livres du teneur de compte de la Société.\nL'exercice par tout investisseur aux BSA T3 au plus tard le 30 juillet 2027 (la « Date de Maturité des BSA\nT3 ») est soumis à : (i) la publication par la Société des données de base annonçant que le critère principal ou\nl'un des deux critères secondaires clés de NATiV3 (la résolution de la NASH sans aggravation de la fibrose et\nl’amélioration de la fibrose hépatique sans aggravation de la NASH), avec l'un des schémas posologiques testés\ndans l'essai ont été atteint au plus tard le 15 juin 2027 (l' « Évènement Déclencheur T3 ») et (ii) la souscription\npar cet investisseur aux ABSA. Les investisseurs peuvent renoncer à l’Evènement Déclencheur T3 et les BSA\nT3 pourront être exercés avant la réalisation de l’Evènement Déclencheur T3 avec l’accord préalable des\ninvestisseurs souhaitant exercer leurs BSA T3 et représentant 60 % de l'ensemble des porteurs des BSA T3\ndans l’un des cas suivant : (i) acquiert le contrôle de la Société (le contrôle ayant le sens prévu à l'Article L.\n233-3 du Code de commerce), (ii) l'annonce ou le dépôt d'une offre publique d'achat, offre publique d'échange,\noffre alternative, offre mixte, (iii) une fusion par laquelle les participations des actionnaires de la Société sont\ndiluées de 30% ou plus ou (iv) la cession de droits significatifs sur le lanifibranor à une entité dans laquelle la\nSociété détient moins de 51% du capital ou des droits de vote ou (v) un accord relatif au lanifibranor ayant ou\npouvant raisonnablement avoir un effet significatif sur les activités, la situation financière ou les perspectives\nde la Société.\nIl est précisé que pour exercer les BSA T3, les détenteurs de BSA T3 devront avoir souscrits aux Actions\nNouvelles T2. Il est également précisé qu’en cas de litige entre la Société et les porteurs de BSA T3 sur les\nconditions d’exercice des BSA T3, la juridiction compétente est le tribunal de commerce de Paris.\nLes BSA T3 pourront être exercés (la « Période d’Exercice des BSA T3 »), en totalité ou en partie, à la\ndiscrétion du porteur, au plus tôt entre (x) le 45ème jour calendaire suivant le jour la réalisation de l’Évènement\nDéclencheur T3 et (y) le troisième jour ouvrable (inclus) précédant la Date de Maturité des BSA T3 en cas de\nsurvenance de l’Évènement Déclencheur T3.\nL’exercice des BSA T3 fera l’objet d’un communiqué de presse au jour de la réunion du Conseil\nd’Administration ou du Directeur Général agissant sur délégation du Conseil d’Administration de la Société\nconstatant la réalisation de l’Évènement Déclencheur T3 ou la renonciation par les investisseurs à cette\ncondition.\nSi l’Évènement Déclencheur T3 n’est pas rempli ou ne se réalise pas dans la période de temps définie, les BSA\nT3 deviendront automatiquement caducs le troisième jour ouvrable suivant la Période d’Exercice des BSA T3.\n27 | 60\nLes BSA T3 non exercés à l’issue de leur période d’exercice seront automatiquement caducs et perdront toute\nvaleur.\nLes BSA T3 sont librement cessibles. Tout cessionnaire s’engage à respecter les termes et conditions des BSA\nT3.\nLe Prix d’Exercice des BSA T3 (tel que défini en section 5.3.1) devra être intégralement libéré en numéraire\nau moment de l’exercice des BSA T3. Pour exercer leurs BSA T3, les porteurs devront faire parvenir à la\nSociété ou à l’intermédiaire habilité mandaté par la Société leur bulletin de souscription dument rempli (avec\ncopie à l’intermédiaire habilité), et verser le montant dû à la Société du fait de cet exercice.\nSociété Générale Securities Services assurera la centralisation de ces opérations.\nLes Actions Issues des BSA T3 feront l'objet de demandes d'admission périodiques aux négociations et au plus\ntard trois jours ouvrés suivant la fin de la Période d’Exercice des BSA T3 soit, au plus tard le 30 juillet 2027.\n4.5.2.5 Maintien du droit des porteurs de BSA T3\nA compter de l’émission des BSA T3, si la Société procède notamment à l’une des opérations mentionnées aux\narticles L.228-99 et L.228-101 du Code de commerce, le maintien des droits des titulaires de BSA T3 sera\nassuré conformément auxdits articles.\nPour la défense de leurs intérêts communs, les titulaires de BSA T3, seront regroupés de plein droit en une\nmasse jouissance de la personnalité morale, conformément aux articles L. 228-47 et L. 228-103 du Code de\ncommerce (décidant dans le cadre d’une majorité des 2/3).\n4.6 Autorisations\n4.6.1 Délégation de compétence et autorisation de l’assemblée générale des actionnaires du 20 juin 2024 (l’\n« Assemblée Générale Annuelle 2024 ») au Conseil d’administration\nL’émission des Actions Nouvelles T1 et des BSA T1, sans droit préférentiel de souscription, est réalisée dans\nle cadre de la 25ème résolution de l’Assemblée Générale Annuelle 2024 aux termes de laquelle :\n\"VINGT-CINQUIEME RESOLUTION (Délégation de compétence à conférer au Conseil d’Administration\nà l’effet de décider l’émission d’actions ordinaires ou de valeurs mobilières donnant accès à des actions\nordinaires à émettre immédiatement ou à terme par la Société, avec suppression du droit préférentiel de\nsouscription des actionnaires au profit de catégories de bénéficiaires)\nL’Assemblée Générale, statuant aux conditions de quorum et de majorité requises pour les assemblées\ngénérales extraordinaires, après avoir pris connaissance du rapport du Conseil d’Administration et du rapport\nsp écial des Commissaires aux comptes, et constaté la libération intégrale du capital social, conformément aux\ndispositions des articles L.225-129 et suivants du Code de commerce, et notamment des articles L.225-129-2,\nL.22-10-49, L.22-10-51, L.225-138, et aux dispositions des articles L.228-91 et suivants dudit Code de\ncommerce,\n1. Délègue au Conseil d’Administration, avec faculté de subdélégation dans les conditions prévues par la loi,\nsa compétence, pour procéder, en une ou plusieurs fois, en France et/ou à l’étranger, dans les proportions et\naux époques qu’il appréciera, à l’émission, en euros ou en monnaie étrangère, ou en toute autre unité\nmonétaire établie par référence à plusieurs monnaies, avec suppression du droit préférentiel de souscription\ndes actionnaires au profit de catégories de bénéficiaires, d’actions ordinaires de la Société et/ou de valeurs\n28 | 60\nmobilières donnant accès par tous moyens, immédiatement et/ou à terme, à des actions ordinaires à émettre\npar la Société.\n2. Décide que le montant nominal total des augmentations de capital pouvant être réalisées dans le cadre de\nla présente délégation ne pourra excéder sept cent mille euros (700.000 €), étant précisé, d’une part, que ce\nplafond est commun au plafond fixé au 2) de la 22ème résolution ci-avant et s’impute sur ce dernier et, d’autre\npart, que le montant nominal des augmentations de capital susceptibles de résulter de la présente résolution\ns’impute sur le plafond global de sept cent mille euros (700.000 €) fixé au 3) de la 21ème résolution ci-avant.\nA ces plafonds s’ajoutera, le cas échéant, la valeur nominale des actions à émettre pour préserver,\nconformément à la loi et, le cas échéant, aux stipulations contractuelles prévoyant d’autres cas d’ajustement,\nles droits des titulaires de valeurs mobilières ou autres droits donnant accès au capital de la Société.\n3. Décide que les valeurs mobilières donnant accès à du capital à émettre par la Société pourront notamment\nconsister en des titres de créance ou être associées à l’émission de tels titres, ou encore en permettre l’émission\ncomme titres intermédiaires. Elles pourront revêtir notamment la forme de titres subordonnés ou non, à durée\ndéterminée ou non, et être émises en euros, en devises étrangères, ou en toutes unités monétaires établies par\nréférence à plusieurs monnaies.\nLe montant nominal des titres de créance susceptibles d’être émis dans le cadre de la présente délégation ne\npourra excéder la somme de cent cinquante millions d’euros (150.000.000 €) ou la contre-valeur de ce montant\nen devises ou en toutes unités monétaires établies par référence à plusieurs monnaies, ce montant s’imputant\nsur le plafond fixé au 4) de la 21ème résolution ci-avant.\n4. Décide de supprimer le droit préférentiel de souscription des actionnaires aux actions et autres valeurs\nmobilières pouvant être émises en application de la présente résolution et de réserver les actions et autres\nvaleurs mobilières à émettre en application de la présente résolution au profit de catégories de bénéficiaires\nprésentant l’une des caractéristiques suivantes, à savoir : i. des personnes physiques ou morales, (en ce\ncompris des sociétés), trusts ou fonds d’investissement, ou autres véhicules de placement, quelle que soit leur\nforme, de droit français ou étranger, investissant à titre habituel dans le secteur pharmaceutique,\nbiotechnologique, ou des technologies médicales ; et/ou ii. des sociétés, institutions ou entités quelle que soit\nleur forme, françaises ou étrangères, exerçant une part significative de leurs activités dans le domaine\npharmaceutique, cosmétique ou chimique ou des dispositifs et/ou technologies médicaux ou de la recherche\ndans ces domaines ; et/ou iii. des prestataires de service d'investissement français ou étranger, ou tout\nétablissement étranger ayant un statut équivalent, susceptibles de garantir la réalisation d'une émission\ndestinée à être placée auprès des personnes visées au (i) et/ou (ii) ci-dessus et, dans ce cadre, de souscrire aux\ntitres émis.\n5. Décide que le Conseil d’Administration, avec faculté de subdélégation dans les conditions prévues par la\nloi, fixera la liste précise des bénéficiaires de cette ou ces augmentations de capital et/ou émissions de valeurs\nmobilières réservées au sein de cette ou ces catégories de personnes et le nombre de titres à attribuer à chacun\nd’eux.\n6. Décide que si les souscriptions n’ont pas absorbé la totalité d’une émission d’actions ou de valeurs\nmobilières donnant accès au capital émises en vertu de la présente résolution, le Conseil d’Administration\npourra limiter l’émission au montant des souscriptions à la condition que celui-ci atteigne les trois-quarts au\nmoins de l’émission décidée.\n7. Prend acte que la présente délégation emporte renonciation des actionnaires à leur droit préférentiel de\nsouscription aux actions de la Société auxquelles les valeurs mobilières qui seraient émises sur le fondement\nde la présente délégation pourront donner droit.\n29 | 60\n8. Décide que le prix d’émission des actions ordinaires et des valeurs mobilières à émettre dans le cadre de la\nprésente résolution sera fixé par le Conseil d’Administration, avec faculté de subdélégation dans les conditions\nprévues par la loi, conformément aux dispositions des articles L.225-138 II et devra au moins être égal : (i)\npour les actions ordinaires : • soit au cours moyen pondéré par les volumes de l'action de la Société sur le\nmarché réglementé d'Euronext à Paris lors de la dernière séance de bourse précédant la fixation du prix\nd'émission ; • soit à la moyenne pondérée par les volumes des cours de l'action de la Société sur le marché\nréglementé d'Euronext à Paris choisis parmi une période comprenant entre trois et sept séances de bourse\nconsécutives parmi les 30 dernières séances de bourse précédant la fixation du prix d'émission ; éventuellement\ndiminué d'une décote maximale de 15 %, le Conseil d’Administration pouvant librement utiliser l'une ou l'autre\ndes deux formules énoncées ci-dessus ; et (ii) (a) le prix d’émission des actions susceptibles de résulter de\nl'exercice des valeurs mobilières donnant accès au capital émises en vertu de la présente délégation, de leur\nconversion, de leur échange ou de leur remboursement pourra le cas échéant être fixé, à la discrétion du\nConseil d’Administration, par référence à une formule de calcul définie par celui-ci et applicable\npostérieurement à l’émission desdites valeurs mobilières (par exemple lors de leur exercice, conversion,\nremboursement ou échange) auquel cas la décote maximale susvisée pourra être appréciée, si le Conseil\nd’Administration le juge opportun, à la date d’application de ladite formule (et non à la date de l’émission de\nla valeur mobilière), et (b) le prix d’émission des valeurs mobilières à émettre dans le cadre de la présente\nrésolution, autres que des actions, sera tel que la somme perçue immédiatement par la Société majorée, le cas\néchéant, de celle susceptible d’être perçue ultérieurement par la Société soit, pour chaque action émise en\nconséquence de l’émission de ces valeurs mobilières, au moins égale au montant visé au paragraphe (i) ci-\ndessus.\n9. Décide que le Conseil d’Administration aura tous pouvoirs, avec faculté de subdélégation dans les\nconditions prévues par la loi, pour mettre en œuvre la présente résolution, et notamment de : – déterminer les\ncaractéristiques, montant et modalités de toute émission ainsi que des titres émis, notamment, la catégorie des\ntitres émis et fixer, compte tenu des indications contenues dans son rapport, leur prix de souscription, avec ou\nsans prime, les modalités de leur libération (qui pourra être opérée en espèces et/ou par compensation avec\ndes créances liquides et exigibles ou pour partie en numéraire et pour partie par incorporation de réserves,\nbénéfices ou primes d’émission), leur date de jouissance éventuellement rétroactive, les modalités selon\nlesquelles les valeurs mobilières émises sur le fondement de la présente résolution donneront accès à des\nactions à émettre de la Société, les conditions dans lesquelles ces valeurs mobilières pourront également\ndonner accès à des titres de capital existants ou à des titres de créance de la Société, les conditions de leur\nrachat et de leur éventuelle annulation ainsi que la possibilité de suspension de l’exercice des droits\nd’attribution d’actions ordinaires attachés aux valeurs mobilières à émettre ; – déterminer lorsque les valeurs\nmobilières émises consisteront ou seront associées à des titres de créance, leur durée déterminée ou non, leur\ncaractère subordonné ou non et leur rémunération ; – prendre toutes mesures nécessaires destinées à protéger\nles droits des titulaires de valeurs mobilières ou autres droits donnant accès au capital et ce, en conformité\navec les dispositions légales et réglementaires et, le cas échéant, les stipulations contractuelles prévoyant\nd’autres cas d’ajustement ; – imputer, le cas échéant, les frais des augmentations de capital sur le montant des\nprimes afférentes à ces augmentations et, s’il le juge opportun, prélever sur ce montant les sommes nécessaires\npour porter la réserve légale au dixième du nouveau capital après chaque augmentation ; – passer toute\nconvention, en particulier en vue de la bonne fin de toute émission, pour procéder en une ou plusieurs fois,\ndans la proportion et aux époques qu’il appréciera, en France et/ou, le cas échéant, à l’étranger, aux émissions\nsusvisées, ainsi que, le cas échéant, pour y surseoir ; – faire procéder, le cas échéant, à l'admission aux\nnégociations sur un marché réglementé et/ou tout autre marché financier situé hors de l'Espace Economique\nEuropéen des actions ordinaires, des valeurs mobilières à émettre ou des actions qui seraient émises par\nexercice des valeurs mobilières donnant accès au capital à émettre ; et – constater la réalisation des\naugmentations de capital résultant de la présente résolution et procéder à la modification corrélative des\nstatuts, ainsi que de procéder à toutes formalités et déclarations et requérir toutes autorisations qui\ns’avèreraient nécessaires à la réalisation et à la bonne fin de ces émissions.\n30 | 60\n10. Décide que la présente délégation est consentie pour une période de 18 mois à compter de la présente\nAssemblée et met fin, avec effet immédiat, à toute délégation antérieure ayant le même objet. Elle prive donc\nd’effet la délégation accordée par l’Assemblée générale mixte du 25 janvier 2023 dans sa 6ème résolution. Le\nConseil d’Administration établira un rapport à la prochaine Assemblée générale ordinaire décrivant les\nconditions définitives des opérations réalisées en application de la présente résolution\".\n4.6.2 Décision du Conseil d’administration ayant arrêté les modalités définitives de l’émission\nAprès avoir constaté que le capital social de la Société est intégralement libéré et après en avoir délibéré, le\nConseil d’administration, à l’unanimité des présents :\n− constate que la moyenne pondérée par les volumes des cours de l'action de la Société sur Euronext\nParis lors des cinq dernières séances de bourse précédant la fixation du prix d’émission, soit les\nséances du 7, 8, 9, 10 et 11 octobre 2024, s'élève à 1,5048 € (le « Prix de Référence ») et diminuée\nd’une décote de 15% s'élève à 1,28 € ;\n− décide de fixer le prix de souscription de chaque Action Nouvelle T1 à 1,35 euro (le « Prix de\nSouscription des Actions Nouvelles T1 ») et le prix d’exercice de chaque BSA T1 à 1,35 euro (le\n« Prix d’Exercice des BSA T1 ») ce qui correspond au Prix de Référence diminuée d’une décote de\n10%, en conformité avec la 25ème résolution de l'Assemblée Générale Annuelle 2024 ;\n− décide de procéder à une augmentation de capital en numéraire avec suppression du droit préférentiel\nde souscription par voie d’offre réservée à des catégories spécifiques d'investisseurs, conformément\naux dispositions de l'article L. 225-138 du Code de commerce, au titre de l’Offre Réservée T1 d’un\nmontant nominal de 346.005,07 euros, par l'émission de 34.600.507 Actions Nouvelles d’une valeur\nnominale de 0,01 euros chacune (et 1,34 euros de prime d’émission) et à libérer intégralement au\nmoment de la souscription, soit une augmentation de capital d’un montant total de 46.710.684,45\neuros, comprenant une prime d’émission d’un montant de 46.364.679,38 euros, en conformité avec\nles plafonds autorisés et disponibles prévus au sein des 21ème, 22ème et 25ème résolutions de\nl'Assemblée Générale Annuelle ;\n− décide de procéder à l’émission de 35.399.481 BSA T1 pour un montant total de 47.435.304,54 euros\nlors de l’émission et de 47.789.299,35 euros en cas d’exercice de la totalité des BSA T1, étant précisé\nque le Prix d’Exercice des BSA T1, soit 1,35 euro, est libéré par anticipation à hauteur de 1,34 euro\n(soit le prix d'exercice moins la valeur nominale d'une Action Issue des BSA T1) au jour de l’émission\ndes BSA T1 et non au jour de l’exercice des BSA T1 (le « Prix d’Exercice Préfinancé »),\n− en conséquence, décide de fixer le montant nominal maximal de l'augmentation de capital résultant\nde l'exercice intégral des BSA T1 à 353.994,81 euros, par émission d’un maximum de 35.399.481\nactions ordinaires, de 0,01 euro de valeur nominale à souscrire en numéraire au prix de 0,01 euro,\net à libérer entièrement au moment de la souscription, soit une augmentation de capital d'un montant\nnominal maximum de 353.994,81 euros (et une prime d’émission correspondant au montant du Prix\nd’Exercice Préfinancé libéré par anticipation au moment de la souscription des BSA T1, étant précisé\nque ce montant ne prend pas en compte la valeur nominale des actions ordinaires à émettre afin de\npréserver les droits des porteurs de valeurs mobilières donnant accès au capital émises ou à émettre,\nconformément aux dispositions légales et réglementaires et aux stipulations contractuelles prévoyant\nd'autres cas d'ajustement le cas échéant) ;\n4.7 Date prévue d’émission des valeurs mobilières\nLa date prévue pour l’émission des Actions Nouvelles T1 et les BSA T1 est le 17 octobre 2024.\n31 | 60\n4.8 Restrictions à la libre négociabilité des Actions Offertes et des BSA T1\nAucune clause statutaire ne limite la libre négociation des actions composant le capital de la Société. Une\ndescription détaillée des engagements pris par la Société et certains de ses actionnaires figure en section 5.4.4\nde la Note d’Opération.\nPar ailleurs, le pacte d'actionnaires conclu entre Monsieur Frédéric Cren et Monsieur Pierre Broqua (les\n« Fondateurs ») précise que toute cession de titres de la Société par l'un des Fondateurs est soumise à un droit\nd’information préalable sur le projet de cession et à un droit de sortie conjointe proportionnelle des autres\nparties, hors certains cas de cessions libres en faveur du conjoint, des descendants et/ou d'une société\npatrimoniale détenue, le cas échéant, par un Fondateur (se référer au paragraphe 6.1.4 du Document\nd'Enregistrement Universel 2023).\nLes investisseurs participant à l'Opération se sont engagés à conserver leurs Actions Nouvelles T1 et leur BSA\nT1 jusqu’à la première des deux dates suivantes : (x) la date d’émission des Actions Nouvelles T2 ou (y) le 20\nmai 2025, sous réserve de certaines exceptions (transfert à un autre investisseur, à une société affiliée de\nl’investisseur ou sous réserve de l’accord de la Société à sa seule discrétion, à une tierce partie qui prendrait\nles mêmes engagements de conservation en ce qui concerne les Actions Nouvelles T1 et les BSA T1).\nEn cas d’émission des Actions Nouvelles T1bis, les investisseurs s’engageront à conserver les Actions\nNouvelles T1bis dans les mêmes conditions que les Actions Nouvelles T1 et les BSA T1.\n4.9 Réglementation française en matière d’offres publiques\nLa Société est soumise aux dispositions législatives et réglementaires en vigueur en France relatives aux offres\npubliques obligatoires, aux offres publiques de retrait et à la procédure de retrait obligatoire.\nEn outre, la Société est soumise aux règles de contrôle des investissements étrangers qu'il convient de prendre\nen compte en cas de réalisation des opérations d’acquisition prévues aux présentes.\n4.9.1 Offre publique obligatoire\nL’article L. 433-3 du Code monétaire et financier fixe les principes directeurs relatifs aux cas d’offre publique\nobligatoire, aux possibilités d’accorder des dérogations, et aux sanctions encourues en l’absence de dépôt d’un\nprojet d’offre publique, en conférant à l’AMF le pouvoir d’en fixer les conditions et modalités d’application.\nLe chapitre IV du titre III du règlement général de l’AMF (« Dépôt obligatoire d’un projet d’offre publique »)\ncomporte, lui, dix articles consacrés à l’offre publique obligatoire, et plus précisément à l’obligation de déposer\nune telle offre.\n4.9.2 Offre publique de retrait et retrait obligatoire\nL’article L. 433-4 du Code monétaire et financier et les articles 236-1 et suivants (offre publique de retrait) et\n237-1 et suivants (retrait obligatoire) du règlement général de l’AMF prévoient les conditions de dépôt d’une\noffre publique de retrait et de mise en œuvre d’une procédure de retrait obligatoire par les actionnaires\nminoritaires d’une société dont les actions sont admises aux négociations sur un marché réglementé.\nL’arrêté du 19 juin 2019, publié au Journal officiel du 21 juin 2019, modifie le livre II du règlement général de\nl’AMF relatif aux offres publiques de retrait et au retrait obligatoire.\nEn particulier, les modifications apportées au règlement général concernent (i) l’abaissement du seuil de\ndéclenchement de l’offre publique de retrait (l’actionnaire majoritaire devant détenir seul ou de concert au\nmoins 90 % du capital ou des droits de vote) ; et (ii) l’abaissement du seuil de déclenchement du retrait\n32 | 60\nobligatoire (l’actionnaire majoritaire devant détenir seul ou de concert au moins 90 % du capital et des droits\nde vote).\n4.9.3 Contrôle des investissements étrangers réalisés en France\nLa réalisation de tout investissement :\n(i) par (a) une personne physique de nationalité étrangère, (b) toute personne physique de nationalité française\nnon domiciliée en France au sens de l'article 4B du Code Général des Impôts, (c) toute entité de droit étranger\net (d) toute entité de droit français contrôlée par une ou plusieurs entités mentionnées au (a) à (c),\n(ii) qui aurait pour conséquence, (a) d'acquérir le contrôle - au sens de l'article L. 233-3 du Code de commerce\n- d'une société française, (b) d'acquérir tout ou partie d'une branche d'activité d'une société française ou (c)\npour les personnes physiques ne possédant pas la nationalité d'un Etat membre de l'Union européenne ou d'un\nEtat partie à l'accord sur l'Espace économique européen ayant conclu une convention d'assistance\nadministrative avec la France et/ou non domiciliées dans l'un de ces Etats ou pour les personnes morales dont\nl'un au moins des membres de la chaine de contrôle ne relève pas du droit de l'un de ces mêmes Etats ou n'en\npossède pas la nationalité et/ou n'y est pas domicilié, de franchir le seuil de 25% de détention des droits de vote\nd'une société française, et\n(iii) dont les activités portent, même à titre occasionnel, sur la recherche et le développement de technologies\ndites critiques, telles que les biotechnologies, et considérées comme essentielles à la protection de la santé\npublique, est soumise à autorisation préalable du Ministre de l'Economie. Le 2 juillet 2020, le Ministère de\nl'Economie et des Finances, a confirmé à la Société que ses activités entraient dans le champ d'application de\nce régime. Dès lors, tous projets d'investissement au capital de la Société correspondant aux critères susvisés\ndevront être autorisés par le Ministre de l'Economie préalablement à leur réalisation définitive, par saisine de\nl'investisseur concerné.\nPar ailleurs, le décret n°2020-892 du 22 juillet 2020 relatif à l'abaissement temporaire du seuil de contrôle des\ninvestissements étrangers dans les sociétés françaises dont les actions sont admises aux négociations sur un\nmarché réglementé, tel que modifié en dernier lieu par le décret 2023 n°2023-1293 du 28 décembre 2023 relatif\naux investissements étrangers en France est venu (i) pérenniser le contrôle du franchissement du seuil de 10 %\ndes droits de vote des sociétés concernées cotées sur un marché réglementé par des investisseurs extra-\neuropéens, et (ii) soumettre ce nouveau seuil à une procédure rapide d’examen (dépôt d’un formulaire simplifié,\ndélai de réponse du Ministre de l’Economie limité à 10 jours, opération réputée autorisée en l’absence de\nréponse à l’issue du délai).\nSi un investissement nécessitant l'autorisation préalable du Ministre de l’Economie est réalisé sans que cette\nautorisation ait été accordée, le Ministre de l’Economie peut demander à l'investisseur concerné de (i)\nsoumettre une demande d'autorisation, (ii) faire rétablir la situation antérieure à l'investissement à ses frais ou\n(iii) modifier l'investissement. L'investisseur concerné risque de voir sa responsabilité pénale engagée et peut\nrecevoir une amende qui ne peut dépasser le plus élevé des montants suivants : (i) deux fois le montant de\nl'investissement en question, (ii) 10% du chiffre d'affaires annuel avant impôts de l'entreprise cible et (iii) 5\nmillions d'euros (pour une entité) ou 1 million d'euros (pour une personne physique). Le non-respect de ces\nmesures pourrait avoir des conséquences importantes pour l'investisseur concerné. Ces mesures pourraient être\nutilisées pour décourager les tentatives de prise de contrôle ce qui peut entraîner une baisse ou une volatilité\naccrue du prix des actions.\n33 | 60\n4.10 Offres publiques d’acquisition lancées par des tiers sur le capital de l’émetteur durant le dernier exercice\net l’exercice en cours\nAucune offre publique d’acquisition émanant de tiers n’a été lancée sur le capital de la Société durant le dernier\nexercice et l’exercice en cours.\n4.11 Traitement fiscal applicable aux revenus liés à la détention des actions de la Société et taxe sur les\ntransactions financières\nIl est rappelé aux investisseurs que le droit fiscal de leur État ainsi que le droit fiscal français, pays dans lequel\nest immatriculée la Société, sont susceptibles d’avoir une incidence sur les revenus tirés des Actions Offertes.\nLes informations ci-après ne constituent qu’un résumé de certaines conséquences fiscales liées à la détention\ndes actions de la Société, en ce compris les Actions Offertes, susceptibles de s’appliquer, en l’état actuel de la\nlégislation fiscale française et sous réserve de l’application éventuelle des conventions fiscales internationales,\n(i) aux actionnaires de la Société dont la résidence fiscale est située en France, personnes morales soumises à\nl’impôt sur les sociétés ou personnes physiques qui détiennent les titres de la Société dans leur patrimoine privé\net ne réalisent pas d’opération de bourse dans des conditions analogues à celles qui caractérisent une activité\nexercée par une personne se livrant à titre professionnel à ce type d’opérations et qui recevront des dividendes\nà raison de ces actions et (ii) aux actionnaires de la Société dont la résidence fiscale est située hors de France,\nqui détiendront des actions de la Société autrement que par l’intermédiaire d’une base fixe en France ou d’un\nétablissement stable en France et qui recevront des dividendes à raison de ces actions.\nLes règles dont il est fait mention ci-après sont susceptibles d’être affectées par d’éventuelles modifications\nlégislatives ou réglementaires (assorties le cas échéant d’un effet rétroactif) ou par un changement de leur\ninterprétation par l’administration fiscale française ou par la jurisprudence.\nEn tout état de cause, l’attention du lecteur est attirée sur le fait que ces informations n’ont pas vocation à\nconstituer une analyse complète de l’ensemble des effets fiscaux susceptibles d’avoir une incidence sur la\nperception de revenus au titre de la détention des actions de la Société et plus généralement aux personnes qui\ndeviendraient actionnaires de la Société.\nCelles-ci sont également invitées à s’informer, auprès de leur conseiller fiscal habituel, de la fiscalité\ns’appliquant à leur cas particulier à raison de l’acquisition, la détention ou la cession des actions de la Société.\nLes non-résidents fiscaux français doivent également se conformer à la législation fiscale en vigueur dans leur\nEtat de résidence et, le cas échéant, aux dispositions des conventions fiscales éventuellement applicables.\nIl est précisé en tant que de besoin que les retenues et prélèvements à la source décrits dans les développements\nqui suivent ne seront en aucun cas pris en charge par la Société.\n4.11.1 Actionnaires dont la résidence fiscale est située en France\n4.11.1.1 Actionnaires personnes physiques dont la résidence fiscale est située en France agissant dans le cadre de leur\npatrimoine privé et en dehors d’un plan d’épargne en actions\nLes paragraphes suivants décrivent le régime fiscal susceptible de s’appliquer aux dividendes versés par la\nSociété aux personnes physiques, ayant leur résidence fiscale en France, détenant les actions de la Société dans\nle cadre de leur patrimoine privé en dehors du cadre d’un plan d’épargne en actions (« PEA ») et ne réalisant\npas d’opérations de bourse à titre professionnel ou dans des conditions analogues à celles qui caractérisent une\nactivité exercée par une personne se livrant à titre professionnel à ce type d’opérations.\n34 | 60\n1) Prélèvement forfaitaire non libératoire et imposition à l’impôt sur le revenu\nEn application de l’article 117 quater du Code général des impôts (« CGI »), les dividendes versés aux\npersonnes physiques fiscalement domiciliées en France sont soumis à un prélèvement forfaitaire non libératoire\nde l’impôt sur le revenu au taux forfaitaire de 12,8% assis sur le montant brut des revenus distribués.\nLe paiement de ce prélèvement forfaitaire non libératoire est effectué par l’établissement payeur des dividendes\ns’il est établi en France. S’il est établi hors de France, les dividendes versés par la Société sont déclarés et le\nprélèvement correspondant payé, dans les 15 premiers jours du mois qui suit celui du paiement des dividendes,\nsoit par le contribuable lui-même auprès du service des impôts de son domicile, soit par l’établissement payeur,\nlorsqu’il est établi dans un Etat partie à l’accord sur l’EEE, et qu’il a été mandaté à cet effet par le contribuable.\nLorsque l’établissement payeur est établi en France, les personnes physiques appartenant à un foyer fiscal dont\nle revenu fiscal de référence de l’avant-dernière année, tel que défini au 1° du IV de l’article 1417 du CGI, est\ninférieur à 50.000 euros pour les contribuables célibataires, divorcés ou veufs, et à 75.000 euros pour les\ncontribuables soumis à une imposition commune, peuvent demander à être dispensés de ce prélèvement dans\nles conditions prévues par l’article 242 quater du CGI, à savoir en produisant à l’établissement payeur et au\nplus tard le 30 novembre de l’année précédant celle du paiement des dividendes, une déclaration sur l’honneur\nindiquant que leur revenu fiscal de référence figurant sur l’avis d’imposition émis au titre des revenus de\nl’avant-dernière année précédant celle du paiement est inférieur aux seuils de revenus imposables\nsusmentionnés. Toutefois, les contribuables qui acquièrent des actions après la date limite de dépôt de la\ndemande de dispense susmentionnée peuvent déposer cette demande de dispense auprès de leur établissement\npayeur lors de l’acquisition de ces actions, conformément à l’interprétation de l’administration fiscale publiée\nau Bulletin Officiel des Finances Publiques (« BOFIP ») (BOI-RPPM-RCM-30-20-10-06/07/2021, n° 320).\nLorsque l’établissement payeur est établi hors de France, seules les personnes physiques qui appartiennent à\nun foyer fiscal dont le revenu fiscal de référence de l’avant-dernière année, tel que défini au 1° du IV de l’article\n1417 du CGI, est égal ou supérieur aux seuils mentionnés dans le paragraphe précédent sont soumis à ce\nprélèvement.\nCe prélèvement forfaitaire non libératoire constitue un acompte d’impôt sur le revenu et s’impute sur l’impôt\nsur le revenu dû au titre de l’année au cours de laquelle il est opéré, l’excédent étant restitué.\nL’imposition définitive de ces dividendes est liquidée à partir des éléments portés dans la déclaration de revenus\nsouscrite l’année suivant celle de leur perception.\nEn principe, les revenus sont soumis à l’impôt sur le revenu à un taux forfaitaire de 12,8% (dit prélèvement\nforfaitaire unique ou PFU). En pratique, le taux du prélèvement forfaitaire non libératoire étant aligné sur celui\ndu PFU, ces dividendes ne donnent généralement pas lieu à imposition complémentaire au titre de l’impôt sur\nle revenu.\nPar exception à ce qui est mentionné ci-dessus et sur option exercée dans la déclaration de revenus, les\ndividendes peuvent être soumis au barème progressif de l’impôt sur le revenu (article 200 A, 2 du CGI). Dans\nce cas, les dividendes sont pris en compte dans le revenu global (articles 13, 2 et 158, 3 du CGI) pour leur\nmontant net après déduction, notamment, d’un abattement égal à 40% du montant des dividendes versés. Cette\noption est globale et porte sur l'ensemble des revenus, gains nets, profits et créances entrant dans le champ\nd'application du PFU.\nEn outre, quel que soit le lieu du domicile fiscal du bénéficiaire, les dividendes payés hors de France dans un\nÉtat ou territoire non coopératif au sens de l’article 238-0 A du CGI (« ETNC ») autre que ceux mentionnés\nau 2° du 2 bis de cet article 238-0 A du CGI (c’est-à-dire autre que ceux figurant sur la liste en raison d’un\ncritère européen autre que celui de la facilitation des structures ou dispositifs extraterritoriaux), une retenue à\n35 | 60\nla source de 75% est applicable. Nonobstant ce qui précède, le prélèvement de 75% ne s’applique pas si le\ndébiteur apporte la preuve que les distributions dans cet ETNC n’ont ni pour objet ni pour effet de permettre,\ndans un but de fraude fiscale, leur localisation dans un tel ETNC. La liste des ETNC est publiée par arrêté\nministériel et peut être mise à jour à tout moment, en principe au moins une fois par an. Les dispositions de\nl’article 238-0 A du CGI s’appliquent aux États ou territoires ajoutés à cette liste à compter du premier jour du\ntroisième mois qui suit la publication de l’arrêté.\nAux termes de l’arrêté du 16 février 2024 modifiant l’arrêté du 12 février 2010 pris en application du deuxième\nalinéa du 1 de l’article 238-0 A du CGI, la liste des ETNC, autres que ceux mentionnés au 2° du 2 bis de cet\narticle 238-0 A du CGI est composée à la date de la Note d’Opération, des Etats et territoires suivants :\nAnguilla, les Bahamas, les Iles Turques et Caïques, les Seychelles, et Vanuatu.\nEn cas d’application de la retenue à la source de 75%, les bénéficiaires résidents de France disposant d’un\ncompte dans un ETNC sont autorisés à imputer la retenue à la source prélevée sur les revenus qu’ils ont perçus\nlorsqu’ils les déclarent à l’impôt sur le revenu, en application de l’article 199 ter, I-a du CGI (BOI-INT-DG-\n20-50-30-14/06/2022, n° 290).\n2) Contribution exceptionnelle sur les hauts revenus\nIl est par ailleurs rappelé qu’en vertu de l’article 223 sexies du CGI, les contribuables passibles de l’impôt sur\nle revenu sont redevables d’une contribution exceptionnelle sur les hauts revenus (« CEHR »), au taux de :\n- 3% sur la fraction du revenu fiscal de référence (i) supérieure à 250.000 euros et inférieure ou égale à\n500.000 euros pour les contribuables célibataires, veufs, séparés ou divorcés ou (ii) supérieure à 500.000\neuros et inférieure ou égale à un million d’euros pour les contribuables soumis à une imposition commune ;\n- 4% sur la fraction du revenu fiscal de référence (i) supérieure à 500.000 euros pour les contribuables\ncélibataires, veufs, séparés ou divorcés ou (ii) supérieure à un million d’euros pour les contribuables soumis\nà une imposition commune.\nL’assiette de la CEHR est constituée du montant du revenu fiscal de référence du foyer fiscal tel que défini au\n1. du IV de l’article 1417 du CGI (le « Revenu Fiscal de Référence »). Le Revenu Fiscal de Référence\ncomprend notamment les dividendes perçus par les contribuables concernés, le cas échéant, avant application\nde l’abattement de 40% mentionné ci-dessus.\n3) Prélèvements sociaux\nLe montant brut des dividendes distribués par la Société est également soumis aux prélèvements sociaux (non\ndéductibles du revenu imposable) au taux global de 17,2%. Toutefois, en cas d'option pour l'imposition au\nbarème progressif de l'impôt sur le revenu, la CSG est déductible à hauteur de 6,8%.\nLes actionnaires sont invités à se rapprocher de leur conseiller fiscal habituel afin de déterminer les modalités\ndéclaratives et les modalités de paiement du prélèvement forfaitaire non libératoire et des prélèvements sociaux\nqui leur seront applicables.\n4.11.1.2 Eligibilité au PEA et au PEA dit « PME-ETI » des Actions Offertes\nLes actions ordinaires de la Société, en ce compris les Actions Offertes, constituent des actifs éligibles au PEA.\nA la date du Prospectus, les actions de la Société constituent des actifs éligibles au PEA « PME - ETI ».\n36 | 60\n4.11.1.3 Actionnaires personnes morales soumis à l’impôt sur les sociétés dans les conditions de droit commun\nLes revenus distribués au titre des actions détenues par les personnes morales dont la résidence fiscale est située\nen France soumis à l’impôt sur les sociétés dans les conditions de droit commun ne sont, en principe, soumis\nà aucune retenue à la source.\nToutefois, en application des articles 119 bis, 2 et 187 du CGI, s’ils sont payés hors de France dans un ETNC,\nà l’exception de ceux mentionnés au 2° du 2 bis l’article 238-0 A du CGI , les dividendes versés par la Société\nfont l’objet d’une retenue à la source au taux de 75%, sauf si le débiteur apporte la preuve que les distributions\nde ces produits n’ont ni pour objet ni pour effet de permettre, dans un but de fraude fiscale, leur localisation\ndans un tel Etat ou territoire (cf. 4.11.1.1 pour la liste de ces ETNC).\nLes dividendes perçus par les personnes morales établies en France sont imposables dans les conditions de\ndroit commun, c’est-à-dire en principe au taux normal de l'impôt sur les sociétés actuellement de 25% et\nmajoré, le cas échéant, de la contribution sociale de 3,3% qui s'applique au montant de l'impôt sur les sociétés\nexcédant 763.000 euros par période de douze mois (article 235 ter ZC du CGI).\nLes entreprises dont le chiffre d’affaires est inférieur à 10 millions d’euros sont susceptibles de bénéficier, dans\nles conditions prévues aux articles 219, I-b et 235 ter ZC du CGI, d’une réduction du taux de l’impôt sur les\nsociétés à 15% pour la fraction de leur bénéfice imposable inférieure à 42.500 euros. Les entreprises dont le\nchiffre d’affaires est inférieur à 7,63 millions d’euros seront quant à elles susceptibles de bénéficier, en plus du\ntaux réduit, d’une exonération de la contribution sociale de 3,3%.\nConformément aux dispositions des articles 145 et 216 du CGI, les personnes morales soumises à l’impôt sur\nles sociétés détenant une participation représentant au moins 5% du capital de la Société, peuvent bénéficier,\nsous certaines conditions et sur option, du régime des sociétés mères en vertu duquel les dividendes perçus par\nla société mère ne sont en principe pas soumis à l’impôt sur les sociétés, à l’exception d’une quote-part\nforfaitaire représentative des frais et charges supportés par cette société et égale à5 % du montant desdits\ndividendes. Pour pouvoir bénéficier de cette exonération, les titres ouvrant droit au régime des sociétés mères\ndoivent, en particulier, être ou avoir été conservés pendant un délai de deux ans.\nLes actionnaires personnes morales sont invités à se rapprocher de leur conseiller fiscal habituel afin de\ndéterminer la fiscalité applicable à leur cas particulier.\n4.11.1.4 Autres actionnaires\nLes actionnaires de la Société soumis à un régime d’imposition autre que ceux visés ci-avant, ou ceux détenant\nleurs actions dans le cadre d'un PEA ou d'un PEA « PME-ETI » sont invités à se rapprocher de leur conseiller\nfiscal habituel afin de déterminer la fiscalité applicable à leur cas particulier.\n4.11.2 Actionnaires dont la résidence fiscale ou le siège social est situé hors de France\n4.11.2.1 Retenue à la source sur les dividendes\nLes informations contenues dans la présente section constituent une synthèse du régime fiscal susceptible de\ns’appliquer, en l’état actuel de la législation française et sous réserve de l’application éventuelle des\nconventions fiscales internationales tendant à éviter les doubles impositions, aux investisseurs (i) qui n’ont pas\nleur résidence fiscale en France au sens de l’article 4 B du CGI ou leur siège social en France et (ii) qui\nrecevront des dividendes à raison des actions de la Société qu’ils détiendront autrement que par l’intermédiaire\nd’une base fixe ou d’un établissement stable en France.\n37 | 60\nCeux‐ci doivent néanmoins s’informer, auprès de leur conseiller fiscal habituel de la fiscalité s’appliquant à\nleur cas particulier. Les non‐résidents fiscaux français doivent également se conformer à la législation fiscale\nen vigueur dans leur État de résidence.\n1) Actionnaires personnes physiques dont la résidence fiscale est située hors de France\nLes dividendes distribués par la Société font, en principe, l’objet d’une retenue à la source, prélevée par\nl’établissement payeur des dividendes, lorsque le domicile fiscal du bénéficiaire effectif personne physique est\nsitué hors de France. Sous réserve de ce qui est indiqué ci‐après, le taux de cette retenue à la source est fixé à\n12,8%. Elle est liquidée sur le montant brut des revenus mis en paiement.\nToutefois, s’ils sont payés hors de France dans un ETNC au sens de l’article 238‐0 A du CGI, à l’exception de\nceux mentionnés au 2° du 2 bis l’article 238-0 A du CGI, les dividendes versés par la Société font l’objet d’une\nretenue à la source au taux de 75%, sauf si le débiteur apporte la preuve que les distributions de ces produits\nn’ont ni pour objet ni pour effet de permettre, dans un but de fraude fiscale, leur localisation dans un tel ETNC\n(cf. 4.11.1.1 pour la liste de ces ETNC).\nCette retenue à la source peut être réduite, voire supprimée, en application des conventions fiscales\ninternationales tendant à éviter les doubles impositions conclues par la France et l’Etat de résidence du\nbénéficiaire (les modalités pratiques d’application des conventions fiscales internationales étant notamment\nprévues au BOI‐INT‐DG‐20‐20‐20‐20-12/09/2012).\n2) Actionnaires personnes morales dont le siège social est situé hors de France\nLes dividendes distribués par la Société font, en principe, l’objet d’une retenue à la source prélevée par\nl’établissement payeur des dividendes :\n(i) au taux de 15 % lorsque le bénéficiaire est un organisme sans but lucratif qui a son siège dans un État\nmembre de l’Union européenne ou dans un autre Etat partie à l’accord sur l’EEE ayant conclu avec la\nFrance une convention d’assistance administrative en vue de lutter contre la fraude et l’évasion fiscales,\nqui serait imposé selon le régime de l’article 206, 5 du CGI s’il avait son siège en France et qui remplit\nles critères prévus par les paragraphes 580 et suivants du BOFIP BOI-IS-CHAMP-10-50-10-40-\n25/03/2013 et par les paragraphes 290 et suivants du BOFIP BOI-INT-DG-20-20-20-20-12/09/2012 et ;\n(ii) au taux de 25 % dans les autres cas.\nLa retenue à la source peut être réduite, voire supprimée, notamment :\n(i) en vertu de l’article 119 ter du CGI, applicable sous certaines conditions aux actionnaires personnes\nmorales (a) ayant leur siège de direction effective dans un Etat Membre de l’Union européenne ou dans\nun autre Etat partie à l’accord sur l’EEE ayant conclu avec la France une convention d’assistance\nadministrative en vue de lutter contre la fraude et l’évasion fiscales (Islande, Norvège et Liechtenstein)\net n’étant pas considérés, aux termes d’une convention en matière de double imposition conclue avec\nun Etat tiers, comme ayant sa résidence fiscale hors de l’Union européenne ou de l’EEE, (b) revêtant\nl’une des formes énumérées à la partie A de l’annexe I à la directive 2011/96/UE du Conseil du 30\nnovembre 2011 concernant le régime fiscal commun applicable aux sociétés mères et filiales d’Etats\nMembres différents ou une forme équivalente lorsque la société a son siège de direction effective dans\nun Etat partie à l'accord sur l’EEE, (c) détenant au moins 10% du capital de la Société pendant deux ans\net remplissant toutes les autres conditions visées par l’article 119 ter et telles qu’interprétées par\nl’administration fiscale (BOI-RPPM-RCM-30-30-20-10-03/07/2019), étant toutefois précisé que ce\ntaux de détention est ramené à 5 % lorsque la personne morale qui est le bénéficiaire effectif des\ndividendes détient une participation satisfaisant aux conditions prévues à l’article 145 du CGI et se\n38 | 60\ntrouve privée de toute possibilité d’imputer la retenue à la source (BOI-RPPM-RCM-30-30-20-40-\n07/06/2016) et (d) étant passibles, dans l’Etat Membre de l’Union européenne ou dans l’Etat partie à\nl’accord sur l’EEE où se trouve leur siège de direction effective, de l’impôt sur les sociétés de cet Etat,\nsans possibilité d’option et sans en être exonérées, étant précisé que cet article 119 ter du CGI ne\ns’applique pas aux dividendes distribués dans le cadre d’un montage ou d’une série de montages qui,\nayant été mis en place pour obtenir, à titre d’objectif principal ou au titre d’un des objectifs principaux,\nun avantage fiscal allant à l’encontre de l’objet ou de la finalité de l’article 119 ter du CGI, n’est pas\nauthentique compte tenu de l’ensemble des faits et circonstances pertinents ;\n(ii) en application des conventions fiscales internationales applicables le cas échéant ;\n(iii) en vertu de l’article 119 quinquies du CGI, applicable aux actionnaires personnes morales faisant l’objet\nd’une procédure comparable à celle mentionnée à l’article L. 640-1 du Code de commerce (ou, à défaut\nd’une telle procédure, qu’elle est dans un état de cessation des paiements et dans une situation où son\nredressement est manifestement impossible) situés (a) dans un Etat membre de l'Union européenne, (b)\ndans un autre Etat partie à l'accord sur l'EEE n'étant pas non coopératif au sens de l'article 238-0 A du\nCGI et ayant conclu avec la France une convention d'assistance administrative en vue de lutter contre\nla fraude et l'évasion fiscales ainsi qu'une convention d'assistance mutuelle en matière de recouvrement\nayant une portée similaire à celle prévue par la directive 2010/24/UE du Conseil du 16 mars 2010 ou,\n(c) dans un État tiers à l'Union européenne ou à l'EEE, n'étant pas un ETNC et ayant conclu avec la\nFrance les conventions d'assistance administrative et d'assistance mutuelle au recouvrement\nmentionnées ci-dessus, sous réserve que la participation de l’actionnaire personne morale dans la\nSociété ne lui permette pas de participer de manière effective à sa gestion ou à son contrôle.\nL’actionnaire personne morale doit par ailleurs remplir les autres conditions énoncées à l’article 119\nquinquies du CGI.\n(iv) Par ailleurs, l’article 235 quater du CGI, prévoit un mécanisme de restitution de la retenue à la source\nassorti d’un report d’imposition applicable aux actionnaires personnes morales (a) dont le résultat fiscal\nau titre de l’exercice de perception du dividende est déficitaire, (b) situés dans un État membre de\nl’Union européenne ou dans un autre État partie à l'accord sur l'EEE n'étant pas non coopératif au sens\nde l'article 238-0 A du CGI et ayant conclu avec la France une convention d'assistance administrative\nen vue de lutter contre la fraude et l'évasion fiscales ainsi qu'une convention d'assistance mutuelle en\nmatière de recouvrement ayant une portée similaire à celle prévue par la directive 2010/24/UE du\nConseil du 16 mars 2010 ou dans un État non membre de l’Union européenne ou qui n’est pas partie à\nl’accord sur l’EEE ayant conclu avec la France une convention d’assistance administrative en vue de\nlutter contre la fraude et l’évasion fiscales ainsi qu’une convention d’assistance mutuelle en matière de\nrecouvrement ayant une portée similaire à celle prévue par la directive 2010/24/UE du Conseil du 16\nmars 2010 concernant l’assistance mutuelle en matière de recouvrement des créances relatives aux\ntaxes, impôts, droits et autres mesures, sous réserve que cet État ne soit pas un ETNC et que la\nparticipation de l'actionnaire personne morale dans la société ne lui permette pas de participer de\nmanière effective à sa gestion ou à son contrôle et (c) se conformant aux obligations déclaratives\nénoncées à l’article 235 quater du CGI. Le report d’imposition prend fin au titre de l’exercice au cours\nduquel l’actionnaire personne morale concerné redevient bénéficiaire ainsi que dans les cas énoncés à\nl’article 235 quater du CGI.\n(v) Enfin, l’article 235 quinquies du CGI prévoit un mécanisme de restitution de retenues à la source destiné\nà prendre en compte les charges supportées pour l’acquisition et la conservation des revenus auxquels\nces retenues s’appliquent. Ce dispositif permet ainsi à certaines sociétés étrangères d’obtenir, sous\nconditions, la restitution de la retenue à la source prévue notamment à l’article 119 bis, 2 du CGI à\nhauteur de la différence entre la retenue à la source versée et celle calculée à partir d’une base nette de\ncharges. Ce dispositif s’applique (a) aux actionnaires personnes morales dont les résultats ne sont pas\n39 | 60\nimposés à l’impôt sur le revenu entre les mains d’un associé et dont le siège ou l’établissement stable\ndans le résultat duquel les produits et sommes sont inclus est situé (x) dans un État membre de l’Union\neuropéenne, (y) dans un autre État partie à l’accord sur l’EEE qui n’est pas un ETNC et ayant conclu\navec la France une convention d’assistance administrative en vue de lutter contre la fraude et l’évasion\nfiscales ou (z) dans un Etat non membre de l’Union européenne ou qui n’est pas partie à l’accord sur\nl’EEE mais ayant conclu avec la France une convention ci-dessus mentionnée, sous réserve que cet Etat\nne soit pas un ETNC et que la participation détenue dans la société distributrice ne permette pas au\nbénéficiaire de la distribution de participer de manière effective à la gestion ou au contrôle de cette\nsociété ou de cet organisme, (b) sous réserve que les charges d’acquisition et de conservation de ces\nproduits et sommes seraient déductibles si le bénéficiaire était situé en France et (c) sous réserve que\nles règles d’imposition dans l’Etat de résidence ne permettent pas au bénéficiaire d’y imputer la retenue\nà la source. L’actionnaire personne morale doit par ailleurs remplirles autres conditions énoncées à\nl’article 235 quinquies du CGI.\nEn outre, sont exonérés de retenue à la source, à l’exception des cas de paiements dans un ETNC au sens de\nl’article 238-0 A du CGI, les revenus distribués aux organismes de placement collectif constitués sur le\nfondement d’un droit étranger situés dans un Etat membre de l’Union européenne ou dans un autre Etat ou\nterritoire ayant conclu avec la France une convention d’assistance administrative en vue de lutter contre la\nfraude et l’évasion fiscales remplissant les conditions visées à l’article 119 bis, 2 du CGI et qui (i) lèvent des\ncapitaux auprès d’un certain nombre d’investisseurs en vue de les investir, conformément à une politique\nd’investissement définie, dans l’intérêt de ces investisseurs et (ii) présentent des caractéristiques similaires à\ncelles d’organismes de placement collectif de droit français relevant de la section 1, des paragraphes 1, 2, 3, 5\net 6 de la sous-section 2, de la sous-section 3, ou de la sous-section 4 de la section 2 du chapitre IV du titre Ier\ndu livre II du code monétaire et financier. Les stipulations de la convention d’assistance administrative\nmentionnée ci-dessus et leur mise en œuvre doivent effectivement permettre à l’administration fiscale française\nd’obtenir des autorités de l’Etat dans lequel l’organisme de placement collectif de droit étranger est situé les\ninformations nécessaires à la vérification du respect par cet organisme des deux conditions mentionnées ci-\ndessus pour bénéficier de l’exonération de retenue à la source. Les conditions de cette exonération ont été\ndétaillées dans le BOI-RPPM-RCM-30-30-20-70-06/10/2021. Les investisseurs concernés sont invités à\nconsulter leur conseiller fiscal habituel afin de déterminer l’application de ces dispositions à leur cas particulier.\nToutefois, les dividendes versés par la Société font l’objet d’une retenue à la source au taux de 75% (sous\nréserve, le cas échéant, des dispositions plus favorables des conventions internationales) s’ils sont payés hors\nde France dans un ETNC au sens des dispositions prévues à l’article 238‐0 A du CGI, à l’exception de ceux\nmentionnés au 2° du 2 bis l’article 238-0 A du CGI, sauf si le débiteur apporte la preuve que les distributions\nde ces produits n’ont ni pour objet ni pour effet de permettre, dans un but de fraude fiscale, leur localisation\ndans un tel ETNC (cf. 4.11.1.1 pour la liste de ces ETNC).\nL'article 119 bis A du CGI, prévoit l’application par l’agent payeur d’une retenue à la source au taux de 25%\nen cas d’opérations de cessions temporaires de titres ou d’opérations similaires, réalisées pendant une période\nde moins de quarante-cinq jours incluant la date à laquelle le droit à une distribution de produits d’actions, de\nparts sociales ou de revenus assimilés est acquis, permettant aux actionnaires non-résidents de sociétés\nfrançaises d’échapper à la retenue à la source normalement applicable. Dans ce cas, la retenue à la source\ns’applique sans que le bénéficiaire puisse se prévaloir de la procédure dite « simplifiée » (BOI-INT-DG-20-\n20-20-20-12/09/2012) en vue de bénéficier des dispositions plus favorables de la convention fiscale\néventuellement applicable. Le texte prévoit toutefois sous certaines conditions une mesure de sauvegarde\npermettant d’obtenir le remboursement de tout ou partie de la retenue à la source ainsi prélevée s’il apporte la\npreuve que ce versement correspond à une opération qui a principalement un objet et un effet autres que d’éviter\nl’application d’une retenue à la source ou d’obtenir l’octroi d’un avantage fiscal.\n40 | 60\nIl appartiendra aux actionnaires concernés de se rapprocher de leur conseil fiscal habituel afin de déterminer\nnotamment s’ils sont susceptibles de se voir appliquer la législation relative aux États et territoires non\ncoopératifs et/ou de bénéficier d’une réduction, d’une exonération ou d’une restitution temporaire de retenue à\nla source.\nLes actionnaires sont également invités à se renseigner sur les modalités pratiques d’application des dispositifs\nde réduction, d’exonération et de restitution temporaire de retenues à la source mentionnées ci-dessus et, le cas\néchéant, des conventions fiscales internationales (et notamment celles prévues par la doctrine administrative\nBOI-INT-DG-20-20-20-20-12/09/2012 relative aux procédures dites « normales » ou « simplifiées » de\nréduction ou d’exonération de la retenue à la source).\n4.11.2.2 Retenue à la source sur les plus-values\nSous réserve de l’application éventuelle des conventions fiscales internationales applicables, les plus-values\nréalisées par des actionnaires qui ne sont pas domiciliés en France ou dont le siège social est situé hors de\nFrance à l’occasion de la cession des actions de la Société ne sont pas soumises à retenue à la source en France\nà condition (i) qu’ils n’aient pas détenu, directement ou indirectement, seuls ou avec des membres de leur\nfamille, une participation représentant plus de 25 % des droits dans les bénéfices de la Société à un moment\nquelconque au cours des cinq années qui précèdent la cession et (ii) qu’ils ne soient pas domiciliés, établis ou\nconstitués dans un ETNC.\n4.11.3 Taxe sur les transactions financières\nConformément aux dispositions de l’article 726, I du CGI, les cessions portant sur les actions de la Société,\ndans la mesure où elles ne sont pas soumises à la taxe sur les transactions financières visée à l’article 235 ter\nZD du CGI, sont susceptibles d’être soumises à un droit d’enregistrement, en cas de constatation desdites\ncessions par un acte (passé en France ou à l’étranger), au taux proportionnel de 0,1% assis sur le prix de cession\ndes actions ou leur valeur vénale si elle est supérieure.\nComme c’était le cas au titre des années 2016 et 2017, les actions de la Société pourraient à nouveau entrer\ndans le champ d’application de la taxe sur les transactions financières (« TTF ») prévue à l’article 235 ter ZD\ndu CGI. En effet, la TTF s’applique, sous certaines conditions, aux acquisitions à titre onéreux de titres de\ncapital et de titres assimilés, admis aux négociations sur un marché réglementé qui sont émis par une société\ndont le siège social est situé en France et dont la capitalisation boursière dépasse un milliard d’euros au 1er\ndécembre de l’année précédant l’année d’acquisition. Une liste des sociétés dont les titres de capital et titres\nassimilés sont dans le champ de la TTF est publiée chaque année par l’administration fiscale. La capitalisation\nboursière de la Société est actuellement inférieure à un milliard d’euros.\nSi, à l’avenir, la Société venait à figurer à nouveau sur cette liste, la TTF serait due, sous réserve de certaines\nexceptions, pour un montant égal à 0,3% de la contrepartie versée pour l’acquisition sur le marché secondaire\nde titres de capital ou assimilés de la Société, en ce compris les Actions Offertes. L’application de la TTF à\nl’avenir serait ainsi de nature à augmenter les coûts transactionnels liés aux achats et ventes des actions de la\nSociété, en ce compris les Actions Offertes en cas de cession ultérieure, et pourraient réduire la liquidité du\nmarché pour ces actions.\n4.12 Incidence potentielle sur l’investissement d’une résolution au titre de la directive 2014/59/UE\nSans objet.\n4.13 Identité et coordonnées de l’offreur des valeurs mobilières\nSans objet.\n41 | 60\n5. MODALITES ET CONDITIONS DE L’OFFRE DE VALEURS MOBILIERES\n5.1 Conditions, statistiques de l’Opération, calendrier prévisionnel et modalités d’une demande de\nsouscription\n5.1.1 Conditions de l’Opération\nL’émission des Actions Nouvelles T1 a été réalisée dans le cadre d’une augmentation de capital avec\nsuppression du droit préférentiel de souscription réservée à des catégories de personnes au sens de l'article\nL. 225-138 du Code de commerce répondant aux caractéristiques fixées par l’Assemblée Générale Annuelle\n2024 dans sa vingt-cinquième résolution. Ces catégories de personnes comprennent : (i) des personnes\nphysiques ou morales, (en ce compris des sociétés), trusts ou fonds d’investissement, ou autres véhicules de\nplacement, quelle que soit leur forme, de droit français ou étranger, investissant à titre habituel dans le secteur\npharmaceutique, biotechnologique, ou des technologies médicales ; et/ou (ii) des sociétés, institutions ou\nentités quelle que soit leur forme, françaises ou étrangères, exerçant une part significative de leurs activités\ndans le domaine pharmaceutique, cosmétique ou chimique ou des dispositifs et/ou technologies médicaux ou\nde la recherche dans ces domaines ; et/ou (iii) des prestataires de service d'investissement français ou étranger,\nou tout établissement étranger ayant un statut équivalent, susceptibles de garantir la réalisation d'une émission\ndestinée à être placée auprès des personnes visées au (i) et/ou (ii) ci-dessus et, dans ce cadre, de souscrire aux\ntitres émis.\nL’émission des BSA T1 a été réalisée dans le cadre d’une émission avec suppression du droit préférentiel de\nsouscription réservée à des catégories de personnes au sens de l'article L. 225-138 du Code de commerce\nrépondant aux caractéristiques fixées par l’Assemblée Générale Annuelle 2024 dans sa vingt-cinquième\nrésolution, mentionnée ci-dessus.\nSur le territoire de l’EEE, aucune action n’a été entreprise et ne sera entreprise à l’effet de permettre une offre\nau public des valeurs mobilières objet du Prospectus rendant nécessaire la publication d’un prospectus dans\nl’un ou l’autre des États membres.\n5.1.2 Montant de l’Opération\nL'émission des Actions Nouvelles T1 et des BSA T1 permettra une levée de fonds potentielle d'un montant\nbrut de 94,1 millions d’euros (86,6 millions d’euros en montant net).\n5.1.3 Période et procédure de souscription\nLa souscription des Actions Nouvelles T1 et des BSA T1 s’est effectuée le 11 octobre 2024 après fermeture\nd’Euronext Paris.\nL’émission par la Société des Actions Nouvelles T1bis (dont l’admission n’est pas demandée dans le cadre du\nprésent prospectus) et leur souscription par chaque investisseur est soumise à l’adoption par l’Assemblée\nGénérale des résolution nécessaires permettant l’émission des Actions Nouvelles T1bis. Dans ce cadre, des\ncontrats de souscription seront signés qui seront similaires aux contrats de souscription des Actions Nouvelles\nT1 ainsi qu’à l’absence de changement défavorable significatif (défini comme tout événement, violation ou\ncirconstance, individuellement ou dans l'ensemble, qui a eu ou pourrait raisonnablement avoir un effet négatif\nimportant sur les étapes du développement clinique du lanifibranor, ou sur la fabrication du nouveau\nmédicament en vue de son lancement commercial, ou en ce qui concerne la capacité de l'entreprise à mener à\nbien l'essai NATiV3 et à obtenir de la Food and Drug Administration (FDA) les autorisations nécessaires (un\n« Changement Défavorable Significatif ») entre l’émission des Actions Nouvelles T1 et des BSA T1 et le\nrèglement-livraison des Actions Nouvelles T1bis. L’adoption des résolutions nécessaires par l’Assemblée\n42 | 60\nGénérale fera l’objet d’un communiqué de presse, en ligne avec les obligations d’information de la Société.\nL’émission des Actions Nouvelles T1bis fera également l’objet d’un communiqué de presse au jour de la\nréunion du Conseil d’Administration ou du Directeur Général agissant sur délégation du Conseil\nd’Administration de la Société décidant de cette émission.\nL’émission par la Société des Actions Nouvelles T2 (dont l’admission n’est pas demandée dans le cadre du\nprésent prospectus) et leur souscription par chaque investisseur est soumise aux conditions suivantes (les\ninvestisseurs peuvent décider de renoncer à une ou plusieurs des conditions (i) à (v) ci-dessous avec l'accord\npréalable des investisseurs souhaitant souscrire aux ABSAs et représentant 60% de l'ensemble des investisseurs\ndevant souscrire aux ABSAs) : (i) aucun Changement Défavorable Significatif entre l’émission des Actions\nNouvelles T1 et le règlement-livraison des ABSAs n’est survenu, (ii) la randomisation du dernier patient dans\nla cohorte principale de NATiV3 intervenant au plus tard le 30 avril 2025, (iii) le Data Monitoring Committee\n(le « DMC »), groupe indépendant d’experts chargé d’assurer le suivi de la sécurité des patients recrutés dans\nl’étude NATiV3 et dont la mise en place est usuelle dans le cadre de certains essais cliniques ne recommande\npas la suspension de l’étude NATiV3 et (iv) le taux d’abandon par les patients dans l’étude NATiV3 avant la\nsemaine 72 est inférieur à 30% (les conditions (i) à (iv) ensemble, les « Évènements Déclencheurs T2 »), (v)\nla souscription et le paiement par les investisseurs de la totalité des Actions Nouvelles T2, (vi) l’adoption par\nl’Assemblée Générale des résolutions nécessaire permettant l’émission des Actions Nouvelles T2 et des BSA\nT3 attachés et (vii) les conditions de règlement-livraison usuelles. L’émission des ABSA fera l’objet d’un\ncommuniqué de presse au jour de la réunion du Conseil d’Administration ou du Directeur Général agissant sur\ndélégation du Conseil d’Administration de la Société constatant la réalisation des Evènements Déclencheurs\nT2 et décidant de cette émission.\nPour l’exercice des BSA T3, voir la section 4.5.2.1 de la Note d’Opération.\nCalendrier indicatif\n14 octobre 2024 Décision du Conseil d’Administration approuvant l’émission des\n(avant ouverture des Actions Nouvelles T1 et des BSA T1 - Signature des contrats de\nmarchés d’Euronext souscription - Diffusion d’un communiqué de presse annonçant les\nParis) modalités de l’Opération et l’émission des Actions Nouvelles T1 et des\nBSA T1, et nommant Mark Pruzanski président du Conseil\nd’Administration sous réserve de l’approbation des résolutions\nsoumises à l’Assemblée Générale, notamment sa nomination en qualité\nde membre du Conseil d’Administration\n14 octobre 2024 Publication du rapport financier semestriel 2024\n14 octobre 2024 Dépôt de l’Amendement au Document d’Enregistrement Universel\n2023 - Approbation du Prospectus par l’AMF\n15 octobre 2024 Publication de l'avis d'admission d'Euronext Paris des Actions\nNouvelles T1\n17 octobre 2024 Règlement-Livraison des Actions Nouvelles T1 et des BSA T1 -\nAdmission des Actions Nouvelles T1 aux négociations sur Euronext\nParis et admission des BSA T1 aux opérations d’Euroclear France\nau plus tard le 16 Assemblée Générale (i) décidant l’émission des Actions Nouvelles\ndécembre 2024 T1bis et (ii) approuvant l’émission des Actions Nouvelles T2 et des\nBSA T3 et nommant Mark Pruzanski membre du conseil\nd’administration et Srinivas Akkaraju membre du conseil\nd’administration ainsi que d’autres administrateurs. Signature des\ncontrats de souscription des Actions Nouvelles T1bis et des ABSAs\nAu plus tard le 30 avril Evènements Déclencheurs T2\n2025\n43 | 60\nAu plus tard le 31 mai Règlement-Livraison des Actions Nouvelles T2 - Détachement des\n2025 BSA T3\nAu plus tard le 15 juin Evènement Déclencheur T3\n2027\nAu plus tard le 30 juillet Date de Maturité des BSA T3\n2027\nAu plus tard le 30 juillet Création et admission au plus tard des Actions Issues des BSA T3 aux\n2027 négociations sur Euronext Paris\n20 octobre 2034 Clôture de la Période d'Exercice et caducité des BSA\n5.1.4 Révocation / suspension de l’Opération\nSans objet.\n5.1.5 Réduction de la souscription\nSans objet.\n5.1.6 Montant minimum et/ou maximum d’une souscription\nIl n’y a pas d’ordre minimum et/ou maximum de souscription.\n5.1.7 Révocation des ordres de souscription\nSans objet.\n5.1.8 Versement des fonds et modalités de délivrance des actions\nL’intégralité du prix de souscription des Actions Nouvelles T1 et du Prix d’Exercice Préfinancé des BSA T1\nsera versé par les investisseurs au plus tard à la date de règlement-livraison des Actions Nouvelles T1 et des\nBSA T1 soit, selon le calendrier indicatif, le 17 octobre 2024.\nLes fonds versés à l’appui des souscriptions seront centralisés par Société Générale Securities Services, qui\nsera chargé d’établir le certificat de dépôt des fonds constatant la réalisation de l’augmentation de capital\n(certificat du dépositaire).\nLes Actions Nouvelles T1 et les BSA T1 seront inscrits en compte le 17 octobre 2024, date à laquelle\ninterviendra le versement à la Société du produit de l’émission.\nChaque demande d'exercice des BSA T1 devra être accompagnée du versement du prix de souscription\ncorrespondant au solde du prix d'exercice par action nouvelle, versé dans son intégralité en numéraire, soit 0,01\neuros. Les demandes d'exercice pour lesquelles les versements n'auraient pas été effectués seront annulées de\nplein droit sans qu'il soit besoin d'une mise en demeure. Le règlement-livraison des Actions Issues des BSA\nT1 interviendra au fil de l'eau, dans les trois jours de bourse suivant la Date d'Exercice.\n5.1.9 Publication des résultats de l’Opération\nLe communiqué de presse annonçant les modalités définitives de l’Opération et notamment le nombre et le\nPrix de Souscription des Actions Nouvelles T1 émises ainsi que le nombre et le Prix d’Exercice Préfinancé des\nBSA T1 a été publié le 14 octobre 2024 et l’avis Euronext d’admission des Actions Nouvelles T1 sera publié\nle 15 octobre 2024.\n44 | 60\n5.1.10 Procédure d’exercice et négociabilité des droits préférentiels de souscription\nSans objet.\n5.2 Plan de distribution et d’allocation des valeurs mobilières\n5.2.1 Catégorie d’investisseurs potentiels – Pays dans lesquels l’Opération a été ouverte\nVoir la section 5.1.1 de la Note d’Opération.\n5.2.2 Engagements et intentions de souscription des principaux actionnaires et des membres du Conseil\nd’administration et de direction et intentions des nouveaux investisseurs\nBVF, détenant une participation de 16,4% du capital social et 13,1% des droits de vote de la Société avant\nl'Opération, a souscrit pour un montant d'environ 11 millions d'euros correspondant à 8.231.034 BSA T1.\nNew Enterprise Associates, détenant une participation de 10,7% du capital social et 8,5% des droits de vote\nde la Société avant l'Opération, a souscrit pour un montant d'environ 20 millions d'euros correspondant à\n2.262.931 Actions Nouvelles T1 et 12.823.276 BSA T1.\nSofinnova Crossover I SLP, détenant une participation de 9,7% du capital social et 9,4% des droits de vote\nde la Société avant l'Opération, a souscrit pour un montant d'environ 1,8 million d'euros correspondant à\n1.369.827 Actions Nouvelles T1.\nYiheng Capital Management, L.P., détenant une participation de 7,4% du capital social et 5,9% des droits de\nvote de la Société avant l'Opération, a souscrit pour un montant d'environ 2,2 millions d'euros correspondant\nà 1.629.310 Actions Nouvelles T1.\nLe nombre d’Actions Nouvelles T1bis, d’ABSA et de BSA T3 sera souscrit par chaque investisseur au prorata\nde sa souscription d’Actions Nouvelles T1 ou BSA T1. En cas de défaut de souscription des ABSA par un\ninvestisseur, la Société s'engage à offrir aux autres investisseurs le droit de souscrire à un nombre d’ABSA\nsupplémentaires, non souscrites par l'investisseur défaillant, qui sera alloué au prorata du nombre d'Actions\nNouvelles T1, de BSA T1, d’Actions Nouvelles T1bis souscrits par chaque investisseur et souhaitant souscrire\nà ces ABSA. Il est rappelé que les investisseurs se sont engagés à souscrire à la totalité des Actions Nouvelles\nT1bis, des Actions Nouvelles T2 et des BSA T3 attachés.\n5.2.3 Information pré-allocation\nSans objet.\n5.2.4 Notification aux souscripteurs\nVoir la section 6.2 du Document d’Enregistrement Universel 2023.\n5.3 Prix d’émission des actions dont l’admission est demandée\n5.3.1 Prix de souscription\nLe prix de souscription des Actions Nouvelles T1 a été fixé à 1,35 euro par action (0,01 euro de valeur nominale\net 1,34 euro de prime d’émission) (le « Prix de Souscription des Actions Nouvelles T1 »). Compte tenu des\ncaractéristiques propres des BSA T1, le prix de souscription d'un BSA T1 est égal au Prix de Souscription des\nActions Nouvelles T1, soit 1,35 euro, dont 1,34 euro est libéré au jour de l’émission du BSA T1 (le « Prix\nd’Exercice Préfinancé ») (soit le Prix de Souscription des Actions Nouvelles T1 moins la valeur nominale\nd’une action ordinaire. Le solde du Prix d’Exercice Préfinancé, égal à la valeur nominale d’une action ordinaire,\nsoit 0,01€, sera libéré au jour de l'exercice du BSA T1. Les souscriptions et versements seront reçus et déposés\n45 | 60\nauprès de Société Générale Securities Services, qui émettra le certificat du dépositaire (pour les Actions\nNouvelles T1) le jour du règlement-livraison.\nConformément aux modalités de détermination du prix fixées par la 25ème résolution de l’Assemblée Générale\nAnnuelle 2024, le Prix de Souscription des Actions Nouvelles T1 fait ressortir une décote de 10% par rapport\nà la moyenne pondérée par les volumes (dans le carnet d’ordre central et hors blocs hors marché) des cours de\nl’action de la Société sur le marché réglementé Euronext Paris lors des 5 dernières séances de bourse précédant\nla fixation du Prix de Souscription des Actions Nouvelles T1, soit 1,5048 euros (le « Prix de Référence »).\nEn cas d’émission des Actions Nouvelles T1bis, le prix de souscription des Actions Nouvelles T1bis\ncorrespondra au Prix de Souscription des Actions Nouvelles T1, soit 1,35 euro (le « Prix de Souscription des\nActions Nouvelles T1bis »).\nSous réserve de la réalisation des Evènements Déclencheurs T2, le prix de souscription des ABSA correspondra\nau prix le plus bas entre (i) le Prix de Souscription des Actions Nouvelles T1, soit 1,35 euro et (ii) la moyenne\npondérée par les volumes (dans le carnet d’ordre central et hors blocs hors marché) des cours de l’action de la\nSociété sur le marché réglementé Euronext Paris lors des 5 dernières séances de bourse précédant la fixation\ndu prix des Actions Nouvelles T2 (étant précisé qu’aucune décote ne sera appliquée à cette moyenne) (le « Prix\nde Souscription des ABSA »).\nSous réserve de l’Evènement Déclencheur T3, le prix d’exercice des BSA T3 correspondra au Prix de\nRéférence (étant précisé qu’aucune décote ne sera appliquée sur ce prix), soit 1,50 € (le « Prix d’Exercice des\nBSA T3 »).\nLe Prix de Souscription des Actions Nouvelles T1bis devra être intégralement libéré en numéraire au moment\nde l’émission desdites actions.\nLe Prix de Souscription des ABSA devra être intégralement libéré en numéraire au moment de l’émission des\nABSA.\nLe Prix d’Exercice des BSA T3 devra être intégralement libéré en numéraire au moment de l’exercice des BSA\nT3.\n5.3.2 Procédure de publication du prix de l'offre\nLe Prix de Souscription des Actions Nouvelles T1 et du Prix d’Exercice Préfinancé des BSA T1 ont été publié\nle 14 octobre 2024, par voie de communiqué de presse.\n5.3.3 Restrictions ou suppression du droit préférentiel de souscription des actionnaires\nL’émission des Actions Nouvelles T1 et des BSA T1 a été réalisée par augmentation de capital avec\nsuppression du droit préférentiel de souscription réservée à des catégories de personnes, conformément à\nl’article L. 225-138 du Code de commerce, répondant à des caractéristiques déterminées par la 25ème résolution\nde l'Assemblée Générale Annuelle 2024.\nLe Prix de Souscription des Actions Nouvelles T1 et du Prix d’Exercice Préfinancé des BSA T1 ont été\ndéterminé par le Conseil d'Administration dans les limités visées au paragraphe 5.3.1.\n5.3.4 Disparité de prix\nNon applicable.\n46 | 60\n5.4 Placement et prise ferme\nAucun contrat de placement ou de prise ferme n'a été conclu.\n5.4.1 Coordonnées des établissements financiers\nSans objet.\n5.4.2 Coordonnées des intermédiaires habilités chargés du dépôt des fonds des souscriptions et du service financier\ndes actions\nLes fonds versés à l’appui des souscriptions sont centralisés chez Société Générale Securities Services / Global\nIssuer Services (32, rue du Champ-de-tir, BP 81236, 44312 Nantes Cedex 03), qui établira le certificat de dépôt\ndes fonds constatant la réalisation de l’augmentation de capital.\nLe service des titres (inscription des actions au nominatif, conversion des actions au porteur) et le service\nfinancier des actions de la Société sont assurés par Société Générale Securities Services / Global Issuer Services\n(32, rue du Champ-de-tir, BP 81236, 44312 Nantes Cedex 03).\n5.4.3 Garantie\nSans objet.\n5.4.4 Engagements d’abstention et de conservation des titres\nCes informations figurent à la section 7.4 de la Note d’Opération.\n47 | 60\n6. ADMISSION A LA NEGOCIATION ET MODALITES DE NEGOCIATION\n6.1 Admission aux négociations\nLes Actions Nouvelles T1 feront l’objet d’une demande d’admission aux négociations sur le marché\nréglementé d’Euronext. Les Actions Nouvelles T1 seront admises aux négociations sur Euronext Paris à\ncompter du 17 octobre 2024.\nLes Actions issues des BSA T1 feront l’objet de demandes périodiques d’admission aux négociations sur\nEuronext Paris jusqu’au troisième jour ouvré suivant la période d’exercice, soit au plus tard le 20 octobre 2034.\nLes Actions Offertes seront immédiatement assimilées aux actions existantes de la Société et seront négociées\nsur la même ligne de cotation sous le code ISIN FR0013233012.\nSous réserve de l’approbation des résolutions nécessaires par l’Assemblée Générale, les Actions Nouvelles\nT1bis feront l’objet d’une demande d’admission aux négociations sur Euronext Paris. Les BSA T1bis ne feront\npas l’objet d’une demande d’admission aux négociations sur Euronext Paris, néanmoins les actions émises par\nexercice des BSA T1bis feront l'objet de demandes d'admission périodiques aux négociations.\nSous réserve de l’approbation des résolutions nécessaires par l’Assemblée Générale et de la réalisation des\nÉvènements Déclencheurs T2, les Actions Nouvelles T2 feront l’objet d’une demande d’admission aux\nnégociations sur Euronext Paris. Les BSA T2 ne feront pas l’objet d’une demande d’admission aux\nnégociations sur Euronext Paris, néanmoins les actions émises par exercice des BSA T2 feront l'objet de\ndemandes d'admission périodiques aux négociations.\nSous réserve des modalités d’exercice des BSA T3, les Actions Issues des BSA T3 feront l'objet de demandes\nd'admission périodiques aux négociations et au plus tard trois jours ouvrés suivant la fin de la Période\nd’Exercice des BSA T3 soit, au plus tard le 30 juillet 2027.\n6.2 Place de cotation\nLes actions de la Société sont admises aux négociations sur le marché réglementé d’Euronext Paris.\n6.3 Offres simultanées d’actions de la Société\nSans objet.\n6.4 Contrat de liquidité\nLa Société a conclu un contrat de liquidité avec Kepler Cheuvreux conforme à la charte de déontologie de\nl’Association française des marchés financiers (AMAFI).\n6.5 Stabilisation – Interventions sur le marché\nSans objet.\n6.6 Surallocation et rallonge\nSans objet.\n48 | 60\n7. DETENTEURS DE VALEURS MOBILIERES SOUHAITANT LES VENDRE\n7.1 Personnes ou entités souhaitant vendre des titres de capital ou des valeurs mobilières donnant accès au\ncapital de la Société\nSans objet.\n7.2 Nombre et catégorie des valeurs mobilières offertes par chacun des détenteurs de valeurs mobilières\nsouhaitant vendre\nSans objet.\n7.3 Taille de la participation de l'actionnaire majoritaire cédant des valeurs mobilières.\nSans objet.\n7.4 Engagements d'abstention et de conservation des titres\n7.4.1 Engagements d’abstention de la Société\nSans objet\n7.4.2 Engagements de conservation\nLes investisseurs participant à l'Opération se sont engagés à conserver leurs Actions Nouvelles T1 et BSA T1\njusqu’à la première des deux dates suivantes : (x) la date d’émission des Actions Nouvelles T2 ou (y) le 20 mai\n2025, sous réserve de certaines exceptions (transfert à un autre investisseur, à une société affiliée de\nl’investisseur ou sous réserve de l’accord de la Société à sa seule discrétion, à une tierce partie qui prendrait\nles mêmes engagements de conservation en ce qui concerne les Actions Nouvelles T1 et les BSA T1).\nEn cas d’émission des Actions Nouvelles T1bis, les investisseurs s’engageront à conserver les Actions\nNouvelles T1bis dans les mêmes conditions que les Actions Nouvelles T1 et BSA T1.\n49 | 60\n8. DEPENSES LIEES A L’OPERATION\nLe produit brut correspond au produit du montant total des souscriptions reçues en euros. Le produit net\ncorrespond au produit brut diminué des charges mentionnées ci-dessous. Celles-ci seront intégralement\nimputées sur la prime d’émission.\nLe produit brut et l’estimation du produit net de l’émission (hors taxes) pour l’émission des Actions Nouvelles\nT1 et des BSA T1 sont de :\n- Produit brut de l’émission des Actions Nouvelles T1 et des BSA T1 : environ 94,1 millions d’euros\n- Rémunération des intermédiaires et frais juridiques et administratifs : environ 5,7 million d’euros\n- Produit net estimé de l’émission des Actions Nouvelles T1 et des BSA T1 : environ 86,6 millions\nd’euros.\n50 | 60\n9. DILUTION\n9.1 Comparaisons\n(a) Comparaison de la participation au capital et des droits de vote détenus par les actionnaires existants\navant et après l’Opération, en supposant qu’ils ne souscrivent pas aux Actions Nouvelles T1, aux BSA\nT1, aux Actions Nouvelles T1bis et aux ABSA\nA titre indicatif, l’incidence de l’émission des Actions Nouvelles T1, des Actions Issues des BSA T1\n(en prenant en compte l’exercice intégral), des Actions Nouvelles T1bis, des Actions Nouvelles T2 et\ndes Actions Issues des BSA T3 (en prenant en compte l’exercice intégral) sur la participation dans le\ncapital d’un actionnaire détenant 1% du capital social de la Société préalablement à l’émission et ne\nsouscrivant pas à celle-ci (calculs effectués sur la base du nombre d’actions composant le capital social\nde la Société à la date de l’approbation sur le Prospectus) est la suivante :\nQuote-part du capital\nBase non diluée Base diluée (1)\nAvant émission des Actions Nouvelles T1 1% 0,87%\nAprès émission des Actions Nouvelles T1 et de 0,60% 0,45%\nl’intégralité des Actions Issues des BSA T1\nAprès émission des Actions Nouvelles T1, de 0,55% 0,41%\nl’intégralité des Actions Issues des BSA T1, des\nActions Nouvelles T1bis\nAprès émission des Actions Nouvelles T1, de 0,29% 0,26%\nl’intégralité des Actions Issues des BSA T1, des\nActions Nouvelles T1bis et des Actions Nouvelles\nT2*\nAprès émission des Actions Nouvelles T1, de 0,20% 0,19%\nl’intégralité des Actions Issues des BSA T1, des\nActions Nouvelles T1bis, des Actions Nouvelles T2*\net de l’intégralité des Actions Issues des BSA T3\n(1) Les calculs sont effectués en prenant pour hypothèse l’exercice de l’ensemble des bons de souscription\nd’actions (BSA), bons de souscription de parts de créateurs d’entreprise (BSPCE) et à l’acquisition définitive\nde toutes les actions gratuites attribuées.\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles\nT1bis et Actions Nouvelles T2 sont réunies, (ii) que les Actions Nouvelles T2 ne seront émises qu’en actions ordinaires et\n(iii) un prix de souscription des ABSA équivalent au Prix de Souscription des Actions Nouvelles T1 (soit un nombre de\n85.925.919 Actions Nouvelles T2).\n(b) Comparaison de la valeur nette d’inventaire par action à la date du dernier bilan avant l’Opération (offre\nde vente et/ou augmentation de capital) et du prix d’offre par action dans le cadre de l’Opération\nA titre indicatif, l’incidence de l’émission des Actions Nouvelles T1, des Actions Issues des BSA T1\n(en prenant en compte l’exercice intégral), des Actions Nouvelles T1bis, des Actions Nouvelles T2 et\ndes Actions Issues des BSA T3 (en prenant en compte l’exercice intégral) sur la quote-part des capitaux\npropres de la Société par action (calculs effectués sur la base des capitaux propres de la Société au 30\n51 | 60\njuin 2024 et du nombre d’actions composant le capital social de la Société à la date de la Note\nd’Opération) est la suivante :\nQuote-part des capitaux propres\npar action en euros\nBase non diluée Base diluée (1)\nAvant émission des Actions Nouvelles T1\n-€1,88 -€1,04\nAprès émission des Actions Nouvelles T1 et de -€0,14 €0,18\nl’intégralité des Actions Issues des BSA T1\nAprès émission des Actions Nouvelles T1, de €0,10 €0,30\nl’intégralité des Actions Issues des BSA T1 et des\nActions Nouvelles T1bis\nAprès émission des Actions Nouvelles T1, de €0,54 €0,56\nl’intégralité des Actions Issues des BSA T1, des Actions\nNouvelles T1bis et des Actions Nouvelles T2*\nAprès émission des Actions Nouvelles T1, de €0,83 €0,80\nl’intégralité des Actions Issues des BSA T1, des Actions\nNouvelles T1bis, des Actions Nouvelles T2* et de\nl’intégralité des Actions Issues des BSA T3\n(1) Les calculs sont effectués en prenant pour hypothèse l’exercice de l’ensemble des bons de souscription\nd’actions (BSA), bons de souscription de parts de créateurs d’entreprise (BSPCE) et à l’acquisition définitive\nde toutes les actions gratuites attribuées.\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles\nT1bis et Actions Nouvelles T2 sont réunies, (ii) que les Actions Nouvelles T2 ne seront émises qu’en actions ordinaires et\n(iii) un prix de souscription des ABSA équivalent au Prix de Souscription des Actions Nouvelles T1 (soit un nombre de\n85.925.919 Actions Nouvelles T2).\n52 | 60\n9.2 Incidence de l’émission sur la situation de l’actionnaire\nLa structure de l'actionnariat de la Société avant l'Opération est la suivante :\nSituation avant l’Opération Situation avant l’Opération des Situation avant l’Opération\nsur une base non diluée instruments dilutifs sur une base diluée\nNbre Nbre\nNbre\n% des d’actions d’actions\nNbre % en d’actions % en % des\nNbre de droits de susceptibles susceptibles Nbre Nbre de\nd'actions capital susceptibles capital droits de\nActionnaires droits de vote (base de résulter de résulter d'actions droits de\n(base non (base non de résulter (base vote (base\nvote non de de (base diluée) vote\ndiluée diluée) du vesting diluée) diluée)\ndiluée) l’exercice l’exercice\ndes A GA\ndes BSPCE de BSA\nFrédéric Cren (1)(3) 5.612.224 10,8% 11.224.448 17,2% 215.000 - 300.000 6.127.224 10,1% 11.739.448 16,0%\nPierre Broqua (1) 3.882.500 7,4% 7.765.000 11,9% 215.000 - 300.000 4.397.500 7,3% 8.280.000 11,3%\nSous-total - Pacte d'actionnaires 9.494.724 18,2% 18.989.448 29,1% 430.000 - 600.000 10.524.724 17,4% 20.019.448 27,3%\nBVF Partners L.P. 8.545.499 16,4% 8.545.499 13,1% - - - 8.545.499 14,1% 8.545.499 11,6%\nNEA 5.572.953 10,7% 5.572.953 8,5% - - - 5.572.953 9,2% 5.572.953 7,6%\nSofinnova 5.070.266 9,7% 6.110.827 9,4% - - - 5.070.266 8,4% 6.110.827 8,3%\nYiheng Capital 3.845.676 7,4% 3.845.676 5,9% - - - 3.845.676 6,3% 3.845.676 5,2%\nQatar Holding LLC 5.157.233 9,9% 5.157.233 7,9% - - - 5.157.233 8,5% 5.157.233 7,0%\nISLS Consulting (2) 111.000 0,2% 222.000 0,3% - 130.333 - 241.333 0,4% 352.333 0,5%\nM. David Nikodem - - - - - 76.000 - 76.000 0,1% 76.000 0,1%\nM. J. Goldberg - - - - 10.000 - 10.000 0,02% 10.000 0,01%\nBanque Européenne\n- - - - 6.022.504 6.022.504 9,9% 6.022.504 8,2%\nd'Investissement (BEI)\nDirigeants et administrateurs (4) 10.000 0,02% 10.000 0,02% - 130.000 - 140.000 0,2% 140.000 0,2%\nSalariés 1.338.127 2,6% 2.282.563 3,5% - - 719.650 2.057.777 3,4% 3.002.213 4,1%\nAutodétention 106.115 0,2% - - - - - 106.115 0,2% - -\nFlottant 13.225.595 24,7% 14.602.674 22,2% - - - 13.225.595 21,8% 14.602.674 19,9%\nTotal 52.477.188 100,0% 65.338.873 100,0% 430.000 6.368.837 1.319.650 60.595.675 100% 73.457.360 100%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé.\n(2) Dont 75.000 BSA 2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées\ndans la participation de ISLS Consulting.\n(3) Dont (i) 475.993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5.136.231 actions détenues en propre par M. Fréderic Cren.\n(4) Montant inférieur à 0,1%.\nL'émission des Actions Nouvelles T1 aura l'impact suivant sur la répartition du capital social et des droits de vote de la Société :\n53 | 60\nAprès l’émission des Actions Nouvelles T1 et des BSA T1\nBase non diluée Base diluée\n% en\n% des droits % des droits\nNbre d'actions (base capital Nbre de droits de Nbre d'actions % en capital Nbre de droits\nActionnaires de vote (base de vote (base\nnon diluée (base non vote (base diluée) (base diluée) de vote\nnon diluée) diluée)\ndiluée)\nFrédéric Cren (1)(4) 5 612 224 6,4% 11 224 448 11,2% 6 127 224 4,6% 11 739 448 8,0%\nPierre Broqua (1) 3 882 500 4,5% 7 765 000 7,8% 4 397 500 3,3% 8 280 000 5,7%\nSous-total - Pacte d'actionnaires 9 494 724 10,9% 18 989 448 19,0% 10 524 724 7,9% 20 019 448 13,7%\nBVF Partners L.P. 8 545 499 9,8% 8 545 499 8,6% 16 776 533 12,6% 16 776 533 11,4%\nNEA 7 835 884 9,0% 7 835 884 7,8% 20 659 160 15,5% 20 659 160 14,1%\nSofinnova 6 440 093 7,4% 7 480 654 7,5% 6 440 093 4,8% 7 480 654 5,1%\nYiheng Capital 5 474 986 6,3% 5 474 986 5,5% 5 474 986 4,1% 5 474 986 3,7%\nQatar Holding LLC 5 157 233 5,9% 5 157 233 5,2% 5 157 233 3,9% 5 157 233 3,5%\nInvus Public Equities L.P. 7 606 810 8,7% 7 606 810 7,6% 7 606 810 5,7% 7 606 810 5,2%\nPerceptive Life Sciences Master Fund, Ltd. 4 525 862 5,2% 4 525 862 4,5% 6 034 482 4,5% 6 034 482 4,1%\nAndera Partners 5 008 620 5,8% 5 008 620 5,0% 5 008 620 3,7% 5 008 620 3,4%\nISLS Consulting (2) 111 000 0,1% 222 000 0,2% 241 333 0,2% 352 333 0,2%\nM. David Nikodem - - - - 76 000 0,1% 76 000 0,1%\nM. J. Goldberg - - - - 10 000 0,0% 10 000 0,0%\nBanque Européenne d'Investissement (BEI) - - - - 9 097 078 6,8% 9 097 078 6,2%\nDirigeants et administrateurs (3) 10 000 0,0% 10 000 0,0% 140 000 0,1% 140 000 0,1%\nSalariés 1 338 127 1,5% 2 282 563 2,3% 2 057 777 1,5% 3 002 213 2,0%\nAutodétention 106 115 0,1% - - 106 115 0,1% 0 0,0%\nFlottant 25 422 742 29,2% 26 799 821 26,8% 38 259 293 28,6% 39 636 372 27,0%\nTotal 87 077 695 100,0% 99 939 380 100,0% 133 670 237 100,0% 146 531 922 100,0%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé.\n(2) Dont 75 000 BSA 2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation\nde ISLS Consulting.\n(3) Montant inférieur à 0,1%.\n(4) Dont (i) 475 993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5 136 231 actions détenues en propre par M. Fréderic Cren.\n54 | 60\nL'émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1 et des Actions Nouvelles T1bis aura l'impact suivant sur la répartition du capital\nsocial et des droits de vote de la Société :\nAprès l’émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1 et des Actions Nouvelles T1bis*\nBase non diluée Base diluée\n% des droits % en % des\n% en capital\nNbre d'actions (base Nbre de droits de de vote Nbre d'actions (base capital Nbre de droits de\nActionnaires (base non\nnon diluée vote (base non diluée) (base droits de vote vote (base\ndiluée)\ndiluée) diluée) diluée)\nFrédéric Cren (1)(4) 5 612 224 5,9% 11 224 448 10,4% 6 127 224 4,1% 11 739 448 7,2%\nPierre Broqua (1) 3 882 500 4,1% 7 765 000 7,2% 4 397 500 2,9% 8 280 000 5,1%\nSous-total - Pacte d'actionnaires 9 494 724 10,0% 18 989 448 17,6% 10 524 724 7,0% 20 019 448 12,3%\nBVF Partners L.P. 8 545 499 9,0% 8 545 499 7,9% 18 649 201 12,5% 18 649 201 11,5%\nNEA 8 350 730 8,8% 8 350 730 7,7% 24 091 470 16,1% 24 091 470 14,8%\nSofinnova 6 751 746 7,1% 7 792 307 7,2% 6 751 746 4,5% 7 792 307 4,8%\nYiheng Capital 5 845 675 6,2% 5 845 675 5,4% 5 845 675 3,9% 5 845 675 3,6%\nQatar Holding LLC 5 157 233 5,4% 5 157 233 4,8% 5 157 233 3,4% 5 157 233 3,2%\nInvus Public Equities L.P. 8 979 734 9,5% 8 979 734 8,3% 8 979 734 6,0% 8 979 734 5,5%\nPerceptive Life Sciences Master Fund, Ltd. 5 555 555 5,9% 5 555 555 5,2% 7 407 406 5,0% 7 407 406 4,6%\nAndera Partners 6 148 147 6,5% 6 148 147 5,7% 6 148 147 4,1% 6 148 147 3,8%\nISLS Consulting (2) 111 000 0,1% 222 000 0,2% 241 333 0,2% 352 333 0,2%\nM. David Nikodem - 0,0% - 0,0% 76 000 0,1% 76 000 0,0%\nM. J. Goldberg - 0,0% - 0,0% 10 000 0,0% 10 000 0,0%\nBanque Européenne d’Investissement - - - - 9 097 078 6,1% 9 097 078 5,6%\nDirigeants et administrateurs (3) 10 000 0,0% 10 000 0,0% 140 000 0,1% 140 000 0,1%\nSalariés 1 338 127 1,4% 2 282 563 2,1% 2 057 777 1,4% 3 002 213 1,8%\nAutodétention 106 115 0,1% 0 0,0% 106 115 0,1% 0 0,0%\nFlottant 28 555 474 30,1% 29 932 553 27,8% 44 312 509 29, 6% 45 689 588 28,1%\n149 596 148 100,0% 162 457 833 100,0%\nTotal 94 949 759 100,0% 107 811 444 100,0%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé.\n(2) Dont 75 000 BSA 2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation\nde ISLS Consulting.\n(3) Montant inférieur à 0,1%.\n(4) Dont (i) 475 993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5 136 231 actions détenues en propre par M. Fréderic Cren.\n55 | 60\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles T1bis sont réunies et (ii) que les BSA T1bis\nseront intégralement exercés.\n56 | 60\nL'émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis et des Actions Nouvelles T2* aura l'impact suivant sur la\nrépartition du capital social et des droits de vote de la Société :\nBase non diluée\nNbre d'actions (base non % en capital (base % des droits de vote\nActionnaires Nbre de droits de vote\ndiluée non diluée) (base non diluée)\nFrédéric Cren (1)(4) 5 612 224 3,1% 11 224 448 5,8%\nPierre Broqua (1) 3 882 500 2,1% 7 765 000 4,0%\nSous-total - Pacte d'actionnaires 9 494 724 5,2% 18 989 448 9,8%\nBVF Partners L.P. 18 649 202 10,3% 18 649 202 9,6%\nNEA 26 869 248 14,9% 26 869 248 13,9%\nSofinnova 8 433 227 4,7% 9 473 788 4,9%\nYiheng Capital 7 845 675 4,3% 7 845 675 4,0%\nQatar Holding LLC 5 157 233 2,9% 5 157 233 2,7%\nInvus Public Equities L.P. 16 387 141 9,1% 16 387 141 8,5%\nPerceptive Life Sciences Master Fund, Ltd. 12 962 962 7,2% 12 962 962 6,7%\nAndera Partners 12 296 295 6,8% 12 296 295 6,3%\nISLS Consulting (2) 111 000 0,1% 222 000 0,1%\nM. David Nikodem - - - -\nM. J. Goldberg - - - -\nBanque Européenne d'Investissement (BEI) - - - -\nDirigeants et administrateurs (3) 10 000 0,0% 10 000 0,0%\nSalariés 1 338 127 0,7% 2 282 563 1,2%\nAutodétention 106 115 0,1% - -\nFlottant 61 214 729 33,8% 62 591 808 32,3%\nTotal 180 875 678 100,0% 193 737 363 100,0%\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé.\n(2) Dont 75 000 BSA 2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation\nde ISLS Consulting.\n(3) Montant inférieur à 0,1%.\n(4) Dont (i) 475 993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5 136 231 actions détenues en propre par M. Fréderic Cren.\n57 | 60\n* Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles T1bis et Actions Nouvelles T2 sont réunies et\n(ii) que les BSA T1bis et les BSA T2 ont été intégralement exercés , (ii) que les Actions Nouvelles T2 ne seront émises qu’en actions ordinaires et (iii) un prix de souscription des\nABSA équivalent au Prix de Souscription des Actions Nouvelles (soit un nombre de 85.925.919 Actions Nouvelles T2).\nL'émission des Actions Nouvelles T1, de l’intégralité des Actions Issues des BSA T1, des Actions Nouvelles T1bis, des Actions Nouvelles T2* et de l’intégralité des\nActions Issues des BSA T3 aura l'impact suivant sur la répartition du capital social et des droits de vote de la Société :\nBase non diluée\nNbre d'actions (base non % en capital (base % des droits de vote\nActionnaires Nbre de droits de vote\ndiluée non diluée) (base non diluée)\nFrédéric Cren (1)(4) 5 612 224 2,2% 11 224 448 4,1%\nPierre Broqua (1) 3 882 500 1,5% 7 765 000 2,9%\nSous-total - Pacte d'actionnaires 9 494 724 3,7% 18 989 448 7,0%\nBVF Partners L.P. 27 713 529 10,7% 27 713 529 10,2%\nNEA 43 482 751 16,9% 43 482 751 16,1%\nSofinnova 9 941 733 3,9% 10 982 294 4,1%\nYiheng Capital 9 639 933 3,7% 9 639 933 3,6%\nQatar Holding LLC 5 157 233 2,0% 5 157 233 1,9%\nInvus Public Equities L.P. 23 032 542 8,9% 23 032 542 8,5%\nPerceptive Life Sciences Master Fund, Ltd. 19 608 363 7,6% 19 608 363 7,2%\nAndera Partners 17 811 978 6,9% 17 811 978 6,6%\nISLS Consulting (2) 111 000 0,0% 222 000 0,1%\nM. David Nikodem - - - -\nM. J. Goldberg - - - -\nBanque Européenne d'Investissement (BEI) - - - -\nDirigeants et administrateurs (3) 10 000 0,0% 10 000 0,0%\nSalariés 1 338 127 0,5% 2 282 563 0,8%\nAutodétention 106 115 0,0% - -\nFlottant 90 514 301 35,1% 91 891 380 33,9%\n58 | 60\n257 962 329 100,0% 270 824 014 100,0%\nTotal\n(1) Actionnaires agissant de concert aux termes du pacte d’actionnaires conclu dans le cadre de l’admission des actions de la Société sur le marché réglementé d’Euronext Paris, tel qu'amendé.\n(2) Dont 75 000 BSA 2017 attribuées à Jean-Louis Junien. Les actions de la Société détenues indirectement par Jean-Louis Junien via sa participation dans ISLS Consulting sont comptabilisées dans la participation\nde ISLS Consulting.\n(3) Montant inférieur à 0,1%.\n(4) Dont (i) 475 993 actions détenues en indivision avec son épouse, Mme Roberta Becherucci, épouse Cren et (ii) 5 136 231 actions détenues en propre par M. Fréderic Cren.\n*Les calculs sont effectués en prenant pour hypothèse (i) que toutes les conditions pour l’émission des Actions Nouvelles T1bis et Actions Nouvelles T2 sont réunies, (ii) que\nles BSA T1bis et les BSA T2 ont été intégralement exercés, (iii) que les Actions Nouvelles T2 ne seront émises qu’en actions ordinaires et (iv) un prix de souscription des BSA\néquivalent au Prix de Souscription des Actions Nouvelles (soit un nombre de 85.925.919 Actions Nouvelles T2).\n59 | 60\n10. INFORMATIONS SUPPLEMENTAIRES\n10.1 Conseillers ayant un lien avec l’Opération\nSans objet.\n10.2 Autres informations vérifiées par les commissaires aux comptes\nSans objet\n10.3 Responsables du contrôle des comptes\nKPMG SA\n2, avenue Gambetta\nCS 60055\n92066 Paris La Défense Cedex\nReprésenté par Monsieur Philippe Grandclerc\nLCA (membre de la compagnie régionale des Commissaires aux comptes de Paris)\n22 rue Fourcroy\n75017 Paris\nReprésenté par Lison Dahan Chouraki\n60 | 60"
        }
      ]
    },
    {
      "section_name": "Presentations",
      "links": [
        {
          "title": "Corporate presentation July 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/07/07-Inventiva-Presentation-ENG-07-31-2024.pdf",
          "content": "Developing innovative therapies in\nNASH\nCorporate Presentation\nJuly 2024\nDISCLAIMER\nThis presentation contains “forward-looking statements” within the meaning of the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical\nfacts, included in this press release are forward-looking statements.\nThese statements include, but are not limited to, forecasts and estimates with respect to Inventiva’scash resources and potential financing or strategic options and potential counterparties, forecasts and estimates\nwith respect to Inventiva’spre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollmentfor those trials, including the ongoing NATiV3 Phase III clinical trial\nwith lanifibranor in MASH/NASH, and the results and timing thereof and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from clinical trials, the potential therapeutic benefits of Inventiva’sproduct candidates, including lanifibranor alone and in combination with empagliflozin in patients with MASH/NASH and T2D, the\npotential of lanifibranor to address patient needs, the estimated market size and patient population, potential regulatory submissions, approvals and commercialization, Inventiva’spipeline and preclinical and\nclinical development plans, the expected benefit of having received Breakthrough Therapy Designation from the FDA and NMPA, including its impact on the development and review timeline of Inventiva’sproduct\ncandidates, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, the expected benefit of Inventiva’s\npartnerships and Inventiva’sability to achieve milestones and receive potential milestones under its partnership agreements. Certain of these statements,forecasts and estimates can be recognized by the use of\nwords such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”,\n“opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but ratherare statements of future expectations and other forward-looking statements that are based\non management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results,\nperformance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva'scontrol. There\ncan be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be\nmaterially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that Inventiva cannot\nprovide assurance on the impacts of the SUSAR on enrollmentor the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company\nwith no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product\nsales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development\nprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’sability to obtain financing and to enter into\npotential transactions, Inventiva'sfuture success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,\npreclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva'sand its partners’ clinical trials may not support Inventiva'sand its partners’ product candidate\nclaims, Inventiva'sexpectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’sclinical trials, Inventiva’sexpectations with\nrespect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not supportthe approval of a New Drug Application, Inventiva and its partners may encounter\nsubstantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and\nretain patients in clinical studies, enrollmentand retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors\noutside Inventiva'sand its partners’ control, Inventiva'sproduct candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial\npotential, Inventiva faces substantial competition and Inventiva’sand its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations\ncould be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollmentand completion\nof Inventiva’sand its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related riskof a larger conflict, health epidemics, and macroeconomic conditions,\nincluding global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates onlyspeak as of the date of this press release. Readers are cautioned not to place\nundue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes MarchésFinanciers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024. Other risks and uncertainties of whichInventiva is not currently aware may also affect its forward-looking statements and\nmay cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention\nand is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva acceptsno liability for any consequences arising from the use of any of the above\nstatements.\nCorporate Presentation | July2024 Property of Inventiva│ 2\nKey take-aways\nA Phase III ready program in R&D Capabilities and Cash\nA Phase III asset in NASH\nMPS(1) Position\nLanifibranor: only pan-PPAR agonist in Odiparcil: a GAG reduction therapy to R&D capabilities including wholly-\nclinical development for NASH potentially treat several forms of MPS owned ‘pharma scale’ discovery\nfacilities with a discovery engine\nPositive Phase IIb results with statistically Reduces GAG accumulation in multiple focused on nuclear receptors,\nsignificant efficacy on histological NASH organs in MPS VI models. Well-tolerated transcription factors and epigenetic\nresolution and one stage fibrosis reduction in MPS VI patients and in 1000s of targets\npatients previously tested(2)\nPositive Phase II, Proof-of-Concept, results of Clinical Ops team in place in Europe\nLEGEND with lanifibranor/empagliflozin Functional improvements to mobility and and the United States\nannounced in Q1 2024 respiratory function and clinical efficacy\nsignals in both ERT treated patients and Strong U.S. and European\nMechanism of action addressing all key ERT-naïve MPS VI patients shareholder base and experienced\nfeatures of NASH senior management team\nMPS VI Orphan Drug Designation\nBreakthrough Therapy Designation granted by granted in the U.S. and in the EU. Rare Cash position allowing a runway until\nFDA and Chinese NMPA Pediatric Disease Designation in MPS VI the beginning of Q3 2024\ngranted in the U.S.\nPivotal Phase III initiated in Q3 2021 with\ntopline results expected H1 2026 Guidance on path to regulatory\nsubmission from FDA with a single\nLicensing and commercialization agreements Phase II/III trial\nin Greater China, Japan and South Korea\nInventiva continues to review potential\noptions to further develop odiparcil which\nmay include pursuing a partnership\n(1)MPS:mucopolysaccharidosis;(2)TrialsconductedbyGSKpriortoInventiva’sfounding\nCorporate Presentation | July2024 Property of Inventiva│ 3\nManagement team with extensive global experience across all stages of\ndrug development and commercialization\nFrédéric Cren, MA/MBA, CEO and Co-Founder Pierre Broqua, Ph.D., CSO and Co-Founder\n Wide expertise within the areas of R&D, marketing,  Successfully managed numerous research programs\nstrategy and commercial operations leading to the discovery, development and\ncommercialization of innovative compounds, including\n Held senior positions at Abbott, Fournier, Solvay\nlanifibranor and Degarelix/ Firmagon®\nPharma and The Boston Consulting Group\n Held several senior research positions at Fournier,\n Former member of both Fournier and Solvay Pharma\nSolvay Pharma and Abbott\nExecutive Committees\nMichael Cooreman, MD, CMO\nJean Volatier, MA, CFO\n Gastroenterologist-hepatologist\n Former Head of controlling at URGO & Financial\nDirector International Operations of Fournier  Held global roles in several companies including\nTakeda Pharmaceuticals, Merck, Mitsubishi Tanabe,\n Held various positions as CFO\nImmusanT and Novartis\n Started his career with PwC in Paris and Philadelphia\nAlice Roudot-Ketelers, PharmD, COO\nPascaline Clerc, Ph.D., EVP Strategy and\nCorporate Affairs  Previously in charge of all drug development programs\nand cross-functional teams in Chemistry, CMC, non-\n Held global roles in academia, non-profit organization,\nclinical and clinical development up to Phase III at one\ngovernment and biotech companies\nof the major biotech companies in the NASH field\nKristina Meyer, Ph.D., Business Development\nDavid Nikodem, Ph.D., VP U.S. Operations\n& Alliance Management\n Former buyside portfolio manager and analyst for +15\n 20+ years experience in business development in the\nyears in public equities and VC\nbiotech industry\nCorporate Presentation | July 2024 Property of Inventiva│ 4\nDeep pipeline\nProgram Indication Discovery IND Enabling Phase I Phase II Phase III\nLanifibranor NASH pan-PPAR\nOdiparcil MPS VI GAG clearance\nYap-Tead\nOncology\nTGF-β\nFibrosis\nCorporate Presentation | July 2024\nProperty of Inventiva│ 5\nKey financials and shareholder base\nKey financials Shareholder base\nFree Float Founders\n25.2% 18.4%\nEmployees & Others BVF\nISIN code FR0013233012 / US46124U1079 2.3% 16.2%\nYiheng\n7.4%\nMarket Euronext Paris / Nasdaq GM\nSofinnova NEA\n9.8% 10.8%\nQatar Holding LLC\nShares outstanding 52,477,188\n9.9%\nEuronext Paris: €117m\nMarket cap\nAnalyst coverage\n(July 31, 2024) Nasdaq Global Market: $121m\nJefferies L. Codrington / M. J. Yee\n€10.1m(1) (vs €35.9m as of December\nGuggenheim S. Fernandez\nCash position 31, 2023(2))\n(as of June 30, 2024) Current cash runway through September, incl. the Stifel A. Samimy\n€20.1m royalty certificates deal of July 18, 2024(3)\nHC Wainwright E. Arce\nCanaccord Genuity E. Nash\nRevenues(1) No revenue end of H1 2024 (vs\n(as of June 30, 2024) €1.9m in H1 2023) LifeSci Capital R. Katkhuda\nKBC J. Mekhael\nR&D expenditures €48.7m in H1 2024 (compared to € Portzamparc M. Kaabouni\n(as of June 30, 2024) 54.1m in H1 2023(1))\nGilbert Dupont P.A. Desir\n(1)Unaudited\n(2)Cashpositionalsoincluded:i.short-termdepositsrecordedinthecategory“othercurrentassets”intheIFRSconsolidatedstatementoffinancialpositionandwereconsideredbytheCompanyasliquidandeasilyavailable,ii.thelong-termdeposithadatwo-yeartermaccessiblepriortothe\nexpirationofthetermwithanoticeperiodof31daysandwasconsideredasliquidbytheCompany.\n(3)https://inventivapharma.com/wp-content/uploads/2024/07/Inventiva-PR-Royalty-Deal-EN-07-18-2024.pdf\nCorporate Presentation | July 2024 Property of Inventiva│ 6\nLanifibranor: licensing and commercialization agreement in Greater China,\nJapan and South Korea\nLicensing agreement in Greater China Licensing agreement in Japan / South Korea\nAgreement with CTTQ an affiliate of Sino Biopharm one of Licensing agreement with Hepalys Pharma, Inc. backed by\nthe largest Chinese pharmaceutical groups listed in Hong Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and\nKong Exchange (HSI composite) with a market cap of MEDIPAL Innovation Fund\nc.US$10bn(1) and c.US$4bn of revenue(2) and ranked top\n$10M upfront payment\n40th pharma globally(3)\nUp to $231M of clinical, regulatory and commercial\n$17 million of non-dilutive payments received\nmilestone payments\nUp to $290 million of clinical, regulatory and commercial\nTiered royalties from mid double digits to low twenties on\nmilestone payments\nnet sales\nTiered royalties from high single-digit to mid-teen double\nInventiva owns a stake of Hepalys Pharma, Inc. and has an\ndigits on net sales made during the first three years of\noption to acquire all outstanding shares at a pre-agreed\ncommercialization and from low to mid-teen double digits\nmultiple of post-money valuation\nstarting from year four.\nRight of first refusal in the event Hepalys receives an offer\nCTTQ will bear all costs associated with the trials conducted\nto sell the license or rights related to lanifibranor.\nin Greater China\nHepalys will bear all costs associated with the trials\nCTTQ to randomize patients into the NATiV3 Phase III\nconducted in Japan and South Korea\nclinical trial in mainland China\nDevelopment includes PK/PD Phase I studies and following\nphase I and NATiV3 results an independent pivotal Phase III\nstudy in Japan and South Korea\nInventiva eligible to more than 500M$ of milestones plus sales royalties\n(1) Information about Sino Biopharm, its business, operations and finances are based on third-party information and disclosures. Inventiva makes no representations regarding the accuracy of such information presented herein; (2) Market\ndata as of Sept 2022 ; (3) Converted from RMB to USD\nCorporate Presentation | July 2024 Property of Inventiva│ 7\nLanifibranor in Nonalcoholic\nSteatohepatitis (NASH)\nLanifibranor: a pan-PPAR agonist in Phase III development in NASH\nModerate and balanced pan-PPAR agonist activity\n Small molecule that activates all three PPAR isoforms in humans\nPPARα\n Differentiated chemical structure: not a fibrate or a TZD\n Once daily oral administration\n Positive Phase IIb trial topline results in NASH\n FAST Track (including in NASH patients with compensated cirrhosis) and\nBreakthrough Therapy designations granted by FDA and Chinese NMPA\n FDA confirmation that the non-clinical toxicology package is complete and\nPPARβ/δ PPARγ\nacceptable for NDA filing\nLANIFIBRANOR  IP: 19 families covering the compound, method of treatment, combination therapy,\nprocess, formulation and diagnostic methods. Last expiry expected in 2045\nPan-PPAR activity expected to improve efficacy in NASH\nINFLAMMATION AND\nMETABOLISM STEATOSIS FIBROSIS VASCULAR\nBALLOONING\nPPARα PPARδ PPARγ PPARγ PPARα PPARδ PPARγ PPARδ PPARγ PPARα PPARγ\nStellate cell\nInsulin sensitivity FA uptake NFkB-dependent Portal pressure\nproliferation and\ngene activation\nactivation\nHDLc FA catabolism LSEC capillarization\nInflammasome\nCollagen and\nTriglycerides Lipogenesis Intrahepatic vascular\nfibronectin\nBallooning resistance\nproduction\nCorporate Presentation | July 2024 Property of Inventiva│ 9\nPatent Extension Timeline\n2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045\nGranted Patent\nProduct:Composition\nof matter\nGranted Patent\nProduct: Crystallines forms of lanifibranor\nGranted patent - Pending Application in the US\nProduct: Deuterated forms of lanifibranor\nPending Application\nProduct: Crystallines forms of lanifibranor\nPending Application\nPCT\nProduct: Crystallines forms of lanifibranor\nGranted Patent Projected Potential Extensions\nApplication : Disease treatment (method claim; fibrosis condition; NASH)\nGranted Patent\nApplication : Disease treatment (method claim; cirrhosis)\nWe expect that NASH patent will be selected for Patent Term Extension (PTE).\nEligibility of the method of use patents for PTE assessed and confirmed by globally recognized IP law firm.\nComposition of matter patent and NASH patent have been granted in > 50 countries incl. EP, US, CN, JP, KR, AU, CA, RU.\nCorporate Presentation | July 2024 Confidential –Property of Inventiva│ 10\nLanifibranor is a differentiated pan-PPAR agonist with moderate and well\nbalanced activity on the three PPAR isoforms\nDifferentiated oral small molecule …\n Small molecule that\nactivates all three PPAR\nisoforms\n Differentiated chemical\nstructure with once daily\noral administration\n Offered in two dosage\nforms (800 mg, 1200 mg)\nModerate and balanced pan-PPAR agonist activity\n150\nPPARα PPARδ PPARγ\nCompound\nEC50 (nM) EC50 (nM) EC50 (nM)\n125\nLanifibranor* 1630 850 230\n100\n75 Fenofibrate 2400 - -\n50 Pioglitazone - - 263\nRosiglitazone - - 13\n25\nElafibranor** 10 100 -\n0\n-10 -8 -6 -4 Seladelpar^ - 2 -\nlanifibranor (M)\nSource: * Company data ** HanfR et al, Diabetes & Vascular Dis Res 2014 ^ Cymabaycompany presentation ^^ J Med Chem. 2018 Feb 15. doi: 10.1021/acs.jmedchem.7b01285\nProperty of Inventiva│ 11\nnoitavitcA%\nLANIFIBRANOR\n… that binds differently than glitazone to PPARγ\nROSI\nLANI\n Induces different coactivator recruitment^^\nhPPARα\nhPPARδ\nhPPARγ\nCorporate Presentation | July 2024\nAdverse events and toxicity previously seen in other single and dual PPAR\nagonists have not been observed with lanifibranor\nSAFETY\nOrgan Isoforms activated Reported PPAR side effects lanifibranor effects\n Fluid retention\nHEART PPARγ\n Cardiac hypertrophy\nSKELETAL\nPPARα  Myofiber degeneration\nMUSCLE\nNOT\nOBSERVED\n > 50% increases in creatinine, degenerative\nKIDNEY PPARα\nchanges in renal tubules\nURINARY\nPPARγ  Proliferative changes in bladder epithelium\nBLADDER\nAdverse events and toxicity of single / dual PPAR agonists not observed in primate and rodent studies\n No adverse clinical signs observed at any dose-level tested\nFAVOURABLE\n No effects on body and heart weight, no haemodilution or creatinine increase\nTOLERABILITY PROFILE in\na 12-month monkey study …  Electrocardiography and clinical pathology investigations did not reveal any\nundesirable effects\n Rat: no observed neoplastic change or increase in tumor types commonly associated\n… and in two-year with single PPARγ and dual PPARα/γ agonists (liver, adipose, bladder, renal and\nCARCINOGENITY STUDIES skin)\nperformed in rat and mice\n Mice: no observed neoplastic changes of human relevance\nConfirmation by FDA that the non-clinical toxicology package is complete and acceptable\nto support NDA filing in NASH\nSource: Company data\nCorporate Presentation | July 2024 Property of Inventiva│ 12\nLanifibranor: comprehensive impact on the histology and biology of NASH\nHISTOLOGY AND MARKERS\n1\nFibrosis Regression\nFibrosis NASH\n&\nRegression Resolution\nNASH Resolution\nHealthy liver Steatosis Steatohepatitis Liver fibrosis Cirrhosis\nSteatosis measured by Biomarkers of inflammation Circulating biomarkers of\nhistological grading, MRI-PDFF (ferritin, CRP), tissue injury fibrosis: Pro-C3, TIMP-\nCAP/Fibroscan; Intra-hepatic (ALT,AST) and apoptosis 1/MMP-2, MACK-3\nTG content by 1H-MRS(1); (CK18) Improvement seen with CT1\nNAFLD resolution scan\nGLUCOSE METABOLISM MARKERS CARDIOVASCULAR RISK MARKERS\nImproves insulin sensitivity and glycemic control in patients with or Improves markers of cardiovascular risk and lipid metabolism\nwithout diabetes\nAPO-B DBP\nHDL-C\nTreatment with lanifibranor decreases the ratio of visceral abdominal\nAPO-B/APO-A1 Adiponectin\nfat to subcutaneous fat, reflecting a shift from pro-inflammatory Triglycerides levels\nAPO-C3\nvisceral fat towards metabolically healthy adipose tissue LDL-cholesterol level\nHs-CRP\nFasting glucose HOMA-IR index Insulin resistance\nFasting insulin Hepatic glucose Hepatic and muscle Improves markers of cardiometabolic health independently of weight\nHbA1c production insulin resistance gain which has been shown to be metabolically healthy\nIncreases adiponectin known to regulate glucose levels, lipid\nmetabolism and insulin sensitivity through its anti-inflammatory, anti-\nfibrotic and antioxidant effects\n(1) Proton magnetic resonance spectroscopy\nCorporate Presentation | July 2024 Property of Inventiva│ 13\nThe Phase IIb NATIVE trial evaluated 800 mg and 1200 mg once-daily\nlanifibranor versus placebo in 247 patients\nPHASE IIb DESIGN OVERVIEW\n24-week treatment + 4-week follow-up\nScreening End of treatment\nDouble blind, randomized, placebo-controlled\n Liver biopsy  Liver biopsy\nPlacebo\nlanifibranor, 800 mg once daily\n• Randomisation 1/1/1\n• Stratification on\nlanifibranor, 1200 mg once daily\ntype 2 diabetes\nmellitus (T2D)\nPatient population # patients Definition\nPatients randomized having received at least one dose of\nSafety / Intention-to-Treat (ITT) 247\nlanifibranor/placebo\nPatients with paired biopsies and without deviation impacting efficacy\nPer Protocol (PP) 194\nresults\n Main inclusion criteria: patients with biopsy-proven NASH confirmed by central reader having Steatosis-Activity-Fibrosis\n(SAF) scores of 1-3 for steatosis, 3-4 for activity, and <4 for fibrosis\n Results published in the New England Journal of Medicine(1):\n(1) https://www.nejm.org/doi/full/10.1056/NEJMoa2036205\nCorporate Presentation | July 2024 Property of Inventiva│ 14\nThe majority of patients successfully completed the 24-week treatment\nPHASE IIb DESIGN TREATMENT ARMS\n247 patients randomised and treated\nPlacebo lanifibranor 800 mg/day lanifibranor 1200 mg/day\nN = 81 N = 83 N = 83\n74 (91%) patients completed 77 (93%) patients completed 77 ( 93%) patients completed\nthe 24-week treatment the 24-week treatment the 24-week treatment\n7 (9%) patients prematurely 6 (7%) patients prematurely 6 (7%) patients prematurely\nwithdrawn: withdrawn: withdrawn:\n- Adverse events (n=3) - Adverse events (n=3) - Adverse events (n=3)\n- Withdrawal by patient (n=2) - Lost to follow-up (n=1) - Lost to follow-up (n=1)\n- Forbidden concomitant - Withdrawal by patient* (n=1) - Withdrawal by patient (n=2)\nmedication (n=2)\n- Non-compliance (n=1)\nNote: * And adverse event as secondary reason\nCorporate Presentation | July 2024 Property of Inventiva│ 15\nPatient population included 58% of female and 42% of patients with T2D\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor Overall\nParameters (unit)\n- 800 mg/day 1200 mg/day -\nn (%) or mean ± SD\nN = 81 N = 83 N = 83 N = 247\nDemographics\nFemale 41 (51%) 54 (65%) 49 (59%) 144 (58%)\nAge (years) 53.4 ± 13.1 55.0 ± 10.4 52.2 ± 13.8 53.6 ± 12.5\nWhite 74 (91%) 80 (96%) 78 (94%) 232 (94%)\nWeight (kg) 95.1 ± 17.3 91.6 ± 19.3 93.0 ± 19.9 93.2 ± 18.9\nBody Mass Index (kg/m²) 32.8 ± 5.1 32.5 ± 5.5 33.3 ± 5.5 32.9 ± 5.4\nType 2 diabetes 35 (43%) 33 (40%) 35 (42%) 103 (42%)\nLiver biopsy characteristics\nSAF Activity score\n3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.5 3.3 ± 0.5\n(inflammation + ballooning)\nNAFLD Activity Score (NAS) ≥6 56 (69.1%) 63 (75.9%) 61 (73.5%) 180 (72.9%)\nFibrosis stage F2/F3 57 (70.4%) 68 (81.9%) 63 (75.9%) 188 (76.1%)\nCorporate Presentation | July 2024 Property of Inventiva│ 16\nSeveral liver tests and markers of lipid and glucose metabolism were\nrecorded\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor\nParameters (unit)\n- 800 mg/day 1200 mg/day\nmean ± SD\nN = 81 N = 83 N = 83\nLiver enzymes\nAlanine aminotransferase, ALT (UI/L) 56.9 ± 31.6 64.1 ± 41.4 63.6 ± 43.4\nAspartate aminotransferase, AST (UI/L) 43.3 ± 24.1 53.9 ± 43.4 43.9 ± 24.8\nGamma glutamyl transferase, GGT (UI/L) 67.9 ± 80.4 101.6 ± 146.1 67.1 ± 93.1\nPlasma lipid levels\nHDL-Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3\nTriglycerides (mmol/L) 2.0 ± 0.8 1.9 ± 0.9 2.0 ± 0.9\nGlucose metabolism for patients with T2D\n(n= 103)\nFasting Glucose (mmol/L) 6.9 ± 2.0 7.3 ± 2.2 6.6 ±1.2\nHbA1c (%) 6.5 ± 0.7 6.7 ± 0.8 6.6 ± 0.7\nInsulin (pmol/L) 222.7 ± 186.5 246.3 ± 213.4 278.5 ± 233.5\nCorporate Presentation | July 2024 Property of Inventiva│ 17\nLanifibranor achieves statistically significant results on the key Phase III\nFDA and EMA primary endpoints\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint: ITT population\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83)\nResolution of NASH and no\n45%\nworsening of fibrosis*\n33%\n19%\n0.043 <0.001\nImprovement of fibrosis by at\nleast one stage and no\n42%\nworsening of NASH** 28%\n24%\n0.53 0.011\nResolution of NASH and\n31%\nimprovement of fibrosis***\n21%\n7%\n0.017 <0.001\n Statistical significance was also demonstrated for the main key histological endpoints in patients with F2-F3 fibrosis stage\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of\nliver fibrosis ≥ 1 stage and no worsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1\nstage\nCorporate Presentation | July 2024 Property of Inventiva│ 18\nResolution of NASH and improvement of fibrosis: effect size is increased in\nF2/F3 patients as well as patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and\nimprovement of fibrosis(1) 3,0more 4,4more\nresponders on 31% responders on\n(N=247) 21%\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in 8,0more 9,6more\nresponders on 29% responders on\npatients with TD2M (N=103) 24%\n3% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3\n3,4more 4,7more\n33%\npatients (N=188) 24% responders on responders on\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3 7,5more 7more responders\n30% responders on 28% on 1200mg vs\npatients with TD2M (N=83)\n4% 800mg vs placebo placebo\n(1) ) Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | July 2024 Property of Inventiva│ 19\nImprovement of fibrosis and no worsening of NASH is achieved in all\nsubgroups analyzed with similar level of effect size\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nImprovement of fibrosis by at least\none stage and no worsening of 1,2more 1,7more\nNASH(1) (N=247) 24% 28% responders on 42% responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\n1,3more 2,0more\nNASH(1) in patients with TD2M\nresponders on 46% responders on\n30%\n(N=103) 23% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nImprovement of fibrosis by at least\none stage and no worsening of\n1,1more 1,6more\nNASH(1) in F2 / F3 patients (N=188) 48%\n30% 32% responders on responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\nNASH(1) in F2 / F3 patients with\n1,2more 1,6more\n48%\nTD2M (N=83) 37% responders on responders on\n30%\n800mg vs placebo 1200mg vs placebo\n(1) improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24\nCorporate Presentation | July 2024 Property of Inventiva│ 20\nResolution of NASH and no worsening of fibrosis: effect size is increased in\nF2/F3 patients as well as in patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and no\n1,7more 2,4more\nworsening of fibrosis(1) (N=247) 45%\n33% responders on responders on\n19%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in patients 2,3more 3,0more\n43%\nwith TD2M (N=103) 33% responders on responders on\n14%\n800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n3,8more 4,8more\n44%\npatients (N=188) 34% responders on responders on\n9%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n8,2more 10,2more\n41%\npatients with TD2M (N=83) 33% responders on responders on\n4%\n800mg vs placebo 1200mg vs placebo\n(1) Resolution of NASH with no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline\nCorporate Presentation | July 2024 Property of Inventiva│ 21\nLanifibranor efficacy on resolution of NASH and improvement of fibrosis of\nat least 1 stage is superior to resmetirom and at par with FGF-21\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=320 N=223 (F2/F3) N=190\nN=247 N=955 N=128 N=126 N=222\nITT ITT ITT PP\nEffect size Effect size Effect size Effect size Effect size\n24% 11% 28% 28% 20%\n35%\n33%\n31%\n26% 28%\n21%\n20%\n16%\n14% 15% 14%\nEndpoint not\n7% 7% reported on\n5% 5%\n0%\nPlacebo 800mg 1200mg Pbo 80mg 100mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg 30mg 44mg\n0.017* <0.001* <0.0001* <0.0001* 0.009* 0.002* <0.01* <0.01* QW(1) QW Q2W\n*** ***\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results; Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023 ; SemaglutideA\nPlacebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome et al. NEJM 2021; 384:1113-1124.; Resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10 and EASL 2023 presentation pg. 8; Efruxifermin EASL 2023 presentation pg.\n8, corporate presentation of March 2024 pg 22 ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Firbosis, The NEJM DOI:\n10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 22\nLanifibranor efficacy on ≥1 stage fibrosis improvement and no worsening\nof NASH is superior to resmetirom and at par with injectables\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n18% 12% 5% 14% 30% 20% 10% 21% 21%\n55%\n51% 51%\n49% 49%\n42% 43% 43%\n38%\n36%\n28% 29% 33% 30% 33% 32% 34% 30%\n24% 24%\n26%\n24%\n26%27%\n22% 22%\n19% 19%\n14%\n7%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo15mg30mg 44mg Pbo 0.1mg 0.2mg 0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\n0.53 0.011* 0.0002* <0.0001* 0.65 QW QW Q2W QW QW QW\n0.033*0.123 <0.01* 0.1*0.008*0.008* 0.48\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 23\nLanifibranor efficacy on NASH resolution and no worsening of fibrosis is\nsuperior to resmetirom and at par with pegozafermin\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n26% 20% 18% 46% 18% 24% 42% 35% 52%\n60% 59% 62%\n56%\n45% 43% 45% 46% 45% 44%\n40% 40%\n33% 37% 37% 36%\n30%\n26% 25% 26%\n23%\n19% 19%\n17%\n14%\n10% 10% 10%\n7%\n2%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg30mg44mg Pbo 0.1mg 0.2mg0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\nQW QW Q2W QW QW QW\n<0.043* <0.001* <0.0001*<0.0001* 0.024* 0.005*<0.001* 0.005* <0.0001* 0.0005* <0.001*\n0.0009*\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 24\nA statistically significant decrease in liver enzymes was observed\n10\n0\n-10\n-20\n0 4 8 12 16 20 24\nProperty of Inventiva│ 25\n)L/IU(\negnahc\netulosba\nnaeM\n10\n0\n-10\n-20\n-30\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/IU(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in ALT Absolute change from baseline in AST\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nAbsolute change from baseline in GGT\n10\n0\n-10\n-20\n-30\n-40\n-50\n0 4 8 12 16 20 24\n)L/IU(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247)\n**\n*\n** ** * **\n** *\n** ** * **\n0 W4 W14 W24\n* p<0.01 **p<0.001\nA statistically significant decrease of ALT,\nAST and GGT in both lanifibranor dose\n** ** groups observed after 4 weeks\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nSTNIOPDNE\nYRADNOCES\nCorporate Presentation | July 2024\nA statistically significant change in HDL-cholesterol and triglycerides was\nseen, without a change in LDL-cholesterol\n0.25\n0.15\n0.05\n-0.05\n0 4 8 12 16 20 24\nProperty of Inventiva│ 26\n)L/lomm(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in HDL-C Absolute change from baseline in triglycerides\n0.2\n0\n**\n-0.2\n-0.4\n-0.6\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/lomm(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247) * p<0.01 **p<0.001\n**\n**\n**\n*\n**\n** **\n**\n**\n0 W4 W14 W24\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200m**g\n No change in LDL-cholesterol\nSTNIOPDNE\nYRADNOCES\nStatistically significant change Statistically significant change\nin HDL-cholesterol in triglycerides\nCorporate Presentation | July 2024\n0.5\n0\n-0.5\n-1\n-1.5\n-2\n0 4 8 12 16 20 24\nProperty of Inventiva│ 27\n)L/lomm(\negnahc\netulosba\nnaeM\nIn patients with NASH and T2D, statistically significant reductions of\nfasting glucose and insulin, HbA1c were observed\nAbsolute change from baseline in HbA1c Absolute change from baseline in fasting glucose\n0.5\n0\n-0.5 **\n**\n**\n**\n-1 **\n**\n0 4 8 12 16 20 24\n0 W4 W14 W24\nPlacebo (N= 35) Lanifibranor 800mg (N= 33)\nLanifibranor 1200mg (N= 35)\n**p<0.001\n)%(\negnahc\netulosba\nnaeM\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo (N = 35) Lanifibranor 800mg (N = 33)\nLanifibranor 1200mg (N = 35)\nAbsolute change from baseline in insulin at W24\n0\n-10\n-20\n-30\nweek 24\n)Lm/UIµ(\negnahc\netulosba\nnaeM\nSecondary endpoints in patients with NASH and T2D (N = 103)\n**\n**\nPlacebo (N= 32) Lanifibranor 800mg (N= 31)\nLanifibranor 1200mg (N= 33)\nSTNIOPDNE\nYRADNOCES\nPHASE IIb EFFICACY OTHER\nLanifibranor associated with improvements\nin insulin sensitivity and glycemic control in\nNASH patients\nCorporate Presentation | July 2024\nLanifibranor leads to significant improvements in hepatic and muscular\ninsulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 28\nnim/gk/gm\nLS mean absolute change from baseline LS mean absolute change from baseline to LS mean absolute change from\nto week 24 in week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\n Data from the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating\nlanifibranor (800mg/day) in patients with NAFLD and type 2 diabetes mellitus (T2D) for 24 weeks\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nDr. Cusi - IIS\nCorporate Presentation | July 2024\nLanifibranor induces a significant decrease in circulating biomarkers\nlanifibranor\nMedian relative change (%) Placebo Pvalue\n(Two doses pooled)\nPro-C3 (4.1%) (13.9%) p= 0.005*\nPro-C3 >14 at\nFibrosis (12.8%) (20.5%) p= 0.017*\nbaseline(1)\nRatio TIMP-1/MMP-2 (4.6%) (22.5%) p < 0.001*\nApoptosis CK18-M30 0.5% (41.1%) p < 0.001*\nFerritin (9.1%) (29.4%) p < 0.001*\nInflammation\nhs-CRP 13.0% (35.5%) p < 0.001*\n(1) Level where it is estimated that fibrogenesis is active and corresponding to F2/F3 patients\nFAS (Full Analysis Set) population with available data at baseline and at week 24\n* Statistically significant\nProperty of Inventiva│ 29\nSERUSAEM\nEMOCTUO\nREHTO\n Data from NATIVE clinical study evaluating lanifibranor (800mg/day and 1200mg/day ) in patients with NASH for 24 weeks\nCorporate Presentation | July 2024\nLanifibranor significantly reduces hepatic steatosis measured by MRI-\nPDFF and MR-spectroscopy\n Data from the Legend clinical study evaluating lanifibranor  Data from the clinical study conducted by Dr. Kenneth\n(800mg/day) in combination with empagliflozin in patients Cusi from the University of Florida, evaluating lanifibranor\nwith NASH and poorly controlled Type 2 Diabetes (T2D) (800mg/day) in patients with NAFLD and type 2 diabetes\nfor 24 weeks mellitus (T2D) for 24 weeks\nDr. Cusi - IIS\nLiver fat measured by MRI-PDFF Liver fat (IHTG) measured by MR-spectroscopy\nN=26 from baseline at week 24 N=38 from baseline at week 24\nLS means relative percent change, FAS LS means relative percent change, FAS\n0% 0%\n0%\n-10% -10%\n-12%\n-20% -20%\n-30% -30%\n*\n-40% -37% -40%\n*\n-44% pa=0.002\n-50%\n-47%*\n-50%\nPlacebo Lani Lani Placebo Lani\nn= 5 n= 12 + Empa n=18 n=20\nn= 9\nBaseline 17.1-19.7%  65% of patients achieved liver fat reduction ≥30% vs 22% under\nplacebo\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)  25% of patients achieved NAFLD resolutions vs 0% under placebo\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before a P-value from an Analysis of Covariance (ANCOVA) using the relative change from baseline to week 24\nWeek 24 as the response, the treatment as covariate as well as the baseline of IHTG. In the FAS, missing data at\nWeek 24 were imputed by baseline data.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 30\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Tirzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo 30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 31\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\n Data from the clinical study evaluating lanifibranor (800mg/day) in combination with empagliflozin in patients with NASH and\npoorly controlled Type 2 Diabetes (T2D) for 24 weeks\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 32\nLanifibranor has a favourable safety profile\nPHASE IIb SAFETY OVERALL\nPlacebo 800 mg 1200 mg\nN (%) patients reporting Adverse Event (AE)\n(N = 81) (N = 83) (N = 83)\n Any Treatment-Emergent AE (TEAE)\n50 (61.7%) 59 (71.1%) 62 (74.7%)\nDrug-related TEAE 19 (23.5%) 25 (30.1%) 23 (27.7%)\n Any TEAE leading to drug withdrawal\n3 (3.7%) 4 (4.8%) 3 (3.6%)\nDrug-related TEAE leading to drug withdrawal 2 (2.5%) 1 (1.2%)(1) 2 (2.4%)(2)\n Any Serious TEAE\n3 (3.7%) 3 (3.6%) 7 (8.4%)\nDrug-related Serious TEAE 2 (2.5%)(3) - -\nFocus of next slide\n(1) One patient with moderate diarrhea ; (2) One patient with mild cardiac failure; one patient with mild diarrhea, abdominal pain, dizziness ;\n(3) 2 SUSARs (placebo arm): one patient with mild cardiac failure; one patient with moderate urticaria\n Consistent with known insulin sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at the\n800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed.\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 81)\n Peripheral edema 2 (2.5%) 5 (6.0%) 7* (8.4%)\nDrug-related peripheral edema - 2 (2.4%) 2 (2.4%)\n Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few\npatients received diuretics. 4 cases were considered study drug related by the investigator (2 at 800\nand 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor\n1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female\n* One AE of severe intensity\npatients\nCorporate Presentation | July 2024 Property of Inventiva│ 33\nA limited number of serious TEAEs occurred\nPHASE IIb SAFETY SERIOUS TEAE\nPatients reporting treatment-emergent Placebo 800 mg 1200 mg\nSerious AE (SAE); N (%) (N = 81) (N = 83) (N = 83)\nTotal 3 (3.7%) 3 (3.6%) 7 (8.4%)\nTreatment-Emergent Serious AE linked to biopsy procedure\nPost-procedural haematoma/haemorrhage - 1 (1.2%) 1 (1.2%)\nPost-procedural pain - - 1 (1.2%)\nPneumobilia (post-procedural) - - 1 (1.2%)\nOther Treatment-Emergent Serious AE\nWrist fracture 1 (1.2%) - -\nAngina unstable - - 1 (1.2%)\nCardiac failure 1 (1.2%) - -\nGastroenteritis - - 1 (1.2%)\nPyelonephritis - - 1 (1.2%)\nPancreatitis - 1 (1.2%) -\nUndifferentiated connective tissue disease - 1 (1.2%) -\nUrticaria 1 (1.2%) - -\nFoot operation - - 1 (1.2%)\nCorporate Presentation | July 2024 Property of Inventiva│ 34\nPhase II results have demonstrated modest weight increase with no impact\non efficacy\n Consistent with known insulin-sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at\nthe 800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed\n According to a six-month study with pioglitazone in patients * with NASH body weight gain is likely attributed to an\nincrease in adipose tissue and not water retention\n Based on a 52-week lanifibranor trial in systemic sclerosis (SSc) patient weight gain is expected to reach a maximum\nby week 24\nSSc lanifibranor study: weight (kg) relative change from baseline over 52 weeks\n(Observed cases under treatment – FAS population)\nExcept for two patients (one placebo, one 600mg BID),\nTEAE time of onset related to weight increase happened in\nKg\n6 the first 24 weeks of treatment\n4\n2\n0 Weeks\n0 2 4 8 12 16 20 24 28 32 36 40 44 48 52\nLanifibranor 600 mg BID Placebo\nNote: * Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholivsteatohepatitis ; Balas, Belfort, Harrison et al. ; Journal of Hepatology 47 (2007) 565-570\nCorporate Presentation | July 2024 Property of Inventiva│ 35\nWeight changes in NATIVE trial: approximately 33% of patients\non lanifibranor show a weight increase of more than 5%\nWeight changes at end of treatment (Week 24) in patients treated with\nlanifibranor versus placebo\nLanifibranor Placebo\n100%\nN=144 N=73\n84%,\nN=61\n80%\n51%,\n60%\nN=73\n33%,\n40%\nN=48\n16%,\n20% N=23 11%,\nN=8 6%,\nN=4\n0%\nStable Moderate Weight Stable Moderate Weight\nweight weight gain weight weight gain\n(≤2.5%) gain (>5%) (≤2.5%) gain (>5%)\n(2.5%-5%) (2.5%-5%)\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 36\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (I/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nFasting HOMA-IR ALT\nMean absolute change at Week 24 from baseline Mean absolute change at Week 24 from baseline (U/L)\nLanifibranor Placebo Lanifibranor Placebo\n4.0\n10 8\n1.7\n2.0 5\n0.0 0\n-0.6\n-2.0 -5\n-5\n-10\n-4.0\n-15\n-6.0 -5.1\n-5.8\n-20\n-8.0 -20\n-8.2 -25 -22\n-10.0\n-26\n-30\nTriglycerides CAP\nMean absolute change at Week 24 from baseline (mmol/L) Mean absolute change at Week 24 from baseline (dB.m-1)\n1\n0.8 Lanifibranor Placebo Lanifibranor Placebo\n35\n30.6\n0.6\n25\n0.4\n0.2 0.12\n0.03 15\n0\n-0.2 5\n-0.4\n-0.42 -0.44 -0.45 -5\n-0.6 -4.6\n-0.8  LDL level do not change but HDL level improves in -15 -10.2\npatients treated with lanifibranorindependently of weight -14.7\n-1 -17\nchanges\n-25\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 37\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (II/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nAPO-C3 APO-B\nMean absolute change at week 24 from baseline (μg/ml) Mean absolute change at week 24 from baseline (mg/dl)\n25 Lanifibranor Placebo Lanifibranor Placebo\n19.1 0\n20\n-0.08\n-2\n15\n-2.58\n-4\n8.9\n10\n-6\n5\n-8\n0\n-10\n-9.66\n-5\n-12\n-10 -7.3 -14 -13.04\n-9.3\n-10.7\n-14.56\n-15 -16\n-20 -18\n-20\nhs-CRP hs-CRP\nMean absolutechange at Week 24 from baseline (%) Mean relativechange at Week 24 from baseline (%)\nLanifibranor Placebo Lanifibranor Placebo\n1.0 0.6\n10\n3\n0.0 0\n-0.1 -1\n-1.0 -0.6 -10\n-20\n-2.0 -21\n-30\n-3.0 -2.7\n-40\n-41\n-4.0 -50\n-4.1\n-60\n-5.0\n-61\n-70\n-6.0\n-80\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | July 2024 Property of Inventiva│ 38\nEffect on weight when combining lanifibranor with empagliflozine\nWeight change, N=32 Ratio VAT/SAT, N=19\nRelative change from Baseline (%) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 93-102 kg\n5 11\n3.6 10\n4\n3 5\n2\n2 1.4 0\n1\n00 -5\n-0.4 -0.4 -5*\n0\n-0.9\n0 -10\n-1\n-0.8 -0.8\n-1.1 -15\n-2\nWeek 4 Week 12 Week 24\nBaseline -17**\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8 -20\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nPlacebo Lani Lani + Empa n= 4 n= 8 n= 7\nAt Week 24, 7 patients without weight values available : SAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n- 5 patients under placebo who prematurely stopped before Week 24 * p=0.08, **p<0.01, versus placebo (ANCOVA)\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly Thirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\nmodified his/her diet (intercurrentevent) before Week 24.\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nThe combination of empagliflozin and lanifibranor addresses the Lanifibranor alone and in combination with empagliflozin leads to\nweight gain observed in some patients treated with lanifibranor alone a shift towards metabolically healthy adipose tissue\nCorporate Presentation | July 2024 Property of Inventiva│ 39\nPhase III NATiV3 should, if positive, allow to file for accelerated approval\nMain Cohort Accelerated\nApproval\n72 weeks treatment\nN~ 950\nLanifibranor: 1200 mg once daily\nNon-cirrhotic NASH &\nLanifibranor: 800 mg once daily\nF2-F3 fibrosis\nActive Treatment Extension\nPlacebo: Once daily\n►Stratification\n48 weeks\n- By diabetic status\nExploratory Cohort\n- By fibrosis stage F2/F3 EoT\n72 weeks treatment Lanifibranor: 1200 mg once daily\nN~ 200\nLanifibranor: 800 mg once daily\nLanifibranor: 1200 mg once daily\nScreen failed patients from the\n►All patients who complete the main or the exploratory cohort\nmain cohort are eligible for the active treatment extension study\nLanifibranor: 800 mg once daily\nNon-cirrhotic NASH & ►Patients to switch to the active treatment extension after the\nF1-F4 fibrosis week 72 visit of the last patient randomized in the main cohort\nPlacebo: Once daily\nor after 120 weeks of treatment, whichever happens first\n►Stratification\n- By diabetic status\n- By fibrosis stage F1-F3/F4\nPrincipal investigators: Dr. S. Francque / Dr. A. Sanyal for the main cohort\nPrimary endpoint: Composite endpoint of patients having both NASH resolution and one stage fibrosis improvement\nKey secondary endpoints: NASH resolution and no worsening of fibrosis / Fibrosis improvement and no worsening of NASH\nGLP1: Patients under a stable dose of GLP1-RA for at least 3 months prior to screening can be included\nStatistical powering: 90% considered for sample size calculations\nCentral biopsy reading: Tie breaker approach by three expert pathologists\nCorporate Presentation | July 2024 Property of Inventiva│ 40\nOver 400 sites and 24 countries involved in NATIV3\nPHASE III DESIGN SITE SELECTION\n► 478 sites activated in 24 countries (as\nof April 1, 2024)\n► 914 randomized patients: 731 in the\nmain cohort and 183 in the exploratory\ncohort (prior to the voluntary pause)\n► Target to achieve LPFV H1 2024\n► Topline data expected H1 2026\nNATiV3 countries\nCorporate Presentation | July 2024 Property of Inventiva│ 41\nOpportunity for lanifibranor\nLanifibranor well positioned alone or in combination in the NASH market\npan-PPAR THR-β FGF-21 GLP-1\nROUTE OF\nOral Oral Injectable Injectable\nADMINISTRATION\nIndirect\nDirect activity Indirect Direct activity Not seen with sema.\nEfficacy on fibrosis\nseen at 6 months seen after 12 months seen at 6 months Reported by BI & Lilly\nafter 12 months\nNASH resolution\nInsulin resistance\nLimited drop-out High drop out due to High drop out due to\nTolerability Limited drop-out GI side effects on GI side-effects & GI side-effects &\ninitiation injections injections\nPatients with advanced F1 patients\nPatients with F2/F3: induction\nTarget patients fibrosis (F2/F3) F2/F3: in\nadvanced fibrosis therapy\npopulation T2D patients combination with\n(F2/F3) F4 patients\nLean patients anti-fibrotic drugs\nCorporate Presentation | July 2024 Property of Inventiva│ 43\nLanifibranor expected to meet key decision drivers for surveyed payers\nand prescribers\nSurveyed Payers Surveyed Prescribers\n Improvement in fibrosis is expected to be the key driver of  Prescribers see improvement in fibrosis and joint\nP&TC decisions* in NASH\nachievement of fibrosis improvement and resolution of\nsteatohepatitisas the key benefits of a new NASH drug\n Payers see lanifibranor as stronger than resmetirom\n(Madrigal) and semaglutide(Novo Nordisk) on fibrosis  Both histological endpoints: over 85% of prescribers\nimprovement\nrate as major benefit\nTop 6 Key attributes (n = 95)\nBoth improves fibrosis and resolves steatohepatitis 99%\nImproves fibrosis 98%\nResolves steatohepatitis 99%\nImproves portal hypertension 93%\nImproves key markers of glucose metabolism 92%\nOral 88%\n% of prescribers 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%\nNot a factor Benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for lanifibranor,\nwhich is currently in Phase III clinical trial and has not been approved.\n*P&TC: Pharmacy & Therapeutics Committee\nCorporate Presentation | July 2024 Property of Inventiva│ 44\nLanifibranor well rated versus resmetirom(1) and the combination of\nlanifibranor + GLP-1 versus GLP-1 alone\nSurveyed prescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.7\n* 5.49\n*\n5.5 5.42\n5.3\n5.1\n4.94\n4.88\n4.9\n4.7\n4.5\nPre-diabetic patients with F2 / F3 Diabetic patients with F2 / F3 NASH\nNASH\nResmetirom Lanifibranor\n* indicates results are statistically significantly higher than the comparator (p<0.05)\nSource: (1) US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on available trial results for lanifibranor, which is currently in Phase III clinical trial\nand has not been approved. *Survey conducted before Resmetiromapproval by the FDA.\nCorporate Presentation | July 2024 Property of Inventiva│ 45\ntifeneb\ndeviecreP\nLanifibranor versus resmetirom Lanifibranor in combination versus GLP-1\n5.7\n* 5.52\n5.5\n5.26\n5.3\n5.1\n4.9\n4.7\n4.5\nNASH patients\nGLP-1 GLP-1 + Lanifibranor\nLanifibranor well positioned in patients with T2D and Lanifibranor could address the need in patients treated\nNASH, a population more present in patients with F2/F3 with GLP-1 to reduce fibrosis with an oral treatment and\nfibrosis and with a faster progressing form of fibrosis without the GI side effects present in the GLP-1 and\nFGF-21 class\nModerate metabolically healthy weight gain induced by lanifibranor is not a\nconcern for payers, and is deemed manageable by surveyed prescribers\nSurveyed Payers Surveyed Prescribers\n Surveyed payers see lanifibranoras safe for chronic use  A majority of surveyed HEPs and ~ half of surveyed GEs stated that\nand any associated moderate weight gain is seen as they would not hesitate to prescribe a new NASH drug that causes 2-3\nmanageable with lifestyle choices or weight loss agents. kg weight gain\n 72% of surveyed prescribers expect they could manage a moderate\n Surveyed payers: “If the message is that you'll weight gain with diet, exercise and counselling.\ngain 3 or 4 lbs but you'll feel better, and you  78% of surveyed prescribers agree that “Combining lanifibranorwith an\nexplain the difference between healthy and SGLT2 or GLP-1 is an opportunity to maintain effectiveness in NASH\nunhealthy weight, you can get through that. If while mitigating weight gain.”\nsomeone is 200 pounds and goes up to 205  73% of surveyed prescribers agree that the benefits of lanifibranor\npounds, I don't think they're going to notice it....” outweigh the moderate weight gain.\n Surveyed prescribers see other SEs as bigger drawbacks\nIs associated with neoplasm growth 63%\nIs associated with sarcopenia 40%\nIs associated with 2-3 kg weight gain 12%\n% of prescribers 0% 20% 40% 60% 80%\nMajor drawback\nThe importance of adherence to treatment and convenience of administration favors\nlanifibranor\n 80% of surveyed prescribers see low discontinuation rate as critical, very critical\nor absolute necessity\n 80% of surveyed prescribers rate oral administration as a key benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists (HEPs), 25 gastroenterologists (GEs), 25 endocrinologists in the United States in Q1 2024. Onlyassets in Phase III clinical trial in NASH at the\ntime of the survey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for\nlanifibranor, which is currently in Phase III clinical trial and has not been approved.\nCorporate Presentation | July 2024 Property of Inventiva│ 46\nPrescribers expect GLP-1 + lanifibranor to be significantly more beneficial than\nGLP-1 alone; suggests a perception of synergy, with lanifibranor enhancing GLP-1\nPrescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.60\n5.52\n5.50\n5.40\n5.30 5.26\n5.20\n5.10\n5.00\nMASH patients\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH/MASH at the time of the survey were\nincluded.\nProperty of Inventiva│ 47\ntifeneb\ndeviecreP\n*\nGLP-1 GLP-1 + Lanifibranor\n* indicates results are significantly higher than the comparator (p<0.05)\nLanifibranor could address the need in patients treated with GLP-1 to reduce fibrosis with an oral treatment\nand without the GI side effects present in the GLP-1 and FGF-21 class\nCorporate Presentation | July 2024\nOpportunity for lanifibranor for the treatment of NASH based on current\nclinical program (F2/F3)\nSteatosis Steatohepatitis Advanced fibrosis\nF1 F2 F3 F4 CC\nPatients with NASH estimated in 2030 (US) 9.0M 6.1M 4.5M 3.5M\nIMPROVEMENT OF FIBROSIS\nLanifibranor RESOLUTION OF NASH\nCARDIOVASCULAR IMPROVEMENT\nINSULIN RESISTANCE IMPROVEMENT\nLean NASH Lanifibranor Even if GLP-1 dominate the\n(10-15%) market, lanifibranor would\nT2D Lanifibranor still target 50-60%of\nEstimated\n(15-20%) patients with NASH:\nNASH patient\npopulation T2D & obesity • Lean NASH: 10-15%\nGLP1+Lani\n(20-25%) • “Needle phobia”: 10-15%\n(%)(1)\n• GLP-1 drop-outs: 32% (40%\nObesity & prediabetes\nDO * 80% of NASH patients\n(50-55%) GLP1+Lani\nunder GLP-1)\nSurveyed prescribers expect to write lanifibranor for ~ 30% of NASH patients if approved –across all of the following:\n30%\n• F2 and F3\n• Pre-diabetic and diabetic patients\n• BMI groups –suggests 2-3 kg weight gain is not a key barrier in surveyed prescribers 70%\nSource: Estes C,RazaviH,Loomba R,YounossiZ,Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology2018;67:123-133; US prescriber survey, February 2024 conducted in 45 hepatologists,\n25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in Phase III clinical trial in NASH/MASH at the time of the survey were included; US Payer Advisory Board, March 2023\nCorporate Presentation | July 2024 Property of Inventiva│ 48\nUpcoming catalysts\nCatalysts\n2024 2025 2026\nLanifibranor\nH1 2024 H2 2024 H1 2026 H2 2026\nLast Patient Last Patient • Last Patient New Drug\nFirst Visit randomized Last Visit Approval\n• Topline filing with\nresults FDA\nOdiparcil\nReview potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing\na partnership\nCorporate Presentation | July 2024 Property of Inventiva│ 50\nContacts\nInventiva Brunswick Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montégon Patricia L. Bank\nExecutive VP Aude Lepreux Investor relations\nStrategy and Corporate Affairs Julia Cailleteau\nMedia relations\npascaline.clerc@inventivapharma.com inventiva@brunswickgroup.com patti.bank@westwicke.com\n+1 202 499 8937 + 33 1 53 96 83 83 +1 415 513 1284\nLanifibranor : back-ups slides\nPhase I and Phase IIa clinical trials* in type 2 diabetes (T2D) patients:\nbeneficial changes in key metabolic markers\n300 p=0.05\np=0.05\n200\np=0.08\n100\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nProperty of Inventiva│ 53\nenilesab\nfo\negnahc\ntnecreP\nAdiponectin (PPARγ)**\nenilesab\nmorf\negnahc\ntnecreP\n40\np<0.05\n30\np<0.05\n20\np=0.13\n10\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nHDL Cholesterol (PPARα/δ)^\nenilesab\nmorf\negnahc\ntnecreP\n0\n-10\n-20\n-30 p=0.08\np<0.05\n-40\np<0.05\n-50\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nTriglycerides (PPARα/δ) ^^\nenilesab\nmorf\negnahc\ntnecreP\nPHASE I AND IIa\nLanifibranor metabolic markers in patients with T2D\nlanifibranor lanifibranor lanifibranor\nPhase I and IIa* clinical findings support the favorable tolerability of lanifibranor\n Phase I trials: > 200 healthy volunteers  Good overall tolerability and no major safety findings\n Phase IIa trial with 47 T2D patients  No increases of creatinine, LFTs, or CPK\n Phase IIb: > 250 patients treated for 24 or 48  No changes in blood pressure, no signal of fluid overload or haemodilution\nweeks  No clinically relevant weight gain\nThorough QT/QTc study demonstrates no impact of the drug on QT intervals\n Study carried out in 2020 and 2021 to prepare the NDA package\n A randomized, double-blind, double-dummy, placebo, positive-controlled (400mg of moxifloxacin) and multiple-dose\n(1200mg and 2400mg as the supratherapeutic dose) cardiac safety study to evaluate the effect of lanifibranor on the QT\ninterval in healthy adult subjects\n At doses of 1200 mg and 2400 mg, lanifibranor has no impact on QT intervals\nNote: * Conducted by Abbott; ** Adiponectin is associated with PPARγactivation; ^ HDL-C is associated with PPARαand d activation; ^^ Triglycerides are associated with PPARαand δ activation\nSource: Company data\nCorporate Presentation | July 2024\n247 patients were randomised across 71 sites worldwide, with the majority\nof patients based in Europe\nPHASE IIb DESIGN SITE SELECTION\n4 sites in 49 sites in\nCanada Europe\nPatients\nCountry\nrandomized\nEurope 183 (74%)\nU.S. 36 (15%)\nAustralia 13 (5%)\n12 sites in the Canada 8 (3%)\nUnited States\nMauritius 7 (3%)\nTotal 247 (100%)\n1 site in 5 sites in\nMauritius Australia\n16 countries worldwide (number of sites having randomized at least 1 patient)\n► Europe: Austria (1), Belgium (5), Bulgaria (5), Czech Republic (3), France (13), Germany (5), Italy (4), Poland (3),\nSlovenia (1), Spain (4), Switzerland (2), United Kingdom (3)\n► North America: United States (12), Canada (4)\n► Australia (5)\n► Mauritius (1)\nCorporate Presentation | July 2024 Property of Inventiva│ 54\nProperty of Inventiva│ 55\nYRAMIRP\nSTNIOPDNE\nYRADNOCES\nTNIOPDNE\nLanifibranor demonstrated statistical significance on all histological\nendpoints in both ITT and PP populations\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint\nN = 247 ITT population N = 197 PP population\nPlacebo 800 mg 1200 mg Placebo 800 mg 1200 mg\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83) (N = 62) (N = 63) (N = 69)\nDecrease of ≥2 points of SAF 27% 41% 49% 34% 51% 55%\nactivity score* and no worsening\n0.061 0.004 0.058 0.015\nof fibrosis\nResolution of NASH and no 19% 33% 45% 23% 40% 49%\nworsening of fibrosis**\n0.043 <0.001 0.039 0.002\nImprovement of fibrosis by at\n42% 46%\nleast one stage and no 24% 28% 29% 32%\nworsening of NASH*** 0.53 0.011 0.75 0.04\nResolution of NASH and 7% 21% 31% 10% 24% 33%\nimprovement of fibrosis^\n0.017 <0.001 0.036 0.001\nDecrease of ≥2 points of NAS\nscore^^ (NAFLD activity score) 32% 52% 64% 40% 62% 71%\nand no worsening of fibrosis\n0.01 <0.001 0.02 <0.001\n* Response is defined as a decrease from baseline to week 24 of at least 2 points of the SAF Activity score (SAF-A) with no worsening of the NAS Fibrosis score (NAS-F). No worsening means that score remains stable or\ndecreases ; ** Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; *** Improvement of liver fibrosis ≥ 1\nstage and no worsening of NASH at week 24; ^ Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage; ^^ NAS score is a commonly accepted,\nsemi-quantitative evaluation of biopsy results that assesses the severity of steatosis, inflammation and ballooning in the liver.\nCorporate Presentation | July 2024\nStatistical significance was also demonstrated for the main key histological\nendpoints in patients with F2-F3 fibrosis stage\nPHASE IIb EFFICACY F2-F3 POPULATION\nxx Statistically significant xx Non-statistically significant\nKey secondary endpoints in FAS F2-F3 patients (N=188)\nlanifibranor\nPPllaacceebboo 880000 mmgg 11220000 mmgg\n(N = 57) (N = 68) (N = 63)\nResolution of NASH and no\n44%\n34%\nworsening of fibrosis* 9%\n0.001 <0.001\nImprovement of fibrosis by at least\n48%\none stage and no worsening of\n30% 32%\nNASH**\n0.736 0.048\nResolution of NASH and improvement\n33%\nof fibrosis*** 7% 24%\n0.012 <0.001\n Similar results in the PP population\n Consistent response in diabetic and non-diabetic patients\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of liver fibrosis ≥ 1 stage and no\nworsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | July 2024 Property of Inventiva│ 56\nPhase III NATiV3 clinical trial confirmatory trial: anticipated\nexpected design to support broader “full approval”\nPHASE III OVERVIEW\nAnticipated event driven trial in patients with NASH compensated cirrhosis\nPhase 3: event driven\nN~ 800 EoT\nPatients with\nLanifibranor: Once daily Potential full approval in U.S.\nNASH and\ncompensated and EU\nPlacebo: Once daily\ncirrhosis\nKEY ENDPOINTS (non-exhaustive) TRIAL END DATE\n Based on time to first clinical event on c.800 patients  Trial expected to last up to 3 years\n• all cause mortality\n• hepatic decompensation events\n− hepatic encephalopathy\n− variceal bleeding or progression to varices that require prophylactic\ntreatment\n− new onset ascites requiring treatment\n• MELD score ≥15\n• liver transplantation\nCorporate Presentation | July 2024 Property of Inventiva│ 57\nLanifibranor clinical trial in patients\nwith NAFLD and T2D\nLanifibranor clinical trial in patients with NAFLD and T2D\nObjective of investigator-initiated trial: Establish safety, efficacy and mechanism of action of lanifibranor in patients with T2D\nand NAFLD. Specifically determine if lanifibranor decreases IHTG(1), improves hepatic insulin sensitivity, endogenous (hepatic)\nglucose production, gluconeogenesis and DNL(2).\nPatients with NAFLD and T2D\n Fasting plasma glucose: 100mg - 250mg/dL\n HbA1c: 6.0% to 9.5%\n Hepatic steatosis: >10%\n24 weeks treatment\nPlacebo\nLanifibranor 800mg/daily\n24 weeks\n6 weeks 4 weeks\nEOT\nRun-in period Run-in period Follow-up\nPrimary endpoint: change in Intrahepatic triglycerides (IHTG)\nSecondary endpoints:\n Proportion of responders reaching a decrease in IHTG from baseline ≥ 30% quantified by proton magnetic resonance\nspectroscopy (¹H-MRS)3\n Proportion of patients with NAFLD resolution (patients with IHTG ≤ 5%) quantified by ¹H-MRS\n Change in hepatic and muscle insulin sensitivity and lipid metabolism\n Safety\n(1) Intrahepatic triglycerides; (2) De-novo lipogenesis; (3) proton magnetic resonance spectroscopy\nCorporate Presentation | July 2024 Property of Inventiva│ 59\nLanifibranor significanty reduces liver fat and resolves NAFLD\nLS means relative percent change Percentage of patients achieving Percentage of patients achieving\nfrom baseline in liver fat (IHTG) at liver fat reduction ≥30% at week 24 NAFLD resolution at week 24\nweek 24 (FAS N=38) (FAS N=38) (FAS N=38)\n0% 100% 100%\n90% 90%\n-10%\n80% pa=0.008 80%\n-12%\n70% 65% 70%\n-20%\n60% 60%\n50% 50%\n-30%\n40% 40%\npb=0.048\n-40% 30% 30% 25%\n22%\n20% 20%\n-44%\n-50% Placebo Lanifibranor 10% 10%\nn=18 800mg\n0%\nn=20 0% 0%\nPlacebo Lanifibranor Placebo Lanifibranor\npa=0.002 n=18 800mg n=18 800mg\nn=20 n=20\na P-value from an Analysis of Covariance (ANCOVA) using the aChi² test bFisher test\nrelative change from baseline to week 24 as the response, the In the FAS, missing data at Week 24 were imputed as NAFLD resolution is defined as IHTG ≤ 5.5% at week 24.\ntreatment as covariate as well as the baseline of IHTG. In the FAS, non-achieving reduction. In the FAS, missing data at Week 24 were imputed as non-\nmissing data at Week 24 were imputed by baseline data. responders\nCorporate Presentation | July 2024 Property of Inventiva│ 60\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Terzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo 30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | July 2024 Property of Inventiva│ 61\nLanifibranor leads to significant improvements in hepatic and\nmuscular insulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 62\nnim/gk/gm\nLS mean absolute change from LS mean absolute change from LS mean absolute change from\nbaseline to week 24 in baseline to week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nCorporate Presentation | July 2024\nLanifibranor treatment increases HDL and adiponectin levels\n9\n7\n6.3\n5\n3\n1\n-0.3 -1\nProperty of Inventiva│ 63\nld/gm\nLS Mean absolute change from baseline to week\n24 in HDL cholesterol (completers N=28)\n9.0\npa=0.016\n7.5\n7.0\n5.0\n3.0\n1.0\n-0.2\n-1.0\naMixed Model Repeated Measures (MMRM).\n No change in LDL-cholesterol\nLm/gμ\nLS Mean absolute change from baseline to week\n24 in adiponectin (completers N=28)\npa<0.001\nPlacebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg\nn=14 n=14\nCorporate Presentation | July 2024\nKey take-aways\n Lanifibranor met the primary efficacy endpoint by inducing a liver fat reduction of 44% in patients with T2D\nand NAFLD treated for 24 weeks.\n– 65% of patients with T2D and NAFLD treated with lanifibranor achieved a greater than 30% liver\ntriglyceride reduction and 25% achieved NAFLD resolution after 24 weeks.\n Lanifibranor has a potent therapeutic effect on insulin sensitivity, and corresponding metabolic markers in\npatients with T2D and NAFLD\n– Potent effect as insulin sensitizer on hepatic and muscular insulin sensitivity\n Lanifibranor significantly improved adiponectin, which is known to regulate glucose levels, lipid metabolism,\nand insulin sensitivity through its anti-inflammatory, anti-fibrotic, and antioxidant effects\n Study confirms the favorable safety and tolerability profile of lanifibranor\nCorporate Presentation | July 2024 Property of Inventiva│ 64\nLegend\nLanifibranor in Combination with the SGLT2 Inhibitor in\npatients with NASH and T2D\nLanifibranor and SGLT2 Inhibitor mechanism of action and\nrationale for LEGEND\nLanifibranor: balanced pan-PPAR Empagliflozin: inhibitor of Sodium-\nagonist (PPARα, PPARγ and PPARδ)1 glucose co-transporter-22\n• Lanifibranorimproves insulin sensitivity, lipid and glucose metabolism, inflammation, liver tissue injury (MASH activity) and fibrosis.\n• Empagliflozinimproves glycaemia, insulin sensitivity, has weight reducing and diuretic effects.\n• The combination of lanifibranor + empagliflozinmay\n• Add additional metabolic benefits\n• Address metabolically healthy weight gain observed in some patients on lanifibranor\nHaas, Francque & Staels. Ann Rev Physiol 2016; Wanner & Marx. Diabetolgia 2018; Goossens G Obes Facts 2017; Pavlides et al. Journal of Hepatology 2016; Alexopoulos et al. Hepatology 2021\nCorporate Presentation | July 2024 Property of Inventiva│ 66\nLEGEND Study Design\nLanifibranor in Combination with the SGLT2 Inhibitor empagliflozin in patients with NASH and Type 2 Diabetes\nLEGEND Study\n24 weeks treatment\nRandomized, double-blind for lanifibranor and placebo, open label\nKey inclusion criteria:\nfor the combination, placebo-controlled\n4 weeks\n1) Adult patients with MASH/NASH:\nFollow-up\n• historical biopsy with NAS ≥ 4 Lanifibranor 800 mg + empagliflozin 10 mg\n• or cT1 ≥ 875 ms\n• or cT1 ≥ 825 ms and MRI-PDFF Lanifibranor 800mg\n≥ 10%\nPlacebo\n2) T2D diagnosed\n3) Screening HbA1c in 7-10%\nSecondary outcome\nPre-specified interim Other outcome\nPrimary outcome measures:\nanalysis planned to be measures:\nmeasure:  Insulin resistance\nconducted when 50% of\n Body weight Safety and\npatients have completed  Hepatic fat (MRI-PDFF)\nHbA1c reduction  Body fat composition tolerability\nthe 24-week treatment  Liver injury markers (AST,\nat Week 24\nperiod, or prematurely ALT)  Hepatic inflammation\ndiscontinued and fibrosis markers\n Lipid markers\nCorporate Presentation | July 2024 Property of Inventiva│ 67\nPatient disposition\nFull Analysis Set (FAS): 32 patients randomized and treated\nLanifibranor 800 mg/day +\nPlacebo Lanifibranor 800 mg/day\nEmpaglifozin 10mg/day\nN = 10 N = 12\nN = 10\n5 (50%) patients completed the 12 (100%) patients completed 10 (100%) patients completed\n24-week treatment the 24-week treatment the 24-week treatment\n5 (50%) patients prematurely\ndiscontinued from study\ntreatment*:\n- Withdrawal by patient (n=2)\n- Lost to follow-up (n=2)\n- Non-compliance with study drug\n(n=1)\n* All but one patient discontinued after week 12.\nOne patient (Withdrawal by patient) discontinued before week 4.\nCorporate Presentation | July 2024 Property of Inventiva│ 68\nBaseline demographics\nPlacebo Lanifibranor + Total\nParameter (unit) [Normal ranges] Lanifibranor (n=12)\n(n=10) Empagliflozin (n=10) (n=32)\nAge (years) 55.5 55.5 56.5 55.5\nSex (% female) 60 50 60 56\nWeight (kg) 92.6 93.9 102.0 96.8\nBMI (kg/m²) 33 33 37 35\nHbA1c (%), [4.0 - 6.0] 7.7 7.7 8.2 7.8\nInsulin (pmol/L) [18.1 - 172.9] 278 152 238 223\nHOMA-IR 19.5 9.4 12.0 10.9\nHDL-C (mmol/L) [F ≥ 0.91, M ≥ 0.78] / (mg/dL) 1.08 / 41.8 1.07 / 41.4 1.02 / 39.4 1.07 / 41.4\nLDL-C (mmol/L) [F ≤ 4.14, M ≤ 3.89] / (mg/dL) 2.26 / 87.4 2.52 / 97.5 2.45 / 94.7 2.52 / 97.5\ncT1 (ms) 942 949 921 931\nHepatic fat content (MRI-PDFF) (%) 17.1 18.5 19.7 18.8\nALT (U/L), [F ≤ 33, M ≤ 41] 33 53 54 39\nAST (U/L), [F ≤ 32, M ≤ 40] 24 30 35 30\nAdiponectin (ug/mL), [0.9 - 21.4] 2.6 3.1 4.0 3.0\nMedian values are presented for continuous parameters.\nALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, BMI: Body Mass Index, cT1: Corrected T1, F: Female, HDL-C: High density lipoprotein cholesterol, HOMA: Homeostasicmodel\nassessment, M: Male, MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction\nCorporate Presentation | July 2024 Property of Inventiva│ 69\nPrimary endpoint was met: statistically significant reductions in HbA1c at week 24\nunder lanifibranor alone and in combination with empaglifozin versus placebo\nFAS, N=30 Completers, N=24\nLS Mean Absolute Change from Baseline to Week 24 Percentage of responders at Week 24\nHbA1c (%) HbA1c < 6.5% HbA1c absolute decrease ≥1%\nWeek 12 Week 24\n100 100\n0.4 0.26 88%\n0.2\n0\n75 75\n-0.2 -0.08 63% 64%\n-0.4 55%\n-0.6 50 50\n-0.8\n-1\n-1.2 * 25 25\n-1.19* -1.14\n-1.4\n*\n-1.6 -1.44\n** 0% 0%\n-1.59\n-1.8 0 0\nPlacebo Lani Lani Placebo Lani Lani Placebo Lani Lani Placebo Lani Lani\n-2\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa n= 5 n=11 + Empa n= 5 n=11 + Empa\nn= 10 n= 10 n= 8 n= 8\n*p<0.01, **p<0.001, versus placebo (Mixed Model Repeated Measure [MMRM]) Eight patients were not considered in the Completers set:\nTwo patients were not considered in the FAS because not having post-treatment HbA1c values - 5 patients under placebo who prematurely stopped before Week 24\navailable: - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent event) before Week\n- 1 patient under placebo who prematurely stopped before Week 4 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nevent) before Week 4 (Results were similar including this patient in a sensitivity analysis). modified his/her diet (intercurrent event) before Week 24.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 70\nLanifibranor improves insulin sensitivity which is further\nimproved in combination with empagliflozin\nInsulin - FAS, N=30 HOMA-IR - FAS, N=30\nLS Mean Absolute Change from Baseline to Week 24 (pmol/L) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 152-278 pmol/L Baseline 9.4-19.5\n0\n-5\n-25 -7\n-15\n-50\n-25\n-58.3\n-75\n-35\n-100 -93.9† -45\n-125 -55 -51*\n-150 -65\n*\n-155.1\n-175 -75 -69**\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM), † p<0.05, versus baseline (MMRM) *p<0.05, **p<0.01, versus placebo (MMRM)\nTwo patients were not considered in the FAS because not having post-treatment insulin values Two patients were not considered in the FAS because not having post-treatment HOMA-IR values\navailable: available:\n- 1 patient under placebo who prematurely stopped before Week 4 - 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent\nevent) before Week 4 event) before Week 4\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 71\nLanifibranor alone and in combination with empagliflozin\nsignificantly improves markers of liver injury\nALT - FAS, N=31 AST - FAS, N=31\nLS Mean Relative change (%) from Baseline to Week 24 LS Mean Relative change (%) from Baseline to Week 24\nBaseline 33-54 IU/L Baseline 24-35 IU/L\n10 20\n0\n10\n-10\n0\n-20\n* -10\n-30 *\n**\n* -20 **\n-40\n*\n-30\n-50 **\n**\n-60 *** -40 ***\nBaseline Week 4 Week 12 Week 24 Baseline Week 4 Week 12 Week 24\nPlacebo n= 9 Lani n= 12 Lani + Empa n= 10 Placebo n= 9 Lani n= 12 Lani + Empa n= 10\n*p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM) *p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because no post-treatment ALT values One patient under placebo was not considered in the FAS because no post-treatment AST values\navailable (Premature discontinuation before Week 4) available (Premature discontinuation before Week 4)\nCorporate Presentation | July 2024 Property of Inventiva│ 72\nLanifibranor alone and in combination with empagliflozin\nsignificantly reduce hepatic steatosis measured by MRI-PDFF\nLiver fat measured by MRI-PDFF, N=26 from Baseline at Week 24\nLS Mean Relative change (%) Individual Relative changes (%)\nBaseline 17.1-19.7%\n20\n0\n0\n-5\n0\n-10\n-15\n-20\n-20\n-25\n-40\n-30\n-35\n-40 -60\n-38*\n-45\n-50 -47* -80 Placebo\nLani Lani\nPlacebo Lani\n+ Empa\nn= 5 n= 12 -100 Lani + Empa\nn= 9\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)\nlanifibranor +\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24: Percentage of responders Lanifibranor\nPlacebo (n=5) empagliflozin\n- 5 patients under placebo who prematurely stopped before Week 24 at Week 24 (n=12)\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before (n=9)\nWeek 24\nMRI-PDFF ≥ 30% 0% 82% 67%\nAbsolute reduction of ≥ 5% 0% 67% 67%\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 73\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 74\nLanifibranor alone and in combination with empagliflozin\nimproves HDL-C and adiponectin\nHDL-C, N=31 Adiponectin, N=30\nLS Mean Absolute change (mmol/L) from Baseline to Week 24 LS Mean Fold change from Baseline to Week 24\nBaseline 1.02-1.07 mmol/L Baseline 2.6-4.0 ug/mL\n0.5 4\n3.5\n0.4 3.0 *\n3 2.8*\n0.3\n2.5\n0.22*\n0.2\n0.17†\n2\n1.5\n0.1 1.1\n1\n0.0\n0.5\n-0.01\n-0.1 0\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 12 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM) † p<0.01, versus baseline (MMRM) *p<0.05, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because of no post-treatment HDL-C Two patients were not considered in the FAS because not having post-treatment adiponectin\nvalues available (premature discontinuation before Week 4) values available:\n- 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as rescue medication (intercurrent event)\nbefore Week 4\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 75\nThe combination of empagliflozin and lanifibranor addresses the weight\ngain observed in some patients treated with lanifibranor alone\nWeight change, N=32\nRelative change from Baseline (%)\nBaseline 93-102 kg\n5\n3.6\n4\n3\n2\n2 1.4\n1\n00\n-0.4 -0.4\n0\n-0.9\n0\n-1\n-0.8 -0.8\n-1.1\n-2\nBaseline Week 4 Week 12 Week 24\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nAt Week 24, 7 patients without weight values available :\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nmodified his/her diet (intercurrentevent) before Week 24.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 76\nLanifibranor alone and in combination with empagliflozin leads\nto a shift towards metabolically healthy adipose tissue\nRatio VAT/SAT, N=19\nLS Mean Relative change (%) from Baseline to Week 24\n11\n10\n5\n0\n-5\n-5*\n-10\n-15\n**\n-17\n-20\nPlacebo Lani Lani + Empa\nn= 4 n= 8 n= 7\nSAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n* p=0.08, **p<0.01, versus placebo (ANCOVA)\nThirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 77\nSafety and tolerability: Treatment-Emergent Adverse Events\n(TEAE)\nPlacebo Lanifibranor Lanifibranor +\nTEAE Overview\n(n=10) (n=12) Empagliflozin (n=10)\nTEAE 6 (60%) 10 (83%) 8 (80%)\nDrug-related TEAE 2 (20%) 3 (30%) 5 (50%)\nTEAE leading to drug withdrawal 0 0 0\nSerious TEAE 0 0 0\nSevere TEAE 0 0 0\nAny AE of Specific Interest\nAminotransferase elevation 0 0 0\nAnemia a 1 2 0\nPeripheral edema 0 0 1b\nHypoglycaemia c 1 0 1d\nMost Frequent (≥10%) TEAEs by SOC\nInfections and infestations 3 ( 30%) 2 ( 17%) 5 ( 50%)\nMusculoskeletal and connective tissue\n3 ( 30%) 1 ( 8%) 1 ( 10%)\ndisorders\nGastrointestinal disorders 2 ( 20%) 3 ( 25%) 2 ( 20%)\nSkin and subcutaneous tissue disorders 2 ( 20%) 4 ( 33%) 0 ( 0%)\nNervous system disorders 1 ( 10%) 2 ( 17%) 1 ( 10%)\na Defined as haemoglobin levels <Lower Limit Normal. The 3 events reported were assessed as not related to study drug.\nb The event was assessed as related to lanifibranor/not related to empaglifozin, of mild severity with no associated symptoms, that further recovered without corrective treatment.\nc Defined as glucose levels <Lower Limit Normal. Glucose values were > 3 mmol/L for the 2 events reported. Both events were assessed as not related to study drug, of mild intesityand required no treatment.\nd Related to empaglifozinonly.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 78\nConclusions\n The primary efficacy endpoint based on reduction of HbA1c was met for both lanifibranor alone and\nfor the combination with empagliflozin.\n The combination of lanifibranor with empagliflozin addresses / neutralizes weight gain seen in some\npatients on lanifibranor alone.\n Both lanifibranor alone and the combination with empagliflozin induce a redistribution of fat from\nvisceral to subcutaneous fat. This is consistent with the improved insulin sensitivity seen with both\nlanifibranor alone and the combination.\n Lanifibranor improves markers of cardiometabolic health, the effect size appear to be further\nimproved when lanifibranor is combined with empagliflozin.\n Lanifibranor alone and in combination with empagliflozin appear to be safe and well tolerated.\nCorporate Presentation | July 2024 Non-confidential –Property of Inventiva│ 79"
        },
        {
          "title": "Corporate presentation June 2024",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/06/06-Inventiva-Presentation-ENG-06-17-2024-1.pdf",
          "content": "Developing innovative therapies in\nNASH\nCorporate Presentation\nJune 2024\nDISCLAIMER\nThis presentation contains “forward-looking statements” within the meaning of the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical\nfacts, included in this press release are forward-looking statements.\nThese statements include, but are not limited to, forecasts and estimates with respect to Inventiva’scash resources and potential financing or strategic options and potential counterparties, forecasts and estimates\nwith respect to Inventiva’spre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollmentfor those trials, including the ongoing NATiV3 Phase III clinical trial\nwith lanifibranor in MASH/NASH, and the results and timing thereof and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be\ngathered from clinical trials, the potential therapeutic benefits of Inventiva’sproduct candidates, including lanifibranor alone and in combination with empagliflozin in patients with MASH/NASH and T2D, the\npotential of lanifibranor to address patient needs, the estimated market size and patient population, potential regulatory submissions, approvals and commercialization, Inventiva’spipeline and preclinical and\nclinical development plans, the expected benefit of having received Breakthrough Therapy Designation from the FDA and NMPA, including its impact on the development and review timeline of Inventiva’sproduct\ncandidates, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, the expected benefit of Inventiva’s\npartnerships and Inventiva’sability to achieve milestones and receive potential milestones under its partnership agreements. Certain of these statements,forecasts and estimates can be recognized by the use of\nwords such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”,\n“opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but ratherare statements of future expectations and other forward-looking statements that are based\non management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results,\nperformance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva'scontrol. There\ncan be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product\ncandidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be\nmaterially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that Inventiva cannot\nprovide assurance on the impacts of the SUSAR on enrollmentor the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company\nwith no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product\nsales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development\nprograms or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’sability to obtain financing and to enter into\npotential transactions, Inventiva'sfuture success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,\npreclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva'sand its partners’ clinical trials may not support Inventiva'sand its partners’ product candidate\nclaims, Inventiva'sexpectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’sclinical trials, Inventiva’sexpectations with\nrespect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not supportthe approval of a New Drug Application, Inventiva and its partners may encounter\nsubstantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and\nretain patients in clinical studies, enrollmentand retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors\noutside Inventiva'sand its partners’ control, Inventiva'sproduct candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial\npotential, Inventiva faces substantial competition and Inventiva’sand its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations\ncould be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollmentand completion\nof Inventiva’sand its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related riskof a larger conflict, health epidemics, and macroeconomic conditions,\nincluding global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of\nsuch forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates onlyspeak as of the date of this press release. Readers are cautioned not to place\nundue reliance on any of these forward-looking statements.\nPlease refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autoritédes MarchésFinanciers on April 3, 2024, and the Annual Report on Form 20-F for the year ended\nDecember 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024. Other risks and uncertainties of whichInventiva is not currently aware may also affect its forward-looking statements and\nmay cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention\nand is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva acceptsno liability for any consequences arising from the use of any of the above\nstatements.\nCorporate Presentation | June 2024 Property of Inventiva│ 2\nKey take-aways\nA Phase III ready program in R&D Capabilities and Cash\nA Phase III asset in NASH\nMPS(1) Position\nLanifibranor: only pan-PPAR agonist in Odiparcil: a GAG reduction therapy to R&D capabilities including wholly-\nclinical development for NASH potentially treat several forms of MPS owned ‘pharma scale’ discovery\nfacilities with a discovery engine\nPositive Phase IIb results with statistically Reduces GAG accumulation in multiple focused on nuclear receptors,\nsignificant efficacy on histological NASH organs in MPS VI models. Well-tolerated transcription factors and epigenetic\nresolution and one stage fibrosis reduction in MPS VI patients and in 1000s of targets\npatients previously tested(2)\nPositive Phase II, Proof-of-Concept, results of Clinical Ops team in place in Europe\nLEGEND with lanifibranor/empagliflozin Functional improvements to mobility and and the United States\nannounced in Q1 2024 respiratory function and clinical efficacy\nsignals in both ERT treated patients and Strong U.S. and European\nMechanism of action addressing all key ERT-naïve MPS VI patients shareholder base and experienced\nfeatures of NASH senior management team\nMPS VI Orphan Drug Designation\nBreakthrough Therapy Designation granted by granted in the U.S. and in the EU. Rare Cash position allowing a runway until\nFDA and Chinese NMPA Pediatric Disease Designation in MPS VI the beginning of Q3 2024\ngranted in the U.S.\nPivotal Phase III initiated in Q3 2021 with\ntopline results expected H1 2026 Guidance on path to regulatory\nsubmission from FDA with a single\nLicensing and commercialization agreements Phase II/III trial\nin Greater China, Japan and South Korea\nInventiva continues to review potential\noptions to further develop odiparcil which\nmay include pursuing a partnership\n(1)MPS:mucopolysaccharidosis;(2)TrialsconductedbyGSKpriortoInventiva’sfounding\nCorporate Presentation | June 2024 Property of Inventiva│ 3\nManagement team with extensive global experience across all stages of\ndrug development and commercialization\nFrédéric Cren, MA/MBA, CEO and Co-Founder Pierre Broqua, Ph.D., CSO and Co-Founder\n Wide expertise within the areas of R&D, marketing,  Successfully managed numerous research programs\nstrategy and commercial operations leading to the discovery, development and\ncommercialization of innovative compounds, including\n Held senior positions at Abbott, Fournier, Solvay\nlanifibranor and Degarelix/ Firmagon®\nPharma and The Boston Consulting Group\n Held several senior research positions at Fournier,\n Former member of both Fournier and Solvay Pharma\nSolvay Pharma and Abbott\nExecutive Committees\nMichael Cooreman, MD, CMO\nJean Volatier, MA, CFO\n Gastroenterologist-hepatologist\n Former Head of controlling at URGO & Financial\nDirector International Operations of Fournier  Held global roles in several companies including\nTakeda Pharmaceuticals, Merck, Mitsubishi Tanabe,\n Held various positions as CFO\nImmusanT and Novartis\n Started his career with PwC in Paris and Philadelphia\nAlice Roudot-Ketelers, PharmD, COO\nPascaline Clerc, Ph.D., EVP Strategy and\nCorporate Affairs  Previously in charge of all drug development programs\nand cross-functional teams in Chemistry, CMC, non-\n Held global roles in academia, non-profit organization,\nclinical and clinical development up to Phase III at one\ngovernment and biotech companies\nof the major biotech companies in the NASH field\nKristina Meyer, Ph.D., Business Development\nDavid Nikodem, Ph.D., VP U.S. Operations\n& Alliance Management\n Former buyside portfolio manager and analyst for +15\n 20+ years experience in business development in the\nyears in public equities and VC\nbiotech industry\nCorporate Presentation | June 2024 Property of Inventiva│ 4\nDeep pipeline\nProgram Indication Discovery IND Enabling Phase I Phase II Phase III\nLanifibranor NASH pan-PPAR\nOdiparcil MPS VI GAG clearance\nYap-Tead\nOncology\nTGF-β\nFibrosis\nCorporate Presentation | June 2024\nProperty of Inventiva│ 5\nKey financials and shareholder base\nKey financials Shareholder base\nFree Float Founders\n25.2% 18.4%\nEmployees & Others BVF\nISIN code FR0013233012 / US46124U1079 2.3% 16.2%\nYiheng\n7.4%\nMarket Euronext Paris / Nasdaq GM\nSofinnova NEA\n9.8% 10.8%\nQatar Holding LLC\nShares outstanding 52,477,188\n9.9%\nEuronext Paris: €145 m\nMarket cap\nAnalyst coverage\n(June14, 2024) Nasdaq Global Market: $155m\nJefferies L. Codrington / M. J. Yee\n€30.2m(1) (vs €35.9m as of December\nGuggenheim S. Fernandez\nCash position 31, 2023)(2)\n(as of March 31, 2024) Current cash runway until early Q3 2024; nb: EIB Stifel A. Samimy\nsecond €25m tranche drawn Jan. 18, 2024\nHC Wainwright E. Arce\nCanaccord Genuity E. Nash\nRevenues(1)\nNo revenue end of Q1 2024 and 2023\n(as of March 31, 2024) LifeSci Capital R. Katkhuda\nKBC J. Mekhael\nR&D expenditures Portzamparc M. Kaabouni\n€110m compared to €60.5m in 2022\n(as of December 31, 2023)\nGilbert Dupont P.A. Desir\n(1)Unaudited\n(2)Cashpositionalsoincludes:i.short-termdepositsrecordedinthecategory“othercurrentassets”intheIFRSconsolidatedstatementoffinancialpositionandareconsideredbytheCompanyasliquidandeasilyavailable,ii.thelong-termdeposithasatwo-yeartermaccessiblepriortothe\nexpirationofthetermwithanoticeperiodof31daysandisconsideredasliquidbytheCompany.\nCorporate Presentation | June 2024 Property of Inventiva│ 6\nLanifibranor: licensing and commercialization agreement in Greater China,\nJapan and South Korea\nLicensing agreement in Greater China Licensing agreement in Japan / South Korea\nAgreement with CTTQ an affiliate of Sino Biopharm one of Licensing agreement with Hepalys Pharma, Inc. backed by\nthe largest Chinese pharmaceutical groups listed in Hong Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and\nKong Exchange (HSI composite) with a market cap of MEDIPAL Innovation Fund\nc.US$10bn(1) and c.US$4bn of revenue(2) and ranked top\n$10M upfront payment\n40th pharma globally(3)\nUp to $231M of clinical, regulatory and commercial\n$17 million of non-dilutive payments received\nmilestone payments\nUp to $290 million of clinical, regulatory and commercial\nTiered royalties from mid double digits to low twenties on\nmilestone payments\nnet sales\nTiered royalties from high single-digit to mid-teen double\nInventiva owns a stake of Hepalys Pharma, Inc. and has an\ndigits on net sales made during the first three years of\noption to acquire all outstanding shares at a pre-agreed\ncommercialization and from low to mid-teen double digits\nmultiple of post-money valuation\nstarting from year four.\nRight of first refusal in the event Hepalys receives an offer\nCTTQ will bear all costs associated with the trials conducted\nto sell the license or rights related to lanifibranor.\nin Greater China\nHepalys will bear all costs associated with the trials\nCTTQ to randomize patients into the NATiV3 Phase III\nconducted in Japan and South Korea\nclinical trial in mainland China\nDevelopment includes PK/PD Phase I studies and following\nphase I and NATiV3 results an independent pivotal Phase III\nstudy in Japan and South Korea\nInventiva eligible to more than 500M$ of milestones plus sales royalties\n(1) Information about Sino Biopharm, its business, operations and finances are based on third-party information and disclosures. Inventiva makes no representations regarding the accuracy of such information presented herein; (2) Market\ndata as of Sept 2022 ; (3) Converted from RMB to USD\nCorporate Presentation | June 2024 Property of Inventiva│ 7\nLanifibranor in Nonalcoholic\nSteatohepatitis (NASH)\nLanifibranor: a pan-PPAR agonist in Phase III development in NASH\nModerate and balanced pan-PPAR agonist activity\n Small molecule that activates all three PPAR isoforms in humans\nPPARα\n Differentiated chemical structure: not a fibrate or a TZD\n Once daily oral administration\n Positive Phase IIb trial topline results in NASH\n FAST Track (including in NASH patients with compensated cirrhosis) and\nBreakthrough Therapy designations granted by FDA and Chinese NMPA\n FDA confirmation that the non-clinical toxicology package is complete and\nPPARβ/δ PPARγ\nacceptable for NDA filing\nLANIFIBRANOR  IP: 19 families covering the compound, method of treatment, combination therapy,\nprocess, formulation and diagnostic methods. Last expiry expected in 2045\nPan-PPAR activity expected to improve efficacy in NASH\nINFLAMMATION AND\nMETABOLISM STEATOSIS FIBROSIS VASCULAR\nBALLOONING\nPPARα PPARδ PPARγ PPARγ PPARα PPARδ PPARγ PPARδ PPARγ PPARα PPARγ\nStellate cell\nInsulin sensitivity FA uptake NFkB-dependent Portal pressure\nproliferation and\ngene activation\nactivation\nHDLc FA catabolism LSEC capillarization\nInflammasome\nCollagen and\nTriglycerides Lipogenesis Intrahepatic vascular\nfibronectin\nBallooning resistance\nproduction\nCorporate Presentation | June 2024 Property of Inventiva│ 9\nPatent Extension Timeline\n2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045\nGranted Patent\nProduct:Composition\nof matter\nGranted Patent\nProduct: Crystallines forms of lanifibranor\nPending Application\nProduct: Deuterated forms of lanifibranor\nPending Application\nProduct: Crystallines forms of lanifibranor\nPending Application\nPCT\nProduct: Crystallines forms of lanifibranor\nGranted Patent Projected Potential Extensions\nApplication : Disease treatment (method claim; fibrosis condition; NASH)\nGranted Patent\nApplication : Disease treatment (method claim; cirrhosis)\nWe expect that NASH patent will be selected for Patent Term Extension (PTE).\nEligibility of the method of use patents for PTE assessed and confirmed by globally recognized IP law firm.\nComposition of matter patent and NASH patent have been granted in > 50 countries incl. EP, US, CN, JP, KR, AU, CA, RU.\nLanifibranor IP review | 2024 Confidential –Property of Inventiva│ 10\nLanifibranor is a differentiated pan-PPAR agonist with moderate and well\nbalanced activity on the three PPAR isoforms\nDifferentiated oral small molecule …\n Small molecule that\nactivates all three PPAR\nisoforms\n Differentiated chemical\nstructure with once daily\noral administration\n Offered in two dosage\nforms (800 mg, 1200 mg)\nModerate and balanced pan-PPAR agonist activity\n150\nPPARα PPARδ PPARγ\nCompound\nEC50 (nM) EC50 (nM) EC50 (nM)\n125\nLanifibranor* 1630 850 230\n100\n75 Fenofibrate 2400 - -\n50 Pioglitazone - - 263\nRosiglitazone - - 13\n25\nElafibranor** 10 100 -\n0\n-10 -8 -6 -4 Seladelpar^ - 2 -\nlanifibranor (M)\nSource: * Company data ** HanfR et al, Diabetes & Vascular Dis Res 2014 ^ Cymabaycompany presentation ^^ J Med Chem. 2018 Feb 15. doi: 10.1021/acs.jmedchem.7b01285\nProperty of Inventiva│ 11\nnoitavitcA%\nLANIFIBRANOR\n… that binds differently than glitazone to PPARγ\nROSI\nLANI\n Induces different coactivator recruitment^^\nhPPARα\nhPPARδ\nhPPARγ\nCorporate Presentation | June 2024\nAdverse events and toxicity previously seen in other single and dual PPAR\nagonists have not been observed with lanifibranor\nSAFETY\nOrgan Isoforms activated Reported PPAR side effects lanifibranor effects\n Fluid retention\nHEART PPARγ\n Cardiac hypertrophy\nSKELETAL\nPPARα  Myofiber degeneration\nMUSCLE\nNOT\nOBSERVED\n > 50% increases in creatinine, degenerative\nKIDNEY PPARα\nchanges in renal tubules\nURINARY\nPPARγ  Proliferative changes in bladder epithelium\nBLADDER\nAdverse events and toxicity of single / dual PPAR agonists not observed in primate and rodent studies\n No adverse clinical signs observed at any dose-level tested\nFAVOURABLE\n No effects on body and heart weight, no haemodilution or creatinine increase\nTOLERABILITY PROFILE in\na 12-month monkey study …  Electrocardiography and clinical pathology investigations did not reveal any\nundesirable effects\n Rat: no observed neoplastic change or increase in tumor types commonly associated\n… and in two-year with single PPARγ and dual PPARα/γ agonists (liver, adipose, bladder, renal and\nCARCINOGENITY STUDIES skin)\nperformed in rat and mice\n Mice: no observed neoplastic changes of human relevance\nConfirmation by FDA that the non-clinical toxicology package is complete and acceptable\nto support NDA filing in NASH\nSource: Company data\nCorporate Presentation | June 2024 Property of Inventiva│ 12\nLanifibranor: comprehensive impact on the histology and biology of NASH\nHISTOLOGY AND MARKERS\n1\nFibrosis Regression\nFibrosis NASH\n&\nRegression Resolution\nNASH Resolution\nHealthy liver Steatosis Steatohepatitis Liver fibrosis Cirrhosis\nSteatosis measured by Biomarkers of inflammation Circulating biomarkers of\nhistological grading, MRI-PDFF (ferritin, CRP), tissue injury fibrosis: Pro-C3, TIMP-\nCAP/Fibroscan; Intra-hepatic (ALT,AST) and apoptosis 1/MMP-2, MACK-3\nTG content by 1H-MRS(1); (CK18) Improvement seen with CT1\nNAFLD resolution scan\nGLUCOSE METABOLISM MARKERS CARDIOVASCULAR RISK MARKERS\nImproves insulin sensitivity and glycemic control in patients with or Improves markers of cardiovascular risk and lipid metabolism\nwithout diabetes\nAPO-B DBP\nHDL-C\nTreatment with lanifibranor decreases the ratio of visceral abdominal\nAPO-B/APO-A1 Adiponectin\nfat to subcutaneous fat, reflecting a shift from pro-inflammatory Triglycerides levels\nAPO-C3\nvisceral fat towards metabolically healthy adipose tissue LDL-cholesterol level\nHs-CRP\nFasting glucose HOMA-IR index Insulin resistance\nFasting insulin Hepatic glucose Hepatic and muscle Improves markers of cardiometabolic health independently of weight\nHbA1c production insulin resistance gain which has been shown to be metabolically healthy\nIncreases adiponectin known to regulate glucose levels, lipid\nmetabolism and insulin sensitivity through its anti-inflammatory, anti-\nfibrotic and antioxidant effects\n(1) Proton magnetic resonance spectroscopy\nCorporate Presentation | June 2024 Property of Inventiva│ 13\nThe Phase IIb NATIVE trial evaluated 800 mg and 1200 mg once-daily\nlanifibranor versus placebo in 247 patients\nPHASE IIb DESIGN OVERVIEW\n24-week treatment + 4-week follow-up\nScreening End of treatment\nDouble blind, randomized, placebo-controlled\n Liver biopsy  Liver biopsy\nPlacebo\nlanifibranor, 800 mg once daily\n• Randomisation 1/1/1\n• Stratification on\nlanifibranor, 1200 mg once daily\ntype 2 diabetes\nmellitus (T2D)\nPatient population # patients Definition\nPatients randomized having received at least one dose of\nSafety / Intention-to-Treat (ITT) 247\nlanifibranor/placebo\nPatients with paired biopsies and without deviation impacting efficacy\nPer Protocol (PP) 194\nresults\n Main inclusion criteria: patients with biopsy-proven NASH confirmed by central reader having Steatosis-Activity-Fibrosis\n(SAF) scores of 1-3 for steatosis, 3-4 for activity, and <4 for fibrosis\n Results published in the New England Journal of Medicine(1):\n(1) https://www.nejm.org/doi/full/10.1056/NEJMoa2036205\nCorporate Presentation | June 2024 Property of Inventiva│ 14\nThe majority of patients successfully completed the 24-week treatment\nPHASE IIb DESIGN TREATMENT ARMS\n247 patients randomised and treated\nPlacebo lanifibranor 800 mg/day lanifibranor 1200 mg/day\nN = 81 N = 83 N = 83\n74 (91%) patients completed 77 (93%) patients completed 77 ( 93%) patients completed\nthe 24-week treatment the 24-week treatment the 24-week treatment\n7 (9%) patients prematurely 6 (7%) patients prematurely 6 (7%) patients prematurely\nwithdrawn: withdrawn: withdrawn:\n- Adverse events (n=3) - Adverse events (n=3) - Adverse events (n=3)\n- Withdrawal by patient (n=2) - Lost to follow-up (n=1) - Lost to follow-up (n=1)\n- Forbidden concomitant - Withdrawal by patient* (n=1) - Withdrawal by patient (n=2)\nmedication (n=2)\n- Non-compliance (n=1)\nNote: * And adverse event as secondary reason\nCorporate Presentation | June 2024 Property of Inventiva│ 15\nPatient population included 58% of female and 42% of patients with T2D\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor Overall\nParameters (unit)\n- 800 mg/day 1200 mg/day -\nn (%) or mean ± SD\nN = 81 N = 83 N = 83 N = 247\nDemographics\nFemale 41 (51%) 54 (65%) 49 (59%) 144 (58%)\nAge (years) 53.4 ± 13.1 55.0 ± 10.4 52.2 ± 13.8 53.6 ± 12.5\nWhite 74 (91%) 80 (96%) 78 (94%) 232 (94%)\nWeight (kg) 95.1 ± 17.3 91.6 ± 19.3 93.0 ± 19.9 93.2 ± 18.9\nBody Mass Index (kg/m²) 32.8 ± 5.1 32.5 ± 5.5 33.3 ± 5.5 32.9 ± 5.4\nType 2 diabetes 35 (43%) 33 (40%) 35 (42%) 103 (42%)\nLiver biopsy characteristics\nSAF Activity score\n3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.5 3.3 ± 0.5\n(inflammation + ballooning)\nNAFLD Activity Score (NAS) ≥6 56 (69.1%) 63 (75.9%) 61 (73.5%) 180 (72.9%)\nFibrosis stage F2/F3 57 (70.4%) 68 (81.9%) 63 (75.9%) 188 (76.1%)\nCorporate Presentation | June 2024 Property of Inventiva│ 16\nSeveral liver tests and markers of lipid and glucose metabolism were\nrecorded\nPHASE IIb DESIGN BASELINE\nPlacebo lanifibranor lanifibranor\nParameters (unit)\n- 800 mg/day 1200 mg/day\nmean ± SD\nN = 81 N = 83 N = 83\nLiver enzymes\nAlanine aminotransferase, ALT (UI/L) 56.9 ± 31.6 64.1 ± 41.4 63.6 ± 43.4\nAspartate aminotransferase, AST (UI/L) 43.3 ± 24.1 53.9 ± 43.4 43.9 ± 24.8\nGamma glutamyl transferase, GGT (UI/L) 67.9 ± 80.4 101.6 ± 146.1 67.1 ± 93.1\nPlasma lipid levels\nHDL-Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3\nTriglycerides (mmol/L) 2.0 ± 0.8 1.9 ± 0.9 2.0 ± 0.9\nGlucose metabolism for patients with T2D\n(n= 103)\nFasting Glucose (mmol/L) 6.9 ± 2.0 7.3 ± 2.2 6.6 ±1.2\nHbA1c (%) 6.5 ± 0.7 6.7 ± 0.8 6.6 ± 0.7\nInsulin (pmol/L) 222.7 ± 186.5 246.3 ± 213.4 278.5 ± 233.5\nCorporate Presentation | June 2024 Property of Inventiva│ 17\nLanifibranor achieves statistically significant results on the key Phase III\nFDA and EMA primary endpoints\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint: ITT population\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83)\nResolution of NASH and no\n45%\nworsening of fibrosis*\n33%\n19%\n0.043 <0.001\nImprovement of fibrosis by at\nleast one stage and no\n42%\nworsening of NASH** 28%\n24%\n0.53 0.011\nResolution of NASH and\n31%\nimprovement of fibrosis***\n21%\n7%\n0.017 <0.001\n Statistical significance was also demonstrated for the main key histological endpoints in patients with F2-F3 fibrosis stage\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of\nliver fibrosis ≥ 1 stage and no worsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1\nstage\nCorporate Presentation | June 2024 Property of Inventiva│ 18\nResolution of NASH and improvement of fibrosis: effect size is increased in\nF2/F3 patients as well as patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and\nimprovement of fibrosis(1) 3,0more 4,4more\nresponders on 31% responders on\n(N=247) 21%\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in 8,0more 9,6more\nresponders on 29% responders on\npatients with TD2M (N=103) 24%\n3% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3\n3,4more 4,7more\n33%\npatients (N=188) 24% responders on responders on\n7% 800mg vs placebo 1200mg vs placebo\nResolution of NASH and\nimprovement of fibrosis(1) in F2 / F3 7,5more 7more responders\n30% responders on 28% on 1200mg vs\npatients with TD2M (N=83)\n4% 800mg vs placebo placebo\n(1) ) Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | June 2024 Property of Inventiva│ 19\nImprovement of fibrosis and no worsening of NASH is achieved in all\nsubgroups analyzed with similar level of effect size\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nImprovement of fibrosis by at least\none stage and no worsening of 1,2more 1,7more\nNASH(1) (N=247) 24% 28% responders on 42% responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\n1,3more 2,0more\nNASH(1) in patients with TD2M\nresponders on 46% responders on\n30%\n(N=103) 23% 800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nImprovement of fibrosis by at least\none stage and no worsening of\n1,1more 1,6more\nNASH(1) in F2 / F3 patients (N=188) 48%\n30% 32% responders on responders on\n800mg vs placebo 1200mg vs placebo\nImprovement of fibrosis by at least\none stage and no worsening of\nNASH(1) in F2 / F3 patients with\n1,2more 1,6more\n48%\nTD2M (N=83) 37% responders on responders on\n30%\n800mg vs placebo 1200mg vs placebo\n(1) improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24\nCorporate Presentation | June 2024 Property of Inventiva│ 20\nResolution of NASH and no worsening of fibrosis: effect size is increased in\nF2/F3 patients as well as in patients with TD2M\nIntention to Treat Population\nLanifibranor\nPlacebo 800 mg 1200 mg\nResolution of NASH and no\n1,7more 2,4more\nworsening of fibrosis(1) (N=247) 45%\n33% responders on responders on\n19%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in patients 2,3more 3,0more\n43%\nwith TD2M (N=103) 33% responders on responders on\n14%\n800mg vs placebo 1200mg vs placebo\nNATiV3 patient population\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n3,8more 4,8more\n44%\npatients (N=188) 34% responders on responders on\n9%\n800mg vs placebo 1200mg vs placebo\nResolution of NASH and no\nworsening of fibrosis(1) in F2 / F3\n8,2more 10,2more\n41%\npatients with TD2M (N=83) 33% responders on responders on\n4%\n800mg vs placebo 1200mg vs placebo\n(1) Resolution of NASH with no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline\nCorporate Presentation | June 2024 Property of Inventiva│ 21\nLanifibranor efficacy on resolution of NASH and improvement of fibrosis of\nat least 1 stage is superior to resmetirom and at par with FGF-21\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=320 N=223 (F2/F3) N=190\nN=247 N=955 N=128 N=126 N=222\nITT ITT ITT PP\nEffect size Effect size Effect size Effect size Effect size\n24% 11% 28% 28% 20%\n35%\n33%\n31%\n26% 28%\n21%\n20%\n16%\n14% 15% 14%\nEndpoint not\n7% 7% reported on\n5% 5%\n0%\nPlacebo 800mg 1200mg Pbo 80mg 100mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg 30mg 44mg\n0.017* <0.001* <0.0001* <0.0001* 0.009* 0.002* <0.01* <0.01* QW(1) QW Q2W\n*** ***\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results; Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023 ; SemaglutideA\nPlacebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome et al. NEJM 2021; 384:1113-1124.; Resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10 and EASL 2023 presentation pg. 8; Efruxifermin EASL 2023 presentation pg.\n8, corporate presentation of March 2024 pg 22 ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Firbosis, The NEJM DOI:\n10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 22\nLanifibranor efficacy on ≥1 stage fibrosis improvement and no worsening\nof NASH is superior to resmetirom and at par with injectables\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n18% 12% 5% 14% 30% 20% 10% 21% 21%\n55%\n51% 51%\n49% 49%\n42% 43% 43%\n38%\n36%\n28% 29% 33% 30% 33% 32% 34% 30%\n24% 24%\n26%\n24%\n26%27%\n22% 22%\n19% 19%\n14%\n7%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo15mg30mg 44mg Pbo 0.1mg 0.2mg 0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\n0.53 0.011* 0.0002* <0.0001* 0.65 QW QW Q2W QW QW QW\n0.033*0.123 <0.01* 0.1*0.008*0.008* 0.48\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation ; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 23\nLanifibranor efficacy on NASH resolution and no worsening of fibrosis is\nsuperior to resmetirom and at par with pegozafermin\nORAL INJECTABLE\nPPARs THR-β FGF-21 GLP1-RA and GLP1-RA dual agonists\nLanifibranor Resmetirom* Efruxifermin Pegozafermin Semaglutide Survodutide Tirzepatide\nPhase II Phase III Phase II Phase IIb Phase IIb Phase II Phase II Phase II Phase II\n6 months 12 months 9 months 6 months 24 months 6 months 18 months 12 months 12 months\nN=247 N=955 N=125 N=128 N=126 N=222 N=320 N=293 N=190\nITT ITT PP ITT PP PP ITT ITT\nEffect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size\n26% 20% 18% 46% 18% 24% 42% 35% 52%\n60% 59% 62%\n56%\n45% 43% 45% 46% 45% 44%\n40% 40%\n33% 37% 37% 36%\n30%\n26% 25% 26%\n23%\n19% 19%\n17%\n14%\n10% 10% 10%\n7%\n2%\nPbo 800mg 1200mg Pbo 80mg 100mg Pbo 80mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 15mg30mg44mg Pbo 0.1mg 0.2mg0.4mg Pbo 2.4 4.8 6mg Pbo 5mg 10mg 15mg\nQW QW Q2W QW QW QW\n<0.043* <0.001* <0.0001*<0.0001* 0.024* 0.005*<0.001* 0.005* <0.0001* 0.0005* <0.001*\n0.0009*\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA.\nSource: lanifibranor native results;; resmetirom MAESTRO NASH top-line results webcast Dec. 19 2022, pg 10; resmetirom : Harrison et al, Lancet 2019 ; S0140-6736(19) 32517-6 Efruxifermin Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis\n(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterology October 2023; corporate presentation of March 2024 pg15; SemaglutideA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis; Newsome\net al. NEJM 2021; 384:1113-1124 ; Pegozafermin, 89Bio Phase IIb ENLIVEN Topline Results presentation; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-\nAssociated Steatohepatitis with Liver Firbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 24\nA statistically significant decrease in liver enzymes was observed\n10\n0\n-10\n-20\n0 4 8 12 16 20 24\nProperty of Inventiva│ 25\n)L/IU(\negnahc\netulosba\nnaeM\n10\n0\n-10\n-20\n-30\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/IU(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in ALT Absolute change from baseline in AST\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nAbsolute change from baseline in GGT\n10\n0\n-10\n-20\n-30\n-40\n-50\n0 4 8 12 16 20 24\n)L/IU(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247)\n**\n*\n** ** * **\n** *\n** ** * **\n0 W4 W14 W24\n* p<0.01 **p<0.001\nA statistically significant decrease of ALT,\nAST and GGT in both lanifibranor dose\n** ** groups observed after 4 weeks\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\nSTNIOPDNE\nYRADNOCES\nCorporate Presentation | June 2024\nA statistically significant change in HDL-cholesterol and triglycerides was\nseen, without a change in LDL-cholesterol\n0.25\n0.15\n0.05\n-0.05\n0 4 8 12 16 20 24\nProperty of Inventiva│ 26\n)L/lomm(\negnahc\netulosba\nnaeM\nAbsolute change from baseline in HDL-C Absolute change from baseline in triglycerides\n0.2\n0\n**\n-0.2\n-0.4\n-0.6\n0 4 8 12 16 20 24\nPlacebo Lanifibranor 800mg Lanifibranor 1200mg\n)L/lomm(\negnahc\netulosba\nnaeM\nPHASE IIb EFFICACY OTHER\nOther secondary endpoints in ITT (N = 247) * p<0.01 **p<0.001\n**\n**\n**\n*\n**\n** **\n**\n**\n0 W4 W14 W24\n0 W4 W14 W24\nPlacebo Lanifibranor 800mg Lanifibranor 1200m**g\n No change in LDL-cholesterol\nSTNIOPDNE\nYRADNOCES\nStatistically significant change Statistically significant change\nin HDL-cholesterol in triglycerides\nCorporate Presentation | June 2024\n0.5\n0\n-0.5\n-1\n-1.5\n-2\n0 4 8 12 16 20 24\nProperty of Inventiva│ 27\n)L/lomm(\negnahc\netulosba\nnaeM\nIn patients with NASH and T2D, statistically significant reductions of\nfasting glucose and insulin, HbA1c were observed\nAbsolute change from baseline in HbA1c Absolute change from baseline in fasting glucose\n0.5\n0\n-0.5 **\n**\n**\n**\n-1 **\n**\n0 4 8 12 16 20 24\n0 W4 W14 W24\nPlacebo (N= 35) Lanifibranor 800mg (N= 33)\nLanifibranor 1200mg (N= 35)\n**p<0.001\n)%(\negnahc\netulosba\nnaeM\n**\n**\n**\n**\n0 W4 W14 W24\nPlacebo (N = 35) Lanifibranor 800mg (N = 33)\nLanifibranor 1200mg (N = 35)\nAbsolute change from baseline in insulin at W24\n0\n-10\n-20\n-30\nweek 24\n)Lm/UIµ(\negnahc\netulosba\nnaeM\nSecondary endpoints in patients with NASH and T2D (N = 103)\n**\n**\nPlacebo (N= 32) Lanifibranor 800mg (N= 31)\nLanifibranor 1200mg (N= 33)\nSTNIOPDNE\nYRADNOCES\nPHASE IIb EFFICACY OTHER\nLanifibranor associated with improvements\nin insulin sensitivity and glycemic control in\nNASH patients\nCorporate Presentation | June 2024\nLanifibranor leads to significant improvements in hepatic and muscular\ninsulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 28\nnim/gk/gm\nLS mean absolute change from baseline LS mean absolute change from baseline to LS mean absolute change from\nto week 24 in week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\n Data from the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating\nlanifibranor (800mg/day) in patients with NAFLD and type 2 diabetes mellitus (T2D) for 24 weeks\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nDr. Cusi - IIS\nCorporate Presentation | June 2024\nLanifibranor induces a significant decrease in circulating biomarkers\nlanifibranor\nMedian relative change (%) Placebo Pvalue\n(Two doses pooled)\nPro-C3 (4.1%) (13.9%) p= 0.005*\nPro-C3 >14 at\nFibrosis (12.8%) (20.5%) p= 0.017*\nbaseline(1)\nRatio TIMP-1/MMP-2 (4.6%) (22.5%) p < 0.001*\nApoptosis CK18-M30 0.5% (41.1%) p < 0.001*\nFerritin (9.1%) (29.4%) p < 0.001*\nInflammation\nhs-CRP 13.0% (35.5%) p < 0.001*\n(1) Level where it is estimated that fibrogenesis is active and corresponding to F2/F3 patients\nFAS (Full Analysis Set) population with available data at baseline and at week 24\n* Statistically significant\nProperty of Inventiva│ 29\nSERUSAEM\nEMOCTUO\nREHTO\n Data from NATIVE clinical study evaluating lanifibranor (800mg/day and 1200mg/day ) in patients with NASH for 24 weeks\nCorporate Presentation | June 2024\nLanifibranor significantly reduces hepatic steatosis measured by MRI-\nPDFF and MR-spectroscopy\n Data from the Legend clinical study evaluating lanifibranor  Data from the clinical study conducted by Dr. Kenneth\n(800mg/day) in combination with empagliflozin in patients Cusi from the University of Florida, evaluating lanifibranor\nwith NASH and poorly controlled Type 2 Diabetes (T2D) (800mg/day) in patients with NAFLD and type 2 diabetes\nfor 24 weeks mellitus (T2D) for 24 weeks\nDr. Cusi - IIS\nLiver fat measured by MRI-PDFF Liver fat (IHTG) measured by MR-spectroscopy\nN=26 from baseline at week 24 N=38 from baseline at week 24\nLS means relative percent change, FAS LS means relative percent change, FAS\n0% 0%\n0%\n-10% -10%\n-12%\n-20% -20%\n-30% -30%\n*\n-40% -37% -40%\n*\n-44% pa=0.002\n-50%\n-47%*\n-50%\nPlacebo Lani Lani Placebo Lani\nn= 5 n= 12 + Empa n=18 n=20\nn= 9\nBaseline 17.1-19.7%  65% of patients achieved liver fat reduction ≥30% vs 22% under\nplacebo\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)  25% of patients achieved NAFLD resolutions vs 0% under placebo\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before a P-value from an Analysis of Covariance (ANCOVA) using the relative change from baseline to week 24\nWeek 24 as the response, the treatment as covariate as well as the baseline of IHTG. In the FAS, missing data at\nWeek 24 were imputed by baseline data.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 30\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Tirzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 31\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\n Data from the clinical study evaluating lanifibranor (800mg/day) in combination with empagliflozin in patients with NASH and\npoorly controlled Type 2 Diabetes (T2D) for 24 weeks\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 32\nLanifibranor has a favourable safety profile\nPHASE IIb SAFETY OVERALL\nPlacebo 800 mg 1200 mg\nN (%) patients reporting Adverse Event (AE)\n(N = 81) (N = 83) (N = 83)\n Any Treatment-Emergent AE (TEAE)\n50 (61.7%) 59 (71.1%) 62 (74.7%)\nDrug-related TEAE 19 (23.5%) 25 (30.1%) 23 (27.7%)\n Any TEAE leading to drug withdrawal\n3 (3.7%) 4 (4.8%) 3 (3.6%)\nDrug-related TEAE leading to drug withdrawal 2 (2.5%) 1 (1.2%)(1) 2 (2.4%)(2)\n Any Serious TEAE\n3 (3.7%) 3 (3.6%) 7 (8.4%)\nDrug-related Serious TEAE 2 (2.5%)(3) - -\nFocus of next slide\n(1) One patient with moderate diarrhea ; (2) One patient with mild cardiac failure; one patient with mild diarrhea, abdominal pain, dizziness ;\n(3) 2 SUSARs (placebo arm): one patient with mild cardiac failure; one patient with moderate urticaria\n Consistent with known insulin sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at the\n800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed.\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 81)\n Peripheral edema 2 (2.5%) 5 (6.0%) 7* (8.4%)\nDrug-related peripheral edema - 2 (2.4%) 2 (2.4%)\n Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few\npatients received diuretics. 4 cases were considered study drug related by the investigator (2 at 800\nand 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor\n1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female\n* One AE of severe intensity\npatients\nCorporate Presentation | June 2024 Property of Inventiva│ 33\nA limited number of serious TEAEs occurred\nPHASE IIb SAFETY SERIOUS TEAE\nPatients reporting treatment-emergent Placebo 800 mg 1200 mg\nSerious AE (SAE); N (%) (N = 81) (N = 83) (N = 83)\nTotal 3 (3.7%) 3 (3.6%) 7 (8.4%)\nTreatment-Emergent Serious AE linked to biopsy procedure\nPost-procedural haematoma/haemorrhage - 1 (1.2%) 1 (1.2%)\nPost-procedural pain - - 1 (1.2%)\nPneumobilia (post-procedural) - - 1 (1.2%)\nOther Treatment-Emergent Serious AE\nWrist fracture 1 (1.2%) - -\nAngina unstable - - 1 (1.2%)\nCardiac failure 1 (1.2%) - -\nGastroenteritis - - 1 (1.2%)\nPyelonephritis - - 1 (1.2%)\nPancreatitis - 1 (1.2%) -\nUndifferentiated connective tissue disease - 1 (1.2%) -\nUrticaria 1 (1.2%) - -\nFoot operation - - 1 (1.2%)\nCorporate Presentation | June 2024 Property of Inventiva│ 34\nPhase II results have demonstrated modest weight increase with no impact\non efficacy\n Consistent with known insulin-sensitizing pharmacology, a mean weight increase from baseline of 2.4 kg (2.6%) at\nthe 800 mg/day dose and 2.7 kg (3.1%) at the 1200 mg/day dose was observed\n According to a six-month study with pioglitazone in patients * with NASH body weight gain is likely attributed to an\nincrease in adipose tissue and not water retention\n Based on a 52-week lanifibranor trial in systemic sclerosis (SSc) patient weight gain is expected to reach a maximum\nby week 24\nSSc lanifibranor study: weight (kg) relative change from baseline over 52 weeks\n(Observed cases under treatment – FAS population)\nExcept for two patients (one placebo, one 600mg BID),\nTEAE time of onset related to weight increase happened in\nKg\n6 the first 24 weeks of treatment\n4\n2\n0 Weeks\n0 2 4 8 12 16 20 24 28 32 36 40 44 48 52\nLanifibranor 600 mg BID Placebo\nNote: * Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholivsteatohepatitis ; Balas, Belfort, Harrison et al. ; Journal of Hepatology 47 (2007) 565-570\nCorporate Presentation | June 2024 Property of Inventiva│ 35\nWeight changes in NATIVE trial: approximately 33% of patients\non lanifibranor show a weight increase of more than 5%\nWeight changes at end of treatment (Week 24) in patients treated with\nlanifibranor versus placebo\nLanifibranor Placebo\n100%\nN=144 N=73\n84%,\nN=61\n80%\n51%,\n60%\nN=73\n33%,\n40%\nN=48\n16%,\n20% N=23 11%,\nN=8 6%,\nN=4\n0%\nStable Moderate Weight Stable Moderate Weight\nweight weight gain weight weight gain\n(≤2.5%) gain (>5%) (≤2.5%) gain (>5%)\n(2.5%-5%) (2.5%-5%)\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 36\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (I/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nFasting HOMA-IR ALT\nMean absolute change at Week 24 from baseline Mean absolute change at Week 24 from baseline (U/L)\nLanifibranor Placebo Lanifibranor Placebo\n4.0\n10 8\n1.7\n2.0 5\n0.0 0\n-0.6\n-2.0 -5\n-5\n-10\n-4.0\n-15\n-6.0 -5.1\n-5.8\n-20\n-8.0 -20\n-8.2 -25 -22\n-10.0\n-26\n-30\nTriglycerides CAP\nMean absolute change at Week 24 from baseline (mmol/L) Mean absolute change at Week 24 from baseline (dB.m-1)\n1\n0.8 Lanifibranor Placebo Lanifibranor Placebo\n35\n30.6\n0.6\n25\n0.4\n0.2 0.12\n0.03 15\n0\n-0.2 5\n-0.4\n-0.42 -0.44 -0.45 -5\n-0.6 -4.6\n-0.8  LDL level do not change but HDL level improves in -15 -10.2\npatients treated with lanifibranorindependently of weight -14.7\n-1 -17\nchanges\n-25\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 37\nMetabolic profile improves in patients treated with lanifibranor, independently of\nweight changes, but worsen in placebo treated patients gaining weight (II/II)\nStable weight (≤2.5%) Moderate weight gain (2.5%-5%) Weight gain (>5%) Stable weight (≤2.5%) Weight gain (>5%)\nAPO-C3 APO-B\nMean absolute change at week 24 from baseline (μg/ml) Mean absolute change at week 24 from baseline (mg/dl)\n25 Lanifibranor Placebo Lanifibranor Placebo\n19.1 0\n20\n-0.08\n-2\n15\n-2.58\n-4\n8.9\n10\n-6\n5\n-8\n0\n-10\n-9.66\n-5\n-12\n-10 -7.3 -14 -13.04\n-9.3\n-10.7\n-14.56\n-15 -16\n-20 -18\n-20\nhs-CRP hs-CRP\nMean absolutechange at Week 24 from baseline (%) Mean relativechange at Week 24 from baseline (%)\nLanifibranor Placebo Lanifibranor Placebo\n1.0 0.6\n10\n3\n0.0 0\n-0.1 -1\n-1.0 -0.6 -10\n-20\n-2.0 -21\n-30\n-3.0 -2.7\n-40\n-41\n-4.0 -50\n-4.1\n-60\n-5.0\n-61\n-70\n-6.0\n-80\nSource: MP. Cooreman, Lanifibranorimproves markers of cardio-metabolic health in NASH patients independent of weight change –EASL 2022\nCorporate Presentation | June 2024 Property of Inventiva│ 38\nEffect on weight when combining lanifibranor with empagliflozine\nWeight change, N=32 Ratio VAT/SAT, N=19\nRelative change from Baseline (%) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 93-102 kg\n5 11\n3.6 10\n4\n3 5\n2\n2 1.4 0\n1\n00 -5\n-0.4 -0.4 -5*\n0\n-0.9\n0 -10\n-1\n-0.8 -0.8\n-1.1 -15\n-2\nWeek 4 Week 12 Week 24\nBaseline -17**\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8 -20\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nPlacebo Lani Lani + Empa n= 4 n= 8 n= 7\nAt Week 24, 7 patients without weight values available : SAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n- 5 patients under placebo who prematurely stopped before Week 24 * p=0.08, **p<0.01, versus placebo (ANCOVA)\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly Thirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\nmodified his/her diet (intercurrentevent) before Week 24.\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nThe combination of empagliflozin and lanifibranor addresses the Lanifibranor alone and in combination with empagliflozin leads to\nweight gain observed in some patients treated with lanifibranor alone a shift towards metabolically healthy adipose tissue\nCorporate Presentation | June 2024 Property of Inventiva│ 39\nPhase III NATiV3 should, if positive, allow to file for accelerated approval\nMain Cohort Accelerated\nApproval\n72 weeks treatment\nN~ 950\nLanifibranor: 1200 mg once daily\nNon-cirrhotic NASH &\nLanifibranor: 800 mg once daily\nF2-F3 fibrosis\nActive Treatment Extension\nPlacebo: Once daily\n►Stratification\n48 weeks\n- By diabetic status\nExploratory Cohort\n- By fibrosis stage F2/F3 EoT\n72 weeks treatment Lanifibranor: 1200 mg once daily\nN~ 200\nLanifibranor: 800 mg once daily\nLanifibranor: 1200 mg once daily\nScreen failed patients from the\n►All patients who complete the main or the exploratory cohort\nmain cohort are eligible for the active treatment extension study\nLanifibranor: 800 mg once daily\nNon-cirrhotic NASH & ►Patients to switch to the active treatment extension after the\nF1-F4 fibrosis week 72 visit of the last patient randomized in the main cohort\nPlacebo: Once daily\nor after 120 weeks of treatment, whichever happens first\n►Stratification\n- By diabetic status\n- By fibrosis stage F1-F3/F4\nPrincipal investigators: Dr. S. Francque / Dr. A. Sanyal for the main cohort\nPrimary endpoint: Composite endpoint of patients having both NASH resolution and one stage fibrosis improvement\nKey secondary endpoints: NASH resolution and no worsening of fibrosis / Fibrosis improvement and no worsening of NASH\nGLP1: Patients under a stable dose of GLP1-RA for at least 3 months prior to screening can be included\nStatistical powering: 90% considered for sample size calculations\nCentral biopsy reading: Tie breaker approach by three expert pathologists\nCorporate Presentation | June 2024 Property of Inventiva│ 40\nOver 400 sites and 24 countries involved in NATIV3\nPHASE III DESIGN SITE SELECTION\n► 478 sites activated in 24 countries (as\nof April 1, 2024)\n► 914 randomized patients: 731 in the\nmain cohort and 183 in the exploratory\ncohort (prior to the voluntary pause)\n► Target to achieve LPFV H1 2024\n► Topline data expected H1 2026\nNATiV3 countries\nCorporate Presentation | June 2024 Property of Inventiva│ 41\nOpportunity for lanifibranor\nLanifibranor well positioned alone or in combination in the NASH market\npan-PPAR THR-β FGF-21 GLP-1\nROUTE OF\nOral Oral Injectable Injectable\nADMINISTRATION\nIndirect\nDirect activity Indirect Direct activity Not seen with sema.\nEfficacy on fibrosis\nseen at 6 months seen after 12 months seen at 6 months Reported by BI & Lilly\nafter 12 months\nNASH resolution\nInsulin resistance\nLimited drop-out High drop out due to High drop out due to\nTolerability Limited drop-out GI side effects on GI side-effects & GI side-effects &\ninitiation injections injections\nPatients with advanced F1 patients\nPatients with F2/F3: induction\nTarget patients fibrosis (F2/F3) F2/F3: in\nadvanced fibrosis therapy\npopulation T2D patients combination with\n(F2/F3) F4 patients\nLean patients anti-fibrotic drugs\nCorporate Presentation | June 2024 Property of Inventiva│ 43\nLanifibranor expected to meet key decision drivers for surveyed payers\nand prescribers\nSurveyed Payers Surveyed Prescribers\n Improvement in fibrosis is expected to be the key driver of  Prescribers see improvement in fibrosis and joint\nP&TC decisions* in NASH\nachievement of fibrosis improvement and resolution of\nsteatohepatitisas the key benefits of a new NASH drug\n Payers see lanifibranor as stronger than resmetirom\n(Madrigal) and semaglutide(Novo Nordisk) on fibrosis  Both histological endpoints: over 85% of prescribers\nimprovement\nrate as major benefit\nTop 6 Key attributes (n = 95)\nBoth improves fibrosis and resolves steatohepatitis 99%\nImproves fibrosis 98%\nResolves steatohepatitis 99%\nImproves portal hypertension 93%\nImproves key markers of glucose metabolism 92%\nOral 88%\n% of prescribers 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%\nNot a factor Benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for lanifibranor,\nwhich is currently in Phase III clinical trial and has not been approved.\n*P&TC: Pharmacy & Therapeutics Committee\nCorporate Presentation | June 2024 Property of Inventiva│ 44\nLanifibranor well rated versus resmetirom(1) and the combination of\nlanifibranor + GLP-1 versus GLP-1 alone\nSurveyed prescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.7\n* 5.49\n*\n5.5 5.42\n5.3\n5.1\n4.94\n4.88\n4.9\n4.7\n4.5\nPre-diabetic patients with F2 / F3 Diabetic patients with F2 / F3 NASH\nNASH\nResmetirom Lanifibranor\n* indicates results are statistically significantly higher than the comparator (p<0.05)\nSource: (1) US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH at the time of the\nsurvey were included. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on available trial results for lanifibranor, which is currently in Phase III clinical trial\nand has not been approved. *Survey conducted before Resmetiromapproval by the FDA.\nCorporate Presentation | June 2024 Property of Inventiva│ 45\ntifeneb\ndeviecreP\nLanifibranor versus resmetirom Lanifibranor in combination versus GLP-1\n5.7\n* 5.52\n5.5\n5.26\n5.3\n5.1\n4.9\n4.7\n4.5\nNASH patients\nGLP-1 GLP-1 + Lanifibranor\nLanifibranor well positioned in patients with T2D and Lanifibranor could address the need in patients treated\nNASH, a population more present in patients with F2/F3 with GLP-1 to reduce fibrosis with an oral treatment and\nfibrosis and with a faster progressing form of fibrosis without the GI side effects present in the GLP-1 and\nFGF-21 class\nModerate metabolically healthy weight gain induced by lanifibranor is not a\nconcern for payers, and is deemed manageable by surveyed prescribers\nSurveyed Payers Surveyed Prescribers\n Surveyed payers see lanifibranoras safe for chronic use  A majority of surveyed HEPs and ~ half of surveyed GEs stated that\nand any associated moderate weight gain is seen as they would not hesitate to prescribe a new NASH drug that causes 2-3\nmanageable with lifestyle choices or weight loss agents. kg weight gain\n 72% of surveyed prescribers expect they could manage a moderate\n Surveyed payers: “If the message is that you'll weight gain with diet, exercise and counselling.\ngain 3 or 4 lbs but you'll feel better, and you  78% of surveyed prescribers agree that “Combining lanifibranorwith an\nexplain the difference between healthy and SGLT2 or GLP-1 is an opportunity to maintain effectiveness in NASH\nunhealthy weight, you can get through that. If while mitigating weight gain.”\nsomeone is 200 pounds and goes up to 205  73% of surveyed prescribers agree that the benefits of lanifibranor\npounds, I don't think they're going to notice it....” outweigh the moderate weight gain.\n Surveyed prescribers see other SEs as bigger drawbacks\nIs associated with neoplasm growth 63%\nIs associated with sarcopenia 40%\nIs associated with 2-3 kg weight gain 12%\n% of prescribers 0% 20% 40% 60% 80%\nMajor drawback\nThe importance of adherence to treatment and convenience of administration favors\nlanifibranor\n 80% of surveyed prescribers see low discontinuation rate as critical, very critical\nor absolute necessity\n 80% of surveyed prescribers rate oral administration as a key benefit\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists (HEPs), 25 gastroenterologists (GEs), 25 endocrinologists in the United States in Q1 2024. Onlyassets in Phase III clinical trial in NASH at the\ntime of the survey were included; US Payer Advisory Board, March 2023. Small survey population may not be indicative of broader payer and prescriber views and key drivers. Survey based on availabletrial results for\nlanifibranor, which is currently in Phase III clinical trial and has not been approved.\nCorporate Presentation | June 2024 Property of Inventiva│ 46\nPrescribers expect GLP-1 + lanifibranor to be significantly more beneficial than\nGLP-1 alone; suggests a perception of synergy, with lanifibranor enhancing GLP-1\nPrescribers\nPerceived benefit of pipeline drugs (n = 95)\n(7-point scale where 1 = not at all beneficial and 7 = extremely beneficial)\n5.60\n5.52\n5.50\n5.40\n5.30 5.26\n5.20\n5.10\n5.00\nMASH patients\nSource: US prescriber survey, February 2024 conducted in 45 hepatologists, 25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in PhaseIII clinical trial in NASH/MASH at the time of the survey were\nincluded.\nProperty of Inventiva│ 47\ntifeneb\ndeviecreP\n*\nGLP-1 GLP-1 + Lanifibranor\n* indicates results are significantly higher than the comparator (p<0.05)\nLanifibranor could address the need in patients treated with GLP-1 to reduce fibrosis with an oral treatment\nand without the GI side effects present in the GLP-1 and FGF-21 class\nCorporate Presentation | June 2024\nOpportunity for lanifibranor for the treatment of NASH based on current\nclinical program (F2/F3)\nSteatosis Steatohepatitis Advanced fibrosis\nF1 F2 F3 F4 CC\nPatients with NASH estimated in 2030 (US) 9.0M 6.1M 4.5M 3.5M\nIMPROVEMENT OF FIBROSIS\nLanifibranor RESOLUTION OF NASH\nCARDIOVASCULAR IMPROVEMENT\nINSULIN RESISTANCE IMPROVEMENT\nLean NASH Lanifibranor Even if GLP-1 dominate the\n(10-15%) market, lanifibranor would\nT2D Lanifibranor still target 50-60%of\nEstimated\n(15-20%) patients with NASH:\nNASH patient\npopulation T2D & obesity • Lean NASH: 10-15%\nGLP1+Lani\n(20-25%) • “Needle phobia”: 10-15%\n(%)(1)\n• GLP-1 drop-outs: 32% (40%\nObesity & prediabetes\nDO * 80% of NASH patients\n(50-55%) GLP1+Lani\nunder GLP-1)\nSurveyed prescribers expect to write lanifibranor for ~ 30% of NASH patients if approved –across all of the following:\n30%\n• F2 and F3\n• Pre-diabetic and diabetic patients\n• BMI groups –suggests 2-3 kg weight gain is not a key barrier in surveyed prescribers 70%\nSource: Estes C,RazaviH,Loomba R,YounossiZ,Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology2018;67:123-133; US prescriber survey, February 2024 conducted in 45 hepatologists,\n25 gastroenterologists, 25 endocrinologists in the United States in Q1 2024. Only assets in Phase III clinical trial in NASH/MASH at the time of the survey were included; US Payer Advisory Board, March 2023\nCorporate Presentation | June 2024 Property of Inventiva│ 48\nUpcoming catalysts\nCatalysts\n2024 2025 2026\nLanifibranor\nH1 2024 H2 2024 H1 2026 H2 2026\nLast Patient Last Patient • Last Patient New Drug\nFirst Visit randomized Last Visit Approval\n• Topline filing with\nresults FDA\nOdiparcil\nReview potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing\na partnership\nCorporate Presentation | June 2024 Property of Inventiva│ 50\nContacts\nInventiva Brunswick Westwicke, an ICR Company\nPascaline Clerc Tristan Roquet Montégon Patricia L. Bank\nExecutive VP Aude Lepreux Investor relations\nStrategy and Corporate Affairs Julia Cailleteau\nMedia relations\npascaline.clerc@inventivapharma.com inventiva@brunswickgroup.com patti.bank@westwicke.com\n+1 202 499 8937 + 33 1 53 96 83 83 +1 415 513 1284\nLanifibranor : back-ups slides\nPhase I and Phase IIa clinical trials* in type 2 diabetes (T2D) patients:\nbeneficial changes in key metabolic markers\n300 p=0.05\np=0.05\n200\np=0.08\n100\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nProperty of Inventiva│ 53\nenilesab\nfo\negnahc\ntnecreP\nAdiponectin (PPARγ)**\nenilesab\nmorf\negnahc\ntnecreP\n40\np<0.05\n30\np<0.05\n20\np=0.13\n10\n0\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nHDL Cholesterol (PPARα/δ)^\nenilesab\nmorf\negnahc\ntnecreP\n0\n-10\n-20\n-30 p=0.08\np<0.05\n-40\np<0.05\n-50\nPlacebo 400 mg 800 mg 1400 mg\nIVA337 IVA337 IVA337\nlanifibranor lanifibranor lanifibranor\nenilesab\nfo\negnahc\ntnecreP\nTriglycerides (PPARα/δ) ^^\nenilesab\nmorf\negnahc\ntnecreP\nPHASE I AND IIa\nLanifibranor metabolic markers in patients with T2D\nlanifibranor lanifibranor lanifibranor\nPhase I and IIa* clinical findings support the favorable tolerability of lanifibranor\n Phase I trials: > 200 healthy volunteers  Good overall tolerability and no major safety findings\n Phase IIa trial with 47 T2D patients  No increases of creatinine, LFTs, or CPK\n Phase IIb: > 250 patients treated for 24 or 48  No changes in blood pressure, no signal of fluid overload or haemodilution\nweeks  No clinically relevant weight gain\nThorough QT/QTc study demonstrates no impact of the drug on QT intervals\n Study carried out in 2020 and 2021 to prepare the NDA package\n A randomized, double-blind, double-dummy, placebo, positive-controlled (400mg of moxifloxacin) and multiple-dose\n(1200mg and 2400mg as the supratherapeutic dose) cardiac safety study to evaluate the effect of lanifibranor on the QT\ninterval in healthy adult subjects\n At doses of 1200 mg and 2400 mg, lanifibranor has no impact on QT intervals\nNote: * Conducted by Abbott; ** Adiponectin is associated with PPARγactivation; ^ HDL-C is associated with PPARαand d activation; ^^ Triglycerides are associated with PPARαand δ activation\nSource: Company data\nCorporate Presentation | June 2024\n247 patients were randomised across 71 sites worldwide, with the majority\nof patients based in Europe\nPHASE IIb DESIGN SITE SELECTION\n4 sites in 49 sites in\nCanada Europe\nPatients\nCountry\nrandomized\nEurope 183 (74%)\nU.S. 36 (15%)\nAustralia 13 (5%)\n12 sites in the Canada 8 (3%)\nUnited States\nMauritius 7 (3%)\nTotal 247 (100%)\n1 site in 5 sites in\nMauritius Australia\n16 countries worldwide (number of sites having randomized at least 1 patient)\n► Europe: Austria (1), Belgium (5), Bulgaria (5), Czech Republic (3), France (13), Germany (5), Italy (4), Poland (3),\nSlovenia (1), Spain (4), Switzerland (2), United Kingdom (3)\n► North America: United States (12), Canada (4)\n► Australia (5)\n► Mauritius (1)\nCorporate Presentation | June 2024 Property of Inventiva│ 54\nProperty of Inventiva│ 55\nYRAMIRP\nSTNIOPDNE\nYRADNOCES\nTNIOPDNE\nLanifibranor demonstrated statistical significance on all histological\nendpoints in both ITT and PP populations\nPHASE IIb EFFICACY KEY ENDPOINTS\nxx Statistically significant xx Non-statistically significant\nKey Phase IIb results by endpoint\nN = 247 ITT population N = 197 PP population\nPlacebo 800 mg 1200 mg Placebo 800 mg 1200 mg\nPlacebo 800 mg 1200 mg\n(N = 81) (N = 83) (N = 83) (N = 62) (N = 63) (N = 69)\nDecrease of ≥2 points of SAF 27% 41% 49% 34% 51% 55%\nactivity score* and no worsening\n0.061 0.004 0.058 0.015\nof fibrosis\nResolution of NASH and no 19% 33% 45% 23% 40% 49%\nworsening of fibrosis**\n0.043 <0.001 0.039 0.002\nImprovement of fibrosis by at\n42% 46%\nleast one stage and no 24% 28% 29% 32%\nworsening of NASH*** 0.53 0.011 0.75 0.04\nResolution of NASH and 7% 21% 31% 10% 24% 33%\nimprovement of fibrosis^\n0.017 <0.001 0.036 0.001\nDecrease of ≥2 points of NAS\nscore^^ (NAFLD activity score) 32% 52% 64% 40% 62% 71%\nand no worsening of fibrosis\n0.01 <0.001 0.02 <0.001\n* Response is defined as a decrease from baseline to week 24 of at least 2 points of the SAF Activity score (SAF-A) with no worsening of the NAS Fibrosis score (NAS-F). No worsening means that score remains stable or\ndecreases ; ** Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; *** Improvement of liver fibrosis ≥ 1\nstage and no worsening of NASH at week 24; ^ Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage; ^^ NAS score is a commonly accepted,\nsemi-quantitative evaluation of biopsy results that assesses the severity of steatosis, inflammation and ballooning in the liver.\nCorporate Presentation | June 2024\nStatistical significance was also demonstrated for the main key histological\nendpoints in patients with F2-F3 fibrosis stage\nPHASE IIb EFFICACY F2-F3 POPULATION\nxx Statistically significant xx Non-statistically significant\nKey secondary endpoints in FAS F2-F3 patients (N=188)\nlanifibranor\nPPllaacceebboo 880000 mmgg 11220000 mmgg\n(N = 57) (N = 68) (N = 63)\nResolution of NASH and no\n44%\n34%\nworsening of fibrosis* 9%\n0.001 <0.001\nImprovement of fibrosis by at least\n48%\none stage and no worsening of\n30% 32%\nNASH**\n0.736 0.048\nResolution of NASH and improvement\n33%\nof fibrosis*** 7% 24%\n0.012 <0.001\n Similar results in the PP population\n Consistent response in diabetic and non-diabetic patients\n* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline; ** Improvement of liver fibrosis ≥ 1 stage and no\nworsening of NASH at week 24; *** Resolution of NASH and improvement of fibrosis at week 24: NAS-I = 0 or 1, NAS-B = 0 and an improvement of NAS-F ≥ 1 stage\nCorporate Presentation | June 2024 Property of Inventiva│ 56\nPhase III NATiV3 clinical trial confirmatory trial: anticipated\nexpected design to support broader “full approval”\nPHASE III OVERVIEW\nAnticipated event driven trial in patients with NASH compensated cirrhosis\nPhase 3: event driven\nN~ 800 EoT\nPatients with\nLanifibranor: Once daily Potential full approval in U.S.\nNASH and\ncompensated and EU\nPlacebo: Once daily\ncirrhosis\nKEY ENDPOINTS (non-exhaustive) TRIAL END DATE\n Based on time to first clinical event on c.800 patients  Trial expected to last up to 3 years\n• all cause mortality\n• hepatic decompensation events\n− hepatic encephalopathy\n− variceal bleeding or progression to varices that require prophylactic\ntreatment\n− new onset ascites requiring treatment\n• MELD score ≥15\n• liver transplantation\nCorporate Presentation | June 2024 Property of Inventiva│ 57\nLanifibranor clinical trial in patients\nwith NAFLD and T2D\nLanifibranor clinical trial in patients with NAFLD and T2D\nObjective of investigator-initiated trial: Establish safety, efficacy and mechanism of action of lanifibranor in patients with T2D\nand NAFLD. Specifically determine if lanifibranor decreases IHTG(1), improves hepatic insulin sensitivity, endogenous (hepatic)\nglucose production, gluconeogenesis and DNL(2).\nPatients with NAFLD and T2D\n Fasting plasma glucose: 100mg - 250mg/dL\n HbA1c: 6.0% to 9.5%\n Hepatic steatosis: >10%\n24 weeks treatment\nPlacebo\nLanifibranor 800mg/daily\n24 weeks\n6 weeks 4 weeks\nEOT\nRun-in period Run-in period Follow-up\nPrimary endpoint: change in Intrahepatic triglycerides (IHTG)\nSecondary endpoints:\n Proportion of responders reaching a decrease in IHTG from baseline ≥ 30% quantified by proton magnetic resonance\nspectroscopy (¹H-MRS)3\n Proportion of patients with NAFLD resolution (patients with IHTG ≤ 5%) quantified by ¹H-MRS\n Change in hepatic and muscle insulin sensitivity and lipid metabolism\n Safety\n(1) Intrahepatic triglycerides; (2) De-novo lipogenesis; (3) proton magnetic resonance spectroscopy\nCorporate Presentation | June 2024 Property of Inventiva│ 59\nLanifibranor significanty reduces liver fat and resolves NAFLD\nLS means relative percent change Percentage of patients achieving Percentage of patients achieving\nfrom baseline in liver fat (IHTG) at liver fat reduction ≥30% at week 24 NAFLD resolution at week 24\nweek 24 (FAS N=38) (FAS N=38) (FAS N=38)\n0% 100% 100%\n90% 90%\n-10%\n80% pa=0.008 80%\n-12%\n70% 65% 70%\n-20%\n60% 60%\n50% 50%\n-30%\n40% 40%\npb=0.048\n-40% 30% 30% 25%\n22%\n20% 20%\n-44%\n-50% Placebo Lanifibranor 10% 10%\nn=18 800mg\n0%\nn=20 0% 0%\nPlacebo Lanifibranor Placebo Lanifibranor\npa=0.002 n=18 800mg n=18 800mg\nn=20 n=20\na P-value from an Analysis of Covariance (ANCOVA) using the aChi² test bFisher test\nrelative change from baseline to week 24 as the response, the In the FAS, missing data at Week 24 were imputed as NAFLD resolution is defined as IHTG ≤ 5.5% at week 24.\ntreatment as covariate as well as the baseline of IHTG. In the FAS, non-achieving reduction. In the FAS, missing data at Week 24 were imputed as non-\nmissing data at Week 24 were imputed by baseline data. responders\nCorporate Presentation | June 2024 Property of Inventiva│ 60\nTreatments effects on liver fat reduction: competitive landscape\nLanifibranor Efruxifermin Pegozafermin Resmetirom* Survodutide Terzepatide Semaglutide\nT2D/NAFLD T2D NASH (F2-F3) NASH (F2-F3) NAFLD NASH (F1-F3) NASH NAFLD\nPhaseII PhaseII Phase IIb Phase IIb Phase III Phase IIb PhaseII PhaseI\n24 weeks** 24 weeks 24weeks 24 weeks*** 52 weeks 48 weeks 52 weeks 24 weeks 48 weeks\nPbo 800mg Pbo 800mg Pbo 30mg 50mg Pbo30mg 44mg Pbo 80mg100mg Pbo 2.4mg 4.8mg6mg Pbo 5mg 10mg15mg Pbo 0.4mg Pbo 0.4mg\nn=18 n=20 n=5 n=12 n=42 n=44 n=35 n=48 QW Q2W n=309n=320n=314 n=63 n=53 n=55 n=50 n=48 n=47 n=47 n=48 n=33 n=34 n=33 n=34\nn=44 n=33\n0\n-6 -6\n-8\n-10 -9\n-11\n-14\n-16\n-36\n-41\n-43\n-47\n-48\n-46\n-50\n-52 -52 -52\n-54\nLiver fat reduction -57 -58\n(%) -61 -62\n-64\nNo head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.\n* Resmetirom has been approved under accelerated approval by the FDA\n** Results reported among completers\n***Reductions reported only for subset of patients with liver fat content ≥10 at baseline\nEfruxifermin – Akero’s Phase 2b Harmony Study Results presentation (sept. 2022), Pegozafermin - 89Bio’ Corporate Presentation (May 2023); Resmetirom – Madrigal’s corporate presentation (May 2023); Semaglutide - Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M,\nVogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi:\n10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692; Survodutide A Phase 2 randomized trial for Survodutide in MASH and fibrosis, The NEJM DOI: 10.1056/NEJMoa2401755 ; Tirzepatide Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver\nFirbosis, The NEJM DOI: 10.1056/NEJMoa2401943\nCorporate Presentation | June 2024 Property of Inventiva│ 61\nLanifibranor leads to significant improvements in hepatic and\nmuscular insulin sensitivity\n0.1\n-0.5\n-1\nProperty of Inventiva│ 62\nnim/gk/gm\nLS mean absolute change from LS mean absolute change from LS mean absolute change from\nbaseline to week 24 in baseline to week 24 in baseline to week 24 in\nendogenous glucose production hepatic insulin resistance index insulin-stimulated muscle glucose\n(completers N=28) (completers N=28) disposal (completers N=28)\n5\n4\n-10\n-9.5\n3\n2.2\n2\n-30\n-30.1\n1\n0\npa=0.001 pa=0.02\n-0.2\n-50 -1\naANCOVA.\nnim/MBL\ngk/gm\npa=0.008\nPlacebo Lanifibranor Placebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg n=14 800mg\nn=14 n=14 n=14\nCorporate Presentation | June 2024\nLanifibranor treatment increases HDL and adiponectin levels\n9\n7\n6.3\n5\n3\n1\n-0.3 -1\nProperty of Inventiva│ 63\nld/gm\nLS Mean absolute change from baseline to week\n24 in HDL cholesterol (completers N=28)\n9.0\npa=0.016\n7.5\n7.0\n5.0\n3.0\n1.0\n-0.2\n-1.0\naMixed Model Repeated Measures (MMRM).\n No change in LDL-cholesterol\nLm/gμ\nLS Mean absolute change from baseline to week\n24 in adiponectin (completers N=28)\npa<0.001\nPlacebo Lanifibranor Placebo Lanifibranor\nn=14 800mg n=14 800mg\nn=14 n=14\nCorporate Presentation | June 2024\nKey take-aways\n Lanifibranor met the primary efficacy endpoint by inducing a liver fat reduction of 44% in patients with T2D\nand NAFLD treated for 24 weeks.\n– 65% of patients with T2D and NAFLD treated with lanifibranor achieved a greater than 30% liver\ntriglyceride reduction and 25% achieved NAFLD resolution after 24 weeks.\n Lanifibranor has a potent therapeutic effect on insulin sensitivity, and corresponding metabolic markers in\npatients with T2D and NAFLD\n– Potent effect as insulin sensitizer on hepatic and muscular insulin sensitivity\n Lanifibranor significantly improved adiponectin, which is known to regulate glucose levels, lipid metabolism,\nand insulin sensitivity through its anti-inflammatory, anti-fibrotic, and antioxidant effects\n Study confirms the favorable safety and tolerability profile of lanifibranor\nCorporate Presentation | June 2024 Property of Inventiva│ 64\nLegend\nLanifibranor in Combination with the SGLT2 Inhibitor in\npatients with NASH and T2D\nLanifibranor and SGLT2 Inhibitor mechanism of action and\nrationale for LEGEND\nLanifibranor: balanced pan-PPAR Empagliflozin: inhibitor of Sodium-\nagonist (PPARα, PPARγ and PPARδ)1 glucose co-transporter-22\n• Lanifibranorimproves insulin sensitivity, lipid and glucose metabolism, inflammation, liver tissue injury (MASH activity) and fibrosis.\n• Empagliflozinimproves glycaemia, insulin sensitivity, has weight reducing and diuretic effects.\n• The combination of lanifibranor + empagliflozinmay\n• Add additional metabolic benefits\n• Address metabolically healthy weight gain observed in some patients on lanifibranor\nHaas, Francque & Staels. Ann Rev Physiol 2016; Wanner & Marx. Diabetolgia 2018; Goossens G Obes Facts 2017; Pavlides et al. Journal of Hepatology 2016; Alexopoulos et al. Hepatology 2021\nCorporate Presentation | June 2024 Property of Inventiva│ 66\nLEGEND Study Design\nLanifibranor in Combination with the SGLT2 Inhibitor empagliflozin in patients with NASH and Type 2 Diabetes\nLEGEND Study\n24 weeks treatment\nRandomized, double-blind for lanifibranor and placebo, open label\nKey inclusion criteria:\nfor the combination, placebo-controlled\n4 weeks\n1) Adult patients with MASH/NASH:\nFollow-up\n• historical biopsy with NAS ≥ 4 Lanifibranor 800 mg + empagliflozin 10 mg\n• or cT1 ≥ 875 ms\n• or cT1 ≥ 825 ms and MRI-PDFF Lanifibranor 800mg\n≥ 10%\nPlacebo\n2) T2D diagnosed\n3) Screening HbA1c in 7-10%\nSecondary outcome\nPre-specified interim Other outcome\nPrimary outcome measures:\nanalysis planned to be measures:\nmeasure:  Insulin resistance\nconducted when 50% of\n Body weight Safety and\npatients have completed  Hepatic fat (MRI-PDFF)\nHbA1c reduction  Body fat composition tolerability\nthe 24-week treatment  Liver injury markers (AST,\nat Week 24\nperiod, or prematurely ALT)  Hepatic inflammation\ndiscontinued and fibrosis markers\n Lipid markers\nCorporate Presentation | June 2024 Property of Inventiva│ 67\nPatient disposition\nFull Analysis Set (FAS): 32 patients randomized and treated\nLanifibranor 800 mg/day +\nPlacebo Lanifibranor 800 mg/day\nEmpaglifozin 10mg/day\nN = 10 N = 12\nN = 10\n5 (50%) patients completed the 12 (100%) patients completed 10 (100%) patients completed\n24-week treatment the 24-week treatment the 24-week treatment\n5 (50%) patients prematurely\ndiscontinued from study\ntreatment*:\n- Withdrawal by patient (n=2)\n- Lost to follow-up (n=2)\n- Non-compliance with study drug\n(n=1)\n* All but one patient discontinued after week 12.\nOne patient (Withdrawal by patient) discontinued before week 4.\nCorporate Presentation | June 2024 Property of Inventiva│ 68\nBaseline demographics\nPlacebo Lanifibranor + Total\nParameter (unit) [Normal ranges] Lanifibranor (n=12)\n(n=10) Empagliflozin (n=10) (n=32)\nAge (years) 55.5 55.5 56.5 55.5\nSex (% female) 60 50 60 56\nWeight (kg) 92.6 93.9 102.0 96.8\nBMI (kg/m²) 33 33 37 35\nHbA1c (%), [4.0 - 6.0] 7.7 7.7 8.2 7.8\nInsulin (pmol/L) [18.1 - 172.9] 278 152 238 223\nHOMA-IR 19.5 9.4 12.0 10.9\nHDL-C (mmol/L) [F ≥ 0.91, M ≥ 0.78] / (mg/dL) 1.08 / 41.8 1.07 / 41.4 1.02 / 39.4 1.07 / 41.4\nLDL-C (mmol/L) [F ≤ 4.14, M ≤ 3.89] / (mg/dL) 2.26 / 87.4 2.52 / 97.5 2.45 / 94.7 2.52 / 97.5\ncT1 (ms) 942 949 921 931\nHepatic fat content (MRI-PDFF) (%) 17.1 18.5 19.7 18.8\nALT (U/L), [F ≤ 33, M ≤ 41] 33 53 54 39\nAST (U/L), [F ≤ 32, M ≤ 40] 24 30 35 30\nAdiponectin (ug/mL), [0.9 - 21.4] 2.6 3.1 4.0 3.0\nMedian values are presented for continuous parameters.\nALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, BMI: Body Mass Index, cT1: Corrected T1, F: Female, HDL-C: High density lipoprotein cholesterol, HOMA: Homeostasicmodel\nassessment, M: Male, MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction\nCorporate Presentation | June 2024 Property of Inventiva│ 69\nPrimary endpoint was met: statistically significant reductions in HbA1c at week 24\nunder lanifibranor alone and in combination with empaglifozin versus placebo\nFAS, N=30 Completers, N=24\nLS Mean Absolute Change from Baseline to Week 24 Percentage of responders at Week 24\nHbA1c (%) HbA1c < 6.5% HbA1c absolute decrease ≥1%\nWeek 12 Week 24\n100 100\n0.4 0.26 88%\n0.2\n0\n75 75\n-0.2 -0.08 63% 64%\n-0.4 55%\n-0.6 50 50\n-0.8\n-1\n-1.2 * 25 25\n-1.19* -1.14\n-1.4\n*\n-1.6 -1.44\n** 0% 0%\n-1.59\n-1.8 0 0\nPlacebo Lani Lani Placebo Lani Lani Placebo Lani Lani Placebo Lani Lani\n-2\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa n= 5 n=11 + Empa n= 5 n=11 + Empa\nn= 10 n= 10 n= 8 n= 8\n*p<0.01, **p<0.001, versus placebo (Mixed Model Repeated Measure [MMRM]) Eight patients were not considered in the Completers set:\nTwo patients were not considered in the FAS because not having post-treatment HbA1c values - 5 patients under placebo who prematurely stopped before Week 24\navailable: - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent event) before Week\n- 1 patient under placebo who prematurely stopped before Week 4 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nevent) before Week 4 (Results were similar including this patient in a sensitivity analysis). modified his/her diet (intercurrent event) before Week 24.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 70\nLanifibranor improves insulin sensitivity which is further\nimproved in combination with empagliflozin\nInsulin - FAS, N=30 HOMA-IR - FAS, N=30\nLS Mean Absolute Change from Baseline to Week 24 (pmol/L) LS Mean Relative change (%) from Baseline to Week 24\nBaseline 152-278 pmol/L Baseline 9.4-19.5\n0\n-5\n-25 -7\n-15\n-50\n-25\n-58.3\n-75\n-35\n-100 -93.9† -45\n-125 -55 -51*\n-150 -65\n*\n-155.1\n-175 -75 -69**\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 11 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM), † p<0.05, versus baseline (MMRM) *p<0.05, **p<0.01, versus placebo (MMRM)\nTwo patients were not considered in the FAS because not having post-treatment insulin values Two patients were not considered in the FAS because not having post-treatment HOMA-IR values\navailable: available:\n- 1 patient under placebo who prematurely stopped before Week 4 - 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent - 1 patient under lanifibranor who received ‘Metformin’ as a rescue medication (intercurrent\nevent) before Week 4 event) before Week 4\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 71\nLanifibranor alone and in combination with empagliflozin\nsignificantly improves markers of liver injury\nALT - FAS, N=31 AST - FAS, N=31\nLS Mean Relative change (%) from Baseline to Week 24 LS Mean Relative change (%) from Baseline to Week 24\nBaseline 33-54 IU/L Baseline 24-35 IU/L\n10 20\n0\n10\n-10\n0\n-20\n* -10\n-30 *\n**\n* -20 **\n-40\n*\n-30\n-50 **\n**\n-60 *** -40 ***\nBaseline Week 4 Week 12 Week 24 Baseline Week 4 Week 12 Week 24\nPlacebo n= 9 Lani n= 12 Lani + Empa n= 10 Placebo n= 9 Lani n= 12 Lani + Empa n= 10\n*p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM) *p<0.05, **p<0.01, ***p<0.001, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because no post-treatment ALT values One patient under placebo was not considered in the FAS because no post-treatment AST values\navailable (Premature discontinuation before Week 4) available (Premature discontinuation before Week 4)\nCorporate Presentation | June 2024 Property of Inventiva│ 72\nLanifibranor alone and in combination with empagliflozin\nsignificantly reduce hepatic steatosis measured by MRI-PDFF\nLiver fat measured by MRI-PDFF, N=26 from Baseline at Week 24\nLS Mean Relative change (%) Individual Relative changes (%)\nBaseline 17.1-19.7%\n20\n0\n0\n-5\n0\n-10\n-15\n-20\n-20\n-25\n-40\n-30\n-35\n-40 -60\n-38*\n-45\n-50 -47* -80 Placebo\nLani Lani\nPlacebo Lani\n+ Empa\nn= 5 n= 12 -100 Lani + Empa\nn= 9\n*p≤0.05, versus placebo (ANCOVA –Analysis of Covariance)\nlanifibranor +\nSix patients were not considered in the FAS because no MRI-PDFF values available at Week 24: Percentage of responders Lanifibranor\nPlacebo (n=5) empagliflozin\n- 5 patients under placebo who prematurely stopped before Week 24 at Week 24 (n=12)\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before (n=9)\nWeek 24\nMRI-PDFF ≥ 30% 0% 82% 67%\nAbsolute reduction of ≥ 5% 0% 67% 67%\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 73\nLanifibranor alone and in combination with empaglifozin\nimproves markers of inflammation and fibrosis measured by cT1\nChanges in Inflammation and Fibrosis measured by cT1, N=25 cT1 Absolute Reduction of >80 ms\nLS Mean Absolute change (ms) from Baseline to Week 24 Percentage of responders at Week 24\nBaseline 921-949 ms 100\n25 15\n75\n0\n50%\n-25\n50 44%\n-50\n25\n-75\n-82* -85*\n0%\n-100\n0\nPlacebo Lani Lani Placebo Lani Lani\nn= 4 n= 12 + Empa n= 4 n=12 + Empa\nn= 9 n= 9\n*p=0.06 both, versus placebo (ANCOVA)\nSeven patients were not considered in the FAS because of no cT1 values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo with a missing value at Week 24\n- 1 patient under lani+empawho significantly modified his/her diet (intercurrent event) before\nWeek 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 74\nLanifibranor alone and in combination with empagliflozin\nimproves HDL-C and adiponectin\nHDL-C, N=31 Adiponectin, N=30\nLS Mean Absolute change (mmol/L) from Baseline to Week 24 LS Mean Fold change from Baseline to Week 24\nBaseline 1.02-1.07 mmol/L Baseline 2.6-4.0 ug/mL\n0.5 4\n3.5\n0.4 3.0 *\n3 2.8*\n0.3\n2.5\n0.22*\n0.2\n0.17†\n2\n1.5\n0.1 1.1\n1\n0.0\n0.5\n-0.01\n-0.1 0\nPlacebo Lani Lani Placebo Lani Lani\nn= 9 n= 12 + Empa n= 9 n= 11 + Empa\nn= 10 n= 10\n*p<0.05, versus placebo (MMRM) † p<0.01, versus baseline (MMRM) *p<0.05, versus placebo (MMRM)\nOne patient under placebo was not considered in the FAS because of no post-treatment HDL-C Two patients were not considered in the FAS because not having post-treatment adiponectin\nvalues available (premature discontinuation before Week 4) values available:\n- 1 patient under placebo who prematurely stopped before Week 4\n- 1 patient under lanifibranor who received ‘Metformin’ as rescue medication (intercurrent event)\nbefore Week 4\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 75\nThe combination of empagliflozin and lanifibranor addresses the weight\ngain observed in some patients treated with lanifibranor alone\nWeight change, N=32\nRelative change from Baseline (%)\nBaseline 93-102 kg\n5\n3.6\n4\n3\n2\n2 1.4\n1\n00\n-0.4 -0.4\n0\n-0.9\n0\n-1\n-0.8 -0.8\n-1.1\n-2\nBaseline Week 4 Week 12 Week 24\nn=10/12/10 n=9/12/10 n=9/12/9 n=5/12/8\n(n=pb/lani/lani+empa)\nPlacebo Lani Lani + Empa\nAt Week 24, 7 patients without weight values available :\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under lani+empawith missing data at Week 24, and 1 patient under lani+empawho significantly\nmodified his/her diet (intercurrentevent) before Week 24.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 76\nLanifibranor alone and in combination with empagliflozin leads\nto a shift towards metabolically healthy adipose tissue\nRatio VAT/SAT, N=19\nLS Mean Relative change (%) from Baseline to Week 24\n11\n10\n5\n0\n-5\n-5*\n-10\n-15\n**\n-17\n-20\nPlacebo Lani Lani + Empa\nn= 4 n= 8 n= 7\nSAT=Subcutaneous Adipose Tissue, VAT=Visceral Adipose Tissue\n* p=0.08, **p<0.01, versus placebo (ANCOVA)\nThirteen patients were not considered in the FAS because of no VAT/SAT values available at Week 24:\n- 5 patients under placebo who prematurely stopped before Week 24\n- 1 patient under placebo / 4 patients under lanifibranor / 3 patients under lani+empawith missing values at Week 24\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 77\nSafety and tolerability: Treatment-Emergent Adverse Events\n(TEAE)\nPlacebo Lanifibranor Lanifibranor +\nTEAE Overview\n(n=10) (n=12) Empagliflozin (n=10)\nTEAE 6 (60%) 10 (83%) 8 (80%)\nDrug-related TEAE 2 (20%) 3 (30%) 5 (50%)\nTEAE leading to drug withdrawal 0 0 0\nSerious TEAE 0 0 0\nSevere TEAE 0 0 0\nAny AE of Specific Interest\nAminotransferase elevation 0 0 0\nAnemia a 1 2 0\nPeripheral edema 0 0 1b\nHypoglycaemia c 1 0 1d\nMost Frequent (≥10%) TEAEs by SOC\nInfections and infestations 3 ( 30%) 2 ( 17%) 5 ( 50%)\nMusculoskeletal and connective tissue\n3 ( 30%) 1 ( 8%) 1 ( 10%)\ndisorders\nGastrointestinal disorders 2 ( 20%) 3 ( 25%) 2 ( 20%)\nSkin and subcutaneous tissue disorders 2 ( 20%) 4 ( 33%) 0 ( 0%)\nNervous system disorders 1 ( 10%) 2 ( 17%) 1 ( 10%)\na Defined as haemoglobin levels <Lower Limit Normal. The 3 events reported were assessed as not related to study drug.\nb The event was assessed as related to lanifibranor/not related to empaglifozin, of mild severity with no associated symptoms, that further recovered without corrective treatment.\nc Defined as glucose levels <Lower Limit Normal. Glucose values were > 3 mmol/L for the 2 events reported. Both events were assessed as not related to study drug, of mild intesityand required no treatment.\nd Related to empaglifozinonly.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 78\nConclusions\n The primary efficacy endpoint based on reduction of HbA1c was met for both lanifibranor alone and\nfor the combination with empagliflozin.\n The combination of lanifibranor with empagliflozin addresses / neutralizes weight gain seen in some\npatients on lanifibranor alone.\n Both lanifibranor alone and the combination with empagliflozin induce a redistribution of fat from\nvisceral to subcutaneous fat. This is consistent with the improved insulin sensitivity seen with both\nlanifibranor alone and the combination.\n Lanifibranor improves markers of cardiometabolic health, the effect size appear to be further\nimproved when lanifibranor is combined with empagliflozin.\n Lanifibranor alone and in combination with empagliflozin appear to be safe and well tolerated.\nCorporate Presentation | June 2024 Non-confidential –Property of Inventiva│ 79"
        },
        {
          "title": "Role of vascular alterations in MASLD/MASH pathophysiology, effect of lanifibranor",
          "url": "https://inventivapharma.com/wp-content/uploads/2024/04/LEGEND-Webcast-Sven-Francque-March-2024_03-19-2024-2.pdf",
          "content": "Role of vascular alterations in MASLD/MASH\npathophysiology\nPre-clinical and human data on the effect of\nlanifibranor\nSven M.A. Francque, MD, PhD\nChair, Department of Gastroenterology and Hepatology\nAntwerp University Hospital, Belgium\nSenior Full Professor of Hepatology\nChair, Translational Sciences in Inflammation and Immunology (TWI2N)\nUniversity of Antwerp, Belgium\n│ 1\nLEGEND presentation | 2024\nPortal Hypertension\nVASCULAR\nHYPOREACTIVITY\nMESENTERIAL SPLANCHNIC\nANGIOGENESIS VASODILATATION\nSPLANCHNIC\nHYPERPERFUSION\nPORTAL\nHYPERTENSION\n↑INTRAHEPATIC\nRESISTANCE\nStructural component Vasoactive component\n• Fibrosis\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 2\nPortal Hypertension in MASLD/MASH\nCollaterals /\nShunts\nE.g.\nPortal Hypertension ▲ Splanchnic Perfusion ▲ Splanchnic vasodilatation and\nvascular hyporeactivity\nIntrahepatic Vascular\nResistance▲\npO ▼\nBlood Supply ▼\n2\nStructural Functional\nE.g. E.g.\nHyperreactivity to\nNarrowing HABR\nvasoconstrictors,\nsinusoids,\nreduced NO\narchitectural\nproduction\ndisorganisation,\nfibrosis\nFrancque et al. Lab Invest 2012\nVan Der Graaff, Kwanten, Francque. Med Hypotheses 2019\n*HABR: Hepatic arterial buffer response\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 3\nPortal Hypertension in MASLD/MASH\n80\n60\n40\n20\n0\n4 8 2 6 0\nk k 1 1 2\nwee wee eek eek eek\nw w w\nGonzalez-Paredes et al. PLoS ONE 2016; Van Der Graaff… Francque. Lab Invest 2018; Van Der Graaff… Francque. J Hep Rep 2022; Lefere et al. Hepatology 2019; Miyao et al. Lab Invest 2015; Van Eyck…Francque… et al. Int J Obesity 2024; Van Der Graaff…Francque. Med Hypotheses 2019\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 4\n)gHmm(\n2Op\n✱ ✱ control\nHFHFD\n)gHmm(\n2OP\nFlow (m L/m in)\n)g\nH\nm\nm(\ntneidarg\nerusserp\ncitapehsnarT\n15\n*\nLean Zucker rats (n=7) *\nZucker fatty rats (n=7)\n**\n10\n**\n**\n**\n***\n5\n0\n0 10 20 30 40 50\nIntrahepatic Vascular Portal Hypertension ▲ Splanchnic Perfusion ▲\nResistance▲\nBlood Supply ▼ pO ▼\n2\nStructural Functional\nControl 8w CDAA 8w Recovery 4w\nRole of PPARs in liver vascular biology\nGuixé-Muntet…Francque et al. Aliment PharmacolTher2022\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 5\nPre-clinical data\nPortal hypertension in a model of MASLD\n4 weeks Diet and preventive treatment\nLanifibranor (but not single PPAR) normalises\n- portal hypertension\n- transhepatic pressure gradient\n- hyperreactivity to methoxanime\n- hyporeactivity to acethylcholine\nChotkoe …Francque. EASL 2023\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 7\nPortal hypertension in an early model of MASLD\nControl diet MCD diet MCD diet + lanifibranor CD34 staining\nLanifibranor\n- improves the sinusoidal organisation\n- decreases the number of blebs\n- inhibits the capillarisation of the LSEC\nChotkoe …Francque. EASL 2023\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 8\nPortal hypertension in an early model of MASH\nHigh-fat\nhigh-\nZucker rat\nfructose diet\n250 g\n(HFHFD)\n56 days diet and preventive treatment\n**** ****\nConfirmation in a second model (being a MASH model) of\n- increase in portal pressure\n- intrahepatic vascular modifications\n- normalisation of all vascular modifications by lanifibranor\nRautou, Chotkoe …Francque. In preparation\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 9\n16\n14\n12\n10\n8\nVeh Lani\nNon-confidential – Property of Inventiva │ 10\n)gHmm(\nerusserp\nlatroP\nPortal pressure\nIntrahepatic vascular\nresistance\n1.5\n-15%\n**\n1.0\n0.5\n0.0\nVeh Lani\n)Lm/nim·gHmm(\nRVHI\n-29% *\nVeh Lani\n10\n9\n8\n7\n6\n5\nVeh Lani\n)%(\neartseneF\n3\n2\n1\n0\nVeh Lani\n*\nANRm\nevitaleR\n1MACI\nfo\nnoisserpxe\n3\n2\n*\n1\n0\nVeh Lani\nANRm\nevitaleR\n1MACV\nfo\nnoisserpxe\n4\n3\np=0.10\n2\n1\n0\nVeh Lani\nANRm\nevitaleR\nleS-E\nfo\nnoisserpxe\nPortal hypertension in a model of cirrhosis: effect of lanifibranor on the portal pressure\n30\n20\n10\n0\nVeh Lani\n*\negatnecrep\nsisorbiF\nGroup 1: Vehicle\nAscites Fibrosis\nGroup 2: Lanifibranor (100 mg/kg))\n12 weeks of cirrhosis 2 weeks of\ninduction (TAA) treatment\n-32% *\nVeh\nElectronic microscopy\nFenestrae\nLanifibranor\n- reduces portal pressure\n- reduces intrahepatic vascular resistance\n- reduces ascites\n- decreases fibrosis\n- effects on sinusoidal endothelial cells (LSEC)\n• restores fenestration\n• induces their decapillarisation\n• deactivation\nBoyer-Diaz et al. 2021 J.Hep\nLEGEND presentation | 2024\nLani\n80\n60\n40\n20\n0\nseticsa\ngnivah\nstar\nfo%\nData confirmed in CBDL model\nPortal hypertension in a non-cirrhotic model: effect of lanifibranor on the portal pressure and\nmesenteric vasculature\nGroup 1: Sham (ctrl)\nCorrosion cast of the mesentieric vasculature\nGroup 2: Vehicle\nGroup 3: Lanifibranor (10 mg/kg)\nPPVL + lani\nGroupe 4: Lanifibranor (30mg/kg) SHAM PPVL + Veh\n(30mg/kg)\n1 week induction (PPVL 1 week of\n(partial portal vein ligation) treatment\nFlow superior\nPortal pressure\nSpleen weight\nmesenteric artery\nVascular wall thickness CD34 staining\nLanifibranor reduces portal pressure by reducing the superior mesenteric artery flow\n- Reduction of vascular wall thickness\n- Reversal of PPVL-induced vascular expansion\nHeldens, EASL 2023\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 11\nClinical data from NATIVE demonstrating liver\nvasculature modification throughout MASH\nprogression and effect of lanifibranor on the\nvascular architecture\nCapillarisation of liver sinusoids in patients with MASH\nCD34 staining on slides from the NATIVE clinical trial (Phase 2b)\nCD34 positive staining is more pronounced in MASH patients than in patients without MASH\nPatients with MASH have significantly more CD34 positive staining within the lobular area\nA similar trend is observed in the periportal area\nRautou, Chotkoe …Francque. In preparation\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 13\nCapillarisation of liver sinusoids in patients with MASH\nDensity of CD34+ vessels\nCD34 positive staining is significantly linked to\n- the severity of liver fibrosis\n- the severity of liver inflammation\nRautou, Chotkoe …Francque. In preparation\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 14\nCapillarisation of liver sinusoids in patients with MASH: effects of lanifibranor\nSignificant improvement in periportal CD34 score\nTrend with a dose effect in lobular CD34 score\nRautou, Chotkoe …Francque. In preparation\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 15\nMechanism to target across the disease spectrum\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 16\nMechanism to target across the disease spectrum\nLanifibranor targeting\nmetabolo-inflammatory drivers\nLanifibranor targeting intrahepatic mechanisms of\nsteatohepatitis and fibrosis\nLanifibranor targeting underlying mechanisms of portal\nhypertension\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 17\nConclusions\n\nMASLD is associated with vascular changes at all disease stages\n• Both structural and functional mechanisms\n\n3 PPAR isotypes closely involved in liver vascular biology\n\nLanifibranor\n• Efficacious on restoring liver vascular biology in animal models\n• Superior to mono-agonists\n• Clinical data on capillarisation suggest also clinical relevance\n\nMechanisms and effect of lanifibranor are relevant along the disease spectrum\n• Pre-clinical data in cirrhosis/PHT models\n• Role of vascular mechanisms in advanced disease\nLEGEND presentation | 2024 Non-confidential – Property of Inventiva │ 18"
        }
      ]
    }
  ]
}